CA3066328A1 - Chemical compounds as atf4 pathway inhibitors - Google Patents
Chemical compounds as atf4 pathway inhibitors Download PDFInfo
- Publication number
- CA3066328A1 CA3066328A1 CA3066328A CA3066328A CA3066328A1 CA 3066328 A1 CA3066328 A1 CA 3066328A1 CA 3066328 A CA3066328 A CA 3066328A CA 3066328 A CA3066328 A CA 3066328A CA 3066328 A1 CA3066328 A1 CA 3066328A1
- Authority
- CA
- Canada
- Prior art keywords
- bicyclo
- azetidinyl
- chlorophenoxy
- pentan
- acetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 308
- 230000037361 pathway Effects 0.000 title claims abstract description 35
- 239000003112 inhibitor Substances 0.000 title claims abstract description 30
- 150000003839 salts Chemical class 0.000 claims abstract description 206
- 238000000034 method Methods 0.000 claims abstract description 164
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 122
- 238000011282 treatment Methods 0.000 claims abstract description 59
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 claims abstract description 35
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 claims abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 13
- -1 azetidinyl-O- Chemical class 0.000 claims description 336
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 195
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 134
- 201000010099 disease Diseases 0.000 claims description 113
- 125000001153 fluoro group Chemical group F* 0.000 claims description 100
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 89
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 79
- 125000001424 substituent group Chemical group 0.000 claims description 75
- 206010028980 Neoplasm Diseases 0.000 claims description 68
- 229910052739 hydrogen Inorganic materials 0.000 claims description 68
- 239000001257 hydrogen Substances 0.000 claims description 67
- 125000002393 azetidinyl group Chemical group 0.000 claims description 64
- 201000011510 cancer Diseases 0.000 claims description 59
- 150000002431 hydrogen Chemical class 0.000 claims description 59
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 57
- 239000003795 chemical substances by application Substances 0.000 claims description 56
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 53
- 125000001072 heteroaryl group Chemical group 0.000 claims description 45
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims description 44
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 42
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 39
- 230000026731 phosphorylation Effects 0.000 claims description 39
- 238000006366 phosphorylation reaction Methods 0.000 claims description 39
- 125000003386 piperidinyl group Chemical group 0.000 claims description 39
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 37
- 125000004193 piperazinyl group Chemical group 0.000 claims description 35
- 210000000056 organ Anatomy 0.000 claims description 34
- 208000030090 Acute Disease Diseases 0.000 claims description 33
- 230000001684 chronic effect Effects 0.000 claims description 33
- 230000004770 neurodegeneration Effects 0.000 claims description 33
- 208000017667 Chronic Disease Diseases 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 31
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 31
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 30
- 125000004076 pyridyl group Chemical group 0.000 claims description 29
- 238000002054 transplantation Methods 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 26
- 208000011580 syndromic disease Diseases 0.000 claims description 26
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 25
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims description 24
- 208000017004 dementia pugilistica Diseases 0.000 claims description 24
- 208000022873 Ocular disease Diseases 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 23
- 125000003566 oxetanyl group Chemical group 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 20
- 230000003938 response to stress Effects 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 19
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 17
- 208000024827 Alzheimer disease Diseases 0.000 claims description 16
- 210000003734 kidney Anatomy 0.000 claims description 16
- 210000004185 liver Anatomy 0.000 claims description 16
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 15
- 208000018737 Parkinson disease Diseases 0.000 claims description 15
- 208000024777 Prion disease Diseases 0.000 claims description 15
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 15
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims description 15
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 15
- 230000009529 traumatic brain injury Effects 0.000 claims description 15
- 201000001320 Atherosclerosis Diseases 0.000 claims description 14
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 14
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 14
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 14
- 206010012289 Dementia Diseases 0.000 claims description 14
- 206010016654 Fibrosis Diseases 0.000 claims description 14
- 208000023105 Huntington disease Diseases 0.000 claims description 14
- 208000002193 Pain Diseases 0.000 claims description 14
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 14
- 239000002246 antineoplastic agent Substances 0.000 claims description 14
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 14
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 14
- 210000004072 lung Anatomy 0.000 claims description 14
- 208000010125 myocardial infarction Diseases 0.000 claims description 14
- 206010061218 Inflammation Diseases 0.000 claims description 13
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 13
- 230000006793 arrhythmia Effects 0.000 claims description 13
- 206010003119 arrhythmia Diseases 0.000 claims description 13
- 230000004054 inflammatory process Effects 0.000 claims description 13
- 208000020431 spinal cord injury Diseases 0.000 claims description 13
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims description 12
- 229940034982 antineoplastic agent Drugs 0.000 claims description 12
- 208000010877 cognitive disease Diseases 0.000 claims description 12
- 230000004761 fibrosis Effects 0.000 claims description 12
- 208000006011 Stroke Diseases 0.000 claims description 11
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 11
- 208000019423 liver disease Diseases 0.000 claims description 11
- 208000019693 Lung disease Diseases 0.000 claims description 10
- 208000012902 Nervous system disease Diseases 0.000 claims description 10
- 208000002780 macular degeneration Diseases 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 208000025966 Neurological disease Diseases 0.000 claims description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 9
- 208000014674 injury Diseases 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 208000028698 Cognitive impairment Diseases 0.000 claims description 8
- 201000002847 Cowden syndrome Diseases 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 208000034578 Multiple myelomas Diseases 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 8
- 208000005017 glioblastoma Diseases 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 230000019491 signal transduction Effects 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000009956 adenocarcinoma Diseases 0.000 claims description 7
- 239000002955 immunomodulating agent Substances 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 7
- 230000008816 organ damage Effects 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- VOKQBCYUBAZZNE-UHFFFAOYSA-N 2-(4-chloro-3-fluorophenoxy)-N-[3-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=C(C=C(OCC(=O)NC23CC(C2)(C3)N2CC(CC2)OC2=CC=C(C=C2)Cl)C=C1)F VOKQBCYUBAZZNE-UHFFFAOYSA-N 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010018404 Glucagonoma Diseases 0.000 claims description 6
- 208000001344 Macular Edema Diseases 0.000 claims description 6
- 206010025415 Macular oedema Diseases 0.000 claims description 6
- 208000006336 acinar cell carcinoma Diseases 0.000 claims description 6
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims description 6
- 206010022498 insulinoma Diseases 0.000 claims description 6
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims description 6
- 201000010230 macular retinal edema Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 5
- CGSVABMLMBTOPG-UHFFFAOYSA-N ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2CC(CC2)OC2=CC=C(C=C2)Cl)C=C1 Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2CC(CC2)OC2=CC=C(C=C2)Cl)C=C1 CGSVABMLMBTOPG-UHFFFAOYSA-N 0.000 claims description 5
- BGHTZYMERJBGTB-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[[2-(4-chlorophenoxy)acetyl]amino]-1-bicyclo[1.1.1]pentanyl]cyclopropane-1-carboxamide Chemical compound ClC1=CC=C(OC2C(C2)C(=O)NC23CC(C2)(C3)NC(COC2=CC=C(C=C2)Cl)=O)C=C1 BGHTZYMERJBGTB-UHFFFAOYSA-N 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 201000007815 Bannayan-Riley-Ruvalcaba syndrome Diseases 0.000 claims description 4
- 208000012609 Cowden disease Diseases 0.000 claims description 4
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 208000022010 Lhermitte-Duclos disease Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 206010046851 Uveitis Diseases 0.000 claims description 4
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 4
- 210000003128 head Anatomy 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 210000003739 neck Anatomy 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 208000021255 pancreatic insulinoma Diseases 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 210000001685 thyroid gland Anatomy 0.000 claims description 4
- VOKQBCYUBAZZNE-WDGBRCNXSA-N 2-(4-chloro-3-fluorophenoxy)-N-[3-[(3R)-3-(4-chlorophenoxy)pyrrolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical class ClC1=C(C=C(OCC(=O)NC23CC(C2)(C3)N2C[C@@H](CC2)OC2=CC=C(C=C2)Cl)C=C1)F VOKQBCYUBAZZNE-WDGBRCNXSA-N 0.000 claims description 3
- WQWFSVIACXQIRZ-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-(3-pyridin-4-yloxypyrrolidin-1-yl)-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2CC(CC2)OC2=CC=NC=C2)C=C1 WQWFSVIACXQIRZ-UHFFFAOYSA-N 0.000 claims description 3
- YGUFKXSZRPNCAI-YUVSOPLDSA-N 2-(4-chlorophenoxy)-N-[3-[(3R)-3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2C([C@@H](CC2)OC2=CC=C(C=C2)Cl)=O)C=C1 YGUFKXSZRPNCAI-YUVSOPLDSA-N 0.000 claims description 3
- CGSVABMLMBTOPG-RDABAPPSSA-N 2-(4-chlorophenoxy)-N-[3-[(3R)-3-(4-chlorophenoxy)pyrrolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2C[C@@H](CC2)OC2=CC=C(C=C2)Cl)C=C1 CGSVABMLMBTOPG-RDABAPPSSA-N 0.000 claims description 3
- UTRKZVKUEXVXAT-BVVFMGSASA-N 2-(4-chlorophenoxy)-N-[3-[(4S)-4-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2C(C[C@@H](C2)OC2=CC=C(C=C2)Cl)=O)C=C1 UTRKZVKUEXVXAT-BVVFMGSASA-N 0.000 claims description 3
- QDNZQRBECDTSDS-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[2-oxo-3-[4-(trifluoromethyl)phenyl]imidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2C(N(CC2)C2=CC=C(C=C2)C(F)(F)F)=O)C=C1 QDNZQRBECDTSDS-UHFFFAOYSA-N 0.000 claims description 3
- URXAAULUVZBGJS-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[3-(4-chlorophenoxy)azetidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2CC(C2)OC2=CC=C(C=C2)Cl)C=C1 URXAAULUVZBGJS-UHFFFAOYSA-N 0.000 claims description 3
- NYKJXABTIUVGJY-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[3-(4-fluorophenoxy)pyrrolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2CC(CC2)OC2=CC=C(C=C2)F)C=C1 NYKJXABTIUVGJY-UHFFFAOYSA-N 0.000 claims description 3
- ZAOSJWFRKBNJRQ-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[3-(5-chloropyridin-2-yl)oxypyrrolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2CC(CC2)OC2=NC=C(C=C2)Cl)C=C1 ZAOSJWFRKBNJRQ-UHFFFAOYSA-N 0.000 claims description 3
- JYWURZRQODLAPA-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[3-[4-(trifluoromethyl)phenoxy]pyrrolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2CC(CC2)OC2=CC=C(C=C2)C(F)(F)F)C=C1 JYWURZRQODLAPA-UHFFFAOYSA-N 0.000 claims description 3
- KPAQRGOBSVTJJC-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[4-(4-chlorophenyl)piperazin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2CCN(CC2)C2=CC=C(C=C2)Cl)C=C1 KPAQRGOBSVTJJC-UHFFFAOYSA-N 0.000 claims description 3
- UAUIDHAIEQMGAV-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[4-(4-chlorophenyl)piperidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2CCC(CC2)C2=CC=C(C=C2)Cl)C=C1 UAUIDHAIEQMGAV-UHFFFAOYSA-N 0.000 claims description 3
- JSPHGRXBURYFSO-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[[2-(3,4-dihydro-2H-chromen-6-yloxy)acetyl]amino]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)NC(COC=2C=C3CCCOC3=CC=2)=O)C=C1 JSPHGRXBURYFSO-UHFFFAOYSA-N 0.000 claims description 3
- UBMMAYRWXNAJJS-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[[2-(5,6,7,8-tetrahydronaphthalen-2-yloxy)acetyl]amino]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)NC(COC2=CC=3CCCCC=3C=C2)=O)C=C1 UBMMAYRWXNAJJS-UHFFFAOYSA-N 0.000 claims description 3
- CGSVABMLMBTOPG-RBKXMNCYSA-N ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2C[C@H](CC2)OC2=CC=C(C=C2)Cl)C=C1 Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2C[C@H](CC2)OC2=CC=C(C=C2)Cl)C=C1 CGSVABMLMBTOPG-RBKXMNCYSA-N 0.000 claims description 3
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- QVYFJWHFGGLMTN-UHFFFAOYSA-N N-[3-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]-2-[4-chloro-3-(trifluoromethyl)phenoxy]acetamide Chemical compound ClC1=C(C=C(OCC(=O)NC23CC(C2)(C3)N2CC(CC2)OC2=CC=C(C=C2)Cl)C=C1)C(F)(F)F QVYFJWHFGGLMTN-UHFFFAOYSA-N 0.000 claims description 3
- LRGLVMDVZQOKLU-UHFFFAOYSA-N N-[4-[[2-(3-bicyclo[4.2.0]octa-1(6),2,4-trienyloxy)acetyl]amino]-1-bicyclo[2.2.1]heptanyl]-2-(4-chlorophenoxy)acetamide Chemical compound C12=CC(=CC=C2CC1)OCC(=O)NC12CCC(CC1)(C2)NC(COC1=CC=C(C=C1)Cl)=O LRGLVMDVZQOKLU-UHFFFAOYSA-N 0.000 claims description 3
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 3
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 3
- 230000000340 anti-metabolite Effects 0.000 claims description 3
- 229940044684 anti-microtubule agent Drugs 0.000 claims description 3
- 229940100197 antimetabolite Drugs 0.000 claims description 3
- 239000002256 antimetabolite Substances 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 230000022131 cell cycle Effects 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 230000003054 hormonal effect Effects 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 claims description 3
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 239000003207 proteasome inhibitor Substances 0.000 claims description 3
- YGUFKXSZRPNCAI-BVVFMGSASA-N 2-(4-chlorophenoxy)-N-[3-[(3S)-3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2C([C@H](CC2)OC2=CC=C(C=C2)Cl)=O)C=C1 YGUFKXSZRPNCAI-BVVFMGSASA-N 0.000 claims description 2
- UTRKZVKUEXVXAT-YUVSOPLDSA-N 2-(4-chlorophenoxy)-N-[3-[(4R)-4-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2C(C[C@H](C2)OC2=CC=C(C=C2)Cl)=O)C=C1 UTRKZVKUEXVXAT-YUVSOPLDSA-N 0.000 claims description 2
- UBEYJMBZYOVPGD-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[4-(4-chlorophenoxy)piperidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2CCC(CC2)OC2=CC=C(C=C2)Cl)C=C1 UBEYJMBZYOVPGD-UHFFFAOYSA-N 0.000 claims description 2
- KSOFRJNENFHUKZ-UHFFFAOYSA-N 2-(5-chloropyridin-2-yl)oxy-N-[3-[3-(5-chloropyridin-2-yl)oxypyrrolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC=1C=CC(=NC=1)OCC(=O)NC12CC(C1)(C2)N1CC(CC1)OC1=NC=C(C=C1)Cl KSOFRJNENFHUKZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 208000014882 Carotid artery disease Diseases 0.000 claims description 2
- 206010008263 Cervical dysplasia Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- GTJIXNYAQZTONT-UHFFFAOYSA-N ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)NC2CN(C2)C2=CC=C(C=C2)Cl)C=C1 Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)NC2CN(C2)C2=CC=C(C=C2)Cl)C=C1 GTJIXNYAQZTONT-UHFFFAOYSA-N 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000019878 Eales disease Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims description 2
- 208000036566 Erythroleukaemia Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims description 2
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 claims description 2
- 208000007256 Nevus Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 208000002774 Paraproteinemias Diseases 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 201000002154 Pterygium Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000007135 Retinal Neovascularization Diseases 0.000 claims description 2
- 201000007527 Retinal artery occlusion Diseases 0.000 claims description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 2
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000000389 T-cell leukemia Diseases 0.000 claims description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 2
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 claims description 2
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims description 2
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims description 2
- 208000002352 blister Diseases 0.000 claims description 2
- 201000011143 bone giant cell tumor Diseases 0.000 claims description 2
- 201000003714 breast lobular carcinoma Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000021039 metastatic melanoma Diseases 0.000 claims description 2
- 208000001491 myopia Diseases 0.000 claims description 2
- 230000004379 myopia Effects 0.000 claims description 2
- 230000009826 neoplastic cell growth Effects 0.000 claims description 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 210000001636 ophthalmic artery Anatomy 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 208000003154 papilloma Diseases 0.000 claims description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical group C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 2
- 208000014081 polyp of colon Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 12
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 6
- 229910006069 SO3H Inorganic materials 0.000 claims 4
- DGTZHTWZRAJJGT-UHFFFAOYSA-N ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2C(N(CC2)C2=CC=C(C=C2)Cl)=O)C=C1 Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2C(N(CC2)C2=CC=C(C=C2)Cl)=O)C=C1 DGTZHTWZRAJJGT-UHFFFAOYSA-N 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- HHEFXCCGQHYYOO-UHFFFAOYSA-N 2-(3-chloro-4-fluorophenoxy)-N-[3-[3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC=1C=C(OCC(=O)NC23CC(C2)(C3)N2C(N(CC2)C2=CC=C(C=C2)Cl)=O)C=CC=1F HHEFXCCGQHYYOO-UHFFFAOYSA-N 0.000 claims 1
- ARRBOSDTHRYVJB-UHFFFAOYSA-N 2-(3-chlorophenoxy)-N-[3-[3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC=1C=C(OCC(=O)NC23CC(C2)(C3)N2C(N(CC2)C2=CC=C(C=C2)Cl)=O)C=CC=1 ARRBOSDTHRYVJB-UHFFFAOYSA-N 0.000 claims 1
- QVSPWYVZTUVJKA-UHFFFAOYSA-N 2-(4-chloro-3-fluorophenoxy)-N-[3-[3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=C(C=C(OCC(=O)NC23CC(C2)(C3)N2C(N(CC2)C2=CC=C(C=C2)Cl)=O)C=C1)F QVSPWYVZTUVJKA-UHFFFAOYSA-N 0.000 claims 1
- LNSLETMWEAPUKQ-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[3-(3-chlorophenyl)-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2C(N(CC2)C2=CC(=CC=C2)Cl)=O)C=C1 LNSLETMWEAPUKQ-UHFFFAOYSA-N 0.000 claims 1
- HAVKYRXFURLEIG-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[3-(4-fluorophenyl)-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2C(N(CC2)C2=CC=C(C=C2)F)=O)C=C1 HAVKYRXFURLEIG-UHFFFAOYSA-N 0.000 claims 1
- PGGWCXFKVRPFHI-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[3-(4-methoxyphenyl)-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2C(N(CC2)C2=CC=C(C=C2)OC)=O)C=C1 PGGWCXFKVRPFHI-UHFFFAOYSA-N 0.000 claims 1
- DYDVECDMYHATQI-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[3-(4-methylsulfanylphenyl)-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2C(N(CC2)C2=CC=C(C=C2)SC)=O)C=C1 DYDVECDMYHATQI-UHFFFAOYSA-N 0.000 claims 1
- YAAGCKFQXHPMIT-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[3-(5-chloropyridin-2-yl)-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2C(N(CC2)C2=NC=C(C=C2)Cl)=O)C=C1 YAAGCKFQXHPMIT-UHFFFAOYSA-N 0.000 claims 1
- LXGKBHYLLBUAOJ-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[3-[4-chloro-3-(trifluoromethyl)phenyl]-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=C(C=C(C=C1)N1C(N(CC1)C12CC(C1)(C2)NC(COC1=CC=C(C=C1)Cl)=O)=O)C(F)(F)F LXGKBHYLLBUAOJ-UHFFFAOYSA-N 0.000 claims 1
- DEEVAGFARXMIAA-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[3-[4-fluoro-3-(trifluoromethyl)phenyl]-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N2C(N(CC2)C2=CC(=C(C=C2)F)C(F)(F)F)=O)C=C1 DEEVAGFARXMIAA-UHFFFAOYSA-N 0.000 claims 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 1
- 208000006402 Ductal Carcinoma Diseases 0.000 claims 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 1
- 208000000265 Lobular Carcinoma Diseases 0.000 claims 1
- GWXYBXFIGYCQND-UHFFFAOYSA-N N-[3-[3-(3-bicyclo[4.2.0]octa-1(6),2,4-trienyloxy)pyrrolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]-2-(4-chlorophenoxy)acetamide Chemical compound C12=CC(=CC=C2CC1)OC1CN(CC1)C12CC(C1)(C2)NC(COC1=CC=C(C=C1)Cl)=O GWXYBXFIGYCQND-UHFFFAOYSA-N 0.000 claims 1
- AEKBETWRWYLZRP-UHFFFAOYSA-N N-[3-[3-(4-chloro-2-fluorophenyl)-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]-2-(4-chlorophenoxy)acetamide Chemical compound ClC1=CC(=C(C=C1)N1C(N(CC1)C12CC(C1)(C2)NC(COC1=CC=C(C=C1)Cl)=O)=O)F AEKBETWRWYLZRP-UHFFFAOYSA-N 0.000 claims 1
- HJMRVLCJWBGZAE-UHFFFAOYSA-N N-[3-[3-(4-chloro-2-methylphenyl)-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]-2-(4-chlorophenoxy)acetamide Chemical compound ClC1=CC(=C(C=C1)N1C(N(CC1)C12CC(C1)(C2)NC(COC1=CC=C(C=C1)Cl)=O)=O)C HJMRVLCJWBGZAE-UHFFFAOYSA-N 0.000 claims 1
- QFKYLZMGGQSYNA-UHFFFAOYSA-N N-[3-[3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]-2-(4-fluorophenoxy)acetamide Chemical compound ClC1=CC=C(C=C1)N1C(N(CC1)C12CC(C1)(C2)NC(COC1=CC=C(C=C1)F)=O)=O QFKYLZMGGQSYNA-UHFFFAOYSA-N 0.000 claims 1
- JYCVSFKOBLBAKC-UHFFFAOYSA-N N-[3-[3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]-2-(4-methoxyphenoxy)acetamide Chemical compound ClC1=CC=C(C=C1)N1C(N(CC1)C12CC(C1)(C2)NC(COC1=CC=C(C=C1)OC)=O)=O JYCVSFKOBLBAKC-UHFFFAOYSA-N 0.000 claims 1
- PNSJUPXNFFWESB-UHFFFAOYSA-N N-[3-[3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]-2-(5-chloropyridin-2-yl)oxyacetamide Chemical compound ClC1=CC=C(C=C1)N1C(N(CC1)C12CC(C1)(C2)NC(COC1=NC=C(C=C1)Cl)=O)=O PNSJUPXNFFWESB-UHFFFAOYSA-N 0.000 claims 1
- AHWJYKCPPVAOMR-UHFFFAOYSA-N N-[3-[3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]-2-[4-(trifluoromethoxy)phenoxy]acetamide Chemical compound ClC1=CC=C(C=C1)N1C(N(CC1)C12CC(C1)(C2)NC(COC1=CC=C(C=C1)OC(F)(F)F)=O)=O AHWJYKCPPVAOMR-UHFFFAOYSA-N 0.000 claims 1
- FRMMOFLSNOIXBK-UHFFFAOYSA-N N-[3-[3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]-2-[4-chloro-3-(trifluoromethyl)phenoxy]acetamide Chemical compound ClC1=C(C=C(OCC(=O)NC23CC(C2)(C3)N2C(N(CC2)C2=CC=C(C=C2)Cl)=O)C=C1)C(F)(F)F FRMMOFLSNOIXBK-UHFFFAOYSA-N 0.000 claims 1
- DJBHMLKLDJQPDF-UHFFFAOYSA-N N-[3-[3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]-2-[4-fluoro-3-(trifluoromethyl)phenoxy]acetamide Chemical compound ClC1=CC=C(C=C1)N1C(N(CC1)C12CC(C1)(C2)NC(COC1=CC(=C(C=C1)F)C(F)(F)F)=O)=O DJBHMLKLDJQPDF-UHFFFAOYSA-N 0.000 claims 1
- LDIZNNYMXQYEFE-UHFFFAOYSA-N N-[3-[[2-(4-chlorophenoxy)acetyl]amino]-1-bicyclo[1.1.1]pentanyl]-2-(4-chlorophenyl)cyclopropane-1-carboxamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)NC(=O)C2C(C2)C2=CC=C(C=C2)Cl)C=C1 LDIZNNYMXQYEFE-UHFFFAOYSA-N 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 claims 1
- 208000003849 large cell carcinoma Diseases 0.000 claims 1
- LDJDHSINBFNMFS-UHFFFAOYSA-N n-[2,4-dimethoxy-5-[(2-piperidin-1-ylphenyl)methylsulfamoyl]phenyl]acetamide Chemical compound C1=C(NC(C)=O)C(OC)=CC(OC)=C1S(=O)(=O)NCC1=CC=CC=C1N1CCCCC1 LDJDHSINBFNMFS-UHFFFAOYSA-N 0.000 claims 1
- 229960000639 pazopanib Drugs 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 abstract description 9
- 150000001924 cycloalkanes Chemical class 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 222
- 235000002639 sodium chloride Nutrition 0.000 description 177
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 124
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 111
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 97
- 239000011541 reaction mixture Substances 0.000 description 96
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 93
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
- 239000000243 solution Substances 0.000 description 81
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 70
- 238000005160 1H NMR spectroscopy Methods 0.000 description 68
- 230000002829 reductive effect Effects 0.000 description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
- 239000007787 solid Substances 0.000 description 53
- 208000027866 inflammatory disease Diseases 0.000 description 51
- 239000012043 crude product Substances 0.000 description 46
- 239000000047 product Substances 0.000 description 46
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 43
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 42
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 41
- 239000000203 mixture Substances 0.000 description 40
- 229940093499 ethyl acetate Drugs 0.000 description 37
- 235000019439 ethyl acetate Nutrition 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 34
- 238000004809 thin layer chromatography Methods 0.000 description 32
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 28
- 125000000217 alkyl group Chemical group 0.000 description 28
- 229940086542 triethylamine Drugs 0.000 description 27
- 239000007858 starting material Substances 0.000 description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- 125000002947 alkylene group Chemical group 0.000 description 23
- 238000003756 stirring Methods 0.000 description 22
- 238000003818 flash chromatography Methods 0.000 description 21
- 208000015122 neurodegenerative disease Diseases 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 20
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 19
- 208000034800 Leukoencephalopathies Diseases 0.000 description 18
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 18
- 239000013058 crude material Substances 0.000 description 18
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 229910052757 nitrogen Inorganic materials 0.000 description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- 235000011152 sodium sulphate Nutrition 0.000 description 17
- 230000004906 unfolded protein response Effects 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 239000007832 Na2SO4 Substances 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 230000014616 translation Effects 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000012267 brine Substances 0.000 description 15
- 239000000284 extract Substances 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 108010074708 B7-H1 Antigen Proteins 0.000 description 14
- 201000006347 Intellectual Disability Diseases 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- 206010003591 Ataxia Diseases 0.000 description 13
- 102100034174 Eukaryotic translation initiation factor 2-alpha kinase 3 Human genes 0.000 description 13
- 108091008010 PERKs Proteins 0.000 description 13
- 210000003169 central nervous system Anatomy 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 13
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 12
- 125000005842 heteroatom Chemical group 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
- 230000035882 stress Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 239000013543 active substance Substances 0.000 description 11
- 125000004429 atom Chemical group 0.000 description 11
- 239000003480 eluent Substances 0.000 description 11
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 10
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 10
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 10
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 9
- 229960003301 nivolumab Drugs 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 101100072149 Drosophila melanogaster eIF2alpha gene Proteins 0.000 description 8
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 102000048362 human PDCD1 Human genes 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 description 6
- PXPYVCQPSLACQC-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[2-(4-chlorophenoxy)ethylamino]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound Clc1ccc(OCCNC23CC(C2)(C3)NC(=O)COc2ccc(Cl)cc2)cc1 PXPYVCQPSLACQC-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 6
- 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 229940124060 PD-1 antagonist Drugs 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000007787 long-term memory Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- WDWZFRPJPZEOBM-UHFFFAOYSA-N tert-butyl n-(1-amino-3-bicyclo[1.1.1]pentanyl)carbamate Chemical compound C1C2(N)CC1(NC(=O)OC(C)(C)C)C2 WDWZFRPJPZEOBM-UHFFFAOYSA-N 0.000 description 6
- 150000003527 tetrahydropyrans Chemical group 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 208000009935 visceral pain Diseases 0.000 description 6
- RHLHDNNWVXMDAF-UHFFFAOYSA-N 2-(4-chlorophenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(Cl)C=C1 RHLHDNNWVXMDAF-UHFFFAOYSA-N 0.000 description 5
- AOPRXJXHLWYPQR-UHFFFAOYSA-N 2-phenoxyacetamide Chemical compound NC(=O)COC1=CC=CC=C1 AOPRXJXHLWYPQR-UHFFFAOYSA-N 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 5
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 5
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 5
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 125000004474 heteroalkylene group Chemical group 0.000 description 5
- 102000048776 human CD274 Human genes 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 230000015654 memory Effects 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 229960002621 pembrolizumab Drugs 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- QIIWEJDTZBWCFT-UHFFFAOYSA-N tert-butyl N-[3-(2-chloroethylcarbamoylamino)-1-bicyclo[1.1.1]pentanyl]carbamate Chemical compound ClCCNC(NC12CC(C1)(C2)NC(OC(C)(C)C)=O)=O QIIWEJDTZBWCFT-UHFFFAOYSA-N 0.000 description 5
- INMWGFPOKUDLGQ-UHFFFAOYSA-N tert-butyl N-[3-(2-oxoimidazolidin-1-yl)-1-bicyclo[1.1.1]pentanyl]carbamate Chemical compound O=C1N(CCN1)C12CC(C1)(C2)NC(OC(C)(C)C)=O INMWGFPOKUDLGQ-UHFFFAOYSA-N 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- CXNVOWPRHWWCQR-UHFFFAOYSA-N 4-Chloro-ortho-toluidine Chemical compound CC1=CC(Cl)=CC=C1N CXNVOWPRHWWCQR-UHFFFAOYSA-N 0.000 description 4
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- ZJKAVQHEMKGINE-UHFFFAOYSA-N N-[3-[2-(4-chloroanilino)ethylamino]-1-bicyclo[1.1.1]pentanyl]-2-(4-chlorophenoxy)acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)NCCNC2=CC=C(C=C2)Cl)C=C1 ZJKAVQHEMKGINE-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 230000001120 cytoprotective effect Effects 0.000 description 4
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- OHCZGDRUZXZWTR-UHFFFAOYSA-N n-(2-bromoethyl)-4-chloroaniline Chemical compound ClC1=CC=C(NCCBr)C=C1 OHCZGDRUZXZWTR-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012746 preparative thin layer chromatography Methods 0.000 description 4
- 230000012846 protein folding Effects 0.000 description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 4
- 210000002955 secretory cell Anatomy 0.000 description 4
- 230000014621 translational initiation Effects 0.000 description 4
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 4
- BCMYXYHEMGPZJN-UHFFFAOYSA-N 1-chloro-2-isocyanatoethane Chemical compound ClCCN=C=O BCMYXYHEMGPZJN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 3
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 description 3
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 3
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- LBZWAZRHOPVPHB-UHFFFAOYSA-N bicyclo[1.1.1]pentane-1,3-diamine;dihydrochloride Chemical compound Cl.Cl.C1C2(N)CC1(N)C2 LBZWAZRHOPVPHB-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229950009791 durvalumab Drugs 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 150000003278 haem Chemical class 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 230000002584 immunomodulator Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229960005386 ipilimumab Drugs 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000004644 retinal vein occlusion Diseases 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 108020005087 unfolded proteins Proteins 0.000 description 3
- YYFLBDSMQRWARK-UHFFFAOYSA-N 1-(2-bromoethoxy)-4-chlorobenzene Chemical compound ClC1=CC=C(OCCBr)C=C1 YYFLBDSMQRWARK-UHFFFAOYSA-N 0.000 description 2
- GWQSENYKCGJTRI-UHFFFAOYSA-N 1-chloro-4-iodobenzene Chemical compound ClC1=CC=C(I)C=C1 GWQSENYKCGJTRI-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- VOUKRQSNMGCRSB-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[2-(4-chlorophenoxy)ethyl-methylamino]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N(C)CCOC2=CC=C(C=C2)Cl)C=C1 VOUKRQSNMGCRSB-UHFFFAOYSA-N 0.000 description 2
- OSTOVIUFSAPTTF-UHFFFAOYSA-N 2-(4-chlorophenoxy)cyclopropane-1-carbonitrile Chemical compound ClC1=CC=C(OC2C(C2)C#N)C=C1 OSTOVIUFSAPTTF-UHFFFAOYSA-N 0.000 description 2
- DCFMKPYJCWBOML-UHFFFAOYSA-N 2-(4-chlorophenoxy)cyclopropane-1-carboxylic acid Chemical compound ClC1=CC=C(OC2C(C2)C(=O)O)C=C1 DCFMKPYJCWBOML-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- DFVMBWYINWAWBX-UHFFFAOYSA-N 2-[4-chloro-3-(trifluoromethyl)phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C(C(F)(F)F)=C1 DFVMBWYINWAWBX-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- KQAMRIFINQHOCC-UHFFFAOYSA-N 3-[3-(4-chlorophenoxy)pyrrolidin-1-yl]bicyclo[1.1.1]pentan-1-amine Chemical compound ClC1=CC=C(OC2CN(CC2)C23CC(C2)(C3)N)C=C1 KQAMRIFINQHOCC-UHFFFAOYSA-N 0.000 description 2
- SWNVKTNAJRNZOV-UHFFFAOYSA-N 4-chloro-n-(2-chloroethyl)-2-methylaniline Chemical compound CC1=CC(Cl)=CC=C1NCCCl SWNVKTNAJRNZOV-UHFFFAOYSA-N 0.000 description 2
- MUDSDYNRBDKLGK-UHFFFAOYSA-N 4-methylquinoline Chemical compound C1=CC=C2C(C)=CC=NC2=C1 MUDSDYNRBDKLGK-UHFFFAOYSA-N 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LUVROFZCUXHUPV-UHFFFAOYSA-N ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)NC(CC2=CC=C(C=C2)Cl)=O)C=C1 Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)NC(CC2=CC=C(C=C2)Cl)=O)C=C1 LUVROFZCUXHUPV-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100030013 Endoribonuclease Human genes 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 2
- 101000905751 Homo sapiens Cyclic AMP-dependent transcription factor ATF-6 alpha Proteins 0.000 description 2
- 101001010783 Homo sapiens Endoribonuclease Proteins 0.000 description 2
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000026301 Postoperative Cognitive Complications Diseases 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 229910007161 Si(CH3)3 Inorganic materials 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- ITLJQGKTDSBQBF-UHFFFAOYSA-N azetidin-3-one 2,2,2-trifluoroacetic acid Chemical compound O=C1CNC1.OC(=O)C(F)(F)F ITLJQGKTDSBQBF-UHFFFAOYSA-N 0.000 description 2
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- FGNLEIGUMSBZQP-UHFFFAOYSA-N cadaverine dihydrochloride Chemical compound Cl.Cl.NCCCCCN FGNLEIGUMSBZQP-UHFFFAOYSA-N 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229950000206 estolate Drugs 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000037417 hyperactivation Effects 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- OSGZHKYFZSNKRI-UHFFFAOYSA-N methyl 2-(4-chlorophenoxy)acetate Chemical compound COC(=O)COC1=CC=C(Cl)C=C1 OSGZHKYFZSNKRI-UHFFFAOYSA-N 0.000 description 2
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 2
- WEQLOSDZTMOREZ-UHFFFAOYSA-N methyl 4-bromo-2-(4-chlorophenoxy)butanoate Chemical compound BrCCC(C(=O)OC)OC1=CC=C(C=C1)Cl WEQLOSDZTMOREZ-UHFFFAOYSA-N 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000009117 preventive therapy Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- LMSBTVJTPJXRKI-UHFFFAOYSA-N tert-butyl N-[3-[2-(4-chloro-2-methylanilino)ethylamino]-1-bicyclo[1.1.1]pentanyl]carbamate Chemical compound ClC1=CC(=C(C=C1)NCCNC12CC(C1)(C2)NC(OC(C)(C)C)=O)C LMSBTVJTPJXRKI-UHFFFAOYSA-N 0.000 description 2
- QZQBYNZIBGIMCZ-UHFFFAOYSA-N tert-butyl N-[3-[2-(4-chloroanilino)ethylamino]-1-bicyclo[1.1.1]pentanyl]carbamate Chemical compound ClC1=CC=C(C=C1)NCCNC12CC(C1)(C2)NC(OC(C)(C)C)=O QZQBYNZIBGIMCZ-UHFFFAOYSA-N 0.000 description 2
- HHDZAQAMJSNIKT-UHFFFAOYSA-N tert-butyl N-[3-[3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl]-1-bicyclo[1.1.1]pentanyl]carbamate Chemical compound ClC1=CC=C(OC2C(N(CC2)C23CC(C2)(C3)NC(OC(C)(C)C)=O)=O)C=C1 HHDZAQAMJSNIKT-UHFFFAOYSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 229940055760 yervoy Drugs 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
- KFHQOZXAFUKFNB-UHFFFAOYSA-N 1,3-oxathiolanyl Chemical group [CH]1OCCS1 KFHQOZXAFUKFNB-UHFFFAOYSA-N 0.000 description 1
- FZTLLUYFWAOGGB-UHFFFAOYSA-N 1,4-dioxane dioxane Chemical compound C1COCCO1.C1COCCO1 FZTLLUYFWAOGGB-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- YIOPFUAZBFCVTA-UHFFFAOYSA-N 1-(4-chlorophenyl)azetidin-3-one Chemical compound ClC1=CC=C(C=C1)N1CC(C1)=O YIOPFUAZBFCVTA-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- FPNVMCMDWZNTEU-UHFFFAOYSA-N 1-bromo-4-chloro-2-fluorobenzene Chemical compound FC1=CC(Cl)=CC=C1Br FPNVMCMDWZNTEU-UHFFFAOYSA-N 0.000 description 1
- ZJLUXBWDBMMBMZ-UHFFFAOYSA-N 1-bromocyclopropane-1-carbonitrile Chemical compound N#CC1(Br)CC1 ZJLUXBWDBMMBMZ-UHFFFAOYSA-N 0.000 description 1
- HXBOFIGSLNDZRW-UHFFFAOYSA-N 1-chloro-4-cyclopropylbenzene Chemical compound C1=CC(Cl)=CC=C1C1CC1 HXBOFIGSLNDZRW-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- YREROAPXUOXCGI-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O.OC(=O)C1=CC(O)=CC=C1O YREROAPXUOXCGI-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- MJANPPVGNVZMAI-UHFFFAOYSA-N 2-(4-chloro-3-fluorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C(F)=C1 MJANPPVGNVZMAI-UHFFFAOYSA-N 0.000 description 1
- TVKINFRBVCEZBE-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[2-(4-chlorophenoxy)ethyl-(oxetan-3-yl)amino]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N(C2COC2)CCOC2=CC=C(C=C2)Cl)C=C1 TVKINFRBVCEZBE-UHFFFAOYSA-N 0.000 description 1
- OPNGJQLKLARJEC-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[[2-(5-chloropyridin-2-yl)oxyacetyl]amino]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)NC(COC2=NC=C(C=C2)Cl)=O)C=C1 OPNGJQLKLARJEC-UHFFFAOYSA-N 0.000 description 1
- LYKDBMBFNTXKNB-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[[2-(6-chloropyridin-3-yl)oxyacetyl]amino]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)NC(COC=2C=NC(=CC=2)Cl)=O)C=C1 LYKDBMBFNTXKNB-UHFFFAOYSA-N 0.000 description 1
- IUDWXPQNXJLBOW-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[3-[[2-(6-methylpyridin-3-yl)oxyacetyl]amino]-1-bicyclo[1.1.1]pentanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)NC(COC=2C=NC(=CC=2)C)=O)C=C1 IUDWXPQNXJLBOW-UHFFFAOYSA-N 0.000 description 1
- HZNXJTPHASRDNR-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[4-[[2-(6-chloropyridin-3-yl)oxyacetyl]amino]-1-bicyclo[2.2.2]octanyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CCC(CC2)(CC3)NC(COC=2C=NC(=CC=2)Cl)=O)C=C1 HZNXJTPHASRDNR-UHFFFAOYSA-N 0.000 description 1
- JZYXJKBNUJJIKU-UHFFFAOYSA-N 2-(4-chlorophenyl)cyclopropane-1-carboxylic acid Chemical compound OC(=O)C1CC1C1=CC=C(Cl)C=C1 JZYXJKBNUJJIKU-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
- XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical class N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- ROADCYAOHVSOLQ-UHFFFAOYSA-N 3-oxetanone Chemical compound O=C1COC1 ROADCYAOHVSOLQ-UHFFFAOYSA-N 0.000 description 1
- GWRSATNRNFYMDI-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound FC=1C=C(NC=2N=C3N(C4CCCC4)CC(F)(F)C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)NC1CCN(C)CC1 GWRSATNRNFYMDI-UHFFFAOYSA-N 0.000 description 1
- QCXJEYYXVJIFCE-UHFFFAOYSA-M 4-acetamidobenzoate Chemical compound CC(=O)NC1=CC=C(C([O-])=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-M 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-M 4-aminobenzenesulfonate Chemical compound NC1=CC=C(S([O-])(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-M 0.000 description 1
- NSMZCUAVEOTJDS-UHFFFAOYSA-N 4-chloro-2-methyl-1-nitrobenzene Chemical compound CC1=CC(Cl)=CC=C1[N+]([O-])=O NSMZCUAVEOTJDS-UHFFFAOYSA-N 0.000 description 1
- ZLFPIEUWXNRPNM-UHFFFAOYSA-N 4-chloro-3-(trifluoromethyl)phenol Chemical compound OC1=CC=C(Cl)C(C(F)(F)F)=C1 ZLFPIEUWXNRPNM-UHFFFAOYSA-N 0.000 description 1
- GJXMHRZHQZBWTB-UHFFFAOYSA-N 4-chloro-N-[3-[[2-(4-chlorophenoxy)acetyl]amino]-1-bicyclo[1.1.1]pentanyl]benzamide Chemical compound ClC1=CC=C(C(=O)NC23CC(C2)(C3)NC(COC2=CC=C(C=C2)Cl)=O)C=C1 GJXMHRZHQZBWTB-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- CDPKJZJVTHSESZ-UHFFFAOYSA-N 4-chlorophenylacetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C=C1 CDPKJZJVTHSESZ-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010004663 Biliary colic Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010005063 Bladder pain Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000023373 Crohn ileitis Diseases 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 102100023583 Cyclic AMP-dependent transcription factor ATF-6 alpha Human genes 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 230000006782 ER associated degradation Effects 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102100038045 Eukaryotic translation initiation factor 2A Human genes 0.000 description 1
- 101710092068 Eukaryotic translation initiation factor 2A Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 1
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 208000003084 Graves Ophthalmopathy Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 101100407305 Homo sapiens CD274 gene Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101100407307 Homo sapiens PDCD1LG2 gene Proteins 0.000 description 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- YDQJXVYGARVLRT-UHFFFAOYSA-N Lepidine Natural products C=1C=CC(CC=2NC=CN=2)=CC=1OC=1C(OC)=CC=CC=1CC1=NC=CN1 YDQJXVYGARVLRT-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 206010065433 Ligament rupture Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- HIQRTIOPZLWVMT-UHFFFAOYSA-N N-[3-[[2-(4-chlorophenoxy)acetyl]amino]-1-bicyclo[1.1.1]pentanyl]-2-(4-methylphenoxy)acetamide Chemical compound Cc1ccc(OCC(=O)NC23CC(C2)(C3)NC(=O)COc2ccc(Cl)cc2)cc1 HIQRTIOPZLWVMT-UHFFFAOYSA-N 0.000 description 1
- BFMOCVRMOYIOTN-UHFFFAOYSA-N N-[3-[[2-(4-chlorophenoxy)acetyl]amino]-1-bicyclo[1.1.1]pentanyl]-2-phenoxyacetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)NC(COC2=CC=CC=C2)=O)C=C1 BFMOCVRMOYIOTN-UHFFFAOYSA-N 0.000 description 1
- WRLAJZYXVQAVJB-UHFFFAOYSA-N N-[3-[acetyl-[2-(4-chlorophenoxy)ethyl]amino]-1-bicyclo[1.1.1]pentanyl]-2-(4-chlorophenoxy)acetamide Chemical compound ClC1=CC=C(OCC(=O)NC23CC(C2)(C3)N(C(C)=O)CCOC2=CC=C(C=C2)Cl)C=C1 WRLAJZYXVQAVJB-UHFFFAOYSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229940123090 PERK inhibitor Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035623 Pleuritic pain Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 208000014675 Prion-associated disease Diseases 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 101100501245 Pythium oligandrum POD-1 gene Proteins 0.000 description 1
- 206010038490 Renal pain Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000032430 Retinal dystrophy Diseases 0.000 description 1
- 208000014139 Retinal vascular disease Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 102100033121 Transcription factor 21 Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 229940124674 VEGF-R inhibitor Drugs 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 102000008165 X-Box Binding Protein 1 Human genes 0.000 description 1
- 108010035430 X-Box Binding Protein 1 Proteins 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- CKFLEUNRYMZPCG-UHFFFAOYSA-N bicyclo[2.2.2]octane-1,4-diamine;dihydrochloride Chemical compound Cl.Cl.C1CC2(N)CCC1(N)CC2 CKFLEUNRYMZPCG-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 1
- 201000010983 breast ductal carcinoma Diseases 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 230000009222 cellular stress response pathway Effects 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- CJXAEXPPLWQRFR-UHFFFAOYSA-N clemizole Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2N=C1CN1CCCC1 CJXAEXPPLWQRFR-UHFFFAOYSA-N 0.000 description 1
- 229950002020 clemizole Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 206010011005 corneal dystrophy Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 208000018180 degenerative disc disease Diseases 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012972 dimethylethanolamine Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 208000011325 dry age related macular degeneration Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000463 effect on translation Effects 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- JZNKBFXRNBAMEK-UHFFFAOYSA-N ethyl 2-[4-chloro-3-(trifluoromethyl)phenoxy]acetate Chemical compound CCOC(=O)COC1=CC=C(Cl)C(C(F)(F)F)=C1 JZNKBFXRNBAMEK-UHFFFAOYSA-N 0.000 description 1
- XBPOBCXHALHJFP-UHFFFAOYSA-N ethyl 4-bromobutanoate Chemical compound CCOC(=O)CCCBr XBPOBCXHALHJFP-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 210000004265 eukaryotic small ribosome subunit Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000043321 human CTLA4 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000005056 memory consolidation Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- DQHIGEQXJBMKKY-UHFFFAOYSA-N methyl 2,4-dibromobutanoate Chemical compound COC(=O)C(Br)CCBr DQHIGEQXJBMKKY-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XTEGVFVZDVNBPF-UHFFFAOYSA-L naphthalene-1,5-disulfonate(2-) Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1S([O-])(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-L 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 235000021231 nutrient uptake Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 230000008789 oxidative DNA damage Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000034223 susceptibility to 2 systemic lupus erythematosus Diseases 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000007645 synaptic failure Effects 0.000 description 1
- 230000007617 synaptic impairment Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- VMKIXWAFFVLJCK-UHFFFAOYSA-N tert-butyl 3-oxoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=O)C1 VMKIXWAFFVLJCK-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 208000002271 trichotillomania Diseases 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000013414 tumor xenograft model Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229940075466 undecylenate Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/06—One of the condensed rings being a six-membered aromatic ring the other ring being four-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/40—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing six carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/44—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epoxy Compounds (AREA)
- Pyridine Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (IIIQ): wherein X6', a, b, C8', D8', L82', L83', R81', R82', R83', R84', R85', R86', z82', z84', z85', and z86' are as defined herein; or salts thereof. The compounds of the invention are inhibitors of the ATF4 pathway. Accordingly, invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
Description
FIELD OF THE INVENTION
The present invention relates to substituted bridged cycloalkane derivatives that are inhibitors of the ATF4 pathway. The present invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of diseases/injuries associated with activated unfolded protein response pathways, such as cancer, pre-cancerous syndromes, Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, neurological disorders, pain, arrhythmias, in organ transplantation and in the transportation of organs for transplantation.
BACKGROUND OF THE INVENTION
In metazoa, diverse stress signals converge at a single phosphorylation event at serine 51 of a common effector, the translation initiation factor elF2a. This step is carried out by four elF2a kinases in mammalian cells:
PERK, which responds to an accumulation of unfolded proteins in the endoplasmic reticulum (ER), GCN2 to amino acid starvation and UV light, PKR to viral infection, and HRI to heme deficiency. This collection of signaling pathways has been termed the "integrated stress response" (ISR), as they converge on the same molecular event. elF2a phosphorylation results in an attenuation of translation with consequences that allow cells to cope with the varied stresses (1).
elF2 (which is comprised of three subunits, a, 13, and y) binds GTP and the initiator Met-tRNA to form the ternary complex (elF2-GTP-Met-tRNAi), which, in tum, associates with the 40S ribosomal subunit scanning the 5'UTR ofmRNAs to select the initiating AUG codon. Upon phosphorylation of its a-subunit, elF2 becomes a competitive inhibitor of its GTP-exchange factor (GEF), elF2B (2). The tight and nonproductive binding of phosphorylated elF2 to elF2B prevents loading of the elF2 complex with GTP
thus blocking ternary complex formation and reducing translation initiation (3). Because elF2B is less abundant than elF2, phosphorylation of only a small fraction of the total elF2 has a dramatic impact on elF2B activity in cells.
Paradoxically, under conditions of reduced protein synthesis, a small group of mRNAs that contain upstream open reading frames (uORFs) in their 5'UTR are translationally up-regulated (4,5). These include mammalian ATF4 (a cAMP
element binding (CREB) transcription factor) and CHOP (a pro-apoptotic transcription factor) (6-8). ATF4 regulates the expression of many genes involved in metabolism and nutrient uptake and additional transcription factors, such as CHOP, which is under both translational and transcriptional control (9). Phosphorylation of elF2a thus leads to preferential translation of key regulatory molecules and directs diverse changes in the transcriptome of cells upon cellular stress.
One of the elF2a kinases, PERK, lies at the intersection of the ISR and the unfolded protein response (UPR) that maintains homeostasis of protein folding rates in the ER (10). The UPR is activated by unfolded or misfolded proteins that accumulate in the ER lumen because of an imbalance between protein folding load and protein folding capacity, a condition known as "ER stress". In mammals, the UPR is comprised of three signaling branches mediated by ER- localized transmembrane sensors, PERK, IRE1, and ATF6. These sensor proteins detect the accumulation of unfolded protein in the ER and transmit the information across the ER membrane, initiating unique signaling pathways that converge in the activation of an extensive transcriptional response, which ultimately results in ER expansion (11). The lumenal stress-sensing domains of PERK and are homologous and likely activated in analogous ways by direct binding to unfolded peptides (12). This binding event leads to oligomerization and trans-autophosphorylation of their cytosolic kinase domains, and, for PERK, phosphorylation of its only known substrate, elF2a. In this way, PERK activation results in a quick reduction in the load of newly synthesized proteins that are translocated into the ER-lumen (13).
Upon ER stress, both the transcription factor XBP 1 s, produced as the consequence of a non-conventional mRNA splicing reaction initiated by IRE1, and the transcription factor ATF6, produced by proteolysis and release from the ER
membrane, collaborate with ATF4 to induce the vast UPR transcriptional response.
Transcriptional targets of the UPR include the ER protein folding machinery, the ER-associated degradation machinery, and many other components functioning in the secretory pathway (14). Although the UPR initially mitigates ER stress and as such confers cytoprotection, persistent and severe ER stress leads to activation of apoptosis that eliminates damaged cells (15,16).
The present invention relates to substituted bridged cycloalkane derivatives that are inhibitors of the ATF4 pathway. The present invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of diseases/injuries associated with activated unfolded protein response pathways, such as cancer, pre-cancerous syndromes, Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, neurological disorders, pain, arrhythmias, in organ transplantation and in the transportation of organs for transplantation.
BACKGROUND OF THE INVENTION
In metazoa, diverse stress signals converge at a single phosphorylation event at serine 51 of a common effector, the translation initiation factor elF2a. This step is carried out by four elF2a kinases in mammalian cells:
PERK, which responds to an accumulation of unfolded proteins in the endoplasmic reticulum (ER), GCN2 to amino acid starvation and UV light, PKR to viral infection, and HRI to heme deficiency. This collection of signaling pathways has been termed the "integrated stress response" (ISR), as they converge on the same molecular event. elF2a phosphorylation results in an attenuation of translation with consequences that allow cells to cope with the varied stresses (1).
elF2 (which is comprised of three subunits, a, 13, and y) binds GTP and the initiator Met-tRNA to form the ternary complex (elF2-GTP-Met-tRNAi), which, in tum, associates with the 40S ribosomal subunit scanning the 5'UTR ofmRNAs to select the initiating AUG codon. Upon phosphorylation of its a-subunit, elF2 becomes a competitive inhibitor of its GTP-exchange factor (GEF), elF2B (2). The tight and nonproductive binding of phosphorylated elF2 to elF2B prevents loading of the elF2 complex with GTP
thus blocking ternary complex formation and reducing translation initiation (3). Because elF2B is less abundant than elF2, phosphorylation of only a small fraction of the total elF2 has a dramatic impact on elF2B activity in cells.
Paradoxically, under conditions of reduced protein synthesis, a small group of mRNAs that contain upstream open reading frames (uORFs) in their 5'UTR are translationally up-regulated (4,5). These include mammalian ATF4 (a cAMP
element binding (CREB) transcription factor) and CHOP (a pro-apoptotic transcription factor) (6-8). ATF4 regulates the expression of many genes involved in metabolism and nutrient uptake and additional transcription factors, such as CHOP, which is under both translational and transcriptional control (9). Phosphorylation of elF2a thus leads to preferential translation of key regulatory molecules and directs diverse changes in the transcriptome of cells upon cellular stress.
One of the elF2a kinases, PERK, lies at the intersection of the ISR and the unfolded protein response (UPR) that maintains homeostasis of protein folding rates in the ER (10). The UPR is activated by unfolded or misfolded proteins that accumulate in the ER lumen because of an imbalance between protein folding load and protein folding capacity, a condition known as "ER stress". In mammals, the UPR is comprised of three signaling branches mediated by ER- localized transmembrane sensors, PERK, IRE1, and ATF6. These sensor proteins detect the accumulation of unfolded protein in the ER and transmit the information across the ER membrane, initiating unique signaling pathways that converge in the activation of an extensive transcriptional response, which ultimately results in ER expansion (11). The lumenal stress-sensing domains of PERK and are homologous and likely activated in analogous ways by direct binding to unfolded peptides (12). This binding event leads to oligomerization and trans-autophosphorylation of their cytosolic kinase domains, and, for PERK, phosphorylation of its only known substrate, elF2a. In this way, PERK activation results in a quick reduction in the load of newly synthesized proteins that are translocated into the ER-lumen (13).
Upon ER stress, both the transcription factor XBP 1 s, produced as the consequence of a non-conventional mRNA splicing reaction initiated by IRE1, and the transcription factor ATF6, produced by proteolysis and release from the ER
membrane, collaborate with ATF4 to induce the vast UPR transcriptional response.
Transcriptional targets of the UPR include the ER protein folding machinery, the ER-associated degradation machinery, and many other components functioning in the secretory pathway (14). Although the UPR initially mitigates ER stress and as such confers cytoprotection, persistent and severe ER stress leads to activation of apoptosis that eliminates damaged cells (15,16).
- 2 -
3 PCT/IN2018/050375 Small-molecule therapeutics that inhibit the UPR and/or the Integrated Stress Response could be used in cancer as a single agent or in combination with other chemotherapeutics ( 1 7, 1 8, 1 9 ) , for enhancement of long-term memory (24,25), in neurodegenerative and prion associated diseases (20), in white matter disease (VWM) (23) and in biotechnology applications that would benefit from increased protein translation.
It is an object of the instant invention to provide novel compounds that prevent the translation of ATF4 or are inhibitors of the ATF4 pathway.
It is also an object of the present invention to provide pharmaceutical compositions that comprise a pharmaceutically acceptable excipient and compounds of Formula (1110).
It is also an object of the present invention to provide a method for treating neurodegenerative diseases, cancer, and other diseases/injuries associated with activated unfolded protein response pathways such as: Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, atherosclerosis, ocular diseases, neurological disorders, pain, arrhythmias, in organ transplantation and in the transportation of organs for transplantation that comprises administering novel inhibitors of the ATF4 pathway.
SUMMARY OF THE INVENTION
The invention is directed to substituted bridged cycloalkane derivatives.
Specifically, the invention is directed to compounds according to Formula 1110:
(R86)z86' i a N (J*L),, 0 3 , 84 X6 :181 , LV R83 N
C8 z82\ 'b (R88)z85 R82 (1110) wherein X6', a, b, 08', D8', L82', L83', R81', R82', R83', R84', R85', R86', z82', z84, z85, and z86' are as defined below; or a salt thereof including a pharmaceutically acceptable salt thereof.
The present invention also relates to the discovery that the compounds of Formula (1110) are active as inhibitors of the ATF4 pathway.
The present invention also relates to the discovery that the compounds of Formula (1110) prevent the translation of ATF4.
This invention also relates to a method of treating Alzheimer's disease, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating Parkinson's disease, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating amyotrophic lateral sclerosis, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating Huntington's disease, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating Creutzfeldt-Jakob Disease, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
It is an object of the instant invention to provide novel compounds that prevent the translation of ATF4 or are inhibitors of the ATF4 pathway.
It is also an object of the present invention to provide pharmaceutical compositions that comprise a pharmaceutically acceptable excipient and compounds of Formula (1110).
It is also an object of the present invention to provide a method for treating neurodegenerative diseases, cancer, and other diseases/injuries associated with activated unfolded protein response pathways such as: Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, atherosclerosis, ocular diseases, neurological disorders, pain, arrhythmias, in organ transplantation and in the transportation of organs for transplantation that comprises administering novel inhibitors of the ATF4 pathway.
SUMMARY OF THE INVENTION
The invention is directed to substituted bridged cycloalkane derivatives.
Specifically, the invention is directed to compounds according to Formula 1110:
(R86)z86' i a N (J*L),, 0 3 , 84 X6 :181 , LV R83 N
C8 z82\ 'b (R88)z85 R82 (1110) wherein X6', a, b, 08', D8', L82', L83', R81', R82', R83', R84', R85', R86', z82', z84, z85, and z86' are as defined below; or a salt thereof including a pharmaceutically acceptable salt thereof.
The present invention also relates to the discovery that the compounds of Formula (1110) are active as inhibitors of the ATF4 pathway.
The present invention also relates to the discovery that the compounds of Formula (1110) prevent the translation of ATF4.
This invention also relates to a method of treating Alzheimer's disease, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating Parkinson's disease, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating amyotrophic lateral sclerosis, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating Huntington's disease, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating Creutzfeldt-Jakob Disease, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
- 4 -This invention also relates to a method of treating progressive supranuclear palsy (PSP), which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating dementia, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating spinal cord injury, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating traumatic brain injury, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating ischemic stroke, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating diabetes, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating a disease state selected from:
myocardial infarction, cardiovascular disease, atherosclerosis, ocular diseases, and arrhythmias, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating an integrated stress response-associated disease in a patient in need of such treatment, which comprises administering a therapeutically effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof, to the patient.
This invention also relates to a method of treating a disease associated with phosphorylation of elF2a in a patient in need of such treatment, which comprises
This invention also relates to a method of treating dementia, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating spinal cord injury, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating traumatic brain injury, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating ischemic stroke, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating diabetes, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating a disease state selected from:
myocardial infarction, cardiovascular disease, atherosclerosis, ocular diseases, and arrhythmias, which comprises administering to a human in need thereof an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
This invention also relates to a method of treating an integrated stress response-associated disease in a patient in need of such treatment, which comprises administering a therapeutically effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof, to the patient.
This invention also relates to a method of treating a disease associated with phosphorylation of elF2a in a patient in need of such treatment, which comprises
- 5 -administering a therapeutically effective amount of a compound of Formula (1110), or a pharmaceutically acceptable salt thereof, to the patient.
This invention also relates to a method of treating a disease in a patient in need of such treatment, which comprises administering a therapeutically effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof, to the patient, wherein the disease is selected from the group consisting of cancer, a neurodegenerative disease, vanishing white matter disease, childhood ataxia with CNS
hypomyelination, and an intellectual disability syndrome.
This invention also relates to a method of improving long-term memory in a patient, which comprises administering a therapeutically effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof, to the patient.
This invention also relates to a method of increasing protein expression of a cell or in vitro expression system, which comprises administering an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof, to the cell or expression system.
This invention also relates to a method of treating an inflammatory disease in a patient in need of such treatment, which comprises administering a therapeutically effective amount of a compound of Formula (1110), or a pharmaceutically acceptable salt thereof, to the patient.
This invention also relates to a method of using the compounds of Formula (1110) in organ transplantation and in the transportation of organs for transplantation.
Also included in the present invention are methods of co-administering the presently invented compounds with further active ingredients.
Included in the present invention is a method for treating neurodegenerative diseases, cancer, and other diseases/injuries associated with activated unfolded protein response pathways, such as: Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and
This invention also relates to a method of treating a disease in a patient in need of such treatment, which comprises administering a therapeutically effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof, to the patient, wherein the disease is selected from the group consisting of cancer, a neurodegenerative disease, vanishing white matter disease, childhood ataxia with CNS
hypomyelination, and an intellectual disability syndrome.
This invention also relates to a method of improving long-term memory in a patient, which comprises administering a therapeutically effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof, to the patient.
This invention also relates to a method of increasing protein expression of a cell or in vitro expression system, which comprises administering an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof, to the cell or expression system.
This invention also relates to a method of treating an inflammatory disease in a patient in need of such treatment, which comprises administering a therapeutically effective amount of a compound of Formula (1110), or a pharmaceutically acceptable salt thereof, to the patient.
This invention also relates to a method of using the compounds of Formula (1110) in organ transplantation and in the transportation of organs for transplantation.
Also included in the present invention are methods of co-administering the presently invented compounds with further active ingredients.
Included in the present invention is a method for treating neurodegenerative diseases, cancer, and other diseases/injuries associated with activated unfolded protein response pathways, such as: Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and
- 6 -acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation that comprises administering the compounds of Formula (1110).
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in therapy.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of Alzheimer's disease.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of Parkinson's disease syndromes.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of amyotrophic lateral sclerosis.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of Huntington's disease.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of Creutzfeldt-Jakob Disease.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of progressive supranuclear palsy (PSP).
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of dementia.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of spinal cord injury.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of traumatic brain injury.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of ischemic stroke.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in therapy.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of Alzheimer's disease.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of Parkinson's disease syndromes.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of amyotrophic lateral sclerosis.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of Huntington's disease.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of Creutzfeldt-Jakob Disease.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of progressive supranuclear palsy (PSP).
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of dementia.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of spinal cord injury.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of traumatic brain injury.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of ischemic stroke.
- 7 -The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of diabetes.
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of a disease state selected from:
myocardial infarction, cardiovascular disease, atherosclerosis, ocular diseases, and arrhythmias.
The invention also relates to the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of an integrated stress response-associated disease.
The invention also relates to the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease associated with phosphorylation of elF2a.
The invention also relates to the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease selected from the group consisting of: cancer, a neurodegenerative disease, vanishing white matter disease, childhood ataxia with CNS
hypomyelination, and an intellectual disability syndrome.
The invention also relates to the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for improving long-term memory.
The invention also relates to the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for increasing protein expression of a cell or in vitro expression system.
The invention also relates to the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of inflammatory disease.
The invention also relates to the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament in organ
The invention also relates to a compound of Formula (1110) or a pharmaceutically acceptable salt thereof for use in the treatment of a disease state selected from:
myocardial infarction, cardiovascular disease, atherosclerosis, ocular diseases, and arrhythmias.
The invention also relates to the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of an integrated stress response-associated disease.
The invention also relates to the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease associated with phosphorylation of elF2a.
The invention also relates to the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease selected from the group consisting of: cancer, a neurodegenerative disease, vanishing white matter disease, childhood ataxia with CNS
hypomyelination, and an intellectual disability syndrome.
The invention also relates to the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for improving long-term memory.
The invention also relates to the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for increasing protein expression of a cell or in vitro expression system.
The invention also relates to the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of inflammatory disease.
The invention also relates to the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament in organ
- 8 -transplantation and in the transportation of organs for transplantation.
The invention also relates to the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease state selected from: neurodegenerative diseases, cancer, and other diseases/injuries associated with activated unfolded protein response pathways such as:
Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, atherosclerosis, ocular diseases, neurological disorders, pain, arrhythmias, in organ transplantation and in the transportation of organs for transplantation.
Included in the present invention are pharmaceutical compositions that comprise a pharmaceutical excipient and a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
The invention also relates to a pharmaceutical composition as defined above for use in therapy.
The invention also relates to a combination for use in therapy which comprises a therapeutically effective amount of (i) a compound of Formula (1110) or a pharmaceutically acceptable salt thereof; and (ii) further active ingredients.
DETAILED DESCRIPTION OF THE INVENTION
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (I):
;
__________________________________________________________ (R Z6 a HNt4õL3 vzHN
( =2 1-1 z5 R2 (I)
The invention also relates to the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease state selected from: neurodegenerative diseases, cancer, and other diseases/injuries associated with activated unfolded protein response pathways such as:
Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, atherosclerosis, ocular diseases, neurological disorders, pain, arrhythmias, in organ transplantation and in the transportation of organs for transplantation.
Included in the present invention are pharmaceutical compositions that comprise a pharmaceutical excipient and a compound of Formula (1110) or a pharmaceutically acceptable salt thereof.
The invention also relates to a pharmaceutical composition as defined above for use in therapy.
The invention also relates to a combination for use in therapy which comprises a therapeutically effective amount of (i) a compound of Formula (1110) or a pharmaceutically acceptable salt thereof; and (ii) further active ingredients.
DETAILED DESCRIPTION OF THE INVENTION
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (I):
;
__________________________________________________________ (R Z6 a HNt4õL3 vzHN
( =2 1-1 z5 R2 (I)
- 9 -wherein:
L2 and L3 are independently a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, substituted or unsubstituted Ci _6alkylene or substituted or unsubstituted Ci _6heteroalkylene;
R5 and R6 are each independently hydrogen, fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -0(0)Ph, -CH3, -CF3, -ON, -S(0)0H3, -OH, -NH2, -000H, -CONH2, -NO2, -0(0)0H3, -CH(0H3)2, -OOH, -CH200H, -S03H, -SO2NH2, ¨NHC(0)NH2, -NHC(0)H, -NHOH, -00F3, -OCHF2, substituted or unsubstituted C1_6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2 and R4 are independently NO, 0, 0H2, or S;
R8 is selected from: hydrogen, Ci _6alkyl and Ci -6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
C and D are independently phenyl or pyridine;
X is 01_3a1ky1ene or 01_3a1ky1ene substituted 1 to 3 times by fluoro;
Z2 and z4 are independently 0 or 1; and Z5 and z6 are independently an integer from 0 to 5;
and salts thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (I).
L2 and L3 are independently a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, substituted or unsubstituted Ci _6alkylene or substituted or unsubstituted Ci _6heteroalkylene;
R5 and R6 are each independently hydrogen, fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -0(0)Ph, -CH3, -CF3, -ON, -S(0)0H3, -OH, -NH2, -000H, -CONH2, -NO2, -0(0)0H3, -CH(0H3)2, -OOH, -CH200H, -S03H, -SO2NH2, ¨NHC(0)NH2, -NHC(0)H, -NHOH, -00F3, -OCHF2, substituted or unsubstituted C1_6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2 and R4 are independently NO, 0, 0H2, or S;
R8 is selected from: hydrogen, Ci _6alkyl and Ci -6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
C and D are independently phenyl or pyridine;
X is 01_3a1ky1ene or 01_3a1ky1ene substituted 1 to 3 times by fluoro;
Z2 and z4 are independently 0 or 1; and Z5 and z6 are independently an integer from 0 to 5;
and salts thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (I).
- 10 -Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (II):
(R16)z16 al ;.=[) 13 HN \ 14L
bl (R15115 0 1-412 Ri2 (II) wherein:
L12 and L13 are independently: -CH2-0-, -0-CH2-, -0-CH2-CH2-, and -CH2-CH2-0-;
R15 and R16 are independently hydrogen or chloro;
R12 and R14 are 0;
a and b are independently 0 or 1;
C and D are independently phenyl or pyridine;
X1 is selected from -CH2- and -CH2-CH2-;
z12 and z14 are independently 0 or 1; and z15 and z16 are independently an integer from 0 to 5;
and salts thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (II).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (III):
(R16)z16 al ;.=[) 13 HN \ 14L
bl (R15115 0 1-412 Ri2 (II) wherein:
L12 and L13 are independently: -CH2-0-, -0-CH2-, -0-CH2-CH2-, and -CH2-CH2-0-;
R15 and R16 are independently hydrogen or chloro;
R12 and R14 are 0;
a and b are independently 0 or 1;
C and D are independently phenyl or pyridine;
X1 is selected from -CH2- and -CH2-CH2-;
z12 and z14 are independently 0 or 1; and z15 and z16 are independently an integer from 0 to 5;
and salts thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (II).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (III):
- 11 -D _______________________________________________________ (R6) z6 a Nji)L3 L*N
b (R5)Z5 .
R2z2 \ R3 (Ill) wherein:
L2 is selected from: a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, substituted or unsubstituted Ci_6alkylene or substituted or unsubstituted Ci_6heteroalkylene, or L2 is further taken together with R3 to form heterocycloalkyl;
L3 is selected from: a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, substituted or unsubstituted Ci_6alkylene or substituted or unsubstituted Ci_6heteroalkylene, or L3 is further taken together with R1 to form heterocycloalkyl;
R1 is selected from: hydrogen, Ci_6alkyl, substituted Ci_6alkyl, heterocycloalkyl, or R1 is taken together with L3 to form heterocycloalkyl;
R3 is selected from: hydrogen, Ci_6alkyl, substituted Ci_6alkyl, heterocycloalkyl, or R3 is taken together with L2 to form heterocycloalkyl;
R5 and R6 are each independently hydrogen, fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(0)Ph, -CH3, -CF3, -ON, -S(0)CH3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(0)CH3, -CH(CH3)2, -CECH, -CH2CECH, -S03H, -SO2NH2, -NHC(0)NH2, -NHC(0)H, -NHOH, -0CF3, -OCHF2, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,
b (R5)Z5 .
R2z2 \ R3 (Ill) wherein:
L2 is selected from: a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, substituted or unsubstituted Ci_6alkylene or substituted or unsubstituted Ci_6heteroalkylene, or L2 is further taken together with R3 to form heterocycloalkyl;
L3 is selected from: a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, substituted or unsubstituted Ci_6alkylene or substituted or unsubstituted Ci_6heteroalkylene, or L3 is further taken together with R1 to form heterocycloalkyl;
R1 is selected from: hydrogen, Ci_6alkyl, substituted Ci_6alkyl, heterocycloalkyl, or R1 is taken together with L3 to form heterocycloalkyl;
R3 is selected from: hydrogen, Ci_6alkyl, substituted Ci_6alkyl, heterocycloalkyl, or R3 is taken together with L2 to form heterocycloalkyl;
R5 and R6 are each independently hydrogen, fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(0)Ph, -CH3, -CF3, -ON, -S(0)CH3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(0)CH3, -CH(CH3)2, -CECH, -CH2CECH, -S03H, -SO2NH2, -NHC(0)NH2, -NHC(0)H, -NHOH, -0CF3, -OCHF2, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,
- 12 -substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2 and R4 are independently NO, 0, CH2, or S;
R8 is selected from: hydrogen, Ci _6alkyl and C1_6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
C and D are independently phenyl or pyridyl;
X is 01_3a1ky1ene or 01_3a1ky1ene substituted 1 to 3 times by fluoro;
z2 and z4 are independently 0 or 1; and z5 and z6 are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (III).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (IV):
a1 13) __ 1-D-D (D16) ,õ
" z ' (it) L -1,1,, N 1 13 b z12\ 11 R
(IR 1 5)1 5 41 (IV) wherein:
L12 is selected from: a bond, -0H2-, -NH-, 0H2-0-, -0-0H2-, -0-0H2-0H2-, and -0H2-0H2-0-, or L12 is further taken together with R11
R2 and R4 are independently NO, 0, CH2, or S;
R8 is selected from: hydrogen, Ci _6alkyl and C1_6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
C and D are independently phenyl or pyridyl;
X is 01_3a1ky1ene or 01_3a1ky1ene substituted 1 to 3 times by fluoro;
z2 and z4 are independently 0 or 1; and z5 and z6 are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (III).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (IV):
a1 13) __ 1-D-D (D16) ,õ
" z ' (it) L -1,1,, N 1 13 b z12\ 11 R
(IR 1 5)1 5 41 (IV) wherein:
L12 is selected from: a bond, -0H2-, -NH-, 0H2-0-, -0-0H2-, -0-0H2-0H2-, and -0H2-0H2-0-, or L12 is further taken together with R11
- 13 -to form imidazolidinyl;
L13 is selected from: a bond, -CH2-, -NH-, CH2-0-, -0-CH2-, -0-CH2-CH2-, and -CH2-CH2-0-, or L13 is further taken together with F113 to form imidazolidinyl;
R11 is selected from: hydrogen, Ci_6alkyl, substituted Ci_6alkyl, oxetanyl, or 1 is taken together with L12 to form imidazolidinyl;
F113 is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, oxetanyl, or F113 is taken together with L13 to form imidazolidinyl;
F115 and F116 are independently hydrogen, methyl, or chloro;
F112 and R14 are 0;
1 1 .
a and b are independently 0 or 1;
C i and D are ndependently phenyl or pyridyl;
X1 is selected from -CH2- and -CH2-CH2-;
Z12 and z14 are independently 0 or 1; and Z15 and z16 are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (IV).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (IIIX):
L13 is selected from: a bond, -CH2-, -NH-, CH2-0-, -0-CH2-, -0-CH2-CH2-, and -CH2-CH2-0-, or L13 is further taken together with F113 to form imidazolidinyl;
R11 is selected from: hydrogen, Ci_6alkyl, substituted Ci_6alkyl, oxetanyl, or 1 is taken together with L12 to form imidazolidinyl;
F113 is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, oxetanyl, or F113 is taken together with L13 to form imidazolidinyl;
F115 and F116 are independently hydrogen, methyl, or chloro;
F112 and R14 are 0;
1 1 .
a and b are independently 0 or 1;
C i and D are ndependently phenyl or pyridyl;
X1 is selected from -CH2- and -CH2-CH2-;
Z12 and z14 are independently 0 or 1; and Z15 and z16 are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (IV).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (IIIX):
- 14 -II) (R26)z26 a N(L 3 LlIvN
b z22 \ R23 (R25)Z25= R22 (IIIX) wherein:
L22 is selected from: a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, substituted or unsubstituted Ci_6alkylene and substituted or unsubstituted Ci_6heteroalkylene, or L22 is taken together with R23 to form heterocycloalkyl;
L23 and R21 are taken together to form heterocycloalkyl;
R23 is selected from: hydrogen, Ci_6alkyl, substituted Ci_6alkyl, heterocycloalkyl, or R23 is taken together with L22 to form heterocycloalkyl;
R25 and R26 are each independently hydrogen, fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(0)Ph, -CH3, -CF3, -ON, -S(0)CH3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(0)CH3, -CH(CH3)2, -CECH, -CH2CECH, -S03H, -SO2NH2, -NHC(0)NH2, -NHC(0)H, -NHOH, -0CF3, -OCHF2, substituted or unsubstituted C1_6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R22 and R24 are independently NR28, 0, CH2, or S;
R28 is selected from: hydrogen, C1_6alkyl and C1-6alkyl substituted -I to 6 times by
b z22 \ R23 (R25)Z25= R22 (IIIX) wherein:
L22 is selected from: a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, substituted or unsubstituted Ci_6alkylene and substituted or unsubstituted Ci_6heteroalkylene, or L22 is taken together with R23 to form heterocycloalkyl;
L23 and R21 are taken together to form heterocycloalkyl;
R23 is selected from: hydrogen, Ci_6alkyl, substituted Ci_6alkyl, heterocycloalkyl, or R23 is taken together with L22 to form heterocycloalkyl;
R25 and R26 are each independently hydrogen, fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(0)Ph, -CH3, -CF3, -ON, -S(0)CH3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(0)CH3, -CH(CH3)2, -CECH, -CH2CECH, -S03H, -SO2NH2, -NHC(0)NH2, -NHC(0)H, -NHOH, -0CF3, -OCHF2, substituted or unsubstituted C1_6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R22 and R24 are independently NR28, 0, CH2, or S;
R28 is selected from: hydrogen, C1_6alkyl and C1-6alkyl substituted -I to 6 times by
- 15 -fluoro;
a and b are independently 0 or 1;
02 and D2 are independently phenyl or pyridyl;
X2 is C-1 -3a1ky1ene or Ci_3alkylene substituted 1 to 3 times by fluoro;
z22 and z24 are independently 0 or 1; and z25 and z26 are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (IIIX).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (IVX):
(R36)z36 a 3 \ 34 ={31 LV N
b z32 \ R33 ( R35) z3541111 R32 (IVX) wherein:
L32 is selected from: a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, substituted or unsubstituted Ci _6alkylene and substituted or unsubstituted Ci_6heteroalkylene;
L33 taken together with R31 to form heterocycloalkyl;
R33 is selected from: hydrogen, Ci _6alkyl, substituted C1_6alkyl, and heterocycloalkyl;
R35 and R36 are each independently hydrogen, fluoro, chloro, bromo, iodo,
a and b are independently 0 or 1;
02 and D2 are independently phenyl or pyridyl;
X2 is C-1 -3a1ky1ene or Ci_3alkylene substituted 1 to 3 times by fluoro;
z22 and z24 are independently 0 or 1; and z25 and z26 are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (IIIX).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (IVX):
(R36)z36 a 3 \ 34 ={31 LV N
b z32 \ R33 ( R35) z3541111 R32 (IVX) wherein:
L32 is selected from: a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, substituted or unsubstituted Ci _6alkylene and substituted or unsubstituted Ci_6heteroalkylene;
L33 taken together with R31 to form heterocycloalkyl;
R33 is selected from: hydrogen, Ci _6alkyl, substituted C1_6alkyl, and heterocycloalkyl;
R35 and R36 are each independently hydrogen, fluoro, chloro, bromo, iodo,
- 16 --OCH3, -OCH2Ph, -C(0)Ph, -CH3, -CF3, -ON, -S(0)CH3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(0)0H3, -CH(0H3)2, -CECH, -CH2CECH, -S03H, -SO2NH2, -NHC(0)NH2, -NHC(0)H, -NHOH, -00F3, -OCHF2, substituted or unsubstituted 01_6a1ky1, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R32 and R34 are independently NR38, 0, 0H2, or S;
R38 is selected from: hydrogen, Ci _6alkyl and C1-6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
C3 and D3 are independently phenyl or pyridyl;
X3 is 01_3alkylene or 01_3alkylene substituted 1 to 3 times by fluoro;
z32 and z34 are independently 0 or 1; and z35 and z38 are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (IVX).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VX):
R32 and R34 are independently NR38, 0, 0H2, or S;
R38 is selected from: hydrogen, Ci _6alkyl and C1-6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
C3 and D3 are independently phenyl or pyridyl;
X3 is 01_3alkylene or 01_3alkylene substituted 1 to 3 times by fluoro;
z32 and z34 are independently 0 or 1; and z35 and z38 are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (IVX).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VX):
- 17 -D4 (D46) , ___________________________________________________________ " Zgo a Nj.t)\ L43 L.11,12 N
b C4 z42 \ 41 R
(R45145 (VX) wherein:
L42 is selected from: a bond, -CH2-, -NH-, CH2-O-, -0-CH2-, -0-CH2-CH2-, and -CH2-CH2-O-, or L42 is taken together with R41 to form imidazolidinyl or pyrrolidinyl;
L43 is taken together with R43 to form imidazolidinyl or pyrrolidinyl;
R41 is selected from: hydrogen, Ci _6alkyl, substituted C1_6alkyl, and oxetanyl, or R41 is taken together with L42 to form imidazolidinyl or pyrrolidinyl;
R45 and R46 are independently hydrogen, methyl, or chloro;
R42 and R44 are 0;
a and b are independently 0 or 1;
C4 and D4 are independently phenyl or pyridyl;
X4 is selected from -CH2- and -CH2-CH2-;
Z42 and z44 are independently 0 or 1; and Z45 and z46 are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VX).
b C4 z42 \ 41 R
(R45145 (VX) wherein:
L42 is selected from: a bond, -CH2-, -NH-, CH2-O-, -0-CH2-, -0-CH2-CH2-, and -CH2-CH2-O-, or L42 is taken together with R41 to form imidazolidinyl or pyrrolidinyl;
L43 is taken together with R43 to form imidazolidinyl or pyrrolidinyl;
R41 is selected from: hydrogen, Ci _6alkyl, substituted C1_6alkyl, and oxetanyl, or R41 is taken together with L42 to form imidazolidinyl or pyrrolidinyl;
R45 and R46 are independently hydrogen, methyl, or chloro;
R42 and R44 are 0;
a and b are independently 0 or 1;
C4 and D4 are independently phenyl or pyridyl;
X4 is selected from -CH2- and -CH2-CH2-;
Z42 and z44 are independently 0 or 1; and Z45 and z46 are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VX).
- 18 -Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VIX):
N 54L53 13 (R56)z56 :153 LVN
b z52\R51 (1:155155 411i) R52 (VIX) wherein:
L52 is selected from: a bond, -CH2-, -NH-, CH2-0-, -0-CH2-, -0-CH2-CH2-, and -CH2-CH2-0-;
L53 is taken together with R53 to form imidazolidinyl or pyrrolidinyl;
R51 is selected from: hydrogen, Ci _6alkyl, substituted C1_6alkyl, and oxetanyl;
R55 and R56 are independently hydrogen, methyl, or chloro;
R52 and R54 are 0;
a and b are independently 0 or 1;
C5 and D5 are independently phenyl or pyridyl;
X5 is selected from -CH2- and -CH2-CH2-;
Z52 and z54 are independently 0 or 1; and Z55 and z56 are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VIX).
N 54L53 13 (R56)z56 :153 LVN
b z52\R51 (1:155155 411i) R52 (VIX) wherein:
L52 is selected from: a bond, -CH2-, -NH-, CH2-0-, -0-CH2-, -0-CH2-CH2-, and -CH2-CH2-0-;
L53 is taken together with R53 to form imidazolidinyl or pyrrolidinyl;
R51 is selected from: hydrogen, Ci _6alkyl, substituted C1_6alkyl, and oxetanyl;
R55 and R56 are independently hydrogen, methyl, or chloro;
R52 and R54 are 0;
a and b are independently 0 or 1;
C5 and D5 are independently phenyl or pyridyl;
X5 is selected from -CH2- and -CH2-CH2-;
Z52 and z54 are independently 0 or 1; and Z55 and z56 are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VIX).
- 19 -Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VIIX):
D6 (R66)z66 N 21 \14L63 if7X Rt L6 ,*N 63 ( C6 z62 \ 61 (VIIX) wherein:
L62 is selected from: a bond, -CH2-, -NH-, CH2-0-, -0-CH2-, -0-CH2-CH2-, and -CH2-CH2-0-, or L62 is taken together with R61 to form imidazolidinyl or pyrrolidinyl;
L63 is taken together with R63 to form imidazolidinyl or pyrrolidinyl;
R61 is selected from: hydrogen, Ci _6alkyl, substituted C1_6alkyl, and oxetanyl, or R61 is taken together with L62 to form imidazolidinyl or pyrrolidinyl;
R66 and R66 are independently hydrogen, methyl, or chloro;
R62 and R64 are 0;
C6 and D6 are independently phenyl or pyridyl;
Z62 and z64 are independently 0 or 1; and Z66 and z66 are independently an integer from 0 to 3;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VIIX).
D6 (R66)z66 N 21 \14L63 if7X Rt L6 ,*N 63 ( C6 z62 \ 61 (VIIX) wherein:
L62 is selected from: a bond, -CH2-, -NH-, CH2-0-, -0-CH2-, -0-CH2-CH2-, and -CH2-CH2-0-, or L62 is taken together with R61 to form imidazolidinyl or pyrrolidinyl;
L63 is taken together with R63 to form imidazolidinyl or pyrrolidinyl;
R61 is selected from: hydrogen, Ci _6alkyl, substituted C1_6alkyl, and oxetanyl, or R61 is taken together with L62 to form imidazolidinyl or pyrrolidinyl;
R66 and R66 are independently hydrogen, methyl, or chloro;
R62 and R64 are 0;
C6 and D6 are independently phenyl or pyridyl;
Z62 and z64 are independently 0 or 1; and Z66 and z66 are independently an integer from 0 to 3;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VIIX).
- 20 -Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VIIIX):
D7 _________________________________________________________ (R76) N (1) L73 1_7N
z72 \R71 (R75175 4111 R72 (VIIIX) wherein:
L72 is selected from: a bond, -CH2-, -NH-, CH2-0-, -0-CH2-, -0-CH2-CH2-, and -CH2-CH2-0-;
L73 is taken together with R73 to form imidazolidinyl or pyrrolidinyl;
R71 is selected from: hydrogen, Ci _6alkyl, substituted C1_6alkyl, and oxetanyl;
R75 and R76 are independently hydrogen, methyl, or chloro;
R72 and R74 are 0;
C7 and D7 are independently phenyl or pyridyl;
Z72 and z74 are independently 0 or 1; and Z75 and z76 are independently an integer from 0 to 3;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VIIIX).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (IIIZ):
D7 _________________________________________________________ (R76) N (1) L73 1_7N
z72 \R71 (R75175 4111 R72 (VIIIX) wherein:
L72 is selected from: a bond, -CH2-, -NH-, CH2-0-, -0-CH2-, -0-CH2-CH2-, and -CH2-CH2-0-;
L73 is taken together with R73 to form imidazolidinyl or pyrrolidinyl;
R71 is selected from: hydrogen, Ci _6alkyl, substituted C1_6alkyl, and oxetanyl;
R75 and R76 are independently hydrogen, methyl, or chloro;
R72 and R74 are 0;
C7 and D7 are independently phenyl or pyridyl;
Z72 and z74 are independently 0 or 1; and Z75 and z76 are independently an integer from 0 to 3;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VIIIX).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (IIIZ):
- 21 -R84 is.1:!:(R86)z86 a N21 41L 3 \ 8 X6 h81 C8 z82 \ R83 (R85)z85 R82 (IIIZ) wherein:
L82 is selected from: a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, cycloalkyl, -0-cycloalkyl, cycloalkyl-0-, -NH- cycloalkyl, cycloalkyl-NH-, azetidinyl, -0-azetidinyl, azetidinyl-0-, -N-azetidinyl, azetidinyl-N-, substituted or unsubstituted C1_6alkylene and substituted or unsubstituted C1_6heteroalkylene, or L82 is taken together with R83 to form:
heterocycloalkyl, heterocycloalkyl-0-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-0-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-;
L83 is selected from: cycloalkyl, -0-cycloalkyl, cycloalkyl-0-, -NH-cycloalkyl, cycloalkyl-NH-, azetidinyl, -0-azetidinyl, azetidinyl-0-, -N-azetidinyl, azetidinyl-N-, or L83 and R81 are taken together to form: heterocycloalkyl, heterocycloalkyl-0-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-0-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-;
R81 is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and heterocycloalkyl, or R81 is taken together with L83 to form:
heterocycloalkyl, heterocycloalkyl-0-, heterocycloalkyl-NH-,
L82 is selected from: a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, cycloalkyl, -0-cycloalkyl, cycloalkyl-0-, -NH- cycloalkyl, cycloalkyl-NH-, azetidinyl, -0-azetidinyl, azetidinyl-0-, -N-azetidinyl, azetidinyl-N-, substituted or unsubstituted C1_6alkylene and substituted or unsubstituted C1_6heteroalkylene, or L82 is taken together with R83 to form:
heterocycloalkyl, heterocycloalkyl-0-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-0-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-;
L83 is selected from: cycloalkyl, -0-cycloalkyl, cycloalkyl-0-, -NH-cycloalkyl, cycloalkyl-NH-, azetidinyl, -0-azetidinyl, azetidinyl-0-, -N-azetidinyl, azetidinyl-N-, or L83 and R81 are taken together to form: heterocycloalkyl, heterocycloalkyl-0-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-0-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-;
R81 is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and heterocycloalkyl, or R81 is taken together with L83 to form:
heterocycloalkyl, heterocycloalkyl-0-, heterocycloalkyl-NH-,
- 22 -heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-;
R83 is selected from: hydrogen, Calkyl, substituted Calkyl, and heterocycloalkyl, or R83 is taken together with L82 to form: heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl- CH2-;
R85 and R86 are each independently fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(0)Ph, -CF3, -ON, -S(0)0H3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(0)0H3, -CECH, -CH2CEECH, -SCH3, -S03H, -SO2NH2, ¨NHC(0)NH2, -NHC(0)H, -NHOH, -00F3, -OCHF2, substituted or unsubstituted C1_6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R82 and R84 are independently NR88, 0, CH2, or S;
R88 is selected from: hydrogen, Ci_6alkyl and Ci-6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
08 and D8 areindependently phenyl or pyridyl;
X6 is 01_3alkylene or 01_3a1ky1ene substituted 1 to 3 times by fluoro;
Z82 and z84 are independently 0 or 1; and Z85 and z86 are independently an integer from 0 to 5;
R83 is selected from: hydrogen, Calkyl, substituted Calkyl, and heterocycloalkyl, or R83 is taken together with L82 to form: heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl- CH2-;
R85 and R86 are each independently fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(0)Ph, -CF3, -ON, -S(0)0H3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(0)0H3, -CECH, -CH2CEECH, -SCH3, -S03H, -SO2NH2, ¨NHC(0)NH2, -NHC(0)H, -NHOH, -00F3, -OCHF2, substituted or unsubstituted C1_6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R82 and R84 are independently NR88, 0, CH2, or S;
R88 is selected from: hydrogen, Ci_6alkyl and Ci-6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
08 and D8 areindependently phenyl or pyridyl;
X6 is 01_3alkylene or 01_3a1ky1ene substituted 1 to 3 times by fluoro;
Z82 and z84 are independently 0 or 1; and Z85 and z86 are independently an integer from 0 to 5;
- 23 -or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (IIIZ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (IVZ):
(R96)z96 a LZN
b C9 z92 \ R93 ( I,, R9 z95 R92 (IVZ) wherein:
L92 is selected from: a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, substituted or unsubstituted C1_6alkylene and substituted or unsubstituted Ci_6heteroalkylene;
L93 is selected from: cycloalkyl, -0-cycloalkyl, and cycloalky1-0-, azetidinyl, -0-azetidinyl, azetidiny1-0-, or L93 is taken together with R91 to form:
heterocycloalkyl, heterocycloalkyl-0-, oxoheterocycloalkyl, or oxoheterocycloalkyl-0-;
R91 is selected from: hydrogen, Ci _6alkyl, substituted C1_6alkyl, and heterocycloalkyl, or R91 is taken together with L93 to form: heterocycloalkyl, heterocycloalkyl-0-, oxoheterocycloalkyl, or oxoheterocycloalkyl-0-;
R93 is selected from: hydrogen, Ci _6alkyl, substituted C1_6alkyl, and heterocycloalkyl;
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (IIIZ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (IVZ):
(R96)z96 a LZN
b C9 z92 \ R93 ( I,, R9 z95 R92 (IVZ) wherein:
L92 is selected from: a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, substituted or unsubstituted C1_6alkylene and substituted or unsubstituted Ci_6heteroalkylene;
L93 is selected from: cycloalkyl, -0-cycloalkyl, and cycloalky1-0-, azetidinyl, -0-azetidinyl, azetidiny1-0-, or L93 is taken together with R91 to form:
heterocycloalkyl, heterocycloalkyl-0-, oxoheterocycloalkyl, or oxoheterocycloalkyl-0-;
R91 is selected from: hydrogen, Ci _6alkyl, substituted C1_6alkyl, and heterocycloalkyl, or R91 is taken together with L93 to form: heterocycloalkyl, heterocycloalkyl-0-, oxoheterocycloalkyl, or oxoheterocycloalkyl-0-;
R93 is selected from: hydrogen, Ci _6alkyl, substituted C1_6alkyl, and heterocycloalkyl;
- 24 -R95 and R96 are independently selected from: fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(0)Ph, -CF3, -ON, -S(0)0H3, -OH, -NH2, -COOH, -CONH2, -NO2, -0(0)0H3, -CECH, -CH2CECH, -SCH3, -S03H, -SO2NH2, -NHC(0)NH2, -NHC(0)H, -NHOH, -00F3, -OCHF2, substituted or unsubstituted C1_6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R92 and R94 are independently NR98, 0, or S;
R98 is selected from: hydrogen, Ci _6alkyl and C1-6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
C9 and D9 are independently phenyl or pyridyl;
X7 is 01_3alkylene or 01_3alkylene substituted 1 to 3 times by fluoro;
Z92 and z94 are independently 0 or 1; and Z95 and z96 are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (IVZ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VZ):
R92 and R94 are independently NR98, 0, or S;
R98 is selected from: hydrogen, Ci _6alkyl and C1-6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
C9 and D9 are independently phenyl or pyridyl;
X7 is 01_3alkylene or 01_3alkylene substituted 1 to 3 times by fluoro;
Z92 and z94 are independently 0 or 1; and Z95 and z96 are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (IVZ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VZ):
- 25 -R104 (-D-Z (Q10 __________________________________________________________________ "
z106 2c_ a N)")---------L103 \ z104 L102 µ N
\ /z R101 (0105) .
" z10 b5 R102 (VZ) wherein:
L102 is selected from: a bond, -CH2-, -NH-, CH2-0-, -0-CH2-, cyclopropyl, -0-cyclopropyl, cyclopropyl-0-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -0-azetidinyl, azetidinyl-0-, -N-azetidinyl, azetidinyl-N-, -0-CH2-CH2-, and -CH2-CH2-0-, or L102 is taken together with R101 to form: imidazolidinyl, azetidinyl, azetidinyl-0-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-0-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperaziny1-0-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperaziny1-0-, oxopiperazinyl-N-, oxopiperazinyl-0H2-, PYrrolidinyl, pyrrolidiny1-0-, pyrrolidinyl-N-, pyrrolidinyl-0H2-, oxopyrrolidinyl, oxopyrrolidiny1-0-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-0H2-;
L103 is selected from: cyclopropyl, azetidinyl, -0-azetidinyl, azetidinyl-0-, -N-azetidinyl, azetidinyl-N-, or L103 is taken together with R103 to form: imidazolidinyl, azetidinyl, azetidinyl-0-, azetidinyl-N-, azetidinyl-0H2-, piperidinyl, piperidinyl-0-, piperidinyl-N-, piperidinyl-0H2-,
z106 2c_ a N)")---------L103 \ z104 L102 µ N
\ /z R101 (0105) .
" z10 b5 R102 (VZ) wherein:
L102 is selected from: a bond, -CH2-, -NH-, CH2-0-, -0-CH2-, cyclopropyl, -0-cyclopropyl, cyclopropyl-0-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -0-azetidinyl, azetidinyl-0-, -N-azetidinyl, azetidinyl-N-, -0-CH2-CH2-, and -CH2-CH2-0-, or L102 is taken together with R101 to form: imidazolidinyl, azetidinyl, azetidinyl-0-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-0-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperaziny1-0-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperaziny1-0-, oxopiperazinyl-N-, oxopiperazinyl-0H2-, PYrrolidinyl, pyrrolidiny1-0-, pyrrolidinyl-N-, pyrrolidinyl-0H2-, oxopyrrolidinyl, oxopyrrolidiny1-0-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-0H2-;
L103 is selected from: cyclopropyl, azetidinyl, -0-azetidinyl, azetidinyl-0-, -N-azetidinyl, azetidinyl-N-, or L103 is taken together with R103 to form: imidazolidinyl, azetidinyl, azetidinyl-0-, azetidinyl-N-, azetidinyl-0H2-, piperidinyl, piperidinyl-0-, piperidinyl-N-, piperidinyl-0H2-,
- 26 -piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R101 is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and oxetanyl, or R101 is taken together with L102 to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R103 is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and oxetanyl, or R103 is taken together with L103 to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R101 is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and oxetanyl, or R101 is taken together with L102 to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R103 is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and oxetanyl, or R103 is taken together with L103 to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
- 27 -R105 and R106 are each independently selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -OF3;
R102 and R104 are 0;
a and b are independently 0 or 1;
5 010 and D are independently phenyl or pyridyl;
X8 is selected from -CH2- and -CH2-CH2-;
Z102 and z104 are independently 0 or 1; and Z106 and z106 are independently an integer from 0 to 5;
10 or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VZ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VIZ):
(R116 z116 ) aL113 N z114 :1 LvN
ziiXR111 (VIZ) wherein:
L112 is selected from: a bond, -0H2-, -NH-, 0H2-0-, -0-0H2-, -0-0H2-0H2-,
R102 and R104 are 0;
a and b are independently 0 or 1;
5 010 and D are independently phenyl or pyridyl;
X8 is selected from -CH2- and -CH2-CH2-;
Z102 and z104 are independently 0 or 1; and Z106 and z106 are independently an integer from 0 to 5;
10 or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VZ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VIZ):
(R116 z116 ) aL113 N z114 :1 LvN
ziiXR111 (VIZ) wherein:
L112 is selected from: a bond, -0H2-, -NH-, 0H2-0-, -0-0H2-, -0-0H2-0H2-,
- 28 -and -CH2-CH2-0-;
L113 is selected from: cyclopropyl, -0-cyclopropyl, cyclopropyl-O-, azetidinyl, -0-azetidinyl, azetidinyl-O-, or L113 is taken together with R113 to form:
imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-;
R113 is selected from: hydrogen, Ci_6alkyl, substituted Ci _6alkyl, and oxetanyl or R113 is taken together with L113 to form: imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-;
R111 is selected from: hydrogen, Ci_6alkyl, substituted Ci _6alkyl, and oxetanyl;
R115 and R116 are each independently selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -OF3;
R112 and R114 are 0;
a and b are independently 0 or 1;
C11 and D11 are independently phenyl or pyridyl;
X9 is selected from -CH2- and -CH2-CH2-;
Z112 and z114 are independently 0 or 1; and Z115 and z116 are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VIZ).
L113 is selected from: cyclopropyl, -0-cyclopropyl, cyclopropyl-O-, azetidinyl, -0-azetidinyl, azetidinyl-O-, or L113 is taken together with R113 to form:
imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-;
R113 is selected from: hydrogen, Ci_6alkyl, substituted Ci _6alkyl, and oxetanyl or R113 is taken together with L113 to form: imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-;
R111 is selected from: hydrogen, Ci_6alkyl, substituted Ci _6alkyl, and oxetanyl;
R115 and R116 are each independently selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -OF3;
R112 and R114 are 0;
a and b are independently 0 or 1;
C11 and D11 are independently phenyl or pyridyl;
X9 is selected from -CH2- and -CH2-CH2-;
Z112 and z114 are independently 0 or 1; and Z115 and z116 are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VIZ).
- 29 -Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VIIZ):
U ___________________________________________________________ (R126)z126 ) N z124 L
\R123 LlifN 0 (R125)z1 200 R122 (VIIZ) wherein:
W is selected from bicyclopentanyl and bicyclohexanyl;
L122 is selected from: a bond, -CH2-, -NH-, CH2-0-, -0-CH2-, cyclopropyl, -0-cyclopropyl, cyclopropyl-0-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -0-azetidinyl, azetidinyl-0-, -N-azetidinyl, azetidinyl-N-, -0-CH2-CH2-, and -CH2-CH2-0-, or L122 is taken together with R121 to form: imidazolidinyl, azetidinyl, azetidinyl-0-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidiny1-0-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperaziny1-0-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperaziny1-0-, oxopiperazinyl-N-, oxopiperazinyl-0H2-, PYrrolidinyl, pyrrolidiny1-0-, pyrrolidinyl-N-, pyrrolidinyl-0H2-, oxopyrrolidinyl, oxopyrrolidiny1-0-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-0H2-;
L123 is selected from: cyclopropyl, -0-cyclopropyl, cyclopropyl-0-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -0-azetidinyl, azetidinyl-0-, -N-azetidinyl, azetidinyl-N-, or L123 is taken together with R123 to form: imidazolidinyl, azetidinyl, azetidinyl-0-, azetidinyl-N-,
U ___________________________________________________________ (R126)z126 ) N z124 L
\R123 LlifN 0 (R125)z1 200 R122 (VIIZ) wherein:
W is selected from bicyclopentanyl and bicyclohexanyl;
L122 is selected from: a bond, -CH2-, -NH-, CH2-0-, -0-CH2-, cyclopropyl, -0-cyclopropyl, cyclopropyl-0-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -0-azetidinyl, azetidinyl-0-, -N-azetidinyl, azetidinyl-N-, -0-CH2-CH2-, and -CH2-CH2-0-, or L122 is taken together with R121 to form: imidazolidinyl, azetidinyl, azetidinyl-0-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidiny1-0-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperaziny1-0-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperaziny1-0-, oxopiperazinyl-N-, oxopiperazinyl-0H2-, PYrrolidinyl, pyrrolidiny1-0-, pyrrolidinyl-N-, pyrrolidinyl-0H2-, oxopyrrolidinyl, oxopyrrolidiny1-0-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-0H2-;
L123 is selected from: cyclopropyl, -0-cyclopropyl, cyclopropyl-0-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -0-azetidinyl, azetidinyl-0-, -N-azetidinyl, azetidinyl-N-, or L123 is taken together with R123 to form: imidazolidinyl, azetidinyl, azetidinyl-0-, azetidinyl-N-,
- 30 -azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R121 is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and oxetanyl, or R121 is taken together with L122 to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R123 is hydrogen or R123 is taken together with L123 to form:
imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R121 is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and oxetanyl, or R121 is taken together with L122 to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R123 is hydrogen or R123 is taken together with L123 to form:
imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
-31 -R126 and R126 are each independently selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3;
R122 and R124 are 0;
12 .
C12 and D are independently phenyl or pyridyl;
Z122 and z124 are independently 0 or 1; and Z126 and z126 are independently an integer from 0 to 3;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VIIZ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VIIIZ):
D13 (R136) z136 t-----z134L133 N;
0 1 \
L1i 133 i)NH
z132 (R135)z13 R132 (WIZ) wherein:
W1 is selected from bicyclopentanyl and bicyclohexanyl;
L132 is selected from: a bond, -CH2-, -NH-, CH2-0-, -0-CH2-, -0-CH2-CH2-, and -CH2-CH2-0-;
L133 is selected from: cyclopropyl, -0-cyclopropyl, cyclopropyl-0-, azetidinyl, -0-azetidinyl, azetidinyl-0-, or L133 is taken together with R133 to form:
imidazolidinyl, azetidinyl, azetidinyl-0-, piperidinyl, piperidiny1-0-,
R122 and R124 are 0;
12 .
C12 and D are independently phenyl or pyridyl;
Z122 and z124 are independently 0 or 1; and Z126 and z126 are independently an integer from 0 to 3;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VIIZ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VIIIZ):
D13 (R136) z136 t-----z134L133 N;
0 1 \
L1i 133 i)NH
z132 (R135)z13 R132 (WIZ) wherein:
W1 is selected from bicyclopentanyl and bicyclohexanyl;
L132 is selected from: a bond, -CH2-, -NH-, CH2-0-, -0-CH2-, -0-CH2-CH2-, and -CH2-CH2-0-;
L133 is selected from: cyclopropyl, -0-cyclopropyl, cyclopropyl-0-, azetidinyl, -0-azetidinyl, azetidinyl-0-, or L133 is taken together with R133 to form:
imidazolidinyl, azetidinyl, azetidinyl-0-, piperidinyl, piperidiny1-0-,
- 32 -piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-;
R133 is hydrogen or R133 is taken together with L133 to form:
imidazolidinyl, azetidinyl, azetidiny1-0-, piperidinyl, piperidiny1-0-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-;
R135 and R136 are each independently selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -OF3;
R132 and R134 are 0;
013 and D13 are each independently phenyl or pyridyl;
Z132 and z134 are each independently 0 or 1; and Z135 and z136 are each independently an integer from 0 to 3;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VIIIZ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (1110):
, , 1 (R86)z86.
;,)........õ , a N L:3 , LVN
b 08 z82 \R83 ' , (R85)z85 R82 (1110) wherein:
L82' is selected from: a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, cycloalkyl,
R133 is hydrogen or R133 is taken together with L133 to form:
imidazolidinyl, azetidinyl, azetidiny1-0-, piperidinyl, piperidiny1-0-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-;
R135 and R136 are each independently selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -OF3;
R132 and R134 are 0;
013 and D13 are each independently phenyl or pyridyl;
Z132 and z134 are each independently 0 or 1; and Z135 and z136 are each independently an integer from 0 to 3;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VIIIZ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (1110):
, , 1 (R86)z86.
;,)........õ , a N L:3 , LVN
b 08 z82 \R83 ' , (R85)z85 R82 (1110) wherein:
L82' is selected from: a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, cycloalkyl,
- 33 --0-cycloalkyl, cycloalkyl-O-, -NH-cycloalkyl, cycloalkyl-NH-, azetidinyl, -0-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, substituted or unsubstituted Ci_6alkylene and substituted or unsubstituted Ci_6heteroalkylene, or L82' is taken together with R83' to form:
heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-, or, L82' is taken together with an R85' substituent adjacent to the point of attachment of L82' to 08' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to 08';
L83' is selected from: cycloalkyl, -0-cycloalkyl, cycloalkyl-O-, -NH-cycloalkyl, cycloalkyl-NH-, azetidinyl, -0-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, or L83' and R81' are taken together to form: heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-, or, L83' is taken together with an R88' substituent adjacent to the point of attachment of L83' to D8' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to D8';
R81' is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and heterocycloalkyl, or R81' is taken together with L83' to form:
heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-,
heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-, or, L82' is taken together with an R85' substituent adjacent to the point of attachment of L82' to 08' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to 08';
L83' is selected from: cycloalkyl, -0-cycloalkyl, cycloalkyl-O-, -NH-cycloalkyl, cycloalkyl-NH-, azetidinyl, -0-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, or L83' and R81' are taken together to form: heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-, or, L83' is taken together with an R88' substituent adjacent to the point of attachment of L83' to D8' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to D8';
R81' is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and heterocycloalkyl, or R81' is taken together with L83' to form:
heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-,
- 34 -heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-;
R83' is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and heterocycloalkyl, or R83' is taken together with L82' to form:
heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-;
R85' is selected from: fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(0)Ph, -CF3, -ON, -S(0)0H3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(0)0H3, -CECH, -CH2CECH, -SCH3, -S03H, -SO2NH2, -NHC(0)NH2, -NHC(0)H, -NHOH, -00F3, -OCHF2, substituted or unsubstituted C1_6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or, two adjacent R85' substituents can combine to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to 08', or, an R85 substituent adjacent to the point of attachment of L82' to 08' can combine with L82' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to 08';
R86' is selected from: fluoro, chloro, bromo, iodo,
R83' is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and heterocycloalkyl, or R83' is taken together with L82' to form:
heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-;
R85' is selected from: fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(0)Ph, -CF3, -ON, -S(0)0H3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(0)0H3, -CECH, -CH2CECH, -SCH3, -S03H, -SO2NH2, -NHC(0)NH2, -NHC(0)H, -NHOH, -00F3, -OCHF2, substituted or unsubstituted C1_6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or, two adjacent R85' substituents can combine to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to 08', or, an R85 substituent adjacent to the point of attachment of L82' to 08' can combine with L82' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to 08';
R86' is selected from: fluoro, chloro, bromo, iodo,
- 35 --OCH3, -OCH2Ph, -0(0)Ph, -CF3, -ON, -S(0)CH3, -OH, -NH2, -000H, -CONH2, -NO2, -0(0)0H3, -CH2CE-CH, -SCH3, -S03H, -SO2NH2, -NHC(0)NH2, -NHC(0)H, -NHOH, -00F3, -OCHF2, substituted or unsubstituted 01_6a1ky1, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or, two adjacent R86' substituents can combine to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to D8', or, an R86' substituent adjacent to the point of attachment of L83' to 11:18 can combine with L83' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to 11:18;
R82' and R84' are independently NR88', 0, CH2, or S;
R88' is selected from: hydrogen, C1_6alkyl and C1_6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
' 08' and D8 areindependently phenyl or pyridyl;
X6 IS 01_3alkylene or 01_3alkylene substituted 1 to 3 times by fluoro;
Z82' and z84' are independently 0 or 1; and Z85' and z86' are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
R82' and R84' are independently NR88', 0, CH2, or S;
R88' is selected from: hydrogen, C1_6alkyl and C1_6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
' 08' and D8 areindependently phenyl or pyridyl;
X6 IS 01_3alkylene or 01_3alkylene substituted 1 to 3 times by fluoro;
Z82' and z84' are independently 0 or 1; and Z85' and z86' are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
- 36 -This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (IIIQ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (IVQ):
(R96)z96.
a N
I , 94 h91 , L N
V
C9 z92\ 93' R
(R95/95 R92 (IVQ) wherein:
L92' is selected from: a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, substituted or unsubstituted C1_6alkylene and substituted or unsubstituted Ci -6heteroalkylene;
L93' is selected from: cycloalkyl, -0-cycloalkyl, and cycloalkyl-0-, azetidinyl, -0-azetidinyl, azetidiny1-0-, or L93' is taken together with R91' to form:
heterocycloalkyl, heterocycloalkyl-0-, oxoheterocycloalkyl, or oxoheterocycloalkyl-0-, or, L93' is taken together with an R96' substituent adjacent to the point of attachment of L93' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring;
R91' is selected from: hydrogen, C1_6alkyl, substituted Ci _6alkyl, and heterocycloalkyl, or R91' is taken together with L93' to form:
heterocycloalkyl, heterocycloalkyl-0-, oxoheterocycloalkyl, or oxoheterocycloalkyl-0-;
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (IVQ):
(R96)z96.
a N
I , 94 h91 , L N
V
C9 z92\ 93' R
(R95/95 R92 (IVQ) wherein:
L92' is selected from: a bond, -NH-, -0-, -S-, -S(0)-, -S(0)2-, substituted or unsubstituted C1_6alkylene and substituted or unsubstituted Ci -6heteroalkylene;
L93' is selected from: cycloalkyl, -0-cycloalkyl, and cycloalkyl-0-, azetidinyl, -0-azetidinyl, azetidiny1-0-, or L93' is taken together with R91' to form:
heterocycloalkyl, heterocycloalkyl-0-, oxoheterocycloalkyl, or oxoheterocycloalkyl-0-, or, L93' is taken together with an R96' substituent adjacent to the point of attachment of L93' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring;
R91' is selected from: hydrogen, C1_6alkyl, substituted Ci _6alkyl, and heterocycloalkyl, or R91' is taken together with L93' to form:
heterocycloalkyl, heterocycloalkyl-0-, oxoheterocycloalkyl, or oxoheterocycloalkyl-0-;
- 37 -R93' is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and heterocycloalkyl;
R95' is selected from: fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(0)Ph, -CF3, -ON, -S(0)0H3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(0)0H3, -CH2CE-CH, -SCH3, -S03H, -SO2NH2, -NHC(0)NH2, -NHC(0)H, -NHOH, -00F3, -OCHF2, substituted or unsubstituted C1_6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R96' is selected from: fluoro, chloro, bromo, iodo, -00H3, -OCH2Ph, -C(0)Ph, -0F3, -ON, -S(0)0H3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(0)0H3, -CECH, -CH2CECH, -SCH3, -S03H, -SO2NH2, -NHC(0)NH2, -NHC(0)H, -NHOH, -00F3, -OCHF2, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or, two adjacent R96' substituents can combine to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to D9', or, an R96' substituent adjacent to the point of attachment of L93' to D9can combine with L93' to form a cycloalkyl ring, a heterocycloalkyl ring, or
R95' is selected from: fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(0)Ph, -CF3, -ON, -S(0)0H3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(0)0H3, -CH2CE-CH, -SCH3, -S03H, -SO2NH2, -NHC(0)NH2, -NHC(0)H, -NHOH, -00F3, -OCHF2, substituted or unsubstituted C1_6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R96' is selected from: fluoro, chloro, bromo, iodo, -00H3, -OCH2Ph, -C(0)Ph, -0F3, -ON, -S(0)0H3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(0)0H3, -CECH, -CH2CECH, -SCH3, -S03H, -SO2NH2, -NHC(0)NH2, -NHC(0)H, -NHOH, -00F3, -OCHF2, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or, two adjacent R96' substituents can combine to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to D9', or, an R96' substituent adjacent to the point of attachment of L93' to D9can combine with L93' to form a cycloalkyl ring, a heterocycloalkyl ring, or
- 38 -heteroaryl ring fused to D9';
R92' and R94' are independently NR98', 0, or S;
R98' is selected from: hydrogen, Calkyl and Ci _6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
C9' and D9' are independently phenyl or pyridyl;
XT is Ci _3alkylene or Ci_3alkylene substituted 1 to 3 times by fluoro;
Z92' and z94' are independently 0 or 1; and Z95' and z96' are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (IVQ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VQ):
R104: D10 (R1061 106' a kijj--------r-11 z104Ll 3 b N(N-102\R101.
(R1051105 (VQ) wherein:
Li 02' is selected from: a bond, -CH2-, -NH-, CH2-0-, -0-CH2-, cyclopropyl, -0-cyclopropyl, cyclopropy1-0-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -0-azetidinyl, azetidiny1-0-, -N-azetidinyl, azetidinyl-N-, -0-CH2-CH2-, and -CH2-CH2-0-, or Li 02' is taken together
R92' and R94' are independently NR98', 0, or S;
R98' is selected from: hydrogen, Calkyl and Ci _6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
C9' and D9' are independently phenyl or pyridyl;
XT is Ci _3alkylene or Ci_3alkylene substituted 1 to 3 times by fluoro;
Z92' and z94' are independently 0 or 1; and Z95' and z96' are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (IVQ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VQ):
R104: D10 (R1061 106' a kijj--------r-11 z104Ll 3 b N(N-102\R101.
(R1051105 (VQ) wherein:
Li 02' is selected from: a bond, -CH2-, -NH-, CH2-0-, -0-CH2-, cyclopropyl, -0-cyclopropyl, cyclopropy1-0-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -0-azetidinyl, azetidiny1-0-, -N-azetidinyl, azetidinyl-N-, -0-CH2-CH2-, and -CH2-CH2-0-, or Li 02' is taken together
-39-with R101' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, PYrrolidinyl, pyrrolidiny1-0-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-, or, L102' is taken together with an R105' substituent adjacent to the point of attachment of L102' to form a heterocycloalkyl ring;
L103' is selected from: cyclopropyl, -0-cyclopropyl, cyclopropy1-0-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -0-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, or L103' is taken together with R103' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, PYrrolidinyl, pyrrolidiny1-0-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-, or, L103' is taken together with an R106' substituent adjacent to the point of attachment of L103' to form a heterocycloalkyl ring;
L103' is selected from: cyclopropyl, -0-cyclopropyl, cyclopropy1-0-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -0-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, or L103' is taken together with R103' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, PYrrolidinyl, pyrrolidiny1-0-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-, or, L103' is taken together with an R106' substituent adjacent to the point of attachment of L103' to form a heterocycloalkyl ring;
-40-R101' is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and oxetanyl, or R101 is taken together with L102' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R103' is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and oxetanyl, or R103' is taken together with L103' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R105 is selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R105 substituent adjacent to the point of attachment of L102' to C can combine with L102' to form a heterocycloalkyl ring fused to 010';
R106' is selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3,
R103' is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and oxetanyl, or R103' is taken together with L103' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R105 is selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R105 substituent adjacent to the point of attachment of L102' to C can combine with L102' to form a heterocycloalkyl ring fused to 010';
R106' is selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3,
-41--OCHF2, and -CF3, or, an R106' substituent adjacent to the point of attachment of L103' to D can combine with L103' to form a heterocycloalkyl ring fused to Di Cr;
R102' and R104' are 0;
a and b are independently 0 or 1;
10' 10' C and D are independently phenyl or pyridyl;
X8' is selected from -CH2- and -0H2-0H2-;
Z102' and z104' are independently 0 or 1; and Z105 and z106' are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VQ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VIQ):
D11 ________________________________________________________ (R116 z116.
a N z114 X9' )0013' 11,Ri11.
(R115) z115 R112 (VIQ) wherein:
L112' is selected from: a bond, -0H2-, -NH-, 0H2-0-, -0-0H2-, -0-0H2-0H2-,
R102' and R104' are 0;
a and b are independently 0 or 1;
10' 10' C and D are independently phenyl or pyridyl;
X8' is selected from -CH2- and -0H2-0H2-;
Z102' and z104' are independently 0 or 1; and Z105 and z106' are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VQ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VIQ):
D11 ________________________________________________________ (R116 z116.
a N z114 X9' )0013' 11,Ri11.
(R115) z115 R112 (VIQ) wherein:
L112' is selected from: a bond, -0H2-, -NH-, 0H2-0-, -0-0H2-, -0-0H2-0H2-,
-42-and -CH2-CH2-0-;
L113' is selected from: cyclopropyl, -0-cyclopropyl, cyclopropyl-O-, azetidinyl, -0-azetidinyl, azetidinyl-O-, or L113' is taken together with R113' to form:
imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-, or, L113' is taken together with an R116' substituent adjacent to the point of attachment of L113' to form a heterocycloalkyl ring;
R1 13' is selected from: hydrogen, Ci_6alkyl, substituted Ci_6alkyl, and oxetanyl or R113' is taken together with L113' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-;
R1 1 1' is selected from: hydrogen, Ci_6alkyl, substituted Ci_6alkyl, and oxetanyl;
R115' is selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3;
R116' is selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R116' substituent adjacent to the point of attachment of L113' to D can combine with L113' to form a heterocycloalkyl ring fused to R112' and R114' are 0;
a and b are independently 0 or 1;
L113' is selected from: cyclopropyl, -0-cyclopropyl, cyclopropyl-O-, azetidinyl, -0-azetidinyl, azetidinyl-O-, or L113' is taken together with R113' to form:
imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-, or, L113' is taken together with an R116' substituent adjacent to the point of attachment of L113' to form a heterocycloalkyl ring;
R1 13' is selected from: hydrogen, Ci_6alkyl, substituted Ci_6alkyl, and oxetanyl or R113' is taken together with L113' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-;
R1 1 1' is selected from: hydrogen, Ci_6alkyl, substituted Ci_6alkyl, and oxetanyl;
R115' is selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3;
R116' is selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R116' substituent adjacent to the point of attachment of L113' to D can combine with L113' to form a heterocycloalkyl ring fused to R112' and R114' are 0;
a and b are independently 0 or 1;
-43-C11' and D11 are independently phenyl or pyridyl;
X9' is selected from -CH2- and -CH2-CH2-;
Z112' and z114' are independently 0 or 1; and Z115' and z116' are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VIQ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VIIQ):
, D12 (R126)z126' f l L123 2' 0 N µ )z124 (R125120 .
L-IiiN :1-123.
z12R121' (VIIQ) wherein:
W is selected from bicyclopentanyl and bicyclohexanyl;
L122' is selected from: a bond, -0H2-, -NH-, 0H2-0-, -0-0H2-, cyclopropyl, -0-cyclopropyl, cyclopropy1-0-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -0-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, -0-0H2-0H2-, and -0H2-0H2-0-, or L122' is taken together with R121' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-0H2-, piperidinyl, piperidiny1-0-, piperidinyl-N-, piperidinyl-0H2-, piperazinyl, piperaziny1-0-, piperazinyl-N-, piperazinyl-0H2-,
X9' is selected from -CH2- and -CH2-CH2-;
Z112' and z114' are independently 0 or 1; and Z115' and z116' are independently an integer from 0 to 5;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VIQ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VIIQ):
, D12 (R126)z126' f l L123 2' 0 N µ )z124 (R125120 .
L-IiiN :1-123.
z12R121' (VIIQ) wherein:
W is selected from bicyclopentanyl and bicyclohexanyl;
L122' is selected from: a bond, -0H2-, -NH-, 0H2-0-, -0-0H2-, cyclopropyl, -0-cyclopropyl, cyclopropy1-0-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -0-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, -0-0H2-0H2-, and -0H2-0H2-0-, or L122' is taken together with R121' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-0H2-, piperidinyl, piperidiny1-0-, piperidinyl-N-, piperidinyl-0H2-, piperazinyl, piperaziny1-0-, piperazinyl-N-, piperazinyl-0H2-,
-44 -oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, PYrrolidinyl, pyrrolidiny1-0-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-, or, L122' is taken together with an R125 substituent adjacent to the point of attachment of L122' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring;
L123' is selected from: cyclopropyl, azetidinyl, -0-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, or L123' is taken together with R123' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperaziny1-0-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, PYrrolidinyl, pyrrolidiny1-0-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-, or, L123' is taken together with an R126' substituent adjacent to the point of attachment of L123' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring;
R121' is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and oxetanyl, or R121' is taken together with L122' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-,
L123' is selected from: cyclopropyl, azetidinyl, -0-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, or L123' is taken together with R123' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperaziny1-0-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, PYrrolidinyl, pyrrolidiny1-0-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-, or, L123' is taken together with an R126' substituent adjacent to the point of attachment of L123' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring;
R121' is selected from: hydrogen, C1_6alkyl, substituted C1_6alkyl, and oxetanyl, or R121' is taken together with L122' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-,
-45-piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidiny1-0-, pyrrolidinyl-N-, PYrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R123' is hydrogen or R123' is taken together with L123' to form:
imidazolidinyl, azetidinyl, azetidiny1-0-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidiny1-0-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, PYrrolidinyl, pyrrolidiny1-0-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R125 is selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R125 substituent adjacent to the point of attachment of L122' to 012' can combine with L122' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring fused to C12';
R126' is selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or,
R123' is hydrogen or R123' is taken together with L123' to form:
imidazolidinyl, azetidinyl, azetidiny1-0-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidiny1-0-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, PYrrolidinyl, pyrrolidiny1-0-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R125 is selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R125 substituent adjacent to the point of attachment of L122' to 012' can combine with L122' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring fused to C12';
R126' is selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or,
-46-an R126' substituent adjacent to the point of attachment of L123' to D12' can combine with L123' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring fused to D12';
R122' and R124' are 0;
12' 12' C and D are independently phenyl or pyridyl;
Z122' and z124' are independently 0 or 1; and Z125' and z126' are independently an integer from 0 to 3;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VIIQ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VIIIQ):
R134 D13' __ (R136)z136' N z134L133 clo R1133' z132 (R135) GIP
(VIIIQ) wherein:
W1 is selected from bicyclopentanyl and bicyclohexanyl;
L132' is selected from: a bond, -CH2-, -NH-, 0H2-0-, -0-CH2-, -0-0H2-0H2-, and -0H2-0H2-0-;
L133' is selected from: cyclopropyl, -0-cyclopropyl, cyclopropy1-0-, azetidinyl, -0-azetidinyl, azetidiny1-0-, or L133' is taken together with R133' to form:
R122' and R124' are 0;
12' 12' C and D are independently phenyl or pyridyl;
Z122' and z124' are independently 0 or 1; and Z125' and z126' are independently an integer from 0 to 3;
or a salt thereof including a pharmaceutically acceptable salt thereof.
This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (VIIQ).
Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (VIIIQ):
R134 D13' __ (R136)z136' N z134L133 clo R1133' z132 (R135) GIP
(VIIIQ) wherein:
W1 is selected from bicyclopentanyl and bicyclohexanyl;
L132' is selected from: a bond, -CH2-, -NH-, 0H2-0-, -0-CH2-, -0-0H2-0H2-, and -0H2-0H2-0-;
L133' is selected from: cyclopropyl, -0-cyclopropyl, cyclopropy1-0-, azetidinyl, -0-azetidinyl, azetidiny1-0-, or L133' is taken together with R133' to form:
-47-imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-0-or, L1 33' is taken together with an R136' substituent adjacent to the point of attachment of L133' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring;
R133' is hydrogen or R133' is taken together with L133' to form:
imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-;
R135' is selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3;
R136' is selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R136' substituent adjacent to the point of attachment of L133' to Dia can combine with L133' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring fused to Dia;
R1 3 2' and R134' are 0;
013' and D13' are each independently phenyl or pyridyl;
Z132' and z134' are each independently 0 or 1; and Z135' and z136' are each independently an integer from 0 to 3;
or a salt thereof including a pharmaceutically acceptable salt thereof.
R133' is hydrogen or R133' is taken together with L133' to form:
imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-;
R135' is selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3;
R136' is selected from: methyl, cyclopropyl, -0CF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R136' substituent adjacent to the point of attachment of L133' to Dia can combine with L133' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring fused to Dia;
R1 3 2' and R134' are 0;
013' and D13' are each independently phenyl or pyridyl;
Z132' and z134' are each independently 0 or 1; and Z135' and z136' are each independently an integer from 0 to 3;
or a salt thereof including a pharmaceutically acceptable salt thereof.
-48-This invention also relates to pharmaceutically acceptable salts of the compounds of Formula (Villa).
Included in the compounds of the invention are:
N,N'-(bicyclo[2.2.2]octane-1 ,4-diy1)bis(2-(4-chlorophenoxy)acetamide);
2-(4-chlorophenoxy)-N-(4-(2-((6-chloropyridin-3-yl)oxy)acetamido)bicyclo[2.2.2]
octan-1-yl)acetamide;
N,N'-(bicyclo[2.2.2]octane-1 ,4-diy1)bis(2-((6-chloropyridin-3-y1)oxy)acetamide);
N,N'-(bicyclo[1 .1 .1 ]pentane-1 ,3-diy1)bis(2-(4-chlorophenoxy)acetamide);
N,N'-(bicyclo[1 .1 .1 ]pentane-1 ,3-diy1)bis(2-phenoxyacetamide);
2-(4-chlorophenoxy)-N-(3-(2-(4-chlorophenyl)acetamido)bicyclo[1 .1 .1 ]pentan-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(p-tolyloxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-((6-chloropyridin-3-yl)oxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-((6-methylpyridin-3-yl)oxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-((5-chloropyridin-2-yl)oxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-phenoxyacetamido)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
4-chloro-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yl)benzamide;
2-((3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yI)(2-(4-chlorophenoxy)ethyl)amino)-N,N-dimethylacetamide;
2-(4-chlorophenoxy)-N-(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-yl)acetamide;
N-(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-((5-chloropyridin-2-yl)oxy)acetamide;
Included in the compounds of the invention are:
N,N'-(bicyclo[2.2.2]octane-1 ,4-diy1)bis(2-(4-chlorophenoxy)acetamide);
2-(4-chlorophenoxy)-N-(4-(2-((6-chloropyridin-3-yl)oxy)acetamido)bicyclo[2.2.2]
octan-1-yl)acetamide;
N,N'-(bicyclo[2.2.2]octane-1 ,4-diy1)bis(2-((6-chloropyridin-3-y1)oxy)acetamide);
N,N'-(bicyclo[1 .1 .1 ]pentane-1 ,3-diy1)bis(2-(4-chlorophenoxy)acetamide);
N,N'-(bicyclo[1 .1 .1 ]pentane-1 ,3-diy1)bis(2-phenoxyacetamide);
2-(4-chlorophenoxy)-N-(3-(2-(4-chlorophenyl)acetamido)bicyclo[1 .1 .1 ]pentan-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(p-tolyloxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-((6-chloropyridin-3-yl)oxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-((6-methylpyridin-3-yl)oxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-((5-chloropyridin-2-yl)oxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-phenoxyacetamido)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
4-chloro-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yl)benzamide;
2-((3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yI)(2-(4-chlorophenoxy)ethyl)amino)-N,N-dimethylacetamide;
2-(4-chlorophenoxy)-N-(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-yl)acetamide;
N-(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-((5-chloropyridin-2-yl)oxy)acetamide;
-49-methyl N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yI)-N-(2-(4-chlorophenoxy)ethyl)glycinate;
ethyl 4-((3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yI)(2-(4-chlorophenoxy)ethyl)amino)butanoate;
2-(4-chlorophenoxy)-N-(3-((2-(4-chlorophenoxy)ethyl)(methyl)amino)bicyclo[1 .1 .1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(N-(2-(4-chlorophenoxy)ethyl)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-ch lorophenoxy)-N-(3-((2-(4-ch lorophenoxy)ethyl)(oxetan-3-yl)amino)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-((2-((4-chlorophenyl)amino)ethyl)amino)bicyclo[1 .1 .1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
1 -(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1 .1 .1 ]pentan-1 -yI)-3-(4-chlorophenyl)imidazolidin-2-one;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
H
OAN
CI H I*
;and CI
H
0 N 1.1 0)LN 1 CI (101 H
=
,
ethyl 4-((3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yI)(2-(4-chlorophenoxy)ethyl)amino)butanoate;
2-(4-chlorophenoxy)-N-(3-((2-(4-chlorophenoxy)ethyl)(methyl)amino)bicyclo[1 .1 .1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(N-(2-(4-chlorophenoxy)ethyl)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-ch lorophenoxy)-N-(3-((2-(4-ch lorophenoxy)ethyl)(oxetan-3-yl)amino)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-((2-((4-chlorophenyl)amino)ethyl)amino)bicyclo[1 .1 .1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
1 -(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1 .1 .1 ]pentan-1 -yI)-3-(4-chlorophenyl)imidazolidin-2-one;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
H
OAN
CI H I*
;and CI
H
0 N 1.1 0)LN 1 CI (101 H
=
,
- 50 -and salts thereof including pharmaceutically acceptable salts thereof.
Included in the compounds of the invention are:
2-(4-chlorophenoxy)-N-(3-(3-(4-chloropheny1)-2-oxoim idazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluoropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-fluorophenoxy)acetamide;
N-(3-(3-(4-chloro-2-methylphenyI)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide;
N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-cyclopropylphenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(5-chloropyridin-2-y1)-2-oxoim idazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(3-chlorophenoxy)-N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-(trifluoromethoxy)phenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chloro-3-(trifluoromethyl)phenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoim idazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(3-ch lorophenyI)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetam ide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenyl)cyclopropane-1 -carboxamide;
N-(4-(2-(4-chlorophenoxy)acetamido)bicyclo[2.1 .1 ]hexan-1 -yI)-2-(4-chlorophenyl)cyclopropane-1 -carboxamide;
2-(4-chlorophenoxy)-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-yl)cyclopropane-1 -carboxamide;
Included in the compounds of the invention are:
2-(4-chlorophenoxy)-N-(3-(3-(4-chloropheny1)-2-oxoim idazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluoropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-fluorophenoxy)acetamide;
N-(3-(3-(4-chloro-2-methylphenyI)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide;
N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-cyclopropylphenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(5-chloropyridin-2-y1)-2-oxoim idazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(3-chlorophenoxy)-N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-(trifluoromethoxy)phenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chloro-3-(trifluoromethyl)phenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoim idazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(3-ch lorophenyI)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetam ide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenyl)cyclopropane-1 -carboxamide;
N-(4-(2-(4-chlorophenoxy)acetamido)bicyclo[2.1 .1 ]hexan-1 -yI)-2-(4-chlorophenyl)cyclopropane-1 -carboxamide;
2-(4-chlorophenoxy)-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-yl)cyclopropane-1 -carboxamide;
- 51 -2-(4-chlorophenoxy)-N-(3-((1-(4-chlorophenyl)azetidin-3-yl)amino)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)azetidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
5-chloro-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yI)-2,3-dihydrobenzofuran-2-carboxamide;
2-(bicyclo[4.2.0]octa-1 (6),2,4-trien-3-yloxy)-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(chroman-6-yloxy)acetamido)bicyclo[1 .1 .1 ]pentan-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenyl)piperidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenyl)piperazin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(bicyclo[4.2.0]octa-1 ,3,5-trien-3-yloxy)-N-(4-(2-(4-chlorophenoxy)acetamido)bicyclo[2.2.1]heptan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
(S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
(R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-fluorophenoxy)acetamide isomer 1;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-fluorophenoxy)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)azetidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
5-chloro-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yI)-2,3-dihydrobenzofuran-2-carboxamide;
2-(bicyclo[4.2.0]octa-1 (6),2,4-trien-3-yloxy)-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(chroman-6-yloxy)acetamido)bicyclo[1 .1 .1 ]pentan-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenyl)piperidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenyl)piperazin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(bicyclo[4.2.0]octa-1 ,3,5-trien-3-yloxy)-N-(4-(2-(4-chlorophenoxy)acetamido)bicyclo[2.2.1]heptan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
(S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
(R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-fluorophenoxy)acetamide isomer 1;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-fluorophenoxy)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
- 52 -N-(3-(3-(3-chloro-4-fluorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide isomer 1;
N-(3-(3-(3-chloro-4-fluorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide isomer 2;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-((5-chloropyridin-2-yl)oxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-(trifluoromethoxy)phenoxy)acetamide;
2-(4-chloro-3-(trifluoromethyl)phenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-cyclopropylphenoxy)acetamide;
N-(3-(3-(4-chloro-3-fluorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide isomer 1;
N-(3-(3-(4-chloro-3-fluorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-(pyridin-4-yloxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
1 -(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1 .1 .1]pentan-1-y1)-3-(4-chlorophenyl)imidazolidin-2-one;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-methoxyphenoxy)acetamide;
2-(3-chloro-4-fluorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1 -
N-(3-(3-(3-chloro-4-fluorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide isomer 2;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-((5-chloropyridin-2-yl)oxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-(trifluoromethoxy)phenoxy)acetamide;
2-(4-chloro-3-(trifluoromethyl)phenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-cyclopropylphenoxy)acetamide;
N-(3-(3-(4-chloro-3-fluorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide isomer 1;
N-(3-(3-(4-chloro-3-fluorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-(pyridin-4-yloxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
1 -(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1 .1 .1]pentan-1-y1)-3-(4-chlorophenyl)imidazolidin-2-one;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-methoxyphenoxy)acetamide;
2-(3-chloro-4-fluorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1 -
- 53 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloro-3-(trifluoromethyl)pheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-(4-chlorophenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluoro-3-(trifluoromethyl)pheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(5-chloroisoindolin-2-yl)bicyclo[1 .1 .1]pentan-1-y1)-2-(4-chlorophenoxy)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-((5-chloropyridin-2-yl)oxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-oxo-3-(4-(trifluoromethyl)phenyl)imidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1]pentan-1-y1)-2-(4-fluoro-3-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-(4-fluoro-3-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-(4-(difluoromethoxy)phenoxy)acetamide;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide isomer 1;
(R)-2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1]pentan-1-yl)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-((5-chloropyridin-2-yl)oxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-((5-ch loropyridin-2-yl)oxy)-N-(3-(3-((5-chloropyridin-2-yl)oxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetam ide;
2-(4-chlorophenoxy)-N-(3-(3-(4-methoxypheny1)-2-oxoimidazolidin -1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloro-2-fluoropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1]pentan-1 -y1)-2-(4-ch lorophenoxy)acetam ide;
N-(3-(3-(bicyclo[4.2.0]octa-1 ,3,5-trien-3-yloxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-(4-chlorophenoxy)acetamide;
(S)-2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
(S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloro-3-(trifluoromethyl)pheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-(4-chlorophenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluoro-3-(trifluoromethyl)pheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(5-chloroisoindolin-2-yl)bicyclo[1 .1 .1]pentan-1-y1)-2-(4-chlorophenoxy)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-((5-chloropyridin-2-yl)oxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-oxo-3-(4-(trifluoromethyl)phenyl)imidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1]pentan-1-y1)-2-(4-fluoro-3-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-(4-fluoro-3-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-(4-(difluoromethoxy)phenoxy)acetamide;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide isomer 1;
(R)-2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1]pentan-1-yl)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-((5-chloropyridin-2-yl)oxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-((5-ch loropyridin-2-yl)oxy)-N-(3-(3-((5-chloropyridin-2-yl)oxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetam ide;
2-(4-chlorophenoxy)-N-(3-(3-(4-methoxypheny1)-2-oxoimidazolidin -1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloro-2-fluoropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1]pentan-1 -y1)-2-(4-ch lorophenoxy)acetam ide;
N-(3-(3-(bicyclo[4.2.0]octa-1 ,3,5-trien-3-yloxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-(4-chlorophenoxy)acetamide;
(S)-2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
(S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
- 54 -(R)-2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
(R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-(methylthio)pheny1)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)acetamide; and 2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)piperidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
and salts thereof including pharmaceutically acceptable salts thereof.
Included in the compounds of the invention are:
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)-2-(4-fluorophenoxy)acetamide;
N-(3-(3-(4-chloro-2-methylpheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-cyclopropylphenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(5-chloropyridin-2-yI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1 -yl)acetamide;
2-(3-chlorophenoxy)-N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)-2-(4-(trifluoromethoxy)phenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chloro-3-(trifluoromethyl)phenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
(R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-(methylthio)pheny1)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)acetamide; and 2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)piperidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
and salts thereof including pharmaceutically acceptable salts thereof.
Included in the compounds of the invention are:
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)-2-(4-fluorophenoxy)acetamide;
N-(3-(3-(4-chloro-2-methylpheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-cyclopropylphenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(5-chloropyridin-2-yI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1 -yl)acetamide;
2-(3-chlorophenoxy)-N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)-2-(4-(trifluoromethoxy)phenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chloro-3-(trifluoromethyl)phenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
- 55 -2-(4-chlorophenoxy)-N-(3-(3-(3-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenyl)cyclopropane-1-carboxamide;
N-(4-(2-(4-chlorophenoxy)acetamido)bicyclo[2.1 .1 ]hexan-1 -yI)-2-(4-chlorophenyl)cyclopropane-1 -carboxamide;
2-(4-chlorophenoxy)-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-yl)cyclopropane-1 -carboxamide;
2-(4-chlorophenoxy)-N-(3-((1 -(4-chlorophenyl)azetidin-3-yl)amino)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)azetidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenyl)piperidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenyl)piperazin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(bicyclo[4.2.0]octa-1 ,3,5-trien-3-yloxy)-N-(4-(2-(4-chlorophenoxy)acetamido)bicyclo[2.2.1]heptan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
(S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
(R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-fluorophenoxy)acetamide isomer 1;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-fluorophenoxy)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenyl)cyclopropane-1-carboxamide;
N-(4-(2-(4-chlorophenoxy)acetamido)bicyclo[2.1 .1 ]hexan-1 -yI)-2-(4-chlorophenyl)cyclopropane-1 -carboxamide;
2-(4-chlorophenoxy)-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-yl)cyclopropane-1 -carboxamide;
2-(4-chlorophenoxy)-N-(3-((1 -(4-chlorophenyl)azetidin-3-yl)amino)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)azetidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenyl)piperidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenyl)piperazin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(bicyclo[4.2.0]octa-1 ,3,5-trien-3-yloxy)-N-(4-(2-(4-chlorophenoxy)acetamido)bicyclo[2.2.1]heptan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
(S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
(R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-fluorophenoxy)acetamide isomer 1;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-fluorophenoxy)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
- 56 -N-(3-(3-(3-chloro-4-fluorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide isomer 1;
N-(3-(3-(3-chloro-4-fluorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide isomer 2;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-((5-chloropyridin-2-yl)oxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-(trifluoromethoxy)phenoxy)acetamide;
2-(4-chloro-3-(trifluoromethyl)phenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-cyclopropylphenoxy)acetamide;
N-(3-(3-(4-chloro-3-fluorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide isomer 1;
N-(3-(3-(4-chloro-3-fluorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-(pyridin-4-yloxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
1 -(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1 .1 .1]pentan-1-y1)-3-(4-chlorophenyl)imidazolidin-2-one;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-methoxyphenoxy)acetamide;
2-(3-chloro-4-fluorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1 -
N-(3-(3-(3-chloro-4-fluorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide isomer 2;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-((5-chloropyridin-2-yl)oxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-(trifluoromethoxy)phenoxy)acetamide;
2-(4-chloro-3-(trifluoromethyl)phenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-cyclopropylphenoxy)acetamide;
N-(3-(3-(4-chloro-3-fluorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide isomer 1;
N-(3-(3-(4-chloro-3-fluorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-chlorophenoxy)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-(pyridin-4-yloxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
1 -(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1 .1 .1]pentan-1-y1)-3-(4-chlorophenyl)imidazolidin-2-one;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yI)-2-(4-methoxyphenoxy)acetamide;
2-(3-chloro-4-fluorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1 -
- 57 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloro-3-(trifluoromethyl)pheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-(4-chlorophenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluoro-3-(trifluoromethyl)pheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-((5-chloropyridin-2-yl)oxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-oxo-3-(4-(trifluoromethyl)phenyl)imidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1]pentan-1-y1)-2-(4-fluoro-3-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1]pentan-1 -y1)-2-(4-fluoro-3-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-(4-.. (difluoromethoxy)phenoxy)acetamide;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide isomer 1;
(R)-2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-((5-chloropyridin-2-yl)oxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-((5-chloropyridin-2-yl)oxy)-N-(3-(3-((5-chloropyridin-2-yl)oxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-methoxypheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloro-2-fluoropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1]pentan-1 -y1)-2-(4-chlorophenoxy)acetamide;
(S)-2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloro-3-(trifluoromethyl)pheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-(4-chlorophenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluoro-3-(trifluoromethyl)pheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-((5-chloropyridin-2-yl)oxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-oxo-3-(4-(trifluoromethyl)phenyl)imidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1]pentan-1-y1)-2-(4-fluoro-3-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1]pentan-1 -y1)-2-(4-fluoro-3-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-(4-.. (difluoromethoxy)phenoxy)acetamide;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide isomer 1;
(R)-2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-((5-chloropyridin-2-yl)oxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-((5-chloropyridin-2-yl)oxy)-N-(3-(3-((5-chloropyridin-2-yl)oxy)pyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-methoxypheny1)-2-oxoimidazolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
N-(3-(3-(4-chloro-2-fluoropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1 .1 .1]pentan-1 -y1)-2-(4-chlorophenoxy)acetamide;
(S)-2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1 .1 .1 ]pentan-1 -yl)acetamide;
- 58 -(S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1 -yl)acetamide;
(R)-2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1 -yl)acetamide;
(R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-(methylthio)phenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1 -yl)acetamide; and 2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)piperidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -.. yl)acetamide;
and salts thereof including pharmaceutically acceptable salts thereof.
Included in the compounds of the invention are:
N-(3-(5-chloroisoindolin-2-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide; and N-(3-(3-(bicyclo[4.2.0]octa-1 ,3,5-trien-3-yloxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-(4-chlorophenoxy)acetamide;
and salts thereof including pharmaceutically acceptable salts thereof.
Included in the compounds of the invention are:
2-(4-chlorophenoxy)-N-(3-(2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
5-chloro-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yI)-2,3-dihydrobenzofuran-2-carboxamide;
2-(bicyclo[4.2.0]octa-1(6),2,4-trien-3-yloxy)-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide; and 2-(4-chlorophenoxy)-N-(3-(2-(chroman-6-yloxy)acetamido)bicyclo[1 .1 .1 ]pentan-yl)acetamide;
(R)-2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1 -yl)acetamide;
(R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1 -yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-(methylthio)phenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1 -yl)acetamide; and 2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)piperidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -.. yl)acetamide;
and salts thereof including pharmaceutically acceptable salts thereof.
Included in the compounds of the invention are:
N-(3-(5-chloroisoindolin-2-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide; and N-(3-(3-(bicyclo[4.2.0]octa-1 ,3,5-trien-3-yloxy)pyrrolidin-1 -yl)bicyclo[1 .1 .1 ]pentan-1 -y1)-2-(4-chlorophenoxy)acetamide;
and salts thereof including pharmaceutically acceptable salts thereof.
Included in the compounds of the invention are:
2-(4-chlorophenoxy)-N-(3-(2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
5-chloro-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1 .1 .1 ]pentan-1 -yI)-2,3-dihydrobenzofuran-2-carboxamide;
2-(bicyclo[4.2.0]octa-1(6),2,4-trien-3-yloxy)-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide; and 2-(4-chlorophenoxy)-N-(3-(2-(chroman-6-yloxy)acetamido)bicyclo[1 .1 .1 ]pentan-yl)acetamide;
- 59 -and salts thereof including pharmaceutically acceptable salts thereof.
To clarify the obvious intent, in any of the above Formulas, when "z" in a moiety is 0, and the adjacent "R*" and "L*" moieties form a ring, such as a heterocycloalkyl, for example a pyrrolidinyl, the "R*" and "L*" moieties do not have to be adjacent in the ring.
Further, in any of the above Formulas, in a moiety, it is understood that "R*" will be absent whenever "Z*" is 0.
Further, in any of the above Formulas, in a (R*)z*
moiety, it is understood that whenever "e" is o, any substituent that could be an "R*" group, will be hydrogen.
Further, in the above Formulas, R85' and R86' are indicated by "each is independently selected from...". To clarify the obvious intent, for R85 and R86, and all corresponding groups in each of the above Formulas, when two of the same groups are on the same molecule, (for example when two R85 groups are on the same molecule), each 85' can be a different substituent. For Example, one R85 can be F and the other R85 can be Cl.
In embodiments, R5 is independently fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(0)Ph, -OF3, -ON, -S(0)0H3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(0)0H3, -CE=CH, -CH2CECH, -S03H, -SO2NH2, -NHC(0)NH2, -NHC(0)H, -NHOH, -00H3, -00F3, -OCHF2, substituted or unsubstituted 01_6a1ky1, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments, R5 is independently hydrogen, fluoro, chloro, bromo, iodo, -00H3, -OCH2Ph, -CH3, -OH, -OF3, -ON, -S(0)0H3, -NO2,
To clarify the obvious intent, in any of the above Formulas, when "z" in a moiety is 0, and the adjacent "R*" and "L*" moieties form a ring, such as a heterocycloalkyl, for example a pyrrolidinyl, the "R*" and "L*" moieties do not have to be adjacent in the ring.
Further, in any of the above Formulas, in a moiety, it is understood that "R*" will be absent whenever "Z*" is 0.
Further, in any of the above Formulas, in a (R*)z*
moiety, it is understood that whenever "e" is o, any substituent that could be an "R*" group, will be hydrogen.
Further, in the above Formulas, R85' and R86' are indicated by "each is independently selected from...". To clarify the obvious intent, for R85 and R86, and all corresponding groups in each of the above Formulas, when two of the same groups are on the same molecule, (for example when two R85 groups are on the same molecule), each 85' can be a different substituent. For Example, one R85 can be F and the other R85 can be Cl.
In embodiments, R5 is independently fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(0)Ph, -OF3, -ON, -S(0)0H3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(0)0H3, -CE=CH, -CH2CECH, -S03H, -SO2NH2, -NHC(0)NH2, -NHC(0)H, -NHOH, -00H3, -00F3, -OCHF2, substituted or unsubstituted 01_6a1ky1, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments, R5 is independently hydrogen, fluoro, chloro, bromo, iodo, -00H3, -OCH2Ph, -CH3, -OH, -OF3, -ON, -S(0)0H3, -NO2,
- 60 --C(0)CH3, -C(0)Ph, -CH(CH3)2, or -C-ECH. In embodiments, R5 is -F. In embodiments, R5 is -Cl. In embodiments, R5 is -Br. In embodiments, R5 is -I. In embodiments, R5 is substituted or unsubstituted Cl_6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments, R5 is unsubstituted Cl_6alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl. In embodiments, R5 is -OCH3. In embodiments, R5 is -OCH2Ph. In embodiments, R5 is -CH3. In embodiments, R5 is -OH. In embodiments, R5 is -CF3. In embodiments, R5 is -ON. In embodiments, R5 is -S(0)0H3. In embodiments, R5 is -NO2. In embodiments, R5 is -C(0)0H3. In embodiments, R51.s -C(0)Ph. In embodiments, R51.s -CH(CH3)2. In embodiments, R51.s In embodiments, R5 is -CH2CECH. In embodiments, R5 is -S03H. In embodiments, R51.s -SO2NH2. In embodiments, R51.s -NHC(0)NH2. In embodiments, is -NHC(0)H. In embodiments, R5 is -NHOH. In embodiments, R5 is-00H3. In embodiments, R is -00F3. In embodiments, R5 is -OCHF2.
In embodiments, R6 is independently fluoro, chloro, bromo, iodo, -00H3, -OCH2Ph, -C(0)Ph, -CF3, -ON, -S(0)CH3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(0)CH3, -OOH, -CH2CECH, -S03H, -SO2NH2, -NHC(0)NH2, -NHC(0)H, -NHOH, -OCH3, -0CF3, -OCHF2, substituted or unsubstituted C1_6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments, R6 is independently hydrogen, fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -CH3, -OH, -CF3, -ON, -S(0)0H3, -NO2, -C(0)0H3, -C(0)Ph, -CH(0H3)2, or -CECH. In embodiments, R6 is -F. In embodiments, R6 is -Cl. In embodiments, R6 is -Br. In embodiments, R6 is -I. In embodiments, R6 is substituted or unsubstituted 0l_6a1ky1, substituted or unsubstituted heteroalkyl, substituted or
In embodiments, R6 is independently fluoro, chloro, bromo, iodo, -00H3, -OCH2Ph, -C(0)Ph, -CF3, -ON, -S(0)CH3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(0)CH3, -OOH, -CH2CECH, -S03H, -SO2NH2, -NHC(0)NH2, -NHC(0)H, -NHOH, -OCH3, -0CF3, -OCHF2, substituted or unsubstituted C1_6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments, R6 is independently hydrogen, fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -CH3, -OH, -CF3, -ON, -S(0)0H3, -NO2, -C(0)0H3, -C(0)Ph, -CH(0H3)2, or -CECH. In embodiments, R6 is -F. In embodiments, R6 is -Cl. In embodiments, R6 is -Br. In embodiments, R6 is -I. In embodiments, R6 is substituted or unsubstituted 0l_6a1ky1, substituted or unsubstituted heteroalkyl, substituted or
-61 -unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments, R6 is unsubstituted Cl_6alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl. In embodiments, R6 is -OCH3. In embodiments, R6 is -OCH2Ph. In embodiments, R6 is -CH3. In embodiments, R6 is -OH. In embodiments, R6 is -CF3. In embodiments, R6 is -ON. In embodiments, R6 is -S(0)0H3. In embodiments, R6 is -NO2. In embodiments, R6 is -C(0)0H3. In embodiments, R6.s -C(0)Ph. In embodiments, R61.s -CH(0H3)2. In embodiments, R6.s -CECH. In embodiments, R6 is -CH2CCH. In embodiments, R6 is -S03H. In embodiments, R6 I.S -SO2NH2. In embodiments, R6 I.s -NHC(0)NH2. In embodiments, R6 is -NHC(0)H. In embodiments, R6 is -NHOH. In embodiments, R6 is -00H3. In embodiments, R61.s -00F3. In embodiments, R61.s -OCHF2.
In embodiments, R2 is NR8. In embodiments, R2 is NH. In embodiments, R2 is 0.
In embodiments, R2 is S. In embodiments, R2 is CH2. In embodiments, R4 is NR8. In embodiments, R4 is NH. In embodiments, R4 is 0. In embodiments, R4 is S. In embodiments, R4 is 0H2. In embodiments, R2 and R4 are NH. In embodiments, R2 and R4 are 0. In embodiments, R2 and R4 are S. In embodiments, R2 and R4 are NR8.
In embodiments, L2 is a bond. In embodiments, L2 is a substituted or unsubstituted Cl_ 6a1ky1ene. In embodiments, L2 is a substituted or unsubstituted 01_6heter0a1ky1ene. In embodiments, L2. is L2A-L2B-L20 and L2A. is bonded to the substituted or unsubstituted phenyl, which may be substituted with R5. L2A is a bond, -0-, -S-, -NH-, -5(0)-, or -5(0)2-.
L2B is a bond or substituted or unsubstituted 01_6a1ky1ene. L20 is a bond, -0-, or -NH-. In embodiments, L2A is a bond. In embodiments, L2A is -0-. In embodiments, L2A is -S-. In embodiments, L2A. is -NH-. In embodiments, L2A. is -5(0)-. In embodiments, L2A. is -S(0)2-In embodiments, L2B is a bond. In embodiments, L2B is a substituted or unsubstituted Cl_ 6a1ky1ene. In embodiments, L2B is an unsubstituted 01_6a1ky1ene. In embodiments, L2B is a
In embodiments, R2 is NR8. In embodiments, R2 is NH. In embodiments, R2 is 0.
In embodiments, R2 is S. In embodiments, R2 is CH2. In embodiments, R4 is NR8. In embodiments, R4 is NH. In embodiments, R4 is 0. In embodiments, R4 is S. In embodiments, R4 is 0H2. In embodiments, R2 and R4 are NH. In embodiments, R2 and R4 are 0. In embodiments, R2 and R4 are S. In embodiments, R2 and R4 are NR8.
In embodiments, L2 is a bond. In embodiments, L2 is a substituted or unsubstituted Cl_ 6a1ky1ene. In embodiments, L2 is a substituted or unsubstituted 01_6heter0a1ky1ene. In embodiments, L2. is L2A-L2B-L20 and L2A. is bonded to the substituted or unsubstituted phenyl, which may be substituted with R5. L2A is a bond, -0-, -S-, -NH-, -5(0)-, or -5(0)2-.
L2B is a bond or substituted or unsubstituted 01_6a1ky1ene. L20 is a bond, -0-, or -NH-. In embodiments, L2A is a bond. In embodiments, L2A is -0-. In embodiments, L2A is -S-. In embodiments, L2A. is -NH-. In embodiments, L2A. is -5(0)-. In embodiments, L2A. is -S(0)2-In embodiments, L2B is a bond. In embodiments, L2B is a substituted or unsubstituted Cl_ 6a1ky1ene. In embodiments, L2B is an unsubstituted 01_6a1ky1ene. In embodiments, L2B is a
- 62 -substituted or unsubstituted 01-05 alkylene. In embodiments, L2B is an unsubstituted C- -05 alkylene. In embodiments, L2B is a substituted or unsubstituted 01-04 alkylene. In embodiments, L2B is an unsubstituted 01-04 alkylene.
In embodiments, L2B is a substituted or unsubstituted 01-03 alkylene. In embodiments, L2B is an unsubstituted C--03 alkylene. In embodiments, L2B is a substituted 01-05 alkylene. In embodiments, L2B is a substituted 01-06 alkylene. In embodiments, L2B is a substituted Ci -05 alkylene. In embodiments, L2B is a substituted 01-04 alkylene. In embodiments, L2B is a 01-alkylene substituted with -CF3. In embodiments, L20 is a bond. In embodiments, L20 is -0-. In embodiments, L20 is -NH-. In embodiments, L2A is a bond; L2B is unsubstituted methylene; and L20 is -0-.
In embodiments, L3 is a bond. In embodiments, L3 is a substituted or unsubstituted Cl_ 6a1ky1ene. In embodiments, L3 is a substituted or unsubstituted 01_6heter0a1ky1ene. In embodiments, L3. is L3A-L3B-L30 and L3A. is bonded to the substituted or unsubstituted phenyl, which may be substituted with R5. L3A is a bond, -0-, -S-, -NH-, -S(0)-, or -S(0)2-.
L3B is a bond or substituted or unsubstituted 01_6a1ky1ene. L30 is a bond, -0-, or -NH-. In embodiments, L3A is a bond. In embodiments, L3A is -0-. In embodiments, L3A is -S-. In embodiments, L3A. is -NH-. In embodiments, L3A. is -S(0)-. In embodiments, L3A. is -S(0)2-In embodiments, L3B is a bond. In embodiments, L3B is a substituted or unsubstituted 6a1ky1ene. In embodiments, L3B is an unsubstituted 01_6a1ky1ene. In embodiments, L3B is a substituted or unsubstituted Ci -05 alkylene. In embodiments, L3B is an unsubstituted Ci -05 alkylene. In embodiments, L3B is a substituted or unsubstituted 01-04 alkylene. In embodiments, L3B is an unsubstituted 01-04 alkylene.
In embodiments, L3B is a substituted or unsubstituted 01-03a1ky1ene. In embodiments, L3B is an unsubstituted C--03 alkylene. In embodiments, L3B is a substituted Ci-05 alkylene. In embodiments, L3B is a substituted 01-06 alkylene. In embodiments, L3B is a substituted Ci -05 alkylene. In embodiments, L3B is a substituted 01-04 alkylene. In embodiments, L3B is a 01-alkylene substituted with -CF3. In embodiments, L30 is a bond. In embodiments, L30 is -0-. In embodiments, L30 is -NH-. In embodiments, L3A is a bond; L3B is unsubstituted
In embodiments, L2B is a substituted or unsubstituted 01-03 alkylene. In embodiments, L2B is an unsubstituted C--03 alkylene. In embodiments, L2B is a substituted 01-05 alkylene. In embodiments, L2B is a substituted 01-06 alkylene. In embodiments, L2B is a substituted Ci -05 alkylene. In embodiments, L2B is a substituted 01-04 alkylene. In embodiments, L2B is a 01-alkylene substituted with -CF3. In embodiments, L20 is a bond. In embodiments, L20 is -0-. In embodiments, L20 is -NH-. In embodiments, L2A is a bond; L2B is unsubstituted methylene; and L20 is -0-.
In embodiments, L3 is a bond. In embodiments, L3 is a substituted or unsubstituted Cl_ 6a1ky1ene. In embodiments, L3 is a substituted or unsubstituted 01_6heter0a1ky1ene. In embodiments, L3. is L3A-L3B-L30 and L3A. is bonded to the substituted or unsubstituted phenyl, which may be substituted with R5. L3A is a bond, -0-, -S-, -NH-, -S(0)-, or -S(0)2-.
L3B is a bond or substituted or unsubstituted 01_6a1ky1ene. L30 is a bond, -0-, or -NH-. In embodiments, L3A is a bond. In embodiments, L3A is -0-. In embodiments, L3A is -S-. In embodiments, L3A. is -NH-. In embodiments, L3A. is -S(0)-. In embodiments, L3A. is -S(0)2-In embodiments, L3B is a bond. In embodiments, L3B is a substituted or unsubstituted 6a1ky1ene. In embodiments, L3B is an unsubstituted 01_6a1ky1ene. In embodiments, L3B is a substituted or unsubstituted Ci -05 alkylene. In embodiments, L3B is an unsubstituted Ci -05 alkylene. In embodiments, L3B is a substituted or unsubstituted 01-04 alkylene. In embodiments, L3B is an unsubstituted 01-04 alkylene.
In embodiments, L3B is a substituted or unsubstituted 01-03a1ky1ene. In embodiments, L3B is an unsubstituted C--03 alkylene. In embodiments, L3B is a substituted Ci-05 alkylene. In embodiments, L3B is a substituted 01-06 alkylene. In embodiments, L3B is a substituted Ci -05 alkylene. In embodiments, L3B is a substituted 01-04 alkylene. In embodiments, L3B is a 01-alkylene substituted with -CF3. In embodiments, L30 is a bond. In embodiments, L30 is -0-. In embodiments, L30 is -NH-. In embodiments, L3A is a bond; L3B is unsubstituted
- 63 -methylene; and L30 IS -0-.
In embodiments, L3 is taken together with R1 to form heterocycloalkyl.
Suitably the heterocycloalkyl is imidazolidinyl or pyrrolidinyl.
Suitably the heterocycloalkyl is imidazolidinyl. Suitably the heterocycloalkyl is pyrrolidinyl.
In embodiments, L2 is taken together with R3 to form heterocycloalkyl.
Suitably the heterocycloalkyl is imidazolidinyl or pyrrolidinyl.
Suitably the heterocycloalkyl is imidazolidinyl. Suitably the heterocycloalkyl is pyrrolidinyl.
In embodiments, L22 is taken together with R23 to form heterocycloalkyl.
Suitably the heterocycloalkyl is imidazolidinyl or pyrrolidinyl.
Suitably the heterocycloalkyl is imidazolidinyl. Suitably the heterocycloalkyl is pyrrolidinyl.
In embodiments, L23 is taken together with R21 to form heterocycloalkyl.
Suitably the heterocycloalkyl is imidazolidinyl or pyrrolidinyl.
Suitably the heterocycloalkyl is imidazolidinyl. Suitably the heterocycloalkyl is pyrrolidinyl.
In embodiments, L33 is taken together with R31 to form heterocycloalkyl.
Suitably the heterocycloalkyl is imidazolidinyl or pyrrolidinyl.
Suitably the heterocycloalkyl is imidazolidinyl. Suitably the heterocycloalkyl is pyrrolidinyl.
In embodiments, L42 is taken together with R41 to form imidazolidinyl or pyrrolidinyl.
Suitably L42 is taken together with R41 to form imidazolidinyl. Suitably L42 is taken together with R41 to form pyrrolidinyl.
In embodiments, L43 is taken together with R43 to form imidazolidinyl or pyrrolidinyl.
Suitably L43 is taken together with R43 to form imidazolidinyl. Suitably L43 is taken together with R43 to form pyrrolidinyl.
In embodiments, L53 is taken together with R53 to form imidazolidinyl or pyrrolidinyl.
Suitably L53 is taken together with R53 to form imidazolidinyl. Suitably L53 is taken together with R53 to form pyrrolidinyl.
In embodiments, L3 is taken together with R1 to form heterocycloalkyl.
Suitably the heterocycloalkyl is imidazolidinyl or pyrrolidinyl.
Suitably the heterocycloalkyl is imidazolidinyl. Suitably the heterocycloalkyl is pyrrolidinyl.
In embodiments, L2 is taken together with R3 to form heterocycloalkyl.
Suitably the heterocycloalkyl is imidazolidinyl or pyrrolidinyl.
Suitably the heterocycloalkyl is imidazolidinyl. Suitably the heterocycloalkyl is pyrrolidinyl.
In embodiments, L22 is taken together with R23 to form heterocycloalkyl.
Suitably the heterocycloalkyl is imidazolidinyl or pyrrolidinyl.
Suitably the heterocycloalkyl is imidazolidinyl. Suitably the heterocycloalkyl is pyrrolidinyl.
In embodiments, L23 is taken together with R21 to form heterocycloalkyl.
Suitably the heterocycloalkyl is imidazolidinyl or pyrrolidinyl.
Suitably the heterocycloalkyl is imidazolidinyl. Suitably the heterocycloalkyl is pyrrolidinyl.
In embodiments, L33 is taken together with R31 to form heterocycloalkyl.
Suitably the heterocycloalkyl is imidazolidinyl or pyrrolidinyl.
Suitably the heterocycloalkyl is imidazolidinyl. Suitably the heterocycloalkyl is pyrrolidinyl.
In embodiments, L42 is taken together with R41 to form imidazolidinyl or pyrrolidinyl.
Suitably L42 is taken together with R41 to form imidazolidinyl. Suitably L42 is taken together with R41 to form pyrrolidinyl.
In embodiments, L43 is taken together with R43 to form imidazolidinyl or pyrrolidinyl.
Suitably L43 is taken together with R43 to form imidazolidinyl. Suitably L43 is taken together with R43 to form pyrrolidinyl.
In embodiments, L53 is taken together with R53 to form imidazolidinyl or pyrrolidinyl.
Suitably L53 is taken together with R53 to form imidazolidinyl. Suitably L53 is taken together with R53 to form pyrrolidinyl.
- 64 -In embodiments, L62 is taken together with R61 to form imidazolidinyl or pyrrolidinyl.
Suitably L62 is taken together with R61 to form imidazolidinyl. Suitably L62 is taken together with R61 to form pyrrolidinyl.
In embodiments, L63 is taken together with R63 to form imidazolidinyl or pyrrolidinyl.
Suitably L63 is taken together with R63 to form imidazolidinyl. Suitably L63 is taken together with R63 to form pyrrolidinyl.
In embodiments, L73 is taken together with R73 to form imidazolidinyl or pyrrolidinyl.
Suitably L73 is taken together with R73 to form imidazolidinyl. Suitably L73 is taken together with R73 to form pyrrolidinyl.
In embodiments, L83 is taken together with R81 to form heterocycloalkyl. In other words, the moiety comprising -NR8-1_(c.R84)24_L83_ represents heterocycloalkyl.
Suitably the heterocycloalkyl is imidazolidinyl or pyrrolidinyl.
Suitably the heterocycloalkyl is imidazolidinyl. Suitably the heterocycloalkyl is pyrrolidinyl. In embodiments, L83 is taken together with R81 to form oxoheterocycloalkyl. In other words, the moiety comprising -NR81-(C=R84)z84-L83- represents oxoheterocycloalkyl. Suitably the oxoheterocycloalkyl is 2-oxoimidazolidinyl. Suitably the oxoheterocycloalkyl is oxopyrrolidinyl. In embodiments, L83 is taken together with R81 to form heterocycloalkyl-O-. In other words, the moiety comprising -NR8-1_(c.R84)24_L83_ represents heterocycloalkyl-O-, wherein the -0- is an oxygen linking atom connecting the heterocycloalkyl to D8. Suitably the heterocycloalkyl-0- is azetidiny1-0- or pyrrolidinyl-0-. Suitably the heterocycloalkyl-0- is pyrrolidinyl-0-.
In embodiments, L82 is taken together with R83 to form heterocycloalkyl.
Suitably the heterocycloalkyl is imidazolidinyl or pyrrolidinyl.
Suitably the heterocycloalkyl is imidazolidinyl. Suitably the heterocycloalkyl is pyrrolidinyl.
In embodiments, L93 is taken together with R91 to form heterocycloalkyl.
Suitably the heterocycloalkyl is imidazolidinyl or pyrrolidinyl.
Suitably the heterocycloalkyl is
Suitably L62 is taken together with R61 to form imidazolidinyl. Suitably L62 is taken together with R61 to form pyrrolidinyl.
In embodiments, L63 is taken together with R63 to form imidazolidinyl or pyrrolidinyl.
Suitably L63 is taken together with R63 to form imidazolidinyl. Suitably L63 is taken together with R63 to form pyrrolidinyl.
In embodiments, L73 is taken together with R73 to form imidazolidinyl or pyrrolidinyl.
Suitably L73 is taken together with R73 to form imidazolidinyl. Suitably L73 is taken together with R73 to form pyrrolidinyl.
In embodiments, L83 is taken together with R81 to form heterocycloalkyl. In other words, the moiety comprising -NR8-1_(c.R84)24_L83_ represents heterocycloalkyl.
Suitably the heterocycloalkyl is imidazolidinyl or pyrrolidinyl.
Suitably the heterocycloalkyl is imidazolidinyl. Suitably the heterocycloalkyl is pyrrolidinyl. In embodiments, L83 is taken together with R81 to form oxoheterocycloalkyl. In other words, the moiety comprising -NR81-(C=R84)z84-L83- represents oxoheterocycloalkyl. Suitably the oxoheterocycloalkyl is 2-oxoimidazolidinyl. Suitably the oxoheterocycloalkyl is oxopyrrolidinyl. In embodiments, L83 is taken together with R81 to form heterocycloalkyl-O-. In other words, the moiety comprising -NR8-1_(c.R84)24_L83_ represents heterocycloalkyl-O-, wherein the -0- is an oxygen linking atom connecting the heterocycloalkyl to D8. Suitably the heterocycloalkyl-0- is azetidiny1-0- or pyrrolidinyl-0-. Suitably the heterocycloalkyl-0- is pyrrolidinyl-0-.
In embodiments, L82 is taken together with R83 to form heterocycloalkyl.
Suitably the heterocycloalkyl is imidazolidinyl or pyrrolidinyl.
Suitably the heterocycloalkyl is imidazolidinyl. Suitably the heterocycloalkyl is pyrrolidinyl.
In embodiments, L93 is taken together with R91 to form heterocycloalkyl.
Suitably the heterocycloalkyl is imidazolidinyl or pyrrolidinyl.
Suitably the heterocycloalkyl is
- 65 -imidazolidinyl. Suitably the heterocycloalkyl is pyrrolidinyl. In embodiments, L93 is taken together with R91 to form oxoheterocycloalkyl. Suitably the oxoheterocycloalkyl is 2-oxoimidazolidinyl. Suitably the oxoheterocycloalkyl is oxopyrrolidinyl. In embodiments, L93 is taken together with R91 to form heterocycloalky1-0-. Suitably the heterocycloalky1-0- is azetidiny1-0- or pyrrolidinyl-O-. Suitably the heterocycloalky1-0- is pyrrolidinyl-O-.
In embodiments, L102 is taken together with R101 to form imidazolidinyl or pyrrolidinyl.
Suitably L192 is taken together with R101 to form imidazolidinyl. Suitably L192 is taken together with R101 to form pyrrolidinyl. In embodiments, L102 is taken together with R101 to form oxoheterocycloalkyl. Suitably the oxoheterocycloalkyl is 2-oxoimidazolidinyl. Suitably the oxoheterocycloalkyl is oxopyrrolidinyl. In embodiments, L102 is taken together with R101 to form heterocycloalky1-0-. Suitably the heterocycloalky1-0- is azetidiny1-0- or pyrrolidinyl-O-. Suitably the heterocycloalky1-0- is pyrrolidinyl-O-.
In embodiments, L103 is taken together with R103 to form imidazolidinyl or pyrrolidinyl.
Suitably L103 is taken together with R103 to form imidazolidinyl. Suitably L103 is taken together with R103 to form pyrrolidinyl. In embodiments, L103 is taken together with R103 to form oxoheterocycloalkyl. Suitably the oxoheterocycloalkyl is 2-oxoimidazolidinyl. Suitably the oxoheterocycloalkyl is oxopyrrolidinyl. In embodiments, L103 is taken together with R103 to form heterocycloalky1-0-. Suitably the heterocycloalky1-0- is azetidiny1-0- or pyrrolidinyl-O-. Suitably the heterocycloalky1-0- is pyrrolidinyl-O-.
In embodiments, L113 is taken together with R113 to form imidazolidinyl, pyrrolidinyl or cyclopropyl. In embodiments, L113 is taken together with R113 to form imidazolidinyl. In embodiments, L113 is taken together with R113 to form pyrrolidinyl. In embodiments, L113 is taken together with R113 to form oxoheterocycloalkyl. Suitably the oxoheterocycloalkyl is 2-oxoimidazolidinyl. Suitably the oxoheterocycloalkyl is oxopyrrolidinyl. In embodiments, L113 is taken together with R113 to form heterocycloalky1-0-. Suitably the heterocycloalkyl-0- is azetidiny1-0- or pyrrolidinyl-0-. Suitably the heterocycloalky1-0- is pyrrolidinyl-0-.
In embodiments, L122 is taken together with R121 to form imidazolidinyl or pyrrolidinyl.
In embodiments, L102 is taken together with R101 to form imidazolidinyl or pyrrolidinyl.
Suitably L192 is taken together with R101 to form imidazolidinyl. Suitably L192 is taken together with R101 to form pyrrolidinyl. In embodiments, L102 is taken together with R101 to form oxoheterocycloalkyl. Suitably the oxoheterocycloalkyl is 2-oxoimidazolidinyl. Suitably the oxoheterocycloalkyl is oxopyrrolidinyl. In embodiments, L102 is taken together with R101 to form heterocycloalky1-0-. Suitably the heterocycloalky1-0- is azetidiny1-0- or pyrrolidinyl-O-. Suitably the heterocycloalky1-0- is pyrrolidinyl-O-.
In embodiments, L103 is taken together with R103 to form imidazolidinyl or pyrrolidinyl.
Suitably L103 is taken together with R103 to form imidazolidinyl. Suitably L103 is taken together with R103 to form pyrrolidinyl. In embodiments, L103 is taken together with R103 to form oxoheterocycloalkyl. Suitably the oxoheterocycloalkyl is 2-oxoimidazolidinyl. Suitably the oxoheterocycloalkyl is oxopyrrolidinyl. In embodiments, L103 is taken together with R103 to form heterocycloalky1-0-. Suitably the heterocycloalky1-0- is azetidiny1-0- or pyrrolidinyl-O-. Suitably the heterocycloalky1-0- is pyrrolidinyl-O-.
In embodiments, L113 is taken together with R113 to form imidazolidinyl, pyrrolidinyl or cyclopropyl. In embodiments, L113 is taken together with R113 to form imidazolidinyl. In embodiments, L113 is taken together with R113 to form pyrrolidinyl. In embodiments, L113 is taken together with R113 to form oxoheterocycloalkyl. Suitably the oxoheterocycloalkyl is 2-oxoimidazolidinyl. Suitably the oxoheterocycloalkyl is oxopyrrolidinyl. In embodiments, L113 is taken together with R113 to form heterocycloalky1-0-. Suitably the heterocycloalkyl-0- is azetidiny1-0- or pyrrolidinyl-0-. Suitably the heterocycloalky1-0- is pyrrolidinyl-0-.
In embodiments, L122 is taken together with R121 to form imidazolidinyl or pyrrolidinyl.
- 66 -Suitably L122 is taken together with R121 to form imidazolidinyl. Suitably L122 is taken together with R121 to form pyrrolidinyl. In embodiments, L122 is taken together with R121 to form oxoheterocycloalkyl. Suitably the oxoheterocycloalkyl is 2-oxoimidazolidinyl. Suitably the oxoheterocycloalkyl is oxopyrrolidinyl. In embodiments, L122 is taken together with R121 to form heterocycloalky1-0-. Suitably the heterocycloalky1-0- is azetidiny1-0- or pyrrolidinyl-O-. Suitably the heterocycloalky1-0- is pyrrolidinyl-O-.
In embodiments, L123 is taken together with R123 to form imidazolidinyl or pyrrolidinyl.
Suitably L123 is taken together with R123 to form imidazolidinyl. Suitably L123 is taken together with R123 to form pyrrolidinyl. In embodiments, L123 is taken together with R123 to form oxoheterocycloalkyl. Suitably the oxoheterocycloalkyl is 2-oxoimidazolidinyl. Suitably the oxoheterocycloalkyl is oxopyrrolidinyl. In embodiments, L123 is taken together with R
to form heterocycloalky1-0-. Suitably the heterocycloalky1-0- is azetidiny1-0-or pyrrolidinyl-O-. Suitably the heterocycloalky1-0- is pyrrolidinyl-O-.
In embodiments, L133 is taken together with R133 to form imidazolidinyl or pyrrolidinyl.
Suitably L133 is taken together with R133 to form imidazolidinyl. Suitably L133 is taken together with R133 to form pyrrolidinyl. In embodiments, L133 is taken together with R133 to form oxoheterocycloalkyl. Suitably the oxoheterocycloalkyl is 2-oxoimidazolidinyl. Suitably the oxoheterocycloalkyl is oxopyrrolidinyl. In embodiments, L133 is taken together with R
to form heterocycloalky1-0-. Suitably the heterocycloalky1-0- is azetidiny1-0-or pyrrolidinyl-O-. Suitably the heterocycloalky1-0- is pyrrolidinyl-O-.
In embodiments, the symbol z2 is 0. In embodiments, the symbol z2 is 1.
In embodiments, the symbol z4 is 0. In embodiments, the symbol z4 is 1. In embodiments, the symbols z2 and z4 are 0. In embodiments, the symbols z2 and z4 are 1. In embodiments, the symbol z5 is 0. In embodiments, the symbol z5 is 1. In embodiments, the symbol z5 is 2. In embodiments, the symbol z5 is 3. In embodiments, the symbol z5 is 4. In embodiments, the symbol z6 is 0. In embodiments, the symbol z6 is 1. In embodiments, the symbol z6 is 2. In embodiments, the symbol z6 is 3. In embodiments, the symbol z6 is 4.
In embodiments, L123 is taken together with R123 to form imidazolidinyl or pyrrolidinyl.
Suitably L123 is taken together with R123 to form imidazolidinyl. Suitably L123 is taken together with R123 to form pyrrolidinyl. In embodiments, L123 is taken together with R123 to form oxoheterocycloalkyl. Suitably the oxoheterocycloalkyl is 2-oxoimidazolidinyl. Suitably the oxoheterocycloalkyl is oxopyrrolidinyl. In embodiments, L123 is taken together with R
to form heterocycloalky1-0-. Suitably the heterocycloalky1-0- is azetidiny1-0-or pyrrolidinyl-O-. Suitably the heterocycloalky1-0- is pyrrolidinyl-O-.
In embodiments, L133 is taken together with R133 to form imidazolidinyl or pyrrolidinyl.
Suitably L133 is taken together with R133 to form imidazolidinyl. Suitably L133 is taken together with R133 to form pyrrolidinyl. In embodiments, L133 is taken together with R133 to form oxoheterocycloalkyl. Suitably the oxoheterocycloalkyl is 2-oxoimidazolidinyl. Suitably the oxoheterocycloalkyl is oxopyrrolidinyl. In embodiments, L133 is taken together with R
to form heterocycloalky1-0-. Suitably the heterocycloalky1-0- is azetidiny1-0-or pyrrolidinyl-O-. Suitably the heterocycloalky1-0- is pyrrolidinyl-O-.
In embodiments, the symbol z2 is 0. In embodiments, the symbol z2 is 1.
In embodiments, the symbol z4 is 0. In embodiments, the symbol z4 is 1. In embodiments, the symbols z2 and z4 are 0. In embodiments, the symbols z2 and z4 are 1. In embodiments, the symbol z5 is 0. In embodiments, the symbol z5 is 1. In embodiments, the symbol z5 is 2. In embodiments, the symbol z5 is 3. In embodiments, the symbol z5 is 4. In embodiments, the symbol z6 is 0. In embodiments, the symbol z6 is 1. In embodiments, the symbol z6 is 2. In embodiments, the symbol z6 is 3. In embodiments, the symbol z6 is 4.
- 67 -The skilled artisan will appreciate that salts, including pharmaceutically acceptable salts, of the compounds according to Formula (1110) may be prepared. Indeed, in certain embodiments of the invention, salts including pharmaceutically-acceptable salts of the compounds according to Formula (1110) may be preferred over the respective free or unsalted compound. Accordingly, the invention is further directed to salts, including pharmaceutically-acceptable salts, of the compounds according to Formula (1110).
The salts, including pharmaceutically acceptable salts, of the compounds of the invention are readily prepared by those of skill in the art.
Typically, the salts of the present invention are pharmaceutically acceptable salts.
Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention.
Representative pharmaceutically acceptable acid addition salts include, but are not limited to, 4-acetamidobenzoate, acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate (besylate), benzoate, bisulfate, bitartrate, butyrate, calcium edetate, camphorate, camphorsulfonate (camsylate), caprate (decanoate), caproate (hexanoate), caprylate (octanoate), cinnamate, citrate, cyclamate, dig luconate, 2,5-dihydroxybenzoate, disuccinate, dodecylsulfate (estolate), edetate (ethylenediaminetetraacetate), estolate (lauryl sulfate), ethane-1 ,2-disulfonate (edisylate), ethanesulfonate (esylate), formate, fumarate, galactarate (mucate), gentisate (2,5-dihydroxybenzoate), glucoheptonate (gluceptate), gluconate, glucuronate, glutamate, glutarate, glycerophosphorate, glycolate, hexylresorcinate, hippurate, hydrabamine (N,N'-di(dehydroabiety1)-ethylenediamine), hydrobromide, hydrochloride, hydroiodide, hydroxynaphthoate, isobutyrate, lactate, lactobionate, laurate, malate, maleate, malonate, mandelate, methanesulfonate (mesylate), methylsulf ate, mucate, naphthalene-1 ,5-disulfonate (napadisylate), naphthalene-2-sulfonate (napsylate), nicotinate, nitrate, oleate, palmitate, p-aminobenzenesulfonate, p-aminosalicyclate, pamoate (embonate), pantothenate, pectinate, persulfate, phenylacetate, phenylethylbarbiturate, phosphate, polygalacturonate, propionate, p-toluenesulfonate (tosylate), pyroglutamate, pyruvate, salicylate, sebacate, stearate, subacetate, succinate, sulfamate, sulfate, tannate, tartrate, teoclate (8-chlorotheophyllinate), thiocyanate, triethiodide, undecanoate, undecylenate, and valerate.
Representative pharmaceutically acceptable base addition salts include, but are not limited to, aluminium, 2-amino-2-(hydroxymethyl)-1 ,3-propanediol (TRIS, tromethamine), arginine, benethamine (N-benzylphenethylamine), benzathine (N,N'-
The salts, including pharmaceutically acceptable salts, of the compounds of the invention are readily prepared by those of skill in the art.
Typically, the salts of the present invention are pharmaceutically acceptable salts.
Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention.
Representative pharmaceutically acceptable acid addition salts include, but are not limited to, 4-acetamidobenzoate, acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate (besylate), benzoate, bisulfate, bitartrate, butyrate, calcium edetate, camphorate, camphorsulfonate (camsylate), caprate (decanoate), caproate (hexanoate), caprylate (octanoate), cinnamate, citrate, cyclamate, dig luconate, 2,5-dihydroxybenzoate, disuccinate, dodecylsulfate (estolate), edetate (ethylenediaminetetraacetate), estolate (lauryl sulfate), ethane-1 ,2-disulfonate (edisylate), ethanesulfonate (esylate), formate, fumarate, galactarate (mucate), gentisate (2,5-dihydroxybenzoate), glucoheptonate (gluceptate), gluconate, glucuronate, glutamate, glutarate, glycerophosphorate, glycolate, hexylresorcinate, hippurate, hydrabamine (N,N'-di(dehydroabiety1)-ethylenediamine), hydrobromide, hydrochloride, hydroiodide, hydroxynaphthoate, isobutyrate, lactate, lactobionate, laurate, malate, maleate, malonate, mandelate, methanesulfonate (mesylate), methylsulf ate, mucate, naphthalene-1 ,5-disulfonate (napadisylate), naphthalene-2-sulfonate (napsylate), nicotinate, nitrate, oleate, palmitate, p-aminobenzenesulfonate, p-aminosalicyclate, pamoate (embonate), pantothenate, pectinate, persulfate, phenylacetate, phenylethylbarbiturate, phosphate, polygalacturonate, propionate, p-toluenesulfonate (tosylate), pyroglutamate, pyruvate, salicylate, sebacate, stearate, subacetate, succinate, sulfamate, sulfate, tannate, tartrate, teoclate (8-chlorotheophyllinate), thiocyanate, triethiodide, undecanoate, undecylenate, and valerate.
Representative pharmaceutically acceptable base addition salts include, but are not limited to, aluminium, 2-amino-2-(hydroxymethyl)-1 ,3-propanediol (TRIS, tromethamine), arginine, benethamine (N-benzylphenethylamine), benzathine (N,N'-
- 68 -dibenzylethylenediamine), bis-(2-hydroxyethyl)amine, bismuth, calcium, chloroprocaine, choline, clemizole (1-p chlorobenzy1-2-pyrrolildine-1'-ylmethylbenzimidazole), cyclohexylamine, dibenzylethylenediamine, diethylamine, diethyltriamine, dimethylamine, dimethylethanolamine, dopamine, ethanolamine, ethylenediamine, L-histidine, iron, isoquinoline, lepidine, lithium, lysine, magnesium, meglumine (N-methylglucamine), piperazine, piperidine, potassium, procaine, quinine, quinoline, sodium, strontium, t-butylamine, and zinc.
The compounds according to Formula (1110) may contain one or more asymmetric centers (also referred to as a chiral center) and may, therefore, exist as individual enantiomers, diastereomers, or other stereoisomeric forms, or as mixtures thereof. Chiral centers, such as chiral carbon atoms, may be present in a substituent such as an alkyl group. Where the stereochemistry of a chiral center present in a compound of Formula (1110), or in any chemical structure illustrated herein, if not specified the structure is intended to encompass all individual stereoisomers and all mixtures thereof.
Thus, compounds according to Formula (1110) containing one or more chiral centers may be used as racemic mixtures, enantiomerically or diastereomerically enriched mixtures, or as enantiomerically or diastereomerically pure individual stereoisomers.
The compounds according to Formula (1110) and pharmaceutically acceptable salts thereof may contain isotopically-labelled compounds, which are identical to those recited in Formula (1110) and following, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of such isotopes include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulphur, fluorine, iodine, and chlorine, such as 2H, 3H, 110, 130, 140, 15N, 170, 180, 31P, 32P, 35S, 18F, 3601, 1231 and 1251.
Isotopically-labelled compounds, for example those into which radioactive isotopes such as 3H or 140 are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 140, isotopes are particularly preferred for their ease of preparation and detectability. 110 and 18F isotopes are particularly useful in PET (positron emission tomography), and 1251 isotopes are particularly useful in SPECT
(single photon emission computerized tomography), both are useful in brain imaging.
Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labelled compounds can generally be prepared by substituting
The compounds according to Formula (1110) may contain one or more asymmetric centers (also referred to as a chiral center) and may, therefore, exist as individual enantiomers, diastereomers, or other stereoisomeric forms, or as mixtures thereof. Chiral centers, such as chiral carbon atoms, may be present in a substituent such as an alkyl group. Where the stereochemistry of a chiral center present in a compound of Formula (1110), or in any chemical structure illustrated herein, if not specified the structure is intended to encompass all individual stereoisomers and all mixtures thereof.
Thus, compounds according to Formula (1110) containing one or more chiral centers may be used as racemic mixtures, enantiomerically or diastereomerically enriched mixtures, or as enantiomerically or diastereomerically pure individual stereoisomers.
The compounds according to Formula (1110) and pharmaceutically acceptable salts thereof may contain isotopically-labelled compounds, which are identical to those recited in Formula (1110) and following, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of such isotopes include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulphur, fluorine, iodine, and chlorine, such as 2H, 3H, 110, 130, 140, 15N, 170, 180, 31P, 32P, 35S, 18F, 3601, 1231 and 1251.
Isotopically-labelled compounds, for example those into which radioactive isotopes such as 3H or 140 are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 140, isotopes are particularly preferred for their ease of preparation and detectability. 110 and 18F isotopes are particularly useful in PET (positron emission tomography), and 1251 isotopes are particularly useful in SPECT
(single photon emission computerized tomography), both are useful in brain imaging.
Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labelled compounds can generally be prepared by substituting
- 69 -a readily available isotopically labelled reagent for a non-isotopically labelled reagent.
The compounds according to Formula (1110) may also contain double bonds or other centers of geometric asymmetry. Where the stereochemistry of a center of geometric asymmetry present in Formula (1110), or in any chemical structure illustrated herein, is not specified, the structure is intended to encompass the trans (E) geometric isomer, the cis (Z) geometric isomer, and all mixtures thereof. Likewise, all tautomeric forms are also included in Formula (1110) whether such tautomers exist in equilibrium or predominately in one form.
The compounds of Formula (1110) or salts, including pharmaceutically acceptable salts, thereof may exist in solid or liquid form. In the solid state, the compounds of the invention may exist in crystalline or noncrystalline form, or as a mixture thereof. For compounds of the invention that are in crystalline form, the skilled artisan will appreciate that pharmaceutically acceptable solvates may be formed wherein solvent molecules are incorporated into the crystalline lattice during crystallization. Solvates wherein water is the solvent that is incorporated into the crystalline lattice are typically referred to as "hydrates."
Hydrates include stoichiometric hydrates as well as compositions containing vaiable amounts of water.
The skilled artisan will further appreciate that certain compounds of Formula (1110) or salts, including pharmaceutically acceptable salts thereof that exist in crystalline form, including the various solvates thereof, may exhibit polymorphism (i.e. the capacity to occur in different crystalline structures). These different crystalline forms are typically known as "polymorphs." Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of the crystalline solid state.
Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification. The skilled artisan will appreciate that different polymorphs may be produced, for example, by changing or adjusting the reaction conditions or reagents, used in making the compound. For example, changes in temperature, pressure, or solvent may result in polymorphs. In addition, one polymorph may spontaneously convert to another polymorph under certain conditions.
While aspects for each variable have generally been listed above separately for each variable this invention includes those compounds in which several or each aspect in
The compounds according to Formula (1110) may also contain double bonds or other centers of geometric asymmetry. Where the stereochemistry of a center of geometric asymmetry present in Formula (1110), or in any chemical structure illustrated herein, is not specified, the structure is intended to encompass the trans (E) geometric isomer, the cis (Z) geometric isomer, and all mixtures thereof. Likewise, all tautomeric forms are also included in Formula (1110) whether such tautomers exist in equilibrium or predominately in one form.
The compounds of Formula (1110) or salts, including pharmaceutically acceptable salts, thereof may exist in solid or liquid form. In the solid state, the compounds of the invention may exist in crystalline or noncrystalline form, or as a mixture thereof. For compounds of the invention that are in crystalline form, the skilled artisan will appreciate that pharmaceutically acceptable solvates may be formed wherein solvent molecules are incorporated into the crystalline lattice during crystallization. Solvates wherein water is the solvent that is incorporated into the crystalline lattice are typically referred to as "hydrates."
Hydrates include stoichiometric hydrates as well as compositions containing vaiable amounts of water.
The skilled artisan will further appreciate that certain compounds of Formula (1110) or salts, including pharmaceutically acceptable salts thereof that exist in crystalline form, including the various solvates thereof, may exhibit polymorphism (i.e. the capacity to occur in different crystalline structures). These different crystalline forms are typically known as "polymorphs." Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of the crystalline solid state.
Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification. The skilled artisan will appreciate that different polymorphs may be produced, for example, by changing or adjusting the reaction conditions or reagents, used in making the compound. For example, changes in temperature, pressure, or solvent may result in polymorphs. In addition, one polymorph may spontaneously convert to another polymorph under certain conditions.
While aspects for each variable have generally been listed above separately for each variable this invention includes those compounds in which several or each aspect in
- 70 -Formula (1110) is selected from each of the aspects listed above. Therefore, this invention is intended to include all combinations of aspects for each variable.
Definitions "Alkyl" and "alkylene", and derivatives thereof, refer to a hydrocarbon chain having the specified number of "member atoms". Alkyl being monovalent and alkylene being bivalent For example, 01-06 alkyl refers to an alkyl group having from 1 to 6 member atoms. Alkyl and alkylene groups may be saturated, unsaturated, straight or branched.
Representative branched alkyl groups have one, two, or three branches. Alkyl and alkylene include:
methyl, ethyl, ethylene, propyl (n-propyl and isopropyl), butene, butyl (n-butyl, isobutyl, and t-butyl), pentyl and hexyl.
"Alkoxy" refers to an -0-alkyl group wherein "alkyl" is as defined herein. For example, 01 -C4alkoxy refers to an alkoxy group having from 1 to 4 member atoms.
Representative branched alkoxy groups have one, two, or three branches. Examples of such groups include methoxy, ethoxy, propoxy, and butoxy.
"Aryl" refers to an aromatic hydrocarbon ring. Aryl groups are monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring member atoms, wherein at least one ring system is aromatic and wherein each ring in the system contains 3 to 7 member atoms, such as phenyl, naphthalene, tetrahydronaphthalene and biphenyl.
Suitably aryl is phenyl.
"Cycloalkyl", unless otherwise defined, refers to a saturated or unsaturated non aromatic hydrocarbon ring having from three to seven carbon atoms. Cycloalkyl groups are monocyclic ring systems. For example, 03-07 cycloalkyl refers to a cycloalkyl group having from 3 to 7 member atoms. Examples of cycloalkyl as used herein include:
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and cycloheptyl. Suitably cycolalkyl is selected from: cyclopropyl, cyclobutyl and cyclohexyl. Suitably cycolalkyl is cyclopropyl.
"Halo" refers to fluoro, chloro, bromo, and iodo.
"Heteroaryl" refers to a monocyclic aromatic 4 to 8 member ring containing 1 to 7 carbon atoms and containing 1 to 4 heteroatoms, provided that when the number of carbon atoms is 3, the aromatic ring contains at least two heteroatoms, or to such aromatic ring is fused
Definitions "Alkyl" and "alkylene", and derivatives thereof, refer to a hydrocarbon chain having the specified number of "member atoms". Alkyl being monovalent and alkylene being bivalent For example, 01-06 alkyl refers to an alkyl group having from 1 to 6 member atoms. Alkyl and alkylene groups may be saturated, unsaturated, straight or branched.
Representative branched alkyl groups have one, two, or three branches. Alkyl and alkylene include:
methyl, ethyl, ethylene, propyl (n-propyl and isopropyl), butene, butyl (n-butyl, isobutyl, and t-butyl), pentyl and hexyl.
"Alkoxy" refers to an -0-alkyl group wherein "alkyl" is as defined herein. For example, 01 -C4alkoxy refers to an alkoxy group having from 1 to 4 member atoms.
Representative branched alkoxy groups have one, two, or three branches. Examples of such groups include methoxy, ethoxy, propoxy, and butoxy.
"Aryl" refers to an aromatic hydrocarbon ring. Aryl groups are monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring member atoms, wherein at least one ring system is aromatic and wherein each ring in the system contains 3 to 7 member atoms, such as phenyl, naphthalene, tetrahydronaphthalene and biphenyl.
Suitably aryl is phenyl.
"Cycloalkyl", unless otherwise defined, refers to a saturated or unsaturated non aromatic hydrocarbon ring having from three to seven carbon atoms. Cycloalkyl groups are monocyclic ring systems. For example, 03-07 cycloalkyl refers to a cycloalkyl group having from 3 to 7 member atoms. Examples of cycloalkyl as used herein include:
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and cycloheptyl. Suitably cycolalkyl is selected from: cyclopropyl, cyclobutyl and cyclohexyl. Suitably cycolalkyl is cyclopropyl.
"Halo" refers to fluoro, chloro, bromo, and iodo.
"Heteroaryl" refers to a monocyclic aromatic 4 to 8 member ring containing 1 to 7 carbon atoms and containing 1 to 4 heteroatoms, provided that when the number of carbon atoms is 3, the aromatic ring contains at least two heteroatoms, or to such aromatic ring is fused
- 71 -one or more rings, such as heteroaryl rings, aryl rings, heterocyclic rings, or cycloalkyl rings. Heteroaryl groups containing more than one heteroatom may contain different heteroatoms. Heteroaryl includes but is not limited to: benzoimidazolyl, benzothiazolyl, benzothiophenyl, benzopyrazinyl, benzotriazolyl, benzotriazinyl, benzo[1,4]dioxanyl, benzofuranyl, 9H-a-carbolinyl, cinnolinyl, furanyl, pyrazolyl, imidazolyi, indolizinyl, naphthyridinyl, oxazolyl, oxothiadiazolyl, oxadiazolyl, phthalazinyl, pyridyl, pyrrolyl, purinyl, pteridinyl, phenazinyl, pyrazolopyrimidinyl, pyrazolopyridinyl, pyrrolizinyl, pyrimidyl, isothiazolyl, furazanyl, pyrimidinyl, tetrazinyl, isoxazolyl, quinoxalinyl, quinazolinyl, quinolinyl, quinolizinyl, thienyl, thiophenyl, triazolyl, triazinyl, tetrazolopyrimidinyl, triazolopyrimidinyl, tetrazolyl, thiazolyl and thiazolidinyl. Suitably heteroaryl is selected from: pyrazolyl, imiciazolyi, oxazolyl and thienyl. Suitably heteroaryl is a pyridyl group or an imidazolyl group. Suitably heteroaryl is a pyridyl.
"Heterocycloalkyl" refers to a saturated or unsaturated non-aromatic ring containing 4 to 12 member atoms, of which 1 to 11 are carbon atoms and from 1 to 6 are heteroatoms.
Heterocycloalkyl groups containing more than one heteroatom may contain different heteroatoms. Heterocycloalkyl groups are monocyclic ring systems or a monocyclic ring fused with an aryl ring or to a heteroaryl ring having from 3 to 6 member atoms.
Heterocycloalkyl includes: pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, pyranyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothienyl, pyrazolidinyl, oxazolidinyl, imidazolidinyl, oxetanyl, thiazolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, 1,3-dioxolanyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-oxathiolanyl, 1,3-oxathianyl, 1,3-dithianyl, 1,3oxazolidin-2-one, hexahydro-1H-azepin, 4,5,6,7,tetrahydro-1H-benzimidazol, piperidinyl, 1 ,2,3 ,6-tetrahydro-pyridinyl and azetidinyl. Suitably, "heterocycloalkyl" includes: piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, imidazolidinyl, oxetanyl, and pyrrolidinyl. Suitably, "heterocycloalkyl" is selected from:
imidazolidinyl, tetrahydropyranyl and pyrrolidinyl.
"Heteroatom" refers to a nitrogen, sulfur or oxygen atom.
"Heteroalkyl" and "heteroalkylene" by itself or in combination with another term, means, unless otherwise stated, a non-cyclic stable straight or branched chain, or combinations thereof, including at least one carbon atom (and up to the number specified) and at least one heteroatom selected from the group consisting of 0, N, P, Si, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. For example, C1_6heteroalkyl(ene) contains at least one and up
"Heterocycloalkyl" refers to a saturated or unsaturated non-aromatic ring containing 4 to 12 member atoms, of which 1 to 11 are carbon atoms and from 1 to 6 are heteroatoms.
Heterocycloalkyl groups containing more than one heteroatom may contain different heteroatoms. Heterocycloalkyl groups are monocyclic ring systems or a monocyclic ring fused with an aryl ring or to a heteroaryl ring having from 3 to 6 member atoms.
Heterocycloalkyl includes: pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, pyranyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothienyl, pyrazolidinyl, oxazolidinyl, imidazolidinyl, oxetanyl, thiazolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, 1,3-dioxolanyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-oxathiolanyl, 1,3-oxathianyl, 1,3-dithianyl, 1,3oxazolidin-2-one, hexahydro-1H-azepin, 4,5,6,7,tetrahydro-1H-benzimidazol, piperidinyl, 1 ,2,3 ,6-tetrahydro-pyridinyl and azetidinyl. Suitably, "heterocycloalkyl" includes: piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, imidazolidinyl, oxetanyl, and pyrrolidinyl. Suitably, "heterocycloalkyl" is selected from:
imidazolidinyl, tetrahydropyranyl and pyrrolidinyl.
"Heteroatom" refers to a nitrogen, sulfur or oxygen atom.
"Heteroalkyl" and "heteroalkylene" by itself or in combination with another term, means, unless otherwise stated, a non-cyclic stable straight or branched chain, or combinations thereof, including at least one carbon atom (and up to the number specified) and at least one heteroatom selected from the group consisting of 0, N, P, Si, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. For example, C1_6heteroalkyl(ene) contains at least one and up
- 72 -to 6 carbon atoms, in addition to at least one heteroatom. Heteroalkyl being monovalent and heteroalkylene being bivalent. The heteroalkyl and heteroalkylene groups may be taken together with another substituent to form a heterocycloalkyl group.
The heteroatom(s) 0, N, P, S, and Si may be placed at any interior position of the heteroalkyl or heteroalkylene group or at the position at which the alkyl group is attached to the remainder of the molecule. Heteroalkyl examples include, but are not limited to:
-CH2-CH2-0-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)2, -CH2-S-CH2-CH3, -5(0)-CH3, -CH2-CH2-S(0)2-CH3, -CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N-OCH3, -CH=CHN(CH3)2, -0-CH3, -0-CH2-CH3, -ON. Heteroalkylene examples include, but are not limited to:
-CH2-CH2-0-CH2-, -CH2-CH2-NH-CH2-, -CH2-CH2-N(CH3)CH2-, -CH2-S-CH2-CH2-, -5(0)-CH2-, -CH2-CH2-S(0)2-CH2-, -CH=CH-O-CH2-, -Si(CH3)20H2-, ¨N(CH3)CH2¨, -0-CH2-CH2-CH2-, -CH2-CH=N-OCH2-, -CH=CHN(CH3)CH2-, -0-CH2-, and -0-CH2-CH2-. Up to two or three heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and --CH2-0-Si(CH3)3.
To clarify the obvious intent, "2-oxoimidazolidinyl" as used herein, is meant the SLNANH N N
monovalent substituent \-1 , or the bivalent substituent depending on it's linkage to the rest of the molecule. Similarly, all other ring substituents used herein may be monovalent, bivalent, etc, depending on it's linkage to the rest of the molecule.
"Substituted" as used herein, unless otherwise defined, is meant that the subject chemical moiety has from one to nine substituents, suitably from one to five substituents, selected from the group consisting of:
fluoro, chloro, bromo, iodo,
The heteroatom(s) 0, N, P, S, and Si may be placed at any interior position of the heteroalkyl or heteroalkylene group or at the position at which the alkyl group is attached to the remainder of the molecule. Heteroalkyl examples include, but are not limited to:
-CH2-CH2-0-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)2, -CH2-S-CH2-CH3, -5(0)-CH3, -CH2-CH2-S(0)2-CH3, -CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N-OCH3, -CH=CHN(CH3)2, -0-CH3, -0-CH2-CH3, -ON. Heteroalkylene examples include, but are not limited to:
-CH2-CH2-0-CH2-, -CH2-CH2-NH-CH2-, -CH2-CH2-N(CH3)CH2-, -CH2-S-CH2-CH2-, -5(0)-CH2-, -CH2-CH2-S(0)2-CH2-, -CH=CH-O-CH2-, -Si(CH3)20H2-, ¨N(CH3)CH2¨, -0-CH2-CH2-CH2-, -CH2-CH=N-OCH2-, -CH=CHN(CH3)CH2-, -0-CH2-, and -0-CH2-CH2-. Up to two or three heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and --CH2-0-Si(CH3)3.
To clarify the obvious intent, "2-oxoimidazolidinyl" as used herein, is meant the SLNANH N N
monovalent substituent \-1 , or the bivalent substituent depending on it's linkage to the rest of the molecule. Similarly, all other ring substituents used herein may be monovalent, bivalent, etc, depending on it's linkage to the rest of the molecule.
"Substituted" as used herein, unless otherwise defined, is meant that the subject chemical moiety has from one to nine substituents, suitably from one to five substituents, selected from the group consisting of:
fluoro, chloro, bromo, iodo,
- 73 -Ci_6alkyl, C1_6alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, and ¨ON, -001_6alkyl, -001_6alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, and ¨ON, mercapto, -SR, where Rx is selected from 01 alkyl, and 01 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, and ¨ON, -S(0)Rx, where Rx is selected from 01 alkyl, and 01 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, and ¨ON, -S(0)2Rx, where Rx is selected from 01 alkyl, and 01 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH,
- 74 --000H, -NH2, and ¨ON, oxo, hydroxy, amino, -NHRx, where Rx is selected from 01_6alkyl, and 01-6alkyl substituted with from Ito 6 substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, and ¨ON, -NRx1Rx2, where Rx1 and Rx2 are each independently selected from 01 alkyl, and 01 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, and ¨ON, guanidino, -0(0)0H, -0(0)0Rx, where Rx is selected from 01_6alkyl, and 01-6alkyl substituted with from Ito 6 substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, and ¨ON, -C(0)NH2, -C(0)NHRx, where Rx is selected from 01_6alkyl, and 01-6alkyl
- 75 -substituted with from Ito 6 substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, and ¨ON, -0(0)NRx1Rx2, x 5 where R1 and Rx2 are each independently selected from 01 alkyl, and 01 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, and ¨ON, -S(0)2NH2, -S(0)2NHRx, where Rx is selected from 01_6alkyl, and 01-6alkyl substituted with from Ito 6 substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, and ¨ON, -S(0)2NRx1Rx2, where Rx1 and Rx2 are each independently selected from 01 alkyl, and 01 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, and ¨ON, -NHS(0)2H, -NHS(0)2Rx, where Rx is selected from 01 alkyl, and 01 alkyl substituted with from Ito 6 substituents
- 76 -independently selected from: fluoro, oxo, -OH, -000H, -NH2, and ¨ON, -NHC(0)H, -NHC(0)Rx, where Rx is selected from 01_6alkyl, and 01-6alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, and ¨ON, -NHC(0)NH2, -NHC(0)NHRx, where Rx is selected from 01_6alkyl, and 01-6alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, and ¨ON, -NHC(0)NRx1Rx2, where Rx1 and Rx2 are each independently selected from 01 alkyl, and 01 alkyl substituted with from 1 to 6 Substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, and ¨ON, nitro, and cyan 0.
Suitably "substituted" means the subject chemical moiety has from one to four substituents selected from the group consisting of:
fluoro, chloro,
Suitably "substituted" means the subject chemical moiety has from one to four substituents selected from the group consisting of:
fluoro, chloro,
- 77 -bra ma, iodo, Ci_4alkyl, Ci_4alkyl substituted with from 1 to 4 substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, and ¨ON, -001_4a1ky1, -001_4a1ky1 substituted with from 1 to 4 substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, and ¨ON, -SH, oxo, hydroxy, amino, -NHRx, where Rx is selected from 01_4a1ky1, and 01 alkyl substituted one to 4 times by fluoro, -NRx1 Rx2, where Rx1 and Rx2 are each independently selected from 01_4a1ky1, and 01_4a1ky1 substituted one to four times by fluoro, guanidino, -0(0)0H, -C(0)0Rx,
- 78 -where Rx is selected from Ci _4a1ky1, and Ci_4alkyl substituted one to four times by fluoro, -C(0)NE12, -C(0)NHRx, where Rx is selected from Ci _4a1ky1, and Ci_4alkyl substituted one to four times by fluoro, -C(0)NRx1 Rx2, where Rx1 and Rx2 are each independently selected from Ci _4a1ky1, and Ci _4a1ky1 substituted one to four times by fluoro, -S(0)2NH2, -NHS(0)2H, -NHC(0)H, -NHC(0)NH2, nitro, and cyan 0.
Suitably "substituted" means the subject chemical moiety has from one to four substituents selected from the group consisting of:
fluoro, chloro, bromo, iodo, Cl _4a1ky1, C-1-4alkyl substituted with from 1 to 4 substituents
Suitably "substituted" means the subject chemical moiety has from one to four substituents selected from the group consisting of:
fluoro, chloro, bromo, iodo, Cl _4a1ky1, C-1-4alkyl substituted with from 1 to 4 substituents
- 79 -independently selected from: fluoro, oxo, -OH, -000H, -NH2, -N1-101_3a1ky1, -N(Ci _3a1ky1)2, ¨001_4a1ky1 and ¨ON, -001_4a1ky1, -001_4a1ky1 substituted with from 1 to 4 substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, -NHC1_3a1ky1, -N(Ci _3a1ky1)2, and ¨ON, -SH, oxo, hydroxy, amino, -NHRx, where Rx is selected from 01_4a1ky1, and 01_4a1ky1 substituted one to 4 times by fluoro, -NRx1Rx2, where Rx1 and Rx2 are each independently selected from 01_4a1ky1, and 01_4a1ky1 substituted one to four times by fluoro, guanidino, -0(0)0H, -0(0)0Rx, where Rx is selected from 01_4a1ky1, and 01_4a1ky1 substituted one to four times by fluoro,
- 80 --C(0)NH2, -C(0)NHRx, where Rx is selected from Ci_4alkyl, and Ci_4alkyl substituted one to four times by fluoro, -C(0)NRx1 Rx2, where Rxl and Rx2 are each independently selected from Ci_4alkyl, and Ci_4alkyl substituted one to four times by fluoro, -S(0)2NH2, -NHS(0)2H, -NHC(0)H, -NHC(0)NH2, nitro, and cyan 0.
Suitably "substituted" means the subject chemical moiety has from one to four substituents selected from the group consisting of:
fluoro, chloro, bromo, iodo, Ci_4alkyl, Ci_4alkyl substituted with from 1 to 4 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, -NHCH3, -N(CH3)2, -OCH3,
Suitably "substituted" means the subject chemical moiety has from one to four substituents selected from the group consisting of:
fluoro, chloro, bromo, iodo, Ci_4alkyl, Ci_4alkyl substituted with from 1 to 4 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, -NHCH3, -N(CH3)2, -OCH3,
- 81 --OCH2CH3, and ¨ON, -001_4a1ky1, -001_4a1ky1 substituted with from 1 to 4 substituents independently selected from: fluoro, oxo, -OH, -000H, -NH2, -NHCH3, -N(0H3)2, and ¨ON, -SH, oxo, hydroxy, amino, -NHRx, where Rx is selected from 01_4a1ky1, and 01 alkyl substituted one to 4 times by fluoro, -NRx1Rx2, where Rx1 and Rx2 are each independently selected from 01_4a1ky1, and 01_4a1ky1 substituted one to four times by fluoro, guanidino, -0(0)0H, -0(0)0Rx, where Rx is selected from 01_4a1ky1, and 01_4a1ky1 substituted one to four times by fluoro, -C(0)NH2, -0(0)NHRx,
- 82 -where Rx is selected from Ci _4a1ky1, and Ci_4alkyl substituted one to four times by fluoro, -0(0)NRx1Rx2, where Rx1 and Rx2 are each independently selected from Ci _4a1ky1, and Ci _4a1ky1 substituted one to four times by fluoro, -S(0)2NH2, -NHS(0)2H, -NHC(0)H, -NHC(0)NH2, nitro, and cyan 0.
Suitably "substituted" means the subject chemical moiety has from one to three substituents selected from the group consisting of:
fluoro, chloro, bromo, Ci _4a1ky1, -001_4a1ky1, oxo, hydroxy, amino, -0(0)0H, -0(0)NE12, nitro, and
Suitably "substituted" means the subject chemical moiety has from one to three substituents selected from the group consisting of:
fluoro, chloro, bromo, Ci _4a1ky1, -001_4a1ky1, oxo, hydroxy, amino, -0(0)0H, -0(0)NE12, nitro, and
- 83 -cyan 0.
As used herein the symbols and conventions used in these processes, schemes and examples are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry. Standard single-letter or three-letter abbreviations are generally used to designate amino acid residues, which are assumed to be in the L-configuration unless otherwise noted. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification. Specifically, the following abbreviations may be used in the examples and throughout the specification:
Ac (acetyl);
ACN (acetonitrile);
BH3.Me2S (borane dimethylsulfide compex);
Bn (benzyl);
Boc (tert-Butoxycarbonyl);
CAN (cerric ammonium nitrate);
C18 (refers to 18-carbon alkyl groups on silicon in HPLC stationary phase);
CH3CN (acetonitrile);
DCM (dichloromethane);
DIAD (diisopropyl azodicarboxylate);
Dioxane (1,4-dioxane);
DMF (N,N-dimethylformamide);
DMSO (dimethylsulfoxide);
Et3N (triethylamine);
Et0Ac (ethyl acetate);
Et20 (diethyl ether);
HCI (hydrochloric acid);
HEPES (4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid);
HPLC (high pressure liquid chromatography);
IPA (isopropyl alcohol);
As used herein the symbols and conventions used in these processes, schemes and examples are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry. Standard single-letter or three-letter abbreviations are generally used to designate amino acid residues, which are assumed to be in the L-configuration unless otherwise noted. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification. Specifically, the following abbreviations may be used in the examples and throughout the specification:
Ac (acetyl);
ACN (acetonitrile);
BH3.Me2S (borane dimethylsulfide compex);
Bn (benzyl);
Boc (tert-Butoxycarbonyl);
CAN (cerric ammonium nitrate);
C18 (refers to 18-carbon alkyl groups on silicon in HPLC stationary phase);
CH3CN (acetonitrile);
DCM (dichloromethane);
DIAD (diisopropyl azodicarboxylate);
Dioxane (1,4-dioxane);
DMF (N,N-dimethylformamide);
DMSO (dimethylsulfoxide);
Et3N (triethylamine);
Et0Ac (ethyl acetate);
Et20 (diethyl ether);
HCI (hydrochloric acid);
HEPES (4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid);
HPLC (high pressure liquid chromatography);
IPA (isopropyl alcohol);
- 84 -K2003 (potassium carbonate);
Li0H.H20 (lithium hydroxide monohydrate);
Me0H (methanol);
NaCNBH3 (sodium cyanoborohydride);
NaHCO3 (sodium bicarbonate);
NaOH (sodium hydroxide);
Na2SO4 (sodium sulfate);
NH401 (ammonium chloride);
rt (room temperature);
TLC (thin layer chromatography);
TEA (triethylamine);
TFA (trifluoroacetic acid);
THF (tetrahydrofuran); and T3Pe (2,4,6-tripropy1-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide).
All references to ether are to diethyl ether and brine refers to a saturated aqueous solution of NaCI.
Methods of Use The compounds according to Formula (1110) and pharmaceutically acceptable salts thereof are inhibitors of the ATF4 pathway. Compounds which are inhibitors of the ATF4 pathway are readily identified by exhibiting activity in the ATF4 Cell Based Assay below.
These compounds are potentially useful in the treatment of conditions wherein the underlying pathology is attributable to (but not limited to) modulation of the elF2alpha pathway, for example, neurodegenerative disorders, cancer, cardiovascular and metabolic diseases. Accordingly, in another aspect the invention is directed to methods of treating such conditions.
The Integrated Stress Response (ISR) is a collection of cellular stress response pathways that converge in phosphorylation of the translation initiation factor elF2a resulting in a reduction in overall translation in cells. Mammalian cells have four elF2a kinases that phosphorylate this initiation factor in the same residue (serine 51); PERK is activated by the accumulation of unfolded proteins in the endoplasmic reticulum (ER),
Li0H.H20 (lithium hydroxide monohydrate);
Me0H (methanol);
NaCNBH3 (sodium cyanoborohydride);
NaHCO3 (sodium bicarbonate);
NaOH (sodium hydroxide);
Na2SO4 (sodium sulfate);
NH401 (ammonium chloride);
rt (room temperature);
TLC (thin layer chromatography);
TEA (triethylamine);
TFA (trifluoroacetic acid);
THF (tetrahydrofuran); and T3Pe (2,4,6-tripropy1-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide).
All references to ether are to diethyl ether and brine refers to a saturated aqueous solution of NaCI.
Methods of Use The compounds according to Formula (1110) and pharmaceutically acceptable salts thereof are inhibitors of the ATF4 pathway. Compounds which are inhibitors of the ATF4 pathway are readily identified by exhibiting activity in the ATF4 Cell Based Assay below.
These compounds are potentially useful in the treatment of conditions wherein the underlying pathology is attributable to (but not limited to) modulation of the elF2alpha pathway, for example, neurodegenerative disorders, cancer, cardiovascular and metabolic diseases. Accordingly, in another aspect the invention is directed to methods of treating such conditions.
The Integrated Stress Response (ISR) is a collection of cellular stress response pathways that converge in phosphorylation of the translation initiation factor elF2a resulting in a reduction in overall translation in cells. Mammalian cells have four elF2a kinases that phosphorylate this initiation factor in the same residue (serine 51); PERK is activated by the accumulation of unfolded proteins in the endoplasmic reticulum (ER),
- 85 -GCN2 is activated by amino acid starvation, PKR by viral infection and HRI by heme deficiency. Activation of these kinases decreases bulk protein synthesis but it also culminates in increased expression of specific mRNAs that contain uORFs. Two examples of these mRNAs are the transcription factor ATF4 and the pro-apoptotic gene CHOP. Phosphorylation of elF2a upon stress and the concomitant reduction in protein translation has been shown to both have cytoprotective and cytotoxic effects depending on the cellular context and duration and severity of the stress. An integrated stress response-associated disease is a disease characterized by increased activity in the integrated stress response (e.g. increased phosphorylation of elF2a by an elF2a kinase compared to a control such as a subject without the disease). A disease associated with phosphorylation of elF2a is disease characterized by an increase in phosphorylation of elF2a relative to a control, such as a subject without the disease.
Activation of PERK occurs upon ER stress and hypoxic conditions and its activation and effect on translation has been shown to be cytoprotective for tumor cells [17]. Adaptation to hypoxia in the tumor microenvironment is critical for survival and metastatic potential. PERK has also been shown to promote cancer proliferation by limiting oxidative DNA damage and death [18, 19]. Moreover, a newly identified PERK
inhibitor has been shown to have antitumor activity in a human pancreatic tumor xenog raft model [20]. Compounds disclosed herein decrease the viability of cells that are subjected to ER-stress. Thus, pharmacological and acute inhibition of the PERK
branch with the compounds disclosed herein results in reduced cellular fitness.
During tumor growth, compounds disclosed herein, that block the cytoprotective effects of elF2a phosphorylation upon stress may prove to be potent anti-proliferative agents.
It is known that under certain stress conditions several elF2a kinases can be simultaneously activated. For example, during tumor growth, the lack of nutrients and hypoxic conditions are known to both activate GCN2 and PERK. Like PERK, GCN2 and their common target, ATF4, have been proposed to play a cytoprotective role [21]. By blocking signaling by both kinases, compounds disclosed herein may bypass the ability of the ISR to protect cancer cells against the effects of low nutrients and oxygen levels encountered during the growth of the tumor.
Prolonged ER stress leads to the accumulation of CHOP, a pro-apoptotic molecule. In a prion mouse model, overexpression of the phosphatase of elF2a increased survival of prion- infected mice whereas sustained elF2a phosphorylation decreased survival [22]. The restoration of protein translation rates during prion disease
Activation of PERK occurs upon ER stress and hypoxic conditions and its activation and effect on translation has been shown to be cytoprotective for tumor cells [17]. Adaptation to hypoxia in the tumor microenvironment is critical for survival and metastatic potential. PERK has also been shown to promote cancer proliferation by limiting oxidative DNA damage and death [18, 19]. Moreover, a newly identified PERK
inhibitor has been shown to have antitumor activity in a human pancreatic tumor xenog raft model [20]. Compounds disclosed herein decrease the viability of cells that are subjected to ER-stress. Thus, pharmacological and acute inhibition of the PERK
branch with the compounds disclosed herein results in reduced cellular fitness.
During tumor growth, compounds disclosed herein, that block the cytoprotective effects of elF2a phosphorylation upon stress may prove to be potent anti-proliferative agents.
It is known that under certain stress conditions several elF2a kinases can be simultaneously activated. For example, during tumor growth, the lack of nutrients and hypoxic conditions are known to both activate GCN2 and PERK. Like PERK, GCN2 and their common target, ATF4, have been proposed to play a cytoprotective role [21]. By blocking signaling by both kinases, compounds disclosed herein may bypass the ability of the ISR to protect cancer cells against the effects of low nutrients and oxygen levels encountered during the growth of the tumor.
Prolonged ER stress leads to the accumulation of CHOP, a pro-apoptotic molecule. In a prion mouse model, overexpression of the phosphatase of elF2a increased survival of prion- infected mice whereas sustained elF2a phosphorylation decreased survival [22]. The restoration of protein translation rates during prion disease
- 86 -was shown to rescue synaptic deficits and neuronal loss. The compounds disclosed herein that make cells insensitive to elF2a phosphorylation sustain protein translation.
Compounds disclosed herein could prove potent inhibitors of neuronal cell death in prion disease by blocking the deleterious effects of prolonged elF2a phosphorylation. Given the prevalence of protein misfolding and activation on the UPR in several neurodegenerative diseases (e.g. Alzheimer's (AD) and Parkinson's (PD)), manipulation of the PERK-elF2a branch could prevent synaptic failure and neuronal death across the spectrum of these disorders.
Another example of tissue-specific pathology that is linked to heightened elF2a phosphorylation is the fatal brain disorder, vanishing white matter disease (VWM) or childhood ataxia with CNS hypomyelination (CACH). This disease has been linked to mutation in elF2B, the GTP exchange factor that is necessary for elF2 function in translation [23]. elF2a phosphorylation inhibits the activity of elF2B and mutations in this exchange factor that reduce its exchange activity exacerbate the effects of elF2a phosphorylation. The severe consequences of the CACH mutations point to the dangers of UPR hyper-activation, especially as it pertains to the myelin-producing oligodendrocyte. Small molecules, such as compounds disclosed herein, that block signaling through elF2a phosphorylation may reduce the deleterious effects of its hyper-activation in VWM.
In another aspect is provided a method of improving long-term memory in a patient, which comprises administering a therapeutically effective amount of a compound of Formula (11 10) to the patient. In embodiments, the patient is human. In embodiments, the patient is a mammal.
The compounds of this invention inhibit the integrated stress response which is implicated in the pathogenesis of neurological disorders. Suitably the present invention relates to a method for treating or lessening the severity of neurological disorders.
Suitably, the disorders treatable with the compounds of the invention include:
Alcoholism, Anxiety, Depression, Schizophrenia, Bipolar Disorder, Obsessive Compulsive Disorder, Panic Disorder, Chronic Pain, Obesity, Senile Dementia, Migraine, Bulimia, Anorexia, Social Phobia, Pre-Menstrual Syndrome (PMS), Adolescent Depression, Trichotillomania, Dysthymia and Substance Abuse.
In embodiments, the neurological disorder is treated in a human patient.
Compounds disclosed herein could prove potent inhibitors of neuronal cell death in prion disease by blocking the deleterious effects of prolonged elF2a phosphorylation. Given the prevalence of protein misfolding and activation on the UPR in several neurodegenerative diseases (e.g. Alzheimer's (AD) and Parkinson's (PD)), manipulation of the PERK-elF2a branch could prevent synaptic failure and neuronal death across the spectrum of these disorders.
Another example of tissue-specific pathology that is linked to heightened elF2a phosphorylation is the fatal brain disorder, vanishing white matter disease (VWM) or childhood ataxia with CNS hypomyelination (CACH). This disease has been linked to mutation in elF2B, the GTP exchange factor that is necessary for elF2 function in translation [23]. elF2a phosphorylation inhibits the activity of elF2B and mutations in this exchange factor that reduce its exchange activity exacerbate the effects of elF2a phosphorylation. The severe consequences of the CACH mutations point to the dangers of UPR hyper-activation, especially as it pertains to the myelin-producing oligodendrocyte. Small molecules, such as compounds disclosed herein, that block signaling through elF2a phosphorylation may reduce the deleterious effects of its hyper-activation in VWM.
In another aspect is provided a method of improving long-term memory in a patient, which comprises administering a therapeutically effective amount of a compound of Formula (11 10) to the patient. In embodiments, the patient is human. In embodiments, the patient is a mammal.
The compounds of this invention inhibit the integrated stress response which is implicated in the pathogenesis of neurological disorders. Suitably the present invention relates to a method for treating or lessening the severity of neurological disorders.
Suitably, the disorders treatable with the compounds of the invention include:
Alcoholism, Anxiety, Depression, Schizophrenia, Bipolar Disorder, Obsessive Compulsive Disorder, Panic Disorder, Chronic Pain, Obesity, Senile Dementia, Migraine, Bulimia, Anorexia, Social Phobia, Pre-Menstrual Syndrome (PMS), Adolescent Depression, Trichotillomania, Dysthymia and Substance Abuse.
In embodiments, the neurological disorder is treated in a human patient.
- 87 -The compounds of this invention inhibit the integrated stress response which is implicated in the pathogenesis of pain. Visceral pain is pain associated with the viscera, which encompass the internal organs of the body. These organs include, e.g., the heart, lungs, reproductive organs, bladder, ureters, the digestive organs, liver, pancreas, spleen, and kidneys. There are a variety of conditions in which visceral pain may exist, such as, for example, pancreatitis, labor, abdominal surgery associated with ileus, cystitis, menstrual period, or dysmenorrhea. Likewise, kidney pain, epigastric pain, pleural pain, and painful biliary colic, appendicitis pain may all be considered to be visceral pain.
Substernal pain or pressure from early myocardial infarction is also visceral.
Diseases of the stomach, dudenum or colon can cause visceral pain. Commonly encountered gastrointestinal (GI) disorders that cause visceral pain include functional bowel disorder (FBD) and inflammatory bowel disease (IBD). These GI disorders include a wide range of disease states that are currently only moderately controlled, including, with respect to FBD, gastro-esophageal reflux, dyspepsia, irritable bowel syndrome (IBS) and functional abdominal pain syndrome (FAPS), and, with respect to 1BD, Crohn's disease, ileitis and ulcerative colitis, all of which regularly produce visceral pain.
Suitably the present invention relates to a method for treating or lessening the severity of pain. The invention can alleviate pain from many causes, including but not limited to shock; limb amputation; severe chemical or thermal burn injury;
sprains, ligament tears, fractures, wounds and other tissue injuries; dental surgery, procedures and maladies; labor and delivery; migraine; during physical therapy; post operative pain;
radiation poisoning; cancer; acquired immunodeficiency syndrome (AIDS);
epidural (or peridural) fibrosis; failed back surgery and failed laminectomy; sciatica;
painful sickle cell crisis; arthritis; autoimmune disease; intractable bladder pain; and the like.
The present invention is directed to the treatment of intractible pain, whatever its cause.
In embodiments, pain is treated in a human patient.
The compounds of this invention inhibit the unfolded protein response which is implicated in the pathogenesis of inter vertebral disc degeneration. Suitably the present invention relates to a method for treating or lessening the severity of vertebral disc degeneration.
In embodiments, the compounds set forth herein are provided as pharmaceutical compositions comprising the compound and a pharmaceutically acceptable excipient. In embodiments of the method, the compound, or a pharmaceutically acceptable salt
Substernal pain or pressure from early myocardial infarction is also visceral.
Diseases of the stomach, dudenum or colon can cause visceral pain. Commonly encountered gastrointestinal (GI) disorders that cause visceral pain include functional bowel disorder (FBD) and inflammatory bowel disease (IBD). These GI disorders include a wide range of disease states that are currently only moderately controlled, including, with respect to FBD, gastro-esophageal reflux, dyspepsia, irritable bowel syndrome (IBS) and functional abdominal pain syndrome (FAPS), and, with respect to 1BD, Crohn's disease, ileitis and ulcerative colitis, all of which regularly produce visceral pain.
Suitably the present invention relates to a method for treating or lessening the severity of pain. The invention can alleviate pain from many causes, including but not limited to shock; limb amputation; severe chemical or thermal burn injury;
sprains, ligament tears, fractures, wounds and other tissue injuries; dental surgery, procedures and maladies; labor and delivery; migraine; during physical therapy; post operative pain;
radiation poisoning; cancer; acquired immunodeficiency syndrome (AIDS);
epidural (or peridural) fibrosis; failed back surgery and failed laminectomy; sciatica;
painful sickle cell crisis; arthritis; autoimmune disease; intractable bladder pain; and the like.
The present invention is directed to the treatment of intractible pain, whatever its cause.
In embodiments, pain is treated in a human patient.
The compounds of this invention inhibit the unfolded protein response which is implicated in the pathogenesis of inter vertebral disc degeneration. Suitably the present invention relates to a method for treating or lessening the severity of vertebral disc degeneration.
In embodiments, the compounds set forth herein are provided as pharmaceutical compositions comprising the compound and a pharmaceutically acceptable excipient. In embodiments of the method, the compound, or a pharmaceutically acceptable salt
- 88 -thereof, is co-adminstered with a second agent (e.g. therapeutic agent). In embodiments of the method, the compound, or a pharmaceutically acceptable salt thereof, is co-adminstered with a second agent (e.g. therapeutic agent), which is administered in a therapeutically effective amount. In embodiments, the second agent is an agent for improving memory.
Induction of long-term memory (LTM) has been shown to be facilitated by decreased and impaired by increased elF2a phosphorylation. The data strongly support the notion that under physiological conditions, a decrease in elF2a phosphorylation constitutes a critical step for the long term synaptic changes required for memory formation and ATF4 has been shown to be an important regulator of these processes [24]
[25] [26]. It is not known what the contributions of the different elF2a kinases to learning is or whether each play a differential role in the different parts of the brain. Regardless of the elF2a kinase/s responsible for phosphorylation of elF2a in the brain, compounds disclosed herein that block translation and ATF4 production make them ideal molecules to block the effects of this phosphorylation event on memory. Pharmacological treatment with compounds disclosed herein increase spatial memory and enhance auditory and contextual fear conditioning.
Regulators of translation, such as the compounds of Formula (I I IQ), could serve as therapeutic agents that improve memory in human disorders associated with memory loss such as Alzheimer's disease and in other neurological disorders that activate the UPR in neurons and thus could have negative effects on memory consolidation such as Parkinson's disease, Amyotrophic lateral sclerosis and prion diseases. In addition, a mutation in elF2y, that disrupts complex integrity linked intellectual disability (intellectual disability syndrome or ID) to impaired translation initiation in humans [27]. Hence, two diseases with impaired elF2 function, ID
and VWM, display distinct phenotypes but both affect mainly the brain and impair learning.
The compounds of Formula (1110) are also useful in applications where increasing protein production output is desirable, such as in vitro cell free systems for protein production. In vitro systems have basal levels of elF2a phosphorylation that reduce translational output [28, 29]. Similarly, production of antibodies by hybridomas may also be improved by addition of compounds disclosed herein.
In another aspect is provided a method of increasing protein expression of a cell or in vitro expression system, which comprises administering an effective amount of a
Induction of long-term memory (LTM) has been shown to be facilitated by decreased and impaired by increased elF2a phosphorylation. The data strongly support the notion that under physiological conditions, a decrease in elF2a phosphorylation constitutes a critical step for the long term synaptic changes required for memory formation and ATF4 has been shown to be an important regulator of these processes [24]
[25] [26]. It is not known what the contributions of the different elF2a kinases to learning is or whether each play a differential role in the different parts of the brain. Regardless of the elF2a kinase/s responsible for phosphorylation of elF2a in the brain, compounds disclosed herein that block translation and ATF4 production make them ideal molecules to block the effects of this phosphorylation event on memory. Pharmacological treatment with compounds disclosed herein increase spatial memory and enhance auditory and contextual fear conditioning.
Regulators of translation, such as the compounds of Formula (I I IQ), could serve as therapeutic agents that improve memory in human disorders associated with memory loss such as Alzheimer's disease and in other neurological disorders that activate the UPR in neurons and thus could have negative effects on memory consolidation such as Parkinson's disease, Amyotrophic lateral sclerosis and prion diseases. In addition, a mutation in elF2y, that disrupts complex integrity linked intellectual disability (intellectual disability syndrome or ID) to impaired translation initiation in humans [27]. Hence, two diseases with impaired elF2 function, ID
and VWM, display distinct phenotypes but both affect mainly the brain and impair learning.
The compounds of Formula (1110) are also useful in applications where increasing protein production output is desirable, such as in vitro cell free systems for protein production. In vitro systems have basal levels of elF2a phosphorylation that reduce translational output [28, 29]. Similarly, production of antibodies by hybridomas may also be improved by addition of compounds disclosed herein.
In another aspect is provided a method of increasing protein expression of a cell or in vitro expression system, which comprises administering an effective amount of a
- 89 -compound of Formula (IIIQ) to the cell or expression system. In embodiments, the method is a method of increasing protein expression by a cell and includes administering an effective amount of a compound of Formula (IIIQ) to the cell.
In embodiments, the method is a method of increasing protein expression by an in vitro protein expression system and includes administering an effective amount of a compound of Formula (I I IQ) to the in vitro (e.g. cell free) protein expression system.
In embodiments, the compounds set forth herein are provided as pharmaceutical compositions comprising the compound and a pharmaceutically acceptable excipient. In embodiments of the method, the compound, or a pharmaceutically acceptable salt thereof, is co-adminstered with a second agent. In embodiments of the method, the compound, or a pharmaceutically acceptable salt thereof, is co-adminstered with a second agent, which is administered in a therapeutically effective amount. In embodiments, the second agent is an agent for improving protein expression.
Suitably, the present invention relates to a method for treating or lessening the severity of breast cancer, including inflammatory breast cancer, ductal carcinoma, and lobular carcinoma.
Suitably the present invention relates to a method for treating or lessening the severity of colon cancer.
Suitably the present invention relates to a method for treating or lessening the severity of pancreatic cancer, including insulinomas, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, and glucagonoma.
Suitably the present invention relates to a method for treating or lessening the severity of skin cancer, including melanoma, including metastatic melanoma.
Suitably the present invention relates to a method for treating or lessening the severity of lung cancer including small cell lung cancer, non-small cell lung cancer, squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.
Suitably the present invention relates to a method for treating or lessening the severity of cancers selected from the group consisting of brain (gliomas), glioblastomas, astrocytomas, glioblastoma multiforme, Bannayan-Zonana syndrome, Cowden disease,
In embodiments, the method is a method of increasing protein expression by an in vitro protein expression system and includes administering an effective amount of a compound of Formula (I I IQ) to the in vitro (e.g. cell free) protein expression system.
In embodiments, the compounds set forth herein are provided as pharmaceutical compositions comprising the compound and a pharmaceutically acceptable excipient. In embodiments of the method, the compound, or a pharmaceutically acceptable salt thereof, is co-adminstered with a second agent. In embodiments of the method, the compound, or a pharmaceutically acceptable salt thereof, is co-adminstered with a second agent, which is administered in a therapeutically effective amount. In embodiments, the second agent is an agent for improving protein expression.
Suitably, the present invention relates to a method for treating or lessening the severity of breast cancer, including inflammatory breast cancer, ductal carcinoma, and lobular carcinoma.
Suitably the present invention relates to a method for treating or lessening the severity of colon cancer.
Suitably the present invention relates to a method for treating or lessening the severity of pancreatic cancer, including insulinomas, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, and glucagonoma.
Suitably the present invention relates to a method for treating or lessening the severity of skin cancer, including melanoma, including metastatic melanoma.
Suitably the present invention relates to a method for treating or lessening the severity of lung cancer including small cell lung cancer, non-small cell lung cancer, squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.
Suitably the present invention relates to a method for treating or lessening the severity of cancers selected from the group consisting of brain (gliomas), glioblastomas, astrocytomas, glioblastoma multiforme, Bannayan-Zonana syndrome, Cowden disease,
- 90 -Lhermitte-Duclos disease, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma, medulloblastoma, head and neck, kidney, liver, melanoma, ovarian, pancreatic, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, insulinoma, prostate, sarcoma, osteosarcoma, giant cell tumor of bone, thyroid, lymphoblastic T cell leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, hairy-cell leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic neutrophilic leukemia, acute lymphoblastic T
cell leukemia, plasmacytoma, lmmunoblastic large cell leukemia, mantle cell leukemia, multiple myeloma, megakaryoblastic leukemia, multiple myeloma, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, malignant lymphoma, hodgkins lymphoma, non-hodgkins lymphoma, lymphoblastic T cell lymphoma, Burkitt's lymphoma, follicular lymphoma, neuroblastoma, bladder cancer, urothelial cancer, vulval cancer, cervical cancer, endometrial cancer, renal cancer, mesothelioma, esophageal cancer, salivary gland cancer, hepatocellular cancer, gastric cancer, nasopharangeal cancer, buccal cancer, cancer of the mouth, GIST (gastrointestinal stromal tumor), neuroendocrine cancers and testicular cancer.
Suitably the present invention relates to a method for treating or lessening the severity of pre-cancerous syndromes in a mammal, including a human, wherein the pre-cancerous syndrome is selected from: cervical intraepithelial neoplasia, monoclonal gammapathy of unknown significance (MGUS), myelodysplastic syndrome, aplastic anemia, cervical lesions, skin nevi (pre-melanoma), prostatic intraepithleial (intraductal) neoplasia (PIN), Ductal Carcinoma in situ (DCIS), colon polyps and severe hepatitis or cirrhosis.
Suitably the present invention relates to a method for treating or lessening the severity of neurodegenerative diseases/injury, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the .. transportation of organs for transplantation.
cell leukemia, plasmacytoma, lmmunoblastic large cell leukemia, mantle cell leukemia, multiple myeloma, megakaryoblastic leukemia, multiple myeloma, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, malignant lymphoma, hodgkins lymphoma, non-hodgkins lymphoma, lymphoblastic T cell lymphoma, Burkitt's lymphoma, follicular lymphoma, neuroblastoma, bladder cancer, urothelial cancer, vulval cancer, cervical cancer, endometrial cancer, renal cancer, mesothelioma, esophageal cancer, salivary gland cancer, hepatocellular cancer, gastric cancer, nasopharangeal cancer, buccal cancer, cancer of the mouth, GIST (gastrointestinal stromal tumor), neuroendocrine cancers and testicular cancer.
Suitably the present invention relates to a method for treating or lessening the severity of pre-cancerous syndromes in a mammal, including a human, wherein the pre-cancerous syndrome is selected from: cervical intraepithelial neoplasia, monoclonal gammapathy of unknown significance (MGUS), myelodysplastic syndrome, aplastic anemia, cervical lesions, skin nevi (pre-melanoma), prostatic intraepithleial (intraductal) neoplasia (PIN), Ductal Carcinoma in situ (DCIS), colon polyps and severe hepatitis or cirrhosis.
Suitably the present invention relates to a method for treating or lessening the severity of neurodegenerative diseases/injury, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the .. transportation of organs for transplantation.
- 91 -Suitably the present invention relates to a method for preventing organ damage during and after organ transplantation and in the transportation of organs for transplantation. The method of preventing organ damage during and after organ transplantation comprises the in vivo administration of a compound of Formula (1110). The method of preventing organ damage during the transportation of organs for transplantation comprises adding a compound of Formula (1110) to the solution housing the organ during transportation.
Suitably, the present invention relates to a method for treating or lessening the severity of neurodegernative ocular diseases, wherein the disease is retinitis pigmentosa.
Suitably, the present invention relates to a method for treating or lessening the severity of ocular diseases, wherein the disease is selected from retinal dystrophies and corneal dystrophies, such as Fuch's corneal dystrophy.
Suitably the present invention relates to a method for treating or lessening the severity of ocular diseases/angiogenesis. The method of treating or lessening the severity of ocular diseases/angiogenesis comprises the in vivo administration of a compound of Formula (III). In embodiments of methods according to the invention, the disorder of ocular diseases, including vascular leakage can be: edema or neovascularization for any occlusive or inflammatory retinal vascular disease, such as rubeosis irides, neovascular glaucoma, pterygium, vascularized glaucoma filtering blebs, conjunctival papilloma;
choroidal neovascularization, such as neovascular age-related macular degeneration (AMD), myopia, prior uveitis, trauma, or idiopathic; macular edema, such as post surgical macular edema, macular edema secondary to uveitis including retinal and/or choroidal inflammation, macular edema secondary to diabetes, and macular edema secondary to retinovascular occlusive disease (i.e. branch and central retinal vein occlusion); retinal neovascularization due to diabetes, such as retinal vein occlusion, uveitis, ocular ischemic syndrome from carotid artery disease, ophthalmic or retinal artery occlusion, sickle cell retinopathy, other ischemic or occlusive neovascular retinopathies, retinopathy of prematurity, or Eale's Disease; and genetic disorders, such as VonHippel-Lindau syndrome.
In some embodiments, the neovascular age-related macular degeneration is wet age-related macular degeneration. In other embodiments, the neovascular age-related macular degeneration is dry age-related macular degeneration and the patient is characterized as being at increased risk of developing wet age-related macular degeneration.
Suitably, the present invention relates to a method for treating or lessening the severity of neurodegernative ocular diseases, wherein the disease is retinitis pigmentosa.
Suitably, the present invention relates to a method for treating or lessening the severity of ocular diseases, wherein the disease is selected from retinal dystrophies and corneal dystrophies, such as Fuch's corneal dystrophy.
Suitably the present invention relates to a method for treating or lessening the severity of ocular diseases/angiogenesis. The method of treating or lessening the severity of ocular diseases/angiogenesis comprises the in vivo administration of a compound of Formula (III). In embodiments of methods according to the invention, the disorder of ocular diseases, including vascular leakage can be: edema or neovascularization for any occlusive or inflammatory retinal vascular disease, such as rubeosis irides, neovascular glaucoma, pterygium, vascularized glaucoma filtering blebs, conjunctival papilloma;
choroidal neovascularization, such as neovascular age-related macular degeneration (AMD), myopia, prior uveitis, trauma, or idiopathic; macular edema, such as post surgical macular edema, macular edema secondary to uveitis including retinal and/or choroidal inflammation, macular edema secondary to diabetes, and macular edema secondary to retinovascular occlusive disease (i.e. branch and central retinal vein occlusion); retinal neovascularization due to diabetes, such as retinal vein occlusion, uveitis, ocular ischemic syndrome from carotid artery disease, ophthalmic or retinal artery occlusion, sickle cell retinopathy, other ischemic or occlusive neovascular retinopathies, retinopathy of prematurity, or Eale's Disease; and genetic disorders, such as VonHippel-Lindau syndrome.
In some embodiments, the neovascular age-related macular degeneration is wet age-related macular degeneration. In other embodiments, the neovascular age-related macular degeneration is dry age-related macular degeneration and the patient is characterized as being at increased risk of developing wet age-related macular degeneration.
- 92 -
93 PCT/IN2018/050375 In embodiments, the ocular disease is treated in a human patient.
The methods of treatment of the invention comprise administering an effective amount of a compound according to Formula (1110) or a pharmaceutically acceptable salt, thereof to a patient in need thereof.
The invention also provides a compound according to Formula (1110) or a pharmaceutically-acceptable salt thereof for use in medical therapy, and particularly in therapy for: cancer, pre-cancerous syndromes, Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, in organ transplantation and arrhythmias. The invention also provides a compound according to Formula (1110) or a pharmaceutically-acceptable salt thereof for use in preventing organ damage during the transportation of organs for transplantation.
Thus, in further aspect, the invention is directed to the use of a compound according to Formula (1110) or a pharmaceutically acceptable salt thereof in the manfacture of a medicament for the treatment of a disorder characterized by activation of the UPR, such as cancer.
The methods of treatment of the invention comprise administering a safe and effective amount of a compound of Formula (1110), or a pharmaceutically acceptable salt thereof to a mammal, suitably a human, in need thereof.
As used herein, "treating", and derivatives thereof, in reference to a condition means: (1) to ameliorate or prevent the condition or one or more of the biological manifestations of the condition, (2) to interfere with (a) one or more points in the biological cascade that leads to or is responsible for the condition or (b) one or more of the biological manifestations of the condition, (3) to alleviate one or more of the symptoms or effects associated with the condition, or (4) to slow the progression of the condition or one or more .. of the biological manifestations of the condition.
The term "treating" and derivatives thereof refers to therapeutic therapy.
Therapeutic therapy is appropriate to alleviate symptions or to treat at early signs of disease or its progression. Prophylactic therapy is appropriate when a subject has, for example, a strong family history of neurodegenerative diseases. Prophylactic therapy is appropriate when a subject has, for example, a strong family history of cancer or is otherwise considered at high risk for developing cancer, or when a subject has been exposed to a carcinogen.
The skilled artisan will appreciate that "prevention" is not an absolute term.
In medicine, "prevention" is understood to refer to the prophylactic administration of a drug to substantially diminish the likelihood or severity of a condition or biological manifestation thereof, or to delay the onset of such condition or biological manifestation thereof.
As used herein, "safe and effective amount" in reference to a compound of Formula (1110), or a pharmaceutically acceptable salt thereof, means an amount of the compound sufficient to treat the patient's condition but low enough to avoid serious side effects (at a reasonable benefit/risk ratio) within the scope of sound medical judgment. A
safe and effective amount of the compound will vary with the particular route of administration chosen; the condition being treated; the severity of the condition being treated; the age, size, weight, and physical condition of the patient being treated; the medical history of the patient to be treated; the duration of the treatment; the nature of concurrent therapy; the desired therapeutic effect; and like factors, but can nevertheless be routinely determined by the skilled artisan.
As used herein, "patient", and derivatives thereof refers to a human or other mammal, suitably a human.
The compounds of Formula (1110) or pharmaceutically acceptable salts thereof may be administered by any suitable route of administration, including systemic administration.
Systemic administration includes oral administration, and parenteral administration.
Parenteral administration refers to routes of administration other than enteral, transdermal, or by inhalation, and is typically by injection or infusion. Parenteral administration includes intravenous, intramuscular, and subcutaneous injection or infusion.
The compounds of Formula (1110) or pharmaceutically acceptable salts thereof may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered
The methods of treatment of the invention comprise administering an effective amount of a compound according to Formula (1110) or a pharmaceutically acceptable salt, thereof to a patient in need thereof.
The invention also provides a compound according to Formula (1110) or a pharmaceutically-acceptable salt thereof for use in medical therapy, and particularly in therapy for: cancer, pre-cancerous syndromes, Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, in organ transplantation and arrhythmias. The invention also provides a compound according to Formula (1110) or a pharmaceutically-acceptable salt thereof for use in preventing organ damage during the transportation of organs for transplantation.
Thus, in further aspect, the invention is directed to the use of a compound according to Formula (1110) or a pharmaceutically acceptable salt thereof in the manfacture of a medicament for the treatment of a disorder characterized by activation of the UPR, such as cancer.
The methods of treatment of the invention comprise administering a safe and effective amount of a compound of Formula (1110), or a pharmaceutically acceptable salt thereof to a mammal, suitably a human, in need thereof.
As used herein, "treating", and derivatives thereof, in reference to a condition means: (1) to ameliorate or prevent the condition or one or more of the biological manifestations of the condition, (2) to interfere with (a) one or more points in the biological cascade that leads to or is responsible for the condition or (b) one or more of the biological manifestations of the condition, (3) to alleviate one or more of the symptoms or effects associated with the condition, or (4) to slow the progression of the condition or one or more .. of the biological manifestations of the condition.
The term "treating" and derivatives thereof refers to therapeutic therapy.
Therapeutic therapy is appropriate to alleviate symptions or to treat at early signs of disease or its progression. Prophylactic therapy is appropriate when a subject has, for example, a strong family history of neurodegenerative diseases. Prophylactic therapy is appropriate when a subject has, for example, a strong family history of cancer or is otherwise considered at high risk for developing cancer, or when a subject has been exposed to a carcinogen.
The skilled artisan will appreciate that "prevention" is not an absolute term.
In medicine, "prevention" is understood to refer to the prophylactic administration of a drug to substantially diminish the likelihood or severity of a condition or biological manifestation thereof, or to delay the onset of such condition or biological manifestation thereof.
As used herein, "safe and effective amount" in reference to a compound of Formula (1110), or a pharmaceutically acceptable salt thereof, means an amount of the compound sufficient to treat the patient's condition but low enough to avoid serious side effects (at a reasonable benefit/risk ratio) within the scope of sound medical judgment. A
safe and effective amount of the compound will vary with the particular route of administration chosen; the condition being treated; the severity of the condition being treated; the age, size, weight, and physical condition of the patient being treated; the medical history of the patient to be treated; the duration of the treatment; the nature of concurrent therapy; the desired therapeutic effect; and like factors, but can nevertheless be routinely determined by the skilled artisan.
As used herein, "patient", and derivatives thereof refers to a human or other mammal, suitably a human.
The compounds of Formula (1110) or pharmaceutically acceptable salts thereof may be administered by any suitable route of administration, including systemic administration.
Systemic administration includes oral administration, and parenteral administration.
Parenteral administration refers to routes of administration other than enteral, transdermal, or by inhalation, and is typically by injection or infusion. Parenteral administration includes intravenous, intramuscular, and subcutaneous injection or infusion.
The compounds of Formula (1110) or pharmaceutically acceptable salts thereof may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered
- 94 -until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound of the invention depend on the pharmacokinetic properties of that compound, such as absorption, distribution, and half-life, which can be determined by the skilled artisan. In addition, suitable dosing regimens, including the duration such regimens are administered, for a compound of the invention depend on the condition being treated, the severity of the condition being treated, the age and physical condition of the patient being treated, the medical history of the patient to be treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual patient's response to the dosing regimen or over time as individual patient needs change.
Additionally, the compounds of Formula (1110) or pharmaceutically-acceptable salts thereof may be administered as prodrugs. As used herein, a "prodrug" of a compound of the invention is a functional derivative of the compound which, upon administration to a patient, eventually liberates the compound of the invention in vivo.
Administration of a compound of the invention as a prodrug may enable the skilled artisan to do one or more of the following: (a) modify the onset of the compound in vivo; (b) modify the duration of action of the compound in vivo; (c) modify the transportation or distribution of the compound in vivo; (d) modify the solubility of the compound in vivo; and (e) overcome a side effect or other difficulty encountered with the compound. Where a -COOH
or -OH
group is present, pharmaceutically acceptable esters can be employed, for example methyl, ethyl, and the like for -COOH, and acetate, maleate, and the like for -OH, and those esters known in the art for modifying solubility or hydrolysis characteristics.
The compounds of Formula (1110) and pharmaceutically acceptable salts thereof may be co-administered with at least one other active agent known to be useful in the treatment of cancer or pre-cancerous syndromes.
By the term "co-administration" as used herein is meant either simultaneous administration or any manner of separate sequential administration of an ATF4 pathway inhibiting compound, as described herein, and a further active agent or agents, known to be useful in the treatment of cancer, including chemotherapy and radiation treatment. The term further active agent or agents, as used herein, includes any compound or therapeutic agent known to or that demonstrates advantageous properties when administered to a patient in need of treatment for cancer.
Preferably, if the administration is not
Additionally, the compounds of Formula (1110) or pharmaceutically-acceptable salts thereof may be administered as prodrugs. As used herein, a "prodrug" of a compound of the invention is a functional derivative of the compound which, upon administration to a patient, eventually liberates the compound of the invention in vivo.
Administration of a compound of the invention as a prodrug may enable the skilled artisan to do one or more of the following: (a) modify the onset of the compound in vivo; (b) modify the duration of action of the compound in vivo; (c) modify the transportation or distribution of the compound in vivo; (d) modify the solubility of the compound in vivo; and (e) overcome a side effect or other difficulty encountered with the compound. Where a -COOH
or -OH
group is present, pharmaceutically acceptable esters can be employed, for example methyl, ethyl, and the like for -COOH, and acetate, maleate, and the like for -OH, and those esters known in the art for modifying solubility or hydrolysis characteristics.
The compounds of Formula (1110) and pharmaceutically acceptable salts thereof may be co-administered with at least one other active agent known to be useful in the treatment of cancer or pre-cancerous syndromes.
By the term "co-administration" as used herein is meant either simultaneous administration or any manner of separate sequential administration of an ATF4 pathway inhibiting compound, as described herein, and a further active agent or agents, known to be useful in the treatment of cancer, including chemotherapy and radiation treatment. The term further active agent or agents, as used herein, includes any compound or therapeutic agent known to or that demonstrates advantageous properties when administered to a patient in need of treatment for cancer.
Preferably, if the administration is not
- 95 -simultaneous, the compounds are administered in a close time proximity to each other.
Furthermore, it does not matter if the compounds are administered in the same dosage form, e.g. one compound may be administered by injection and another compound may be administered orally.
Typically, any anti-neoplastic agent that has activity versus a susceptible tumor being treated may be co-administered in the treatment of cancer in the present invention.
Examples of such agents can be found in Cancer Principles and Practice of Oncology by V.T. Devita and S. Hellman (editors), 6th edition (February 15, 2001), Lippincott Williams &
Wilkins Publishers. A person of ordinary skill in the art would be able to discern which combinations of agents would be useful based on the particular characteristics of the drugs and the cancer involved. Typical anti-neoplastic agents useful in the present invention include, but are not limited to, anti-microtubule agents such as diterpenoids and vinca alkaloids; platinum coordination complexes; alkylating agents such as nitrogen mustards, oxazaphosphorines, alkylsulfonates, nitrosoureas, and triazenes; antibiotic agents such as anthracyclins, actinomycins and bleomycins; topoisomerase ll inhibitors such as epipodophyllotoxins; antimetabolites such as purine and pyrimidine analogues and anti-folate compounds; topoisomerase I inhibitors such as camptothecins; hormones and hormonal analogues; signal transduction pathway inhibitors; non-receptor tyrosine kinase angiogenesis inhibitors; immunotherapeutic agents; proapoptotic agents; cell cycle signaling inhibitors; proteasome inhibitors; and inhibitors of cancer metabolism.
Examples of a further active ingredient or ingredients (anti-neoplastic agent) for use in combination or co-administered with the presently invented ATF4 pathway inhibiting compounds are chemotherapeutic agents.
Suitably, the pharmaceutically active compounds of the invention are used in combination with a VEGFR inhibitor, suitably 5-[[4-[(2,3-dimethy1-2H-indazol-6-Amethylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt, suitably the monohydrochloride salt thereof, which is disclosed and claimed in in International Application No. PCT/US01/49367, having an International filing date of December 19, 2001, International Publication Number W002/059110 and an International Publication date of August 1, 2002, the entire disclosure of which is hereby incorporated by reference, and which is the compound of Example 69. 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide can be prepared as described in International Application No. PCT/US01/49367.
Furthermore, it does not matter if the compounds are administered in the same dosage form, e.g. one compound may be administered by injection and another compound may be administered orally.
Typically, any anti-neoplastic agent that has activity versus a susceptible tumor being treated may be co-administered in the treatment of cancer in the present invention.
Examples of such agents can be found in Cancer Principles and Practice of Oncology by V.T. Devita and S. Hellman (editors), 6th edition (February 15, 2001), Lippincott Williams &
Wilkins Publishers. A person of ordinary skill in the art would be able to discern which combinations of agents would be useful based on the particular characteristics of the drugs and the cancer involved. Typical anti-neoplastic agents useful in the present invention include, but are not limited to, anti-microtubule agents such as diterpenoids and vinca alkaloids; platinum coordination complexes; alkylating agents such as nitrogen mustards, oxazaphosphorines, alkylsulfonates, nitrosoureas, and triazenes; antibiotic agents such as anthracyclins, actinomycins and bleomycins; topoisomerase ll inhibitors such as epipodophyllotoxins; antimetabolites such as purine and pyrimidine analogues and anti-folate compounds; topoisomerase I inhibitors such as camptothecins; hormones and hormonal analogues; signal transduction pathway inhibitors; non-receptor tyrosine kinase angiogenesis inhibitors; immunotherapeutic agents; proapoptotic agents; cell cycle signaling inhibitors; proteasome inhibitors; and inhibitors of cancer metabolism.
Examples of a further active ingredient or ingredients (anti-neoplastic agent) for use in combination or co-administered with the presently invented ATF4 pathway inhibiting compounds are chemotherapeutic agents.
Suitably, the pharmaceutically active compounds of the invention are used in combination with a VEGFR inhibitor, suitably 5-[[4-[(2,3-dimethy1-2H-indazol-6-Amethylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt, suitably the monohydrochloride salt thereof, which is disclosed and claimed in in International Application No. PCT/US01/49367, having an International filing date of December 19, 2001, International Publication Number W002/059110 and an International Publication date of August 1, 2002, the entire disclosure of which is hereby incorporated by reference, and which is the compound of Example 69. 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide can be prepared as described in International Application No. PCT/US01/49367.
- 96 -In one embodiment, the cancer treatment method of the claimed invention includes the co-administration a compound of Formula (1110) and/or a pharmaceutically acceptable salt thereof and at least one anti-neoplastic agent, such as one selected from the group consisting of anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase ll inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, cell cycle signaling inhibitors; proteasome inhibitors; and inhibitors of cancer metabolism.
"Chemotherapeutic" or "chemotherapeutic agent" is used in accordance with its plain ordinary meaning and refers to a chemical composition or compound having antineoplastic properties or the ability to inhibit the growth or proliferation of cells.
Additionally, the compounds described herein can be co-administered with conventional immunotherapeutic agents including, but not limited to, immunostimulants (e.g., Bacillus Calmette-Guerin (BOG), levamisole, interleukin-2, alpha-interferon, etc.), monoclonal antibodies (e.g., anti-0D20, anti-HER2, anti-0D52, anti-HLA-DR, and anti-VEGF monoclonal antibodies), immunotoxins (e.g., anti-0D33 monoclonal antibody-calicheamicin conjugate, anti-0D22 monoclonal antibody-pseudomonas exotoxin conjugate, etc.), and radioimmunotherapy (e.g., anti-0D20 monoclonal antibody conjugated to 1111n, 90Y, or 1311, etc.).
In a further embodiment, the compounds described herein can be co-administered with conventional radiotherapeutic agents including, but not limited to, radionuclides such as 47 64 64C 67C, 89 86 86Y, 87Y, and 212Bi, optionally conjugated to antibodies directed against tumor antigens.
Additional examples of a further active ingredient or ingredients (anti-neoplastic agent) for use in combination or co-administered with the presently invented ATF4 pathway inhibiting compounds are anti-PD-L1 agents.
Anti-PD-L1 antibodies and methods of making the same are known in the art.
Such antibodies to PD-L1 may be polyclonal or monoclonal, and/or recombinant, and/or humanized.
Exemplary PD-L1 antibodies are disclosed in:
US Patent No. 8,217,149; 12/633,339;
"Chemotherapeutic" or "chemotherapeutic agent" is used in accordance with its plain ordinary meaning and refers to a chemical composition or compound having antineoplastic properties or the ability to inhibit the growth or proliferation of cells.
Additionally, the compounds described herein can be co-administered with conventional immunotherapeutic agents including, but not limited to, immunostimulants (e.g., Bacillus Calmette-Guerin (BOG), levamisole, interleukin-2, alpha-interferon, etc.), monoclonal antibodies (e.g., anti-0D20, anti-HER2, anti-0D52, anti-HLA-DR, and anti-VEGF monoclonal antibodies), immunotoxins (e.g., anti-0D33 monoclonal antibody-calicheamicin conjugate, anti-0D22 monoclonal antibody-pseudomonas exotoxin conjugate, etc.), and radioimmunotherapy (e.g., anti-0D20 monoclonal antibody conjugated to 1111n, 90Y, or 1311, etc.).
In a further embodiment, the compounds described herein can be co-administered with conventional radiotherapeutic agents including, but not limited to, radionuclides such as 47 64 64C 67C, 89 86 86Y, 87Y, and 212Bi, optionally conjugated to antibodies directed against tumor antigens.
Additional examples of a further active ingredient or ingredients (anti-neoplastic agent) for use in combination or co-administered with the presently invented ATF4 pathway inhibiting compounds are anti-PD-L1 agents.
Anti-PD-L1 antibodies and methods of making the same are known in the art.
Such antibodies to PD-L1 may be polyclonal or monoclonal, and/or recombinant, and/or humanized.
Exemplary PD-L1 antibodies are disclosed in:
US Patent No. 8,217,149; 12/633,339;
- 97 -US Patent No. 8,383,796; 13/091,936;
US Patent No 8,552,154; 13/120,406;
US patent publication No. 20110280877; 13/068337;
US Patent Publication No. 20130309250; 13/892671;
W02013019906;
W02013079174;
US Application No. 13/511,538 (filed August 7, 2012), which is the US National Phase of International Application No. PCT/US10/58007 (filed 2010);
and US Application No. 13/478,511 (filed May 23, 2012).
Additional exemplary antibodies to PD-L1 (also referred to as 0D274 or B7-H1) and methods for use are disclosed in US Patent No. 7,943,743; US20130034559, W02014055897, US Patent No. 8,168,179; and US Patent No. 7,595,048. PD-L1 antibodies are in development as immuno-modulatory agents for the treatment of cancer.
In one embodiment, the antibody to PD-L1 is an antibody disclosed in US Patent No. 8,217,149. In another embodiment, the anti-PD-L1 antibody comprises the CDRs of an antibody disclosed in US Patent No. 8,217,149.
In another embodiment, the antibody to PD-L1 is an antibody disclosed in US
Application No. 13/511,538. In another embodiment, the anti-PD-L1 antibody comprises the CDRs of an antibody disclosed in US Application No. 13/511,538.
In another embodiment, the antibody to PD-L1 is an antibody disclosed in Application No. 13/478,511. In another embodiment, the anti-PD-L1 antibody comprises the CDRs of an antibody disclosed in US Application No. 13/478,511.
In one embodiment, the anti-PD-L1 antibody is BMS-936559 (MDX-1105). In another embodiment, the anti-PD-L1 antibody is MPDL3280A (RG7446). In another embodiment, the anti-PD-L1 antibody is MEDI4736. In another embodiment, the anti-PD-L1 antibody is atezolizumab.
In another embodiment, the anti-PD-L1 antibody is avelumab. In another embodiment, the anti-PD-L1 antibody is durvalumab.
Additional examples of a further active ingredient or ingredients (anti-neoplastic agent) for use in combination or co-administered with the presently invented ATF4 pathway inhibiting compounds are PD-1 antagonist.
US Patent No 8,552,154; 13/120,406;
US patent publication No. 20110280877; 13/068337;
US Patent Publication No. 20130309250; 13/892671;
W02013019906;
W02013079174;
US Application No. 13/511,538 (filed August 7, 2012), which is the US National Phase of International Application No. PCT/US10/58007 (filed 2010);
and US Application No. 13/478,511 (filed May 23, 2012).
Additional exemplary antibodies to PD-L1 (also referred to as 0D274 or B7-H1) and methods for use are disclosed in US Patent No. 7,943,743; US20130034559, W02014055897, US Patent No. 8,168,179; and US Patent No. 7,595,048. PD-L1 antibodies are in development as immuno-modulatory agents for the treatment of cancer.
In one embodiment, the antibody to PD-L1 is an antibody disclosed in US Patent No. 8,217,149. In another embodiment, the anti-PD-L1 antibody comprises the CDRs of an antibody disclosed in US Patent No. 8,217,149.
In another embodiment, the antibody to PD-L1 is an antibody disclosed in US
Application No. 13/511,538. In another embodiment, the anti-PD-L1 antibody comprises the CDRs of an antibody disclosed in US Application No. 13/511,538.
In another embodiment, the antibody to PD-L1 is an antibody disclosed in Application No. 13/478,511. In another embodiment, the anti-PD-L1 antibody comprises the CDRs of an antibody disclosed in US Application No. 13/478,511.
In one embodiment, the anti-PD-L1 antibody is BMS-936559 (MDX-1105). In another embodiment, the anti-PD-L1 antibody is MPDL3280A (RG7446). In another embodiment, the anti-PD-L1 antibody is MEDI4736. In another embodiment, the anti-PD-L1 antibody is atezolizumab.
In another embodiment, the anti-PD-L1 antibody is avelumab. In another embodiment, the anti-PD-L1 antibody is durvalumab.
Additional examples of a further active ingredient or ingredients (anti-neoplastic agent) for use in combination or co-administered with the presently invented ATF4 pathway inhibiting compounds are PD-1 antagonist.
- 98 -"PD-1 antagonist" means any chemical compound or biological molecule that blocks binding of PD-L1 expressed on a cancer cell to PD-1 expressed on an immune cell (T
cell, B cell or NKT cell) and preferably also blocks binding of PD-L2 expressed on a cancer cell to the immune-cell expressed PD-1. Alternative names or synonyms for PD-1 and its ligands include: PDCD1, PD1, 0D279 and SLEB2 for PD-1; PDCD1L1, PDL1, B7H1, B7-4, 0D274 and B7-H for PD-L1; and PDCD1L2, PDL2, B7-DC, Btdc and 0D273 for PD-L2. In any embodiments of the aspects or embodiments of the present invention in which a human individual is to be treated, the PD-1 antagonist blocks binding of human PD-L1 to human PD-1, and preferably blocks binding of both human PD-L1 and PD-L2 to human PD-1. Human PD-1 amino acid sequences can be found in NCB! Locus No.: NP 005009. Human PD-L1 and PD-L2 amino acid sequences can be found in NCB! Locus No.: NP 054862 and NP 079515, respectively.
PD-1 antagonists useful in the any of the aspects of the present invention include a monoclonal antibody (mAb), or antigen binding fragment thereof, which specifically binds to PD-1 or PD-L1, and preferably specifically binds to human PD-1 or human PD-L1. The mAb may be a human antibody, a humanized antibody or a chimeric antibody, and may include a human constant region. In some embodiments, the human constant region is selected from the group consisting of IgG1, IgG2, IgG3 and IgG4 constant regions, and in preferred embodiments, the human constant region is an IgG1 or IgG4 constant region. In some embodiments, the antigen binding fragment is selected from the group consisting of Fab, Fab'-SH, F(ab')2, scFv and Fv fragments.
Examples of mAbs that bind to human PD-1, and useful in the various aspects and embodiments of the present invention, are described in U57488802, US7521051, U58008449, U58354509, US8168757, W02004/004771, W02004/072286, W02004/056875, and US2011/0271358.
Specific anti-human PD-1 mAbs useful as the PD-1 antagonist in any of the aspects and embodiments of the present invention include: MK-3475, a humanized IgG4 mAb with the structure described in WHO Drug Information, Vol. 27, No. 2, pages (2013) and which comprises the heavy and light chain amino acid sequences shown in Figure 6; nivolumab, a human IgG4 mAb with the structure described in WHO Drug Information, Vol. 27, No. 1, pages 68-69 (2013) and which comprises the heavy and light chain amino acid sequences shown in Figure 7; the humanized antibodies h409A11, h409A16 and h409A17, which are described in W02008/156712, and AMP-514, which
cell, B cell or NKT cell) and preferably also blocks binding of PD-L2 expressed on a cancer cell to the immune-cell expressed PD-1. Alternative names or synonyms for PD-1 and its ligands include: PDCD1, PD1, 0D279 and SLEB2 for PD-1; PDCD1L1, PDL1, B7H1, B7-4, 0D274 and B7-H for PD-L1; and PDCD1L2, PDL2, B7-DC, Btdc and 0D273 for PD-L2. In any embodiments of the aspects or embodiments of the present invention in which a human individual is to be treated, the PD-1 antagonist blocks binding of human PD-L1 to human PD-1, and preferably blocks binding of both human PD-L1 and PD-L2 to human PD-1. Human PD-1 amino acid sequences can be found in NCB! Locus No.: NP 005009. Human PD-L1 and PD-L2 amino acid sequences can be found in NCB! Locus No.: NP 054862 and NP 079515, respectively.
PD-1 antagonists useful in the any of the aspects of the present invention include a monoclonal antibody (mAb), or antigen binding fragment thereof, which specifically binds to PD-1 or PD-L1, and preferably specifically binds to human PD-1 or human PD-L1. The mAb may be a human antibody, a humanized antibody or a chimeric antibody, and may include a human constant region. In some embodiments, the human constant region is selected from the group consisting of IgG1, IgG2, IgG3 and IgG4 constant regions, and in preferred embodiments, the human constant region is an IgG1 or IgG4 constant region. In some embodiments, the antigen binding fragment is selected from the group consisting of Fab, Fab'-SH, F(ab')2, scFv and Fv fragments.
Examples of mAbs that bind to human PD-1, and useful in the various aspects and embodiments of the present invention, are described in U57488802, US7521051, U58008449, U58354509, US8168757, W02004/004771, W02004/072286, W02004/056875, and US2011/0271358.
Specific anti-human PD-1 mAbs useful as the PD-1 antagonist in any of the aspects and embodiments of the present invention include: MK-3475, a humanized IgG4 mAb with the structure described in WHO Drug Information, Vol. 27, No. 2, pages (2013) and which comprises the heavy and light chain amino acid sequences shown in Figure 6; nivolumab, a human IgG4 mAb with the structure described in WHO Drug Information, Vol. 27, No. 1, pages 68-69 (2013) and which comprises the heavy and light chain amino acid sequences shown in Figure 7; the humanized antibodies h409A11, h409A16 and h409A17, which are described in W02008/156712, and AMP-514, which
- 99 -is being developed by Medimmune.
Other PD-1 antagonists useful in the any of the aspects and embodiments of the present invention include an immunoadhesin that specifically binds to PD-1, and preferably specifically binds to human PD-1, e.g., a fusion protein containing the extracellular or PD-1 binding portion of PD-L1 or PD-L2 fused to a constant region such as an Fc region of an immunoglobulin molecule. Examples of immunoadhesion molecules that specifically bind to PD-1 are described in W02010/027827 and W02011/066342. Specific fusion proteins useful as the PD-1 antagonist in the treatment method, medicaments and uses of the present invention include AMP-(also known as B7-DCIg), which is a PD-L2-FC fusion protein and binds to human PD-1.
Other examples of mAbs that bind to human PD-L1, and useful in the treatment method, medicaments and uses of the present invention, are described in W02013/019906, W02010/077634 Al and U58383796. Specific anti-human PD-L1 mAbs useful as the PD-1 antagonist in the treatment method, medicaments and uses of the present invention include MPDL3280A, BMS-936559, MEDI4736, MSB0010718C.
KEYTRUDA /pembrolizumab is an anti-PD-1 antibody marketed for the treatment of lung cancer by Merck. The amino acid sequence of pembrolizumab and methods of using are disclosed in US Patent No. 8,168,757.
Opdive/nivolumab is a fully human monoclonal antibody marketed by Bristol Myers Squibb directed against the negative immunoregulatory human cell surface receptor PD-1 .. (programmed death-1 or programmed cell death-1/POD-1) with immunopotentiation activity. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens.
Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P1 3k/Akt pathway activation. Other names for nivolumab include: BMS-936558, MDX-1106, and ONO-4538. The amino acid sequence for nivolumab and methods of using and making are disclosed in US Patent No. US 8,008,449.
Additional examples of a further active ingredient or ingredients (anti-neoplastic .. agent) for use in combination or co-administered with the presently invented ATF4 pathway inhibiting compounds are immuno-modulators.
Other PD-1 antagonists useful in the any of the aspects and embodiments of the present invention include an immunoadhesin that specifically binds to PD-1, and preferably specifically binds to human PD-1, e.g., a fusion protein containing the extracellular or PD-1 binding portion of PD-L1 or PD-L2 fused to a constant region such as an Fc region of an immunoglobulin molecule. Examples of immunoadhesion molecules that specifically bind to PD-1 are described in W02010/027827 and W02011/066342. Specific fusion proteins useful as the PD-1 antagonist in the treatment method, medicaments and uses of the present invention include AMP-(also known as B7-DCIg), which is a PD-L2-FC fusion protein and binds to human PD-1.
Other examples of mAbs that bind to human PD-L1, and useful in the treatment method, medicaments and uses of the present invention, are described in W02013/019906, W02010/077634 Al and U58383796. Specific anti-human PD-L1 mAbs useful as the PD-1 antagonist in the treatment method, medicaments and uses of the present invention include MPDL3280A, BMS-936559, MEDI4736, MSB0010718C.
KEYTRUDA /pembrolizumab is an anti-PD-1 antibody marketed for the treatment of lung cancer by Merck. The amino acid sequence of pembrolizumab and methods of using are disclosed in US Patent No. 8,168,757.
Opdive/nivolumab is a fully human monoclonal antibody marketed by Bristol Myers Squibb directed against the negative immunoregulatory human cell surface receptor PD-1 .. (programmed death-1 or programmed cell death-1/POD-1) with immunopotentiation activity. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens.
Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P1 3k/Akt pathway activation. Other names for nivolumab include: BMS-936558, MDX-1106, and ONO-4538. The amino acid sequence for nivolumab and methods of using and making are disclosed in US Patent No. US 8,008,449.
Additional examples of a further active ingredient or ingredients (anti-neoplastic .. agent) for use in combination or co-administered with the presently invented ATF4 pathway inhibiting compounds are immuno-modulators.
- 100 -As used herein "immuno-modulators" refer to any substance including monoclonal antibodies that affects the immune system. The ICOS binding proteins of the present invention can be considered immune-modulators. lmmuno-modulators can be used as anti-neoplastic agents for the treatment of cancer. For example, immune-modulators include, but are not limited to, anti-CTLA-4 antibodies such as ipilimumab (YERVOY ) and anti-PD-1 antibodies (Opdive/nivolumab and Keytrude/pembrolizumab). Other immuno-modulators include, but are not limited to, OX-40 antibodies, PD-L1 antibodies, LAG3 antibodies, TIM-3 antibodies, 4i BB antibodies and GITR antibodies.
Yervoy (ipilimumab) is a fully human CTLA-4 antibody marketed by Bristol Myers Squibb. The protein structure of ipilimumab and methods are using are described in US
Patent Nos. 6,984,720 and 7,605,238.
Suitably, the compounds of the invention are combined with an inhibitor of the activity of the protein kinase R (PKR)-like ER kinase, PERK.
Suitably, the compounds of the invention are combined with an inhibitor of the activity of the elF2a kinases protein kinase R, (PKR), Heme-regulated elF2a kinase (HRI), or general control non-derepressible 2 (GCN2).
Suitably, the compounds of Formula (1110) and pharmaceutically acceptable salts thereof may be co-administered with at least one other active agent known to be useful in the treatment of neurodegenerative diseases/injury.
Suitably, the compounds of Formula (1110) and pharmaceutically acceptable salts thereof may be co-administered with at least one other active agent known to be useful in the treatment of diabetes.
Suitably, the compounds of Formula (1110) and pharmaceutically acceptable salts thereof may be co-administered with at least one other active agent known to be useful in the treatment of cardiovascular disease.
Suitably, the compounds of Formula (1110) and pharmaceutically acceptable salts thereof may be co-administered with at least one other active agent known to be useful in the treatment of ocular diseases.
Yervoy (ipilimumab) is a fully human CTLA-4 antibody marketed by Bristol Myers Squibb. The protein structure of ipilimumab and methods are using are described in US
Patent Nos. 6,984,720 and 7,605,238.
Suitably, the compounds of the invention are combined with an inhibitor of the activity of the protein kinase R (PKR)-like ER kinase, PERK.
Suitably, the compounds of the invention are combined with an inhibitor of the activity of the elF2a kinases protein kinase R, (PKR), Heme-regulated elF2a kinase (HRI), or general control non-derepressible 2 (GCN2).
Suitably, the compounds of Formula (1110) and pharmaceutically acceptable salts thereof may be co-administered with at least one other active agent known to be useful in the treatment of neurodegenerative diseases/injury.
Suitably, the compounds of Formula (1110) and pharmaceutically acceptable salts thereof may be co-administered with at least one other active agent known to be useful in the treatment of diabetes.
Suitably, the compounds of Formula (1110) and pharmaceutically acceptable salts thereof may be co-administered with at least one other active agent known to be useful in the treatment of cardiovascular disease.
Suitably, the compounds of Formula (1110) and pharmaceutically acceptable salts thereof may be co-administered with at least one other active agent known to be useful in the treatment of ocular diseases.
- 101 -The compounds described herein can be used in combination with one another, with other active agents known to be useful in treating cancer (e.g.
pancreatic cancer, breast cancer, multiple myeloma, or cancers of secretory cells), neurodegenerative diseases, vanishing white matter disease, childhood ataxia with CNS
hypomyelination, and/or intellectual disability syndromes (e.g. associated with impaired function of elF2 or components in a signal transduction pathway including elF2), or with adjunctive agents that may not be effective alone, but may contribute to the efficacy of the active agent.
In embodiments, the compounds set forth herein are provided as pharmaceutical compositions comprising the compound and a pharmaceutically acceptable excipient. In embodiments of the method, the compound, or a pharmaceutically acceptable salt thereof, is co- adminstered with a second agent (e.g. therapeutic agent). In embodiments of the method, the compound, or a pharmaceutically acceptable salt thereof, is co-adminstered with a second agent (e.g. therapeutic agent), which is administered in a therapeutically effective amount. In embodiments of the method, the second agent is an agent for treating cancer (e.g. pancreatic cancer, breast cancer, multiple myeloma, or cancers of secretory cells), neurodegenerative diseases, vanishing white matter disease, childhood ataxia with CNS hypomyelination, and/or intellectual disability syndromes (e.g.
associated with impaired function of elF2 or components in a signal transduction pathway including elF2), or an inflammatory disease (e.g. ROOD or TI31). In embodiments, the second agent is an anti-cancer agent.
In embodiments, the second agent is a chemotherapeutic. In embodiments, the second agent is an agent for improving memory.
In embodiments, the second agent is an agent for treating a neurodegenerative disease.
In embodiments, the second agent is an agent for treating vanishing white matter disease. In embodiments, the second agent is an agent for treating childhood ataxia with CNS hypo-myelination. In embodiments, the second agent is an agent for treating an intellectual disability syndrome. In embodiments, the second agent is an agent for treating pancreatic cancer. In embodiments, the second agent is an agent for treating breast cancer. In embodiments, the second agent is an agent for treating multiple myeloma. In embodiments, the second agent is an agent for treating myeloma. In embodiments, the second agent is an agent for treating a cancer of a secretory cell. In embodiments, the second agent is an agent for reducing elF2a phosphorylation.
In embodiments, the second agent is an agent for inhibiting a pathway activated by elF2a phosphorylation.
In embodiments, the second agent is an agent for inhibiting the integrated stress response. In embodiments, the second agent is an anti-inflammatory agent.
pancreatic cancer, breast cancer, multiple myeloma, or cancers of secretory cells), neurodegenerative diseases, vanishing white matter disease, childhood ataxia with CNS
hypomyelination, and/or intellectual disability syndromes (e.g. associated with impaired function of elF2 or components in a signal transduction pathway including elF2), or with adjunctive agents that may not be effective alone, but may contribute to the efficacy of the active agent.
In embodiments, the compounds set forth herein are provided as pharmaceutical compositions comprising the compound and a pharmaceutically acceptable excipient. In embodiments of the method, the compound, or a pharmaceutically acceptable salt thereof, is co- adminstered with a second agent (e.g. therapeutic agent). In embodiments of the method, the compound, or a pharmaceutically acceptable salt thereof, is co-adminstered with a second agent (e.g. therapeutic agent), which is administered in a therapeutically effective amount. In embodiments of the method, the second agent is an agent for treating cancer (e.g. pancreatic cancer, breast cancer, multiple myeloma, or cancers of secretory cells), neurodegenerative diseases, vanishing white matter disease, childhood ataxia with CNS hypomyelination, and/or intellectual disability syndromes (e.g.
associated with impaired function of elF2 or components in a signal transduction pathway including elF2), or an inflammatory disease (e.g. ROOD or TI31). In embodiments, the second agent is an anti-cancer agent.
In embodiments, the second agent is a chemotherapeutic. In embodiments, the second agent is an agent for improving memory.
In embodiments, the second agent is an agent for treating a neurodegenerative disease.
In embodiments, the second agent is an agent for treating vanishing white matter disease. In embodiments, the second agent is an agent for treating childhood ataxia with CNS hypo-myelination. In embodiments, the second agent is an agent for treating an intellectual disability syndrome. In embodiments, the second agent is an agent for treating pancreatic cancer. In embodiments, the second agent is an agent for treating breast cancer. In embodiments, the second agent is an agent for treating multiple myeloma. In embodiments, the second agent is an agent for treating myeloma. In embodiments, the second agent is an agent for treating a cancer of a secretory cell. In embodiments, the second agent is an agent for reducing elF2a phosphorylation.
In embodiments, the second agent is an agent for inhibiting a pathway activated by elF2a phosphorylation.
In embodiments, the second agent is an agent for inhibiting the integrated stress response. In embodiments, the second agent is an anti-inflammatory agent.
- 102 -The term "eIF2alpha" or "eIF2a" refers to the protein "Eukaryotic translation initiation factor 2A". In embodiments, "eIF2alpha" or "eIF2a" refers to the human protein.
Included in the term "eIF2alpha" or "eIF2a" are the wildtype and mutant forms of the protein. In embodiments, "eIF2alpha" or "eIF2a" refers to the protein associated with .. Entrez Gene 83939, OMIM 609234, UniProt 09BY44, and/or Ref Seq (protein) NP
114414.
Suitably, the present invention relates to a method for treating an integrated stress response associated disease in a patient in need of such treatment, the method including administering a therapeutically effective amount of a compound of Formula (IIIQ), or a pharmaceutically acceptable salt thereof, to the patient.
Suitably, the integrated stress response-associated disease is cancer.
Suitably, the integrated stress response-associated disease is a neurodegenerative disease.
Suitably, the integrated stress response-associated disease is vanishing white matter disease.
Suitably, the integrated stress response-associated disease is childhood ataxia with CNS
hypomyelination. Suitably, the integrated stress response-associated disease is an intellectual disability syndrome.
Suitably, the present invention relates to a method for treating a disease associated with phosphorylation of elF2a in a patient in need of such treatment, which comprises administering a therapeutically effective amount of a compound of Formula (IIIZ), or a pharmaceutically acceptable salt thereof, to the patient.
Suitably, the disease associated with phosphorylation of elF2 a is cancer.
Suitably, the disease associated with phosphorylation of elF2 a is a neurodegenerative disease.
Suitably, the disease associated with phosphorylation of elF2 a is vanishing white matter disease. Suitably, the disease associated with phosphorylation of elF2 a is childhood ataxia with CNS hypomyelination. Suitably, the disease associated with phosphorylation of elF2 a is an intellectual disability syndrome.
Suitably, the present invention relates to a method for treating a disease selected from the group consisting of cancer, a neurodegenerative disease, vanishing white matter disease, childhood ataxia with CNS hypomyelination, and an intellectual disability syndrome.
Suitably, the present invention relates to a method for treating an inflammatory disease in a patient in need of such treatment, which comprises administering a
Included in the term "eIF2alpha" or "eIF2a" are the wildtype and mutant forms of the protein. In embodiments, "eIF2alpha" or "eIF2a" refers to the protein associated with .. Entrez Gene 83939, OMIM 609234, UniProt 09BY44, and/or Ref Seq (protein) NP
114414.
Suitably, the present invention relates to a method for treating an integrated stress response associated disease in a patient in need of such treatment, the method including administering a therapeutically effective amount of a compound of Formula (IIIQ), or a pharmaceutically acceptable salt thereof, to the patient.
Suitably, the integrated stress response-associated disease is cancer.
Suitably, the integrated stress response-associated disease is a neurodegenerative disease.
Suitably, the integrated stress response-associated disease is vanishing white matter disease.
Suitably, the integrated stress response-associated disease is childhood ataxia with CNS
hypomyelination. Suitably, the integrated stress response-associated disease is an intellectual disability syndrome.
Suitably, the present invention relates to a method for treating a disease associated with phosphorylation of elF2a in a patient in need of such treatment, which comprises administering a therapeutically effective amount of a compound of Formula (IIIZ), or a pharmaceutically acceptable salt thereof, to the patient.
Suitably, the disease associated with phosphorylation of elF2 a is cancer.
Suitably, the disease associated with phosphorylation of elF2 a is a neurodegenerative disease.
Suitably, the disease associated with phosphorylation of elF2 a is vanishing white matter disease. Suitably, the disease associated with phosphorylation of elF2 a is childhood ataxia with CNS hypomyelination. Suitably, the disease associated with phosphorylation of elF2 a is an intellectual disability syndrome.
Suitably, the present invention relates to a method for treating a disease selected from the group consisting of cancer, a neurodegenerative disease, vanishing white matter disease, childhood ataxia with CNS hypomyelination, and an intellectual disability syndrome.
Suitably, the present invention relates to a method for treating an inflammatory disease in a patient in need of such treatment, which comprises administering a
- 103 -therapeutically effective amount of a compound of Formula (1110), or a pharmaceutically acceptable salt thereof, to the patient.
Suitably, the inflammatory disease is associated with neurological inflammation.
Suitably, the inflammatory disease is postoperative cognitive dysfunction.
Suitably, the inflammatory disease is traumatic brain injury or chronic traumatic encephalopathy (CTE).
In embodiments of the method of treating a disease, the disease is selected from the group consisting of cancer, a neurodegenerative disease, vanishing white matter disease, childhood ataxia with CNS hypomyelination, and an intellectual disability syndrome. In embodiments of the method of treating a disease, the disease is cancer. In embodiments of the method of treating a disease, the disease is a neurodegenerative disease. In embodiments of the method of treating a disease, the disease is vanishing white matter disease. In embodiments of the method of treating a disease, the disease is childhood ataxia with CNS hypomyelination. In embodiments of the method of treating a disease, the disease is an intellectual disability syndrome. In embodiments of the method of treating a disease, the disease is associated with phosphorylation of elF2a. In embodiments of the method of treating a disease, the disease is associated with an elF2a signaling pathway. In embodiments of the method of treating a disease, the disease is a cancer of a secretory cell type. In embodiments of the method of treating a disease, the disease is pancreatic cancer. In embodiments of the method of treating a disease, the disease is breast cancer. In embodiments of the method of treating a disease, the disease is multiple myeloma. In embodiments of the method of treating a disease, the disease is lymphoma. In embodiments of the method of treating a disease, the disease is leukemia. In embodiments of the method of treating a disease, the disease is a hematopoietic cell cancer.
In embodiments of the method of treating a disease, the disease is Alzheimer's disease. In embodiments of the method of treating a disease, the disease is Amyotrophic .. lateral sclerosis. In embodiments of the method of treating a disease, the disease is Creutzfeldt-Jakob disease. In embodiments of the method of treating a disease, the disease is frontotemporal dementia. In embodiments of the method of treating a disease, the disease is Gerstmann-Straussler-Scheinker syndrome. In embodiments of the method of treating a disease, the disease is Huntington's disease. In embodiments of the method of treating a disease, the disease is HIV-associated dementia. In embodiments of the method of treating a disease, the disease is kuru. In embodiments of the method of treating a disease, the disease is Lewy body dementia. In embodiments of the method
Suitably, the inflammatory disease is associated with neurological inflammation.
Suitably, the inflammatory disease is postoperative cognitive dysfunction.
Suitably, the inflammatory disease is traumatic brain injury or chronic traumatic encephalopathy (CTE).
In embodiments of the method of treating a disease, the disease is selected from the group consisting of cancer, a neurodegenerative disease, vanishing white matter disease, childhood ataxia with CNS hypomyelination, and an intellectual disability syndrome. In embodiments of the method of treating a disease, the disease is cancer. In embodiments of the method of treating a disease, the disease is a neurodegenerative disease. In embodiments of the method of treating a disease, the disease is vanishing white matter disease. In embodiments of the method of treating a disease, the disease is childhood ataxia with CNS hypomyelination. In embodiments of the method of treating a disease, the disease is an intellectual disability syndrome. In embodiments of the method of treating a disease, the disease is associated with phosphorylation of elF2a. In embodiments of the method of treating a disease, the disease is associated with an elF2a signaling pathway. In embodiments of the method of treating a disease, the disease is a cancer of a secretory cell type. In embodiments of the method of treating a disease, the disease is pancreatic cancer. In embodiments of the method of treating a disease, the disease is breast cancer. In embodiments of the method of treating a disease, the disease is multiple myeloma. In embodiments of the method of treating a disease, the disease is lymphoma. In embodiments of the method of treating a disease, the disease is leukemia. In embodiments of the method of treating a disease, the disease is a hematopoietic cell cancer.
In embodiments of the method of treating a disease, the disease is Alzheimer's disease. In embodiments of the method of treating a disease, the disease is Amyotrophic .. lateral sclerosis. In embodiments of the method of treating a disease, the disease is Creutzfeldt-Jakob disease. In embodiments of the method of treating a disease, the disease is frontotemporal dementia. In embodiments of the method of treating a disease, the disease is Gerstmann-Straussler-Scheinker syndrome. In embodiments of the method of treating a disease, the disease is Huntington's disease. In embodiments of the method of treating a disease, the disease is HIV-associated dementia. In embodiments of the method of treating a disease, the disease is kuru. In embodiments of the method of treating a disease, the disease is Lewy body dementia. In embodiments of the method
- 104 -of treating a disease, the disease is Multiple sclerosis. In embodiments of the method of treating a disease, the disease is Parkinson's disease. In embodiments of the method of treating a disease, the disease is a Prion disease.
In embodiments of the method of treating a disease, the disease is an inflammatory disease.
In embodiments, the inflammatory disease is postoperative cognitive dysfunction. In embodiments, the inflammatory disease is traumatic brain injury. In embodiments, the inflammatory disease is arthritis. In embodiments, the inflammatory disease is rheumatoid arthritis. In embodiments, the inflammatory disease lo is psoriatic arthritis. In embodiments, the inflammatory disease is juvenile idiopathic arthritis. In embodiments, the inflammatory disease is multiple sclerosis.
In embodiments, the inflammatory disease is systemic lupus erythematosus (SLE).
In embodiments, the inflammatory disease is myasthenia gravis. In embodiments, the inflammatory disease is juvenile onset diabetes. In embodiments, the inflammatory disease is diabetes mellitus type 1. In embodiments, the inflammatory disease is Guillain-Barre syndrome. In embodiments, the inflammatory disease is Hashimoto's encephalitis. In embodiments, the inflammatory disease is Hashimoto's thyroiditis. In embodiments, the inflammatory disease is ankylosing spondylitis. In embodiments, the inflammatory disease is psoriasis. In embodiments, the inflammatory disease is Sjogren's syndrome. In embodiments, the inflammatory disease is vasculitis. In embodiments, the inflammatory disease is glomerulonephritis. In embodiments, the inflammatory disease is auto-immune thyroiditis. In embodiments, the inflammatory disease is Behcet's disease.
In embodiments, the inflammatory disease is Crohn's disease. In embodiments, the inflammatory disease is ulcerative colitis. In embodiments, the inflammatory disease is bullous pemphigoid. In embodiments, the inflammatory disease is sarcoidosis.
In embodiments, the inflammatory disease is ichthyosis. In embodiments, the inflammatory disease is Graves ophthalmopathy.
In embodiments, the inflammatory disease is inflammatory bowel disease. In embodiments, the inflammatory disease is Addison's disease. In embodiments, the inflammatory disease is Vitiligo. In embodiments, the inflammatory disease is asthma. In embodiments, the inflammatory disease is allergic asthma. In embodiments, the inflammatory disease is acne vulgaris. In embodiments, the inflammatory disease is celiac disease. In embodiments, the inflammatory disease is chronic prostatitis. In embodiments, the inflammatory disease is inflammatory bowel disease. In embodiments, the inflammatory disease is pelvic inflammatory disease. In embodiments, the inflammatory disease is reperfusion injury. In embodiments, the inflammatory disease is sarcoidosis.
In embodiments, the inflammatory disease is transplant rejection. In embodiments, the inflammatory disease is interstitial cystitis. In
In embodiments of the method of treating a disease, the disease is an inflammatory disease.
In embodiments, the inflammatory disease is postoperative cognitive dysfunction. In embodiments, the inflammatory disease is traumatic brain injury. In embodiments, the inflammatory disease is arthritis. In embodiments, the inflammatory disease is rheumatoid arthritis. In embodiments, the inflammatory disease lo is psoriatic arthritis. In embodiments, the inflammatory disease is juvenile idiopathic arthritis. In embodiments, the inflammatory disease is multiple sclerosis.
In embodiments, the inflammatory disease is systemic lupus erythematosus (SLE).
In embodiments, the inflammatory disease is myasthenia gravis. In embodiments, the inflammatory disease is juvenile onset diabetes. In embodiments, the inflammatory disease is diabetes mellitus type 1. In embodiments, the inflammatory disease is Guillain-Barre syndrome. In embodiments, the inflammatory disease is Hashimoto's encephalitis. In embodiments, the inflammatory disease is Hashimoto's thyroiditis. In embodiments, the inflammatory disease is ankylosing spondylitis. In embodiments, the inflammatory disease is psoriasis. In embodiments, the inflammatory disease is Sjogren's syndrome. In embodiments, the inflammatory disease is vasculitis. In embodiments, the inflammatory disease is glomerulonephritis. In embodiments, the inflammatory disease is auto-immune thyroiditis. In embodiments, the inflammatory disease is Behcet's disease.
In embodiments, the inflammatory disease is Crohn's disease. In embodiments, the inflammatory disease is ulcerative colitis. In embodiments, the inflammatory disease is bullous pemphigoid. In embodiments, the inflammatory disease is sarcoidosis.
In embodiments, the inflammatory disease is ichthyosis. In embodiments, the inflammatory disease is Graves ophthalmopathy.
In embodiments, the inflammatory disease is inflammatory bowel disease. In embodiments, the inflammatory disease is Addison's disease. In embodiments, the inflammatory disease is Vitiligo. In embodiments, the inflammatory disease is asthma. In embodiments, the inflammatory disease is allergic asthma. In embodiments, the inflammatory disease is acne vulgaris. In embodiments, the inflammatory disease is celiac disease. In embodiments, the inflammatory disease is chronic prostatitis. In embodiments, the inflammatory disease is inflammatory bowel disease. In embodiments, the inflammatory disease is pelvic inflammatory disease. In embodiments, the inflammatory disease is reperfusion injury. In embodiments, the inflammatory disease is sarcoidosis.
In embodiments, the inflammatory disease is transplant rejection. In embodiments, the inflammatory disease is interstitial cystitis. In
- 105 -embodiments, the inflammatory disease is atherosclerosis.
In embodiments, the inflammatory disease is atopic dermatitis.
In embodiments, the method of treatment is a method of prevention. For example, a method of treating postsurgical cognitive dysfunction may include preventing postsurgical cognitive dysfunction or a symptom of postsurgical cognitive dysfunction or reducing the severity of a symptom of postsurgical cognitive dysfunction by administering a compound described herein prior to surgery.
In an embodiment, this invention provides a compound of Formula (IIIQ), or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease selected from the group consisting of cancer, a neurodegenerative disease, vanishing white matter disease, childhood ataxia with CNS hypomyelination, and an intellectual disability syndrome.
In an embodiment, this invention provides a compound of Formula (IIIQ), or a pharmaceutically acceptable salt thereof, for use in the treatment of an integrated stress response associated disease.
In an embodiment, this invention provides a compound of Formula (IIIQ), or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease associated with phosphorylation of el F2a.
In an embodiment, this invention provides for the use of a compound of Formula (IIIQ), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease selected from the group consisting of cancer, a neurodegenerative disease, vanishing white matter disease, childhood ataxia with CNS
hypomyelination, and an intellectual disability syndrome..
In an embodiment, this invention provides for the use of a compound of Formula (IIIQ), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment an integrated stress response associated disease.
In an embodiment, this invention provides for the use of a compound of Formula (IIIQ), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease associated with phosphorylation of el F2a.
In embodiments, the inflammatory disease is atopic dermatitis.
In embodiments, the method of treatment is a method of prevention. For example, a method of treating postsurgical cognitive dysfunction may include preventing postsurgical cognitive dysfunction or a symptom of postsurgical cognitive dysfunction or reducing the severity of a symptom of postsurgical cognitive dysfunction by administering a compound described herein prior to surgery.
In an embodiment, this invention provides a compound of Formula (IIIQ), or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease selected from the group consisting of cancer, a neurodegenerative disease, vanishing white matter disease, childhood ataxia with CNS hypomyelination, and an intellectual disability syndrome.
In an embodiment, this invention provides a compound of Formula (IIIQ), or a pharmaceutically acceptable salt thereof, for use in the treatment of an integrated stress response associated disease.
In an embodiment, this invention provides a compound of Formula (IIIQ), or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease associated with phosphorylation of el F2a.
In an embodiment, this invention provides for the use of a compound of Formula (IIIQ), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease selected from the group consisting of cancer, a neurodegenerative disease, vanishing white matter disease, childhood ataxia with CNS
hypomyelination, and an intellectual disability syndrome..
In an embodiment, this invention provides for the use of a compound of Formula (IIIQ), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment an integrated stress response associated disease.
In an embodiment, this invention provides for the use of a compound of Formula (IIIQ), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease associated with phosphorylation of el F2a.
- 106 -Compositions The pharmaceutically active compounds within the scope of this invention are useful as ATF4 pathway inhibitors in mammals, particularly humans, in need thereof.
The present invention therefore provides a method of treating cancer, neurodegeneration and other conditions requiring ATF4 pathway inhibition, which comprises administering an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof. The compounds of Formula (1110) also provide for a method of treating the above indicated disease states because of their demonstrated .. ability to act as ATF4 pathway inhibitors. The drug may be administered to a patient in need thereof by any conventional route of administration, including, but not limited to, intravenous, intramuscular, oral, topical, subcutaneous, intradermal, intraocular and parenteral. Suitably, a ATF4 pathway inhibitor may be delivered directly to the brain by intrathecal or intraventricular route, or implanted at an appropriate anatomical location within a device or pump that continuously releases the ATF4 pathway inhibiting drug.
The pharmaceutically active compounds of the present invention are incorporated into convenient dosage forms such as capsules, tablets, or injectable preparations. Solid or liquid pharmaceutical carriers are employed. Solid carriers include, starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Liquid carriers include syrup, peanut oil, olive oil, saline, and water. Similarly, the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies widely but, preferably, will be from about 25 mg to about 1 g per dosage unit. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampoule, or an aqueous or nonaqueous liquid suspension.
The pharmaceutical compositions are made following conventional techniques of a pharmaceutical chemist involving mixing, granulating, and compressing, when necessary, for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired oral or parenteral products.
Doses of the presently invented pharmaceutically active compounds in a pharmaceutical dosage unit as described above will be an efficacious, nontoxic quantity preferably selected from the range of 0.001 - 100 mg/kg of active compound, preferably
The present invention therefore provides a method of treating cancer, neurodegeneration and other conditions requiring ATF4 pathway inhibition, which comprises administering an effective amount of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof. The compounds of Formula (1110) also provide for a method of treating the above indicated disease states because of their demonstrated .. ability to act as ATF4 pathway inhibitors. The drug may be administered to a patient in need thereof by any conventional route of administration, including, but not limited to, intravenous, intramuscular, oral, topical, subcutaneous, intradermal, intraocular and parenteral. Suitably, a ATF4 pathway inhibitor may be delivered directly to the brain by intrathecal or intraventricular route, or implanted at an appropriate anatomical location within a device or pump that continuously releases the ATF4 pathway inhibiting drug.
The pharmaceutically active compounds of the present invention are incorporated into convenient dosage forms such as capsules, tablets, or injectable preparations. Solid or liquid pharmaceutical carriers are employed. Solid carriers include, starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Liquid carriers include syrup, peanut oil, olive oil, saline, and water. Similarly, the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies widely but, preferably, will be from about 25 mg to about 1 g per dosage unit. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampoule, or an aqueous or nonaqueous liquid suspension.
The pharmaceutical compositions are made following conventional techniques of a pharmaceutical chemist involving mixing, granulating, and compressing, when necessary, for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired oral or parenteral products.
Doses of the presently invented pharmaceutically active compounds in a pharmaceutical dosage unit as described above will be an efficacious, nontoxic quantity preferably selected from the range of 0.001 - 100 mg/kg of active compound, preferably
- 107 -0.001 - 50 mg/kg. When treating a human patient in need of a ATF4 pathway inhibitor, the selected dose is administered preferably from 1-6 times daily, orally or parenterally.
Preferred forms of parenteral administration include topically, rectally, transdermally, by injection and continuously by infusion. Oral dosage units for human administration preferably contain from 0.05 to 3500 mg of active compound. Oral administration, which uses lower dosages, is preferred. Parenteral administration, at high dosages, however, also can be used when safe and convenient for the patient.
Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular ATF4 pathway inhibitor in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition.
Additional factors depending on the particular patient being treated will result in a need to adjust dosages, including patient age, weight, diet, and time of administration.
When administered to prevent organ damage in the transportation of organs for transplantation, a compound of Formula (1110) is added to the solution housing the organ during transportation, suitably in a buffered solution.
The method of this invention of inducing ATF4 pathway inhibitory activity in mammals, including humans, comprises administering to a subject in need of such activity an effective ATF4 pathway inhibiting amount of a pharmaceutically active compound of the present invention.
The invention also provides for the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for inhibiting the ATF4 pathway.
The invention also provides for the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in treating cancer, pre-cancerous syndromes, Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for
Preferred forms of parenteral administration include topically, rectally, transdermally, by injection and continuously by infusion. Oral dosage units for human administration preferably contain from 0.05 to 3500 mg of active compound. Oral administration, which uses lower dosages, is preferred. Parenteral administration, at high dosages, however, also can be used when safe and convenient for the patient.
Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular ATF4 pathway inhibitor in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition.
Additional factors depending on the particular patient being treated will result in a need to adjust dosages, including patient age, weight, diet, and time of administration.
When administered to prevent organ damage in the transportation of organs for transplantation, a compound of Formula (1110) is added to the solution housing the organ during transportation, suitably in a buffered solution.
The method of this invention of inducing ATF4 pathway inhibitory activity in mammals, including humans, comprises administering to a subject in need of such activity an effective ATF4 pathway inhibiting amount of a pharmaceutically active compound of the present invention.
The invention also provides for the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for inhibiting the ATF4 pathway.
The invention also provides for the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in treating cancer, pre-cancerous syndromes, Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for
- 108 -transplantation.
The invention also provides for the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in preventing organ damage during the transportation of organs for transplantation.
The invention also provides for a pharmaceutical composition for use as a ATF4 pathway inhibitor which comprises a compound of Formula (1110) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
The invention also provides for a pharmaceutical composition for use in the treatment of cancer which comprises a compound of Formula (1110) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
In addition, the pharmaceutically active compounds of the present invention can be co-administered with further active ingredients, such as other compounds known to treat cancer, or compounds known to have utility when used in combination with a pathway inhibitor.
The invention also provides novel processes and novel intermedites useful in preparing the presently invented compounds.
The invention also provides a pharmaceutical composition comprising from 0.5 to 1,000 mg of a compound of Formula (1110) or pharmaceutically acceptable salt thereof and from 0.5 to 1,000 mg of a pharmaceutically acceptable excipient.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent.
The following Examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way.
EXAMPLES
The following examples illustrate the invention. These examples are not intended to limit the scope of the present invention, but rather to provide guidance to the skilled artisan to prepare and use the compounds, compositions, and methods of the present invention. While particular embodiments of the present invention are described, the skilled artisan will appreciate that various changes and modifications can be made without
The invention also provides for the use of a compound of Formula (1110) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in preventing organ damage during the transportation of organs for transplantation.
The invention also provides for a pharmaceutical composition for use as a ATF4 pathway inhibitor which comprises a compound of Formula (1110) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
The invention also provides for a pharmaceutical composition for use in the treatment of cancer which comprises a compound of Formula (1110) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
In addition, the pharmaceutically active compounds of the present invention can be co-administered with further active ingredients, such as other compounds known to treat cancer, or compounds known to have utility when used in combination with a pathway inhibitor.
The invention also provides novel processes and novel intermedites useful in preparing the presently invented compounds.
The invention also provides a pharmaceutical composition comprising from 0.5 to 1,000 mg of a compound of Formula (1110) or pharmaceutically acceptable salt thereof and from 0.5 to 1,000 mg of a pharmaceutically acceptable excipient.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent.
The following Examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way.
EXAMPLES
The following examples illustrate the invention. These examples are not intended to limit the scope of the present invention, but rather to provide guidance to the skilled artisan to prepare and use the compounds, compositions, and methods of the present invention. While particular embodiments of the present invention are described, the skilled artisan will appreciate that various changes and modifications can be made without
- 109 -departing from the spirit and scope of the invention.
Example I
N,N1bicyclo12.2.2loctane-114-divnbis(2-(4-chlorophenoxy)acetamide) *0 CI
* OµA
CI
Br AC) Ojo/ OjOH
1101 ci (101 -1111 Step 2 CI
jaNH2.1-1C1 N/%..0C11-11-12N
Step 3 OJLN
CI
Step 1: To a solution of 4-chlorophenol (15 g, 116.67 mmol, 1 equiv) in DMF
(100 mL) at room temperature was added anhydrous potassium carbonate (24.15 g, 175.01 mmol, 1.5 equiv) portionwise. After stirring for 2 minutes, methyl-2-bromoacetate (13.3 mL, 140.01 mmol, 1.2 equiv) was added. The reaction mixture was heated at 80 C for 4 h.
After consumption of the starting material (TLC, 5 % Et0Ac in hexane), the reaction mixture was cooled to room temperature, diluted with water (100 mL) and extracted with Et0Ac (2 x 100 mL). The combined organic layer was washed with brine solution (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated en vacuo to give the crude product.
The crude product was purified by flash column chromatography (Combiflashie) using a silica gel column and the product was eluted at 15% ethyl acetate in hexane.
Fractions containing product were concentrated to give methyl 2-(4-chlorophenoxy)acetate (22.5 g, 96.5% yield) as pale yellow liquid. LCMS (ES) m/z = 200.0 [M+H]. 1H NMR (400 MHz,
Example I
N,N1bicyclo12.2.2loctane-114-divnbis(2-(4-chlorophenoxy)acetamide) *0 CI
* OµA
CI
Br AC) Ojo/ OjOH
1101 ci (101 -1111 Step 2 CI
jaNH2.1-1C1 N/%..0C11-11-12N
Step 3 OJLN
CI
Step 1: To a solution of 4-chlorophenol (15 g, 116.67 mmol, 1 equiv) in DMF
(100 mL) at room temperature was added anhydrous potassium carbonate (24.15 g, 175.01 mmol, 1.5 equiv) portionwise. After stirring for 2 minutes, methyl-2-bromoacetate (13.3 mL, 140.01 mmol, 1.2 equiv) was added. The reaction mixture was heated at 80 C for 4 h.
After consumption of the starting material (TLC, 5 % Et0Ac in hexane), the reaction mixture was cooled to room temperature, diluted with water (100 mL) and extracted with Et0Ac (2 x 100 mL). The combined organic layer was washed with brine solution (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated en vacuo to give the crude product.
The crude product was purified by flash column chromatography (Combiflashie) using a silica gel column and the product was eluted at 15% ethyl acetate in hexane.
Fractions containing product were concentrated to give methyl 2-(4-chlorophenoxy)acetate (22.5 g, 96.5% yield) as pale yellow liquid. LCMS (ES) m/z = 200.0 [M+H]. 1H NMR (400 MHz,
- 110 -CDCI3): 6 ppm 3.67 (s, 3 H), 4.78 (s, 2 H), 6.91 -6.95 (m, 2 H), 7.28 - 7.32 (m, 2 H).
Step 2: To a solution of methyl 2-(4-chlorophenoxy)acetate (22.5 g, 112.15 mmol, 1 equiv) in ethanol (100 mL) at 0 C was added a solution of sodium hydroxide (5.38 g, 134.58 mmol, 1.2 equiv) in water (100 mL). After stirring for 5 minutes at 0 C, the reaction mixture was allowed to warm to room temperature and then refluxed for 2.5 h during which the starting material was completely consumed. Heating was removed and the reaction mixture was allowed to cool down to room temperature. Ethanol was removed en vacuo and the reaction mixture was diluted with water (50 mL) followed by extraction with Et20 (50 mL). The aqueous layer was acidified with 1 N HCI upto pH 3 and the precipitated product was filtered through a cintered funnel, washed with ice-cold water (10 mL) and dried under high vacuum to give 2-(4-chlorophenoxy)acetic acid (20 g, 95.6%
yield) as white solid. LCMS (ES) m/z= 186.1 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 4.65 (s, 2 H), 6.91 (d, J= 9.2 Hz, 2 H), 7.29 (d, J= 8.8 Hz, 2 H), 12.98 (bs, 1 H).
Step 3: To bicyclo[2.2.2]octane-1,4-diamine dihydrochloride (0.200 g, 0.938 mmol, 1 equiv) taken in DCM (10 mL) at 0 C was added triethylamine (0.660 mL, 4.69 mmol, 5 equiv) and 2-(4-chlorophenoxy)acetic acid (0.437 g, 2.34 mmol, 2.5 equiv). After stirring for 5 minutes at 0 C, T3Pe (50 wt. % in ethyl acetate) (1.79 mL, 2.81 mmol, 3 equiv) was added and the reaction mixture was stirred at room temperature for 16 h at which time the staring materials were completely consumed. The reaction mixture was diluted with water (5 mL) and extracted with DCM (2 x 10 mL). The combined organic extract was washed with saturated aqueous NaH0O3 solution (8 mL) and water (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to .. give the crude product. The crude material was purified by flash column chromatography using a silica gel column where the product was eluted at 4 - 5 % methanol in DOM.
Fractions containing product were concentrated under reduced pressure to give N,N'-(bicyclo[2.2.2]octane-1,4-diy1)bis(2-(4-chlorophenoxy)acetamide) (0.040 g, 8.94 % yield) as white solid. LCMS (ES) m/z = 477.1 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.87 (s, 12 H), 4.35 (s, 4 H), 6.9 (d, J= 9.2 Hz, 4 H), 7.30 (d, J= 8.8 Hz, 4 H), 7.37 (s, 2 H).
Step 2: To a solution of methyl 2-(4-chlorophenoxy)acetate (22.5 g, 112.15 mmol, 1 equiv) in ethanol (100 mL) at 0 C was added a solution of sodium hydroxide (5.38 g, 134.58 mmol, 1.2 equiv) in water (100 mL). After stirring for 5 minutes at 0 C, the reaction mixture was allowed to warm to room temperature and then refluxed for 2.5 h during which the starting material was completely consumed. Heating was removed and the reaction mixture was allowed to cool down to room temperature. Ethanol was removed en vacuo and the reaction mixture was diluted with water (50 mL) followed by extraction with Et20 (50 mL). The aqueous layer was acidified with 1 N HCI upto pH 3 and the precipitated product was filtered through a cintered funnel, washed with ice-cold water (10 mL) and dried under high vacuum to give 2-(4-chlorophenoxy)acetic acid (20 g, 95.6%
yield) as white solid. LCMS (ES) m/z= 186.1 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 4.65 (s, 2 H), 6.91 (d, J= 9.2 Hz, 2 H), 7.29 (d, J= 8.8 Hz, 2 H), 12.98 (bs, 1 H).
Step 3: To bicyclo[2.2.2]octane-1,4-diamine dihydrochloride (0.200 g, 0.938 mmol, 1 equiv) taken in DCM (10 mL) at 0 C was added triethylamine (0.660 mL, 4.69 mmol, 5 equiv) and 2-(4-chlorophenoxy)acetic acid (0.437 g, 2.34 mmol, 2.5 equiv). After stirring for 5 minutes at 0 C, T3Pe (50 wt. % in ethyl acetate) (1.79 mL, 2.81 mmol, 3 equiv) was added and the reaction mixture was stirred at room temperature for 16 h at which time the staring materials were completely consumed. The reaction mixture was diluted with water (5 mL) and extracted with DCM (2 x 10 mL). The combined organic extract was washed with saturated aqueous NaH0O3 solution (8 mL) and water (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to .. give the crude product. The crude material was purified by flash column chromatography using a silica gel column where the product was eluted at 4 - 5 % methanol in DOM.
Fractions containing product were concentrated under reduced pressure to give N,N'-(bicyclo[2.2.2]octane-1,4-diy1)bis(2-(4-chlorophenoxy)acetamide) (0.040 g, 8.94 % yield) as white solid. LCMS (ES) m/z = 477.1 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.87 (s, 12 H), 4.35 (s, 4 H), 6.9 (d, J= 9.2 Hz, 4 H), 7.30 (d, J= 8.8 Hz, 4 H), 7.37 (s, 2 H).
- 111 -Example ll N,N1bicyclo11.1.11pentane-1,3-divnbis(2-(4-chlorophenoxv)acetamide) CI
0)(N ro CI
OH 0)LN ro -Ow io Step 1 CI CI
Step 1: To bicyclo[1.1.1]pentane-1,3-diamine dihydrochloride (0.200 g, 1.169 mmol, 1 equiv) taken in DCM (10 mL) at 0 C was added triethylamine (0.820 mL, 5.845 mmol, 5 equiv) and 2-(4-chlorophenoxy)acetic acid (0.479 g, 2.572 mmol, 2.2 equiv).
After stirring for 5 minutes at 0 C, T3Pe (50 wt. % in ethyl acetate) (2.22 mL, 3.507 mmol, 3 equiv) was added and the reaction mixture was stirred at room temperature for 16 h at which time starting materials were completely consumed. The reaction mixture was diluted with water (5 mL) and extracted with DCM (2 x 15 mL). The combined organic extract was washed with saturated aqueous NaHCO3 solution (8 mL) and water (5 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude material was purified by flash column chromatography using a silica gel column where the product was eluted at 1 ¨ 3 % methanol in DCM as eluant. Fractions containing product were concentrated under reduced pressure to give N,N'-(bicyclo[1.1.1]pentane-1,3-diy1)bis(2-(4-chlorophenoxy)acetamide) (0.260 g, 51.38 %
yield) as white solid. LCMS (ES) m/z = 435 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 PPm 2.23 (s, 6 H), 4.40 (s, 4 H), 6.94 (d, J= 8.8 Hz, 4 H), 7.31 (d, J= 8.8 Hz, 4 H), 8.65 (s, 2 H).
0)(N ro CI
OH 0)LN ro -Ow io Step 1 CI CI
Step 1: To bicyclo[1.1.1]pentane-1,3-diamine dihydrochloride (0.200 g, 1.169 mmol, 1 equiv) taken in DCM (10 mL) at 0 C was added triethylamine (0.820 mL, 5.845 mmol, 5 equiv) and 2-(4-chlorophenoxy)acetic acid (0.479 g, 2.572 mmol, 2.2 equiv).
After stirring for 5 minutes at 0 C, T3Pe (50 wt. % in ethyl acetate) (2.22 mL, 3.507 mmol, 3 equiv) was added and the reaction mixture was stirred at room temperature for 16 h at which time starting materials were completely consumed. The reaction mixture was diluted with water (5 mL) and extracted with DCM (2 x 15 mL). The combined organic extract was washed with saturated aqueous NaHCO3 solution (8 mL) and water (5 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude material was purified by flash column chromatography using a silica gel column where the product was eluted at 1 ¨ 3 % methanol in DCM as eluant. Fractions containing product were concentrated under reduced pressure to give N,N'-(bicyclo[1.1.1]pentane-1,3-diy1)bis(2-(4-chlorophenoxy)acetamide) (0.260 g, 51.38 %
yield) as white solid. LCMS (ES) m/z = 435 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 PPm 2.23 (s, 6 H), 4.40 (s, 4 H), 6.94 (d, J= 8.8 Hz, 4 H), 7.31 (d, J= 8.8 Hz, 4 H), 8.65 (s, 2 H).
- 112 -Examples III and IV
The Compounds of Examples III and IV were prepared generally according to the procedures described above for Examples I and II.
Table I.
Cmpd LCMS miz 1H-NMR (400 MHz, Structure Name [M+Hr DMSO-d6) #
ci r=
HN,µ 0 1.87 (s, 12H), 4.36 (s, 2H), 4.47 (s, 2H), 2-(4-chlorophenoxy)-N-(4- 6.90 (d, J= 9.2 Hz, (2-((6-chloropyridin-3- 478.1 2H), 7.30 (d, J=
8.4 o yl)oxy)acetamido)bicyclo[2 Hz, 2H), 7.37 ¨
7.40 qii .2.2]octan-1-yl)acetamide (m, 3H), 7.48 (s, 1H), oT 8.06 (s, 1H).
=
i CI
....1 I
HN o 1.87 (s, 12H), 4.47 IV 479.1 (s, 4H), 7.40 (s, 4H), 7.48 (s, 2H), 8.06 (s, o (µ?i 2H).
TN,N'-o (bicyclo[2.2.2]octane-1,4-diy1)bis(2-((6-=
I chloropyridin-3-yl)oxy)acetamide)
The Compounds of Examples III and IV were prepared generally according to the procedures described above for Examples I and II.
Table I.
Cmpd LCMS miz 1H-NMR (400 MHz, Structure Name [M+Hr DMSO-d6) #
ci r=
HN,µ 0 1.87 (s, 12H), 4.36 (s, 2H), 4.47 (s, 2H), 2-(4-chlorophenoxy)-N-(4- 6.90 (d, J= 9.2 Hz, (2-((6-chloropyridin-3- 478.1 2H), 7.30 (d, J=
8.4 o yl)oxy)acetamido)bicyclo[2 Hz, 2H), 7.37 ¨
7.40 qii .2.2]octan-1-yl)acetamide (m, 3H), 7.48 (s, 1H), oT 8.06 (s, 1H).
=
i CI
....1 I
HN o 1.87 (s, 12H), 4.47 IV 479.1 (s, 4H), 7.40 (s, 4H), 7.48 (s, 2H), 8.06 (s, o (µ?i 2H).
TN,N'-o (bicyclo[2.2.2]octane-1,4-diy1)bis(2-((6-=
I chloropyridin-3-yl)oxy)acetamide)
- 113 -Example V
KN'-(bicyclo11.1.11pentane-113-divnbis(2-phenoxyacetamide) 0,A ro411 V
(3.==)L0H
N HCI *11111. 0 H2N."4-4 rpõ,r,=Boc 0)( o Step 1 CIH H2NA=I N
Step 2 )r V
Step 1:10 a stirred solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.1 g, 0.50 mmol, 1.0 equiv.) in DCM (3.0 mL) was added 4M HCI in dioxane (1.0 mL) dropwise at 0 C and the reaction mixture was stirred at room temperaturefor 3 h. After the 10 starting material was consumed (TLC, 5 % Me0H in DCM), the reaction mixture was concentrated under reduced pressure and the resultant solid was washed with n-pentane (2 x 10 mL and dried under high vaccum to give bicyclo[1.1.1]pentane-1,3-diamine dihydrochloride (0.08 g, 93 % yield) as off white solid. 1H NMR (400 MHz, DMSO-d6) 6 PPm 2.19 (s, 6 H), 9.04 (s, 6 H).
Step 2: To a solution of bicyclo[1.1.1]pentane-1,3-diamine dihydrochloride (0.08 g, 0.46 mmol, 1.0 equiv) in DCM (8.0 mL) at 0 C was added triethylamine (0.33 mL, 2.35 mmol, 5.0 equiv). The reaction was stirred for 10 minutes and then 2 2-phenoxyacetic acid (0.17 g, 1.17 mmol, 2.5 equiv.) and T3Pe (50 wt. % in ethyl acetate) (0.56 mL, 0.94 mmol, 2.0 equiv.) were added to the reaction mixture. The reaction mixture was allowed to stir at room temperature (25 C) for 3 h. After consumption of the starting material (TLC, 5 %
Me0H in DCM), the solvent was concentrated under reduced pressure and to the crude material was added saturated sodium bicarbonate solution (20 mL). The mixture was stirred for 20 mins and the solid was filtered, washed with water (10 mL) and n-pentane (20 mL), and dried under high vaccum to give N,N'-(bicyclo[1.1.1]pentane-1,3-diy1)bis(2-phenoxyacetamide) (0.135 g, 78.9 % yield) as off white solid. LCMS (ES) m/z =
367.2 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.25 (s, 6 H), 4.39 (s, 4 H), 6.94 (t, J= 8.0 Hz, 6 H), 7.27 (t, J= 8.0 Hz, 4 H), 8.63 (s, 2 H).
KN'-(bicyclo11.1.11pentane-113-divnbis(2-phenoxyacetamide) 0,A ro411 V
(3.==)L0H
N HCI *11111. 0 H2N."4-4 rpõ,r,=Boc 0)( o Step 1 CIH H2NA=I N
Step 2 )r V
Step 1:10 a stirred solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.1 g, 0.50 mmol, 1.0 equiv.) in DCM (3.0 mL) was added 4M HCI in dioxane (1.0 mL) dropwise at 0 C and the reaction mixture was stirred at room temperaturefor 3 h. After the 10 starting material was consumed (TLC, 5 % Me0H in DCM), the reaction mixture was concentrated under reduced pressure and the resultant solid was washed with n-pentane (2 x 10 mL and dried under high vaccum to give bicyclo[1.1.1]pentane-1,3-diamine dihydrochloride (0.08 g, 93 % yield) as off white solid. 1H NMR (400 MHz, DMSO-d6) 6 PPm 2.19 (s, 6 H), 9.04 (s, 6 H).
Step 2: To a solution of bicyclo[1.1.1]pentane-1,3-diamine dihydrochloride (0.08 g, 0.46 mmol, 1.0 equiv) in DCM (8.0 mL) at 0 C was added triethylamine (0.33 mL, 2.35 mmol, 5.0 equiv). The reaction was stirred for 10 minutes and then 2 2-phenoxyacetic acid (0.17 g, 1.17 mmol, 2.5 equiv.) and T3Pe (50 wt. % in ethyl acetate) (0.56 mL, 0.94 mmol, 2.0 equiv.) were added to the reaction mixture. The reaction mixture was allowed to stir at room temperature (25 C) for 3 h. After consumption of the starting material (TLC, 5 %
Me0H in DCM), the solvent was concentrated under reduced pressure and to the crude material was added saturated sodium bicarbonate solution (20 mL). The mixture was stirred for 20 mins and the solid was filtered, washed with water (10 mL) and n-pentane (20 mL), and dried under high vaccum to give N,N'-(bicyclo[1.1.1]pentane-1,3-diy1)bis(2-phenoxyacetamide) (0.135 g, 78.9 % yield) as off white solid. LCMS (ES) m/z =
367.2 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.25 (s, 6 H), 4.39 (s, 4 H), 6.94 (t, J= 8.0 Hz, 6 H), 7.27 (t, J= 8.0 Hz, 4 H), 8.63 (s, 2 H).
- 114 -Table ll LCMS
1H-NMR (400 MHz, Name miz Cmpd # Structure DMSO-d6) [M+H]
2.25 (s, 6 H), 4.39 (s, 4 V
HN/Co N,N'-(bicyclo[1.1.1]pentane-H), 6.94 (t, J= 8.0 Hz, 6 1,3-diy1)bis(2-367.2 H) 7.27 (t, J= 8.0 Hz, 4 H), 8.63 (s, 2 H).
phenoxyacetamide) 0) Example VI
2-(4-chlorophenoxv)-N-(3-(2-(4-chlorophenvpacetamido)bicyclo11.1.11pentan-1-Vnacetamide o NH
C)ANH I
= 1.0 CI
CI
Vi OH
NH
0 NH2 'HCI =
I
CI =
CI NH
Stel (10 LW
CI
CI
VI
1H-NMR (400 MHz, Name miz Cmpd # Structure DMSO-d6) [M+H]
2.25 (s, 6 H), 4.39 (s, 4 V
HN/Co N,N'-(bicyclo[1.1.1]pentane-H), 6.94 (t, J= 8.0 Hz, 6 1,3-diy1)bis(2-367.2 H) 7.27 (t, J= 8.0 Hz, 4 H), 8.63 (s, 2 H).
phenoxyacetamide) 0) Example VI
2-(4-chlorophenoxv)-N-(3-(2-(4-chlorophenvpacetamido)bicyclo11.1.11pentan-1-Vnacetamide o NH
C)ANH I
= 1.0 CI
CI
Vi OH
NH
0 NH2 'HCI =
I
CI =
CI NH
Stel (10 LW
CI
CI
VI
- 115 -Step 1: To a solution of N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide hydrochloride (0.08 g, 0.26 mmol, 1 equiv) in DCM
(15.0 mL) at 0 C was added triethylamine (0.11 mL, 0.79 mmol, 3 equiv). The reaction was stirred for 10 minutes and then 2-(4-chlorophenyl)acetic acid (0.049 g, 0.31 mmol, 1.2 equiv) and T3P (50 wt. % in ethyl acetate) (0.33 mL, 0.52 mmol, 2 equiv) were added to the reaction mixture. The reaction mixture was then allowed to stir at room temperature (25 C) for 16 h.
After consumption of the starting material, the reaction mixture was diluted with water (5 mL) and extracted with DCM (2 X 10 mL). The combined organic extract was washed with a saturated aqueous NaHCO3 solution (8 mL) and then water (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude material was purified by flash column chromatography using a silica gel column where the product eluted at 2 - 3 %
methanol in DCM. Fractions containing the product were concentrated under reduced pressure to give 2-(4-chlorophenoxy)-N-(3-(2-(4-chlorophenyl)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide (0.053 g, 48% yield) as an off-white solid. LCMS (ES) m/z = 419.1 [M+H]. 1H
NMR (400 MHz, DMSO-d6): 6 ppm 2.18 (s, 6 H), 3.34 (s, 2 H), 4.39 (s, 2 H), 6.93 - 6.95 (m. 2 H), 7.21 - 7.23 (m, 2 H), 7.30 - 7.33 (m, 4 H), 8.62 - 8.63 (m, 2 H).
The Compounds of Examples VII to XII were prepared generally according to the procedures described above for Example VI.
Table III
LCMS 1H-NMR (400 MHz, Cmpd # Structure Name miz DM50-d6) [M+H]
2.18 (s, 6 H), 3.34 (s, 2 2-(4- H), 4.39 (s, 2 H), 6.93 -VI
chlorophenoxy)-N- 419.1 6.95 (m. 2 H), 7.21 -(3-(2-(4- 7.23 (m, 2 H), 7.30 -chlorophenyl)acet 7.33 (m, 4 H), 8.62 -amido)bicyclo[1.1. 8.63 (m, 2 H).
l]pentan-1-yl)acetamide
(15.0 mL) at 0 C was added triethylamine (0.11 mL, 0.79 mmol, 3 equiv). The reaction was stirred for 10 minutes and then 2-(4-chlorophenyl)acetic acid (0.049 g, 0.31 mmol, 1.2 equiv) and T3P (50 wt. % in ethyl acetate) (0.33 mL, 0.52 mmol, 2 equiv) were added to the reaction mixture. The reaction mixture was then allowed to stir at room temperature (25 C) for 16 h.
After consumption of the starting material, the reaction mixture was diluted with water (5 mL) and extracted with DCM (2 X 10 mL). The combined organic extract was washed with a saturated aqueous NaHCO3 solution (8 mL) and then water (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude material was purified by flash column chromatography using a silica gel column where the product eluted at 2 - 3 %
methanol in DCM. Fractions containing the product were concentrated under reduced pressure to give 2-(4-chlorophenoxy)-N-(3-(2-(4-chlorophenyl)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide (0.053 g, 48% yield) as an off-white solid. LCMS (ES) m/z = 419.1 [M+H]. 1H
NMR (400 MHz, DMSO-d6): 6 ppm 2.18 (s, 6 H), 3.34 (s, 2 H), 4.39 (s, 2 H), 6.93 - 6.95 (m. 2 H), 7.21 - 7.23 (m, 2 H), 7.30 - 7.33 (m, 4 H), 8.62 - 8.63 (m, 2 H).
The Compounds of Examples VII to XII were prepared generally according to the procedures described above for Example VI.
Table III
LCMS 1H-NMR (400 MHz, Cmpd # Structure Name miz DM50-d6) [M+H]
2.18 (s, 6 H), 3.34 (s, 2 2-(4- H), 4.39 (s, 2 H), 6.93 -VI
chlorophenoxy)-N- 419.1 6.95 (m. 2 H), 7.21 -(3-(2-(4- 7.23 (m, 2 H), 7.30 -chlorophenyl)acet 7.33 (m, 4 H), 8.62 -amido)bicyclo[1.1. 8.63 (m, 2 H).
l]pentan-1-yl)acetamide
- 116 -CI
o NH
k c), 10 2-(4- 2.21 (s, 3 H), 2.24 (s, 6 . H), 4.34 (s, 2 H), 4.41 (s, r chlorophenoxy)-N-2 H), 6.81 (d, J= 8.4 Hz, VII FIN."0 (3-(2-(0-2 H), 6.95 (d, J = 8.8 Hz, tolyloxy)acetamido 415.1 2 H), 7.07 (d, J= 8.4 Hz, )bicyclo[1.1.1]pent ) an-1-yl)acetamide 2 H), 7.32 (d, J= 8.8 Hz, 2 H), 8.59 (s, 1 H), 8.65 4 (s, 1 H).
ci qi...14 I / 2-(4- 2.24 (s, 6 H), 4.41 (s, 2 chlorophenoxy)-N- H), 4.53 (s, 2 H), 6.95 (d, VIII HeLo (3-(2-((6- J= 8.8 Hz, 2 H), 7.32 (d, chloropyridin-3- 436.1 J= 8.8 Hz, 2 H), 7.41 ¨
0 4(PH yl)oxy)acetamido) 7.46 (m, 2 H), 8.10 (s, 1 I' bicyclo[1.1.1]penta H), 8.66 (s, 1 H), 8.71 (s, 01.11 n-l-yl)acetamide 1 H).
o NH
k c), 10 2-(4- 2.21 (s, 3 H), 2.24 (s, 6 . H), 4.34 (s, 2 H), 4.41 (s, r chlorophenoxy)-N-2 H), 6.81 (d, J= 8.4 Hz, VII FIN."0 (3-(2-(0-2 H), 6.95 (d, J = 8.8 Hz, tolyloxy)acetamido 415.1 2 H), 7.07 (d, J= 8.4 Hz, )bicyclo[1.1.1]pent ) an-1-yl)acetamide 2 H), 7.32 (d, J= 8.8 Hz, 2 H), 8.59 (s, 1 H), 8.65 4 (s, 1 H).
ci qi...14 I / 2-(4- 2.24 (s, 6 H), 4.41 (s, 2 chlorophenoxy)-N- H), 4.53 (s, 2 H), 6.95 (d, VIII HeLo (3-(2-((6- J= 8.8 Hz, 2 H), 7.32 (d, chloropyridin-3- 436.1 J= 8.8 Hz, 2 H), 7.41 ¨
0 4(PH yl)oxy)acetamido) 7.46 (m, 2 H), 8.10 (s, 1 I' bicyclo[1.1.1]penta H), 8.66 (s, 1 H), 8.71 (s, 01.11 n-l-yl)acetamide 1 H).
- 117 -,...:1 I / 2.24 (s, 6 H), 2.37 (s, 3 H), 4.41 (s, 2 H), 4.44 (s, FiN,L0 coh-l(o 2-(4-2r-o(p(6h-enoxy)-N-2 H), 6.95 (d, J= 8.8 Hz, IX methylpyridin-3- 416.1 2 H), 7.15 (d, J = 8.8 Hz, yl)oxy)acetamido) 1 H), 7.22 - 7.25 (m, 1 41)F1' 0, ) bicyclo[1.1.1]penta H), 7.32 (d, J= 8.8 Hz, 2 0 n-l-yl)acetamide H), 8.13 - 8.14 (m, 1 H), 4 8.66 (d, J= 6.0 Hz, 2 H).
ci 2-(4-2.21 (s, 6 H), 4.40 (s, 2 r= chlorophenoxy)-N-H), 4.64 (s, 2 H), 6.91 -X HNO (3-(2-((5-6.95 (m, 3 H), 7.32 (d, J
chloropyridin-2- 436.2 = 8.8 Hz, 2 H), 7.80 -(:).....4)>Fi yl)oxy)acetamido) 7.83 (m, 1 H), 8.15 (s, 1 0) bicyclo[1.1.1]penta I: N H), 8.60 - 8.64 (m, 2 H).
e n-l-yl)acetamide = I
r= = 2-(4-HNO chlorophenoxy)-N- 2.24 (s, 6 H), 4.40 (d, J =
XI (3-(2- 6.8 Hz, 4 H), 6.93 (t, J =
.0 phenoxyacetamid 401.1 8.0 Hz, 5 H), 7.33 - 7.26 ....,4:
o)bicyclo[1.1.1]pe (m, 4 H), 8.64 (d, J = 8.8 0) ntan-1- Hz, 2 H).
* yl)acetamide
ci 2-(4-2.21 (s, 6 H), 4.40 (s, 2 r= chlorophenoxy)-N-H), 4.64 (s, 2 H), 6.91 -X HNO (3-(2-((5-6.95 (m, 3 H), 7.32 (d, J
chloropyridin-2- 436.2 = 8.8 Hz, 2 H), 7.80 -(:).....4)>Fi yl)oxy)acetamido) 7.83 (m, 1 H), 8.15 (s, 1 0) bicyclo[1.1.1]penta I: N H), 8.60 - 8.64 (m, 2 H).
e n-l-yl)acetamide = I
r= = 2-(4-HNO chlorophenoxy)-N- 2.24 (s, 6 H), 4.40 (d, J =
XI (3-(2- 6.8 Hz, 4 H), 6.93 (t, J =
.0 phenoxyacetamid 401.1 8.0 Hz, 5 H), 7.33 - 7.26 ....,4:
o)bicyclo[1.1.1]pe (m, 4 H), 8.64 (d, J = 8.8 0) ntan-1- Hz, 2 H).
* yl)acetamide
- 118 -CI
* 2.31 (s, 6 H), 4.42 (s, 2 H), 6.96 (d, J = 8.0 Hz, 2 HN 0 4-chloro-N-(3-(2-XII H), 7.32 (d, J = 8.8 Hz, 2 (4-405.3 H), 7.50 (d, J = 8.0 Hz, 2 0/44:1 chlorophenoxy)ac H), 7.83 (d, J = 8.0 Hz, 2 etamido)bicyclo[1.
0) H), 8.68 (bs, 1 H), 9.05 1.1]pentan-1-101 yl)benzamide (bs, 1 H).
Example XIII
2-((3-(2-(4-chlorophenoxy)acetamido)bicyclo11.1.11pentan-1-y1)(2-(4-chlorophenoxy)ethynamino)-N1N-dimethylacetamide N)i CI
0 =/.0 I.
1101 OAN jf.ar H Xiii CI
al \/'Br alibi CI
H
J
NH2 'HCI N/er 0 Cl _________________________________________ v.
H
CI 1.1 H Step-1 CI
CIN oyl CI
_________________ PIP, OANe Step 2 W H
CI XIII
* 2.31 (s, 6 H), 4.42 (s, 2 H), 6.96 (d, J = 8.0 Hz, 2 HN 0 4-chloro-N-(3-(2-XII H), 7.32 (d, J = 8.8 Hz, 2 (4-405.3 H), 7.50 (d, J = 8.0 Hz, 2 0/44:1 chlorophenoxy)ac H), 7.83 (d, J = 8.0 Hz, 2 etamido)bicyclo[1.
0) H), 8.68 (bs, 1 H), 9.05 1.1]pentan-1-101 yl)benzamide (bs, 1 H).
Example XIII
2-((3-(2-(4-chlorophenoxy)acetamido)bicyclo11.1.11pentan-1-y1)(2-(4-chlorophenoxy)ethynamino)-N1N-dimethylacetamide N)i CI
0 =/.0 I.
1101 OAN jf.ar H Xiii CI
al \/'Br alibi CI
H
J
NH2 'HCI N/er 0 Cl _________________________________________ v.
H
CI 1.1 H Step-1 CI
CIN oyl CI
_________________ PIP, OANe Step 2 W H
CI XIII
- 119 -Step 1: To a solution of N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide hydrochloride (0.3 g, 0.99 mmol, 1 equiv) in TEA (0.55 mL, 3.96 mmol, 4 equiv) was added 1-(2-bromoethoxy)-4-chlorobenzene(0.27 g , 1.18 mmol, 1.2 equiv) and the reaction mixture was stirred at room temperature for 10 mins.
The reaction mixture was then heated at 100 C for 1 h. After the starting material was consumed (TLC, 5 % DCM in methanol), the reaction mixture was cooled to room temperature, diluted with water (10 mL) and extracted with Et0Ac (2 X 10 mL). The combined organic layer was washed with a brine solution (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by flash column chromatography (Combiflashe) using a silica gel column and the product eluted at 2% methanol in DCM. Fractions containing product were concentrated to give 2-(4-chlorophenoxy)-N-(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-yl)acetamide (0.15 g, 36% yield) as pale brownish liquid. LCMS (ES) m/z =
421.1 [M+H].
1H NMR (400 MHz, DMSO-d6) 6 ppm 1.95 (bs, 6 H), 2.81 (bs, 2 H), 3.92 - 3.95 (m, 2 H), .. 4.39 (s, 2 H), 6.92 - 6.95 (m, 4 H), 7.30 (t, J= 8.0 Hz, 4 H), 8.55 (bs, 1 H).
Step 2: To a solution of 2-(4-chlorophenoxy)-N-(3-((4chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.04 g, 0.09 mmol 1 equiv) in TEA (0.05 mL, 0.36 mmol, 4 equiv) was added 2-chloro-N,N-dimethylacetamide (0.043 g, 0.36 mmol, 4 equiv) and the reaction mixture was heated at 80 C for 1 h. After the starting material was consumed (TLC, 5 % methanol in DCM), the reaction mixture was cooled to room temperature, diluted with water(10 mL) and extracted with Et0Ac (2x10 mL). The combined organic layer was washed with a brine solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
The crude material was purified by flash column chromatography (Combiflashe) using a silica gel column and the product eluted at 5% ethyl methanol in DCM. Fractions containing product were concentrated to give 2-((3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-y1)(2-(4-chlorophenoxy)ethyl)amino)-N,N-dimethylacetamide (0.02 g, 41% yield) as off white color solid. LCMS (ES) m/z = 506.2 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.99 (s, 6 H), 2.74 (s, 3 H), 2.90- 2.91 (m, 2 H), 2.93 - 2.95 (m, 3 H), 3.37 (s, 2 H), 3.93 -3.96 (m, 2 H), 4.39 (s, 2 H), 6.89 - 6.95 (m, 4 H), 7.31 (t, J= 8.0 Hz, 4 H), 8.57 (s,1 H).
The Compounds of Examples XIV and XV were prepared generally according to the procedures described above for Example XIII.
The reaction mixture was then heated at 100 C for 1 h. After the starting material was consumed (TLC, 5 % DCM in methanol), the reaction mixture was cooled to room temperature, diluted with water (10 mL) and extracted with Et0Ac (2 X 10 mL). The combined organic layer was washed with a brine solution (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by flash column chromatography (Combiflashe) using a silica gel column and the product eluted at 2% methanol in DCM. Fractions containing product were concentrated to give 2-(4-chlorophenoxy)-N-(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-yl)acetamide (0.15 g, 36% yield) as pale brownish liquid. LCMS (ES) m/z =
421.1 [M+H].
1H NMR (400 MHz, DMSO-d6) 6 ppm 1.95 (bs, 6 H), 2.81 (bs, 2 H), 3.92 - 3.95 (m, 2 H), .. 4.39 (s, 2 H), 6.92 - 6.95 (m, 4 H), 7.30 (t, J= 8.0 Hz, 4 H), 8.55 (bs, 1 H).
Step 2: To a solution of 2-(4-chlorophenoxy)-N-(3-((4chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.04 g, 0.09 mmol 1 equiv) in TEA (0.05 mL, 0.36 mmol, 4 equiv) was added 2-chloro-N,N-dimethylacetamide (0.043 g, 0.36 mmol, 4 equiv) and the reaction mixture was heated at 80 C for 1 h. After the starting material was consumed (TLC, 5 % methanol in DCM), the reaction mixture was cooled to room temperature, diluted with water(10 mL) and extracted with Et0Ac (2x10 mL). The combined organic layer was washed with a brine solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
The crude material was purified by flash column chromatography (Combiflashe) using a silica gel column and the product eluted at 5% ethyl methanol in DCM. Fractions containing product were concentrated to give 2-((3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-y1)(2-(4-chlorophenoxy)ethyl)amino)-N,N-dimethylacetamide (0.02 g, 41% yield) as off white color solid. LCMS (ES) m/z = 506.2 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.99 (s, 6 H), 2.74 (s, 3 H), 2.90- 2.91 (m, 2 H), 2.93 - 2.95 (m, 3 H), 3.37 (s, 2 H), 3.93 -3.96 (m, 2 H), 4.39 (s, 2 H), 6.89 - 6.95 (m, 4 H), 7.31 (t, J= 8.0 Hz, 4 H), 8.57 (s,1 H).
The Compounds of Examples XIV and XV were prepared generally according to the procedures described above for Example XIII.
- 120 -Table XIV
1H-NMR (400 MHz, Cmpd # Structure Name LCMS miz [M+H] DMSO-d6) CI
2-((3-(2-(4- 1.99 (s, 6 H), 2.74 (s, 3 chlorophenoxy)ac H), 2.90 - 2.91 (m, 2 H), etamido)bicyclo[1. 2.93 - 2.95 (m, 3 H), XIII
1.1]pentan-1-yI)(2-506.2 (4-o 3.37 (s, 2 H), 3.93 - 3.96 (m, 2 H), 4.39 (s, 2 H), NH
chlorophenoxy)eth 6.89 - 6.95 (m, 4 H), yl)amino)-N,N- 7.31 (t, J= 8.0 Hz, 4 H), 141 dimethylacetamide 8.57 (s, 1 H).
CI
2-(4-2.19 (s, 6 H), 2.98 (t, J =
HN-C 5.6 Hz, 2 H), 4.02 (t, J =
X
.4))>
(3-((2-(4- 421.1 5.2 Hz, 2 H), 4.39 (s, 2 IV chlorophenoxy)-N-o NH H), 6.81 - 6.86 (m, 5 H), chlorophenoxy)eth opY 7.21 - 7.28 (m, 4 H).
yl)amino)bicyclo[1.
1.1]pentan-1-yl)acetamide
1H-NMR (400 MHz, Cmpd # Structure Name LCMS miz [M+H] DMSO-d6) CI
2-((3-(2-(4- 1.99 (s, 6 H), 2.74 (s, 3 chlorophenoxy)ac H), 2.90 - 2.91 (m, 2 H), etamido)bicyclo[1. 2.93 - 2.95 (m, 3 H), XIII
1.1]pentan-1-yI)(2-506.2 (4-o 3.37 (s, 2 H), 3.93 - 3.96 (m, 2 H), 4.39 (s, 2 H), NH
chlorophenoxy)eth 6.89 - 6.95 (m, 4 H), yl)amino)-N,N- 7.31 (t, J= 8.0 Hz, 4 H), 141 dimethylacetamide 8.57 (s, 1 H).
CI
2-(4-2.19 (s, 6 H), 2.98 (t, J =
HN-C 5.6 Hz, 2 H), 4.02 (t, J =
X
.4))>
(3-((2-(4- 421.1 5.2 Hz, 2 H), 4.39 (s, 2 IV chlorophenoxy)-N-o NH H), 6.81 - 6.86 (m, 5 H), chlorophenoxy)eth opY 7.21 - 7.28 (m, 4 H).
yl)amino)bicyclo[1.
1.1]pentan-1-yl)acetamide
- 121 -CI
* N-(3-((2-(4- 1.92 (s, 6 H), 2.80 (t, J =
5.6 Hz, 2 H), 3.93 (t, J =
. chlorophenoxy)eth HNI yl)amino)bicyclo[1. 5.6 Hz, 2 H), 4.63 (s, 2 XV
4)* 1.1]pentan-1-yI)-2-((5-chloropyridin- H), 6.92 (d, J = 8.8 Hz, 3 422.0 H), 7.29 (d, J = 8.8 Hz, 2 H), 7.81 (dd, J = 6.4 Hz, J = 2.4 Hz, 1 H), 8.15(d, 0oYNH
yl)oxy)acetamide J = 2.4 Hz, 1 H), 8.50 (s, I 1 H).
=
i Example XVI
Methyl N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo11.1.11pentan-1-y1)-N-(2-(4-chlorophenoxy)ethvnalycinate ?0 is Cl 0 NN.0 OAN
Cl . H
XVI
o ci ci o o .
H 41 BrA / JN)::rNo 0 p., NO 0 W
H
OAN-y f-..../ Step 1 I
CI XVI
Step 1: To a solution of 2-(4-chlorophenoxy)-N-(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.06 g, 0.14 mmol, 1
* N-(3-((2-(4- 1.92 (s, 6 H), 2.80 (t, J =
5.6 Hz, 2 H), 3.93 (t, J =
. chlorophenoxy)eth HNI yl)amino)bicyclo[1. 5.6 Hz, 2 H), 4.63 (s, 2 XV
4)* 1.1]pentan-1-yI)-2-((5-chloropyridin- H), 6.92 (d, J = 8.8 Hz, 3 422.0 H), 7.29 (d, J = 8.8 Hz, 2 H), 7.81 (dd, J = 6.4 Hz, J = 2.4 Hz, 1 H), 8.15(d, 0oYNH
yl)oxy)acetamide J = 2.4 Hz, 1 H), 8.50 (s, I 1 H).
=
i Example XVI
Methyl N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo11.1.11pentan-1-y1)-N-(2-(4-chlorophenoxy)ethvnalycinate ?0 is Cl 0 NN.0 OAN
Cl . H
XVI
o ci ci o o .
H 41 BrA / JN)::rNo 0 p., NO 0 W
H
OAN-y f-..../ Step 1 I
CI XVI
Step 1: To a solution of 2-(4-chlorophenoxy)-N-(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.06 g, 0.14 mmol, 1
- 122 -equiv) in DMF (15 mL) at room temperature was added potassium carbonate (0.029 g, 0.21 mmol, 1.5 equiv) portionwise. After stirring for 2 minutes, methyl 2-bromoacetate (0.016 g, 0.16 mmol, 1.2 equiv) was added. The reaction mixture was heated at 80 C for 6 h. After the starting material was consumed (TLC, 15 % Et0Ac in hexane), the reaction mixture was cooled to room temperature, diluted with water (10 mL) and extracted with Et0Ac (2 x 10 mL). The combined organic layer was washed with a brine solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by flash column chromatography using a silica gel column and the product eluted at 40% ethyl acetate in hexane. Fractions containing product were concentrated to give methyl N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-y1)-N-(2-(4-chlorophenoxy)ethyl)glycinate (0.006 g, 8% yield) as colorless gum. LCMS (ES) m/z = 493.1 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.98 (s, 6 H), 2.99- 3.02 (m, 2 H), 3.47 (s, 2 H), 3.56 (s, 3 H), 3.95 -3.98 (m, 2 H), 4.39 (s, 2 H), 6.95 -6.89 (m, 4 H), 7.31 (t, J= 8.0 Hz, 4 H), 8.58 (s, 1 H).
Table V
LCMS miz 1H-NMR (400 MHz, Cmpd # Structure Name [M+H] DMSO-d6) CI
110 methyl N-(3-(2-(4- 1.98 (s, 6 H), 2.99 -3.02 ( chlorophenoxy)ac (m, 2 H), 3.47 (s, 2 H), XVI etamido)bicyclo[1. 3.56 (s, 3 H), 3.95 -3.98 1.1]pentan-1-yI)-N- 493.1 (m, 2 H), 4.39 (s, 2 H), (2-(4- 6.95 - 6.89 (m, 4 H), 7.31 chlorophenoxy)eth (t, j= 8.0 Hz, 4 H), 8.58 o) 1101 yl)g lycinate (s, 1 H).
Example XVII
ethyl 4-((3-(2-(4-chlorophenoxy)acetamido)bicyclo11.1.11pentan-1-y1)(2-(4-chlorophenoxy)ethynamino)butanoate
Table V
LCMS miz 1H-NMR (400 MHz, Cmpd # Structure Name [M+H] DMSO-d6) CI
110 methyl N-(3-(2-(4- 1.98 (s, 6 H), 2.99 -3.02 ( chlorophenoxy)ac (m, 2 H), 3.47 (s, 2 H), XVI etamido)bicyclo[1. 3.56 (s, 3 H), 3.95 -3.98 1.1]pentan-1-yI)-N- 493.1 (m, 2 H), 4.39 (s, 2 H), (2-(4- 6.95 - 6.89 (m, 4 H), 7.31 chlorophenoxy)eth (t, j= 8.0 Hz, 4 H), 8.58 o) 1101 yl)g lycinate (s, 1 H).
Example XVII
ethyl 4-((3-(2-(4-chlorophenoxy)acetamido)bicyclo11.1.11pentan-1-y1)(2-(4-chlorophenoxy)ethynamino)butanoate
- 123 -(0 C) 0 * CI
* 0\...AN.tro 0 CI H
XVII
(0 (:) CI Bro,"=õ====1=* .= ,..=
H
0 N gip CI
1. 0At Step 1 "..
il 0(Djirr ..^..0 CI WI*
XVII
Step 1: To a solution of 2-(4-ch lorophenoxy)-N-(3-.. ((4chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.09 g, 0.21 mmol, 1 equiv) in TEA (0.086 mL, 0.84 mmol, 4 equiv) was added ethyl 4-bromobutanoate (0.053 mL, 0.31 mmol, 1.5 equiv) and the reaction mixture was heated at 100 C for 1 h. After the starting material was consumed (TLC, 5 % methanol in DCM), the reaction mixture was cooled to room temperature, diluted with water (10mL) and extracted with Et0Ac (2 x 10 .. mL). The combined organic layer was washed with a brine solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
The crude material was purified by flash column chromatography using a silica gel column and the product eluted at 2.5% methanol in DOM. Fractions containing product were concentrated to provide ethyl 4-((3-(2-(4-ch lorophenoxy)acetam ido)bicyclo[1.1.1]pentan-1-yI)(2-(4-chlorophenoxy)ethyl)amino)butanoate (0.04g, 35% yield) as pale yellow gum.
LCMS (ES) m/z = 535.2 [M+H]. 1H NMR (400 MHz, DMSO-d66 ppm 1.12- 1.22 (m, 3 H), 1.59-1.63 (m, 2 H), 1.98 (s, 6 H), 2.26 - 2.30 (m, 2 H), 2.48 (bs, 2 H), 2.80 - 2.83 (m, 2 H), 3.90 -3.93 (m, 2 H), 3.98 - 4.03 (m, 2 H), 4.40 (s, 2 H), 6.90- 6.95 (m, 4 H), 7.30 (t, J= 8.0 Hz, 4 H), 8.58 (s, 1 H).
* 0\...AN.tro 0 CI H
XVII
(0 (:) CI Bro,"=õ====1=* .= ,..=
H
0 N gip CI
1. 0At Step 1 "..
il 0(Djirr ..^..0 CI WI*
XVII
Step 1: To a solution of 2-(4-ch lorophenoxy)-N-(3-.. ((4chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.09 g, 0.21 mmol, 1 equiv) in TEA (0.086 mL, 0.84 mmol, 4 equiv) was added ethyl 4-bromobutanoate (0.053 mL, 0.31 mmol, 1.5 equiv) and the reaction mixture was heated at 100 C for 1 h. After the starting material was consumed (TLC, 5 % methanol in DCM), the reaction mixture was cooled to room temperature, diluted with water (10mL) and extracted with Et0Ac (2 x 10 .. mL). The combined organic layer was washed with a brine solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
The crude material was purified by flash column chromatography using a silica gel column and the product eluted at 2.5% methanol in DOM. Fractions containing product were concentrated to provide ethyl 4-((3-(2-(4-ch lorophenoxy)acetam ido)bicyclo[1.1.1]pentan-1-yI)(2-(4-chlorophenoxy)ethyl)amino)butanoate (0.04g, 35% yield) as pale yellow gum.
LCMS (ES) m/z = 535.2 [M+H]. 1H NMR (400 MHz, DMSO-d66 ppm 1.12- 1.22 (m, 3 H), 1.59-1.63 (m, 2 H), 1.98 (s, 6 H), 2.26 - 2.30 (m, 2 H), 2.48 (bs, 2 H), 2.80 - 2.83 (m, 2 H), 3.90 -3.93 (m, 2 H), 3.98 - 4.03 (m, 2 H), 4.40 (s, 2 H), 6.90- 6.95 (m, 4 H), 7.30 (t, J= 8.0 Hz, 4 H), 8.58 (s, 1 H).
- 124 -Table VI
LCMS
' Cmpd # Structure Name miz H-NMR (400 MHz, DMSO-d6) [M+H]
1.12- 1.22 (m, 3 H), 1.59 ethyl 4-((3-(2-(4-chlorophenoxy)aceta 1.63 (m, 2 H), 1.98 (s, 6 H), 2.26 - 2.30 (m, 2 H), 2.48 (bs, XVII mido)bicyclo[1.1.1]p entan-1-yI)(2-(4- 535.2 2 H), 2.80 - 2.83 (m, 2 H), 3.90 0) H - 3.93 (m, 2 H), 3.98- 4.03 (m, chlorophenoxy)ethyl) 141 2 H), 4.40 (s, 2 H), 6.90 - 6.95 amino)butanoate (m, 4 H), 7.30 (t, J= 8.0 Hz, 4 H), 8.58 (s, 1 H).
Example XVIII
2-(4-chlorophenoxv)-N-(3-((2-(4-chlorophenoxv)ethvl)(methvnamino)bicycloll.1.11pentan-1-vpacetamide CI
CI
XVIII
CI
0 N=0 0 p=...)143 O
ArsviCr -vow CI Step 1 CI
XVIII
Step 1: To a solution of 2-(4-chlorophenoxy)-N-(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.050 g, 0.118 mmol, 1 equiv) in tetrahydrofuran (5 mL) at 0 C were added aqueous formaldehyde (0.2 mL) and acetic acid (0.050 mL). After stirring for 1 h at room temperature sodiumtriacetoxy borohydrate (0.037 g, 0.178 mmol, 1.5 equiv) was added at 0 C. After stirring for 5
LCMS
' Cmpd # Structure Name miz H-NMR (400 MHz, DMSO-d6) [M+H]
1.12- 1.22 (m, 3 H), 1.59 ethyl 4-((3-(2-(4-chlorophenoxy)aceta 1.63 (m, 2 H), 1.98 (s, 6 H), 2.26 - 2.30 (m, 2 H), 2.48 (bs, XVII mido)bicyclo[1.1.1]p entan-1-yI)(2-(4- 535.2 2 H), 2.80 - 2.83 (m, 2 H), 3.90 0) H - 3.93 (m, 2 H), 3.98- 4.03 (m, chlorophenoxy)ethyl) 141 2 H), 4.40 (s, 2 H), 6.90 - 6.95 amino)butanoate (m, 4 H), 7.30 (t, J= 8.0 Hz, 4 H), 8.58 (s, 1 H).
Example XVIII
2-(4-chlorophenoxv)-N-(3-((2-(4-chlorophenoxv)ethvl)(methvnamino)bicycloll.1.11pentan-1-vpacetamide CI
CI
XVIII
CI
0 N=0 0 p=...)143 O
ArsviCr -vow CI Step 1 CI
XVIII
Step 1: To a solution of 2-(4-chlorophenoxy)-N-(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.050 g, 0.118 mmol, 1 equiv) in tetrahydrofuran (5 mL) at 0 C were added aqueous formaldehyde (0.2 mL) and acetic acid (0.050 mL). After stirring for 1 h at room temperature sodiumtriacetoxy borohydrate (0.037 g, 0.178 mmol, 1.5 equiv) was added at 0 C. After stirring for 5
- 125 -minutes, the reaction mixture was allowed to stir at room temperature for 14 h. The reaction mixture was then quenched with a saturated sodium bicarbonate (1 mL) and extracted with ethyl acetate (2 x 15 mL). The combined organic layer was washed with water (2.0 mL), brine (3 mL) and then dried over anhydrous sodium sulfate. The organic layer was filtered and concentrated under reduced pressure to give the crude product which was purified by preparative TLC using 3% methanol in DCM as mobile phase. The product was concentrated under reduced pressure and dried under high vacuum to provide 2-(4-chlorophenoxy)-N-(3-((2-(4-chlorophenoxy)ethyl)(methyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.027 g, 52.94% yield) white solid. LCMS (ES) rniz = 435.1 [M+H]+. 1H
NMR (400 MHz, DMSO-d6): 6 ppm 1.96 (s, 6 H), 2.20 (s, 3 H), 2.70 (t, J= 5.6 Hz, 2 H), 3.99 (t, J = 5.6 Hz, 2 H), 4.40 (s, 2 H), 6.92 ¨ 6.95 (m, 4 H), 7.28 ¨ 7.33 (m, 4 H), 8.60 (s, 1 H).
Table VII
LCMS
Cmpd # Structure miz 'H-NMR (400 MHz, DMSO-d6) Name [M+H]
CI
1101 1.96 (s, 6 H), 2.20 (s, 3 H), 2.70 (t, J= 5.6 Hz, 2 H), 3.99 (t, J=
2-(4-5.6 Hz, 2 H), 4.40 (s, 2 H), 6.92 Nf chlorophenoxy)-XVIII N-(3-((2-(4- 435.1 ¨ 6.95 (m, 4 H), 7.28 ¨ 7.33 (m, chlorophenoxy)et 4 H), 8.60 (s, 1 H).
hyl)(methyl)amino o) )bicyclo[1.1.1]pent an-1-yl)acetamide
NMR (400 MHz, DMSO-d6): 6 ppm 1.96 (s, 6 H), 2.20 (s, 3 H), 2.70 (t, J= 5.6 Hz, 2 H), 3.99 (t, J = 5.6 Hz, 2 H), 4.40 (s, 2 H), 6.92 ¨ 6.95 (m, 4 H), 7.28 ¨ 7.33 (m, 4 H), 8.60 (s, 1 H).
Table VII
LCMS
Cmpd # Structure miz 'H-NMR (400 MHz, DMSO-d6) Name [M+H]
CI
1101 1.96 (s, 6 H), 2.20 (s, 3 H), 2.70 (t, J= 5.6 Hz, 2 H), 3.99 (t, J=
2-(4-5.6 Hz, 2 H), 4.40 (s, 2 H), 6.92 Nf chlorophenoxy)-XVIII N-(3-((2-(4- 435.1 ¨ 6.95 (m, 4 H), 7.28 ¨ 7.33 (m, chlorophenoxy)et 4 H), 8.60 (s, 1 H).
hyl)(methyl)amino o) )bicyclo[1.1.1]pent an-1-yl)acetamide
- 126 -Example XIX
2-(4-chlorophenoxv)-N-(3-(N-(2-(4-chlorophenoxv)ethypacetamido)bicyclo11.1.11pentan-1-vpacetamide is CI
OAN
CI XIX
ci ci 0 N õ
0j(Nerr Step 1 OA) N
a CI XIX
Step 1: To a solution of 2-(4-chlorophenoxy)-N-(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.050 g, 0.118 mmol, 1 equiv) in DMF (5 mL) at 0 C were added triethylamine (0.066 mL, 0.47 mmol, 4 equiv) and acetic acid (0.009 mL, 0.166 mmol, 1.4 equiv). After stirring for 5 minutes, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.034 g, 0.178 mmol, 1.5 equiv) and hydroxybenzotriazole (0.027 g, 0.178 mmol, 1.5 equiv) were added. Then reaction mixture was allowed to stir at room temperature for 14 h. The reaction mixture was diluted with water (5 mL) and extracted with ethyl acetate (2 x 10 mL). The combined organic extract was washed with a saturated solution of aqueous NaHCO3 (3 mL), water (10 mL) and dried over anhydrous sodium sulfate. The organic layer was filtered and concentrated under reduced pressure to give the crude product which was purified by following preparative HPLC method.
Column: intersil ODS 3V (250mm x4.6mm x5mic) Mobile phase (A): 0.1% Ammonia in water Mobile phase (B): ACN
Flow rate: 1.0 mL/min T/ /06:0/20, 10/80, 25/90, 27/20, 30/20 Yield: 0.029 g, white solid, 53.70%
2-(4-chlorophenoxv)-N-(3-(N-(2-(4-chlorophenoxv)ethypacetamido)bicyclo11.1.11pentan-1-vpacetamide is CI
OAN
CI XIX
ci ci 0 N õ
0j(Nerr Step 1 OA) N
a CI XIX
Step 1: To a solution of 2-(4-chlorophenoxy)-N-(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.050 g, 0.118 mmol, 1 equiv) in DMF (5 mL) at 0 C were added triethylamine (0.066 mL, 0.47 mmol, 4 equiv) and acetic acid (0.009 mL, 0.166 mmol, 1.4 equiv). After stirring for 5 minutes, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.034 g, 0.178 mmol, 1.5 equiv) and hydroxybenzotriazole (0.027 g, 0.178 mmol, 1.5 equiv) were added. Then reaction mixture was allowed to stir at room temperature for 14 h. The reaction mixture was diluted with water (5 mL) and extracted with ethyl acetate (2 x 10 mL). The combined organic extract was washed with a saturated solution of aqueous NaHCO3 (3 mL), water (10 mL) and dried over anhydrous sodium sulfate. The organic layer was filtered and concentrated under reduced pressure to give the crude product which was purified by following preparative HPLC method.
Column: intersil ODS 3V (250mm x4.6mm x5mic) Mobile phase (A): 0.1% Ammonia in water Mobile phase (B): ACN
Flow rate: 1.0 mL/min T/ /06:0/20, 10/80, 25/90, 27/20, 30/20 Yield: 0.029 g, white solid, 53.70%
- 127 -LCMS (ES) rniz = 463.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6): 6 ppm 2.05 (s, 3 H), 2.30 (s, 6 H), 3.62 (t, J = 5.6 Hz, 2 H), 4.03 (t, J = 5.2 Hz, 2 H), 4.41 (s, 2 H), 6.93 ¨ 6.97 (m, 4 H), 7.27 ¨ 7.31 (m, 4 H), 8.41 (s, 1 H).
Table VIII
LCMS
'H-NMR (400 MHz, DMSO-d6) Cmpd # Structure Name miz [M+H]
CI
2-(4- 2.05 (s, 3 H), 2.30 (s, 6 H), 3.62 ON' chlorophenoxy)-N- (t, J= 5.6 Hz, 2 H), 4.03 (t, J=
OON (3-(N-(2-(4-XIX 5.2 Hz, 2 H), 4.41 (s, 2 H), 6.93 chlorophenoxy)ethyl 463.1 _ 6.97 (m, 4 H), 7.27 ¨ 7.31 (m, )acetamido)bicyclo[ 4 H), 8.41 (s, 1 H).
o) 1.1.1]pentan-1-yl)acetamide Example XX
2-(4-chlorophenoxv)-N-(3-((2-(4-chlorophenoxv)ethvl)(oxetan-3-vnamino)bicyclo11.1.11pentan-1-vpacetamide ci OJL ON
XX
CI
ci CI
Step 1 CI
Cl XX
Table VIII
LCMS
'H-NMR (400 MHz, DMSO-d6) Cmpd # Structure Name miz [M+H]
CI
2-(4- 2.05 (s, 3 H), 2.30 (s, 6 H), 3.62 ON' chlorophenoxy)-N- (t, J= 5.6 Hz, 2 H), 4.03 (t, J=
OON (3-(N-(2-(4-XIX 5.2 Hz, 2 H), 4.41 (s, 2 H), 6.93 chlorophenoxy)ethyl 463.1 _ 6.97 (m, 4 H), 7.27 ¨ 7.31 (m, )acetamido)bicyclo[ 4 H), 8.41 (s, 1 H).
o) 1.1.1]pentan-1-yl)acetamide Example XX
2-(4-chlorophenoxv)-N-(3-((2-(4-chlorophenoxv)ethvl)(oxetan-3-vnamino)bicyclo11.1.11pentan-1-vpacetamide ci OJL ON
XX
CI
ci CI
Step 1 CI
Cl XX
- 128 -Step 1: To a solution of 2-(4-chlorophenoxy)-N-(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.060 g, 0.142 mmol, 1 equiv) in methanol (5 mL) was added oxetan-3-one (0.012 mL, 0.213 mmol, 1.5 equiv) and ZnCl2 (0.5 M in THF, 1.13 mL, 0.569 mmol, 4 equiv). Then reaction mixture was then cooled with an ice bath and sodium cyanoborohydride (0.026 g, 0.427 mmol, 3 equiv) was added at 0 C. The reaction mixture was then stirred at 50 C for 5 h then cooled to room temperature and concentrated under reduced pressure. The residue was diluted with water (5 mL) and then extracted with ethyl acetate (2 x 10 mL). The combined organic layer was washed with water (5 mL), brine (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product which was purified by preparative TLC using 3% methanol in DCM as mobile phase. The fractions containing product were concentrated under reduced pressure and dried under high vacuum to provide 2-(4-chlorophenoxy)-N-(3-((2-(4-chlorophenoxy)ethyl)(oxetan-3-yl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.024 g, 35.82 % yield) as a white solid.
LCMS (ES) rniz = 477.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.96 (s, 6 H), 2.82 - 2.84 (m, 2 H), 3.89 - 3.96 (m, 3 H), 4.39 - 4.43 (m, 4 H), 4.52 - 4.55 (m, 2 H), 6.93 (d, J
= 8.8 Hz, 4 H), 7.29 -7.32 (m, 4 H), 8.60 (s, 1 H).
Table IX
Cmpd # Structure Name LCMS m/z 1H-NMR (400 MHz, DMSO-d6) [M+Hr 2-(4- 1.96 (s, 6 H), 2.82 - 2.84 (m, 2 H), 3.89 - 3.96 (m, 3 H), 4.39 -( chlorophenoxy)-H.,""zro 4.43 (m, 4 H), 4.52 -4.55 (m, 2 XX
4?* N-(3-((2-(4-chlorophenoxy)et 477.1 H), 6.93 (d, J= 8.8 Hz, 4 H), 7.29 - 7.32 (m, 4 H), 8.60 (s, 1 hyl)(oxetan-3-H).
01 yl)amino)bicyclo[
1.1.1]pentan-1-yl)acetamide Example XXI
LCMS (ES) rniz = 477.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.96 (s, 6 H), 2.82 - 2.84 (m, 2 H), 3.89 - 3.96 (m, 3 H), 4.39 - 4.43 (m, 4 H), 4.52 - 4.55 (m, 2 H), 6.93 (d, J
= 8.8 Hz, 4 H), 7.29 -7.32 (m, 4 H), 8.60 (s, 1 H).
Table IX
Cmpd # Structure Name LCMS m/z 1H-NMR (400 MHz, DMSO-d6) [M+Hr 2-(4- 1.96 (s, 6 H), 2.82 - 2.84 (m, 2 H), 3.89 - 3.96 (m, 3 H), 4.39 -( chlorophenoxy)-H.,""zro 4.43 (m, 4 H), 4.52 -4.55 (m, 2 XX
4?* N-(3-((2-(4-chlorophenoxy)et 477.1 H), 6.93 (d, J= 8.8 Hz, 4 H), 7.29 - 7.32 (m, 4 H), 8.60 (s, 1 hyl)(oxetan-3-H).
01 yl)amino)bicyclo[
1.1.1]pentan-1-yl)acetamide Example XXI
- 129 -2-(4-chlorophenoxv)-N-(3-((2-((4-chlorophenynamino)ethynamino)bicyclo11.1.11pentan-1-ynacetamide CI
ONAN C
XXI
CI IO
CI
J(Nxr NH2 'FICI
CI 9111 0 etp N OP) 0 0 n CI 1:001 Step 1 CI 41111111fri. N*".4.1 XXi Step 1: N-(3-aminobicyclo[1.1.1]pentan-1-y1)-2-(4-chlorophenoxy)acetamide hydrochloride (0.300 g, 0.989 mmol, 1 equiv), triethylamine (0.556 mL, 3.95 mmol, 4 equiv) and N-(2-bromoethyl)-4-chloroaniline (0.278 g, 1.18 mmol, 1.2 equiv) were added to a sealed tube.
The reaction mixture was then sealed and heated at 100 C for 1 h. at which time it was cooled to room temperature, diluted with water (5 mL) and extracted with Et0Ac (2 x 20 mL). The combined organic extract was washed with water (10 mL) followed by a saturated brine solution (8 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by flash column chromatography using a silica gel column and a mixture of methanol in DCM as eluent and the product eluted at 4 ¨ 5% methanol in DOM. Fractions containing product were concentrated to give 2-(4-chlorophenoxy)-N-(3-((2-((4-chlorophenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-1-.. yl)acetamide (0.130 g, 31.32 % yield) as off white solid. LCMS (ES) rniz =
420.1 [M+H]+, 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.93 (s, 6 H), 2.61 ¨ 2.64 (m, 2 H), 2.99 ¨
3.03 (m, 2 H), 4.39 (s, 2 H), 5.63 ¨ 5.66 (m, 1 H), 6.53 (d, J = 8.8 Hz, 2 H), 6.94 (d, J
= 8.8 Hz, 2 H), 7.05 (d, J= 8.8 Hz, 2 H), 7.31 (d, J= 8.8 Hz, 2 H), 8.54 (s, 1 H).
ONAN C
XXI
CI IO
CI
J(Nxr NH2 'FICI
CI 9111 0 etp N OP) 0 0 n CI 1:001 Step 1 CI 41111111fri. N*".4.1 XXi Step 1: N-(3-aminobicyclo[1.1.1]pentan-1-y1)-2-(4-chlorophenoxy)acetamide hydrochloride (0.300 g, 0.989 mmol, 1 equiv), triethylamine (0.556 mL, 3.95 mmol, 4 equiv) and N-(2-bromoethyl)-4-chloroaniline (0.278 g, 1.18 mmol, 1.2 equiv) were added to a sealed tube.
The reaction mixture was then sealed and heated at 100 C for 1 h. at which time it was cooled to room temperature, diluted with water (5 mL) and extracted with Et0Ac (2 x 20 mL). The combined organic extract was washed with water (10 mL) followed by a saturated brine solution (8 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by flash column chromatography using a silica gel column and a mixture of methanol in DCM as eluent and the product eluted at 4 ¨ 5% methanol in DOM. Fractions containing product were concentrated to give 2-(4-chlorophenoxy)-N-(3-((2-((4-chlorophenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-1-.. yl)acetamide (0.130 g, 31.32 % yield) as off white solid. LCMS (ES) rniz =
420.1 [M+H]+, 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.93 (s, 6 H), 2.61 ¨ 2.64 (m, 2 H), 2.99 ¨
3.03 (m, 2 H), 4.39 (s, 2 H), 5.63 ¨ 5.66 (m, 1 H), 6.53 (d, J = 8.8 Hz, 2 H), 6.94 (d, J
= 8.8 Hz, 2 H), 7.05 (d, J= 8.8 Hz, 2 H), 7.31 (d, J= 8.8 Hz, 2 H), 8.54 (s, 1 H).
- 130 -Table X
LCMS miz 1H-NMR (400 MHz, DMSO-d6) Cmpd # Structure Name [M+H]
CI
. 1.93 (s, 6 H), 2.61 ¨ 2.64 (m, 2 H 2-(4-chlorophenoxy)- H), 2.99 ¨ 3.03 (m, 2 H), 4.39 (s, H)' N-(3-((2-((4-chlorophenyl)amino)e 2 H), 5.63 ¨5.66 (m, 1 H), 6.53 XXI thyl)amino)bicyclo[1.1 (d, J= 8.8 Hz, 2 H), 6.94 (d, J=
.1]pentan-1- 420.1 8.8 Hz, 2 H), 7.05 (d, J= 8.8 Hz, H yl)acetamide 2 H), 7.31 (d, J= 8.8 Hz, 2 H), (:)./
8.54 (s, 1 H).
0) Example XXII
2-(4-chlorophenoxy)-N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-Vnbicyclo11.1.11pentan-l-vpacetamide r\N
0 j:iiN 11* CI
H XXII
CI
H ahh, a ir\N
1" 0:30AN Fsij V': -pp. OjLisv .1 IIP CI
Step 1 H H
CI Wil CI XXII
LCMS miz 1H-NMR (400 MHz, DMSO-d6) Cmpd # Structure Name [M+H]
CI
. 1.93 (s, 6 H), 2.61 ¨ 2.64 (m, 2 H 2-(4-chlorophenoxy)- H), 2.99 ¨ 3.03 (m, 2 H), 4.39 (s, H)' N-(3-((2-((4-chlorophenyl)amino)e 2 H), 5.63 ¨5.66 (m, 1 H), 6.53 XXI thyl)amino)bicyclo[1.1 (d, J= 8.8 Hz, 2 H), 6.94 (d, J=
.1]pentan-1- 420.1 8.8 Hz, 2 H), 7.05 (d, J= 8.8 Hz, H yl)acetamide 2 H), 7.31 (d, J= 8.8 Hz, 2 H), (:)./
8.54 (s, 1 H).
0) Example XXII
2-(4-chlorophenoxy)-N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-Vnbicyclo11.1.11pentan-l-vpacetamide r\N
0 j:iiN 11* CI
H XXII
CI
H ahh, a ir\N
1" 0:30AN Fsij V': -pp. OjLisv .1 IIP CI
Step 1 H H
CI Wil CI XXII
- 131 -Step 1: To a solution of 2-(4-chlorophenoxy)-N-(3-((2-((4-chlorophenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.090 g, 0.21 mmol, 1 equiv) in DCM (5 mL) at 0 C, triethylamine (0.150 mL, 1.07 mmol, 5 equiv) and triphosgene (0.038 g, 0.128 mmol, 0.6 equiv) were added. After stirring for 5 minutes, the reaction mixture was allowed to stir at room temperature for 3 h. Then reaction mixture was quenched with a saturated sodium bicarbonate solution, extracted with DCM (2 x 10 mL).
The combined organic extract was washed with cold water (8 mL) followed by a saturated brine solution (6 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by flash column chromatography using a silica gel column and a mixture ethyl acetate in hexane as eluent and the product eluted at 35 - 40% ethyl acetate in hexane to provide 2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.044 g, 46.31 % yield) as white solid. LCMS (ES) m/z = 446.1 [M+H]. 1H
NMR (400 MHz, DMSO-d6) 6 ppm 2.29 (s, 6 H), 3.42 (t, J = 8.4 Hz, 2 H), 3.75 (t, J = 6.8 Hz, 2 H), 4.42 (s, 2 H), 6.96 (d, J= 9.2 Hz, 2 H), 7.32 (d, J= 8.8 Hz, 4 H), 7.55 (d, J= 8.8 Hz, 2 H), 8.71 (s, 1 H).
Table XI
Cmpd # Structure Name LCMS m/z 1H-NMR (400 MHz, DMSO-d6) [M+Hr CI
* 2-(4- 2.29 (s, 6 H), 3.42 (t, J=
8.4 Hz, chlorophenoxy)-N- 2 H), 3.75 (t, J= 6.8 Hz, 2 H), XXII HNO (3-(3-(4- 4.42 (s, 2 H), 6.96 (d, J=
9.2 chlorophenyI)-2-oxoimidazolidin-1- 446.1 Hz, 2 H), 7.32 (d, J= 8.8 Hz, 4 H), 7.55 (d, J= 8.8 Hz, 2 H), OJ yl)bicyclo[1.1.1]pen 8.71 (s, 1 H).
= tan-1-yl)acetamide
The combined organic extract was washed with cold water (8 mL) followed by a saturated brine solution (6 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by flash column chromatography using a silica gel column and a mixture ethyl acetate in hexane as eluent and the product eluted at 35 - 40% ethyl acetate in hexane to provide 2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.044 g, 46.31 % yield) as white solid. LCMS (ES) m/z = 446.1 [M+H]. 1H
NMR (400 MHz, DMSO-d6) 6 ppm 2.29 (s, 6 H), 3.42 (t, J = 8.4 Hz, 2 H), 3.75 (t, J = 6.8 Hz, 2 H), 4.42 (s, 2 H), 6.96 (d, J= 9.2 Hz, 2 H), 7.32 (d, J= 8.8 Hz, 4 H), 7.55 (d, J= 8.8 Hz, 2 H), 8.71 (s, 1 H).
Table XI
Cmpd # Structure Name LCMS m/z 1H-NMR (400 MHz, DMSO-d6) [M+Hr CI
* 2-(4- 2.29 (s, 6 H), 3.42 (t, J=
8.4 Hz, chlorophenoxy)-N- 2 H), 3.75 (t, J= 6.8 Hz, 2 H), XXII HNO (3-(3-(4- 4.42 (s, 2 H), 6.96 (d, J=
9.2 chlorophenyI)-2-oxoimidazolidin-1- 446.1 Hz, 2 H), 7.32 (d, J= 8.8 Hz, 4 H), 7.55 (d, J= 8.8 Hz, 2 H), OJ yl)bicyclo[1.1.1]pen 8.71 (s, 1 H).
= tan-1-yl)acetamide
- 132 -Example XXIII
1-(3-((2-(4-chlorophenoxv)ethvnamino)bimlo11.1.11pentan-1-v1)-3-(4-chlorophenvnimidazolidin-2-one CI
\
XXIII
H CI Li pry" `Boc r¨)4 H2N--1,:r NsBoc steic. IP' 110 1111w sir Step 2 CI
CI
ao o..___ CI
N __________________________________________________________________ 0 a 40 c, _ yip CIH' H2N1:r /110 CI
Step 3 Step 4 LiN
XXIII
Step 1: In a sealed tube tert-buty1(3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.400 g, 2.01 mmol, 1 equiv), triethylamine (0.709 mL, 5.04 mmol, 2.5 equiv) and N-(2-bromoethyl)-4-chloroaniline (0.567 g, 2.42 mmol, 1.2 equiv) were added. The reaction mixture was sealed and heated at 100 C for 1 h. The reaction mixture was cooled to room temperature, diluted with water (5 mL) and extracted with Et0Ac (2 x 15 mL). The combined organic extract was washed with cold water (5 mL) followed by a saturated brine solution (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by flash column chromatography using a silica gel column and a mixture of methanol in DCM as eluent and the product eluted at 4 ¨ 5% methanol in DOM. Fractions containing product were concentrated to give tert-butyl (3-((2-((4-chlorophenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)carbamate (0.305 g, 43.01 % yield) as light yellow gum. LCMS (ES) rniz = 352.3 [M+H]+,
1-(3-((2-(4-chlorophenoxv)ethvnamino)bimlo11.1.11pentan-1-v1)-3-(4-chlorophenvnimidazolidin-2-one CI
\
XXIII
H CI Li pry" `Boc r¨)4 H2N--1,:r NsBoc steic. IP' 110 1111w sir Step 2 CI
CI
ao o..___ CI
N __________________________________________________________________ 0 a 40 c, _ yip CIH' H2N1:r /110 CI
Step 3 Step 4 LiN
XXIII
Step 1: In a sealed tube tert-buty1(3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.400 g, 2.01 mmol, 1 equiv), triethylamine (0.709 mL, 5.04 mmol, 2.5 equiv) and N-(2-bromoethyl)-4-chloroaniline (0.567 g, 2.42 mmol, 1.2 equiv) were added. The reaction mixture was sealed and heated at 100 C for 1 h. The reaction mixture was cooled to room temperature, diluted with water (5 mL) and extracted with Et0Ac (2 x 15 mL). The combined organic extract was washed with cold water (5 mL) followed by a saturated brine solution (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by flash column chromatography using a silica gel column and a mixture of methanol in DCM as eluent and the product eluted at 4 ¨ 5% methanol in DOM. Fractions containing product were concentrated to give tert-butyl (3-((2-((4-chlorophenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)carbamate (0.305 g, 43.01 % yield) as light yellow gum. LCMS (ES) rniz = 352.3 [M+H]+,
- 133 -(400 MHz, DMSO-d6) 6 ppm 1.34 (s, 9 H), 1.80 (s, 6 H), 2.58 - 2.60 (m, 2 H), 2.98 - 3.02 (m, 2 H), 5.64 (bs, 1 H), 6.53 (d, J= 8.8 Hz, 2 H), 7.04 (d, J= 8.8 Hz, 2 H), 7.35 (bs, 1 H).
Step 2: To a solution of tert-butyl (3-((2-((4-chlorophenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)carbamate (0.305 g, 0.86 mmol, 1 equiv) in DCM (10 mL) at 0 C, triethylamine (0.609 mL, 4.33 mmol, 5 equiv) and triphosgene (0.154 g, 0.520 mmol, 0.6 equiv) were added. After stirring 5 minutes, the reaction mixture was allowed to stir at room temperature for 2.5 h. Then reaction mixture was quenched with a saturated sodium bicarbonate solution, extracted with DCM
(2 x 10 mL). The combined organic extract was washed with water (10 mL) followed by a saturated brine solution (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by flash column chromatography using a silica gel column and a mixture ethyl acetate in hexane as eluent and the product eluted at 80 - 90% ethyl acetate in hexane. Fractions containing product were concentrated to give tert-butyl (3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.240 g, 73.39% yield) as white solid.
LCMS (ES) rniz = 378.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.36 (s, 9 H), 2.16 (s, 6 H), 3.40 (t, J= 8.0 Hz, 2 H), 3.74 (t, J= 6.8 Hz, 2 H), 7.32 (d, J= 8.8 Hz, 2 H), 7.53 - 7.55 (m, 3H).
Step 3: To a solution of tert-butyl (3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.240 g, 0.635 mmol, 1 equiv) in DCM
(8 mL) at 0 C was added 4 M HCI in 1,4-dioxane (5 mL). Then reaction mixture was allowed to stir at room temperature (25 C) for 2.5 h. Then solvent was evaporated under reduced pressure.
The resultant crude material was washed with n-pentane (10 mL). The pentane was then decanted and the solid dried to give crude product of 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenyl)imidazolidin-2-one hydrochloride (0.185 g, white solid, Crude). LCMS
(ES) rniz = 278.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.27 (s, 6 H), 3.43 (t, J=
8.0 Hz, 2 H), 3.77 (t, J = 7.6 Hz, 2 H), 7.34 (d, J= 8.8 Hz, 2 H), 7.54 (d, J=
9.2 Hz, 2 H), 8.74 (s, 3 H).
Step 4:
1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenyl)imidazolidin-2-one hydrochloride (0.120 g, 0.381 mmol, 1 equiv), triethylamine (0.214 mL, 1.52 mmol, 4 equiv) and 1-(2-bromoethoxy)-4-chlorobenzene (0.107 g, 0.458 mmol, 1.2 equiv) were added to a sealed tube. The reaction mixture was sealed and heated at 100 C for 1 h.
Reaction mixture was cooled to room temperature, diluted with water (5 mL) and extracted with
Step 2: To a solution of tert-butyl (3-((2-((4-chlorophenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)carbamate (0.305 g, 0.86 mmol, 1 equiv) in DCM (10 mL) at 0 C, triethylamine (0.609 mL, 4.33 mmol, 5 equiv) and triphosgene (0.154 g, 0.520 mmol, 0.6 equiv) were added. After stirring 5 minutes, the reaction mixture was allowed to stir at room temperature for 2.5 h. Then reaction mixture was quenched with a saturated sodium bicarbonate solution, extracted with DCM
(2 x 10 mL). The combined organic extract was washed with water (10 mL) followed by a saturated brine solution (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by flash column chromatography using a silica gel column and a mixture ethyl acetate in hexane as eluent and the product eluted at 80 - 90% ethyl acetate in hexane. Fractions containing product were concentrated to give tert-butyl (3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.240 g, 73.39% yield) as white solid.
LCMS (ES) rniz = 378.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.36 (s, 9 H), 2.16 (s, 6 H), 3.40 (t, J= 8.0 Hz, 2 H), 3.74 (t, J= 6.8 Hz, 2 H), 7.32 (d, J= 8.8 Hz, 2 H), 7.53 - 7.55 (m, 3H).
Step 3: To a solution of tert-butyl (3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.240 g, 0.635 mmol, 1 equiv) in DCM
(8 mL) at 0 C was added 4 M HCI in 1,4-dioxane (5 mL). Then reaction mixture was allowed to stir at room temperature (25 C) for 2.5 h. Then solvent was evaporated under reduced pressure.
The resultant crude material was washed with n-pentane (10 mL). The pentane was then decanted and the solid dried to give crude product of 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenyl)imidazolidin-2-one hydrochloride (0.185 g, white solid, Crude). LCMS
(ES) rniz = 278.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.27 (s, 6 H), 3.43 (t, J=
8.0 Hz, 2 H), 3.77 (t, J = 7.6 Hz, 2 H), 7.34 (d, J= 8.8 Hz, 2 H), 7.54 (d, J=
9.2 Hz, 2 H), 8.74 (s, 3 H).
Step 4:
1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenyl)imidazolidin-2-one hydrochloride (0.120 g, 0.381 mmol, 1 equiv), triethylamine (0.214 mL, 1.52 mmol, 4 equiv) and 1-(2-bromoethoxy)-4-chlorobenzene (0.107 g, 0.458 mmol, 1.2 equiv) were added to a sealed tube. The reaction mixture was sealed and heated at 100 C for 1 h.
Reaction mixture was cooled to room temperature, diluted with water (5 mL) and extracted with
- 134 -Et0Ac (2 x 15 mL). The combined organic extract was washed with cold water (5 mL) followed by a saturated brine solution (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product, which was purified by preparative TLC using 2.5% methanol in DCM as mobile phase. The mixture was .. concentrated under reduced pressure and dried under high vacuum to provide 1-(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-1-y1)-3-(4-chlorophenyl)imidazolidin-2-one (0.028 g, 16.96% yield) off-white solid. LCMS (ES) rniz = 432.1 [M+H]+. 1H NMR
(400 MHz, DMSO-d6): 6 ppm 2.00 (s, 6 H), 2.60 (bs, 1 H), 2.82- 2.84 (m, 2 H), 3.40 (t, J= 8.4 Hz, 2 H), 3.74 (t, J= 7.2 Hz, 2 H), 3.96 (t, J= 5.6 Hz, 2 H), 6.94 (d, J= 8.0 Hz, 2H), 7.28 -7.33 (m, 4 H), 7.54 (d, J= 9.2 Hz, 2 H).
Table XII
Cmpd # Structure LCMS nilz 1H-NMR (400 MHz, DMSO-d6) [M+H]
Name CI
1-(3-((2-(4- 2.00 (s, 6 H), 2.60 (bs, 1 H), chlorophenoxy)eth 2.82 - 2.84 (m, 2 H), 3.40 (t, J=
XXIII yl)amino)bicyclo[1. 8.4 Hz, 2 H), 3.74 (t, J=
7.2 Hz, 1.1]pentan-1-y1)-3- 432.1 2 H), 3.96 (t, J= 5.6 Hz, 2 H), (4- 6.94 (d, J = 8.0 Hz, 2H), 7.28 -; chlorophenyl)imida 7.33 (m, 4 H), 7.54 (d, J=
9.2 zolidin-2-one Hz, 2 H), Example XXIV and Example 6a 2-(4-chlorophenoxv)-N-(3-(3-(4-chlorophenoxv)uvrrolidin-1-vnbicyclo11.1.11pentan-1-Vnacetamide
(400 MHz, DMSO-d6): 6 ppm 2.00 (s, 6 H), 2.60 (bs, 1 H), 2.82- 2.84 (m, 2 H), 3.40 (t, J= 8.4 Hz, 2 H), 3.74 (t, J= 7.2 Hz, 2 H), 3.96 (t, J= 5.6 Hz, 2 H), 6.94 (d, J= 8.0 Hz, 2H), 7.28 -7.33 (m, 4 H), 7.54 (d, J= 9.2 Hz, 2 H).
Table XII
Cmpd # Structure LCMS nilz 1H-NMR (400 MHz, DMSO-d6) [M+H]
Name CI
1-(3-((2-(4- 2.00 (s, 6 H), 2.60 (bs, 1 H), chlorophenoxy)eth 2.82 - 2.84 (m, 2 H), 3.40 (t, J=
XXIII yl)amino)bicyclo[1. 8.4 Hz, 2 H), 3.74 (t, J=
7.2 Hz, 1.1]pentan-1-y1)-3- 432.1 2 H), 3.96 (t, J= 5.6 Hz, 2 H), (4- 6.94 (d, J = 8.0 Hz, 2H), 7.28 -; chlorophenyl)imida 7.33 (m, 4 H), 7.54 (d, J=
9.2 zolidin-2-one Hz, 2 H), Example XXIV and Example 6a 2-(4-chlorophenoxv)-N-(3-(3-(4-chlorophenoxv)uvrrolidin-1-vnbicyclo11.1.11pentan-1-Vnacetamide
- 135 -01 * 4 N
H
6a Br arla, OH a Br Boo>.....NH2 a Br 0....C. I slt liep 1 5,1c.
1 -IP' CO () 11.-) 2 11 .NI
2 3 _<>_Nr _ii... Step CI
0,R 4<>N H2 H CI
iiii... ,--1-01, ci 00 ii a Step 4 5 Step 5 6a Step 1: To a solution of methyl 2,4-dibromobutanoate (1.2 g, 1 equiv) in DMF
(15 mL) was 5 added 4-chlorophenol (0.59 g, 1 equiv) at rt followed by K2003 (0.636 g, 1 equiv) and the reaction was stirred at 60 00 for 3 h. The reaction mixture was then allowed to come to rt.
Water (5 mL) was added and the mixture was extracted with Et0Ac (3 X 50 mL).
The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under vacuum. The crude material was purified by flash column chromatography eluting the 10 product at 10 `)/0 Et0Ac in hexane. The fractions containing the product were combined and the solvent was evaporated to provide methyl 4-bromo-2-(4-chlorophenoxy)butanoate as gum (1 g). 1H NMR (400 MHz, CDCI3) 6 ppm 2.3 - 2.5 (m, 2 H), 3.55- 3.64 (m, 2 H), 3.76 (s, 3 H), 4.83 -4.85 (m, 1 H), 6.86 (d, J= 3.2 Hz, 2 H), 7.23 - 7.25 (m, 2H).
Step 2: Methyl 4-bromo-2-(4-chlorophenoxy)butanoate (0.3 g, 1.01 mmol, 1 equiv) and tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.2 g, 1.01 mmol, 1 equiv) were charged to a sealed tube and Et3N (0.6 mL) was added. The mixture was then heated at 100 00 using an oil bath for 1 h. The reaction mixture was diluted with water (50 mL) and extracted with Et0Ac (2 X 50 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 45% Et0Ac in hexane to obtain the desired product tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as off-white solid (0.1 g, 25.6 `)/0). LCMS (ES) m/z = 337.1 [M+H] (loss of tert-butyl group) 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.44 (s, 9 H), 2.04 - 2.18 (m, 1 H), 2.39 (s, 6 H), 2.46 - 2.54 (m, 1 H), 3.29 - 3.35 (m, 1 H), 3.42 - 3.47 (m, 1 H), 4.77 (t, J = 7.2 Hz, 1 H), 4.94 (bs, 1 H), 6.98 (d, J= 9.2 Hz, 2 H), 7.21 (d, J= 8.8 Hz, 2 H).
H
6a Br arla, OH a Br Boo>.....NH2 a Br 0....C. I slt liep 1 5,1c.
1 -IP' CO () 11.-) 2 11 .NI
2 3 _<>_Nr _ii... Step CI
0,R 4<>N H2 H CI
iiii... ,--1-01, ci 00 ii a Step 4 5 Step 5 6a Step 1: To a solution of methyl 2,4-dibromobutanoate (1.2 g, 1 equiv) in DMF
(15 mL) was 5 added 4-chlorophenol (0.59 g, 1 equiv) at rt followed by K2003 (0.636 g, 1 equiv) and the reaction was stirred at 60 00 for 3 h. The reaction mixture was then allowed to come to rt.
Water (5 mL) was added and the mixture was extracted with Et0Ac (3 X 50 mL).
The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under vacuum. The crude material was purified by flash column chromatography eluting the 10 product at 10 `)/0 Et0Ac in hexane. The fractions containing the product were combined and the solvent was evaporated to provide methyl 4-bromo-2-(4-chlorophenoxy)butanoate as gum (1 g). 1H NMR (400 MHz, CDCI3) 6 ppm 2.3 - 2.5 (m, 2 H), 3.55- 3.64 (m, 2 H), 3.76 (s, 3 H), 4.83 -4.85 (m, 1 H), 6.86 (d, J= 3.2 Hz, 2 H), 7.23 - 7.25 (m, 2H).
Step 2: Methyl 4-bromo-2-(4-chlorophenoxy)butanoate (0.3 g, 1.01 mmol, 1 equiv) and tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.2 g, 1.01 mmol, 1 equiv) were charged to a sealed tube and Et3N (0.6 mL) was added. The mixture was then heated at 100 00 using an oil bath for 1 h. The reaction mixture was diluted with water (50 mL) and extracted with Et0Ac (2 X 50 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 45% Et0Ac in hexane to obtain the desired product tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as off-white solid (0.1 g, 25.6 `)/0). LCMS (ES) m/z = 337.1 [M+H] (loss of tert-butyl group) 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.44 (s, 9 H), 2.04 - 2.18 (m, 1 H), 2.39 (s, 6 H), 2.46 - 2.54 (m, 1 H), 3.29 - 3.35 (m, 1 H), 3.42 - 3.47 (m, 1 H), 4.77 (t, J = 7.2 Hz, 1 H), 4.94 (bs, 1 H), 6.98 (d, J= 9.2 Hz, 2 H), 7.21 (d, J= 8.8 Hz, 2 H).
- 136 -Step 3: To a solution of tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.1 g, 0.25 mmol) in DCM (5 mL) at 0 C was added 2 mL of 4 M HCI in 1,4-dioxane and the mixture was stirred at rt for 16 h. The reaction mixture was concentrated to give 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenoxy)pyrrolidin-2-one, hydrochloride (crude yield 0.08 g, 96.3%), which was taken to the next step without further purification. LCMS (ES) m/z = 293 [M+H]
+. 1H NMR
(400 MHz, DMSO-d6) 6 ppm 1.89 - 1.90 (m, 1 H), 2.18 - 2.19 (m, 1 H), 2.28 -2.33 (m, 6 H), 4.98 (t, J= 7.2 Hz, 1 H), 7.02 (d, J= 8.8 Hz, 2 H), 7.3 (d, J= 9.6 Hz, 1 H), 8.79 (s, 3 H).
Step 4: To a solution of 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenoxy)pyrrolidin-2-one hydrochloride (0.08 g, 0.24 mmol, 1 equiv) in THF (5 mL) was added BH3.Me2S (0.06 mL, 0.61 mmol, 2,5 equiv) at 0 C. The reaction mixture was then allowed to stir at rt for 16 h. Then the reaction mixture quenched with Me0H (1 mL) at 0 C and stirred for 30 min, and concentrated under reduced pressure at rotavapor to obtain the crude product. This crude material was then dissolved in DCM (50 mL) and washed with saturated Na2HCO3 solution. The organic phase was dried over anhydrous Na2SO4, filtered and evaporated under vacuum to yield 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.06 g, crude yield), which was used for the next step without further purification. LCMS (ES) m/z= 279 [M+H] .
Step 5: To a solution of 2-(4-chlorophenoxy)acetic acid (0.06 g, 0.23 mmol, 1.5 equiv) in DCM (5 mL) at 0 C was added triethylamine (0.15 mL, 1.07 mmol, 5 equiv) followed by T3Pe (50 wt% in Et0Ac) (0.25 mL, 0.43 mmol, 2 equiv). The mixture was stirred at 0 C
for 10 min, at which time, T3Pe (50 wt. % in ethyl acetate) (1.12 g, 1.768 mmol, 2 equiv) in dichloromethane (10 mL) was added at 0 C and stirred for 10 min. To this reaction mixture was added 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.06 g) in DCM (1 mL) slowly at 0 C and the reaction was stirred at rt for 16 h. The reaction mixture was diluted with water (50 mL) and extracted with DCM (2 x 50 mL). The combined organic layer was washed with saturated aqueous NaH0O3 solution (50 mL) and then dried over anhydrous Na2SO4, filtered and evaporated under vacuum under reduced pressure. The crude product was purified by preparative TLC using 40 % Et0Ac in hexanes. After final drying, the desired product 2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide was obtained as white solid (0.0108 g, 11.2%). LCMS (ES) m/z = 447.3 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6
+. 1H NMR
(400 MHz, DMSO-d6) 6 ppm 1.89 - 1.90 (m, 1 H), 2.18 - 2.19 (m, 1 H), 2.28 -2.33 (m, 6 H), 4.98 (t, J= 7.2 Hz, 1 H), 7.02 (d, J= 8.8 Hz, 2 H), 7.3 (d, J= 9.6 Hz, 1 H), 8.79 (s, 3 H).
Step 4: To a solution of 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenoxy)pyrrolidin-2-one hydrochloride (0.08 g, 0.24 mmol, 1 equiv) in THF (5 mL) was added BH3.Me2S (0.06 mL, 0.61 mmol, 2,5 equiv) at 0 C. The reaction mixture was then allowed to stir at rt for 16 h. Then the reaction mixture quenched with Me0H (1 mL) at 0 C and stirred for 30 min, and concentrated under reduced pressure at rotavapor to obtain the crude product. This crude material was then dissolved in DCM (50 mL) and washed with saturated Na2HCO3 solution. The organic phase was dried over anhydrous Na2SO4, filtered and evaporated under vacuum to yield 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.06 g, crude yield), which was used for the next step without further purification. LCMS (ES) m/z= 279 [M+H] .
Step 5: To a solution of 2-(4-chlorophenoxy)acetic acid (0.06 g, 0.23 mmol, 1.5 equiv) in DCM (5 mL) at 0 C was added triethylamine (0.15 mL, 1.07 mmol, 5 equiv) followed by T3Pe (50 wt% in Et0Ac) (0.25 mL, 0.43 mmol, 2 equiv). The mixture was stirred at 0 C
for 10 min, at which time, T3Pe (50 wt. % in ethyl acetate) (1.12 g, 1.768 mmol, 2 equiv) in dichloromethane (10 mL) was added at 0 C and stirred for 10 min. To this reaction mixture was added 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.06 g) in DCM (1 mL) slowly at 0 C and the reaction was stirred at rt for 16 h. The reaction mixture was diluted with water (50 mL) and extracted with DCM (2 x 50 mL). The combined organic layer was washed with saturated aqueous NaH0O3 solution (50 mL) and then dried over anhydrous Na2SO4, filtered and evaporated under vacuum under reduced pressure. The crude product was purified by preparative TLC using 40 % Et0Ac in hexanes. After final drying, the desired product 2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide was obtained as white solid (0.0108 g, 11.2%). LCMS (ES) m/z = 447.3 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6
- 137 -ppm 1.76 - 1.77 (m, 1.5 H), 1.95 (s, 6 H), 2.2 - 2.27 (m, 1.5 H), 2.58 - 2.61 (m, 1 H), 2.65 -2.69 (m, 1 H), 2.84 (m, 1 H), 4.4 (s, 2 H), 4.85 (bs, 1 H), 6.88 (d, J= 8.8 Hz, 2 H), 6.94 (d, J= 8.8 Hz, 2 H), 7.28 (d, J= 8.4 Hz, 2 H), 7.32 (d, J= 8.8 Hz, 2 H), 8.61 (s, 1 H).
Table XIII
LCMS
Cmpd # Structure Name miz H-NMR (400 MHz, DMSO-d6) [M+H]
ci 2-(4-chlorophenoxy)-dq 1.76- 1.77 (m, 1.5 H), 1.95 (s, 6 N-(3-(3-(4-chlorophenoxy)py H), 2.2 - 2.27 (m, 1.5 H), 2.58 -N
2.61 (m, 1 H), 2.65 - 2.69 (m, 1 XXIV
rrolidin-1- 447.3 H), 2.84 (m, 1 H), 4.4 (s, 2 H), 0, 11 yl)bicyclo[1:1=1]P 4.85 (bs, 1 H), 6.88 (d, J=
8.8 Hz, ) entan-1- 2 H), 6.94 (d, J= 8.8 Hz, 2 H), yl)acetamide 7.28 (d, J= 8.4 Hz, 2 H), 7.32 (d, J
4 = 8.8 Hz, 2 H), 8.61 (s, 1 H).
i Example XXIV A and B
The compounds of the following two structures are readily prepared by those of skill in the art generally according to the above Examples.
0 id y=(10 CI OjNir H
;and CI
H
OAN
CI 1:101 H 0
Table XIII
LCMS
Cmpd # Structure Name miz H-NMR (400 MHz, DMSO-d6) [M+H]
ci 2-(4-chlorophenoxy)-dq 1.76- 1.77 (m, 1.5 H), 1.95 (s, 6 N-(3-(3-(4-chlorophenoxy)py H), 2.2 - 2.27 (m, 1.5 H), 2.58 -N
2.61 (m, 1 H), 2.65 - 2.69 (m, 1 XXIV
rrolidin-1- 447.3 H), 2.84 (m, 1 H), 4.4 (s, 2 H), 0, 11 yl)bicyclo[1:1=1]P 4.85 (bs, 1 H), 6.88 (d, J=
8.8 Hz, ) entan-1- 2 H), 6.94 (d, J= 8.8 Hz, 2 H), yl)acetamide 7.28 (d, J= 8.4 Hz, 2 H), 7.32 (d, J
4 = 8.8 Hz, 2 H), 8.61 (s, 1 H).
i Example XXIV A and B
The compounds of the following two structures are readily prepared by those of skill in the art generally according to the above Examples.
0 id y=(10 CI OjNir H
;and CI
H
OAN
CI 1:101 H 0
- 138 -Example la and XXII
2-(4-chlorophenoxv)-N-(3-(3-(4-chlorophenvI)-2-oxoimidazolidin-1-vl)bicyclo11.1.11pentan-1-vpacetamide H 0 * CI
CI *
0/....111.õ...NAN
\--/
la c)AN j:;r ci H
io Br ===="%v, Br H Step io 11 CI "Ill=le 0 NN ir W
Step 2 I
CI H
I CI
H
-IP' CI 41 0./.1 ..Ø....N NX. N 41 Step 3 \--I
la Step 1: To a solution of 4-chloroaniline (5 g, 39.37 mmol, 1 equiv) in acetonitrile (30 mL) was added 1,2-dibromoethane (6.7 mL, 78.74 mmol, 2 equiv) at rt. After stirring at 85 C
for 16 h, the reaction mixture was allowed to come to rt and concentrated under vacuum.
The crude material was purified by flash column chromatography (6% Et0Ac in hexanes).
The fractions containing the product were combined and concentrated to provide N-(2-bromoethyl)-4-chloroaniline as a brown liquid (1 g, 11%). 1H NMR (400 MHz, DMSO¨d6) 6 ppm 3.29 ¨ 3.43 (m, 2 H), 3.52 ¨ 3.55 (m, 2 H), 6.05 (bs, 1H), 6.59 (d, J =
8.8 Hz, 2 H), 7.08 (d, J= 8.8 Hz, 2 H).
Step 2: [Note :- This reaction was performed in two batches, each batch with 0.25 g, ie 0.25 X 2 = 0.5 g]
In a sealed tube was added N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (0.25 g, 0.93 mmol, 1 equiv), followed by triethylamine (0.6 mL, 4.68 mmol) and N-(2-bromoethyl)-4-chloroaniline (0.26 g, 1.12 mmol, 1.2 equiv). The reaction mixture was sealed and heated at 100 C using an oil bath for 1 h.
The reaction mixture was cooled to rt, diluted with water (50 mL), and extracted with Et0Ac (2 X 15 mL).
The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and evaporated
2-(4-chlorophenoxv)-N-(3-(3-(4-chlorophenvI)-2-oxoimidazolidin-1-vl)bicyclo11.1.11pentan-1-vpacetamide H 0 * CI
CI *
0/....111.õ...NAN
\--/
la c)AN j:;r ci H
io Br ===="%v, Br H Step io 11 CI "Ill=le 0 NN ir W
Step 2 I
CI H
I CI
H
-IP' CI 41 0./.1 ..Ø....N NX. N 41 Step 3 \--I
la Step 1: To a solution of 4-chloroaniline (5 g, 39.37 mmol, 1 equiv) in acetonitrile (30 mL) was added 1,2-dibromoethane (6.7 mL, 78.74 mmol, 2 equiv) at rt. After stirring at 85 C
for 16 h, the reaction mixture was allowed to come to rt and concentrated under vacuum.
The crude material was purified by flash column chromatography (6% Et0Ac in hexanes).
The fractions containing the product were combined and concentrated to provide N-(2-bromoethyl)-4-chloroaniline as a brown liquid (1 g, 11%). 1H NMR (400 MHz, DMSO¨d6) 6 ppm 3.29 ¨ 3.43 (m, 2 H), 3.52 ¨ 3.55 (m, 2 H), 6.05 (bs, 1H), 6.59 (d, J =
8.8 Hz, 2 H), 7.08 (d, J= 8.8 Hz, 2 H).
Step 2: [Note :- This reaction was performed in two batches, each batch with 0.25 g, ie 0.25 X 2 = 0.5 g]
In a sealed tube was added N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (0.25 g, 0.93 mmol, 1 equiv), followed by triethylamine (0.6 mL, 4.68 mmol) and N-(2-bromoethyl)-4-chloroaniline (0.26 g, 1.12 mmol, 1.2 equiv). The reaction mixture was sealed and heated at 100 C using an oil bath for 1 h.
The reaction mixture was cooled to rt, diluted with water (50 mL), and extracted with Et0Ac (2 X 15 mL).
The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and evaporated
- 139 -under vacuum. The crude material obtained was purified by flash column chromatography (5 % Me0H in DCM) to obtain the desired product 2-(4-chlorophenoxy)-N-(3-((2-((4-chlorophenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-l-yl)acetamide (0.4 g, 78 /0). LCMS
(ES) m/z= 420.1 [M+H]+
Step 3: To a solution of 2-(4-chlorophenoxy)-N-(3-((2-((4-chlorophenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.3 g, 0.71 mmol, 1 equiv) in DCM (15 mL) at 0 C was added triethylamine (0.5 mL, 3.57 mmol, 5 equiv) followed by addition of triphosgene (0.21 g, 0.71 mmol, 1 equiv). After the reaction stirred at rt for 12 h, the reaction mixture was quenched with saturated aqueous NaHCO3 solution (5 mL) at 0 C and extracted with DCM (2 x 15 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain the crude product (0.08 g) which was purified by preparative HPLC to afford the product 2-(4-ch lorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoim idazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.04 g) as an off-white solid. LCMS (ES) m/z = 446.3 [M+H] +. 1H
NMR (400 MHz, DMS0d6) 6 ppm 2.29 (s, 6 H), 3.43 (t, J= 8 Hz, 2 H), 3.75 (t, J= 8 Hz, 2 H), 4.43 (s, 2 H), 6.96 (d, J= 8.4 Hz, 2 H), 7.33 (d, J= 8.4 Hz, 4 H), 7.55 (d, J= 8.4 Hz, 2 H), 8.73 (s, 1H).
The Compounds of Examples lb to lc were prepared generally according to the procedure described above for Example la.
Table 1 LCMS 1H-pi ..-w--ul (400 MHz, DMSO-Cmpd # Structure miz d6) Name [M+H]
CI
it 2-(4-chlorophenoxy)-2.29 (s, 6 H), 3.43 (t, J = 8 CN N-(3-(3-(4-Hz, 2 H), 3.75 (t, J= 8 Hz, la chlorophenyI)-2-2 H), 4.43 (s, 2 H), 6.96 (d, oxoimidazolidin-1-446.3J = 8.4 Hz, 2 H), 7.33 (d, J
yl)bicyclo[1.1.1]pentan = 8.4 Hz, 4 H), 7.55 (d, J=
o) - 1-yl)acetamide 8.4 Hz, 2 H), 8.73 (s, 1H).
(ES) m/z= 420.1 [M+H]+
Step 3: To a solution of 2-(4-chlorophenoxy)-N-(3-((2-((4-chlorophenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.3 g, 0.71 mmol, 1 equiv) in DCM (15 mL) at 0 C was added triethylamine (0.5 mL, 3.57 mmol, 5 equiv) followed by addition of triphosgene (0.21 g, 0.71 mmol, 1 equiv). After the reaction stirred at rt for 12 h, the reaction mixture was quenched with saturated aqueous NaHCO3 solution (5 mL) at 0 C and extracted with DCM (2 x 15 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain the crude product (0.08 g) which was purified by preparative HPLC to afford the product 2-(4-ch lorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoim idazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.04 g) as an off-white solid. LCMS (ES) m/z = 446.3 [M+H] +. 1H
NMR (400 MHz, DMS0d6) 6 ppm 2.29 (s, 6 H), 3.43 (t, J= 8 Hz, 2 H), 3.75 (t, J= 8 Hz, 2 H), 4.43 (s, 2 H), 6.96 (d, J= 8.4 Hz, 2 H), 7.33 (d, J= 8.4 Hz, 4 H), 7.55 (d, J= 8.4 Hz, 2 H), 8.73 (s, 1H).
The Compounds of Examples lb to lc were prepared generally according to the procedure described above for Example la.
Table 1 LCMS 1H-pi ..-w--ul (400 MHz, DMSO-Cmpd # Structure miz d6) Name [M+H]
CI
it 2-(4-chlorophenoxy)-2.29 (s, 6 H), 3.43 (t, J = 8 CN N-(3-(3-(4-Hz, 2 H), 3.75 (t, J= 8 Hz, la chlorophenyI)-2-2 H), 4.43 (s, 2 H), 6.96 (d, oxoimidazolidin-1-446.3J = 8.4 Hz, 2 H), 7.33 (d, J
yl)bicyclo[1.1.1]pentan = 8.4 Hz, 4 H), 7.55 (d, J=
o) - 1-yl)acetamide 8.4 Hz, 2 H), 8.73 (s, 1H).
- 140 -F
* 2-(4-chlorophenoxy)-2.29 (s, 6 H), 3.42 (t, J= 8 N-(3-(3-(4-CN fluorophenyI)-2- Hz, 2 H), 3.75 (t, J= 7.6 Hz, 2 H), 4.43 (s, 2 H), 6.97 1 b oxoimidazolidin-1-430.3 (s, 2 H), 7.13 (t, J= 8.8 Hz, yl)bicyclo[1.1.1]pentan 2 H), 7.33 (d, J= 8.4 Hz, 2 -1-yl)acetamide H), 7.53 (t, J= 8.4 Hz, 2 o) H), 8.73 (s, 1 H).
CI
41 N-(3-(3-(4-2.29 (s, 6 H), 3.42 (t, J=
C-No chlorophenyI)-2-8.0 Hz, 2 H), 3.75 (t, J=
oxoimidazolidin-1-1 c 7.6 Hz, 2 H), 4.40 (s, 2 H), yl)bicyclo[1.1.1]pentan 430.3 14ZH 6.94 -6.97 (m, 2 H), 7.09 -o, -1-yI)-2-(4-7.13 (m, 2 H), 7.32 (d, J=
fluorophenoxy)acetam o) 8.8 Hz, 2 H), 7.55 (d, J=
4 ide 8.8 Hz, 2 H), 8.70 (s, 1H).
Example ld N-(3-(3-(4-chloro-2-methylphenv1)-2-oxoimidazolidin-l-vnbicvclo[1.1.11pentan-l-v1)-2-(4-chlorophenoxv)acetamide CI
4410 0\4 CI NY, N
HN----<>"--- \)
* 2-(4-chlorophenoxy)-2.29 (s, 6 H), 3.42 (t, J= 8 N-(3-(3-(4-CN fluorophenyI)-2- Hz, 2 H), 3.75 (t, J= 7.6 Hz, 2 H), 4.43 (s, 2 H), 6.97 1 b oxoimidazolidin-1-430.3 (s, 2 H), 7.13 (t, J= 8.8 Hz, yl)bicyclo[1.1.1]pentan 2 H), 7.33 (d, J= 8.4 Hz, 2 -1-yl)acetamide H), 7.53 (t, J= 8.4 Hz, 2 o) H), 8.73 (s, 1 H).
CI
41 N-(3-(3-(4-2.29 (s, 6 H), 3.42 (t, J=
C-No chlorophenyI)-2-8.0 Hz, 2 H), 3.75 (t, J=
oxoimidazolidin-1-1 c 7.6 Hz, 2 H), 4.40 (s, 2 H), yl)bicyclo[1.1.1]pentan 430.3 14ZH 6.94 -6.97 (m, 2 H), 7.09 -o, -1-yI)-2-(4-7.13 (m, 2 H), 7.32 (d, J=
fluorophenoxy)acetam o) 8.8 Hz, 2 H), 7.55 (d, J=
4 ide 8.8 Hz, 2 H), 8.70 (s, 1H).
Example ld N-(3-(3-(4-chloro-2-methylphenv1)-2-oxoimidazolidin-l-vnbicvclo[1.1.11pentan-l-v1)-2-(4-chlorophenoxv)acetamide CI
4410 0\4 CI NY, N
HN----<>"--- \)
- 141 -NO2 NN2 CVyH )K1N
di,r CI
Step 1 (401 Step 2 401 Step 3 __ 9CoiN H CI
ULOH
CI CI
-Now 0 CI 411111fr.
Step 4 H3 Step 5 CIH \,..) H3 Step 6 CI
CI * i';) 0 1 d Step 1 : To a solution of 4-chloro-2-methyl-1-nitrobenzene (5.0 g, 29.14 mmol, 1.0 equiv) in methanol (250 mL) at 0 C was added ammonium chloride (8.57 g, 160.27 mmol, 5.5 equiv), stirred for 5 mins and then zinc dust (28.58 g, 437.1 mmol, 15.0 equiv) was added and the reaction mixture was stirred at room temperature for 3 h. After the consumption of the starting material (TLC, 10% ethyl acetate in hexane), the reaction mixture was filtered through a Celitee bed and concentrated under reduced pressure. The crude material was purified by column chromatography (8 - 10 % Et0Ac in hexane) to obtain the desired product 4-chloro-2-methylaniline as a brown liquid (3.0 g, 73.2 % yield). LCMS
(ES) m/z =
di,r CI
Step 1 (401 Step 2 401 Step 3 __ 9CoiN H CI
ULOH
CI CI
-Now 0 CI 411111fr.
Step 4 H3 Step 5 CIH \,..) H3 Step 6 CI
CI * i';) 0 1 d Step 1 : To a solution of 4-chloro-2-methyl-1-nitrobenzene (5.0 g, 29.14 mmol, 1.0 equiv) in methanol (250 mL) at 0 C was added ammonium chloride (8.57 g, 160.27 mmol, 5.5 equiv), stirred for 5 mins and then zinc dust (28.58 g, 437.1 mmol, 15.0 equiv) was added and the reaction mixture was stirred at room temperature for 3 h. After the consumption of the starting material (TLC, 10% ethyl acetate in hexane), the reaction mixture was filtered through a Celitee bed and concentrated under reduced pressure. The crude material was purified by column chromatography (8 - 10 % Et0Ac in hexane) to obtain the desired product 4-chloro-2-methylaniline as a brown liquid (3.0 g, 73.2 % yield). LCMS
(ES) m/z =
142.1 [M+H] . 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.01 (s, 3 H), 4.94 (s, 2 H), 6.56 (d, J
= 8.0 Hz, 1 H), 6.87 (d, J= 8.4 Hz, 1 H), 6.92 (s, 1 H).
Step 2: To a solution of 4-chloro-2-methylaniline (0.5 g, 3.53 mmol, 1.0 equiv.) in methanol (20 mL) was added 2-chloroacetaldehyde (55 % aqueous solution) (0.76 mL, 5.29 mmol, 1.5 equiv.) at room temperature followed by a catalytic amount of acetic acid (5-6 drops with syringe). After the reaction mixture stirred for 30 min, it was cooled to 0 C and sodium cyanoborohydride (0.44 g, 7.06 mmol, 2.0 equiv.) was added. The reaction mixture was stirred at room temperature for 16 h. After the consumption of the starting material (TLC, 10% ethyl acetate in hexane), the reaction mixture was concentrated under reduced pressure. The crude was dissolved in ethyl acetate (200 mL) and washed with water (2 x 50 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude material was purified by column chromatography (5% Et0Ac in hexane) to obtain the desired product 4-chloro-N-(2-chloroethyl)-2-methylaniline as a yellow liquid (0.34 g, 47.3 % yield). LCMS
(ES) m/z =
204.0 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.05 (s, 3 H), 3.42 (d, J= 6.0 Hz, 2 H), 3.68 - 3.71 (m, 2 H), 5.19 (s, 1 H), 6.51 -6.56 (m, 1 H), 7.01 (s, 2 H).
Step 3:10 a solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.3 g, 1.51 mmol, 1.0 equiv.) in triethylamine (0.85 mL, 6.04 mmol, 4.0 equiv.) was added 4-chloro-N-(2-chloroethyl)-2-methylaniline (0.37 g, 1.81 mmol, 1.2 equiv.) at room temperature. After the reaction mixture stirred at 100 C for 16 h and consumption of the starting material (TLC, 50 `)/0 ethyl acetate in hexane), the reaction mixture was diluted with ethyl acetate (100 mL) and washed with water (2 x 10 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude material was purified by column chromatography (50 - 60 `)/0 Et0Ac in hexane) to obtain the desired product tert-butyl (3-((2-((4-chloro-2-methylphenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)carbamate as pale yellow liquid (0.28 g, 50.9% yield). LCMS (ES) m/z =
366.1 [M+H]
Step 4: To a solution of tert-butyl (3-((2-((4-chloro-2-methylphenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)carbamate (0.26 g, 0.71 mmol, 1.0 equiv.) in DCM (20 mL) was added triethylamine (0.5 mL, 3.55 mmol, 5.0 equiv.) at 0 C, stirred for 10 mins and then triphosgene (0.21 g, 0.71 mmol, 1.0 equiv.) was added at 0 C and the reaction mixture was stirred at room temperature for 3 h. After the consumption of the starting material (TLC, 50 `)/0 ethyl acetate in hexane), the reaction mixture was quenched with sodium bicarbonate solution at 0 C and extracted with ethyl acetate (2 x 70 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude material was purified by column chromatography (50 - 60 `)/0 Et0Ac in hexane) to obtain the desired product tert-butyl (3-(3-(4-chloro-2-methylpheny1)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)carbamate as a pale yellow liquid (0.09 g, 32.1 `)/0 yield). LCMS (ES) m/z = 392.1 [M+H] +.
1H NMR (400 MHz, DMSO-d6) 6 ppm 1.36 (s, 9 H), 2.13 - 2.15 (m, 9 H), 3.39 (t, J= 7.6 Hz, 2 H), 3.60 (t, J= 7.8 Hz, 2 H), 7.19 - 7.21 (m, 2 H), 7.32 (s, 1 H), 7.52 (bs, 1 H).
Step 5: To a solution of tert-butyl (3-(3-(4-chloro-2-methylphenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.09 g, 0.23 mmol, 1.0 equiv.) in DCM
(5.0 mL) at 0 C was added 2.0 mL of 4 M HCI in 1,4-dioxane and the mixture was stirred at room temperature for 16 h. After the consumption of the starting material (TLC, 5 %
Me0H in DCM), the reaction mixture was concentrated and the crude was triturated with n-pentane
= 8.0 Hz, 1 H), 6.87 (d, J= 8.4 Hz, 1 H), 6.92 (s, 1 H).
Step 2: To a solution of 4-chloro-2-methylaniline (0.5 g, 3.53 mmol, 1.0 equiv.) in methanol (20 mL) was added 2-chloroacetaldehyde (55 % aqueous solution) (0.76 mL, 5.29 mmol, 1.5 equiv.) at room temperature followed by a catalytic amount of acetic acid (5-6 drops with syringe). After the reaction mixture stirred for 30 min, it was cooled to 0 C and sodium cyanoborohydride (0.44 g, 7.06 mmol, 2.0 equiv.) was added. The reaction mixture was stirred at room temperature for 16 h. After the consumption of the starting material (TLC, 10% ethyl acetate in hexane), the reaction mixture was concentrated under reduced pressure. The crude was dissolved in ethyl acetate (200 mL) and washed with water (2 x 50 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude material was purified by column chromatography (5% Et0Ac in hexane) to obtain the desired product 4-chloro-N-(2-chloroethyl)-2-methylaniline as a yellow liquid (0.34 g, 47.3 % yield). LCMS
(ES) m/z =
204.0 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.05 (s, 3 H), 3.42 (d, J= 6.0 Hz, 2 H), 3.68 - 3.71 (m, 2 H), 5.19 (s, 1 H), 6.51 -6.56 (m, 1 H), 7.01 (s, 2 H).
Step 3:10 a solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.3 g, 1.51 mmol, 1.0 equiv.) in triethylamine (0.85 mL, 6.04 mmol, 4.0 equiv.) was added 4-chloro-N-(2-chloroethyl)-2-methylaniline (0.37 g, 1.81 mmol, 1.2 equiv.) at room temperature. After the reaction mixture stirred at 100 C for 16 h and consumption of the starting material (TLC, 50 `)/0 ethyl acetate in hexane), the reaction mixture was diluted with ethyl acetate (100 mL) and washed with water (2 x 10 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude material was purified by column chromatography (50 - 60 `)/0 Et0Ac in hexane) to obtain the desired product tert-butyl (3-((2-((4-chloro-2-methylphenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)carbamate as pale yellow liquid (0.28 g, 50.9% yield). LCMS (ES) m/z =
366.1 [M+H]
Step 4: To a solution of tert-butyl (3-((2-((4-chloro-2-methylphenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)carbamate (0.26 g, 0.71 mmol, 1.0 equiv.) in DCM (20 mL) was added triethylamine (0.5 mL, 3.55 mmol, 5.0 equiv.) at 0 C, stirred for 10 mins and then triphosgene (0.21 g, 0.71 mmol, 1.0 equiv.) was added at 0 C and the reaction mixture was stirred at room temperature for 3 h. After the consumption of the starting material (TLC, 50 `)/0 ethyl acetate in hexane), the reaction mixture was quenched with sodium bicarbonate solution at 0 C and extracted with ethyl acetate (2 x 70 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude material was purified by column chromatography (50 - 60 `)/0 Et0Ac in hexane) to obtain the desired product tert-butyl (3-(3-(4-chloro-2-methylpheny1)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)carbamate as a pale yellow liquid (0.09 g, 32.1 `)/0 yield). LCMS (ES) m/z = 392.1 [M+H] +.
1H NMR (400 MHz, DMSO-d6) 6 ppm 1.36 (s, 9 H), 2.13 - 2.15 (m, 9 H), 3.39 (t, J= 7.6 Hz, 2 H), 3.60 (t, J= 7.8 Hz, 2 H), 7.19 - 7.21 (m, 2 H), 7.32 (s, 1 H), 7.52 (bs, 1 H).
Step 5: To a solution of tert-butyl (3-(3-(4-chloro-2-methylphenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.09 g, 0.23 mmol, 1.0 equiv.) in DCM
(5.0 mL) at 0 C was added 2.0 mL of 4 M HCI in 1,4-dioxane and the mixture was stirred at room temperature for 16 h. After the consumption of the starting material (TLC, 5 %
Me0H in DCM), the reaction mixture was concentrated and the crude was triturated with n-pentane
- 143 -(2 X 5 mL) and dried under high vacuum to afford 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chloro-2-methylphenyl)imidazolidin-2-one hydrochloride (crude yield 0.07 g, 93.4 `)/0 yield), which was taken to the next step without further purification. LCMS
(ES) m/z =
292.1[M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.15 (s, 3 H), 2.25 (s, 6 H), 3.43 -3.45 (m, 2 H), 3.61 - 3.63 (m, 2 H), 7.19 - 7.23 (m, 2 H), 7.33 (s, 1 H), 8.89 (bs, 3 H).
Step 6: To a solution of 2-(4-chlorophenoxy)acetic acid (0.05 g, 0.26 mmol, 1.2 equiv.) in DCM (8 mL) at 000 was added triethylamine (0.12 mL, 0.84 mmol, 4.0 equiv), stirred for 10 mins and T3Pe (50 wt% in Et0Ac) (0.25 mL, 0.42 mmol, 2.0 equiv.) was added.
After the reaction mixture was stirred at 0 C for 10 min, 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chloro-2-methylphenyl)imidazolidin-2-one hydrochloride ((0.07 g, 0.21 mmol, 1.0 equiv.) which was neutralized with 0.2 mL of triethylamine in DCM) was added at 0 C
and the reaction stirred at room temperature for 16 h. After the consumption of the starting material (TLC, 70 `)/0 Et0Ac in hexane), the reaction mixture was diluted with DCM (100 mL) and was washed with saturated aqueous NaHCO3 solution (2 x 10 mL) and water (2 x 10 mL).
The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure.
The crude product was purified by silica gel column chromatography (50 - 60 `)/0 Et0Ac in hexane). It was again purified by Prep HPLC
(Analytical conditions: lnertsil ODS 3V (250 mm x 4.6 mm x 5 mic); Mobile phase (A) : 0.1 % ammonia in water; Mobile phase (B): Acetonitrile; Flow rate: 1.0 mL/min) to afford the desired product N-(3-(3-(4-chloro-2-methylpheny1)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)-2-(4-chlorophenoxy)acetamide as an off-white solid (0.025 g, 25.5% yield). LCMS (ES) m/z = 460.3 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.16 (s, 3 H), 2.26 (s, 6 H), 3.42 (t, J= 7.4 Hz, 2 H), 3.62 (t, J= 7.4 Hz, 2 H), 4.42 (s, 2 H), 6.96 (d, J= 8.4 Hz, 2 H), 7.22 (s, 2 H), 7.32 (s, 3 H), 8.70 (s, 1 H).
The Compounds of Examples le to lk were prepared generally according to the procedure described above for Example ld.
(ES) m/z =
292.1[M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.15 (s, 3 H), 2.25 (s, 6 H), 3.43 -3.45 (m, 2 H), 3.61 - 3.63 (m, 2 H), 7.19 - 7.23 (m, 2 H), 7.33 (s, 1 H), 8.89 (bs, 3 H).
Step 6: To a solution of 2-(4-chlorophenoxy)acetic acid (0.05 g, 0.26 mmol, 1.2 equiv.) in DCM (8 mL) at 000 was added triethylamine (0.12 mL, 0.84 mmol, 4.0 equiv), stirred for 10 mins and T3Pe (50 wt% in Et0Ac) (0.25 mL, 0.42 mmol, 2.0 equiv.) was added.
After the reaction mixture was stirred at 0 C for 10 min, 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chloro-2-methylphenyl)imidazolidin-2-one hydrochloride ((0.07 g, 0.21 mmol, 1.0 equiv.) which was neutralized with 0.2 mL of triethylamine in DCM) was added at 0 C
and the reaction stirred at room temperature for 16 h. After the consumption of the starting material (TLC, 70 `)/0 Et0Ac in hexane), the reaction mixture was diluted with DCM (100 mL) and was washed with saturated aqueous NaHCO3 solution (2 x 10 mL) and water (2 x 10 mL).
The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure.
The crude product was purified by silica gel column chromatography (50 - 60 `)/0 Et0Ac in hexane). It was again purified by Prep HPLC
(Analytical conditions: lnertsil ODS 3V (250 mm x 4.6 mm x 5 mic); Mobile phase (A) : 0.1 % ammonia in water; Mobile phase (B): Acetonitrile; Flow rate: 1.0 mL/min) to afford the desired product N-(3-(3-(4-chloro-2-methylpheny1)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)-2-(4-chlorophenoxy)acetamide as an off-white solid (0.025 g, 25.5% yield). LCMS (ES) m/z = 460.3 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.16 (s, 3 H), 2.26 (s, 6 H), 3.42 (t, J= 7.4 Hz, 2 H), 3.62 (t, J= 7.4 Hz, 2 H), 4.42 (s, 2 H), 6.96 (d, J= 8.4 Hz, 2 H), 7.22 (s, 2 H), 7.32 (s, 3 H), 8.70 (s, 1 H).
The Compounds of Examples le to lk were prepared generally according to the procedure described above for Example ld.
- 144 -Table 2 LCMS
1H-NMR (400 MHz, Cmpd # Structure Name miz DMSO-d6) [M+H]
ci IP cH3 2.16 (s, 3 H), 2.26 (s, 6 oN) N-(3-(3-(4-chloro-2-methylphenyI)- H), 3.42 (t, J=
7.4 Hz, H* Hz, 2 H), 4.42 (s, 2 H), 2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)-2-(4- 460.3 2 H), 3.62 (t, J = 7.4 I d Neo chlorophenoxy)acetamide 6.96 (d, J= 8.4 Hz, 2 H), 7.22 (s, 2 H), 7.32 * (s, 3 H), 8.70 (s, 1 H).
C
0.55 - 0.56 (m, 2 H), CI 0.84 - 0.86 (m, 2 H), * 1.82 - 1.87 (m, 1 H), 2.29 (s, 6 H), 3.42 (t, J
CNo = 7.6 Hz, 2 H), 3.75 (t, N-(3-(3-(4-chlorophenyI)-2-le 4;' oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)-2-(4- 452.4 J = 7.8 Hz, 2 H), 4.36 H
(s, 2 H), 6.82 (d, J =
c), cyclopropylphenoxy)acetamide 8.4 Hz, 2 H), 6.99 (d, J
= 8.4 Hz, 2 H), 7.33 (d, 4 J= 8.8 Hz, 2 H), 7.55 (d, J= 8.8 Hz, 2 H), A
8.66 (s, 1 H).
1H-NMR (400 MHz, Cmpd # Structure Name miz DMSO-d6) [M+H]
ci IP cH3 2.16 (s, 3 H), 2.26 (s, 6 oN) N-(3-(3-(4-chloro-2-methylphenyI)- H), 3.42 (t, J=
7.4 Hz, H* Hz, 2 H), 4.42 (s, 2 H), 2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)-2-(4- 460.3 2 H), 3.62 (t, J = 7.4 I d Neo chlorophenoxy)acetamide 6.96 (d, J= 8.4 Hz, 2 H), 7.22 (s, 2 H), 7.32 * (s, 3 H), 8.70 (s, 1 H).
C
0.55 - 0.56 (m, 2 H), CI 0.84 - 0.86 (m, 2 H), * 1.82 - 1.87 (m, 1 H), 2.29 (s, 6 H), 3.42 (t, J
CNo = 7.6 Hz, 2 H), 3.75 (t, N-(3-(3-(4-chlorophenyI)-2-le 4;' oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)-2-(4- 452.4 J = 7.8 Hz, 2 H), 4.36 H
(s, 2 H), 6.82 (d, J =
c), cyclopropylphenoxy)acetamide 8.4 Hz, 2 H), 6.99 (d, J
= 8.4 Hz, 2 H), 7.33 (d, 4 J= 8.8 Hz, 2 H), 7.55 (d, J= 8.8 Hz, 2 H), A
8.66 (s, 1 H).
- 145 -0 2.36 (s, 6 H), 3.44 (t, J
= 8.0 Hz, 2 H), 3.88 (t, J= 8.0 Hz, 2 H), 4.43 2-(4-chlorophenoxy)-N-(3-(3-(5- (s, 2 H), 6.96 (d, J=
chloropyridin-2-y1)-2- 8.8 Hz, 2 H), 7.33 (d, J
it oxoimidazolidin-1- 447.3 = 8.8 Hz, 2 H), 7.80 (d, 4iPH
) yl)bicyclo[1.1.1]pentan-1- J= 9.2 Hz, 1 H), 7.16 0 yl)acetamide (d, J= 9.2 Hz, 1 H), 8.30 (bs, 1 H), 8.73 (s, 1 1 H).
CI
= 2.29 (s, 6 H), 3.42 (t, J
= 7.2 Hz, 2 H), 3.74 (t, J = 8.0 Hz, 2 H), 4.46 CN 2-(3-chlorophenoxy)-N-(3-(3-(4-(s, 2 H), 6.92 (d, J=
44' chlorophenyI)-2-oxoimidazolidin-1-446.3 7.6 Hz, 1 H), 7.00¨
yl)bicyclo[1.1.1]pentan-1-7.04(m, 2 H), 7.29¨
1 g NH
yl)acetamide 7.34 (m, 3 H), 7.55 (d, 0) J= 8.8 Hz, 2 H), 8.75 Cl
= 8.0 Hz, 2 H), 3.88 (t, J= 8.0 Hz, 2 H), 4.43 2-(4-chlorophenoxy)-N-(3-(3-(5- (s, 2 H), 6.96 (d, J=
chloropyridin-2-y1)-2- 8.8 Hz, 2 H), 7.33 (d, J
it oxoimidazolidin-1- 447.3 = 8.8 Hz, 2 H), 7.80 (d, 4iPH
) yl)bicyclo[1.1.1]pentan-1- J= 9.2 Hz, 1 H), 7.16 0 yl)acetamide (d, J= 9.2 Hz, 1 H), 8.30 (bs, 1 H), 8.73 (s, 1 1 H).
CI
= 2.29 (s, 6 H), 3.42 (t, J
= 7.2 Hz, 2 H), 3.74 (t, J = 8.0 Hz, 2 H), 4.46 CN 2-(3-chlorophenoxy)-N-(3-(3-(4-(s, 2 H), 6.92 (d, J=
44' chlorophenyI)-2-oxoimidazolidin-1-446.3 7.6 Hz, 1 H), 7.00¨
yl)bicyclo[1.1.1]pentan-1-7.04(m, 2 H), 7.29¨
1 g NH
yl)acetamide 7.34 (m, 3 H), 7.55 (d, 0) J= 8.8 Hz, 2 H), 8.75 Cl
- 146 -CI
ait 2.29 (s, 6 H), 3.45 -CN N-(3-(3-(4-chlorophenyI)-2- 3.41 (m, 2 H), 3.77 -3.73 (m, 2 H), 4.46 (s, oxoimidazolidin-1-1 h 496.3 2 H), 7.04 - 7.02 (m, 2 4:?'H yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-(trifluoromethoxy)phenoxy)acetamid H), 7.34 - 7.72 (m, 4 0) H), 7.56 - 7.54 (m, 2 e 4 H), 8.73 (s, 1 H).
.
F;;( CI
2.00 (s, 6 H), 2.60 (s, 1 H), 2.82 - 2.84 (m, 2 rN
H), 3.40 (t, J= 8.4 Hz, ii and ruo'd 2 H), 3.74 (t, J= 7.2 XXIII 1-(3-((2-(4-432.1 Hz, 2 H), 3.96 (t, J=
4 i=iS chlorophenoxy)ethyl)amino)bicyclo[
5.6 Hz, 2 H), 6.94 (d, J
1.1.1]pentan-1-yI)-3-(4-I = 8.0 Hz, 2 H), 7.28 -chlorophenyl)imidazolidin-2-one LP
7.33 (m, 4 H), 7.54 (d, J= 9.2 Hz, 2 H).
C
ait 2.29 (s, 6 H), 3.45 -CN N-(3-(3-(4-chlorophenyI)-2- 3.41 (m, 2 H), 3.77 -3.73 (m, 2 H), 4.46 (s, oxoimidazolidin-1-1 h 496.3 2 H), 7.04 - 7.02 (m, 2 4:?'H yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-(trifluoromethoxy)phenoxy)acetamid H), 7.34 - 7.72 (m, 4 0) H), 7.56 - 7.54 (m, 2 e 4 H), 8.73 (s, 1 H).
.
F;;( CI
2.00 (s, 6 H), 2.60 (s, 1 H), 2.82 - 2.84 (m, 2 rN
H), 3.40 (t, J= 8.4 Hz, ii and ruo'd 2 H), 3.74 (t, J= 7.2 XXIII 1-(3-((2-(4-432.1 Hz, 2 H), 3.96 (t, J=
4 i=iS chlorophenoxy)ethyl)amino)bicyclo[
5.6 Hz, 2 H), 6.94 (d, J
1.1.1]pentan-1-yI)-3-(4-I = 8.0 Hz, 2 H), 7.28 -chlorophenyl)imidazolidin-2-one LP
7.33 (m, 4 H), 7.54 (d, J= 9.2 Hz, 2 H).
C
- 147 -'CI
2.30 (s, 6 H), 3.45 ¨
Ci,j/() 3.43 (m, 2 H), 3.87 ¨
(m, 2 H), 4.43 (s, 1j chlorophenyI)-2-oxoimidazolidin-1- 446.3 2 H), 7.03 ¨7.95 (m, 3 H yl)bicyclo[1.1.1]pentan-1-o yl)acetamide H), 7.36 ¨ 7.32 (m, 4 H), 7.74 (s, 1 H), 8.72 o) (s, 1 H).
CI
2.25 (s, 6 H), 3.41 (t, J
*
= 8.0 Hz, 2 H), 3.74 (t, J = 7.6 Hz, 2 H), 4.65 Cr,j (s, 2 H), 6.93 (d, J =
1k N-(3-(3-(4-chlorophenyI)-2- 9.2 Hz, 1 H), 7.32 (d, J 447.32 oxoimidazolidin-1- = 8.8 Hz, 2 H), 7.54 (d, 'Pli o/ yl)bicyclo[1.1.1]pentan-1-y1)-2-((5-chloropyridin-2-yl)oxy)acetamide J = 8.8 Hz, 2 H), 7.82 (d, J = 8.8 Hz, 1 H), o) t.? 8.16 (s, 1 H), 8.67 (s, 1 \ / H).
Example 11 2-(4-chloro-3-(trifluoromethvl)phenoxv)-N-(3-(3-(4-chlorophenv1)-2-oxoimidazolidin-1-vl)bicyclo[1.1.11pentan-1-vpacetamide FsC OjNX:r CI
IIP
a 1.1 H
2.30 (s, 6 H), 3.45 ¨
Ci,j/() 3.43 (m, 2 H), 3.87 ¨
(m, 2 H), 4.43 (s, 1j chlorophenyI)-2-oxoimidazolidin-1- 446.3 2 H), 7.03 ¨7.95 (m, 3 H yl)bicyclo[1.1.1]pentan-1-o yl)acetamide H), 7.36 ¨ 7.32 (m, 4 H), 7.74 (s, 1 H), 8.72 o) (s, 1 H).
CI
2.25 (s, 6 H), 3.41 (t, J
*
= 8.0 Hz, 2 H), 3.74 (t, J = 7.6 Hz, 2 H), 4.65 Cr,j (s, 2 H), 6.93 (d, J =
1k N-(3-(3-(4-chlorophenyI)-2- 9.2 Hz, 1 H), 7.32 (d, J 447.32 oxoimidazolidin-1- = 8.8 Hz, 2 H), 7.54 (d, 'Pli o/ yl)bicyclo[1.1.1]pentan-1-y1)-2-((5-chloropyridin-2-yl)oxy)acetamide J = 8.8 Hz, 2 H), 7.82 (d, J = 8.8 Hz, 1 H), o) t.? 8.16 (s, 1 H), 8.67 (s, 1 \ / H).
Example 11 2-(4-chloro-3-(trifluoromethvl)phenoxv)-N-(3-(3-(4-chlorophenv1)-2-oxoimidazolidin-1-vl)bicyclo[1.1.11pentan-1-vpacetamide FsC OjNX:r CI
IIP
a 1.1 H
- 148 -F3c io OH F3c F3c 0_ 1 v -OH
CI Step 1 CI Step 2 LW CI
CI_ 0 v -NCO H H
N
Boc%N.õ40, NH2 Boc Step 3 N
Step 4 CI F3C 0_ v -OH
I = CI
0 * 0 CI
CI
Step 5 Step 6 step 7 Boo \.0) CI
F3c rti N"'"4 OJL
Step 1: To a solution of 4-chloro-3-(trifluoromethyl)phenol (1.5 g, 7.63 mmol, 1 equiv.) in acetone (30 mL) was added K2003 (3.15 g, 22.82 mmol, 3 equiv.) followed by the addition of ethyl 2-bromoacetate (1.52 g, 9.10 mmol, 1.2 equiv) dropwise at 0 C. The reaction .. mixture stirred at 60 C for 4 h. After consumption of the starting material (TLC, 5 % Et0Ac in Hexane), the reaction mixture was filtered through a Buchner funnel, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (Combiflashe) using a silica gel column and the product was eluted at 5 %
ethyl acetate in hexane as eluent to obtain the title compound ethyl 2-(4-chloro-3-(trifluoromethyl)phenoxy)acetate (1.3 g) as a colourless liquid. LCMS (ES) m/z = 282.0 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.18 (t, J= 7.2 Hz, 3 H), 4.13 - 4.18 (m, 2 H), 4.91 (s, 2 H), 7.25- 7.28 (m, 1 H), 7.34 (d, J= 2.8 Hz, 1 H), 7.61 (d, J= 9.2 Hz, 1 H).
Step 2: To a solution of ethyl 2-(4-chloro-3-(trifluoromethyl)phenoxy)acetate (1.3 g, 4.59 MMOI, 1 equiv.) in a mixture of THF (20 mL) and water (20 mL) was added Li0H.H20 (0.27 g, 11.45 mmol, 2.5 equiv.) at 0 C and the resulting mixture stirred at room temperature for 3 h. After consumption of the starting material (TLC, 5% Methanol in DCM), THF
was removed under reduced pressure. The residue was diluted with water (20 mL), and washed with Et20 (2 X 15 mL) to remove unreacted ethyl 2-bromoacetate. The aqueous layer was acidified with 1 N HCI up to pH -2 at 0 C and extracted with Et0Ac (2 X 30 mL).
CI Step 1 CI Step 2 LW CI
CI_ 0 v -NCO H H
N
Boc%N.õ40, NH2 Boc Step 3 N
Step 4 CI F3C 0_ v -OH
I = CI
0 * 0 CI
CI
Step 5 Step 6 step 7 Boo \.0) CI
F3c rti N"'"4 OJL
Step 1: To a solution of 4-chloro-3-(trifluoromethyl)phenol (1.5 g, 7.63 mmol, 1 equiv.) in acetone (30 mL) was added K2003 (3.15 g, 22.82 mmol, 3 equiv.) followed by the addition of ethyl 2-bromoacetate (1.52 g, 9.10 mmol, 1.2 equiv) dropwise at 0 C. The reaction .. mixture stirred at 60 C for 4 h. After consumption of the starting material (TLC, 5 % Et0Ac in Hexane), the reaction mixture was filtered through a Buchner funnel, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (Combiflashe) using a silica gel column and the product was eluted at 5 %
ethyl acetate in hexane as eluent to obtain the title compound ethyl 2-(4-chloro-3-(trifluoromethyl)phenoxy)acetate (1.3 g) as a colourless liquid. LCMS (ES) m/z = 282.0 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.18 (t, J= 7.2 Hz, 3 H), 4.13 - 4.18 (m, 2 H), 4.91 (s, 2 H), 7.25- 7.28 (m, 1 H), 7.34 (d, J= 2.8 Hz, 1 H), 7.61 (d, J= 9.2 Hz, 1 H).
Step 2: To a solution of ethyl 2-(4-chloro-3-(trifluoromethyl)phenoxy)acetate (1.3 g, 4.59 MMOI, 1 equiv.) in a mixture of THF (20 mL) and water (20 mL) was added Li0H.H20 (0.27 g, 11.45 mmol, 2.5 equiv.) at 0 C and the resulting mixture stirred at room temperature for 3 h. After consumption of the starting material (TLC, 5% Methanol in DCM), THF
was removed under reduced pressure. The residue was diluted with water (20 mL), and washed with Et20 (2 X 15 mL) to remove unreacted ethyl 2-bromoacetate. The aqueous layer was acidified with 1 N HCI up to pH -2 at 0 C and extracted with Et0Ac (2 X 30 mL).
- 149 -The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain title compound 2-(4-chloro-3-(trifluoromethyl)phenoxy)acetic acid (1.05 g, 90 % yield) as a white solid.
LCMS (ES) m/z=
253.0 [M-H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 4.81 (s,2 H), 7.24 (d, J= 8.8 Hz, 1 H), 7.32 (d, J= 2.4 Hz, 1 H), 7.61 (d, J= 8.8 Hz, 1 H), 13.10 (s, 1 H).
Step 3: To a solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (5 g, 25.21 mmol, 1.0 equiv.) in 0H0I3 (50 mL) was added 1-chloro-2-isocyanatoethane (3.22 mL, 37.82 mmol, 1.5 equiv.) at 0 C and heated to 60 C for 1 h. After the completion of the reaction, (TLC in 5 c)/0 Methanol in DCM) the reaction mixture was cooled to room temperature and concentrated under reduced pressure to yield crude product. To the above crude, n-pentane (150 mL) was added and stirred for 0.5 h at room temperature.
The solid formed and was filtered and washed with n-pentane to afford tert-butyl (3-(3-(2-chloroethypureido)bicyclo[1.1.1]pentan-1-yl)carbamate as a white solid (7 g, 91 `)/0 yield).
LCMS (ES) m/z = 304.1 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.34 (s, 9 H), 2.00 (s, 6 H), 3.24 - 3.25 (m, 2 H), 3.52 (t, J = 6.0 Hz, 2 H), 5.93 (s, 1 H), 6.66 (s, 1H), 7.41 (bs, 1 H).
Step 4: To a solution of tert-butyl (3-(3-(2-chloroethyl)ureido)bicyclo[1.1.1]pentan-1-yl)carbamate (7 g, 23.04 mmol, 1.0 equiv.) in acetonitrile (70 mL) was added cesium carbonate (15 g, 46.08 mmol, 2.0 equiv.) at room temperature. The reaction was gradually allowed to heat to 100 C and stirred for 12 h. After the completion of the reaction, (TLC in 5 % Methanol in DCM) reaction mixture was allowed to cool to room temperature, diluted with water (150 mL) and extracted with Et0Ac (3 X 100 mL). The .. combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and concentrated under vacuum to give crude product. To the above crude, diethyl ether (100 mL) was added and stirred for 0.5 h at room temperature. Solid formed and was filtered and washed with diethyl ether to afford tert-butyl (3-(2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as a white solid (4 g, 65 `)/0 yield). LCMS (ES) m/z = 268.1 [M+H]. 1H NMR
.. (400 MHz, DMSO-d6) 6 ppm 1.35 (s, 9 H), 2.06 (s, 6 H), 3.15 - 3.17 (m, 2 H), 3.21 -3.23 (m, 2 H), 6.31 (s, 1 H), 7.47 (bs, 1 H).
Step 5: To a solution of tert-butyl (3-(2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (2.0 g, 7.49 mmol, 1.0 equiv.), in DMSO (20 mL) was added K3PO4 (3.18 g, .. 14.98 mmol, 2.0 equiv.), DMEDA (0.16 mL, 1.498 mmol, 0.2 equiv.) and Cul (0.142 g, 0.749 mmol, 0.1 equiv.) and stirred at room temperature for 10-15 minutes. To the above
LCMS (ES) m/z=
253.0 [M-H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 4.81 (s,2 H), 7.24 (d, J= 8.8 Hz, 1 H), 7.32 (d, J= 2.4 Hz, 1 H), 7.61 (d, J= 8.8 Hz, 1 H), 13.10 (s, 1 H).
Step 3: To a solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (5 g, 25.21 mmol, 1.0 equiv.) in 0H0I3 (50 mL) was added 1-chloro-2-isocyanatoethane (3.22 mL, 37.82 mmol, 1.5 equiv.) at 0 C and heated to 60 C for 1 h. After the completion of the reaction, (TLC in 5 c)/0 Methanol in DCM) the reaction mixture was cooled to room temperature and concentrated under reduced pressure to yield crude product. To the above crude, n-pentane (150 mL) was added and stirred for 0.5 h at room temperature.
The solid formed and was filtered and washed with n-pentane to afford tert-butyl (3-(3-(2-chloroethypureido)bicyclo[1.1.1]pentan-1-yl)carbamate as a white solid (7 g, 91 `)/0 yield).
LCMS (ES) m/z = 304.1 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.34 (s, 9 H), 2.00 (s, 6 H), 3.24 - 3.25 (m, 2 H), 3.52 (t, J = 6.0 Hz, 2 H), 5.93 (s, 1 H), 6.66 (s, 1H), 7.41 (bs, 1 H).
Step 4: To a solution of tert-butyl (3-(3-(2-chloroethyl)ureido)bicyclo[1.1.1]pentan-1-yl)carbamate (7 g, 23.04 mmol, 1.0 equiv.) in acetonitrile (70 mL) was added cesium carbonate (15 g, 46.08 mmol, 2.0 equiv.) at room temperature. The reaction was gradually allowed to heat to 100 C and stirred for 12 h. After the completion of the reaction, (TLC in 5 % Methanol in DCM) reaction mixture was allowed to cool to room temperature, diluted with water (150 mL) and extracted with Et0Ac (3 X 100 mL). The .. combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and concentrated under vacuum to give crude product. To the above crude, diethyl ether (100 mL) was added and stirred for 0.5 h at room temperature. Solid formed and was filtered and washed with diethyl ether to afford tert-butyl (3-(2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as a white solid (4 g, 65 `)/0 yield). LCMS (ES) m/z = 268.1 [M+H]. 1H NMR
.. (400 MHz, DMSO-d6) 6 ppm 1.35 (s, 9 H), 2.06 (s, 6 H), 3.15 - 3.17 (m, 2 H), 3.21 -3.23 (m, 2 H), 6.31 (s, 1 H), 7.47 (bs, 1 H).
Step 5: To a solution of tert-butyl (3-(2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (2.0 g, 7.49 mmol, 1.0 equiv.), in DMSO (20 mL) was added K3PO4 (3.18 g, .. 14.98 mmol, 2.0 equiv.), DMEDA (0.16 mL, 1.498 mmol, 0.2 equiv.) and Cul (0.142 g, 0.749 mmol, 0.1 equiv.) and stirred at room temperature for 10-15 minutes. To the above
- 150 -reaction mixture 1-chloro-4-iodobenzene (2.14 g, 8.98 mmol, 1.2 equiv.) was added drop wise and allowed to stir at room temperature for 12 h. After the completion of the reaction (TLC in 40 % ethyl acetate in hexane) the reaction mixture was diluted with water (30 mL) and extracted with Et0Ac (3 X 30 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and concentrated under vacuum to give crude product. The crude product was purified by silica gel column chromatography (60% Ethyl acetate in Hexane) to afford tert-butyl (3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.8 g, 30% yield) as a brown solid.
LCMS (ES) m/z = 378.1 [M+H]. 1H NMR (400 MHz, 0D0I3) 6 ppm 1.45 (s, 9 H), 2.36 (s, 6 H), 3.46 (t, J=
8.4 Hz, 2 H), 5.00 (bs, 1 H), 7.25 - 7.27 (m, 2 H), 7.47 (d, J= 8.8 Hz, 2 H).
Step 6: To a solution of tert-butyl (3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.8 g, 2.11 mmol, 1 equiv) in DCM (8 mL) at 0 C
was added 4M HCI in 1,4-dioxane (8 mL) and the reaction mixture was allowed to stir at room temperature for 6 h. After the completion of the reaction, the reaction mixture was evaporated under vacuum to afford crude 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenyl)imidazolidin-2-one hydrochloride (0.587 g, 100%) as an off-white solid. LCMS
(ES) rniz = 278.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.27 (s, 6 H), 3.43 -3.45 (m, 2 H), 3.75 - 3.77 (m, 2 H), 7.34 (d, J= 8.4 Hz, 2 H), 7.54 (d, J= 8.4 Hz, 2 H), 8.80 (bs, 3H).
Step 7: To a solution of 2-(4-chloro-3-(trifluoromethyl)phenoxy)acetic acid (0.078 g, 0.30 mmol, 1.2 equiv) in dichloromethane (2 mL) was added triethylamine (0.05 g, 0.5 mmol, 2.0 equiv) at room temperature. After stirring for 5 min, T3P (50 wt. % in ethyl acetate) (0.12 g, 0.37 mmol, 1.5 equiv) was added to the reaction mass at room temperature and stirred for 10 min before adding 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenyl)imidazolidin-2-one hydrochloride (0.08 g, 0.25 mmol, 1.0 equiv) along with triethylamine (0.05 g, 0.5 mmol, 2.0 equiv) in DCM (2 mL). The reaction mixture stirred at room temperature for 16 h. After completion of the reaction, the reaction mixture was diluted with water (10 mL) and extracted with DCM (2 X 25 mL). The combined organic extract was washed with saturated aqueous NaHCO3 solution (10 mL), brine solution (7 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude material was purified by flash column chromatography using a silica gel column where the product along with a very close impurity was eluted at 3 % methanol in DOM. Finally, this crude product was purified by preparative HPLC to afford 2-(4-chloro-3-(trifluoromethyl)phenoxy)-N-(3-(3-(4-
LCMS (ES) m/z = 378.1 [M+H]. 1H NMR (400 MHz, 0D0I3) 6 ppm 1.45 (s, 9 H), 2.36 (s, 6 H), 3.46 (t, J=
8.4 Hz, 2 H), 5.00 (bs, 1 H), 7.25 - 7.27 (m, 2 H), 7.47 (d, J= 8.8 Hz, 2 H).
Step 6: To a solution of tert-butyl (3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.8 g, 2.11 mmol, 1 equiv) in DCM (8 mL) at 0 C
was added 4M HCI in 1,4-dioxane (8 mL) and the reaction mixture was allowed to stir at room temperature for 6 h. After the completion of the reaction, the reaction mixture was evaporated under vacuum to afford crude 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenyl)imidazolidin-2-one hydrochloride (0.587 g, 100%) as an off-white solid. LCMS
(ES) rniz = 278.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.27 (s, 6 H), 3.43 -3.45 (m, 2 H), 3.75 - 3.77 (m, 2 H), 7.34 (d, J= 8.4 Hz, 2 H), 7.54 (d, J= 8.4 Hz, 2 H), 8.80 (bs, 3H).
Step 7: To a solution of 2-(4-chloro-3-(trifluoromethyl)phenoxy)acetic acid (0.078 g, 0.30 mmol, 1.2 equiv) in dichloromethane (2 mL) was added triethylamine (0.05 g, 0.5 mmol, 2.0 equiv) at room temperature. After stirring for 5 min, T3P (50 wt. % in ethyl acetate) (0.12 g, 0.37 mmol, 1.5 equiv) was added to the reaction mass at room temperature and stirred for 10 min before adding 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenyl)imidazolidin-2-one hydrochloride (0.08 g, 0.25 mmol, 1.0 equiv) along with triethylamine (0.05 g, 0.5 mmol, 2.0 equiv) in DCM (2 mL). The reaction mixture stirred at room temperature for 16 h. After completion of the reaction, the reaction mixture was diluted with water (10 mL) and extracted with DCM (2 X 25 mL). The combined organic extract was washed with saturated aqueous NaHCO3 solution (10 mL), brine solution (7 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude material was purified by flash column chromatography using a silica gel column where the product along with a very close impurity was eluted at 3 % methanol in DOM. Finally, this crude product was purified by preparative HPLC to afford 2-(4-chloro-3-(trifluoromethyl)phenoxy)-N-(3-(3-(4-
- 151 -chlorophenyI)-2-oxoim idazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.04 g, 17.5%
yield) as a white solid. LCMS (ES) m/z = 514.4 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.29 (s, 6 H), 3.43 (t, J= 8.0 Hz, 2 H), 3.75 (t, J= 8.0 Hz, 2 H), 4.55 (s, 2 H), 7.26 (d, J
= 8.4 Hz, 1 H), 7.33 (d, J= 8.8 Hz, 2 H), 7.40 (d, J= 2.4 Hz, 1 H), 7.55 (d, J= 9.2 Hz, 2 H), 7.63 (d, J= 8.8 Hz, 1 H), 8.77 (s, 1 H).
Example 1m 2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-VI)bicycloll.1.11pentan-1-vpacetamide CI *
CI_ 0 v -NCO H H
N
Boc,N .NN2 Boc...N.Zr Bo%
Step 1 Step 2 0.)LOH
CI
I * CI
CI
____________________________________________________________________________ 110.
Step 3 Step 4 1),V.N Step 5 Boo NCI' F1214".. \) r\I CI
C I
lm Step 1:10 a stirred solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (5.0 g, 25.21 mmol, 1.0 equiv.) in 0H0I3 (50 mL) was added 1-chloro-2-isocyanatoethane (3.22 mL, 37.82 mmol, 1.5 equiv.) at 0 C and the reaction mixture was stirred at 60 C for 1 h.
After consumption of the starting material (TLC, 5 % Me0H in DCM), the reaction mixture was cooled to RI and concentrated under reduced pressure to give crude product. To this was added n-pentane (150mL), stirred for 0.5 h at RI, and then filtered. The compound was washed with n-pentane to give tert-butyl (3-(3-(2-chloroethyl)ureido)bicyclo[1.1.1]pentan-1-yl)carbamate (7.0 g, 91 % yield) as a white solid.
LCMS (ES) m/z = 304.1 [M+H]+.1H NMR (400 MHz, DMSO-d6) 6 ppm 1.34 (s, 9H),2.00 (s,
yield) as a white solid. LCMS (ES) m/z = 514.4 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.29 (s, 6 H), 3.43 (t, J= 8.0 Hz, 2 H), 3.75 (t, J= 8.0 Hz, 2 H), 4.55 (s, 2 H), 7.26 (d, J
= 8.4 Hz, 1 H), 7.33 (d, J= 8.8 Hz, 2 H), 7.40 (d, J= 2.4 Hz, 1 H), 7.55 (d, J= 9.2 Hz, 2 H), 7.63 (d, J= 8.8 Hz, 1 H), 8.77 (s, 1 H).
Example 1m 2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-VI)bicycloll.1.11pentan-1-vpacetamide CI *
CI_ 0 v -NCO H H
N
Boc,N .NN2 Boc...N.Zr Bo%
Step 1 Step 2 0.)LOH
CI
I * CI
CI
____________________________________________________________________________ 110.
Step 3 Step 4 1),V.N Step 5 Boo NCI' F1214".. \) r\I CI
C I
lm Step 1:10 a stirred solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (5.0 g, 25.21 mmol, 1.0 equiv.) in 0H0I3 (50 mL) was added 1-chloro-2-isocyanatoethane (3.22 mL, 37.82 mmol, 1.5 equiv.) at 0 C and the reaction mixture was stirred at 60 C for 1 h.
After consumption of the starting material (TLC, 5 % Me0H in DCM), the reaction mixture was cooled to RI and concentrated under reduced pressure to give crude product. To this was added n-pentane (150mL), stirred for 0.5 h at RI, and then filtered. The compound was washed with n-pentane to give tert-butyl (3-(3-(2-chloroethyl)ureido)bicyclo[1.1.1]pentan-1-yl)carbamate (7.0 g, 91 % yield) as a white solid.
LCMS (ES) m/z = 304.1 [M+H]+.1H NMR (400 MHz, DMSO-d6) 6 ppm 1.34 (s, 9H),2.00 (s,
- 152 -6 H), 3.24 - 3.25 (m, 2 H), 3.52(t, J = 6.0 Hz, 2 H), 5.93 (s, 1 H), 6.66 (s, 1H), 7.41 (bs, 1 H).
Step 2:10 a stirred solution of tert-butyl (3-(3-(2-chloroethyl)ureido)bicyclo[1.1.1]pentan-1-yl)carbamate (7.0 g, 23.04 mmol, 1.0 equiv.) in CH3CN (70 mL) at RI was added (15 g, 46.08 mmol, 2.0 equiv). The reaction was then heated to 100 C for 12 h.
After consumption of the starting material (TLC, 5 `)/0 Me0H in DCM), the reaction mixture was diluted with H20 (200mL) and extracted with Et0Ac (3X100 mL).The combined organics were dried over anhydrous Na2SO4, filtered and concentrated to give the crude compound.
To the crude was added diethyl ether (100mL), stirred for 0.5 h at RI and then filtered.
The product was washed with diethyl ether to give tert-butyl (3-(2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (4.0g, 65% yield) as a white solid.
LCMS (ES) m/z = 268.1 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.35 (s, 9H), 2.06 (s, 6 H), 3.15 -3.17 (m, 2 H), 3.21 -3.23(m, 2 H), 6.31 (s, 1 H), 7.47 (bs, 1 H).
Step 3: To a sealed tube, tert-butyl (3-(2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (2.0 g, 7.49 mmol, 1.0 equiv.), 1-chloro-4-iodobenzene (2.14 g, 8.98 mmol, 1.2 equiv.), copper iodide(0.142 g, 0.749 mmol, 0.1 equiv.), DMEDA (0.16 mL, 1.498 mmol, 0.2 equiv.), K3PO4(3.18 g, 14.98 mmol, 2.0 equiv.) and DMSO (20 mL) were added at RT.
The resulting reaction mixture stirred for 12 h at RT. After consumption of the starting material (TLC, 40 % Et0Ac in hexane), the reaction mixture was filtered through a Celite bed and washed with Et0Ac (50mL). The filtered organics were diluted with H20 (100mL) and extracted into Et0Ac (3X100mL). The combined organics were washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the crude product. The crude product was purified by flash column chromatography (Combiflashe) using a silica gel column (60 `)/0 ethyl acetate in hexane) to obtain tert-butyl (3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)carbamate (0.8g, 30% yield) as a brown solid. LCMS (ES) m/z = 378.1 [M+H].
(400 MHz, 0D0I3) 6 ppm 1.45 (s, 9 H), 2.36 (s, 6 H), 3.46 (t, J= 8.4 Hz, 2 H), 5.00(bs, 1 H), 7.25 - 7.27 (m, 2 H), 7.47 (d, J= 8.8 Hz, 2 H).
Step 4: 4M HCI in dioxane (8 mL) was added to the stirred solution of tert-butyl (3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)carbamate (0.8 g, 2.11 mmol, 1 equiv) in DCM (8 mL) at 0 C. The resulting mixture was allowed to warm to 27 C
and stirred for 6 h. The progress of the reaction was monitored by TLC. After completion of reaction, the mixture was concentrated under reduced pressure to obtain 1-(3-
Step 2:10 a stirred solution of tert-butyl (3-(3-(2-chloroethyl)ureido)bicyclo[1.1.1]pentan-1-yl)carbamate (7.0 g, 23.04 mmol, 1.0 equiv.) in CH3CN (70 mL) at RI was added (15 g, 46.08 mmol, 2.0 equiv). The reaction was then heated to 100 C for 12 h.
After consumption of the starting material (TLC, 5 `)/0 Me0H in DCM), the reaction mixture was diluted with H20 (200mL) and extracted with Et0Ac (3X100 mL).The combined organics were dried over anhydrous Na2SO4, filtered and concentrated to give the crude compound.
To the crude was added diethyl ether (100mL), stirred for 0.5 h at RI and then filtered.
The product was washed with diethyl ether to give tert-butyl (3-(2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (4.0g, 65% yield) as a white solid.
LCMS (ES) m/z = 268.1 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.35 (s, 9H), 2.06 (s, 6 H), 3.15 -3.17 (m, 2 H), 3.21 -3.23(m, 2 H), 6.31 (s, 1 H), 7.47 (bs, 1 H).
Step 3: To a sealed tube, tert-butyl (3-(2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (2.0 g, 7.49 mmol, 1.0 equiv.), 1-chloro-4-iodobenzene (2.14 g, 8.98 mmol, 1.2 equiv.), copper iodide(0.142 g, 0.749 mmol, 0.1 equiv.), DMEDA (0.16 mL, 1.498 mmol, 0.2 equiv.), K3PO4(3.18 g, 14.98 mmol, 2.0 equiv.) and DMSO (20 mL) were added at RT.
The resulting reaction mixture stirred for 12 h at RT. After consumption of the starting material (TLC, 40 % Et0Ac in hexane), the reaction mixture was filtered through a Celite bed and washed with Et0Ac (50mL). The filtered organics were diluted with H20 (100mL) and extracted into Et0Ac (3X100mL). The combined organics were washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford the crude product. The crude product was purified by flash column chromatography (Combiflashe) using a silica gel column (60 `)/0 ethyl acetate in hexane) to obtain tert-butyl (3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)carbamate (0.8g, 30% yield) as a brown solid. LCMS (ES) m/z = 378.1 [M+H].
(400 MHz, 0D0I3) 6 ppm 1.45 (s, 9 H), 2.36 (s, 6 H), 3.46 (t, J= 8.4 Hz, 2 H), 5.00(bs, 1 H), 7.25 - 7.27 (m, 2 H), 7.47 (d, J= 8.8 Hz, 2 H).
Step 4: 4M HCI in dioxane (8 mL) was added to the stirred solution of tert-butyl (3-(3-(4-chloropheny1)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)carbamate (0.8 g, 2.11 mmol, 1 equiv) in DCM (8 mL) at 0 C. The resulting mixture was allowed to warm to 27 C
and stirred for 6 h. The progress of the reaction was monitored by TLC. After completion of reaction, the mixture was concentrated under reduced pressure to obtain 1-(3-
- 153 -am inobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenyl)im idazolidin-2-one hydrochloride (0.587 g, 100%) as an off-white solid. LCMS (ES) m/z = 278.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.27 (s, 6 H), 3.43 -3.45 (m, 2 H), 3.75 -3.77 (m, 2 H), 7.34 (d, J= 8.4 Hz, 2 H), 7.54 (d, J= 8.4 Hz, 2 H), 8.80 (bs, 3 H).
Step 5: To a mixture of 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenyl)imidazolidin-2-one hydrochloride (0.075 g, 0.238 mmol, 1 equiv), 2-(4-chloro-3-fluorophenoxy)acetic acid (0.058 g, 0.285 mmol, 1.2 equiv) and triethylamine (0.166 mL, 1.19 mmol, 5.0 equiv) in dichloromethane (5 mL) was added T3P (50 wt. % in ethyl acetate) (0.3 g, 0.476 mmol, 2.0 equiv) at 0 C. The reaction mixture was allowed to warm to 27 C, and stirred for 16 h. The progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was diluted with dichloromethane (10 mL), washed with 10% sodium bicarbonate solution (10 mL), water (5 mL), brine (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by flash column chromatography (Combiflashe) using a silica gel column (2% methanol in DCM) to obtain the title compound as 99% pure, but contained a small impurity. Again purified by preparative HPLC [Analytical conditions: Column: lnertsil ODS 3V (250mm X 4.6mm X Sum), Mobile phase (A): 0.1%Ammonia in water, Mobile phase (B): ACN; Flow rate: 1.0 mL/min, Time /013: 0/10, 10/80, 25/90, 27/10, 30/10]. Pure fractions were concentrated under reduced pressure and lyophilized to give 2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoim idazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetam ide (0.03 g, 27%) as white solid. LCMS (ES) m/z = 464.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.29 (s, 6 H), 3.42 (t, J = 8.0 Hz, 2 H), 3.75 (t, J = 8.4 Hz, 2 H), 4.47(s, 2 H), 6.82 - 6.85 (m, 1 H), 7.04 - 7.07 (m, 1 H), 7.33(d, J= 8.8 Hz, 2 H), 7.48(t, J= 8.8 Hz, 1H), 7.55(d, J= 9.2 Hz, 2 H), 8.73 (s, 1 H).
The compounds of Examples 1n-1u were prepared generally according to the procedure described above for Examples 11 and lm.
The Compounds of Examples ln to lu were prepared generally according to the procedure described above for Examples 11 and lm.
Step 5: To a mixture of 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenyl)imidazolidin-2-one hydrochloride (0.075 g, 0.238 mmol, 1 equiv), 2-(4-chloro-3-fluorophenoxy)acetic acid (0.058 g, 0.285 mmol, 1.2 equiv) and triethylamine (0.166 mL, 1.19 mmol, 5.0 equiv) in dichloromethane (5 mL) was added T3P (50 wt. % in ethyl acetate) (0.3 g, 0.476 mmol, 2.0 equiv) at 0 C. The reaction mixture was allowed to warm to 27 C, and stirred for 16 h. The progress of the reaction was monitored by TLC. After completion of reaction, the reaction mixture was diluted with dichloromethane (10 mL), washed with 10% sodium bicarbonate solution (10 mL), water (5 mL), brine (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by flash column chromatography (Combiflashe) using a silica gel column (2% methanol in DCM) to obtain the title compound as 99% pure, but contained a small impurity. Again purified by preparative HPLC [Analytical conditions: Column: lnertsil ODS 3V (250mm X 4.6mm X Sum), Mobile phase (A): 0.1%Ammonia in water, Mobile phase (B): ACN; Flow rate: 1.0 mL/min, Time /013: 0/10, 10/80, 25/90, 27/10, 30/10]. Pure fractions were concentrated under reduced pressure and lyophilized to give 2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenyI)-2-oxoim idazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetam ide (0.03 g, 27%) as white solid. LCMS (ES) m/z = 464.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.29 (s, 6 H), 3.42 (t, J = 8.0 Hz, 2 H), 3.75 (t, J = 8.4 Hz, 2 H), 4.47(s, 2 H), 6.82 - 6.85 (m, 1 H), 7.04 - 7.07 (m, 1 H), 7.33(d, J= 8.8 Hz, 2 H), 7.48(t, J= 8.8 Hz, 1H), 7.55(d, J= 9.2 Hz, 2 H), 8.73 (s, 1 H).
The compounds of Examples 1n-1u were prepared generally according to the procedure described above for Examples 11 and lm.
The Compounds of Examples ln to lu were prepared generally according to the procedure described above for Examples 11 and lm.
- 154 -Table 2b Cm LCMS 1H-NMR (400 MHz, pd Structure Name miz DM50-d6) # [M+H]
CI
4* 2.29 (s, 6 H), 3.43 (t, J =
8.0 Hz, 2 H), 3.75 (t, J =
2-(4-chloro-3-CN (trifluoromethyl)pheno 8.0 Hz, 2 H), 4.55 (s, 2 H), 7.26 (d, J = 8.4 Hz, 1 H), 11 xy)-N-(3-(3-(4-chlorophenyI)-2- 514.4 7.33 (d, J = 8.8 Hz, 2 H), 4kH
oxoimidazolidin-1-7.40 (d, J = 2.4 Hz, 1 H), yl)bicyclo[1.1.1]pentan c, 7.55 (d, J = 9.2 Hz, 2 H), -1-yl)acetamide 7.63 (d, J = 8.8 Hz, 1 H), 4 8.77 (s, 1 H).
F3c CI
F
* 2.29 (s, 6 H), 3.42 (t, J =
8.0 Hz, 2 H), 3.75 (t, J =
(= 2-(4-chloro-3- 8.4 Hz, 2 H), 4.47 (s, 2 H), HN/o fluorophenoxy)-N-(3- 6.82 -6.85 (m, 1 H), 7.04 1m 41)' (3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan 464.3 - 7.07 (m, 1 H), 7.33 (d, J
8.8 Hz, 1H), 7.55 (d, J =
8.8 Hz, 2 H), 7.48 (t, J=
oi..)-1-yl)acetamide 9.2 Hz, 2 H), 8.73 (s, 1 it H).
CI
CI
4* 2.29 (s, 6 H), 3.43 (t, J =
8.0 Hz, 2 H), 3.75 (t, J =
2-(4-chloro-3-CN (trifluoromethyl)pheno 8.0 Hz, 2 H), 4.55 (s, 2 H), 7.26 (d, J = 8.4 Hz, 1 H), 11 xy)-N-(3-(3-(4-chlorophenyI)-2- 514.4 7.33 (d, J = 8.8 Hz, 2 H), 4kH
oxoimidazolidin-1-7.40 (d, J = 2.4 Hz, 1 H), yl)bicyclo[1.1.1]pentan c, 7.55 (d, J = 9.2 Hz, 2 H), -1-yl)acetamide 7.63 (d, J = 8.8 Hz, 1 H), 4 8.77 (s, 1 H).
F3c CI
F
* 2.29 (s, 6 H), 3.42 (t, J =
8.0 Hz, 2 H), 3.75 (t, J =
(= 2-(4-chloro-3- 8.4 Hz, 2 H), 4.47 (s, 2 H), HN/o fluorophenoxy)-N-(3- 6.82 -6.85 (m, 1 H), 7.04 1m 41)' (3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan 464.3 - 7.07 (m, 1 H), 7.33 (d, J
8.8 Hz, 1H), 7.55 (d, J =
8.8 Hz, 2 H), 7.48 (t, J=
oi..)-1-yl)acetamide 9.2 Hz, 2 H), 8.73 (s, 1 it H).
CI
- 155 -\o * N-(3-(3-(4-chlorophenyI)-2- 2.29 (s, 6 H), 3.42 (t, J =
= oxoimidazolidin-1-8.0 Hz, 2 H), 3.68 (s, 3 H), (3. yl)bicyclo[1.1.1]pentan 3.73 -3.77 (m, 2 H), 4.34 NH
in -1-yI)-2-(4-methoxyphenoxy)acet 442.4 (s, 2 H), 6.83 -6.90 (m, 4 H), 7.33 (d, J = 9.2 Hz, 2 amide H), 7.55 (d, J = 9.2 Hz, 2 H), 8.65 (s, 1 H).
i CI
* 2.29 (s, 6 H), 3.42 (t, J =
oND 2-(3-chloro-4- 8.0 Hz, 2 H), 3.75 (t, J =
fluorophenoxy)-N-(3-7.2 Hz, 2 H), 4.45 (s, 2 H), (3-(4-chloropheny1)-6.97 - 6.95 (m, 1 H), 7.36 lo 464.0 -7.18 (m, 4 H), 7.55 (d, J
2-oxoimidazolidin-1 -H
0 = 8.8 Hz 2 H), 8.71 (s, 1 yl)bicyclo[1.1.1]pent H).
an-1-yl)acetamide CI.
Cl 411, õ3 N-(3-(3-(4-chloro-3- 2.30 (s, 6 H), 3.46 (t, J =
CNo (trifluoromethyl)phenyl 7.6 Hz, 2 H), 3.82 (t, J= 8 )-2-oxoimidazolidin-1- Hz, 2 H), 4.43 (s, 2 H), 1 p yl)bicyclo[1.1.11pentan 514.33 6.96 (d, J = 8.8 Hz, 2 H), k _1-yI)-2-(4- 7.33 (d, J = 8.8 Hz, 2 H), o chlorophenoxy)aceta 7.62 (s, 2 H), 8.22 (s, 1 H), oi mide 8.74 (s, 1 H).
*
i
= oxoimidazolidin-1-8.0 Hz, 2 H), 3.68 (s, 3 H), (3. yl)bicyclo[1.1.1]pentan 3.73 -3.77 (m, 2 H), 4.34 NH
in -1-yI)-2-(4-methoxyphenoxy)acet 442.4 (s, 2 H), 6.83 -6.90 (m, 4 H), 7.33 (d, J = 9.2 Hz, 2 amide H), 7.55 (d, J = 9.2 Hz, 2 H), 8.65 (s, 1 H).
i CI
* 2.29 (s, 6 H), 3.42 (t, J =
oND 2-(3-chloro-4- 8.0 Hz, 2 H), 3.75 (t, J =
fluorophenoxy)-N-(3-7.2 Hz, 2 H), 4.45 (s, 2 H), (3-(4-chloropheny1)-6.97 - 6.95 (m, 1 H), 7.36 lo 464.0 -7.18 (m, 4 H), 7.55 (d, J
2-oxoimidazolidin-1 -H
0 = 8.8 Hz 2 H), 8.71 (s, 1 yl)bicyclo[1.1.1]pent H).
an-1-yl)acetamide CI.
Cl 411, õ3 N-(3-(3-(4-chloro-3- 2.30 (s, 6 H), 3.46 (t, J =
CNo (trifluoromethyl)phenyl 7.6 Hz, 2 H), 3.82 (t, J= 8 )-2-oxoimidazolidin-1- Hz, 2 H), 4.43 (s, 2 H), 1 p yl)bicyclo[1.1.11pentan 514.33 6.96 (d, J = 8.8 Hz, 2 H), k _1-yI)-2-(4- 7.33 (d, J = 8.8 Hz, 2 H), o chlorophenoxy)aceta 7.62 (s, 2 H), 8.22 (s, 1 H), oi mide 8.74 (s, 1 H).
*
i
- 156 -F
* C F 3 2.30 (s, 6 H), 3.44 (t, J =
7.8 Hz, 2 H), 3.82 (t, J= 8 Cri 2-(4-chlorophenoxy)-N-(3-(3-(4-fluoro-3- Hz, 2 H), 4.43 (s, 2 H), 6.96 (d, J = 8.8 Hz, 2 H), 1 q k (trifluoromethyl)phenyl 497.87 7.33 (d, J = 8.8 Hz, 2 H), )-2-oxoimidazolidin-1-7.42 - 7.47 (m, 1 H), 7.65 o, yl)bicyclo[1.1.1]pentan -1-yl)acetamide - 7.68 (m, 1 H), 8.07 -8.08 (m, 1 H), 8.73 (s, 1 IP H).
cF3 * 2.48 (s, 6 H), 3.46 (t, J =
2-(4-chlorophenoxy)-- 8.4 Hz, 2 H), 3.85 (t, J =
N-(3-(2-0x0-3-(4 k 7.2 Hz, 2 H), 4.43 (s, 2 H), 1 r (trifluoromethyl)phenyl 479.88 6.96 (d, J = 8.8 Hz, 2 H), )imidazolidin-1-7.33 (d, J = 8.8 Hz, 2 H), o/
yl)bicyclo[1.1.1]pentan 7.74 - 7.62 (m, 4 H), 8.73 o) -1-yl)acetamide (s, 1 H).
CI
*
N-(3-(3-(4-Crq chlorophenyI)-2- 2.29 (s, 6 H), 3.43 (t, J =
8.0 Hz, 2 H), 3.75 (t, J =
4kH oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan 498.0 7.8 Hz, 2 H), 4.52 (s, 2 H), 7.30 - 7.34 (m, 4 H), 7.44 o./ -1-yI)-2-(4-fluoro-3-(t, J = 10.0 Hz, 1 H), 7.55 (trifluoromethyl)pheno o) (d, J = 8.8 Hz, 2 H), 8.75 xy)acetamide 110 (s, 1 H).
* C F 3 2.30 (s, 6 H), 3.44 (t, J =
7.8 Hz, 2 H), 3.82 (t, J= 8 Cri 2-(4-chlorophenoxy)-N-(3-(3-(4-fluoro-3- Hz, 2 H), 4.43 (s, 2 H), 6.96 (d, J = 8.8 Hz, 2 H), 1 q k (trifluoromethyl)phenyl 497.87 7.33 (d, J = 8.8 Hz, 2 H), )-2-oxoimidazolidin-1-7.42 - 7.47 (m, 1 H), 7.65 o, yl)bicyclo[1.1.1]pentan -1-yl)acetamide - 7.68 (m, 1 H), 8.07 -8.08 (m, 1 H), 8.73 (s, 1 IP H).
cF3 * 2.48 (s, 6 H), 3.46 (t, J =
2-(4-chlorophenoxy)-- 8.4 Hz, 2 H), 3.85 (t, J =
N-(3-(2-0x0-3-(4 k 7.2 Hz, 2 H), 4.43 (s, 2 H), 1 r (trifluoromethyl)phenyl 479.88 6.96 (d, J = 8.8 Hz, 2 H), )imidazolidin-1-7.33 (d, J = 8.8 Hz, 2 H), o/
yl)bicyclo[1.1.1]pentan 7.74 - 7.62 (m, 4 H), 8.73 o) -1-yl)acetamide (s, 1 H).
CI
*
N-(3-(3-(4-Crq chlorophenyI)-2- 2.29 (s, 6 H), 3.43 (t, J =
8.0 Hz, 2 H), 3.75 (t, J =
4kH oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan 498.0 7.8 Hz, 2 H), 4.52 (s, 2 H), 7.30 - 7.34 (m, 4 H), 7.44 o./ -1-yI)-2-(4-fluoro-3-(t, J = 10.0 Hz, 1 H), 7.55 (trifluoromethyl)pheno o) (d, J = 8.8 Hz, 2 H), 8.75 xy)acetamide 110 (s, 1 H).
- 157 -\O
2.27 (s, 6 H), 3.36 - 3.40 C0 2-(4-chlorophenoxy)- (m, 2 H), 3.70 - 3.73 (m, 5 N N-(3-(3-(4- H), 4.42 (s, 2 H), 6.86 (d, J
methoxyphenyI)-2-442.1 = 9.2 Hz, 2 H), 6.96 (d, J=
it oxoimidazolidin-1- 8.8 Hz, 2 H), 7.32 (d, J =
) 0 )1-1 yl)bicyclo[1.1.1]pentan 8.8 Hz, 2 H), 7.40 (d, J=
- 1 -yl)acetamide 9.2 Hz, 2 H), 8.70 (s, 1 H).
*
I
\S
4f*
2.28 (s, 6 H), 2.41 (s, 3 H), C 0 2-(4-chlorophenoxy)-3.41 (t, J = 8.0 Hz, 2 H), N N-(3-(3-(4-3.73 (t, J = 8.4 Hz, 2 H), (methylthio)phenyI)-2-lu 458.0 4.42 (s, 2 H), 6.96 (d, J =
oxoimidazolidin-1-H 8.8 Hz, 2 H), 7.21 (d, J =
scs, yl)bicyclo[1.1.1]pentan - 1 -yl)acetamide 8.8 Hz, 2 H), 7.32 (d, J =
0) 8.8 Hz, 2 H), 7.48 (d, J =
4 8.8 Hz, 2 H), 8.71 (s, 1 H).
i Example "ly N-(3-(3-(4-chloro-2-fluoropheny1)-2-oxoimidazolidin-1-y1)bicycloll.1.11pentan-1-y1)-2-(4-chlorophenoxy)acetamide ci \-..i CI 4I or-i, iv
2.27 (s, 6 H), 3.36 - 3.40 C0 2-(4-chlorophenoxy)- (m, 2 H), 3.70 - 3.73 (m, 5 N N-(3-(3-(4- H), 4.42 (s, 2 H), 6.86 (d, J
methoxyphenyI)-2-442.1 = 9.2 Hz, 2 H), 6.96 (d, J=
it oxoimidazolidin-1- 8.8 Hz, 2 H), 7.32 (d, J =
) 0 )1-1 yl)bicyclo[1.1.1]pentan 8.8 Hz, 2 H), 7.40 (d, J=
- 1 -yl)acetamide 9.2 Hz, 2 H), 8.70 (s, 1 H).
*
I
\S
4f*
2.28 (s, 6 H), 2.41 (s, 3 H), C 0 2-(4-chlorophenoxy)-3.41 (t, J = 8.0 Hz, 2 H), N N-(3-(3-(4-3.73 (t, J = 8.4 Hz, 2 H), (methylthio)phenyI)-2-lu 458.0 4.42 (s, 2 H), 6.96 (d, J =
oxoimidazolidin-1-H 8.8 Hz, 2 H), 7.21 (d, J =
scs, yl)bicyclo[1.1.1]pentan - 1 -yl)acetamide 8.8 Hz, 2 H), 7.32 (d, J =
0) 8.8 Hz, 2 H), 7.48 (d, J =
4 8.8 Hz, 2 H), 8.71 (s, 1 H).
i Example "ly N-(3-(3-(4-chloro-2-fluoropheny1)-2-oxoimidazolidin-1-y1)bicycloll.1.11pentan-1-y1)-2-(4-chlorophenoxy)acetamide ci \-..i CI 4I or-i, iv
- 158 -H H
Boc N
µN --Ow goc \) Step 2 µ14 Step 1 goc CI CI
CI
Br 101 0 * 0 4 -Dow Step 3 Step 4 goc 0.A CI
OH
CI
0,, I I.
Step 5 ci iv Step 1:10 a stirred solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (2 g, 10.08 mmol, 1.0 equiv) in chloroform (20 mL) was added 1-chloro-2-isocyanatoethane (1.29 mL, 15.13 mmol, 1.5 equiv) at 0 C and the mixture was heated to 60 C
for 1 h. After the completion of the reaction (TLC in 5 % Methanol in DCM), the reaction mixture was cooled to room temperature and concentrated under reduced pressure to yield crude product. The obtained crude was triturated with n-pentane (50 mL) and stirred for 0.5 h at room temperature. The solid compound was filtered and washed with n-pentane to afford tert-butyl (3-(3-(2-chloroethyl)ureido)bicyclo[1.1.1]pentan-1-yl)carbamate (2.5 g, 83% yield) as a white solid. LCMS (ES) m/z = 304.1 [M+H] ; 1H NMR (400 MHz, DMSO-d6) 6 PPm 1.35 (s, 9 H), 2.01 (s, 6 H), 3.25 ¨ 3.24 (m, 2 H), 3.52 ¨ 3.53 (m, 2 H), 5.93 (s, 1 H), 6.66 (s, 1 H), 7.41 (bs, 1 H).
.. Step 2:10 a stirred solution of tert-butyl (3-(3-(2-chloroethyl)ureido)bicyclo[1.1.1]pentan-1-yl)carbamate (2.5 g, 8.22 mmol, 1.0 equiv) in acetonitrile (25 mL) was added cesium carbonate (4.64 g, 14.24 mmol, 2.0 equiv) at room temperature and the mixture was heated to 80 C and stirred for 12 h. After the completion of the reaction (TLC in 5 %
Methanol in DCM), the reaction mixture was allowed to cool to room temperature, diluted with water (100 mL) and extracted with ethyl acetate (2 X 50 mL). The combined ethyl acetate extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford the crude product which was purified by silica gel column chromatography (Combiflashe) using 10 % Me0H in dichloromethane as eluent to afford
Boc N
µN --Ow goc \) Step 2 µ14 Step 1 goc CI CI
CI
Br 101 0 * 0 4 -Dow Step 3 Step 4 goc 0.A CI
OH
CI
0,, I I.
Step 5 ci iv Step 1:10 a stirred solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (2 g, 10.08 mmol, 1.0 equiv) in chloroform (20 mL) was added 1-chloro-2-isocyanatoethane (1.29 mL, 15.13 mmol, 1.5 equiv) at 0 C and the mixture was heated to 60 C
for 1 h. After the completion of the reaction (TLC in 5 % Methanol in DCM), the reaction mixture was cooled to room temperature and concentrated under reduced pressure to yield crude product. The obtained crude was triturated with n-pentane (50 mL) and stirred for 0.5 h at room temperature. The solid compound was filtered and washed with n-pentane to afford tert-butyl (3-(3-(2-chloroethyl)ureido)bicyclo[1.1.1]pentan-1-yl)carbamate (2.5 g, 83% yield) as a white solid. LCMS (ES) m/z = 304.1 [M+H] ; 1H NMR (400 MHz, DMSO-d6) 6 PPm 1.35 (s, 9 H), 2.01 (s, 6 H), 3.25 ¨ 3.24 (m, 2 H), 3.52 ¨ 3.53 (m, 2 H), 5.93 (s, 1 H), 6.66 (s, 1 H), 7.41 (bs, 1 H).
.. Step 2:10 a stirred solution of tert-butyl (3-(3-(2-chloroethyl)ureido)bicyclo[1.1.1]pentan-1-yl)carbamate (2.5 g, 8.22 mmol, 1.0 equiv) in acetonitrile (25 mL) was added cesium carbonate (4.64 g, 14.24 mmol, 2.0 equiv) at room temperature and the mixture was heated to 80 C and stirred for 12 h. After the completion of the reaction (TLC in 5 %
Methanol in DCM), the reaction mixture was allowed to cool to room temperature, diluted with water (100 mL) and extracted with ethyl acetate (2 X 50 mL). The combined ethyl acetate extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford the crude product which was purified by silica gel column chromatography (Combiflashe) using 10 % Me0H in dichloromethane as eluent to afford
- 159 -tert-butyl (3-(2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.4 g, 18 % yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.35 (s, 9 H), 2.06 (s, 6 H), 3.15 -3.17 (m, 2 H), 3.22 -3.24 (m, 2 H), 6.31 (s, 1 H), 7.47 (bs, 1 H).
Step 3: In a sealed tube, to a stirred solution of tert-butyl (3-(2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.25 g, 0.935 mmol, 1.0 equiv.) in 1, 4-dioxane (5 mL) was added 1-bromo-4-chloro-2-fluorobenzene (0.19 g, 0.935 mmol, 1.0 equiv). The mixture was degassed by purging with argon for 5 minutes. Then Pd2(dba)3 (0.085 g, 0.093 mmol, 0.1 equiv), xanthphos (0.1 g, 0.187 mmol, 0.2 equiv) and 052003 (1.21 g, 3.74 mmol, 4.0 equiv) were added to the reaction mixture under argon atmosphere, and the sealed tube was capped and the mixture was stirred at 80 C for 16 h. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (20 mL), filtered through a Celite bed, and the Celite bed washed with excess ethyl acetate. The filtrate was concentrated under reduced pressure to afford the crude product, which was purified by silica gel column chromatography (Combiflashe) using 50 % Ethyl acetate in hexane as eluent to obtain tert-butyl 3-(3-(4-chloro-2-fluorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.17 g, 65% yield) as an off-white solid. LCMS (ES) m/z= 396.1 [M+H] .
.. Step 4: To a stirred solution of tert-butyl (3-(3-(4-chloro-2-fluorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.17 g, 0.42 mmol, 1.0 equiv.) in dichloromethane (2 mL) was added 4 M HCI solution in 1,4-dioxane (1.5 mL) at 0 C. The resulting mixture was allowed to warm to room temperature and stirred for 3 h.
The progress of the reaction was monitored by TLC (30 % ethyl acetate in hexane).
After .. completion of reaction, the reaction mixture was concentrated under reduced pressure, and the obtained residue was triturated with n-pentane. The product was dried under high vaccum to obtain 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chloro-2-fluorophenyl)imidazolidin-2-one hydrochloride (0.09 g, crude) as a pale brown solid. Used without further purification. LCMS (ES) m/z= 296.1[M+H] .
Step 5: To a stirred solution of 2-(4-chlorophenoxy)acetic acid (0.05 g, 0.27 mmol, 1 equiv.) and triethylamine (0.076 mL, 0.54 mmol, 2 equiv) in dichloromethane (10 mL) was added T3P (50 % wt. in ethyl acetate) at 0 C. The resulting mixture was allowed to warm to room temperature and stirred for 20 min. After 20 min, the reaction mixture was cooled to 0 C and a solution of 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chloro-2-fluorophenyl)imidazolidin-2-one hydrochloride (0.09 g crude, 0.27 mmol, 1.0 equiv) and
Step 3: In a sealed tube, to a stirred solution of tert-butyl (3-(2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.25 g, 0.935 mmol, 1.0 equiv.) in 1, 4-dioxane (5 mL) was added 1-bromo-4-chloro-2-fluorobenzene (0.19 g, 0.935 mmol, 1.0 equiv). The mixture was degassed by purging with argon for 5 minutes. Then Pd2(dba)3 (0.085 g, 0.093 mmol, 0.1 equiv), xanthphos (0.1 g, 0.187 mmol, 0.2 equiv) and 052003 (1.21 g, 3.74 mmol, 4.0 equiv) were added to the reaction mixture under argon atmosphere, and the sealed tube was capped and the mixture was stirred at 80 C for 16 h. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (20 mL), filtered through a Celite bed, and the Celite bed washed with excess ethyl acetate. The filtrate was concentrated under reduced pressure to afford the crude product, which was purified by silica gel column chromatography (Combiflashe) using 50 % Ethyl acetate in hexane as eluent to obtain tert-butyl 3-(3-(4-chloro-2-fluorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.17 g, 65% yield) as an off-white solid. LCMS (ES) m/z= 396.1 [M+H] .
.. Step 4: To a stirred solution of tert-butyl (3-(3-(4-chloro-2-fluorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.17 g, 0.42 mmol, 1.0 equiv.) in dichloromethane (2 mL) was added 4 M HCI solution in 1,4-dioxane (1.5 mL) at 0 C. The resulting mixture was allowed to warm to room temperature and stirred for 3 h.
The progress of the reaction was monitored by TLC (30 % ethyl acetate in hexane).
After .. completion of reaction, the reaction mixture was concentrated under reduced pressure, and the obtained residue was triturated with n-pentane. The product was dried under high vaccum to obtain 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chloro-2-fluorophenyl)imidazolidin-2-one hydrochloride (0.09 g, crude) as a pale brown solid. Used without further purification. LCMS (ES) m/z= 296.1[M+H] .
Step 5: To a stirred solution of 2-(4-chlorophenoxy)acetic acid (0.05 g, 0.27 mmol, 1 equiv.) and triethylamine (0.076 mL, 0.54 mmol, 2 equiv) in dichloromethane (10 mL) was added T3P (50 % wt. in ethyl acetate) at 0 C. The resulting mixture was allowed to warm to room temperature and stirred for 20 min. After 20 min, the reaction mixture was cooled to 0 C and a solution of 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chloro-2-fluorophenyl)imidazolidin-2-one hydrochloride (0.09 g crude, 0.27 mmol, 1.0 equiv) and
- 160 -triethylamine (0.11 mL, 0.81 mmol, 3 equiv) in dichloromethane (10 mL) was added at 0 C. The resulting mixture was allowed to warm to room temperature and stirred for 3 h. The progress of the reaction was monitored by TLC (5 % methanol in DCM). After completion of the reaction, the reaction mixture was diluted with dichloromethane (100 mL), washed with saturated aqueous sodium bicarbonate solution (50 mL), water (30 mL) and brine (30 mL), and finally dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.The crude product was purified by silica gel column chromatography (Combiflashe) using 4 % methanol in dichloromethane as eluent to obtain the title compound N-(3-(3-(4-chloro-2-fluorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (0.08 g) as a white solid. LCMS (ES) m/z =
464.0 [M+H]
; 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.27 (s, 6 H), 3.44 (t, J= 7.6 Hz, 2 H), 3.73 (t, J=
7.2Hz, 2 H), 4.42 (s, 2 H), 6.96 (d, J= 8.8 Hz, 2 H), 7.25 (d, J= 7.2 Hz, 1 H), 7.32 (d, J=
8.8 Hz, 2 H), 7.45 - 7.52 (m, 2 H), 8.70 (s, 1 H).
Table 3 LCM
Name S miz 1H-NMR (400 MHz, Cmpd # Structure DMSO-d6) [M+H]
CI
* F
2.27 (s, 6 H), 3.44 (t, J=
o D N-(3-(3-(4-chloro-2-7.6 Hz, 2 H), 3.73 (t, J=
fluorophenyI)-2-N
7.2 Hz, 2 H), 4.42 (s, 2 SS oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-H), 6.96 (d, J= 8.8 Hz, 2 1 v 464.0 H), 7.25 (d, J = 7.2 Hz, 1 ,sp yI)-2-(4-chlorophenoxy)acetamide H), 7.32 (d, J= 8.8 Hz, 2 H), 7.45 - 7.52 (m, 2 H), 8.70 (s, 1 H).
*
C
464.0 [M+H]
; 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.27 (s, 6 H), 3.44 (t, J= 7.6 Hz, 2 H), 3.73 (t, J=
7.2Hz, 2 H), 4.42 (s, 2 H), 6.96 (d, J= 8.8 Hz, 2 H), 7.25 (d, J= 7.2 Hz, 1 H), 7.32 (d, J=
8.8 Hz, 2 H), 7.45 - 7.52 (m, 2 H), 8.70 (s, 1 H).
Table 3 LCM
Name S miz 1H-NMR (400 MHz, Cmpd # Structure DMSO-d6) [M+H]
CI
* F
2.27 (s, 6 H), 3.44 (t, J=
o D N-(3-(3-(4-chloro-2-7.6 Hz, 2 H), 3.73 (t, J=
fluorophenyI)-2-N
7.2 Hz, 2 H), 4.42 (s, 2 SS oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-H), 6.96 (d, J= 8.8 Hz, 2 1 v 464.0 H), 7.25 (d, J = 7.2 Hz, 1 ,sp yI)-2-(4-chlorophenoxy)acetamide H), 7.32 (d, J= 8.8 Hz, 2 H), 7.45 - 7.52 (m, 2 H), 8.70 (s, 1 H).
*
C
- 161 -Example 2a N-(4-(2-(4-chlorophenoxy)acetamido)bicyclo12.1.11hexan-1-v1)-2-(4-chlorophenyncyclopropane-1-carboxamide CI CI
A OH
NH.....erMH2 0 rsli *
CI
CI 0/....1 Step 1 CI4N....e( 2b Step 1: To a solution of 2-(4-chlorophenyl)cyclopropane-1-carboxylic acid (0.06 g, 0.29 mmol, 1.2 equiv.) in DCM ( 5 mL) at 0 C was added triethylamine (0.14 mL, 1.00 mmol, 4.0 equiv), and stirred for 10 min followed by addition of T3Pe (50 wt% in Et0Ac) (0.3 mL, 0.50 mmol, 2.0 equiv.). The reaction mixture was stirred at 0 C for 10 min and then N-(4-aminobicyclo[2.1.1]hexan-1-y1)-2-(4-chlorophenoxy)acetamide (0.07 g, 0.25 mmol, 1.0 equiv.) was added at 0 C and the reaction was stirred at rt for 16 h. After the consumption of the starting material (TLC, 5 `)/0 Me0H in DCM), the reaction mixture was diluted with DCM (50 mL) and was washed with saturated aqueous NaHCO3 solution (2 x 10 mL) and water (2 x 10 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure to get the crude. The crude product was purified by silica gel column chromatography using 1 - 2 `)/0 Me0H in DCM as eluent to afford the title compound which was then triturated with n-pentane (2 x 5 mL). The solid was dried under high vacuum to afford the desired product N-(4-(2-(4-chlorophenoxy)acetamido)bicyclo[2.1.1]hexan-1-y1)-2-(4-chlorophenyl)cyclopropane-1-carboxamide as an off-white solid (0.07 g, 61.4 `)/0). LCMS (ES) m/z = 459.3 [M+H] +. 1H
NMR (400 MHz, DMSO-d6) 6 ppm 1.11 -1.15 (m, 1H), 1.28 - 1.33 (m, 1 H), 1.72 -1.75 (m, 6 H), 1.79 - 1.83 (m, 1 H), 2.06 (s, 2 H), 2.19 - 2.23 (m, 1 H), 4.40 (s, 2 H), 6.95 (d, J
= 8.8 Hz, 2 H), 7.13 (d, J= 8.0 Hz, 2 H), 7.31 (t, J= 9.2 Hz, 4 H), 8.40 (s, 1 H), 8.48 (s, 1 H).
The compound of Example 2b was prepared generally according to the procedure described above for Example 2a.
A OH
NH.....erMH2 0 rsli *
CI
CI 0/....1 Step 1 CI4N....e( 2b Step 1: To a solution of 2-(4-chlorophenyl)cyclopropane-1-carboxylic acid (0.06 g, 0.29 mmol, 1.2 equiv.) in DCM ( 5 mL) at 0 C was added triethylamine (0.14 mL, 1.00 mmol, 4.0 equiv), and stirred for 10 min followed by addition of T3Pe (50 wt% in Et0Ac) (0.3 mL, 0.50 mmol, 2.0 equiv.). The reaction mixture was stirred at 0 C for 10 min and then N-(4-aminobicyclo[2.1.1]hexan-1-y1)-2-(4-chlorophenoxy)acetamide (0.07 g, 0.25 mmol, 1.0 equiv.) was added at 0 C and the reaction was stirred at rt for 16 h. After the consumption of the starting material (TLC, 5 `)/0 Me0H in DCM), the reaction mixture was diluted with DCM (50 mL) and was washed with saturated aqueous NaHCO3 solution (2 x 10 mL) and water (2 x 10 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure to get the crude. The crude product was purified by silica gel column chromatography using 1 - 2 `)/0 Me0H in DCM as eluent to afford the title compound which was then triturated with n-pentane (2 x 5 mL). The solid was dried under high vacuum to afford the desired product N-(4-(2-(4-chlorophenoxy)acetamido)bicyclo[2.1.1]hexan-1-y1)-2-(4-chlorophenyl)cyclopropane-1-carboxamide as an off-white solid (0.07 g, 61.4 `)/0). LCMS (ES) m/z = 459.3 [M+H] +. 1H
NMR (400 MHz, DMSO-d6) 6 ppm 1.11 -1.15 (m, 1H), 1.28 - 1.33 (m, 1 H), 1.72 -1.75 (m, 6 H), 1.79 - 1.83 (m, 1 H), 2.06 (s, 2 H), 2.19 - 2.23 (m, 1 H), 4.40 (s, 2 H), 6.95 (d, J
= 8.8 Hz, 2 H), 7.13 (d, J= 8.0 Hz, 2 H), 7.31 (t, J= 9.2 Hz, 4 H), 8.40 (s, 1 H), 8.48 (s, 1 H).
The compound of Example 2b was prepared generally according to the procedure described above for Example 2a.
- 162 -Table 4 LCMS 1H-NMR (400 MHz, Structur Cmpd # Name miz DMSO-d6) e [M+H]
CI
* 1.11 - 1.15 (m, 1H), 1.28 - 1.33 (m, 1 H), A
o N-(4-(2-(4- 1.72 - 1.75 (m, 6 H), H chlorophenoxy)acetamido) 1.79 - 1.83 (m, 1 H), 2a bicyclo[2.1.1]hexan-1-yI)-2- 2.06 (s, 2 H), 2.19 -459.3 (4- 2.23 (m, 1 H), 4.40 (s, ,- chlorophenyl)cyclopropane 2 H), 6.95 (d, J = 8.8 o -1-carboxamide Hz, 2 H), 7.13 (d, J =
* 8.0 Hz, 2 H), 7.31 (t, J
= 9.2 Hz, 4 H), 8.40 (s, I 1 H), 8.48 (s, 1 H).
ci # 1.16 - 1.20 (m, 1 H), 1.30 - 1.32 (m, 1 H), 1 N-(3-(2-(4-1.74 - 1.76 (m, 1 H), HN chlorophenoxy)acetamido) 2.30 (s, 7 H), 4.40 (s, 2b and ,:t bicyclo[1.1.1]pentan-1-yI)-445.3 2 H), 6.95 (d, J = 8.8 XXIVB o " 2-(4-chlorophenyl)cyclopropane Hz, 2 H), 7.12 (d, J =
8.4 Hz, 2 H), 7.28 -4 -1-carboxamide 7.33 (m, 4 H), 8.64 (bs, 1 H), 8.69 (bs, 1 H).
CI
* 1.11 - 1.15 (m, 1H), 1.28 - 1.33 (m, 1 H), A
o N-(4-(2-(4- 1.72 - 1.75 (m, 6 H), H chlorophenoxy)acetamido) 1.79 - 1.83 (m, 1 H), 2a bicyclo[2.1.1]hexan-1-yI)-2- 2.06 (s, 2 H), 2.19 -459.3 (4- 2.23 (m, 1 H), 4.40 (s, ,- chlorophenyl)cyclopropane 2 H), 6.95 (d, J = 8.8 o -1-carboxamide Hz, 2 H), 7.13 (d, J =
* 8.0 Hz, 2 H), 7.31 (t, J
= 9.2 Hz, 4 H), 8.40 (s, I 1 H), 8.48 (s, 1 H).
ci # 1.16 - 1.20 (m, 1 H), 1.30 - 1.32 (m, 1 H), 1 N-(3-(2-(4-1.74 - 1.76 (m, 1 H), HN chlorophenoxy)acetamido) 2.30 (s, 7 H), 4.40 (s, 2b and ,:t bicyclo[1.1.1]pentan-1-yI)-445.3 2 H), 6.95 (d, J = 8.8 XXIVB o " 2-(4-chlorophenyl)cyclopropane Hz, 2 H), 7.12 (d, J =
8.4 Hz, 2 H), 7.28 -4 -1-carboxamide 7.33 (m, 4 H), 8.64 (bs, 1 H), 8.69 (bs, 1 H).
- 163 -Example 2c and XXIVA
2-(4-chlorophenoxv)-N-(3-(2-(4-chlorophenoxv)acetamido)bicyclo11.1.11pentan-1-Vncyclopropane-1-carboxamide CI
OAN J.H1r46 OH I><CBrN 0 CN
140 oycH
c, stept c, Step 2 CI
0)(N
CI
0 r&NH0 _______________________ pir 0)(N
Step 1:10 a stirred solution of 4-chlorophenol (0.5 g, 3.90 mmol, 1 equiv) in DMF (15 mL) at room temperature was added cesium carbonate (1.98 g, 5.85 mmol, 1.5 equiv.) and 1-bromocyclopropane-1-carbonitrile (0.57 g, 3.90 mmol, 1 equiv). The resulting mixture was heated to 90 C and stirred for 16 h. The progress of the reaction was monitored by TLC.
After consumption of the starting material, the reaction mixture was cooled to room temperature, diluted with water (50 mL) and extracted with Et0Ac (2 x 100 mL).
The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford the crude product. The crude product was purified by flash column chromatography using a silica gel column (10%
ethyl acetate in hexane) to afford 2-(4-chlorophenoxy)cyclopropane-1-carbonitrile (0.15 g, 20% yield) as an off-white solid. 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.47¨ 1.49 (m, 1 H), 1.54 ¨ 1.59 (m, 1 H), 2.13 ¨ 2.16 (m, 1 H), 4.40 ¨ 4.49 (s, 1 H), 7.04 (d, J= 8.8 Hz, 2 H), 7.4 (d, J = 8.8 Hz, 2 H). 130 NMR (100 MHz, DMSO-d6): 6 ppm 4.47, 14.40, 55.86, 117.19, 120.17, 126.29, 129.93, 156.63.
Step 2: To a stirred solution of 2-(4-chlorophenoxy)cyclopropane-1-carbonitrile (0.15 g, 0.773 mmol, 1 equiv) in water (5 mL) was added a 10 % aqueous solution of NaOH
(5 mL)
2-(4-chlorophenoxv)-N-(3-(2-(4-chlorophenoxv)acetamido)bicyclo11.1.11pentan-1-Vncyclopropane-1-carboxamide CI
OAN J.H1r46 OH I><CBrN 0 CN
140 oycH
c, stept c, Step 2 CI
0)(N
CI
0 r&NH0 _______________________ pir 0)(N
Step 1:10 a stirred solution of 4-chlorophenol (0.5 g, 3.90 mmol, 1 equiv) in DMF (15 mL) at room temperature was added cesium carbonate (1.98 g, 5.85 mmol, 1.5 equiv.) and 1-bromocyclopropane-1-carbonitrile (0.57 g, 3.90 mmol, 1 equiv). The resulting mixture was heated to 90 C and stirred for 16 h. The progress of the reaction was monitored by TLC.
After consumption of the starting material, the reaction mixture was cooled to room temperature, diluted with water (50 mL) and extracted with Et0Ac (2 x 100 mL).
The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford the crude product. The crude product was purified by flash column chromatography using a silica gel column (10%
ethyl acetate in hexane) to afford 2-(4-chlorophenoxy)cyclopropane-1-carbonitrile (0.15 g, 20% yield) as an off-white solid. 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.47¨ 1.49 (m, 1 H), 1.54 ¨ 1.59 (m, 1 H), 2.13 ¨ 2.16 (m, 1 H), 4.40 ¨ 4.49 (s, 1 H), 7.04 (d, J= 8.8 Hz, 2 H), 7.4 (d, J = 8.8 Hz, 2 H). 130 NMR (100 MHz, DMSO-d6): 6 ppm 4.47, 14.40, 55.86, 117.19, 120.17, 126.29, 129.93, 156.63.
Step 2: To a stirred solution of 2-(4-chlorophenoxy)cyclopropane-1-carbonitrile (0.15 g, 0.773 mmol, 1 equiv) in water (5 mL) was added a 10 % aqueous solution of NaOH
(5 mL)
- 164 -and the resulting mixture was heated to 70 C for 12 h. The progress of the reaction was monitored by TLC. After consumption of the starting material the reaction mixture was cooled to room temperature and acidified with 1 N HCI to pH -2. The product was extracted with Et0Ac (2 x 50 mL). The combined organic layer was washed with brine .. solution (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 2-(4-chlorophenoxy)cyclopropane-1-carboxylic acid (0.085 g, 50% yield) as sticky solid. LCMS (ES) m/z = 212.2 [M-H]. 1H NMR (400 MHz, DMSO-d6):
6 ppm 1.32 - 1.36 (m, 1 H), 1.36 - 1.41 (m, 1 H), 1.92 - 1.97 (m, 1 H), 4.09 -4.11(m, 1 H), 7.03 (d, J= 8.4 Hz, 2 H), 7.32 (d, J= 8.4 Hz, 2 H), 12.03 (bs, 1 H).
Step 3: To a stirred solution of 2-(4-chlorophenoxy)cyclopropane-1-carboxylic acid (0.083 g, 0.393 mmol, 1.5 equiv) and triethylamine (0.15 mL, 1.04 mmol, 4.0 equiv) in dichloromethane (5 mL) was added T3P (50 wt. % in ethyl acetate) (0.25 mL, 0.393 mmol, 1.5 equiv) at 0 C and the mixture was stirred for 10 min. Then N-(3-.. aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (0.07 g, 0.262 mmol, 1 equiv) was added to the above reaction mixture. The resulting mixture was stirred for 16 h during which it warmed up to room temperature. The progress of the reaction was monitored by TLC. After completion of the reaction, the mixture was diluted with dichloromethane (50 mL), washed with water (2 x 30 mL), brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel flash column chromatography using 4 % methanol in dichloromethane as eluent. The obtained product was re-purified by preparative HPLC [Analytical condition: Column: ZORBAX (150mm X 4.6mm X 5mic), mobile phase(A) : 0.1% Ammonia in water, mobile phase(B) : CH3CN, flow rate :
1.0 mL/min, gradient: 0/10,10/60, 25/90, 27/10, 30/10] to afford the title compound 2-(4-chlorophenoxy)-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)cyclopropane-1-carboxamide (0.03 g, 25% yield) as a white solid. LCMS (ES) m/z =
461.3 [M+H]. 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.10 - 1.13 (m, 1 H), 1.39 -1.40 9m, 1 H), 1.84 - 1.88 (m, 1 H), 1.94 - 2.00 (m, 6 H), 3.98 - 3.99 (m, 1 H), 4.37 (s, 2 H), 6.92 -7.00 (m, 4 H), 7.25 - 7.32 (m, 4 H), 8.45 (s, 1 H), 8.56 (s, 1 H). 130 NMR
(100 MHz, DMSO-d6): 6 ppm 10.88, 22.47, 44.59, 44.96, 54.74, 55.61, 67.47, 116.95, 117.26, 125.11, 125.27, 129.24, 129.62, 157.08, 157.49, 167.27, 168.07. HPLC Purity 99.79 % at 225 nm.
6 ppm 1.32 - 1.36 (m, 1 H), 1.36 - 1.41 (m, 1 H), 1.92 - 1.97 (m, 1 H), 4.09 -4.11(m, 1 H), 7.03 (d, J= 8.4 Hz, 2 H), 7.32 (d, J= 8.4 Hz, 2 H), 12.03 (bs, 1 H).
Step 3: To a stirred solution of 2-(4-chlorophenoxy)cyclopropane-1-carboxylic acid (0.083 g, 0.393 mmol, 1.5 equiv) and triethylamine (0.15 mL, 1.04 mmol, 4.0 equiv) in dichloromethane (5 mL) was added T3P (50 wt. % in ethyl acetate) (0.25 mL, 0.393 mmol, 1.5 equiv) at 0 C and the mixture was stirred for 10 min. Then N-(3-.. aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (0.07 g, 0.262 mmol, 1 equiv) was added to the above reaction mixture. The resulting mixture was stirred for 16 h during which it warmed up to room temperature. The progress of the reaction was monitored by TLC. After completion of the reaction, the mixture was diluted with dichloromethane (50 mL), washed with water (2 x 30 mL), brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel flash column chromatography using 4 % methanol in dichloromethane as eluent. The obtained product was re-purified by preparative HPLC [Analytical condition: Column: ZORBAX (150mm X 4.6mm X 5mic), mobile phase(A) : 0.1% Ammonia in water, mobile phase(B) : CH3CN, flow rate :
1.0 mL/min, gradient: 0/10,10/60, 25/90, 27/10, 30/10] to afford the title compound 2-(4-chlorophenoxy)-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)cyclopropane-1-carboxamide (0.03 g, 25% yield) as a white solid. LCMS (ES) m/z =
461.3 [M+H]. 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.10 - 1.13 (m, 1 H), 1.39 -1.40 9m, 1 H), 1.84 - 1.88 (m, 1 H), 1.94 - 2.00 (m, 6 H), 3.98 - 3.99 (m, 1 H), 4.37 (s, 2 H), 6.92 -7.00 (m, 4 H), 7.25 - 7.32 (m, 4 H), 8.45 (s, 1 H), 8.56 (s, 1 H). 130 NMR
(100 MHz, DMSO-d6): 6 ppm 10.88, 22.47, 44.59, 44.96, 54.74, 55.61, 67.47, 116.95, 117.26, 125.11, 125.27, 129.24, 129.62, 157.08, 157.49, 167.27, 168.07. HPLC Purity 99.79 % at 225 nm.
- 165 -Table 5 LCMS Cmpd #
Structur Name miz , 'H-NMR (400 MHz, DMSO-d6) e [M+H]
CI
=
2-(4-chlorophenoxy)- 1.10 ¨ 1.13 (m, 1 H), 1.39 ¨
N-(3-(2-(4- 1.40 (m, 1 H), 1.84 ¨ 1.88 (m, 1 2c HNO
chlorophenoxy)aceta H), 1.94 ¨ 2.00 (m, 6 H), 3.98 ¨
'l mido)bicyclo[1.1.1]p 461.3 3.99 (m, 1 H), 4.37 (s, 2 H), entan-1- 6.92 ¨7.0 (m, 4 H), 7.25¨
7.32 o/
yl)cyclopropane-1- (m, 4 H), 8.45 (s, 1 H), 8.56 (s, o) carboxamide 1 H).
Example 3a 2-(4-chlorophenoxv)-N-(34(1-(4-chlorophenvnazetidin-3-Vnamino)bicyclo11.1.11pentan-1-vpacetamide H
N
OJLN
0 fc:( =01 * Cl Cl
Structur Name miz , 'H-NMR (400 MHz, DMSO-d6) e [M+H]
CI
=
2-(4-chlorophenoxy)- 1.10 ¨ 1.13 (m, 1 H), 1.39 ¨
N-(3-(2-(4- 1.40 (m, 1 H), 1.84 ¨ 1.88 (m, 1 2c HNO
chlorophenoxy)aceta H), 1.94 ¨ 2.00 (m, 6 H), 3.98 ¨
'l mido)bicyclo[1.1.1]p 461.3 3.99 (m, 1 H), 4.37 (s, 2 H), entan-1- 6.92 ¨7.0 (m, 4 H), 7.25¨
7.32 o/
yl)cyclopropane-1- (m, 4 H), 8.45 (s, 1 H), 8.56 (s, o) carboxamide 1 H).
Example 3a 2-(4-chlorophenoxv)-N-(34(1-(4-chlorophenvnazetidin-3-Vnamino)bicyclo11.1.11pentan-1-vpacetamide H
N
OJLN
0 fc:( =01 * Cl Cl
- 166 -OH
`OH
Boc CI
It7 Step 1 ' Step 2 TFA
CI
OH Cl."%/11%0H 0 H2N--G¨N1-1 Oj CI io N,G_N,Boc OH ¨11IMP
CI 110 Step 3 .1 Step 4 0/1 CI
NH2 'HCI CI
Step 5 C
Step 6 CI 41, Step 7 0=N
(101 H
CI
3a Step 1: Tert-butyl 3-oxoazetidine-1-carboxylate (4.0 g, 23.364 mmol, 1 equiv) at 0 C was treated with TFA (8 mL). After the reaction mixture was stirred at 0 C for 4 h, the reaction mixture was concentrated to give crude azetidin-3-one 2,2,2-trifluoroacetate (5.1 g, crude) as a light yellow gum. LCMS (ES) m/z = 72.0 [M+H]. 1H NMR (400 MHz, DMSO-d6):
ppm 5.01 (s, 4 H), 9.49 (s, 2 H).
Step 2: To a stirred solution of azetidin-3-one 2,2,2-trifluoroacetate (3.0 g, 16.189 mmol, 1 equiv, this 3 g was performed as 5X0.600 g batches) in DCM (30 mL), was added triethylamine (9.10 mL, 64.75 mmol, 4.0 equiv) followed by copper(I1)acetate (5.88 g 32.37 mmol, 2 equiv), and purged with air for 45 minutes. Then (4-chlorophenyl)boronic acid was added and again purged with air for 10 min. The reaction mixture stirred at room temperature for 5 h. After completion of the reaction, the reaction mixture was filtered through a Celite bed which was washed with DOM. The filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (20 % ethylacetate in n-Hexane) to afford the title compound 1-(4-chlorophenyl)azetidin-3-one (0.042 g, 1.43 % yield) as an off-white solid.
LCMS (ES) m/z =
`OH
Boc CI
It7 Step 1 ' Step 2 TFA
CI
OH Cl."%/11%0H 0 H2N--G¨N1-1 Oj CI io N,G_N,Boc OH ¨11IMP
CI 110 Step 3 .1 Step 4 0/1 CI
NH2 'HCI CI
Step 5 C
Step 6 CI 41, Step 7 0=N
(101 H
CI
3a Step 1: Tert-butyl 3-oxoazetidine-1-carboxylate (4.0 g, 23.364 mmol, 1 equiv) at 0 C was treated with TFA (8 mL). After the reaction mixture was stirred at 0 C for 4 h, the reaction mixture was concentrated to give crude azetidin-3-one 2,2,2-trifluoroacetate (5.1 g, crude) as a light yellow gum. LCMS (ES) m/z = 72.0 [M+H]. 1H NMR (400 MHz, DMSO-d6):
ppm 5.01 (s, 4 H), 9.49 (s, 2 H).
Step 2: To a stirred solution of azetidin-3-one 2,2,2-trifluoroacetate (3.0 g, 16.189 mmol, 1 equiv, this 3 g was performed as 5X0.600 g batches) in DCM (30 mL), was added triethylamine (9.10 mL, 64.75 mmol, 4.0 equiv) followed by copper(I1)acetate (5.88 g 32.37 mmol, 2 equiv), and purged with air for 45 minutes. Then (4-chlorophenyl)boronic acid was added and again purged with air for 10 min. The reaction mixture stirred at room temperature for 5 h. After completion of the reaction, the reaction mixture was filtered through a Celite bed which was washed with DOM. The filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (20 % ethylacetate in n-Hexane) to afford the title compound 1-(4-chlorophenyl)azetidin-3-one (0.042 g, 1.43 % yield) as an off-white solid.
LCMS (ES) m/z =
- 167 -181.9 [M+H] +.1H NMR (400 MHz, CDCI3): 6 ppm 4.65 (s, 4 H), 6.51 (d, J = 8.4 Hz, 2 H), 7.23 - 7.25 (m, 2 H).
Step 3 : To a solution of 4-chlorophenol (117 g, 914.06 mmol, 1 equiv) in water (1200 mL) at 0 C was added a solution of sodium hydroxide (146.25 g, 3656.25 mmol, 4 equiv), and stirred at 0 C for 15 min. Then 4-chloroacetic acid (120.9 g, 1279.68 mmol, 1.4 equiv) was added portion-wise at 0 C and stirred for 10 min at the same temperature.
Then the reaction mixture was heated at 100 C for 12 h. After consumption of the starting material (TLC, 5 % methanol in DCM), the reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with water (200 mL), and the aqueous layer was washed with ethyl acetate (2 X 150 mL). The aqueous layer was acidified with conc.
HCI up to pH = 1 and the precipitated product was filtered through a sintered funnel, washed with ice-cold water (100 mL), n - hexane (300 mL), and dried under high vacuum to afford 2-(4-chlorophenoxy)acetic acid (68.0 g, 40 % yield) as a white solid. LCMS (ES) M/Z = 185 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 4.65 (s, 2 H), 6.91 (d, J=
8.8 Hz, 2 H), 7.30 (d, J= 8.8 Hz, 2 H), 12.99 (bs, 1 H).
Step 4: To a solution of 2-(4-chlorophenoxy)acetic acid (33.87 g, 181.57 mmol, 1.2 equiv) in DCM ( 300 mL) at 0 C was added triethylamine (63.35 mL, 453.93 mmol, 3 equiv) and was stirred for 5 minutes at 0 C. T3P (50 wt. % in ethyl acetate) (135.1 mL, 226.96 mmol, 1.5 equiv) was added and the reaction mixture was stirred at 0 C for 10 mins. Then tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (30.0 g, 151.31 mmol, 1 equiv) was added to the reaction mixture, and the reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was diluted with water (200 mL) and extracted with DCM (2X300 mL). The combined organic layer was washed with saturated sodium bicarbonate solution (200 mL), filtered and concentrated under reduced pressure to afford the product. Following the same procedure another 30 g batch reaction of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate was performed to give the final combined yield of 108 g of tert-butyl (3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate (97.24 % yield) as an off-white solid. LCMS (ES) m/z = 311.1 [M+H] + ( t- butyl cleavage mass was observed). 1H
NMR (400MHz, DMSO-d6) 6 ppm 1.35 (s, 9 H), 2.11(s, 6 H), 4.39 (s, 2 H), 6.94 (d, J= 8.8 Hz, 2 H), 7.31 (d, J= 8.8 Hz, 2 H), 7.46 (bs, 1 H), 8.60 (s, 1 H).
Step 5: To a solution of tert-butyl (3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate (27 g, 73.57 mmol, 1 equiv) in DCM (400 mL) was added 4M HCI in 1,4-
Step 3 : To a solution of 4-chlorophenol (117 g, 914.06 mmol, 1 equiv) in water (1200 mL) at 0 C was added a solution of sodium hydroxide (146.25 g, 3656.25 mmol, 4 equiv), and stirred at 0 C for 15 min. Then 4-chloroacetic acid (120.9 g, 1279.68 mmol, 1.4 equiv) was added portion-wise at 0 C and stirred for 10 min at the same temperature.
Then the reaction mixture was heated at 100 C for 12 h. After consumption of the starting material (TLC, 5 % methanol in DCM), the reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with water (200 mL), and the aqueous layer was washed with ethyl acetate (2 X 150 mL). The aqueous layer was acidified with conc.
HCI up to pH = 1 and the precipitated product was filtered through a sintered funnel, washed with ice-cold water (100 mL), n - hexane (300 mL), and dried under high vacuum to afford 2-(4-chlorophenoxy)acetic acid (68.0 g, 40 % yield) as a white solid. LCMS (ES) M/Z = 185 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 4.65 (s, 2 H), 6.91 (d, J=
8.8 Hz, 2 H), 7.30 (d, J= 8.8 Hz, 2 H), 12.99 (bs, 1 H).
Step 4: To a solution of 2-(4-chlorophenoxy)acetic acid (33.87 g, 181.57 mmol, 1.2 equiv) in DCM ( 300 mL) at 0 C was added triethylamine (63.35 mL, 453.93 mmol, 3 equiv) and was stirred for 5 minutes at 0 C. T3P (50 wt. % in ethyl acetate) (135.1 mL, 226.96 mmol, 1.5 equiv) was added and the reaction mixture was stirred at 0 C for 10 mins. Then tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (30.0 g, 151.31 mmol, 1 equiv) was added to the reaction mixture, and the reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was diluted with water (200 mL) and extracted with DCM (2X300 mL). The combined organic layer was washed with saturated sodium bicarbonate solution (200 mL), filtered and concentrated under reduced pressure to afford the product. Following the same procedure another 30 g batch reaction of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate was performed to give the final combined yield of 108 g of tert-butyl (3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate (97.24 % yield) as an off-white solid. LCMS (ES) m/z = 311.1 [M+H] + ( t- butyl cleavage mass was observed). 1H
NMR (400MHz, DMSO-d6) 6 ppm 1.35 (s, 9 H), 2.11(s, 6 H), 4.39 (s, 2 H), 6.94 (d, J= 8.8 Hz, 2 H), 7.31 (d, J= 8.8 Hz, 2 H), 7.46 (bs, 1 H), 8.60 (s, 1 H).
Step 5: To a solution of tert-butyl (3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate (27 g, 73.57 mmol, 1 equiv) in DCM (400 mL) was added 4M HCI in 1,4-
- 168 -dioxane (90 mL) at 0 C and the reaction mixture stirred at room temperature for 12 h.
After consumption of the starting material (TLC, 5 % methanol in DCM), DCM was evaporated under reduced pressure, and the obtained solid was triturated with diethyl ether (300 mL) and dried under high vacuum to afford N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide hydrochloride. Following the same procedure another 3 batches were performed to give a total of 84 g (94.52 % yield) of N-(3-aminobicyclo[1.1.1]pentan-1-y1)-2-(4-chlorophenoxy)acetamide hydrochloride as an off-white solid. From this, 29.7 g was blended with 105.6 g, prepared by following a similar procedure, by dissolving in 500 mL of DCM and finally concentrated under reduced pressure to afford the product as an off-white solid (135.3 g crude). LCMS (ES) m/z = not ionised.' H NMR (400 MHz, DMSO-d6) 6 ppm 2.22 (s, 6 H), 4.44 (s, 2 H), 6.95 (d, J= 8.8 Hz, 2 H), 7.32 (d, J= 9.2 Hz, 2 H), 8.87 (s, 1 H), 9.0 (bs, 3 H).
Step 6: To a stirred solution of N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide hydrochloride (15 .0 g, 49.66 mmol, 1 equiv) in ethyl acetate (200 mL) at room temperature was added saturated sodium bicarbonate (300 mL).
After 30 min at room temperature, the reaction mixture was extracted with ethyl acetate (2 x 250 mL). The combined organic extract was washed with water (100 mL) and brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford the crude N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (13 g, crude) as a brown gum. 5 g of the crude material was further purified by using reversed phase HPLC purification [Column : 018, Mobile phase (A): 0.1% ammonia in water, Mobile phase (B): Acetonitrile]. The obtained material was stirred in n-pentane (40 mL) at room temperature for 1 h. Then the solid was filtered and dried to give N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (3.0 g, 60 %
yield) as a white solid. LCMS (ES) m/z = 267.1 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.90 (s, 6 H), 2.11 (s, 2 H), 4.37 (s, 2 H), 6.93 (d, J= 8.8 Hz, 2 H), 7.30 - 7.32 (m, 2 H), 8.47 (s, 1 H).
Step 7: To a stirred solution of N-(3-aminobicyclo[1.1.1]pentan-1-y1)-2-(4-chlorophenoxy)acetamide (0.070 g, 0.262 mmol, 1 equiv) in methanol (3 mL) at room temperature, 1-(4-chlorophenyl)azetidin-3-one (0.052 g, 0.288 mmol, 1.1 equiv) and acetic acid (0.05 mL) were added. After stirring for 45 minutes at room temperature, the reaction mixture was cooled to 0 C and sodium cyanoborohydride (0.032 g, 0.524 mmol, 2 equiv) was added. After the reaction stirred at room temperature for 4 h, the solvent was evaporated under reduced pressure. Obtained crude was diluted with water (5 mL) and
After consumption of the starting material (TLC, 5 % methanol in DCM), DCM was evaporated under reduced pressure, and the obtained solid was triturated with diethyl ether (300 mL) and dried under high vacuum to afford N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide hydrochloride. Following the same procedure another 3 batches were performed to give a total of 84 g (94.52 % yield) of N-(3-aminobicyclo[1.1.1]pentan-1-y1)-2-(4-chlorophenoxy)acetamide hydrochloride as an off-white solid. From this, 29.7 g was blended with 105.6 g, prepared by following a similar procedure, by dissolving in 500 mL of DCM and finally concentrated under reduced pressure to afford the product as an off-white solid (135.3 g crude). LCMS (ES) m/z = not ionised.' H NMR (400 MHz, DMSO-d6) 6 ppm 2.22 (s, 6 H), 4.44 (s, 2 H), 6.95 (d, J= 8.8 Hz, 2 H), 7.32 (d, J= 9.2 Hz, 2 H), 8.87 (s, 1 H), 9.0 (bs, 3 H).
Step 6: To a stirred solution of N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide hydrochloride (15 .0 g, 49.66 mmol, 1 equiv) in ethyl acetate (200 mL) at room temperature was added saturated sodium bicarbonate (300 mL).
After 30 min at room temperature, the reaction mixture was extracted with ethyl acetate (2 x 250 mL). The combined organic extract was washed with water (100 mL) and brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford the crude N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (13 g, crude) as a brown gum. 5 g of the crude material was further purified by using reversed phase HPLC purification [Column : 018, Mobile phase (A): 0.1% ammonia in water, Mobile phase (B): Acetonitrile]. The obtained material was stirred in n-pentane (40 mL) at room temperature for 1 h. Then the solid was filtered and dried to give N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (3.0 g, 60 %
yield) as a white solid. LCMS (ES) m/z = 267.1 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.90 (s, 6 H), 2.11 (s, 2 H), 4.37 (s, 2 H), 6.93 (d, J= 8.8 Hz, 2 H), 7.30 - 7.32 (m, 2 H), 8.47 (s, 1 H).
Step 7: To a stirred solution of N-(3-aminobicyclo[1.1.1]pentan-1-y1)-2-(4-chlorophenoxy)acetamide (0.070 g, 0.262 mmol, 1 equiv) in methanol (3 mL) at room temperature, 1-(4-chlorophenyl)azetidin-3-one (0.052 g, 0.288 mmol, 1.1 equiv) and acetic acid (0.05 mL) were added. After stirring for 45 minutes at room temperature, the reaction mixture was cooled to 0 C and sodium cyanoborohydride (0.032 g, 0.524 mmol, 2 equiv) was added. After the reaction stirred at room temperature for 4 h, the solvent was evaporated under reduced pressure. Obtained crude was diluted with water (5 mL) and
- 169 -extracted with ethyl acetate (2 x 10 mL). The combined organic extract was washed with water (10 mL) and brine (5 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford the crude product. The crude material was purified by flash column chromatography using a silica gel column where the product was eluted along with a polar impurity at 2 - 3 c)/0 methanol in DCM. This mixture was further purified by using preparative TLC (2.5 % methanol in DCM) to afford 2-(4-chlorophenoxy)-N-(3-((1-(4-chlorophenyl)azetidin-3-yl)am ino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.028 g, 24.77 % yield) as an off-white solid. LCMS (ES) m/z =
432.3 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.93 (s, 6 H), 3.12 (d, J= 10.0 Hz, 1 H), 3.37 (t, J= 6.8 Hz, 2 H), 3.62 - 3.68 (m, 1 H), 4.01 (t, J= 6.8 Hz, 2 H), 4.44 (s, 2 H), 6.38 (d, J=
8.8 Hz, 2 H), 6.94 (d, J= 8.8 Hz, 2 H), 7.14 (d, J= 8.4 Hz, 2 H), 7.32 (d, J=
8.8 Hz, 2 H), 8.56 (s, 1 H).
Table 6 LCMS 1H-NMR (400 MHz, DMSO-Cmpd # Structure Name miz d6) [M+H]
CI
* 2-(4-chlorophenoxy)-N-(3- 1.93 (s, 6 H), 3.12 (d, J =
r. IN
)-1 ((1-(4- 10.0 Hz, 1 H), 3.37 (t, J= 6.8 HN
k chlorophenyl)azetidin-3-Hz, 2 H), 3.62 - 3.68 (m, 1 3a yl)amino)bicyclo[1.1.1]pen tan-1-yl)acetamide 432.3 H), 4.01 (t, J=
6.8 Hz, 2 H), 4.44 (s, 2 H), 6.38 (d, J = 8.8 o,/
Hz, 2 H), 6.94 (d, J= 8.8 Hz, o) 2 H), 7.14(d, J=
8.4 Hz, 2 * H), 7.32 (d, J= 8.8 Hz, 2 H), 8.56 (s, 1 H).
Example 3b 2-(4-chlorophenoxv)-N-(3-(3-(4-chlorophenoxv)azetidin-l-vnbicycloll.1.11pentan-Vnacetamide
432.3 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.93 (s, 6 H), 3.12 (d, J= 10.0 Hz, 1 H), 3.37 (t, J= 6.8 Hz, 2 H), 3.62 - 3.68 (m, 1 H), 4.01 (t, J= 6.8 Hz, 2 H), 4.44 (s, 2 H), 6.38 (d, J=
8.8 Hz, 2 H), 6.94 (d, J= 8.8 Hz, 2 H), 7.14 (d, J= 8.4 Hz, 2 H), 7.32 (d, J=
8.8 Hz, 2 H), 8.56 (s, 1 H).
Table 6 LCMS 1H-NMR (400 MHz, DMSO-Cmpd # Structure Name miz d6) [M+H]
CI
* 2-(4-chlorophenoxy)-N-(3- 1.93 (s, 6 H), 3.12 (d, J =
r. IN
)-1 ((1-(4- 10.0 Hz, 1 H), 3.37 (t, J= 6.8 HN
k chlorophenyl)azetidin-3-Hz, 2 H), 3.62 - 3.68 (m, 1 3a yl)amino)bicyclo[1.1.1]pen tan-1-yl)acetamide 432.3 H), 4.01 (t, J=
6.8 Hz, 2 H), 4.44 (s, 2 H), 6.38 (d, J = 8.8 o,/
Hz, 2 H), 6.94 (d, J= 8.8 Hz, o) 2 H), 7.14(d, J=
8.4 Hz, 2 * H), 7.32 (d, J= 8.8 Hz, 2 H), 8.56 (s, 1 H).
Example 3b 2-(4-chlorophenoxv)-N-(3-(3-(4-chlorophenoxv)azetidin-l-vnbicycloll.1.11pentan-Vnacetamide
- 170 -o oAN ci CI
HO
OH
r....õNE12 soe id J1 ijo.OH ci Coe Step 2 B'e=Nj":1 Step 3 ¨.Nix step 4 Step 1 'N
ULM
d.j.. ci 31. FF,(11,0H iry CI IW
-IP. Cjry,L.-Ii Step 5 CI Step 6 H
3b Step 1: To a solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (3.0 g, 15.15 mmol, 1 equiv) in IPA (30 mL) was added 2-(chloromethyl)oxirane (1.4 g, 15.15 mmol, 1 equiv) at 0 C and the reaction mixture was stirred at room temperature for 48 h.
After this time, solvent was evaparated under reduced pressure to give tert-butyl (3-((3-chloro-2-hydroxypropyl)amino)bicyclo[1.1.1]pentan-1-yl)carbamate (crude yield 4.4 g, 100%), which was taken to the next step without further purification. LCMS
(ES) m/z = 291 [M+H] .
Step 2: To a solution of tert-butyl (3-((3-chloro-2-hydroxypropyl)amino)bicyclo[1.1.1]pentan-1-yl)carbamate (4.4 g, 15.20 mmol, 1 equiv) in diethyl ether (45 mL) was added potassium hydroxide (1.7 g, 30.40 mmol, 2 equiv) at 0 C.
-- After the reaction mixture was stirred at room temperature for 16h, solvent was evaporated under reduced pressure to afford the crude product. The obtained crude product was purified by Combiflash using a 40 g silica gel cartridge with gradient elution of 0% Me0H
in DCM to 5% Me0H/DCM over a 30 min period to afford tert-butyl (3-((oxiran-2-ylmethyl)amino)bicyclo[1.1.1]pentan-1-yl)carbamate (colorless syrup, 1.27 g, 33%). LCMS
-- (ES) m/z = 255 [M+H] . 1H NMR (400 MHz, CDCI3) 6 ppm 1.43 (s, 9 H), 2.02 (s, 6 H), 2.58 ¨2.63 (m, 2 H), 2.76 ¨2.78 (m, 1 H), 2.89 ¨2.93 (m, 1 H), 3.05¨ 3.08 (m, 1 H), 4.88 (bs, 1 H).
Step 3: To a solution of tert-butyl (3-((oxiran-2-ylmethyl)amino)bicyclo[1.1.1]pentan-1-yl)carbamate (4.4 g, 15.20 mmol, 1 equiv) in 1,4-dioxane (45 mL) was added magnesium
HO
OH
r....õNE12 soe id J1 ijo.OH ci Coe Step 2 B'e=Nj":1 Step 3 ¨.Nix step 4 Step 1 'N
ULM
d.j.. ci 31. FF,(11,0H iry CI IW
-IP. Cjry,L.-Ii Step 5 CI Step 6 H
3b Step 1: To a solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (3.0 g, 15.15 mmol, 1 equiv) in IPA (30 mL) was added 2-(chloromethyl)oxirane (1.4 g, 15.15 mmol, 1 equiv) at 0 C and the reaction mixture was stirred at room temperature for 48 h.
After this time, solvent was evaparated under reduced pressure to give tert-butyl (3-((3-chloro-2-hydroxypropyl)amino)bicyclo[1.1.1]pentan-1-yl)carbamate (crude yield 4.4 g, 100%), which was taken to the next step without further purification. LCMS
(ES) m/z = 291 [M+H] .
Step 2: To a solution of tert-butyl (3-((3-chloro-2-hydroxypropyl)amino)bicyclo[1.1.1]pentan-1-yl)carbamate (4.4 g, 15.20 mmol, 1 equiv) in diethyl ether (45 mL) was added potassium hydroxide (1.7 g, 30.40 mmol, 2 equiv) at 0 C.
-- After the reaction mixture was stirred at room temperature for 16h, solvent was evaporated under reduced pressure to afford the crude product. The obtained crude product was purified by Combiflash using a 40 g silica gel cartridge with gradient elution of 0% Me0H
in DCM to 5% Me0H/DCM over a 30 min period to afford tert-butyl (3-((oxiran-2-ylmethyl)amino)bicyclo[1.1.1]pentan-1-yl)carbamate (colorless syrup, 1.27 g, 33%). LCMS
-- (ES) m/z = 255 [M+H] . 1H NMR (400 MHz, CDCI3) 6 ppm 1.43 (s, 9 H), 2.02 (s, 6 H), 2.58 ¨2.63 (m, 2 H), 2.76 ¨2.78 (m, 1 H), 2.89 ¨2.93 (m, 1 H), 3.05¨ 3.08 (m, 1 H), 4.88 (bs, 1 H).
Step 3: To a solution of tert-butyl (3-((oxiran-2-ylmethyl)amino)bicyclo[1.1.1]pentan-1-yl)carbamate (4.4 g, 15.20 mmol, 1 equiv) in 1,4-dioxane (45 mL) was added magnesium
- 171 -bromide (1.7 g, 30.40 mmol, 2 equiv) at room temperature. After the reaction mixture was stirred at 90 C for 16 h, the solvent was evaporated under reduced pressure to afford the crude product. The obtained crude product was purified by Combiflash using a 24 g silica gel cartridge with gradient elution of 0% Me0H in DCM to 5% Me0H/DCM over a 30 min period to afford tert-butyl (3-(3-hydroxyazetidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (colorless syrup, 0.42 g, 32%). LCMS (ES) m/z = 255 [M+H]+ 1H NMR (400 MHz, CDCI3) 6 ppm 1.43 (s, 9 H), 1.95 (s, 6 H), 2.99 - 3.02 (m, 2 H), 3.54 - 3.57 (m, 2 H), 4.40 - 4.54 (m, 1 H), 4.89 (bs, 1 H).
Step 4: To a solution of tert-butyl (3-(3-hydroxyazetidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.4 g, 1.57 mmol, 1 equiv) and 4-chlorophenol (0.22 g, 1.73 mmol, 1.1 equiv) in DCM (10 mL) was added triphenylphosphine (0.61 g, 2.35 mmol, 1.5 equiv) followed by DIAD (0.47 g, 2.35 mmol, 1.5 equiv) at 0 C. After the reaction mixture was stirred at room temperature for 16 h, the solvent was evaporated under reduced pressure to afford the crude product. The obtained crude product was purified by Combiflash using a 24 g silica gel cartridge with gradient elution of 0% Me0H in DCM to 5% Me0H/DCM over a 30 min period to afford tert-butyl (3-(3-(4-chlorophenoxy)azetidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.4g). LCMS (ES) m/z = 365 [M+H] . 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.34 (s, 9 H), 1.78 (s, 6 H), 3.01 - 3.04 (m, 2 H), 3.58 -3.63 (m, 2 H), 4.72 -4.75 (m, 1 H), 6.82 (d, J= 8.8 Hz, 2 H), 7.28 (d, J= 8.4 Hz, 2 H).
Step 5: To a solution of tert-butyl (3-(3-(4-chlorophenoxy)azetidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.4 g, 1.09 mmol, 1 equiv) in DCM (4 mL) was added 2,2,2-trifluoroacetic acid (2 mL) at 0 C. After the reaction mixture was stirred at room temperature for 16 h, the solvent was evaporated under reduced pressure to afford the crude product. The obtained crude product was triturated with diethyl ether (3 X 25 mL) to give 3-(3-(4-chlorophenoxy)azetidin-1-yl)bicyclo[1.1.1]pentan-1-amine 2,2,2-trifluoroacetate (0.21 g).
LCMS (ES) m/z = 265.1 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.05 (s, 6 H), 3.49 (bs, 2 H), 3.99 (bs, 2 H), 4.87 (bs, 1 H), 6.85 (d, J= 8.4 Hz, 2 H), 7.32 (d, J= 8.8 Hz, 2 H), 8.69 (bs, 3 H).
Step 6: To a solution of 2-(4-chlorophenoxy)acetic acid (0.12 g, 0.63 mmol, 1.2 equiv) in dichloromethane (4 mL) was added triethylamine (0.11 g, 1.04 mmol, 2.0 equiv) at room temperature. After stirring for 5 min, T3P (50 wt. % in ethyl acetate) (0.24 g, 0.78 mmol, 1.5 equiv) was added to the reaction mixture at room temperature and stirred for 10 min followed by 3-(3-(4-chlorophenoxy)azetidin-1-yl)bicyclo[1.1.1]pentan-1-amine 2,2,2-
Step 4: To a solution of tert-butyl (3-(3-hydroxyazetidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.4 g, 1.57 mmol, 1 equiv) and 4-chlorophenol (0.22 g, 1.73 mmol, 1.1 equiv) in DCM (10 mL) was added triphenylphosphine (0.61 g, 2.35 mmol, 1.5 equiv) followed by DIAD (0.47 g, 2.35 mmol, 1.5 equiv) at 0 C. After the reaction mixture was stirred at room temperature for 16 h, the solvent was evaporated under reduced pressure to afford the crude product. The obtained crude product was purified by Combiflash using a 24 g silica gel cartridge with gradient elution of 0% Me0H in DCM to 5% Me0H/DCM over a 30 min period to afford tert-butyl (3-(3-(4-chlorophenoxy)azetidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.4g). LCMS (ES) m/z = 365 [M+H] . 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.34 (s, 9 H), 1.78 (s, 6 H), 3.01 - 3.04 (m, 2 H), 3.58 -3.63 (m, 2 H), 4.72 -4.75 (m, 1 H), 6.82 (d, J= 8.8 Hz, 2 H), 7.28 (d, J= 8.4 Hz, 2 H).
Step 5: To a solution of tert-butyl (3-(3-(4-chlorophenoxy)azetidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.4 g, 1.09 mmol, 1 equiv) in DCM (4 mL) was added 2,2,2-trifluoroacetic acid (2 mL) at 0 C. After the reaction mixture was stirred at room temperature for 16 h, the solvent was evaporated under reduced pressure to afford the crude product. The obtained crude product was triturated with diethyl ether (3 X 25 mL) to give 3-(3-(4-chlorophenoxy)azetidin-1-yl)bicyclo[1.1.1]pentan-1-amine 2,2,2-trifluoroacetate (0.21 g).
LCMS (ES) m/z = 265.1 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.05 (s, 6 H), 3.49 (bs, 2 H), 3.99 (bs, 2 H), 4.87 (bs, 1 H), 6.85 (d, J= 8.4 Hz, 2 H), 7.32 (d, J= 8.8 Hz, 2 H), 8.69 (bs, 3 H).
Step 6: To a solution of 2-(4-chlorophenoxy)acetic acid (0.12 g, 0.63 mmol, 1.2 equiv) in dichloromethane (4 mL) was added triethylamine (0.11 g, 1.04 mmol, 2.0 equiv) at room temperature. After stirring for 5 min, T3P (50 wt. % in ethyl acetate) (0.24 g, 0.78 mmol, 1.5 equiv) was added to the reaction mixture at room temperature and stirred for 10 min followed by 3-(3-(4-chlorophenoxy)azetidin-1-yl)bicyclo[1.1.1]pentan-1-amine 2,2,2-
- 172 -trifluoroacetate (0.2 g, 0.52 mmol, 1.0 equiv) and triethylamine (0.1 g, 1.04 mmol, 2.0 equiv) in DCM (3 mL). After the reaction mixture stirred at room temperature for 16 h, the reaction mixture was diluted with water (10 mL) and extracted with DCM (2 X 25 mL). The combined organic extract was washed with saturated aqueous NaHCO3 solution (10 mL), brine solution (7 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude material was purified by flash column chromatography using a silica gel column where the product along with a very close impurity was eluted at 2 - 3 % methanol in DCM. Finally, this crude product was purified by preparative HPLC to afford 2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)azetidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.04 g, 17.5%
yield) as a white solid. LCMS (ES) m/z = 433.3 [M+H] . 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.91 (s, 6 H), 3.04 - 3.08 (m, 2 H), 3.62 - 3.63 (m, 2 H), 4.40 (s, 2 H), 4.74 - 4.76 (m, 1 H), 6.83 (d, J= 8.4 Hz, 2 H), 6.94 (d, J= 8.4 Hz, 2 H), 7.28 - 7.32 (m, 4 H), 8.64 (s, 1 H).
Table 7 LCMS
Cmpd # Structure Name miz H-NMR (400 MHz, DMSO-d6) [M+H]
o 2-(4- 1.91(s, 6 H), 3.04 - 3.08 (m, 2 chlorophenoxy)- H), 3.62 - 3.63 (m, 2 H), 4.40 3b N-(3-(3-(4- (s, 2 H), 4.74 - 4.76 (m, 1 H), chlorophenoxy)az 43" 6.83 (d, J= 8.4 Hz, 2 H), 6.94 etidin-1- (d, J= 8.4 Hz, 2 H), 7.28 -7.32 yl)bicyclo[1.1.1]p (m, 4 H), 8.64 (s, 1 H).
141 entan-1-c yl)acetamide Example 4a 2-(4-chlorophenoxv)-N-(3-(2-((5,6,7,8-tetrahvdronaphthalen-2-VI)oxv)acetamido)bicycloll.1.11pentan-1-vpacetamide
yield) as a white solid. LCMS (ES) m/z = 433.3 [M+H] . 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.91 (s, 6 H), 3.04 - 3.08 (m, 2 H), 3.62 - 3.63 (m, 2 H), 4.40 (s, 2 H), 4.74 - 4.76 (m, 1 H), 6.83 (d, J= 8.4 Hz, 2 H), 6.94 (d, J= 8.4 Hz, 2 H), 7.28 - 7.32 (m, 4 H), 8.64 (s, 1 H).
Table 7 LCMS
Cmpd # Structure Name miz H-NMR (400 MHz, DMSO-d6) [M+H]
o 2-(4- 1.91(s, 6 H), 3.04 - 3.08 (m, 2 chlorophenoxy)- H), 3.62 - 3.63 (m, 2 H), 4.40 3b N-(3-(3-(4- (s, 2 H), 4.74 - 4.76 (m, 1 H), chlorophenoxy)az 43" 6.83 (d, J= 8.4 Hz, 2 H), 6.94 etidin-1- (d, J= 8.4 Hz, 2 H), 7.28 -7.32 yl)bicyclo[1.1.1]p (m, 4 H), 8.64 (s, 1 H).
141 entan-1-c yl)acetamide Example 4a 2-(4-chlorophenoxv)-N-(3-(2-((5,6,7,8-tetrahvdronaphthalen-2-VI)oxv)acetamido)bicycloll.1.11pentan-1-vpacetamide
- 173 -H
OAN ro CI io H
o o OH
0)k OAOH
Or Step 1 0. 311....tep 2 0 i. 0 .)k NH2 ci W N
H
N OW
DV 0,AN,i,- ro Step 3 LW H
CI 4a Step 1: To a solution 5,6,7,8-tetrahydronaphthalen-2-ol (0.5 g, 3.373 mmol 1 equiv) in DMF (8 mL) was added K2003 (0.69 g, 5.059 mmol, 1.5 equiv) followed by addition of ethyl bromoacetate (0.44 mL, 4.048 mmol, 1.2 equiv) dropwise at 0 C. The reaction mixture was allowed to stir at 80 C for 4 h. After consumption of the starting material (TLC, 5 A, Et0Ac in Hexane), the reaction mixture was allowed to cool to room temperature, diluted with water (20 mL) and extracted with Et0Ac (2 x 25 mL). The combined organic layer was .. washed with water (2 x 10 mL), brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to get the crude product. The crude product was purified by flash column chromatography using a silica gel column (9.8 A, ethyl acetate in hexane) to obtain the title compound ethyl 2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetate (0.35 g, 44 A, yield) as a gum. 1H NMR (400 MHz, CDCI3) 6 ppm 1.31 ¨ 1.26 (m, 3 H), 1.76 (s, 4 H), 2.70 (d, J = 13.6 Hz, 4 H), 4.26 ¨ 4.24 (m, 2 H), 4.57 (s, 2 H), 6.61 (s, 1 H). 6.67 (d, J= 8.4 Hz, 1 H), 6.96 (d, J= 8 Hz, 1H).
Step 2: To a solution of ethyl 2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetate (0.35 g 1.495 mmol, 1 equiv) in a mixture of THF (4 mL) and water (1 mL) was added Li0H.H20 (0.154 g, 3.739mm01 2.5 equiv) at 0 C. The resulting mixture was stirred at room temperature for 1 h. THF was removed under reduced pressure and the residue was diluted with water (10 mL), and washed with Et20 (20 mL). The aqueous layer was acidified
OAN ro CI io H
o o OH
0)k OAOH
Or Step 1 0. 311....tep 2 0 i. 0 .)k NH2 ci W N
H
N OW
DV 0,AN,i,- ro Step 3 LW H
CI 4a Step 1: To a solution 5,6,7,8-tetrahydronaphthalen-2-ol (0.5 g, 3.373 mmol 1 equiv) in DMF (8 mL) was added K2003 (0.69 g, 5.059 mmol, 1.5 equiv) followed by addition of ethyl bromoacetate (0.44 mL, 4.048 mmol, 1.2 equiv) dropwise at 0 C. The reaction mixture was allowed to stir at 80 C for 4 h. After consumption of the starting material (TLC, 5 A, Et0Ac in Hexane), the reaction mixture was allowed to cool to room temperature, diluted with water (20 mL) and extracted with Et0Ac (2 x 25 mL). The combined organic layer was .. washed with water (2 x 10 mL), brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to get the crude product. The crude product was purified by flash column chromatography using a silica gel column (9.8 A, ethyl acetate in hexane) to obtain the title compound ethyl 2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetate (0.35 g, 44 A, yield) as a gum. 1H NMR (400 MHz, CDCI3) 6 ppm 1.31 ¨ 1.26 (m, 3 H), 1.76 (s, 4 H), 2.70 (d, J = 13.6 Hz, 4 H), 4.26 ¨ 4.24 (m, 2 H), 4.57 (s, 2 H), 6.61 (s, 1 H). 6.67 (d, J= 8.4 Hz, 1 H), 6.96 (d, J= 8 Hz, 1H).
Step 2: To a solution of ethyl 2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetate (0.35 g 1.495 mmol, 1 equiv) in a mixture of THF (4 mL) and water (1 mL) was added Li0H.H20 (0.154 g, 3.739mm01 2.5 equiv) at 0 C. The resulting mixture was stirred at room temperature for 1 h. THF was removed under reduced pressure and the residue was diluted with water (10 mL), and washed with Et20 (20 mL). The aqueous layer was acidified
- 174 -with 1 N HCI up to pH -2 at 0 C and then extracted with Et0Ac (2 x 15 mL).
The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain the title compound 2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetic acid (0.237 g, 79% yield) as a white solid. LCMS (ES) m/z =
205.1 [M-H].1H
NMR (400 MHz, DMSO-d6) 6 ppm 1.67 (s, 4 H), 2.64 - 2.60 (m, 4 H), 4.56 (s, 2 H), 6.55 (s, 1 H), 6.60 (d, J=8 Hz 1 H), 6.91 (s, J=8.4 Hz, 1H), 12.85 (s, 1H). This compound was directly taken to the next step without further purification.
Step 3: To a stirred solution of 2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetic acid (0.11 g, 0.563 mmol, 1.5 equiv) and triethylamine (0.20 mL, 1.5 mmol, 4.0 equiv) in dichloromethane (4 mL) was added propylphosphonic anhydride solution (T3P , 50 wt. `)/0 in ethyl acetate) (0.477 mL, 0.75 mmol, 2 equiv) at 0 C and stirred for 10 min. Then a solution of N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (0.1 g, 0.375 mmol, 1.0 equiv) in dichloromethane (5 mL) was added to the reaction mixture at 0 C. The reaction mixture was then stirred at room temperature for 16 h. After consumption of the starting material (TLC, 5 `)/0 Me0H in DCM), the reaction mixture was diluted with DCM (100 mL), washed with saturated aqueous sodium bicarbonate solution (2 x 20 mL) and water (2 x 20 mL), brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford the crude product. The obtained crude was purified by flash column chromatography (2 - 3 `)/0 of methanol in dichloromethane) to afford the title compound 2-(4-chlorophenoxy)-N-(3-(2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide (0.032 g, 18% yield) as an off-white solid. LCMS (ES) m/z = 455.4 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.68 (s, 4 H), 2.24 (s, 6 H), 2.65 - 2.61 (m, 4 H), 4.32 (s, 2 H), 4.41 (s, 2 H), 6.66 - 6.62 (m, 2 H), 6.96 -6.92 (m, 3 H), 7.32 (d, J= 8.8 Hz, 2 H), 8.58 (s, 1 H), 8.65 (s, 1 H).
The Compounds of Examples 4b to 4d were prepared generally according to the procedure described above for Example 4a.
The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain the title compound 2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetic acid (0.237 g, 79% yield) as a white solid. LCMS (ES) m/z =
205.1 [M-H].1H
NMR (400 MHz, DMSO-d6) 6 ppm 1.67 (s, 4 H), 2.64 - 2.60 (m, 4 H), 4.56 (s, 2 H), 6.55 (s, 1 H), 6.60 (d, J=8 Hz 1 H), 6.91 (s, J=8.4 Hz, 1H), 12.85 (s, 1H). This compound was directly taken to the next step without further purification.
Step 3: To a stirred solution of 2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetic acid (0.11 g, 0.563 mmol, 1.5 equiv) and triethylamine (0.20 mL, 1.5 mmol, 4.0 equiv) in dichloromethane (4 mL) was added propylphosphonic anhydride solution (T3P , 50 wt. `)/0 in ethyl acetate) (0.477 mL, 0.75 mmol, 2 equiv) at 0 C and stirred for 10 min. Then a solution of N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (0.1 g, 0.375 mmol, 1.0 equiv) in dichloromethane (5 mL) was added to the reaction mixture at 0 C. The reaction mixture was then stirred at room temperature for 16 h. After consumption of the starting material (TLC, 5 `)/0 Me0H in DCM), the reaction mixture was diluted with DCM (100 mL), washed with saturated aqueous sodium bicarbonate solution (2 x 20 mL) and water (2 x 20 mL), brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford the crude product. The obtained crude was purified by flash column chromatography (2 - 3 `)/0 of methanol in dichloromethane) to afford the title compound 2-(4-chlorophenoxy)-N-(3-(2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide (0.032 g, 18% yield) as an off-white solid. LCMS (ES) m/z = 455.4 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.68 (s, 4 H), 2.24 (s, 6 H), 2.65 - 2.61 (m, 4 H), 4.32 (s, 2 H), 4.41 (s, 2 H), 6.66 - 6.62 (m, 2 H), 6.96 -6.92 (m, 3 H), 7.32 (d, J= 8.8 Hz, 2 H), 8.58 (s, 1 H), 8.65 (s, 1 H).
The Compounds of Examples 4b to 4d were prepared generally according to the procedure described above for Example 4a.
- 175 -Table 8 LCMS , 'H-NMR (400 MHz, DMSO-d6) Cmpd # Structure Name miz [M+H]
e is2-(4-chlorophenoxy)-= N-(3-(2-((5,6,7,8-1.68 (s, 4 H), 2.24 (s, 6 H), /C tetrahydronaphthale HN 0 2.65 - 2.61 (m, 4 H), 4.32 (s, n-2-4a H), 4.41 (s, 2 H), 6.66 -6.62 yl)oxy)acetamido)bic 455.4 (m, 2 H), 6.96 - 6.92 (m, 3 H), o 41-1 yclo[1.1.1]pentan-1-7.32 (d, J= 8.8 Hz, 2 H), 8.58 yl)acetamide ol/ (s, 1 H), 8.65 (s, 1 H).
CI
2.22 (s, 6 H), 3.39 - 3.46 (m, 2 5-chloro-N-(3-(2-(4- H), 4.40 (s, 2 H), 5.06 - 5.11 HN chlorophenoxy)aceta (m, 1 H), 6.81 (d, J= 8.4 Hz, 1 4b mido)bicyclo[1.1.1]p H), 6.95 (d, J= 8.8 Hz, 2 H), 447.3 entan-1-yI)-2,3-o 7.13 (d, J= 8.4 Hz, 1 H), 7.24 dihydrobenzofuran- (s, 1 H), 7.32 (d, J= 8.4 Hz, 2 o) 2-carboxamide H), 8.64 (s, 1 H), 8.74 (s, 1 H).
e is2-(4-chlorophenoxy)-= N-(3-(2-((5,6,7,8-1.68 (s, 4 H), 2.24 (s, 6 H), /C tetrahydronaphthale HN 0 2.65 - 2.61 (m, 4 H), 4.32 (s, n-2-4a H), 4.41 (s, 2 H), 6.66 -6.62 yl)oxy)acetamido)bic 455.4 (m, 2 H), 6.96 - 6.92 (m, 3 H), o 41-1 yclo[1.1.1]pentan-1-7.32 (d, J= 8.8 Hz, 2 H), 8.58 yl)acetamide ol/ (s, 1 H), 8.65 (s, 1 H).
CI
2.22 (s, 6 H), 3.39 - 3.46 (m, 2 5-chloro-N-(3-(2-(4- H), 4.40 (s, 2 H), 5.06 - 5.11 HN chlorophenoxy)aceta (m, 1 H), 6.81 (d, J= 8.4 Hz, 1 4b mido)bicyclo[1.1.1]p H), 6.95 (d, J= 8.8 Hz, 2 H), 447.3 entan-1-yI)-2,3-o 7.13 (d, J= 8.4 Hz, 1 H), 7.24 dihydrobenzofuran- (s, 1 H), 7.32 (d, J= 8.4 Hz, 2 o) 2-carboxamide H), 8.64 (s, 1 H), 8.74 (s, 1 H).
- 176 -1'W 2-(bicyclo[4.2.0]octa-=
lileL 1(6),2,4-trien-3-2.24 (s, 6 H), 3.03 (d, J = 3.2 o yloxy)-N-(3-(2-(4-Hz, 4 H), 4.33 (s, 2 H), 4.41 (s, 4c chlorophenoxy)aceta 427.3 2 H), 6.70 - 6.76 (m, 2 H), 6.95 mido)bicyclo[1.1.1]p 41:1 (d, J= 8.8 Hz, 3 H), 7.32 (d, J=
entan-1-o) 8.8 Hz, 2 H), 8.59 (s, 1 H), 8.66 yl)acetamide 4 (s, 1 H).
=
*
=
( 2-(4-chlorophenoxy)- 1.84 - 1.87 (m, 2 H), 2.24 (s, 6 HN/sD N-(3-(2-(chroman-6- H), 2.66 - 2.69 (m, 2 H), 4.02 -4d yloxy)acetamido)bicy 457.3 4.05 (m, 2 H), 4.28 (s, 2 H), clo[1.1.1]pentan-1- 4.41 (s, 2 H), 6.61 -6.67 (m, 3 k o yl)acetamide H), 6.95 (d, J = 8.8 Hz, 2 H), 7.32 (d, J = 8.4 Hz, 2 H), 8.56 4 (s, 1 H), 8.61 (s, 1 H).
Example 4e N-(3-(5-chloroisoindolin-2-yObicyclo11.1.11pentan-1-y1)-2-(4-chlorophenoxy)acetamide CI
Ilit HisVCer rµO
CI 00)
lileL 1(6),2,4-trien-3-2.24 (s, 6 H), 3.03 (d, J = 3.2 o yloxy)-N-(3-(2-(4-Hz, 4 H), 4.33 (s, 2 H), 4.41 (s, 4c chlorophenoxy)aceta 427.3 2 H), 6.70 - 6.76 (m, 2 H), 6.95 mido)bicyclo[1.1.1]p 41:1 (d, J= 8.8 Hz, 3 H), 7.32 (d, J=
entan-1-o) 8.8 Hz, 2 H), 8.59 (s, 1 H), 8.66 yl)acetamide 4 (s, 1 H).
=
*
=
( 2-(4-chlorophenoxy)- 1.84 - 1.87 (m, 2 H), 2.24 (s, 6 HN/sD N-(3-(2-(chroman-6- H), 2.66 - 2.69 (m, 2 H), 4.02 -4d yloxy)acetamido)bicy 457.3 4.05 (m, 2 H), 4.28 (s, 2 H), clo[1.1.1]pentan-1- 4.41 (s, 2 H), 6.61 -6.67 (m, 3 k o yl)acetamide H), 6.95 (d, J = 8.8 Hz, 2 H), 7.32 (d, J = 8.4 Hz, 2 H), 8.56 4 (s, 1 H), 8.61 (s, 1 H).
Example 4e N-(3-(5-chloroisoindolin-2-yObicyclo11.1.11pentan-1-y1)-2-(4-chlorophenoxy)acetamide CI
Ilit HisVCer rµO
CI 00)
- 177 -a .47NH2 ci 0 Br lit HN Br rko _3111.
Step 1 (ro CI *
401 4e ci Step 1: To a stirred solution of N-(3-am inobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (0.15 g, 0.56 mmol, 1.0 equivalent) in acetonitrile (3 mL), was added triethylamine (0.31 mL) and 1,2-bis(bromomethyl)-4-chlorobenzene (0.167 g, 0.56 mmol) in a sealed tube at room temperature. The reaction mixture was heated at for 1 h.The reaction mixture was evaporated by using high vacuum to afford the crude product. The crude product was purified by flash column chromatography (Combiflashe) using a silica gel column (2% methanol in DCM) to afford the product as a white solid. The solid was washed with Me0H (2mL) and submitted for LCMS. From LCMS data the desired product was 98% pure with a 2% deschloro product observed. To remove the impurity the crude product was purified by preparative HPLC [Column: X ¨
Bridge 018 (100mm X 4.6mm X 3.5mic), Mobile phase (A): 0.1% Ammonia in water, Mobile phase (B):
ACN, Flow rate: 1.0 mL/min, T/ /013: 0/20, 7/60, 13/20, 15/20]. Fractions containing product were concentrated under reduced pressure to afford the title compound N-(3-(5-chloroisoindolin-2-yl)bicyclo[1.1.1]pentan-1-y1)-2-(4-chlorophenoxy)acetamide(0.08 g, 35%
yield) as a white solid. LCMS (ES) m/z = 403.3 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.04 (s, 6 H), 3.85 ¨ 3.87 (m, 4 H), 4.41 (s, 2 H), 6.95 (d, J = 8.8 Hz, 2 H), 7.22 (s, 2 H), 7.32 (d, J= 8.8 Hz, 3 H), 8.64 (s, 1 H).
Step 1 (ro CI *
401 4e ci Step 1: To a stirred solution of N-(3-am inobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (0.15 g, 0.56 mmol, 1.0 equivalent) in acetonitrile (3 mL), was added triethylamine (0.31 mL) and 1,2-bis(bromomethyl)-4-chlorobenzene (0.167 g, 0.56 mmol) in a sealed tube at room temperature. The reaction mixture was heated at for 1 h.The reaction mixture was evaporated by using high vacuum to afford the crude product. The crude product was purified by flash column chromatography (Combiflashe) using a silica gel column (2% methanol in DCM) to afford the product as a white solid. The solid was washed with Me0H (2mL) and submitted for LCMS. From LCMS data the desired product was 98% pure with a 2% deschloro product observed. To remove the impurity the crude product was purified by preparative HPLC [Column: X ¨
Bridge 018 (100mm X 4.6mm X 3.5mic), Mobile phase (A): 0.1% Ammonia in water, Mobile phase (B):
ACN, Flow rate: 1.0 mL/min, T/ /013: 0/20, 7/60, 13/20, 15/20]. Fractions containing product were concentrated under reduced pressure to afford the title compound N-(3-(5-chloroisoindolin-2-yl)bicyclo[1.1.1]pentan-1-y1)-2-(4-chlorophenoxy)acetamide(0.08 g, 35%
yield) as a white solid. LCMS (ES) m/z = 403.3 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.04 (s, 6 H), 3.85 ¨ 3.87 (m, 4 H), 4.41 (s, 2 H), 6.95 (d, J = 8.8 Hz, 2 H), 7.22 (s, 2 H), 7.32 (d, J= 8.8 Hz, 3 H), 8.64 (s, 1 H).
- 178 -Table 8A
LCMS , 'H-NMR (400 MHz, DMSO-d6) Cmpd # Structure Name miz [M+H]
CI
N-(3-(5- 2.04 (s, 6 H), 3.85 ¨ 3.87 (m, 4 chloroisoindolin-2- H), 4.41 (s, 2 H), 6.95 (d, J=
4e yl)bicyclo[1.1.1]pent 403.3 8.8 Hz, 2 H), 7.22 (s, 2 H), an-1-yI)-2-(4-0 NH 7.32 (d, J= 8.8 Hz, 3 H), 8.64 chlorophenoxy)aceta (s, 1 H).
mide Example 5a 2-(4-chlorophenoxv)-N-(3-(4-(4-chlorophenyl)piperidin-1-yl)bicyclo11.1.11pentan-1-VI)acetamide a o)(N
O
C) H
COOMe Step 3 Ari OH -11....step 1 ci 0 sterai.
oome 140 . OH
CI 71111 CI "IP' NI-12 is CI
HO Ojri 0'13 101 H
OH
Step Step 4 5 0 Step 6 CI H
CI
5a 0s.k....
LCMS , 'H-NMR (400 MHz, DMSO-d6) Cmpd # Structure Name miz [M+H]
CI
N-(3-(5- 2.04 (s, 6 H), 3.85 ¨ 3.87 (m, 4 chloroisoindolin-2- H), 4.41 (s, 2 H), 6.95 (d, J=
4e yl)bicyclo[1.1.1]pent 403.3 8.8 Hz, 2 H), 7.22 (s, 2 H), an-1-yI)-2-(4-0 NH 7.32 (d, J= 8.8 Hz, 3 H), 8.64 chlorophenoxy)aceta (s, 1 H).
mide Example 5a 2-(4-chlorophenoxv)-N-(3-(4-(4-chlorophenyl)piperidin-1-yl)bicyclo11.1.11pentan-1-VI)acetamide a o)(N
O
C) H
COOMe Step 3 Ari OH -11....step 1 ci 0 sterai.
oome 140 . OH
CI 71111 CI "IP' NI-12 is CI
HO Ojri 0'13 101 H
OH
Step Step 4 5 0 Step 6 CI H
CI
5a 0s.k....
- 179 -Step 1: To a solution of (E)-3-(4-chlorophenyl)acrylic acid (2.0 g, 1 equiv) in Me0H (20 mL) was added thionyl chloride (3.16 mL, 4 equiv) at rt. The resulting solution stirred at rt for 18 h, and then was evaporated to dryness. The crude compound was diluted with Et0Ac (50mL), washed with saturated sodium bicarbonate solution (25 mL) and brine (15 mL).
-- The organics were dried over anhydrous Na2SO4, filtered and distilled under vacuum to provide methyl (E)-3-(4-chlorophenyl) acrylate (2.0 g, 93%) as a white solid.
1H NMR (400 MHz, CDCI3) 6 ppm 3.80 (s, 3 H), 6.41 (d, J= 16.0 Hz, 1 H), 7.35 (d, J= 8.0 Hz, 2 H), 7.45 (d, J= 8.4 Hz, 2 H), 7.63 (d, J= 15.6 Hz, 1 H).
-- Step 2: To a solution of sodium methoxide in Me0H (prepared by dissolving sodium metal (0.31 g, 13.41 mmol, 1.2 equiv) in 15 mL of anhydrous Me0H at 0 C) under dry atmosphere at 000 was added a solution of dimethyl malonate (1.54mL, 13.41 mmol, 1.2 equiv) in Me0H (1.0 mL) and stirred for 0.5 h at 0 C. Finally methyl (E)-3-(4-chlorophenyl) acrylate (2.2 g, 11.18 mmol, 1 equiv) was added to the reaction mixture, and the reaction -- was gradually warmed to rt and subsequently heated at reflux (80 C). The reaction mixture was evaporated and the residue was dissolved into Et0Ac (50 mL) and washed with water (25 mL) and brine (15 mL). The organic phase was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude material was purified by flash column chromatography (20 `)/0 Et0Ac in hexane) to obtain the desired product trimethyl 2-(4--- chlorophenyl)propane-1,1,3-tricarboxylate as a semi-solid (2.6 g, 70 `)/0).
LCMS (ES) m/z =
329.0 [M+H] +. 1H NMR (400 MHz, CDCI3) 6 ppm 2.58 - 2.75 (m, 2 H), 2.81 - 2.86 (m, 1 H), 3.51 -3.54 (m, 6 H), 3.75 (s, 3 H), 3.89 - 3.93 (m, 1 H), 7.18 (d, J= 8.8 Hz, 2 H), 7.25 (d, J= 8.4 Hz, 2 H).
-- Step 3: A suspension of trimethyl 2-(4-chlorophenyl)propane-1,1,3-tricarboxylate (3.0 g, 9.12 mmol) in 2 N NaOH (8 mL) was gently reluxed for 12 h at 9000. The reaction mixture was cooled to rt and acidified with concentrated HCI to pH -0 - 1 and then heated to 100 C for 12 h. The aqueous solution was distilled to remove most of the water and then extracted with Et0Ac (2 x 30 mL), dried over anhydrous Na2SO4, filtered and evaporated -- under reduced pressure to afford 3-(4-chlorophenyl)pentanedioic acid as an off-white solid (2 g, 90 `)/0). LCMS (ES) m/z = 240.9 EM-H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.68 -2.92 (m, 4 H), 3.58 - 3.77 (m, 1 H), 7.17 (d, J = 8.0 Hz, 2 H), 7.31 (d, J =
8.4Hz, 1 H), 10.39 (s, 2 H).
-- Step 4: To a solution of 3-(4-chlorophenyl)pentanedioic acid (1.0 g, 4.12 mmol, 1 equiv) in THF (10 mL) was added BH3.Me2S (1.17 mL, 12.36 mmol, 3.0 equiv) at 000. The reaction
-- The organics were dried over anhydrous Na2SO4, filtered and distilled under vacuum to provide methyl (E)-3-(4-chlorophenyl) acrylate (2.0 g, 93%) as a white solid.
1H NMR (400 MHz, CDCI3) 6 ppm 3.80 (s, 3 H), 6.41 (d, J= 16.0 Hz, 1 H), 7.35 (d, J= 8.0 Hz, 2 H), 7.45 (d, J= 8.4 Hz, 2 H), 7.63 (d, J= 15.6 Hz, 1 H).
-- Step 2: To a solution of sodium methoxide in Me0H (prepared by dissolving sodium metal (0.31 g, 13.41 mmol, 1.2 equiv) in 15 mL of anhydrous Me0H at 0 C) under dry atmosphere at 000 was added a solution of dimethyl malonate (1.54mL, 13.41 mmol, 1.2 equiv) in Me0H (1.0 mL) and stirred for 0.5 h at 0 C. Finally methyl (E)-3-(4-chlorophenyl) acrylate (2.2 g, 11.18 mmol, 1 equiv) was added to the reaction mixture, and the reaction -- was gradually warmed to rt and subsequently heated at reflux (80 C). The reaction mixture was evaporated and the residue was dissolved into Et0Ac (50 mL) and washed with water (25 mL) and brine (15 mL). The organic phase was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude material was purified by flash column chromatography (20 `)/0 Et0Ac in hexane) to obtain the desired product trimethyl 2-(4--- chlorophenyl)propane-1,1,3-tricarboxylate as a semi-solid (2.6 g, 70 `)/0).
LCMS (ES) m/z =
329.0 [M+H] +. 1H NMR (400 MHz, CDCI3) 6 ppm 2.58 - 2.75 (m, 2 H), 2.81 - 2.86 (m, 1 H), 3.51 -3.54 (m, 6 H), 3.75 (s, 3 H), 3.89 - 3.93 (m, 1 H), 7.18 (d, J= 8.8 Hz, 2 H), 7.25 (d, J= 8.4 Hz, 2 H).
-- Step 3: A suspension of trimethyl 2-(4-chlorophenyl)propane-1,1,3-tricarboxylate (3.0 g, 9.12 mmol) in 2 N NaOH (8 mL) was gently reluxed for 12 h at 9000. The reaction mixture was cooled to rt and acidified with concentrated HCI to pH -0 - 1 and then heated to 100 C for 12 h. The aqueous solution was distilled to remove most of the water and then extracted with Et0Ac (2 x 30 mL), dried over anhydrous Na2SO4, filtered and evaporated -- under reduced pressure to afford 3-(4-chlorophenyl)pentanedioic acid as an off-white solid (2 g, 90 `)/0). LCMS (ES) m/z = 240.9 EM-H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.68 -2.92 (m, 4 H), 3.58 - 3.77 (m, 1 H), 7.17 (d, J = 8.0 Hz, 2 H), 7.31 (d, J =
8.4Hz, 1 H), 10.39 (s, 2 H).
-- Step 4: To a solution of 3-(4-chlorophenyl)pentanedioic acid (1.0 g, 4.12 mmol, 1 equiv) in THF (10 mL) was added BH3.Me2S (1.17 mL, 12.36 mmol, 3.0 equiv) at 000. The reaction
- 180 -mixture was then allowed to stir at rt for 12 h. Then the reaction mixture was quenched with Me0H (1 mL) at 0 C and stirred for 30 min, and concentrated under reduced pressure to obtain the crude product. The crude material was purified by column chromatography (50%
Et0Ac in hexane) to afford 3-(4-chlorophenyl)pentane-1,5-diol (0.7 g, 80 %) as an oily compound. LCMS (ES) m/z= 215.1 [M+H] +.1H NMR (400 MHz, 0D013) 6 ppm 1.68 -1.83 (m, 2 H), 1.92 - 2.08 (m, 2 H), 2.88 - 2.97 (m, 1 H), 3.42 - 3.48 (m, 2 H), 3.53 - 3.79 (m, 2 H), 7.13 (d, J= 8.0 Hz, 2 H), 7.25 - 7.28(m, 2 H).
Step 5: To a stirred solution of 3-(4-chlorophenyl)pentane-1,5-diol (0.2 g, 0.93 mmol, 1.0 equiv.) in DCM (10 mL) was added methanesulfonyl chloride (0.22 mL, 3.0 equiv.) at 0 C
followed by dropwise addition of Et3N (0.51 mL, 3.72 mmol, 4.00 equiv.). After stirring at 0 C for 0.5 h, the reaction mixture was slowly brought to rt and stirred at rt for 2 h. To the reaction mixture was added aq. NH401 (5 mL) and the aqueous phase was extracted with Et0Ac (2 x 25 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure to afford 3-(4-chlorophenyl)pentane-1,5-diyl-dimethanesulfonate (0.25 g, crude) as a semi-solid which was directly used for the next step without further purification. 1H NMR (400 MHz, 0D013) 6 ppm 1.91 - 2.00 (m, 2 H), 2.15 - 2.34 (m, 2 H), 2.93 (s, 6 h), 3.13 - 3.22 (m, 1 H), 3.84 - 4.06 (m, 2 H), 4.10 - 4.28 (m, 2 H), 7.13 (d, J = 8.0 Hz, 2 H), 7.32 (d, J = 8.0 Hz, 2 H).
Step 6: 3-(4-Chlorophenyl)pentane-1,5-diyl-dimethanesulfonate (0.2 g, 0.539 mmol, 1 equiv) and N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (0.14 g, 0.539 mmol, 1 equiv) were charged to a sealed tube and Et3N (0.37 mL, 2.69 mmol, 5 equiv)) was added. The mixture was then heated at 90 C using an oil bath for 1 h. The reaction mixture was evaporated under reduced pressure to obtain crude compound. The crude material was purified by column chromatography using an eluent of 50 %
Et0Ac in hexane. The product was further re-purified by preparative TLC using 50 %
Et0Ac in hexane as the mobile phase. After prep TLC purification, the compound was dissolved in 0.5 mL CH3CN. To this was added 5 mL n-pentane, stirred for 0.5 h and then filtered to afford 2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenyl)piperidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.003 g, 1.2%) as an off-white solid. LCMS (ES) m/z = 445.4 [M+H] +. 1H
NMR (400 MHz, DMSO-d6) 6 ppm 1.55 - 1.58 (m, 2 H), 1.69 (s, 2 H), 1.95 - 2.03 (m, 9 H), 2.86 - 2.88 (m, 2 H), 4.40 (m, 2 H), 6.95 (d, J = 7.6 Hz, 2 H), 7.25 - 7.30 (m, 6 H), 8.61 (s, 1 H).
Et0Ac in hexane) to afford 3-(4-chlorophenyl)pentane-1,5-diol (0.7 g, 80 %) as an oily compound. LCMS (ES) m/z= 215.1 [M+H] +.1H NMR (400 MHz, 0D013) 6 ppm 1.68 -1.83 (m, 2 H), 1.92 - 2.08 (m, 2 H), 2.88 - 2.97 (m, 1 H), 3.42 - 3.48 (m, 2 H), 3.53 - 3.79 (m, 2 H), 7.13 (d, J= 8.0 Hz, 2 H), 7.25 - 7.28(m, 2 H).
Step 5: To a stirred solution of 3-(4-chlorophenyl)pentane-1,5-diol (0.2 g, 0.93 mmol, 1.0 equiv.) in DCM (10 mL) was added methanesulfonyl chloride (0.22 mL, 3.0 equiv.) at 0 C
followed by dropwise addition of Et3N (0.51 mL, 3.72 mmol, 4.00 equiv.). After stirring at 0 C for 0.5 h, the reaction mixture was slowly brought to rt and stirred at rt for 2 h. To the reaction mixture was added aq. NH401 (5 mL) and the aqueous phase was extracted with Et0Ac (2 x 25 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure to afford 3-(4-chlorophenyl)pentane-1,5-diyl-dimethanesulfonate (0.25 g, crude) as a semi-solid which was directly used for the next step without further purification. 1H NMR (400 MHz, 0D013) 6 ppm 1.91 - 2.00 (m, 2 H), 2.15 - 2.34 (m, 2 H), 2.93 (s, 6 h), 3.13 - 3.22 (m, 1 H), 3.84 - 4.06 (m, 2 H), 4.10 - 4.28 (m, 2 H), 7.13 (d, J = 8.0 Hz, 2 H), 7.32 (d, J = 8.0 Hz, 2 H).
Step 6: 3-(4-Chlorophenyl)pentane-1,5-diyl-dimethanesulfonate (0.2 g, 0.539 mmol, 1 equiv) and N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (0.14 g, 0.539 mmol, 1 equiv) were charged to a sealed tube and Et3N (0.37 mL, 2.69 mmol, 5 equiv)) was added. The mixture was then heated at 90 C using an oil bath for 1 h. The reaction mixture was evaporated under reduced pressure to obtain crude compound. The crude material was purified by column chromatography using an eluent of 50 %
Et0Ac in hexane. The product was further re-purified by preparative TLC using 50 %
Et0Ac in hexane as the mobile phase. After prep TLC purification, the compound was dissolved in 0.5 mL CH3CN. To this was added 5 mL n-pentane, stirred for 0.5 h and then filtered to afford 2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenyl)piperidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.003 g, 1.2%) as an off-white solid. LCMS (ES) m/z = 445.4 [M+H] +. 1H
NMR (400 MHz, DMSO-d6) 6 ppm 1.55 - 1.58 (m, 2 H), 1.69 (s, 2 H), 1.95 - 2.03 (m, 9 H), 2.86 - 2.88 (m, 2 H), 4.40 (m, 2 H), 6.95 (d, J = 7.6 Hz, 2 H), 7.25 - 7.30 (m, 6 H), 8.61 (s, 1 H).
- 181 -Table 9 LCMS
1H-NMR (400 MHz, DMSO-Cmpd # Structure Name rrilz d6) [M+H]
CI
1.55 ¨ 1.58 (m, 2 H), 1.69 (s, 2 H), 1.95 ¨ 2.03 (m, 9 2-(4-chlorophenoxy)-N-(3-H), 2.86 ¨ 2.88 (m, 2 H), 5a (4-(4-445.4 chlorophenyl)piperidin-1-4.40 (m, 2 H), 6.95 (d, J=
7.6 Hz, 2 H), 7.25 ¨ 7.30 yl)bicyclo[1.1.1]pentan-1-0oYNH
(m, 6 H), 8.61 (s, 1 H).
yl)acetamide Example 5b 2-(4-chlorophenoxv)-N-(3-(4-(4-chlorophenvppiperazin-1-vnbicycloll.1.11pentan-vl)acetamide * Cl Cl 0 inN
OAOH
Boc low. 110 Boc CI Alla N"--4 CI CLo NH2 'HCI
Step 1 Step 2 ir 0/1 N=./N3r 0 pi. I 2 0)( CI lir filL CI
N
N
Step 3 Step 4 cl CI
Br ite, CI
Br 0 ["N
ON.s.AN
CI W.
Step 5 5b
1H-NMR (400 MHz, DMSO-Cmpd # Structure Name rrilz d6) [M+H]
CI
1.55 ¨ 1.58 (m, 2 H), 1.69 (s, 2 H), 1.95 ¨ 2.03 (m, 9 2-(4-chlorophenoxy)-N-(3-H), 2.86 ¨ 2.88 (m, 2 H), 5a (4-(4-445.4 chlorophenyl)piperidin-1-4.40 (m, 2 H), 6.95 (d, J=
7.6 Hz, 2 H), 7.25 ¨ 7.30 yl)bicyclo[1.1.1]pentan-1-0oYNH
(m, 6 H), 8.61 (s, 1 H).
yl)acetamide Example 5b 2-(4-chlorophenoxv)-N-(3-(4-(4-chlorophenvppiperazin-1-vnbicycloll.1.11pentan-vl)acetamide * Cl Cl 0 inN
OAOH
Boc low. 110 Boc CI Alla N"--4 CI CLo NH2 'HCI
Step 1 Step 2 ir 0/1 N=./N3r 0 pi. I 2 0)( CI lir filL CI
N
N
Step 3 Step 4 cl CI
Br ite, CI
Br 0 ["N
ON.s.AN
CI W.
Step 5 5b
- 182 -Step 1: To a solution of 2-(4-chlorophenoxy)acetic acid (25.32 g, 136.17 mmol, 1.2 equiv) in DCM (250 mL) at 0 C was added triethylamine (63 mL, 453.92 mmol, 4 equiv) and was stirred for 5 minutes at 0 C. T3P (50 wt. % in ethyl acetate) (108.4 mL, 170.22 mmol, 1.5 equiv) was added and the reaction mixture was stirred at 0 for 10 mins.
Then, tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (22.5 g, 113.48 mmol, 1 equiv) was added to the reaction mixture, and the reaction mixture was stirred at room temperature for 12 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to obtain the crude product, which was triturated by adding saturated aqueous NaHCO3 solution (50 mL) and water (50 mL). The obtained light brown solid was filtered through a sintered funnel and dried. The obtained solid was dissolved in DCM and washed with water. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford tert-butyl (3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate (39 g, 93% yield) as a light brown solid. LCMS (ES) m/z = 311.1 [M+H] ( t- butyl cleavage mass was observed). 1H
NMR (400 MHz, DMSO-d6) 6 ppm 1.35 (s, 9 H), 2.11 (s, 6 H), 4.39 (s, 2 H), 6.94 (d, J= 8.8 Hz, 2 H), 7.31 (d, J= 8.8 Hz, 2 H), 7.46 (bs, 1 H), 8.60 (s, 1 H).
Step 2: To a solution of tert-butyl (3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate ( 20 g, 54.49 mmol, 1 equiv) in DCM (225 mL) was added 4M HCI
in 1,4-dioxane (60 mL) at 0 C. The reaction mixture stirred at room temperature for 12 h. After consumption of the starting material (TLC, 5% methanol in DCM), DCM was evaporated under reduced pressure, and the obtained solid was triturated with n-pentane (100 mL) and diethyl ether (100 mL) and dried under high vacuum to afford N-(3-am inobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetam ide hydrochloride(14 g, 84%) as a light brown solid. LCMS (ES) m/z = 267.1 [M+H]. (Free amine mass was observed).
1H NMR (400 MHz, DMSO-d6) 6 ppm 2.22 (s, 6 H), 4.43 (s, 2 H), 6.95 (d, J= 9.2 Hz, 2 H), 7.32 (d, J= 8.8 Hz, 2 H), 8.65 (s, 3 H), 8.81 (s, 1 H).
Step 3: To a stirred solution of N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide hydrochloride (15 .0 g, 49.66 mmol, 1 equiv) in ethyl acetate (200 mL) at room temperature was added saturated sodium bicarbonate. After stirring at room temperature for 30 minutes, it was extracted with ethyl acetate (2 x 250 mL). The combined organic extract was washed with water (100 mL) and brine (50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (13 g, crude) as a brown gum. The crude material was purified by reverse phase HPLC:
[Column
Then, tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (22.5 g, 113.48 mmol, 1 equiv) was added to the reaction mixture, and the reaction mixture was stirred at room temperature for 12 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to obtain the crude product, which was triturated by adding saturated aqueous NaHCO3 solution (50 mL) and water (50 mL). The obtained light brown solid was filtered through a sintered funnel and dried. The obtained solid was dissolved in DCM and washed with water. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford tert-butyl (3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate (39 g, 93% yield) as a light brown solid. LCMS (ES) m/z = 311.1 [M+H] ( t- butyl cleavage mass was observed). 1H
NMR (400 MHz, DMSO-d6) 6 ppm 1.35 (s, 9 H), 2.11 (s, 6 H), 4.39 (s, 2 H), 6.94 (d, J= 8.8 Hz, 2 H), 7.31 (d, J= 8.8 Hz, 2 H), 7.46 (bs, 1 H), 8.60 (s, 1 H).
Step 2: To a solution of tert-butyl (3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate ( 20 g, 54.49 mmol, 1 equiv) in DCM (225 mL) was added 4M HCI
in 1,4-dioxane (60 mL) at 0 C. The reaction mixture stirred at room temperature for 12 h. After consumption of the starting material (TLC, 5% methanol in DCM), DCM was evaporated under reduced pressure, and the obtained solid was triturated with n-pentane (100 mL) and diethyl ether (100 mL) and dried under high vacuum to afford N-(3-am inobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetam ide hydrochloride(14 g, 84%) as a light brown solid. LCMS (ES) m/z = 267.1 [M+H]. (Free amine mass was observed).
1H NMR (400 MHz, DMSO-d6) 6 ppm 2.22 (s, 6 H), 4.43 (s, 2 H), 6.95 (d, J= 9.2 Hz, 2 H), 7.32 (d, J= 8.8 Hz, 2 H), 8.65 (s, 3 H), 8.81 (s, 1 H).
Step 3: To a stirred solution of N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide hydrochloride (15 .0 g, 49.66 mmol, 1 equiv) in ethyl acetate (200 mL) at room temperature was added saturated sodium bicarbonate. After stirring at room temperature for 30 minutes, it was extracted with ethyl acetate (2 x 250 mL). The combined organic extract was washed with water (100 mL) and brine (50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (13 g, crude) as a brown gum. The crude material was purified by reverse phase HPLC:
[Column
- 183 -: 018, Mobile phase (A): 0.1% ammonia in water, Mobile phase (B):
Acetonitrile]. Fractions containing product were concentrated under reduced pressure and the obtained material was stirred in n-pentane (40 mL) at room temperature for 1 h. Then the solid was filtered and dried to afford N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (6.6 g, 50.7 `)/0 yield) as a white solid. LCMS (ES) m/z = 267.1 [M+H]. 1H NMR
(400 MHz, DMSO-d6) 6 PPm 1.90 (s, 6 H), 2.11 (s,2 H), 4.37 (s, 2 H), 6.93 (d, J= 8.8 Hz, 2 H), 7.30 -7.32 (m, 2 H), 8.47 (s, 1 H).
Step 4: To a solution of N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (0.2 g, 0.74 mmol, 1.0 equiv) in triethylamine (0.52 mL, 3.7 mmol, 5.0 equiv) was added N-(2-bromoethyl)-4-chloroaniline (0.21 g, 0.89 mmol, 1.2 equiv) at room temperature in a sealed tube. The reaction mixture was maintained at 100 C for 2 h. The reaction mixture was diluted with DCM (400 mL), and the combined organic layers were washed with cold water (2 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude material was purified by flash chromatography using 0.1 `)/0 to 10 `)/0 methanol in DCM as an eluent to obtain 2-(4-chlorophenoxy)-N-(3-((2-((4-chlorophenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.5 g, 41.66% yield, 0.2 g scale reactions with 4 batches (0.8g)) as an off-white solid. LCMS (ES) m/z = 420.0 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.94 (s, 6 H), 2.64 (d, J= 8.0 Hz, 2 H), 2.99 -3.04 (m, 2 H), 4.39 (s, 2 H), 5.66 (bs, 1 H), 6.54 (d, J= 8.8 Hz, 2 H),6.94 (d, J= 8.8 Hz, 2 H), 7.05 (d, J= 8.4 Hz, 2 H), 7.32 (d, J= 8.4 Hz, 2 H), 8.56 (s, 1 H). NH
proton was not observed.
Step 5: To a solution of 2-(4-chlorophenoxy)-N-(3-((2-((4-chlorophenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.2 g, 0.47 mmol, 1.0 equiv) in DMF (5 mL) was added 1,2-dibromoethane (0.041 mL, 0.47 mmol, 1.0 equiv) and K2003 (0.32 g, 2.3 mmol, 5.0 equiv) at room temperature. After the reaction mixture was maintained at 100 C for 2 h, it was cooled to room temperature and quenched with crushed ice (25 mL) and extracted with DCM (2 x 50 mL). The combined organic layers were washed with cold water (2 x 25 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude material was purified by flash chromatography using 0.5 `)/0 to 70 `)/0 ethyl acetate in n-hexane as an eluent and repurified by preparative HPLC [Analytical conditions: Column:
lnertsil ODS 3V
(250 mm x 4.6 mm x 5 m). Mobile phase (A): 0.1 % Ammonia in water, Mobile phase (B):
Acetonitrile, Flow rate: 1.0 mL/min, compound RT: 20.99 minutes] to obtain 2-(4-
Acetonitrile]. Fractions containing product were concentrated under reduced pressure and the obtained material was stirred in n-pentane (40 mL) at room temperature for 1 h. Then the solid was filtered and dried to afford N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (6.6 g, 50.7 `)/0 yield) as a white solid. LCMS (ES) m/z = 267.1 [M+H]. 1H NMR
(400 MHz, DMSO-d6) 6 PPm 1.90 (s, 6 H), 2.11 (s,2 H), 4.37 (s, 2 H), 6.93 (d, J= 8.8 Hz, 2 H), 7.30 -7.32 (m, 2 H), 8.47 (s, 1 H).
Step 4: To a solution of N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (0.2 g, 0.74 mmol, 1.0 equiv) in triethylamine (0.52 mL, 3.7 mmol, 5.0 equiv) was added N-(2-bromoethyl)-4-chloroaniline (0.21 g, 0.89 mmol, 1.2 equiv) at room temperature in a sealed tube. The reaction mixture was maintained at 100 C for 2 h. The reaction mixture was diluted with DCM (400 mL), and the combined organic layers were washed with cold water (2 x 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude material was purified by flash chromatography using 0.1 `)/0 to 10 `)/0 methanol in DCM as an eluent to obtain 2-(4-chlorophenoxy)-N-(3-((2-((4-chlorophenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.5 g, 41.66% yield, 0.2 g scale reactions with 4 batches (0.8g)) as an off-white solid. LCMS (ES) m/z = 420.0 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.94 (s, 6 H), 2.64 (d, J= 8.0 Hz, 2 H), 2.99 -3.04 (m, 2 H), 4.39 (s, 2 H), 5.66 (bs, 1 H), 6.54 (d, J= 8.8 Hz, 2 H),6.94 (d, J= 8.8 Hz, 2 H), 7.05 (d, J= 8.4 Hz, 2 H), 7.32 (d, J= 8.4 Hz, 2 H), 8.56 (s, 1 H). NH
proton was not observed.
Step 5: To a solution of 2-(4-chlorophenoxy)-N-(3-((2-((4-chlorophenyl)amino)ethyl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide (0.2 g, 0.47 mmol, 1.0 equiv) in DMF (5 mL) was added 1,2-dibromoethane (0.041 mL, 0.47 mmol, 1.0 equiv) and K2003 (0.32 g, 2.3 mmol, 5.0 equiv) at room temperature. After the reaction mixture was maintained at 100 C for 2 h, it was cooled to room temperature and quenched with crushed ice (25 mL) and extracted with DCM (2 x 50 mL). The combined organic layers were washed with cold water (2 x 25 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude material was purified by flash chromatography using 0.5 `)/0 to 70 `)/0 ethyl acetate in n-hexane as an eluent and repurified by preparative HPLC [Analytical conditions: Column:
lnertsil ODS 3V
(250 mm x 4.6 mm x 5 m). Mobile phase (A): 0.1 % Ammonia in water, Mobile phase (B):
Acetonitrile, Flow rate: 1.0 mL/min, compound RT: 20.99 minutes] to obtain 2-(4-
- 184 -chlorophenoxy)-N-(3-(4-(4-chlorophenyl)piperazin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.045 g, 21.5% yield) as a white solid. LCMS (ES) m/z = 446.3 [M+H]. 1H NMR
(400 MHz, DMSO-d6) 6 ppm 1.97 (s, 6 H), 2.48 (s, 4 H), 3.41 (s, 4 H), 4.41 (s, 2 H), 6.91 ¨6.96 (m, 4 H), 7.20 (d, J= 8.0 Hz, 2 H), 7.32 (d, J= 8.4 Hz, 2 H), 8.63 (s, 1 H).
Table 10 LCMS 1H-NMR (400 MHz, Cmpd # Structure Name miz DM50-d6) [M+H]
CI
1.97 (s, 6 H), 2.48 (s, 4 H), 3.41 (s, 4 H), 5b 2-(4-chlorophenoxy)-N-(3-(4-446.3 4.41 (s, 2 H), 6.91 ¨
(4-chlorophenyl)piperazin-1-6.96 (m, 4 H), 7.20 0YNH yl)bicyclo[1.1.1]pentan-1-(d, J= 8.0 Hz, 2 H), yl)acetamide 7.32 (d, J= 8.4 Hz, 2 o H), 8.63 (s, 1 H).
Example 5c 2-(bicyclo[4.2.0locta-1,315-trien-3-yloxy)-N-(4-(2-(4-chlorophenoxv)acetamido)b1cyc1012.2.11heptan-1-vpacetamide 0 * Cl Cl * 1:s\J(Nr
(400 MHz, DMSO-d6) 6 ppm 1.97 (s, 6 H), 2.48 (s, 4 H), 3.41 (s, 4 H), 4.41 (s, 2 H), 6.91 ¨6.96 (m, 4 H), 7.20 (d, J= 8.0 Hz, 2 H), 7.32 (d, J= 8.4 Hz, 2 H), 8.63 (s, 1 H).
Table 10 LCMS 1H-NMR (400 MHz, Cmpd # Structure Name miz DM50-d6) [M+H]
CI
1.97 (s, 6 H), 2.48 (s, 4 H), 3.41 (s, 4 H), 5b 2-(4-chlorophenoxy)-N-(3-(4-446.3 4.41 (s, 2 H), 6.91 ¨
(4-chlorophenyl)piperazin-1-6.96 (m, 4 H), 7.20 0YNH yl)bicyclo[1.1.1]pentan-1-(d, J= 8.0 Hz, 2 H), yl)acetamide 7.32 (d, J= 8.4 Hz, 2 o H), 8.63 (s, 1 H).
Example 5c 2-(bicyclo[4.2.0locta-1,315-trien-3-yloxy)-N-(4-(2-(4-chlorophenoxv)acetamido)b1cyc1012.2.11heptan-1-vpacetamide 0 * Cl Cl * 1:s\J(Nr
- 185 -CI
411) NI-12 '4_ ci 0 -1"Step 1 Step 2 JO
CI
CI
goc H2N¨Q¨N1H 0 * Step 3 CI N
CI
¨Dow Step 4 CIFI.H2N.--40.---C) OAOH
CI *I * CI
\j(N
Step 5 01 * 0 Step 1: To a stirred solution of 4-chloroaniline (2.0 g, 15.75 mmol, 1.0 equivalent) in acetone (50 mL) was added K2003 (3.04 g, 22.05 mmol, 1.4 equiv) followed by ethyl 2-bromoacetate (1.91 mL, 17.32 mmol, 1.1 equiv) and the reaction mixture was heated to ref lux for 16 h. After completion of the reaction, the reaction mixture was filtered through a Buchner funnel with a Celite bed. The Celite bed was washed with ethyl acetate (100 mL). The filtrate was concentrated under reduced pressure to give the crude product. The crude material was purified by silica gel column chromatography using 15%
ethyl acetate in n-Hexane as an eluent to afford ethyl (4-chlorophenyl)glycinate (1.3 g, 38.92%) as an off-white solid. LCMS (ES) m/z= 214.1 [M+H]. 1H-NMR (400 MHz, DMSO-d6): 1.17 (t, J= 7.0 Hz, 3 H), 3.86 (d, J= 6.0Hz, 2 H), 4.09 (q, J= 6.9 Hz, 2 H), 6.15 (s, 1 H), 6.54 (d, J= 8.4 Hz, 2 H), 7.07 (d, J= 8.4 Hz, 2 H).
Step 2: To a solution of ethyl (4-chlorophenyl)glycinate (1.0 g, 4.67 mmol, 1 equiv) in methanol (20 mL), was added 2-chloroacetaldehyde (6.7 mL, 46.73 mmol, 10 equiv) followed by acetic acid (0.5 mL) and stirred for 15 min at rt. NaCNBH3 (1.17 g, 18.69 mmol, 4 equiv) was added at 0 C and then the reaction mixture was allowed to stir at rt for 16 h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to obtain crude product. The crude product was dissolved in ethyl acetate (200 mL) and washed with water (100 mL) and brine solution (100 m L), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel column chromatography by
411) NI-12 '4_ ci 0 -1"Step 1 Step 2 JO
CI
CI
goc H2N¨Q¨N1H 0 * Step 3 CI N
CI
¨Dow Step 4 CIFI.H2N.--40.---C) OAOH
CI *I * CI
\j(N
Step 5 01 * 0 Step 1: To a stirred solution of 4-chloroaniline (2.0 g, 15.75 mmol, 1.0 equivalent) in acetone (50 mL) was added K2003 (3.04 g, 22.05 mmol, 1.4 equiv) followed by ethyl 2-bromoacetate (1.91 mL, 17.32 mmol, 1.1 equiv) and the reaction mixture was heated to ref lux for 16 h. After completion of the reaction, the reaction mixture was filtered through a Buchner funnel with a Celite bed. The Celite bed was washed with ethyl acetate (100 mL). The filtrate was concentrated under reduced pressure to give the crude product. The crude material was purified by silica gel column chromatography using 15%
ethyl acetate in n-Hexane as an eluent to afford ethyl (4-chlorophenyl)glycinate (1.3 g, 38.92%) as an off-white solid. LCMS (ES) m/z= 214.1 [M+H]. 1H-NMR (400 MHz, DMSO-d6): 1.17 (t, J= 7.0 Hz, 3 H), 3.86 (d, J= 6.0Hz, 2 H), 4.09 (q, J= 6.9 Hz, 2 H), 6.15 (s, 1 H), 6.54 (d, J= 8.4 Hz, 2 H), 7.07 (d, J= 8.4 Hz, 2 H).
Step 2: To a solution of ethyl (4-chlorophenyl)glycinate (1.0 g, 4.67 mmol, 1 equiv) in methanol (20 mL), was added 2-chloroacetaldehyde (6.7 mL, 46.73 mmol, 10 equiv) followed by acetic acid (0.5 mL) and stirred for 15 min at rt. NaCNBH3 (1.17 g, 18.69 mmol, 4 equiv) was added at 0 C and then the reaction mixture was allowed to stir at rt for 16 h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to obtain crude product. The crude product was dissolved in ethyl acetate (200 mL) and washed with water (100 mL) and brine solution (100 m L), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel column chromatography by
- 186 -using 8% ethylacetate in n-Hexane as an eluent to afford ethyl N-(2-chloroethyl)-N-(4-chlorophenyl) glycinate (0.9 g, 70.31%) as a pale yellow liquid. LCMS (ES) m/z = 276.0 [M+H] . 1H-NMR (400 MHz, DMSO-d6): 1.17 (t, J= 7.0 Hz, 3 H), 3.67 - 3.71 (m, 4 H), 4.09 (q, J= 7.0 Hz, 2 H), 4.21 (s, 2 H), 6.63 (d, J= 8.8 Hz, 2 H), 7.17 (d, J= 9.2 Hz, 2 H).
Step 3: Ethyl N-(2-chloroethyl)-N-(4-chlorophenyl)glycinate (0.35 g, 1.26 mmol, 1 equiv) and tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.25 g, 1.26 mmol, 1 equiv) were charged to a sealed tube and diisopropylethylamine (0.87 mL, 5.05 mmol, 4 equiv) was added. The mixture was then heated at 100 C for 16 h. After that time the reaction mixture was concentrated under reduced pressure to give the crude product. The crude material was purified by silica gel column chromatography by using 35% ethyl acetate in n-Hexane as an eluent to afford tert-butyl (3-(4-(4-chloropheny1)-2-oxopiperazin-yl)bicyclo[1.1.1]pentan-1-y1)carbamate (0.16 g, 16.33%) as a light yellow colour solid.
LCMS (ES) m/z = 392.1 [M+H] +. 1H-NMR (400 MHz, DMSO-d6): 1.36 (s, 9 H), 2.21 (s, 6 H), 3.35 (s, 2 H), 3.42 (s, 2 H), 3.7 (s, 2 H), 6.9 (d, J= 8.4 Hz, 2 H), 7.22 (d, J= 8.4 Hz, 2 H), 7.5 (s, 1 H).
Step 4: To a solution of tert-butyl (3-(4-(4-chloropheny1)-2-oxopiperazin-1-yl)bicyclo[1.1.1]pentan-1-y1)carbamate (0.16 g, 0.41 mmol, 1 equiv) in DCM (5 mL) at 000 was added 3 mL of 4M HCI in 1,4-dioxane and the mixture was stirred at rt for 4 h. The reaction mixture was concentrated to afford crude product. The crude product was washed with dry n-pentane (50 mL) and dried under high vacuum to afford 1-(3-am inobicyclo[1.1.1]pentan-1-yI)-4-(4-chlorophenyl)piperazin-2-one hydrochloride (0.133 g crude) which was taken to the next step without further purification. LCMS
(ES) m/z =
292.1 [M+H] .
Step 5: To a solution of 2-(4-chlorophenoxy)acetic acid (0.11 g, 0.59 mmol, 1.5 equiv) in DCM (5 mL) at 0 C was added triethylamine (0.22 mL, 1.58 mmol, 4 equiv) followed by T3P (50 wt% in Et0Ac) (0.47 mL, 0.79 mmol, 2 equiv) and the mixture was stirred at 0 C
for 10 min. To this reaction mixture was added 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-4-(4-chlorophenyl)piperazin-2-one hydrochloride (0.13 g, 0.39 mmol, 1 equiv) in DCM
(2 mL) and triethylamine (0.055 mL, 0.39 mmol, 1 equiv) slowly at 0 C and the reaction was stirred at rt for 16 h. The reaction mixture was diluted with water (50 mL) and extracted with DCM (2 x 50 mL). The combined organic layer was washed with saturated aqueous NaH0O3 solution (50 mL) and then dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography twice using an
Step 3: Ethyl N-(2-chloroethyl)-N-(4-chlorophenyl)glycinate (0.35 g, 1.26 mmol, 1 equiv) and tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.25 g, 1.26 mmol, 1 equiv) were charged to a sealed tube and diisopropylethylamine (0.87 mL, 5.05 mmol, 4 equiv) was added. The mixture was then heated at 100 C for 16 h. After that time the reaction mixture was concentrated under reduced pressure to give the crude product. The crude material was purified by silica gel column chromatography by using 35% ethyl acetate in n-Hexane as an eluent to afford tert-butyl (3-(4-(4-chloropheny1)-2-oxopiperazin-yl)bicyclo[1.1.1]pentan-1-y1)carbamate (0.16 g, 16.33%) as a light yellow colour solid.
LCMS (ES) m/z = 392.1 [M+H] +. 1H-NMR (400 MHz, DMSO-d6): 1.36 (s, 9 H), 2.21 (s, 6 H), 3.35 (s, 2 H), 3.42 (s, 2 H), 3.7 (s, 2 H), 6.9 (d, J= 8.4 Hz, 2 H), 7.22 (d, J= 8.4 Hz, 2 H), 7.5 (s, 1 H).
Step 4: To a solution of tert-butyl (3-(4-(4-chloropheny1)-2-oxopiperazin-1-yl)bicyclo[1.1.1]pentan-1-y1)carbamate (0.16 g, 0.41 mmol, 1 equiv) in DCM (5 mL) at 000 was added 3 mL of 4M HCI in 1,4-dioxane and the mixture was stirred at rt for 4 h. The reaction mixture was concentrated to afford crude product. The crude product was washed with dry n-pentane (50 mL) and dried under high vacuum to afford 1-(3-am inobicyclo[1.1.1]pentan-1-yI)-4-(4-chlorophenyl)piperazin-2-one hydrochloride (0.133 g crude) which was taken to the next step without further purification. LCMS
(ES) m/z =
292.1 [M+H] .
Step 5: To a solution of 2-(4-chlorophenoxy)acetic acid (0.11 g, 0.59 mmol, 1.5 equiv) in DCM (5 mL) at 0 C was added triethylamine (0.22 mL, 1.58 mmol, 4 equiv) followed by T3P (50 wt% in Et0Ac) (0.47 mL, 0.79 mmol, 2 equiv) and the mixture was stirred at 0 C
for 10 min. To this reaction mixture was added 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-4-(4-chlorophenyl)piperazin-2-one hydrochloride (0.13 g, 0.39 mmol, 1 equiv) in DCM
(2 mL) and triethylamine (0.055 mL, 0.39 mmol, 1 equiv) slowly at 0 C and the reaction was stirred at rt for 16 h. The reaction mixture was diluted with water (50 mL) and extracted with DCM (2 x 50 mL). The combined organic layer was washed with saturated aqueous NaH0O3 solution (50 mL) and then dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography twice using an
- 187 -eluent of 50% Et0Ac in hexane and again it was purified by preparative HPLC
(Analytical conditions: Column :lnertsil ODS 3V(250mm X 4.6mm X 5mic); Mobile phase(A) :
0.1%
Ammonia in water; Mobile phase (B) : CAN; Flow rate : 1.0 mL/min (40:60)) to afford 2-(4-chlorophenoxy)-N-(3-(4-(4-chloropheny1)-2-oxopiperazin-1-yl)bicyclo[1.1.1]pentan-1 -yl)acetamide (0.017 g, 9.4%) as a white solid. LCMS (ES) m/z = 460.3 [M+H] +.
(400 MHz, DMSO-d6): 2.34 (s, 6 H), 3.37 - 3.43 (m, 4 H), 3.71 (s, 2 H), 4.42 (s, 2 H), 6.91 (d, J= 9.2 Hz, 2 H), 6.95 (d, J= 9.2 Hz, 2 H), 7.22 (d, J= 8.8 Hz, 2 H), 7.32 (d, J= 8.8 Hz, 2 H), 8.71 (s, 1 H).
Table 11 LCMS 1H-NMR (400 MHz, DMSO-Cmpd # Structure Name rn/z d6) [M+H]
CI
1. 2-(4-chlorophenoxy)-L
0 N) chlorophenyI)-2-oxopiperazin-1- 2.34 (s, 6 H), 3.37 -3.43 (m, 4 H), 3.71 (s, 2 H), 4.42 5c yl)bicyclo[1.1.1]pentan- (s, 2 H), 6.91 (d, J =
9.2 o....4 1-yl)acetamide 460.3 Hz, 2 H), 6.95 (d, J= 9.2 Hz, 2 H), 7.22 (d, J= 8.8 Hz, 2 H), 7.32 (d, J= 8.8 o) Hz, 2 H), 8.71 (s, 1 H).
.1 C
Example 6a and Example XXIV
2-(4-chlorophenoxv)-N-(3-(3-(4-chlorophenoxv)uvrrolidin-1-vnbicycloll.1.11pentan-1-vl)acetamide a CI * 0\j(N........0 o H
(Analytical conditions: Column :lnertsil ODS 3V(250mm X 4.6mm X 5mic); Mobile phase(A) :
0.1%
Ammonia in water; Mobile phase (B) : CAN; Flow rate : 1.0 mL/min (40:60)) to afford 2-(4-chlorophenoxy)-N-(3-(4-(4-chloropheny1)-2-oxopiperazin-1-yl)bicyclo[1.1.1]pentan-1 -yl)acetamide (0.017 g, 9.4%) as a white solid. LCMS (ES) m/z = 460.3 [M+H] +.
(400 MHz, DMSO-d6): 2.34 (s, 6 H), 3.37 - 3.43 (m, 4 H), 3.71 (s, 2 H), 4.42 (s, 2 H), 6.91 (d, J= 9.2 Hz, 2 H), 6.95 (d, J= 9.2 Hz, 2 H), 7.22 (d, J= 8.8 Hz, 2 H), 7.32 (d, J= 8.8 Hz, 2 H), 8.71 (s, 1 H).
Table 11 LCMS 1H-NMR (400 MHz, DMSO-Cmpd # Structure Name rn/z d6) [M+H]
CI
1. 2-(4-chlorophenoxy)-L
0 N) chlorophenyI)-2-oxopiperazin-1- 2.34 (s, 6 H), 3.37 -3.43 (m, 4 H), 3.71 (s, 2 H), 4.42 5c yl)bicyclo[1.1.1]pentan- (s, 2 H), 6.91 (d, J =
9.2 o....4 1-yl)acetamide 460.3 Hz, 2 H), 6.95 (d, J= 9.2 Hz, 2 H), 7.22 (d, J= 8.8 Hz, 2 H), 7.32 (d, J= 8.8 o) Hz, 2 H), 8.71 (s, 1 H).
.1 C
Example 6a and Example XXIV
2-(4-chlorophenoxv)-N-(3-(3-(4-chlorophenoxv)uvrrolidin-1-vnbicycloll.1.11pentan-1-vl)acetamide a CI * 0\j(N........0 o H
- 188 -Br * OH ci Br Br õcN Boo 51r 0\ 101 0\ -III. -0-41 Step 3 110 0/QN-O-NH2 HO!
Step 1 0 Step 2 j=ori o o c, Step 4CI Step 5 6a Step 1: To a solution of methyl 2,4-dibromobutanoate (1.2 g, 1 equiv) in DMF
(15 mL) was added 4-chlorophenol (0.59 g, 1 equiv) at rt followed by K2003 (0.636 g, 1 equiv) and the reaction was stirred at 60 00 for 3 h. The reaction mixture was then allowed to warm to rt.
Water (5 mL) was added and the mixture was extracted with Et0Ac (3 X 50 mL).
The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under vacuum. The crude material was purified by flash column chromatography eluting the product at 10 `)/0 Et0Ac in hexane to provide methyl 4-bromo-2-(4-chlorophenoxy)butanoate as a gum (1 g). 1H NMR (400 MHz, CDCI3) 6 ppm 2.3 -2.5 (m, 2 H), 3.55 - 3.64 (m, 2 H), 3.76 (s, 3 H), 4.83 - 4.85 (m, 1 H), 6.86 (d, J =
3.2 Hz, 2 H), 7.23 - 7.25 (m, 2H).
Step 2: Methyl 4-bromo-2-(4-chlorophenoxy)butanoate (0.3 g, 1.01 mmol, 1 equiv) and tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.2 g, 1.01 mmol, 1 equiv) were charged to a sealed tube and Et3N (0.6 mL) was added. The mixture was then heated at 100 00 using an oil bath for 1 h. The reaction mixture was diluted with water (50 mL) and extracted with Et0Ac (2 X 50 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 45% Et0Ac in hexane to obtain the desired product tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (0.1 g, 25.6 `)/0). LCMS (ES) m/z = 337.1 [M+H]+ (loss of tert-butyl group). 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.44 (s, 9 H), 2.04- 2.18 (m, 1 H), 2.39 (s, 6 H), 2.46 - 2.54 (m, 1 H), 3.29 - 3.35 (m, 1 H), 3.42 - 3.47 (m, 1 H), 4.77 (t, J =
7.2 Hz, 1 H), 4.94 (bs, 1 H), 6.98 (d, J= 9.2 Hz, 2 H), 7.21 (d, J= 8.8 Hz, 2 H).
Step 3: To a solution of tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.1 g, 0.25 mmol) in DCM (5 mL) at 0 C was added 2 mL of 4 M HCI in 1,4-dioxane and the mixture was stirred at rt for 16 h. The reaction mixture was concentrated to give 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenoxy)pyrrolidin-2-one, hydrochloride (crude yield 0.08 g, 96.3%), which was
Step 1 0 Step 2 j=ori o o c, Step 4CI Step 5 6a Step 1: To a solution of methyl 2,4-dibromobutanoate (1.2 g, 1 equiv) in DMF
(15 mL) was added 4-chlorophenol (0.59 g, 1 equiv) at rt followed by K2003 (0.636 g, 1 equiv) and the reaction was stirred at 60 00 for 3 h. The reaction mixture was then allowed to warm to rt.
Water (5 mL) was added and the mixture was extracted with Et0Ac (3 X 50 mL).
The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under vacuum. The crude material was purified by flash column chromatography eluting the product at 10 `)/0 Et0Ac in hexane to provide methyl 4-bromo-2-(4-chlorophenoxy)butanoate as a gum (1 g). 1H NMR (400 MHz, CDCI3) 6 ppm 2.3 -2.5 (m, 2 H), 3.55 - 3.64 (m, 2 H), 3.76 (s, 3 H), 4.83 - 4.85 (m, 1 H), 6.86 (d, J =
3.2 Hz, 2 H), 7.23 - 7.25 (m, 2H).
Step 2: Methyl 4-bromo-2-(4-chlorophenoxy)butanoate (0.3 g, 1.01 mmol, 1 equiv) and tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.2 g, 1.01 mmol, 1 equiv) were charged to a sealed tube and Et3N (0.6 mL) was added. The mixture was then heated at 100 00 using an oil bath for 1 h. The reaction mixture was diluted with water (50 mL) and extracted with Et0Ac (2 X 50 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 45% Et0Ac in hexane to obtain the desired product tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (0.1 g, 25.6 `)/0). LCMS (ES) m/z = 337.1 [M+H]+ (loss of tert-butyl group). 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.44 (s, 9 H), 2.04- 2.18 (m, 1 H), 2.39 (s, 6 H), 2.46 - 2.54 (m, 1 H), 3.29 - 3.35 (m, 1 H), 3.42 - 3.47 (m, 1 H), 4.77 (t, J =
7.2 Hz, 1 H), 4.94 (bs, 1 H), 6.98 (d, J= 9.2 Hz, 2 H), 7.21 (d, J= 8.8 Hz, 2 H).
Step 3: To a solution of tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.1 g, 0.25 mmol) in DCM (5 mL) at 0 C was added 2 mL of 4 M HCI in 1,4-dioxane and the mixture was stirred at rt for 16 h. The reaction mixture was concentrated to give 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenoxy)pyrrolidin-2-one, hydrochloride (crude yield 0.08 g, 96.3%), which was
- 189 -taken to the next step without further purification. LCMS (ES) m/z = 293 [M+H]
+. H NMR
(400 MHz, DMSO-d6) 6 ppm 1.89 - 1.90 (m, 1 H), 2.18 - 2.19 (m, 1 H), 2.28 -2.33 (m, 6 H), 4.98 (t, J= 7.2 Hz, 1 H), 7.02 (d, J= 8.8 Hz, 2 H), 7.3 (d, J= 9.6 Hz, 1 H), 8.79 (s, 3 H).
Step 4: To a solution of 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenoxy)pyrrolidin-2-one hydrochloride (0.08 g, 0.24 mmol, 1 equiv) in THF (5 mL) was added BH3.Me2S (0.06 mL, 0.61 mmol, 2,5 equiv) at 0 C. The reaction mixture was then allowed to stir at rt for 16 h. The reaction mixture was quenched with Me0H (1 mL) at 0 C and stirred for 30 min, and concentrated under reduced pressure to obtain the crude product. This crude material was then dissolved in DCM (50 mL) and washed with saturated Na2HCO3 solution. The organic phase was dried over anhydrous Na2SO4, filtered and evaporated under vacuum to yield 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.06 g, crude yield), which was used for the next step without further purification. LCMS (ES) m/z= 279 [M+H] .
Step 5: To a solution of 2-(4-chlorophenoxy)acetic acid (0.06 g, 0.23 mmol, 1.5 equiv) in DCM (5 mL) at 0 C was added triethylamine (0.15 mL, 1.07 mmol, 5 equiv) followed by T3P (50 wt% in Et0Ac) (0.25 mL, 0.43 mmol, 2 equiv). The mixture was stirred at 0 C
for 10 min, at which time, T3P (50 wt. A, in ethyl acetate) (1.12 g, 1.768 mmol, 2 equiv) in dichloromethane (10 mL) was added at 000 and stirred for 10 min. To this reaction mixture was added 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.06 g) in DCM (1 mL) slowly at 0 C and the reaction was stirred at rt for 16 h. The reaction mixture was diluted with water (50 mL) and extracted with DCM (2 x 50 mL). The combined organic layer was washed with saturated aqueous NaH0O3 solution (50 mL) and then dried over .. anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude product was purified by preparative TLC using 40 % Et0Ac in hexanes. After final drying, the desired product 2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide was obtained as a white solid (0.0108 g, 11.2%).
LCMS (ES) m/z = 447.3 [M+H] . 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.76 - 1.77 (m, 1.5 H), 1.95 (s, 6 H), 2.2 - 2.27 (m, 1.5 H), 2.58 - 2.61 (m, 1 H), 2.65 - 2.69 (m, 1 H), 2.84 (m, 1 H), 4.4 (s, 2 H), 4.85 (bs, 1 H), 6.88 (d, J= 8.8 Hz, 2 H), 6.94 (d, J= 8.8 Hz, 2 H), 7.28 (d, J= 8.4 Hz, 2 H), 7.32 (d, J= 8.8 Hz, 2 H), 8.61 (s, 1 H).
+. H NMR
(400 MHz, DMSO-d6) 6 ppm 1.89 - 1.90 (m, 1 H), 2.18 - 2.19 (m, 1 H), 2.28 -2.33 (m, 6 H), 4.98 (t, J= 7.2 Hz, 1 H), 7.02 (d, J= 8.8 Hz, 2 H), 7.3 (d, J= 9.6 Hz, 1 H), 8.79 (s, 3 H).
Step 4: To a solution of 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenoxy)pyrrolidin-2-one hydrochloride (0.08 g, 0.24 mmol, 1 equiv) in THF (5 mL) was added BH3.Me2S (0.06 mL, 0.61 mmol, 2,5 equiv) at 0 C. The reaction mixture was then allowed to stir at rt for 16 h. The reaction mixture was quenched with Me0H (1 mL) at 0 C and stirred for 30 min, and concentrated under reduced pressure to obtain the crude product. This crude material was then dissolved in DCM (50 mL) and washed with saturated Na2HCO3 solution. The organic phase was dried over anhydrous Na2SO4, filtered and evaporated under vacuum to yield 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.06 g, crude yield), which was used for the next step without further purification. LCMS (ES) m/z= 279 [M+H] .
Step 5: To a solution of 2-(4-chlorophenoxy)acetic acid (0.06 g, 0.23 mmol, 1.5 equiv) in DCM (5 mL) at 0 C was added triethylamine (0.15 mL, 1.07 mmol, 5 equiv) followed by T3P (50 wt% in Et0Ac) (0.25 mL, 0.43 mmol, 2 equiv). The mixture was stirred at 0 C
for 10 min, at which time, T3P (50 wt. A, in ethyl acetate) (1.12 g, 1.768 mmol, 2 equiv) in dichloromethane (10 mL) was added at 000 and stirred for 10 min. To this reaction mixture was added 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.06 g) in DCM (1 mL) slowly at 0 C and the reaction was stirred at rt for 16 h. The reaction mixture was diluted with water (50 mL) and extracted with DCM (2 x 50 mL). The combined organic layer was washed with saturated aqueous NaH0O3 solution (50 mL) and then dried over .. anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude product was purified by preparative TLC using 40 % Et0Ac in hexanes. After final drying, the desired product 2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide was obtained as a white solid (0.0108 g, 11.2%).
LCMS (ES) m/z = 447.3 [M+H] . 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.76 - 1.77 (m, 1.5 H), 1.95 (s, 6 H), 2.2 - 2.27 (m, 1.5 H), 2.58 - 2.61 (m, 1 H), 2.65 - 2.69 (m, 1 H), 2.84 (m, 1 H), 4.4 (s, 2 H), 4.85 (bs, 1 H), 6.88 (d, J= 8.8 Hz, 2 H), 6.94 (d, J= 8.8 Hz, 2 H), 7.28 (d, J= 8.4 Hz, 2 H), 7.32 (d, J= 8.8 Hz, 2 H), 8.61 (s, 1 H).
- 190 -Example 6b (S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxY)PYrrolidin-1-YObicyclo11.1.11pentan-1-ynacetamide Example 6c (R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxftyrrolidin-1-Y1)bicycloll.1.11pentan-1-ynacetamide Separation of the enantiomers of Example 6b and 6c by chiral prep HPLC
purification:
Example 6a was subjected to chiral prep HPLC to obtain Example 6b and Example 6c by using the following conditions: Column: CHIRALPAK 1C (100mm x 4.6 mm x 3 mic), mobile phase: Hexane: IPA (85:15) with 0.1% DEA.
oCI
6b 0 o 410, 6a 0 o CI ______________________________________________________________ A
sc Comparing the observed VCD and IR spectra of example 6b with the calculated spectra of the modeled (R)- structure, the absolute configuration of example 6b was assigned as (S)-.
Comparing the observed VCD and IR spectra of example 6c with the calculated spectra of the modeled (R)- structure, the absolute configuration of example 6c was assigned as (R)-.
The Compounds of Examples 6d to 6e were prepared generally according to the procedure described above for Example 6a-6c.
purification:
Example 6a was subjected to chiral prep HPLC to obtain Example 6b and Example 6c by using the following conditions: Column: CHIRALPAK 1C (100mm x 4.6 mm x 3 mic), mobile phase: Hexane: IPA (85:15) with 0.1% DEA.
oCI
6b 0 o 410, 6a 0 o CI ______________________________________________________________ A
sc Comparing the observed VCD and IR spectra of example 6b with the calculated spectra of the modeled (R)- structure, the absolute configuration of example 6b was assigned as (S)-.
Comparing the observed VCD and IR spectra of example 6c with the calculated spectra of the modeled (R)- structure, the absolute configuration of example 6c was assigned as (R)-.
The Compounds of Examples 6d to 6e were prepared generally according to the procedure described above for Example 6a-6c.
- 191 -Table 12 (400 MHz, Cmpd # Structure Name miz DMSO-d6) [M+H]
CI
I* 1.76 - 1.77 (m, 1.5 H), 1.95 (s, 6 H), 2.2 - 2.27 =
r_< 2-(4-chlorophenoxy)-N-(3- (m, 1.5 H), 2.58 - 2.61 C N (3-(4- (m, 1 H), 2.65 - 2.69 (m, ) 6a chlorophenoxy)pyrrolidin- 1 H), 2.84 (m, 1 H), 4.4 447.3 1-yl)bicyclo[1.1.1]pentan- (s, 2 H), 4.85 (bs, 1 H), s:::44:1 1-yl)acetamide 6.88 (d, J= 8.8 Hz, 2 H), o) 6.94 (d, J= 8.8 Hz, 2 H), Oil 7.28 (d, J= 8.4 Hz, 2 H), 7.32 (d, J= 8.8 Hz, 2 H), I 8.61 (s, 1 H).
CI
* 1.76 - 1.75 (m, 1 H), 1.95 = (s, 6 H), 2.24 - 2.1 (m, 1 d=
(R)-2-(4-chlorophenoxy)- H), 2.68 - 2.48 (m, 3 H), N
6b N-(3-(3-(4- 2.87 - 2.83 (m, 1 H), 4.39 chlorophenoxy)pyrrolidin- 447.3 (s, 2 H), 4.84 (s, 1 H), o H 1-yl)bicyclo[1.1.1]pentan- 6.88 (d, J= 7.2 Hz, 2 H), 1-yl)acetamide 6.94 (d, J= 8.4 Hz, 2 H), iDT
7.28 (d, J= 9.2 Hz, 2 H), Olti 7.31 (d, J= 8.8 Hz, 2 H), 8.61 (s, 1 H).
CI
I* 1.76 - 1.77 (m, 1.5 H), 1.95 (s, 6 H), 2.2 - 2.27 =
r_< 2-(4-chlorophenoxy)-N-(3- (m, 1.5 H), 2.58 - 2.61 C N (3-(4- (m, 1 H), 2.65 - 2.69 (m, ) 6a chlorophenoxy)pyrrolidin- 1 H), 2.84 (m, 1 H), 4.4 447.3 1-yl)bicyclo[1.1.1]pentan- (s, 2 H), 4.85 (bs, 1 H), s:::44:1 1-yl)acetamide 6.88 (d, J= 8.8 Hz, 2 H), o) 6.94 (d, J= 8.8 Hz, 2 H), Oil 7.28 (d, J= 8.4 Hz, 2 H), 7.32 (d, J= 8.8 Hz, 2 H), I 8.61 (s, 1 H).
CI
* 1.76 - 1.75 (m, 1 H), 1.95 = (s, 6 H), 2.24 - 2.1 (m, 1 d=
(R)-2-(4-chlorophenoxy)- H), 2.68 - 2.48 (m, 3 H), N
6b N-(3-(3-(4- 2.87 - 2.83 (m, 1 H), 4.39 chlorophenoxy)pyrrolidin- 447.3 (s, 2 H), 4.84 (s, 1 H), o H 1-yl)bicyclo[1.1.1]pentan- 6.88 (d, J= 7.2 Hz, 2 H), 1-yl)acetamide 6.94 (d, J= 8.4 Hz, 2 H), iDT
7.28 (d, J= 9.2 Hz, 2 H), Olti 7.31 (d, J= 8.8 Hz, 2 H), 8.61 (s, 1 H).
- 192 -CI
* 1.76 - 1.75 (m, 1 H), 1.95 = (s, 6 H), 2.24 - 2.1 (m, 1 p 0 (S)-2-(4-chlorophenoxy)- H), 2.68 - 2.48 (m, 3 H), ni N-(3-(3-(4- 2.87 - 2.83 (m, 1 H), 4.39 6c chlorophenoxy)pyrrolidin- 447.3 (s, 2 H), 4.84 (s, 1 H), o IH 1-yl)bicyclo[1.1.1]pentan- 6.88 (d, J= 7.2 Hz, 2 H), 1-yl)acetamide 6.94 (d, J= 8.4 Hz, 2 H), oT
7.28 (d, J= 9.2 Hz, 2 H), 4 7.31 (d, J= 8.8 Hz, 2 H), 8.61 (s, 1 H).
ci I, 1.73 - 1.77 (m, 1 H), 1.95 (s, 6 H), 2.20 - 2.30 (m, 1 =
d N N-(3-(3-(4- H), 2.53 (d, J= 10.0 Hz, 1 H), 2.65 - 2.70 (m, 2 H
chlorophenoxy)pyrrolidin-), 2.83 - 2.88 (m, 1 H), 6d 4.37 (s 2 H) 4.84 (bs, 1 1-yl)bicyclo[1.1.1]pentan- 431.3 ' ' 0 44)11 1-yI)-2-(4-H), 6.88 (d, J= 8.8 Hz, 2 fluorophenoxy)acetamide H), 6.92 - 6.95 (m, 2 H), oT
7.10 (t, J= 8.8 Hz, 2 H), 140 7.28 (d, J= 8.8 Hz, 2 H), 8.59 (s, 1 H).
Isomer-1
* 1.76 - 1.75 (m, 1 H), 1.95 = (s, 6 H), 2.24 - 2.1 (m, 1 p 0 (S)-2-(4-chlorophenoxy)- H), 2.68 - 2.48 (m, 3 H), ni N-(3-(3-(4- 2.87 - 2.83 (m, 1 H), 4.39 6c chlorophenoxy)pyrrolidin- 447.3 (s, 2 H), 4.84 (s, 1 H), o IH 1-yl)bicyclo[1.1.1]pentan- 6.88 (d, J= 7.2 Hz, 2 H), 1-yl)acetamide 6.94 (d, J= 8.4 Hz, 2 H), oT
7.28 (d, J= 9.2 Hz, 2 H), 4 7.31 (d, J= 8.8 Hz, 2 H), 8.61 (s, 1 H).
ci I, 1.73 - 1.77 (m, 1 H), 1.95 (s, 6 H), 2.20 - 2.30 (m, 1 =
d N N-(3-(3-(4- H), 2.53 (d, J= 10.0 Hz, 1 H), 2.65 - 2.70 (m, 2 H
chlorophenoxy)pyrrolidin-), 2.83 - 2.88 (m, 1 H), 6d 4.37 (s 2 H) 4.84 (bs, 1 1-yl)bicyclo[1.1.1]pentan- 431.3 ' ' 0 44)11 1-yI)-2-(4-H), 6.88 (d, J= 8.8 Hz, 2 fluorophenoxy)acetamide H), 6.92 - 6.95 (m, 2 H), oT
7.10 (t, J= 8.8 Hz, 2 H), 140 7.28 (d, J= 8.8 Hz, 2 H), 8.59 (s, 1 H).
Isomer-1
- 193 -CI
* 1.73 - 1.77 (m, 1 H), 1.95 = (s, 6 H), 2.20 - 2.26 (m, 1 dH), 2.58 - 2.70 (m, 3 H), 2.83 - 2.88 (m, 1 H), 4.37 chlorophenoxy)pyrrolidin- (s, 2 H), 4.84 (bs, 1 H), 6e 1-yl)bicyclo[1.1.1]pentan- 431.3 6.88 (d, J= 8.8 Hz, 2 H), cs,/4:1 ) 1-yI)-2-(4- 6.92 - 6.95 (m, 2 H), 7.10 fluorophenoxy)acetamide 0 (t, J= 8.8 Hz, 2 H), 7.28 1011 (d, J= 8.8 Hz, 2 H), 8.59 (s, 1 H).
Isomer-2 F
1.74 - 1.77 (m, 1 H),1.96 ID(s, 6 H), 2.13 - 2.26 (m, 1 = H), 2.40 - 2.50 (m, 1 H), 2.58 - 2.60 (m, 1 H), 2.65 2-(4-chlorophenoxy)-N-(3- d N
- 2.70 (m, 1 H), 2.84 -(3-(4- 2.88 (m, 1 H), 4.40 (s, 2 6d & e fluorophenoxy)pyrrolidin-1- 431 H), 4.82 - 4.85 (m, 1 H), vl)bicyclop 1 1]pentan-1-0 H ' ' " 6.85 - 6.89 (m, 2 H), 6.95 yl)acetamide (d, J= 8.8 Hz, 2 H), 7.08 07 (t, J= 8.8 Hz, 2 H), 7.32 140 (d, J= 8.8 Hz, 2 H), 8.61 (s, 1 H).
I
* 1.73 - 1.77 (m, 1 H), 1.95 = (s, 6 H), 2.20 - 2.26 (m, 1 dH), 2.58 - 2.70 (m, 3 H), 2.83 - 2.88 (m, 1 H), 4.37 chlorophenoxy)pyrrolidin- (s, 2 H), 4.84 (bs, 1 H), 6e 1-yl)bicyclo[1.1.1]pentan- 431.3 6.88 (d, J= 8.8 Hz, 2 H), cs,/4:1 ) 1-yI)-2-(4- 6.92 - 6.95 (m, 2 H), 7.10 fluorophenoxy)acetamide 0 (t, J= 8.8 Hz, 2 H), 7.28 1011 (d, J= 8.8 Hz, 2 H), 8.59 (s, 1 H).
Isomer-2 F
1.74 - 1.77 (m, 1 H),1.96 ID(s, 6 H), 2.13 - 2.26 (m, 1 = H), 2.40 - 2.50 (m, 1 H), 2.58 - 2.60 (m, 1 H), 2.65 2-(4-chlorophenoxy)-N-(3- d N
- 2.70 (m, 1 H), 2.84 -(3-(4- 2.88 (m, 1 H), 4.40 (s, 2 6d & e fluorophenoxy)pyrrolidin-1- 431 H), 4.82 - 4.85 (m, 1 H), vl)bicyclop 1 1]pentan-1-0 H ' ' " 6.85 - 6.89 (m, 2 H), 6.95 yl)acetamide (d, J= 8.8 Hz, 2 H), 7.08 07 (t, J= 8.8 Hz, 2 H), 7.32 140 (d, J= 8.8 Hz, 2 H), 8.61 (s, 1 H).
I
- 194 -Example 6f and 6d N-(3-(3-(3-chlor0-4-fluorophenoxY)PYrrolidin-1-yObicyclo[1.1.11pentan-1-y1)-2-(4-chlorophenoxy)acetamide F
ci fik 0\....AN......40.....0 H
CI OH
WI 13'lc Br CI Br N.
µ--0 F "-' H CI
F
F goc Nii _Do.
Br = Step 1 * 0 \ step 3 Step 2 0 0.AOH
CI CI 1.
F CI
110 ...1R
N-0¨NH2HCI ¨ow Step F Si õCN¨<>¨NH2 W.
0 4 0 Step 5 CI
F 0 0 411, CI
100 e 1-<>---N-/
Cl ' 0 0 * CI _____________________ ISOrner 1 6f F
0 0 * C
F
I
______________________________________________ 110. 4 1 isomer 2 - 6g Step 1: To a solution of methyl 3-chloro-4-fluorophenol (2.0 g, 13.65 mmol, 1.0 equiv.) in DMF (50 mL) was added K2003 (1.88 g, 13.65 mmol, 1.0 equiv.) at 0 C, stirred for 10 mins and then methyl 2,4-dibromobutanoate (1.9 mL, 13.65 mmol, 1.0 equiv.) was added and the reaction was stirred at 60 C for 3 h. After consumption of the starting material (TLC, 10 A, ethyl acetate in hexane), the reaction mixture was diluted with ice cold water (100 mL) and was extracted with Et0Ac (2 X 100 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under vacuum. The crude material was purified by flash column chromatography eluting the product at 2 ¨ 5 A, Et0Ac in hexane to
ci fik 0\....AN......40.....0 H
CI OH
WI 13'lc Br CI Br N.
µ--0 F "-' H CI
F
F goc Nii _Do.
Br = Step 1 * 0 \ step 3 Step 2 0 0.AOH
CI CI 1.
F CI
110 ...1R
N-0¨NH2HCI ¨ow Step F Si õCN¨<>¨NH2 W.
0 4 0 Step 5 CI
F 0 0 411, CI
100 e 1-<>---N-/
Cl ' 0 0 * CI _____________________ ISOrner 1 6f F
0 0 * C
F
I
______________________________________________ 110. 4 1 isomer 2 - 6g Step 1: To a solution of methyl 3-chloro-4-fluorophenol (2.0 g, 13.65 mmol, 1.0 equiv.) in DMF (50 mL) was added K2003 (1.88 g, 13.65 mmol, 1.0 equiv.) at 0 C, stirred for 10 mins and then methyl 2,4-dibromobutanoate (1.9 mL, 13.65 mmol, 1.0 equiv.) was added and the reaction was stirred at 60 C for 3 h. After consumption of the starting material (TLC, 10 A, ethyl acetate in hexane), the reaction mixture was diluted with ice cold water (100 mL) and was extracted with Et0Ac (2 X 100 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under vacuum. The crude material was purified by flash column chromatography eluting the product at 2 ¨ 5 A, Et0Ac in hexane to
- 195 -afford methyl 4-bromo-2-(3-chloro-4-fluorophenoxy)butanoate as a light pink liquid (2.76 g, 62.0 % yield). 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.34 - 2.43 (m, 2 H), 3.58 -3.68 (m, 5 H), 4.98 - 5.04 (m, 1 H), 6.92 - 6.96 (m, 1 H), 7.18 - 7.21 (m, 1 H), 7.29 -7.40 (m, 1 H).
Step 2:10 a solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.8 g, 4.03 mmol, 1.0 equiv.) in Et3N (2.27 mL, 16.12 mmol, 4.0 equiv.) was added methyl 4-bromo-2-(3-chloro-4-fluorophenoxy)butanoate (1.57 g, 4.84 mmol, 1.2 equiv) at 0 C in a sealed tube and the mixture was then heated at 100 C using an oil bath for 1 h.
(Note: The reaction was carried out by dividing 0.8 g into 4 batches). After the consumption of the starting material (TLC, 50 % ethyl acetate in hexane), the reaction mixture was diluted with ethyl acetate (200 mL) and was washed with water (2 X 20 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 60 %
Et0Ac in hexane to obtain the desired product tert-butyl (3-(3-(3-chloro-4-fluorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as a colorless liquid (0.91 g, 55.1 %). LCMS (ES) m/z = 411 [M+H] , 355.0 [M+H] (loss of tert-butyl group). 1H
NMR (400 MHz, DMSO-d6) 6 ppm 1.44 (s, 9 H), 2.09 - 2.18 (m, 1 H), 2.39 (s, 6 H), 2.46 -2.54 (m, 1 H), 3.29 - 3.35 (m, 1 H), 3.42 - 3.47 (m, 1 H), 4.73 (t, J = 7.4 Hz, 1 H), 4.96 (bs, 1 H), 6.92 - 6.95 (m, 1 H), 7.00 - 7.04 (m, 1 H), 7.10 - 7.12 (m, 1 H).
Step 3: To a solution of tert-butyl (3-(3-(3-chloro-4-fluorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.91 g, 2.21 mmol, 1.0 equiv.) in DCM
(20 mL) at 0 C was added 10 mL of 4 M HCI in 1,4-dioxane and the mixture was stirred at rt for 3 h.
After the consumption of the starting material (TLC, 5 % Me0H in DCM), the reaction mixture was concentrated and the crude was triturated with n-pentane (2 X 10 mL) and dried under high vacuum to obtain 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(3-chloro-4-fluorophenoxy)pyrrolidin-2-one hydrochloride (crude yield 0.58 g, 85.2 /0), which was taken to the next step without further purification. LCMS (ES) m/z = 311.1 [M+H] +.
1H NMR (400 MHz, DMSO-d6) 6 ppm 1.87 - 1.96 (m, 1 H), 2.30 (q, J= 7.0 Hz, 6 H), 2.55 -2.58 (m, 1 H), 3.25 - 3.31 (m, 1 H), 3.39 (t, J = 8.0 Hz, 1 H), 5.02 (t, J = 7.6 Hz, 1 H), 6.99 - 7.01 (m, 1 H), 7.26 - 7.34 (m, 2 H), 8.79 (bs, 3 H).
Step 4: To a solution of 1-(3-aminobicyclo[1.1.1]pentan-1-y1)-3-(3-chloro-4-fluorophenoxy)pyrrolidin-2-one hydrochloride (0.75 g, 2.16 mmol, 1.0 equiv.) in THF (10 mL) was added BH3.Me2S (0.63 mL, 6.69 mmol, 3.1 equiv.) at 0 C and the reaction was stirred for 40 h. (Note: 0.75 g was divided into 2 batches and the reaction was performed.
Step 2:10 a solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.8 g, 4.03 mmol, 1.0 equiv.) in Et3N (2.27 mL, 16.12 mmol, 4.0 equiv.) was added methyl 4-bromo-2-(3-chloro-4-fluorophenoxy)butanoate (1.57 g, 4.84 mmol, 1.2 equiv) at 0 C in a sealed tube and the mixture was then heated at 100 C using an oil bath for 1 h.
(Note: The reaction was carried out by dividing 0.8 g into 4 batches). After the consumption of the starting material (TLC, 50 % ethyl acetate in hexane), the reaction mixture was diluted with ethyl acetate (200 mL) and was washed with water (2 X 20 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 60 %
Et0Ac in hexane to obtain the desired product tert-butyl (3-(3-(3-chloro-4-fluorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as a colorless liquid (0.91 g, 55.1 %). LCMS (ES) m/z = 411 [M+H] , 355.0 [M+H] (loss of tert-butyl group). 1H
NMR (400 MHz, DMSO-d6) 6 ppm 1.44 (s, 9 H), 2.09 - 2.18 (m, 1 H), 2.39 (s, 6 H), 2.46 -2.54 (m, 1 H), 3.29 - 3.35 (m, 1 H), 3.42 - 3.47 (m, 1 H), 4.73 (t, J = 7.4 Hz, 1 H), 4.96 (bs, 1 H), 6.92 - 6.95 (m, 1 H), 7.00 - 7.04 (m, 1 H), 7.10 - 7.12 (m, 1 H).
Step 3: To a solution of tert-butyl (3-(3-(3-chloro-4-fluorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.91 g, 2.21 mmol, 1.0 equiv.) in DCM
(20 mL) at 0 C was added 10 mL of 4 M HCI in 1,4-dioxane and the mixture was stirred at rt for 3 h.
After the consumption of the starting material (TLC, 5 % Me0H in DCM), the reaction mixture was concentrated and the crude was triturated with n-pentane (2 X 10 mL) and dried under high vacuum to obtain 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(3-chloro-4-fluorophenoxy)pyrrolidin-2-one hydrochloride (crude yield 0.58 g, 85.2 /0), which was taken to the next step without further purification. LCMS (ES) m/z = 311.1 [M+H] +.
1H NMR (400 MHz, DMSO-d6) 6 ppm 1.87 - 1.96 (m, 1 H), 2.30 (q, J= 7.0 Hz, 6 H), 2.55 -2.58 (m, 1 H), 3.25 - 3.31 (m, 1 H), 3.39 (t, J = 8.0 Hz, 1 H), 5.02 (t, J = 7.6 Hz, 1 H), 6.99 - 7.01 (m, 1 H), 7.26 - 7.34 (m, 2 H), 8.79 (bs, 3 H).
Step 4: To a solution of 1-(3-aminobicyclo[1.1.1]pentan-1-y1)-3-(3-chloro-4-fluorophenoxy)pyrrolidin-2-one hydrochloride (0.75 g, 2.16 mmol, 1.0 equiv.) in THF (10 mL) was added BH3.Me2S (0.63 mL, 6.69 mmol, 3.1 equiv.) at 0 C and the reaction was stirred for 40 h. (Note: 0.75 g was divided into 2 batches and the reaction was performed.
- 196 -1.5 equiv. of BH3.Me2S was added, stirred for 16 h, monitored the progress of the reaction, added again 0.8 equiv. of BH3.Me2S, stirred for 8 h and again 0.8 equiv. of BH3.Me2S was added and the reaction was stirred for 16 h.). Then the reaction mixture was cooled to 0 C, quenched with Me0H (5 mL), stirred for 30 min, and concentrated under reduced pressure to obtain the crude product. This crude material was triturated with n-pentane (50 mL) and dried under high vacuum to yield 3-(3-(3-chloro-4-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine as an off-white solid (0.56 g, crude yield), which was used for the next step without further purification. LCMS (ES) m/z= 297.1 [M+H] .
Step 5: To a solution of 2-(4-chlorophenoxy)acetic acid (0.42 g, 0.23 mmol, 1.2 equiv.) in DCM (5 mL) at 000 was added triethylamine (1.06 mL, 7.52 mmol, 4.0 equiv.), stirred for 10 mins, followed by addition of T3P (50 wt% in Et0Ac) (2.25 mL, 3.76 mmol, 2 equiv).
The mixture was stirred at 0 C for 10 min and then 3-(3-(3-chloro-4-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.56 g, 1.88 mmol, 1.0 equiv.) in DCM (5 mL) was slowly added at 0 C and the reaction was stirred at rt for 16 h. After the consumption of the starting material (TLC, 70 % ethyl acetate in hexane), the reaction mixture was diluted with DCM (150 mL) and washed with saturated NaHCO3 (2 x 10 mL) and water (2 x 10 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude material was purified by column chromatography using an eluent of 70 - 80 % Et0Ac in hexane to obtain the desired product N-(3-(3-(3-chloro-4-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide as a white solid (0.21 g, 24.1 /0). Racemic product was further submitted for chiral prep HPLC to separate the isomers by using the following analytical conditions: [Column: CHIRALPAK IC (100 mm x 4.6 mm x 3 mic); Flow rate: 1.0 mL/min; Mobile phase: n-Hexane:IPA with 0.1 A, DEA (85:15)]. Fractions containing product were evaporated separately under reduced pressure, washed with n-pentane (10 mL) and dried under high vacuum.
Isomer 1 (6f, Single Unknown stereochemistry):
Recovery: 0.055 g (as off white solid). LCMS (ES) m/z = 465.3 [M+H] +. 1H NMR
(400 MHz, DMSO-d6) 6 ppm 1.76 (bs, 1 H), 1.95 (s, 6 H), 2.21 - 2.23 (m, 1 H), 2.58 -2.68 (m, 3 H), 2.82 - 2.88 (m, 1 H), 4.40 (s, 2 H), 4.87 (bs, 1 H), 6.88 (s, 1 H), 6.94 (d, J = 8.4 Hz, 2 H), 7.08 (s, 1 H), 7.27 - 7.32 (m, 3 H), 8.62 (s, 1 H). Chiral HPLC purity:
100.0 % at 220 nm ; % ee: 100.0 %
Isomer 2 (6g, Single Unknown stereochemistry):
Step 5: To a solution of 2-(4-chlorophenoxy)acetic acid (0.42 g, 0.23 mmol, 1.2 equiv.) in DCM (5 mL) at 000 was added triethylamine (1.06 mL, 7.52 mmol, 4.0 equiv.), stirred for 10 mins, followed by addition of T3P (50 wt% in Et0Ac) (2.25 mL, 3.76 mmol, 2 equiv).
The mixture was stirred at 0 C for 10 min and then 3-(3-(3-chloro-4-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.56 g, 1.88 mmol, 1.0 equiv.) in DCM (5 mL) was slowly added at 0 C and the reaction was stirred at rt for 16 h. After the consumption of the starting material (TLC, 70 % ethyl acetate in hexane), the reaction mixture was diluted with DCM (150 mL) and washed with saturated NaHCO3 (2 x 10 mL) and water (2 x 10 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude material was purified by column chromatography using an eluent of 70 - 80 % Et0Ac in hexane to obtain the desired product N-(3-(3-(3-chloro-4-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide as a white solid (0.21 g, 24.1 /0). Racemic product was further submitted for chiral prep HPLC to separate the isomers by using the following analytical conditions: [Column: CHIRALPAK IC (100 mm x 4.6 mm x 3 mic); Flow rate: 1.0 mL/min; Mobile phase: n-Hexane:IPA with 0.1 A, DEA (85:15)]. Fractions containing product were evaporated separately under reduced pressure, washed with n-pentane (10 mL) and dried under high vacuum.
Isomer 1 (6f, Single Unknown stereochemistry):
Recovery: 0.055 g (as off white solid). LCMS (ES) m/z = 465.3 [M+H] +. 1H NMR
(400 MHz, DMSO-d6) 6 ppm 1.76 (bs, 1 H), 1.95 (s, 6 H), 2.21 - 2.23 (m, 1 H), 2.58 -2.68 (m, 3 H), 2.82 - 2.88 (m, 1 H), 4.40 (s, 2 H), 4.87 (bs, 1 H), 6.88 (s, 1 H), 6.94 (d, J = 8.4 Hz, 2 H), 7.08 (s, 1 H), 7.27 - 7.32 (m, 3 H), 8.62 (s, 1 H). Chiral HPLC purity:
100.0 % at 220 nm ; % ee: 100.0 %
Isomer 2 (6g, Single Unknown stereochemistry):
- 197 -Recovery: 0.025 g (as off white solid). LCMS (ES) m/z = 465.3 [M+H] +. H NMR
(400 MHz, DMSO-d6) 6 ppm 1.74 (bs, 1 H), 1.95 (s, 6 H), 2.21 - 2.22 (m, 1 H), 2.58 -2.68 (m, 3 H), 2.82 - 2.88 (m, 1 H), 4.39 (s, 2 H), 4.86 (bs, 1 H), 6.87 (s, 1 H), 6.94 (d, J = 7.6 Hz, 2 H), 7.07 (s, 1 H), 7.26 - 7.32 (m, 3 H), 8.60 (s, 1 H). Chiral HPLC purity:
100.0 % at 225 nm ; ee: 100.0 /0.
Table 13 LCMS m/z 1H-NMR (400 MHz, Cmpd # Structure Name [M
DMSO-d6) +Hr F CI
1.76 (bs, 1 H), 1.95 (s, 6 N-(3-(3-(3-chloro-4- H), 2.21 - 2.23 (m, 1 H), 2.58 - 2.68 (m, 3 H), 2.82 6f fluorophenoxy)pyrrolidin-1- 465 - 2.88 (m, 1 H), 4.40 (s, 2 .3 yl)bicyclo[1.1.1]pentan-1-yI)-2- H), 4.87 (bs, 1 H), 6.88 (s, 0) (4-chlorophenoxy)acetamide 1 H), 6.94 (d, J= 8.4 Hz, 2 011) H), 7.08 (s, 1 H), 7.27 -7.32 (m, 3 H), 8.62 (s, 1 H).
isomer 1 F CI
1.74 (bs, 1 H), 1.95 (s, 6 H), 2.21 -2.22 (m, 1 H), 2.58 - 2.68 (m, 3 H), 2.82 N-(3-(3-(3-chloro-4- - 2.88 (m, 1 H), 4.39 (s, 2 fluorophenoxy)pyrrolidin-1- 465.3 H), 4.86 (bs, 1 H), 6.87 (s, 6g yl)bicyclo[1.1.1]pentan-1-yI)-2- 1 H), 6.94 (d, J=
7.6 Hz, 2 0) (4-chlorophenoxy)acetamide H), 7.07 (s, 1 H), 7.26 -7.32 (m, 3 H), 8.60 (s, 1 H).
isomer 2
(400 MHz, DMSO-d6) 6 ppm 1.74 (bs, 1 H), 1.95 (s, 6 H), 2.21 - 2.22 (m, 1 H), 2.58 -2.68 (m, 3 H), 2.82 - 2.88 (m, 1 H), 4.39 (s, 2 H), 4.86 (bs, 1 H), 6.87 (s, 1 H), 6.94 (d, J = 7.6 Hz, 2 H), 7.07 (s, 1 H), 7.26 - 7.32 (m, 3 H), 8.60 (s, 1 H). Chiral HPLC purity:
100.0 % at 225 nm ; ee: 100.0 /0.
Table 13 LCMS m/z 1H-NMR (400 MHz, Cmpd # Structure Name [M
DMSO-d6) +Hr F CI
1.76 (bs, 1 H), 1.95 (s, 6 N-(3-(3-(3-chloro-4- H), 2.21 - 2.23 (m, 1 H), 2.58 - 2.68 (m, 3 H), 2.82 6f fluorophenoxy)pyrrolidin-1- 465 - 2.88 (m, 1 H), 4.40 (s, 2 .3 yl)bicyclo[1.1.1]pentan-1-yI)-2- H), 4.87 (bs, 1 H), 6.88 (s, 0) (4-chlorophenoxy)acetamide 1 H), 6.94 (d, J= 8.4 Hz, 2 011) H), 7.08 (s, 1 H), 7.27 -7.32 (m, 3 H), 8.62 (s, 1 H).
isomer 1 F CI
1.74 (bs, 1 H), 1.95 (s, 6 H), 2.21 -2.22 (m, 1 H), 2.58 - 2.68 (m, 3 H), 2.82 N-(3-(3-(3-chloro-4- - 2.88 (m, 1 H), 4.39 (s, 2 fluorophenoxy)pyrrolidin-1- 465.3 H), 4.86 (bs, 1 H), 6.87 (s, 6g yl)bicyclo[1.1.1]pentan-1-yI)-2- 1 H), 6.94 (d, J=
7.6 Hz, 2 0) (4-chlorophenoxy)acetamide H), 7.07 (s, 1 H), 7.26 -7.32 (m, 3 H), 8.60 (s, 1 H).
isomer 2
- 198 -Example 6h N-(3-(3-(4-chlorophenoxV)PVrrolidin-1-vnbicyclo11.1.11pentan-1-v0-24(5-chloropyridin-2-vpoxv)acetamide CI
C1.-0-. 4 H
Br Br ci * OH ci B1) BOc..Ø...NH2 0 r C)".. Step 1 * 0 C).... -- Step 2 -- 10 0*.q1¨<>¨Nli 1r ¨ills.
Step 3 CI
.13...
...Ø ". JOH
CI /61 0....CN¨O¨NH2 HCI _ii.. CI
Step 4 Step 7 V
6h BrIC'\
}3FI
ciCI Step kr C')C
Step 6 k)4/ )CF1 CI " CI
Step 1: To a solution of 4-chlorophenol (3.9 g, 30.46 mmol, 1.0 equiv.) in DMF
(180 mL), K2003 (4.2 g, 30.46 mmol, 1.0 equiv) was added followed by the addition of methyl-2,4-dibromobutanoate (4.26 mL, 30.46 mmol, 1.0 equiv.) at room temperature and the reaction was stirred at 60 C for 3 h (Note: Reaction was performed by dividing 3.9 g into 3 batches.). After the completion of the reaction (TLC, 10% Et0Ac in hexane), the reaction mixture was then allowed to come to room temperature. Water (200 mL) was added and the mixture was extracted with Et0Ac (3 X 100 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under vacuum. The crude material was purified by flash column chromatography eluting the product at 5 % Et0Ac in hexane to provide methyl 4-bromo-2-(4-chlorophenoxy)butanoate as a colorless liquid (5.8 g, 62.0 %
yield). 1H NMR (400 MHz, CDCI3) 6 ppm 2.42 ¨ 2.52 (m, 2 H), 3.52 ¨ 3.60 (m, 2 H), 3.76 (s, 3 H), 4.82 ¨4.85 (m, 1 H), 6.85 (d, J= 8.4 Hz, 2 H), 7.26 (d, J= 8.0 Hz, 2 H).
Step 2: To a solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (3.64 g,
C1.-0-. 4 H
Br Br ci * OH ci B1) BOc..Ø...NH2 0 r C)".. Step 1 * 0 C).... -- Step 2 -- 10 0*.q1¨<>¨Nli 1r ¨ills.
Step 3 CI
.13...
...Ø ". JOH
CI /61 0....CN¨O¨NH2 HCI _ii.. CI
Step 4 Step 7 V
6h BrIC'\
}3FI
ciCI Step kr C')C
Step 6 k)4/ )CF1 CI " CI
Step 1: To a solution of 4-chlorophenol (3.9 g, 30.46 mmol, 1.0 equiv.) in DMF
(180 mL), K2003 (4.2 g, 30.46 mmol, 1.0 equiv) was added followed by the addition of methyl-2,4-dibromobutanoate (4.26 mL, 30.46 mmol, 1.0 equiv.) at room temperature and the reaction was stirred at 60 C for 3 h (Note: Reaction was performed by dividing 3.9 g into 3 batches.). After the completion of the reaction (TLC, 10% Et0Ac in hexane), the reaction mixture was then allowed to come to room temperature. Water (200 mL) was added and the mixture was extracted with Et0Ac (3 X 100 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under vacuum. The crude material was purified by flash column chromatography eluting the product at 5 % Et0Ac in hexane to provide methyl 4-bromo-2-(4-chlorophenoxy)butanoate as a colorless liquid (5.8 g, 62.0 %
yield). 1H NMR (400 MHz, CDCI3) 6 ppm 2.42 ¨ 2.52 (m, 2 H), 3.52 ¨ 3.60 (m, 2 H), 3.76 (s, 3 H), 4.82 ¨4.85 (m, 1 H), 6.85 (d, J= 8.4 Hz, 2 H), 7.26 (d, J= 8.0 Hz, 2 H).
Step 2: To a solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (3.64 g,
- 199 -18.38 mmol, 1.0 equiv) in Et3N (10.5 mL, 73.52 mmol, 4.0 equiv.) in a sealed tube was added methyl 4-bromo-2-(4-chlorophenoxy)butanoate (5.67 g, 18.38 mmol, 1.0 equiv.) and the mixture was heated at 100 C for 1 h. (Note: Reaction was performed in multiple batches like 0.52 g x 7). After completion of the reaction (TLC, 50 `)/0 Et0Ac in hexane), the reaction mixture was diluted with water (100 mL) and extracted with DCM (2 X
100 mL).
The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 35 `)/0 Et0Ac in hexane to obtain the desired product tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (3.0 g, 42.0%
yield). LCMS (ES) m/z = 393.1 [M+H] . 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.44 (s, 9 H), 2.11 -2.18 (m, 1 H), 2.39 (s, 6 H), 2.48 - 2.51 (m, 1 H), 3.32 - 3.35 (m, 1 H), 3.43 - 3.47 (m, 1 H), 4.77 (t, J= 7.0 Hz, 1 H), 4.95 (s, 1 H), 6.98 (d, J= 6.8 Hz, 2 H), 7.21 (d, J= 7.2 Hz, 2 H).
Step 3: To a solution of tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (1.8 g, 4.58 mmol, 1.0 equiv.) in THF
(30 mL) was added BH3.Me2S (0.87 mL, 9.16 mmol, 3 equiv) at 0 C. (Note: 1.8 g was divided into 2 batches and the reaction was performed). After completion of the reaction (TLC, 50 `)/0 Et0Ac in hexane), the reaction mixture was quenched with methanol at 0 C and stirred for 2 h. The reaction mixture was concentrated under reduced pressure to give crude product, which was diluted with water (200 mL) and extracted with DCM (3 X 100 mL). The combined organic layer was washed with brine solution (100 mL) and dried over anhydrous Na2SO4, filtered and concentrated to obtain the crude product. The curde material was purified by silica gel column chromatography using 55 `)/0 Et0Ac in hexane as an eluent to yield tert-butyl (3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (0.8 g, 46.24% yield). LCMS (ES) m/z = 379.1 [M+H] . 1H
NMR (400 MHz, DMSO-d6) 6 ppm 1.44 (s, 9 H), 1.91 (bs, 1 H), 2.03 (s, 6 H), 2.17 - 2.32 (m, 1 H), 2.60 - 2.61 (m, 1 H), 2.76 - 2.84 (m, 2 H), 2.95 (bs, 1 H), 4.78 (s, 1 H), 4.89 (s, 1 H), 6.76 (d, J= 8.8 Hz, 2 H), 7.21 (d, J= 8.8 Hz, 2 H).
Step 4: To a solution of tert-butyl (3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.8 g, 2.11 mmol, 1.0 equiv.) in DCM
(10 mL) at 0 C was added 5 mL of 4 M HCI in 1,4-dioxane and the mixture was stirred at room temperature for 16 h. After completion of the reaction (TLC, 5 `)/0 Me0H in DCM), the reaction mixture was concentrated to obtain 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine hydrochloride (crude yield 0.65 g, 98.48 `)/0 yield), which
100 mL).
The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 35 `)/0 Et0Ac in hexane to obtain the desired product tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (3.0 g, 42.0%
yield). LCMS (ES) m/z = 393.1 [M+H] . 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.44 (s, 9 H), 2.11 -2.18 (m, 1 H), 2.39 (s, 6 H), 2.48 - 2.51 (m, 1 H), 3.32 - 3.35 (m, 1 H), 3.43 - 3.47 (m, 1 H), 4.77 (t, J= 7.0 Hz, 1 H), 4.95 (s, 1 H), 6.98 (d, J= 6.8 Hz, 2 H), 7.21 (d, J= 7.2 Hz, 2 H).
Step 3: To a solution of tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (1.8 g, 4.58 mmol, 1.0 equiv.) in THF
(30 mL) was added BH3.Me2S (0.87 mL, 9.16 mmol, 3 equiv) at 0 C. (Note: 1.8 g was divided into 2 batches and the reaction was performed). After completion of the reaction (TLC, 50 `)/0 Et0Ac in hexane), the reaction mixture was quenched with methanol at 0 C and stirred for 2 h. The reaction mixture was concentrated under reduced pressure to give crude product, which was diluted with water (200 mL) and extracted with DCM (3 X 100 mL). The combined organic layer was washed with brine solution (100 mL) and dried over anhydrous Na2SO4, filtered and concentrated to obtain the crude product. The curde material was purified by silica gel column chromatography using 55 `)/0 Et0Ac in hexane as an eluent to yield tert-butyl (3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (0.8 g, 46.24% yield). LCMS (ES) m/z = 379.1 [M+H] . 1H
NMR (400 MHz, DMSO-d6) 6 ppm 1.44 (s, 9 H), 1.91 (bs, 1 H), 2.03 (s, 6 H), 2.17 - 2.32 (m, 1 H), 2.60 - 2.61 (m, 1 H), 2.76 - 2.84 (m, 2 H), 2.95 (bs, 1 H), 4.78 (s, 1 H), 4.89 (s, 1 H), 6.76 (d, J= 8.8 Hz, 2 H), 7.21 (d, J= 8.8 Hz, 2 H).
Step 4: To a solution of tert-butyl (3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.8 g, 2.11 mmol, 1.0 equiv.) in DCM
(10 mL) at 0 C was added 5 mL of 4 M HCI in 1,4-dioxane and the mixture was stirred at room temperature for 16 h. After completion of the reaction (TLC, 5 `)/0 Me0H in DCM), the reaction mixture was concentrated to obtain 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine hydrochloride (crude yield 0.65 g, 98.48 `)/0 yield), which
- 200 -was taken to the next step without further purification. LCMS (ES) m/z = 279.1 [M+H] +. 1H
NMR (400 MHz, DMSO-d6) 6 ppm 2.09 (bs, 1 H), 2.24 (s, 6 H), 3.30- 3.67 (m, 5 H), 5.10 (s, 1 H), 6.96 (d, J= 8.8 Hz, 2 H), 7.34 (d, J= 8.8 Hz, 2 H), 9.10 (s, 3 H).
Step 5: To a solution of 5-chloropyridin-2-ol (2.0 g, 15.44 mmol, 1.0 equiv.) in DMF (20 mL) was added silver carbonate (5.96 g, 21.61 mmol, 1.4 equiv.) at 0 C, stirred for 10 min and then ethyl 2-bromoacetate (2.56 mL, 23.16 mmol, 1.5 equiv.) was added and the mixture was heated at 80 C for 2 h. After the completion of the reaction (TLC, 20 %
Et0Ac in hexane), the reaction mixture was filtered through a Celite bed, and washed the Celite bed with ethyl acetate (100 mL). The filtrate was evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 10 - 15 `)/0 Et0Ac in hexane to obtain the desired product ethyl 2-((5-chloropyridin-2-yl)oxy)acetate as a colorless liquid (0.67 g, 20.0% yield). LCMS (ES) m/z = 216.1 [M+H]+ 1H NMR
(400 MHz, DMSO-d6) 6 ppm 1.15 (t, J= 7.0 Hz, 3 H), 4.10 (q, J= 6.9 Hz, 2 H), 4.87 (s, 2 H), 6.97 (d, J
= 8.8 Hz, 1 H), 7.83 (d, J= 8.4 Hz, 1 H), 8.16 (s, 1 H).
Step 6: To a solution of ethyl 2-((5-chloropyridin-2-yl)oxy)acetate (0.67 g, 3.11 mmol, 1.0 equiv.) in THF (4 mL) and water (4 mL) was added lithium hydroxide monohydrate (1.3 g, 31.1 mmol, 10.0 equiv.) at 0 C and the mixture was stirred at room temperature for 6 h.
After the completion of the reaction (TLC, 5 `)/0 Me0H in DCM), the reaction mixture was evaporated under vacuum and the aqueous layer was extracted with ethyl acetate (2 x 10 mL). Then the aqueous layer was cooled to 0 C and acidified with concentrated HCI (pH
adjusted to 1) and was extracted with ethyl acetate (2 x 50 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The crude material was triturated with n-pentane (2 x 5 mL) and dried under high vacuum to obtain the desired product 2-((5-chloropyridin-2-yl)oxy)acetic acid as an off-white solid (0.43 g, 73.9 `)/0 yield).
LCMS (ES) m/z = 188.0 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 4.79 (s, 2 H), 6.94 (d, J= 8.8 Hz, 1 H), 7.82 (dd, J= 8.8 Hz, 2.4 Hz, 1 H), 8.162 - 8.168 (m, 1 H), 12.85 (bs, 1 H).
Step 7: To a solution of 2-((5-chloropyridin-2-yl)oxy)acetic acid (0.054 g, 0.28 mmol, 1.5 equiv.) in DCM (6 mL) at 0 C was added triethylamine (0.11 mL, 0.76 mmol, 4.0 equiv), stirred for 10 mins and T3P (50 wt% in Et0Ac) (0.23 mL, 0.38 mmol, 2.0 equiv.) was added. The reaction mixture was stirred at 0 C for 10 min and then 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine hydrochloride (0.06 g, 0.19 mmol, 1.0 equiv.) (which was neutralized with triethyl amine in DCM) was added at 0 C
NMR (400 MHz, DMSO-d6) 6 ppm 2.09 (bs, 1 H), 2.24 (s, 6 H), 3.30- 3.67 (m, 5 H), 5.10 (s, 1 H), 6.96 (d, J= 8.8 Hz, 2 H), 7.34 (d, J= 8.8 Hz, 2 H), 9.10 (s, 3 H).
Step 5: To a solution of 5-chloropyridin-2-ol (2.0 g, 15.44 mmol, 1.0 equiv.) in DMF (20 mL) was added silver carbonate (5.96 g, 21.61 mmol, 1.4 equiv.) at 0 C, stirred for 10 min and then ethyl 2-bromoacetate (2.56 mL, 23.16 mmol, 1.5 equiv.) was added and the mixture was heated at 80 C for 2 h. After the completion of the reaction (TLC, 20 %
Et0Ac in hexane), the reaction mixture was filtered through a Celite bed, and washed the Celite bed with ethyl acetate (100 mL). The filtrate was evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 10 - 15 `)/0 Et0Ac in hexane to obtain the desired product ethyl 2-((5-chloropyridin-2-yl)oxy)acetate as a colorless liquid (0.67 g, 20.0% yield). LCMS (ES) m/z = 216.1 [M+H]+ 1H NMR
(400 MHz, DMSO-d6) 6 ppm 1.15 (t, J= 7.0 Hz, 3 H), 4.10 (q, J= 6.9 Hz, 2 H), 4.87 (s, 2 H), 6.97 (d, J
= 8.8 Hz, 1 H), 7.83 (d, J= 8.4 Hz, 1 H), 8.16 (s, 1 H).
Step 6: To a solution of ethyl 2-((5-chloropyridin-2-yl)oxy)acetate (0.67 g, 3.11 mmol, 1.0 equiv.) in THF (4 mL) and water (4 mL) was added lithium hydroxide monohydrate (1.3 g, 31.1 mmol, 10.0 equiv.) at 0 C and the mixture was stirred at room temperature for 6 h.
After the completion of the reaction (TLC, 5 `)/0 Me0H in DCM), the reaction mixture was evaporated under vacuum and the aqueous layer was extracted with ethyl acetate (2 x 10 mL). Then the aqueous layer was cooled to 0 C and acidified with concentrated HCI (pH
adjusted to 1) and was extracted with ethyl acetate (2 x 50 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The crude material was triturated with n-pentane (2 x 5 mL) and dried under high vacuum to obtain the desired product 2-((5-chloropyridin-2-yl)oxy)acetic acid as an off-white solid (0.43 g, 73.9 `)/0 yield).
LCMS (ES) m/z = 188.0 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 4.79 (s, 2 H), 6.94 (d, J= 8.8 Hz, 1 H), 7.82 (dd, J= 8.8 Hz, 2.4 Hz, 1 H), 8.162 - 8.168 (m, 1 H), 12.85 (bs, 1 H).
Step 7: To a solution of 2-((5-chloropyridin-2-yl)oxy)acetic acid (0.054 g, 0.28 mmol, 1.5 equiv.) in DCM (6 mL) at 0 C was added triethylamine (0.11 mL, 0.76 mmol, 4.0 equiv), stirred for 10 mins and T3P (50 wt% in Et0Ac) (0.23 mL, 0.38 mmol, 2.0 equiv.) was added. The reaction mixture was stirred at 0 C for 10 min and then 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine hydrochloride (0.06 g, 0.19 mmol, 1.0 equiv.) (which was neutralized with triethyl amine in DCM) was added at 0 C
- 201 -and the reaction was stirred at room temperature for 2 h. After the consumption of the starting material (TLC, 5 `)/0 Me0H in DCM), the reaction mixture was diluted with DCM
(100 mL) and was washed with saturated aqueous NaHCO3 solution (2 x 10 mL) and water (2 x 10 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure to get the crude. The crude product was purified by silica gel column chromatography using 6 - 7 `)/0 Me0H in DCM as an eluent to afford the desired product N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)-2-((5-chloropyridin-2-yl)oxy)acetamide as an off-white solid (0.06 g, 70.6 `)/0 yield).
LCMS (ES) m/z = 448.3 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.73 ¨ 1.76 (m, H), 1.95 (s, 6 H), 2.17¨ 2.26 (m, 1 H), 2.56 ¨2.69 (m, 3 H), 2.82 ¨2.86 (m, 1 H), 4.63 (s, 2 H), 4.82 ¨ 4.84 (m, 1 H), 6.86 ¨ 6.93 (s, 3 H), 7.28 (d, J = 9.2 Hz, 2 H), 7.81 (dd, J = 8.8 Hz, 6.4 Hz, 1 H), 8.14 (d, J= 2.0 Hz, 1 H), 8.55 (s, 1 H).
Example 61 N-(3-(3-(4-chlorophenoxY)PYrrolidin-l-yObicyclo[1.1.11pentan-l-y1)-2-(4-(trifluoromethyl)phenoxy)acetamide CF
I* OC\IN)L" 4 3 H
Br lir& OH
51/*** Br Boc ,ii.....0õ...NH
Boc -3...
Br (:)"%. Step 1 2 CI ID 0 ,.. Step 2 IW 0 Step 3 HCI F3C 4111111" ceq-00¨NH2 CI Amish r...\_40)_NH2 ___________________________________________________________________ DI.
Step 4 r o'L/ Step 5 0 0 *ci cF3 0 0,01-40--Ni
(100 mL) and was washed with saturated aqueous NaHCO3 solution (2 x 10 mL) and water (2 x 10 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure to get the crude. The crude product was purified by silica gel column chromatography using 6 - 7 `)/0 Me0H in DCM as an eluent to afford the desired product N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)-2-((5-chloropyridin-2-yl)oxy)acetamide as an off-white solid (0.06 g, 70.6 `)/0 yield).
LCMS (ES) m/z = 448.3 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.73 ¨ 1.76 (m, H), 1.95 (s, 6 H), 2.17¨ 2.26 (m, 1 H), 2.56 ¨2.69 (m, 3 H), 2.82 ¨2.86 (m, 1 H), 4.63 (s, 2 H), 4.82 ¨ 4.84 (m, 1 H), 6.86 ¨ 6.93 (s, 3 H), 7.28 (d, J = 9.2 Hz, 2 H), 7.81 (dd, J = 8.8 Hz, 6.4 Hz, 1 H), 8.14 (d, J= 2.0 Hz, 1 H), 8.55 (s, 1 H).
Example 61 N-(3-(3-(4-chlorophenoxY)PYrrolidin-l-yObicyclo[1.1.11pentan-l-y1)-2-(4-(trifluoromethyl)phenoxy)acetamide CF
I* OC\IN)L" 4 3 H
Br lir& OH
51/*** Br Boc ,ii.....0õ...NH
Boc -3...
Br (:)"%. Step 1 2 CI ID 0 ,.. Step 2 IW 0 Step 3 HCI F3C 4111111" ceq-00¨NH2 CI Amish r...\_40)_NH2 ___________________________________________________________________ DI.
Step 4 r o'L/ Step 5 0 0 *ci cF3 0 0,01-40--Ni
- 202 -Step 1: To a solution of methyl 2,4-dibromobutanoate (2 g, 7.69 mmol, 1 equiv) in DMF (60 mL) was added 4-chlorophenol (0.98 g, 7.69 mmol, 1 equiv) at rt followed by K2003 (1.06 g, 7.69 mmol, 1 equiv) and the reaction was stirred at 60 00 for 3 h. The reaction mixture was then allowed to come to rt, ice cold water (100 mL) was added and the mixture was .. extracted with Et0Ac (2 X 100 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under vacuum. The crude material was purified by flash column chromatography eluting the product at 3.7 % Et0Ac in hexane to afford methyl 4-bromo-2-(4-chlorophenoxy)butanoate as a gum (1.3 g, 56 %). LCMS (ES) m/z =
308 [M+H] +, 1H NMR (400 MHz, CDCI3) 6 ppm 2.44 - 2.52 (m, 2 H), 3.48 - 3.58 (m, 2 H), 3.76 (s, 3 H), 4.83 -4.85 (m, 1 H), 6.84- 6.86 (m, 2 H), 7.23 -7.25 (m, 2 H).
Step 2: Note: - This reaction was performed in two batches, each batch with 0.4 g, ie 2 X
0.4 g = 0.8 g]. Methyl 4-bromo-2-(4-chlorophenoxy)butanoate (0.62 g, 2.02 mmol, 1 equiv) and tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.4 g, 2.02 mmol, 1 equiv) were charged to a sealed tube and Et3N (1.1 mL, 8.08 mmol , 4 equiv) was added. The reaction mixtures were then heated at 100 C using an oil bath for 1.5 h.
After completion, the reaction mixtures were cooled to room temperature, diluted with water (15 mL) and extracted with Et0Ac (2 X 50 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 35% Et0Ac in hexane to obtain the desired product tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (0.7 g, 70 /0). LCMS (ES) m/z = 393.1 [M+H] .1H NMR
(400 MHz, 0D013-d6) 6 ppm 1.44 (s, 9 H), 2.13 - 2.16 (m, 1 H), 2.39 (s, 6 H), 2.45 - 2.50 (m, 1 H), 3.31 - 3.33 (m, 1 H), 3.43 - 3.45 (m, 1 H), 4.76 - 4.79 (m, 1 H), 6.82 (bs, 1 H), 6.98 (d, J= 8.8 Hz, 2 H), 7.21 (d, J= 8.4 Hz, 2 H).
Step 3: To a solution of tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.7 g, 1.78 mmol, 1 equiv) in DCM (15 mL) at 000 was added 10 mL of 4 M HCI in 1,4-dioxane and the mixture was stirred at rt for 12 h. The reaction mixture was concentrated to give 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenoxy)pyrrolidin-2-one hydrochloride (0.5 g, crude), which was taken to the next step without further purification. LCMS (ES) m/z = 293.1 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.89 - 1.92 (m, 2 H), 2.31 (s, 6 H), 3.28 - 3.30 (m, 1 H), 3.36 - 3.39 (m, 1 H), 4.96 - 5.00 (m, 1 H), 7.02 (d, J = 8.8 Hz, 2 H), 7.31 (d, J = 8.4 Hz, 2 H), 8.71 - 8.87 (5, 3 H).
308 [M+H] +, 1H NMR (400 MHz, CDCI3) 6 ppm 2.44 - 2.52 (m, 2 H), 3.48 - 3.58 (m, 2 H), 3.76 (s, 3 H), 4.83 -4.85 (m, 1 H), 6.84- 6.86 (m, 2 H), 7.23 -7.25 (m, 2 H).
Step 2: Note: - This reaction was performed in two batches, each batch with 0.4 g, ie 2 X
0.4 g = 0.8 g]. Methyl 4-bromo-2-(4-chlorophenoxy)butanoate (0.62 g, 2.02 mmol, 1 equiv) and tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.4 g, 2.02 mmol, 1 equiv) were charged to a sealed tube and Et3N (1.1 mL, 8.08 mmol , 4 equiv) was added. The reaction mixtures were then heated at 100 C using an oil bath for 1.5 h.
After completion, the reaction mixtures were cooled to room temperature, diluted with water (15 mL) and extracted with Et0Ac (2 X 50 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 35% Et0Ac in hexane to obtain the desired product tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (0.7 g, 70 /0). LCMS (ES) m/z = 393.1 [M+H] .1H NMR
(400 MHz, 0D013-d6) 6 ppm 1.44 (s, 9 H), 2.13 - 2.16 (m, 1 H), 2.39 (s, 6 H), 2.45 - 2.50 (m, 1 H), 3.31 - 3.33 (m, 1 H), 3.43 - 3.45 (m, 1 H), 4.76 - 4.79 (m, 1 H), 6.82 (bs, 1 H), 6.98 (d, J= 8.8 Hz, 2 H), 7.21 (d, J= 8.4 Hz, 2 H).
Step 3: To a solution of tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.7 g, 1.78 mmol, 1 equiv) in DCM (15 mL) at 000 was added 10 mL of 4 M HCI in 1,4-dioxane and the mixture was stirred at rt for 12 h. The reaction mixture was concentrated to give 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenoxy)pyrrolidin-2-one hydrochloride (0.5 g, crude), which was taken to the next step without further purification. LCMS (ES) m/z = 293.1 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.89 - 1.92 (m, 2 H), 2.31 (s, 6 H), 3.28 - 3.30 (m, 1 H), 3.36 - 3.39 (m, 1 H), 4.96 - 5.00 (m, 1 H), 7.02 (d, J = 8.8 Hz, 2 H), 7.31 (d, J = 8.4 Hz, 2 H), 8.71 - 8.87 (5, 3 H).
- 203 -Step 4: To a solution of 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenoxy)pyrrolidin-2-one hydrochloride (0.5 g, 1.52 mmol, 1 equiv) in THF (10 mL) was added BH3.Me2S (0.4 mL, 4.5 mmol, 3 equiv) at 0 C. (Note: BH3.Me2S was added at 3 interval points of time. First 1.5 equivalents were added and stirred for 16 h and again 0.75 equivalents were added and stirred for 8 h. After that time reaction progress was monitored by LCMS, which showed the presence of starting material and again 0.75 equivalents were added and stirred for 8 h.) After completion of the reaction, the reaction mixture was quenched with Me0H (3 mL) at 0 C, stirred for 30 min, and concentrated under reduced pressure to obtain the crude product. This crude material was washed with n-pentane (15 mL) and dried under vacuum to yield 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.6 g, crude), which was used for the next step without further purification. LCMS (ES) m/z = 279 [M+H] .
Step 5: To a solution of 2-(4-(trifluoromethyl)phenoxy)acetic acid (0.56 g, 2.58 mmol, 1.2 .. equiv) in DCM (10 mL) at 0 C was added triethylamine (1.2 mL, 8.60 mmol, 4 equiv) followed by T3P (50 wt% in Et0Ac) (2.5 mL, 4.30 mmol, 2 equiv). The mixture was stirred at 0 C for 10 min, at which time, this reaction mixture was added: 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.6 g, 2.15 mmol, 1 equiv) in DCM (10 mL) slowly at 0 C, and the reaction was stirred at rt for 12 h. The reaction mixture was diluted with water (10 mL) and extracted with DCM (2 x 20 mL). The combined organic layer was washed with saturated aqueous NaH0O3 solution (15 mL) and then dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude product was purified by preparative TLC using 50 % Et0Ac in hexanes. After final drying, the desired product N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-(trifluoromethyl)phenoxy)acetamide was obtained as a white solid (0.097 g, 19 `)/0). LCMS
(ES) m/z = 481.4 [M+Fl] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.73 - 1.77 (m, 1 H), 1.95 (s,6 H), 2.12 - 2.26 (m, 1 H), 2.58 - 2.70 (m, 3 H), 2.84 - 2.88 (m, 1 H), 4.51 (s,2 H), 4.83 - 4.86 (m, 1 H), 6.88 (d, J = 8.8 Hz, 2 H), 7.09 (d, J = 8.8 Hz, 2 H), 7.28 (d, J = 8.8 Hz, 2 H), 7.64 (d, J= 8.4 Hz, 2 H), 8.67 (s, 1 H).
The Compounds of Examples 6j -60 were prepared generally according to the procedure described above for Examples 6h and 6i.
Step 5: To a solution of 2-(4-(trifluoromethyl)phenoxy)acetic acid (0.56 g, 2.58 mmol, 1.2 .. equiv) in DCM (10 mL) at 0 C was added triethylamine (1.2 mL, 8.60 mmol, 4 equiv) followed by T3P (50 wt% in Et0Ac) (2.5 mL, 4.30 mmol, 2 equiv). The mixture was stirred at 0 C for 10 min, at which time, this reaction mixture was added: 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.6 g, 2.15 mmol, 1 equiv) in DCM (10 mL) slowly at 0 C, and the reaction was stirred at rt for 12 h. The reaction mixture was diluted with water (10 mL) and extracted with DCM (2 x 20 mL). The combined organic layer was washed with saturated aqueous NaH0O3 solution (15 mL) and then dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude product was purified by preparative TLC using 50 % Et0Ac in hexanes. After final drying, the desired product N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-(trifluoromethyl)phenoxy)acetamide was obtained as a white solid (0.097 g, 19 `)/0). LCMS
(ES) m/z = 481.4 [M+Fl] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.73 - 1.77 (m, 1 H), 1.95 (s,6 H), 2.12 - 2.26 (m, 1 H), 2.58 - 2.70 (m, 3 H), 2.84 - 2.88 (m, 1 H), 4.51 (s,2 H), 4.83 - 4.86 (m, 1 H), 6.88 (d, J = 8.8 Hz, 2 H), 7.09 (d, J = 8.8 Hz, 2 H), 7.28 (d, J = 8.8 Hz, 2 H), 7.64 (d, J= 8.4 Hz, 2 H), 8.67 (s, 1 H).
The Compounds of Examples 6j -60 were prepared generally according to the procedure described above for Examples 6h and 6i.
- 204 -Table 14 11-I-NMR (400 MHz, Cmpd LCMS m/z Structure Name DMSO-d6) [M+Hr 1.73 - 1.76 (m, 1 H), CI
1.95 (s, 6 H), 2.17 -11 2.26 (m, 1 H), 2.56 -= 2.69 (m, 3 H), 2.82 _ 2.86 (m, 1 H), 4.63 (s, 2 H), 4.82 - 4.84 N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-6h (m, 1 H), 6.86 - 6.93 yObicyclo[1.1.1]pentan-1-y1)-2-((5- 448.3 (s, 3 H), 7.28(d, J=
0 41'H chloropyridin-2-yl)oxy)acetamide 9.2 Hz, 2 H), 7.81 ol/ (dd, J= 8.8 Hz, 6.4 Hz, 1 H), 8.14 (d, J=
Li:ii 2.0 Hz, 1 H), 8.55 (s, 1 H).
1.73 - 1.77 (m, 1 H), CI
1.95 (s, 6 H), 2.12 -2.26 (m, 1 H), 2.58 -= 2.70 (m, 3 H), 2.84 _ 2.88 (m, 1 H), 4.51 N-(3-(3-(4-chlorophenoxy)pyrrolidin-1- (s, 2 H), 4.83 - 4.86 6i yObicyclo[1.1.1]pentan-1-y1)-2-(4- 481.4 (m, 1 H), 6.88 (d, J=
(trifluoromethyl)phenoxy)acetamide 8.8 Hz, 2 H), 7.09 (d, o) J= 8.8 Hz, 2 H), 7.28 gir (d, J= 8.8 Hz, 2 H), 7.64 (d, J= 8.4 Hz, 2 F3 H), 8.67 (s, 1 H).
1.95 (s, 6 H), 2.17 -11 2.26 (m, 1 H), 2.56 -= 2.69 (m, 3 H), 2.82 _ 2.86 (m, 1 H), 4.63 (s, 2 H), 4.82 - 4.84 N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-6h (m, 1 H), 6.86 - 6.93 yObicyclo[1.1.1]pentan-1-y1)-2-((5- 448.3 (s, 3 H), 7.28(d, J=
0 41'H chloropyridin-2-yl)oxy)acetamide 9.2 Hz, 2 H), 7.81 ol/ (dd, J= 8.8 Hz, 6.4 Hz, 1 H), 8.14 (d, J=
Li:ii 2.0 Hz, 1 H), 8.55 (s, 1 H).
1.73 - 1.77 (m, 1 H), CI
1.95 (s, 6 H), 2.12 -2.26 (m, 1 H), 2.58 -= 2.70 (m, 3 H), 2.84 _ 2.88 (m, 1 H), 4.51 N-(3-(3-(4-chlorophenoxy)pyrrolidin-1- (s, 2 H), 4.83 - 4.86 6i yObicyclo[1.1.1]pentan-1-y1)-2-(4- 481.4 (m, 1 H), 6.88 (d, J=
(trifluoromethyl)phenoxy)acetamide 8.8 Hz, 2 H), 7.09 (d, o) J= 8.8 Hz, 2 H), 7.28 gir (d, J= 8.8 Hz, 2 H), 7.64 (d, J= 8.4 Hz, 2 F3 H), 8.67 (s, 1 H).
- 205 -CI
= 1.77 (s, 1 H), 1.95 (s, 6 H), 2.23 (m, 2 H), N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yObicyclo[1.1.1]pentan-1-y1)-2-(4- 2.61 - 2.58 (m, 1 H), 2.65 (m, 1 H), 2.86 (trifluoromethoxy)phenoxy)acetamide (m, 1 H), 4.42 (s, 2 497.4 H), 7.85 (s, 1 H), 6.88 6j H (d, J= 7.2 Hz, 2 H), 7.00 (d, J= 6.4 Hz, 2 H),7.28 (d, J= 7.6 Hz, 4 H), 8.62 (s, 1 H).
F3c' ci 1.74 - 1.77 (m, 1 H), 1.96(s, 6 H), 2.22 -2.25 (m, 1 H), 2.61 2-(4-chloro-3-(trifluoromethyl)phenoxy)- 2.69 (m, 3 H), 2.84 -N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 - 2.88 (m, 1 H), 4.52 6k yObicyclo[1.1.1]pentan-1-yl)acetamide 515.4 (s, 2 H), 4.85 (bs, 1 H), 6.88 (d, J= 8.8 Hil o Hz, 2 H), 7.24 - 7.29 Co (m, 3 H), 7.39 (s, 1 cF3 H), 7.62 (d, J=
9.2 Hz, 1 H), 8.67 (s, 1 H).
= 1.77 (s, 1 H), 1.95 (s, 6 H), 2.23 (m, 2 H), N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yObicyclo[1.1.1]pentan-1-y1)-2-(4- 2.61 - 2.58 (m, 1 H), 2.65 (m, 1 H), 2.86 (trifluoromethoxy)phenoxy)acetamide (m, 1 H), 4.42 (s, 2 497.4 H), 7.85 (s, 1 H), 6.88 6j H (d, J= 7.2 Hz, 2 H), 7.00 (d, J= 6.4 Hz, 2 H),7.28 (d, J= 7.6 Hz, 4 H), 8.62 (s, 1 H).
F3c' ci 1.74 - 1.77 (m, 1 H), 1.96(s, 6 H), 2.22 -2.25 (m, 1 H), 2.61 2-(4-chloro-3-(trifluoromethyl)phenoxy)- 2.69 (m, 3 H), 2.84 -N-(3-(3-(4-chlorophenoxy)pyrrolidin-1 - 2.88 (m, 1 H), 4.52 6k yObicyclo[1.1.1]pentan-1-yl)acetamide 515.4 (s, 2 H), 4.85 (bs, 1 H), 6.88 (d, J= 8.8 Hil o Hz, 2 H), 7.24 - 7.29 Co (m, 3 H), 7.39 (s, 1 cF3 H), 7.62 (d, J=
9.2 Hz, 1 H), 8.67 (s, 1 H).
- 206 -ci 1.75 - 1.77 (m, 1 H), 1.96 (s, 6 H), 2.20 -=
rsi 2.27 (m, 1 H), 2.58-2.71 (m, 3 H), 2.84-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1- 2.88 (m, 1 H), 4.49 61 yObicyclo[1.1.1]pentan-1-y1)-2-(4-fluoro- 499.0 (s, 2 H), 4.84 (bs, 1 0 4d*H 3-(trifluoromethyl)phenoxy)acetamide H), 6.88 (d, J= 8.8 Hz, 2 H), 7.27 - 7.29 o (m, 4 H), 7.43 (t, J=
9.6 Hz, 1 H), 8.65 (s, cF3 1 H).
CI
1.95 -2.06 (m, 1 H), 2.13 (s, 6 H), 2.25-2.23 (m, 1 H), 2.60 -=
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-2.66 (m, 1 H), 2.82 -yObicyclo[1.1.1]pentan-1-y1)-2-(4- 2.90 (m, 2 H), 2.94 -6m (difluoromethoxy)phenoxy)acetamide 479.4 2.98 (m, 1 H), 4.43 44?: (s, 2 H), 4.88 - 4.89 (m, 1 H), 6.48 - 6.86 01' (m, 4 H), 6.97 - 6.99 (m, 2 H), 7.08 (d, J =
8.8 Hz, 2 H), 7.23 (d, scHF2 J = 8.8 Hz, 2 H).
rsi 2.27 (m, 1 H), 2.58-2.71 (m, 3 H), 2.84-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1- 2.88 (m, 1 H), 4.49 61 yObicyclo[1.1.1]pentan-1-y1)-2-(4-fluoro- 499.0 (s, 2 H), 4.84 (bs, 1 0 4d*H 3-(trifluoromethyl)phenoxy)acetamide H), 6.88 (d, J= 8.8 Hz, 2 H), 7.27 - 7.29 o (m, 4 H), 7.43 (t, J=
9.6 Hz, 1 H), 8.65 (s, cF3 1 H).
CI
1.95 -2.06 (m, 1 H), 2.13 (s, 6 H), 2.25-2.23 (m, 1 H), 2.60 -=
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-2.66 (m, 1 H), 2.82 -yObicyclo[1.1.1]pentan-1-y1)-2-(4- 2.90 (m, 2 H), 2.94 -6m (difluoromethoxy)phenoxy)acetamide 479.4 2.98 (m, 1 H), 4.43 44?: (s, 2 H), 4.88 - 4.89 (m, 1 H), 6.48 - 6.86 01' (m, 4 H), 6.97 - 6.99 (m, 2 H), 7.08 (d, J =
8.8 Hz, 2 H), 7.23 (d, scHF2 J = 8.8 Hz, 2 H).
- 207 -1.76 - 1.77 (m, 1 H), 1.95(s,CI
6 H), 2.20 -IP2.25 (m, 2 H), 2.58 -= 2.60 (m, 1 H), 2.65-dri 2.68 (m, 1 H), 2.84-N 2.88 (m, 1 H), 4.44 2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-(s, 2 H), 4.84 (s, 1 6n chlorophenoxy)pyrrolidin-1- 465.0 N/4(FI yObicyclo[1.1.1]pentan-1-yl)acetamide H), 6.82 (d, J = 8.8 Hz, 1 H), 6.88 (d, J =
o) isomer 1 9.2 Hz, 2 H), 7.02 -7.05 (m, 1 H), 7.28 7.46 (d, J = 8.8 Hz, 1 H), 8.62 (s, 1 H) 1.75 - 1.77 (m, 1 H), CI
1.95 (s, 6 H), 2.20 -IP2.30 (m, 2 H), 2.58 -= 2.60 (m, 1 H), 2.65 _ dri 2.68 (m, 1 H), 2.84-N 2.88 (m, 1 H), 4.44 2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-(s, 2 H), 4.84 (s, 1 6o chlorophenoxy)pyrrolidin-1- 465.0 yObicyclo[1.1.1]pentan-1-yl)acetamide H), 6.82 (d, J = 8.8 Hz, 1 H), 6.86 (d, J =
o) isomer 2 8.8 Hz, 2 H), 7.02 -7.05 (m, 1 H), 7.28 F (d, J = 8.8 Hz, 2 H), 7.46 (d, J = 8.8 Hz, 1 H), 8.62 (s, 1 H).
Example 6p 2-(4-chlorophenoxy)-N-(3-(3-(4-(trifluoromethypphenoxV)P1frrolidin-1-Vnbicycloll.1.11pentan-1-ynacetamide OC\N)\---j Cl
6 H), 2.20 -IP2.25 (m, 2 H), 2.58 -= 2.60 (m, 1 H), 2.65-dri 2.68 (m, 1 H), 2.84-N 2.88 (m, 1 H), 4.44 2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-(s, 2 H), 4.84 (s, 1 6n chlorophenoxy)pyrrolidin-1- 465.0 N/4(FI yObicyclo[1.1.1]pentan-1-yl)acetamide H), 6.82 (d, J = 8.8 Hz, 1 H), 6.88 (d, J =
o) isomer 1 9.2 Hz, 2 H), 7.02 -7.05 (m, 1 H), 7.28 7.46 (d, J = 8.8 Hz, 1 H), 8.62 (s, 1 H) 1.75 - 1.77 (m, 1 H), CI
1.95 (s, 6 H), 2.20 -IP2.30 (m, 2 H), 2.58 -= 2.60 (m, 1 H), 2.65 _ dri 2.68 (m, 1 H), 2.84-N 2.88 (m, 1 H), 4.44 2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-(s, 2 H), 4.84 (s, 1 6o chlorophenoxy)pyrrolidin-1- 465.0 yObicyclo[1.1.1]pentan-1-yl)acetamide H), 6.82 (d, J = 8.8 Hz, 1 H), 6.86 (d, J =
o) isomer 2 8.8 Hz, 2 H), 7.02 -7.05 (m, 1 H), 7.28 F (d, J = 8.8 Hz, 2 H), 7.46 (d, J = 8.8 Hz, 1 H), 8.62 (s, 1 H).
Example 6p 2-(4-chlorophenoxy)-N-(3-(3-(4-(trifluoromethypphenoxV)P1frrolidin-1-Vnbicycloll.1.11pentan-1-ynacetamide OC\N)\---j Cl
- 208 -Br õC * H F3 õC edvii 0 '-eS-1,11re Br \ Step 1 C101 0 () Stel2 III' lir µ.' illm.tep 3 51 5y INS 0eq-0-14112HCI _a F3C l. * c/CN_<>_NH2 ci * ===-=Aoh DP-Step 4 Step 5 0 0 CI F3C A 0....cN...40....1..../
6p Step 1: To a solution of methyl 2,4-dibromobutanoate (1 g, 3.84 mmol, 1 equiv) in DMF (30 mL) was added 4-(trifluoromethyl)phenol (0.49 g, 3.84 mmol, 1 equiv) at rt followed by .. K2CO3 (0.53 g, 3.84 mmol, 1 equiv) and the reaction was stirred at 60 00 for 3 h. The reaction mixture was then allowed to come to rt. Ice cold water (100 mL) was added and the mixture was extracted with Et0Ac (2 X 100 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under vacuum. The crude material was purified by flash column chromatography eluting the product at 3.9 `)/0 Et0Ac in hexane to provide methyl 4-bromo-2-(4-(trifluoromethyl)phenoxy)butanoate as a gum (0.8 g, 61 `)/0).
LCMS (ES) m/z = 342.9 [M+H] , 1H NMR (400 MHz, CDCI3) 6 ppm 2.36 - 2.44 (m, 2 H), 3.59 - 3.68 (m, 2 H), 3.69 (s, 3 H), 5.08 - 5.11 (m, 1 H), 7.10 (d, J= 8.4 Hz, 2 H), 7.65(d, J
= 8.4 Hz, 2 H).
Step 2: [Note: - This reaction was performed in two batches, each batch with 0.23 g, ie 2 X 0.23 g = 0.46 g]. To a solution of methyl 4-bromo-2-(4-(trifluoromethyl)phenoxy)butanoate (0.39 g, 1.16 mmol, 1 equiv) and tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.23 g, 1.16 mmol, 1 equiv) charged to a sealed tube was added Et3N (0.64 mL, 4.64 mmol, 4 equiv). The mixture was then heated at 100 00 using an oil bath for 1.5 h. After completion, the reaction mixtures were cooled to room temperature, diluted with water (15 mL) and extracted with Et0Ac (2 X 50 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 36 `)/0 Et0Ac in hexane to obtain the desired product tert-butyl (3-(2-oxo-3-(4-.. (trifluoromethyl)phenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (0.5g, 55%). LCMS (ES) m/z = 371.1 [M+H]+ (loss of tert-butyl group).1H
NMR (400
6p Step 1: To a solution of methyl 2,4-dibromobutanoate (1 g, 3.84 mmol, 1 equiv) in DMF (30 mL) was added 4-(trifluoromethyl)phenol (0.49 g, 3.84 mmol, 1 equiv) at rt followed by .. K2CO3 (0.53 g, 3.84 mmol, 1 equiv) and the reaction was stirred at 60 00 for 3 h. The reaction mixture was then allowed to come to rt. Ice cold water (100 mL) was added and the mixture was extracted with Et0Ac (2 X 100 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under vacuum. The crude material was purified by flash column chromatography eluting the product at 3.9 `)/0 Et0Ac in hexane to provide methyl 4-bromo-2-(4-(trifluoromethyl)phenoxy)butanoate as a gum (0.8 g, 61 `)/0).
LCMS (ES) m/z = 342.9 [M+H] , 1H NMR (400 MHz, CDCI3) 6 ppm 2.36 - 2.44 (m, 2 H), 3.59 - 3.68 (m, 2 H), 3.69 (s, 3 H), 5.08 - 5.11 (m, 1 H), 7.10 (d, J= 8.4 Hz, 2 H), 7.65(d, J
= 8.4 Hz, 2 H).
Step 2: [Note: - This reaction was performed in two batches, each batch with 0.23 g, ie 2 X 0.23 g = 0.46 g]. To a solution of methyl 4-bromo-2-(4-(trifluoromethyl)phenoxy)butanoate (0.39 g, 1.16 mmol, 1 equiv) and tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.23 g, 1.16 mmol, 1 equiv) charged to a sealed tube was added Et3N (0.64 mL, 4.64 mmol, 4 equiv). The mixture was then heated at 100 00 using an oil bath for 1.5 h. After completion, the reaction mixtures were cooled to room temperature, diluted with water (15 mL) and extracted with Et0Ac (2 X 50 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 36 `)/0 Et0Ac in hexane to obtain the desired product tert-butyl (3-(2-oxo-3-(4-.. (trifluoromethyl)phenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (0.5g, 55%). LCMS (ES) m/z = 371.1 [M+H]+ (loss of tert-butyl group).1H
NMR (400
- 209 -MHz, CDCI3-d6) 6 ppm 1.26 - 1.28 (m, 1 H), 1.44 (s, 9 H), 2.16 - 2.20 (m, 1 H), 2.40 (s, 6 H), 2.53 (bs, 1 H), 3.34 - 3.36 (m, 1 H), 3.47 - 3.52 (m, 1 H), 4.88 - 4.90 (m, 1 H), 7.11 (d, J= 7.6 Hz, 2 H), 7.53 (d, J= 8.4 Hz, 2 H).
Step 3: To a solution of tert-butyl (3-(2-oxo-3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.5 g, 1.17 mmol, 1 equiv) in DCM (15 mL) at 000 was added 10 mL of 4 M HCI in 1,4-dioxane and the mixture was stirred at rt for 12 h. The reaction mixture was concentrated to obtain 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-(trifluoromethyl)phenoxy)pyrrolidin-2-one hydrochloride (0.4 g, crude), which was taken to the next step without further purification. LCMS (ES) m/z = 327.1 [M+H] +. 1H
NMR (400 MHz, DMSO-d6) 6 ppm 2.34 (m, 6 H), 3.30 - 3.41 (m, 4 H), 5.13 - 5.16 (m, 1 H), 7.18 (d, J
= 8.4 Hz, 2 H), 7.63 (d, J= 8 Hz, 2 H), 8.74 - 8.86 (s, 3 H).
Step 4: To a solution of 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-(trifluoromethyl)phenoxy)pyrrolidin-2-one hydrochloride (0.4 g, 1.10 mmol, 1 equiv) in THF
(10 mL) was added BH3.Me2S (0.31 mL, 3.30 mmol, 3 equiv) at 000. (Note:
BH3.Me2S was added at 3 interval points of time: first 1.5 equivalents were added and stirred for 16 h and again 0.75 equivalents were added and stirred for 8 h. After that time, the reaction progress was monitored by LCMS, which showed the presence of starting material and again 0.75 equivalents were added and stirred for 8 h.). After completion of the reaction, the reaction mixture was quenched with Me0H (3 mL) at 0 C, stirred for 30 min, and concentrated under reduced pressure to obtain the crude product. This crude material was washed with n-pentane (15 mL) and dried under vacuum to afford 3-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.27 g, crude), which was used for the next step without further purification. LCMS (ES) m/z= 313.1 [M+H].
Step 5: To a solution of 2-(4-chlorophenoxy)acetic acid (0.19 g, 1.03 mmol, 1.2 equiv) in DCM (10 mL) at 0 C was added triethylamine (0.36 mL, 2.59 mmol, 3 equiv) followed by T3P (50 wt% in Et0Ac) (1.03 mL, 1.72 mmol, 2 equiv). The mixture was stirred at 0 C
for 10 min, at which time, this reaction mixture was added: 3-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.27 g, 0.86 mmol, 1 equiv) in DCM (10 mL), slowly at 0 C and the reaction was stirred at rt for 12 h. The reaction mixture was diluted with water (10 mL) and extracted with DCM (2 x 20 mL). The combined organic layer was washed with saturated aqueous NaH0O3 solution (15 mL) and then dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude product was purified by preparative TLC using 50 `)/0 Et0Ac in hexanes.
After final
Step 3: To a solution of tert-butyl (3-(2-oxo-3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.5 g, 1.17 mmol, 1 equiv) in DCM (15 mL) at 000 was added 10 mL of 4 M HCI in 1,4-dioxane and the mixture was stirred at rt for 12 h. The reaction mixture was concentrated to obtain 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-(trifluoromethyl)phenoxy)pyrrolidin-2-one hydrochloride (0.4 g, crude), which was taken to the next step without further purification. LCMS (ES) m/z = 327.1 [M+H] +. 1H
NMR (400 MHz, DMSO-d6) 6 ppm 2.34 (m, 6 H), 3.30 - 3.41 (m, 4 H), 5.13 - 5.16 (m, 1 H), 7.18 (d, J
= 8.4 Hz, 2 H), 7.63 (d, J= 8 Hz, 2 H), 8.74 - 8.86 (s, 3 H).
Step 4: To a solution of 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-(trifluoromethyl)phenoxy)pyrrolidin-2-one hydrochloride (0.4 g, 1.10 mmol, 1 equiv) in THF
(10 mL) was added BH3.Me2S (0.31 mL, 3.30 mmol, 3 equiv) at 000. (Note:
BH3.Me2S was added at 3 interval points of time: first 1.5 equivalents were added and stirred for 16 h and again 0.75 equivalents were added and stirred for 8 h. After that time, the reaction progress was monitored by LCMS, which showed the presence of starting material and again 0.75 equivalents were added and stirred for 8 h.). After completion of the reaction, the reaction mixture was quenched with Me0H (3 mL) at 0 C, stirred for 30 min, and concentrated under reduced pressure to obtain the crude product. This crude material was washed with n-pentane (15 mL) and dried under vacuum to afford 3-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.27 g, crude), which was used for the next step without further purification. LCMS (ES) m/z= 313.1 [M+H].
Step 5: To a solution of 2-(4-chlorophenoxy)acetic acid (0.19 g, 1.03 mmol, 1.2 equiv) in DCM (10 mL) at 0 C was added triethylamine (0.36 mL, 2.59 mmol, 3 equiv) followed by T3P (50 wt% in Et0Ac) (1.03 mL, 1.72 mmol, 2 equiv). The mixture was stirred at 0 C
for 10 min, at which time, this reaction mixture was added: 3-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.27 g, 0.86 mmol, 1 equiv) in DCM (10 mL), slowly at 0 C and the reaction was stirred at rt for 12 h. The reaction mixture was diluted with water (10 mL) and extracted with DCM (2 x 20 mL). The combined organic layer was washed with saturated aqueous NaH0O3 solution (15 mL) and then dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude product was purified by preparative TLC using 50 `)/0 Et0Ac in hexanes.
After final
- 210 -drying, the desired product 2-(4-chlorophenoxy)-N-(3-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide was obtained as a white solid (0.087 g, 21 /0). LCMS (ES) m/z = 481.4 [M+H] +. 1H NMR (400 MHz, CD30D) 6 ppm 1.93 - 2.02 (m, 1 H), 2.13 (s, 6 H), 2.31 -2.39 (m, 1 H), 2.64 -2.68 (m, 1 H), 2.85 - 2.92 (m, 2 H), 2.98 - 3.02 (m, 1 H), 4.48 (s, 2 H), 4.97 - 5.00 (m, 1 H), 6.95 (d, J= 9.2 Hz, 2 H), 7.01 (d, J= 8.4 Hz, 2 H), 7.27 (d, J= 9.2 Hz, 2 H), 7.56 (d, J= 8.4 Hz, 2 H).
Table 15 LCMS
1H-NMR 1400 MHz, Cmpd # Structure Name miz CD30D) [M+H]
F3c 1.93 - 2.02 (m, 1 H),2.13 (s, 6 H), 2.31 -2.39 (m, 1 H), 2.64 - 2.68 (m, 1 H), d 2-(4-chlorophenoxy)-N-(3-(3-(4-2.85 - 2.92 (m, 2 H), 2.98 N
6p (trifluoromethyl)phenoxy)pyrrolidi - 3.02 (m, 1 H), 4.48 (s, 2 n-1-yl)bicyclo[1.1.1]pentan-1-481.4 H), 4.97 - 5.00 (m, 1 H), H
yl)acetamide 6.95 (d, J= 9.2 Hz, 2 H), 0 7.01 (d, J= 8.4 Hz, 2 H), 010 7.27 (d, J= 9.2 Hz, 2 H), 7.56 (d, J= 8.4 Hz, 2 H).
Example 6g 2-(4-chloro-3-fluorophenoxv)-N-(3-(3-(4-chlorophenoxv)uvrrolidin-1-vnbicycloll .1.11pentan-1-vpacetamide Cl Cl *
Table 15 LCMS
1H-NMR 1400 MHz, Cmpd # Structure Name miz CD30D) [M+H]
F3c 1.93 - 2.02 (m, 1 H),2.13 (s, 6 H), 2.31 -2.39 (m, 1 H), 2.64 - 2.68 (m, 1 H), d 2-(4-chlorophenoxy)-N-(3-(3-(4-2.85 - 2.92 (m, 2 H), 2.98 N
6p (trifluoromethyl)phenoxy)pyrrolidi - 3.02 (m, 1 H), 4.48 (s, 2 n-1-yl)bicyclo[1.1.1]pentan-1-481.4 H), 4.97 - 5.00 (m, 1 H), H
yl)acetamide 6.95 (d, J= 9.2 Hz, 2 H), 0 7.01 (d, J= 8.4 Hz, 2 H), 010 7.27 (d, J= 9.2 Hz, 2 H), 7.56 (d, J= 8.4 Hz, 2 H).
Example 6g 2-(4-chloro-3-fluorophenoxv)-N-(3-(3-(4-chlorophenoxv)uvrrolidin-1-vnbicycloll .1.11pentan-1-vpacetamide Cl Cl *
- 211 -OH BrO 0 0 31õ 0)L
õ OH
CI ¨1111P-Step 1 F _Step 2 CI CI
Br * OH Br goc B NH2 goc CI CI %FIN CI 101 C515'sir= Step 3 Step 4 Step OAOH
CI pi ¨40¨NH2 HCI CI is CI 1111111 Step 6 r\N Step 7 CI
6q Step 1: To a solution of 4-chloro-3-fluorophenol (3 g, 20.47 mmol, 1 equiv.) in DMF (20 mL) was added K2003 (8.47 g, 61.41 mmol, 3 equiv.) followed by the addition of ethyl 2-bromoacetate (6.83 g, 40.94 mmol, 2 equiv) dropwise at 0 C. The reaction mixture was allowed to stir at 80 C for 16 h. The resulting mixture was allowed to warm to 25 C (rt).
After consumption of the starting material (TLC, 10 % Et0Ac in Hexane), the reaction mixture was filtered through a Buchner funnel and the filtrate was concentrated under reduced pressure. The crude product was purified by flash column chromatography (Combiflashe) using a silica gel column (5 % ethyl acetate in hexane) to obtain the title compound ethyl 2-(4-chloro-3-fluorophenoxy)acetate (3.8 g, as a colorless liquid. LCMS
(ES) m/z= 232 [M+H]. 1H NMR (400 MHz, CDCI3) 6 ppm 1.30 ¨ 1.27 (m, 3 H), 4.29 ¨4.23 (m, 2 H), 4.60 (s, 2 H), 6.65¨ 6.63 (m, 1 H), 6.73 ¨ 6.70 (m, 1 H), 7.29 ¨
7.25 (m, 1H).
Step 2: To a solution of ethyl 2-(4-chloro-3-fluorophenoxy) acetate (3.8 g 16.334 mmol, 1 equiv.) in a mixture of THF (15 mL) and water (15 mL) was added Li0H.H20 (6.85 g, 41.95 mmol, 10 equiv.) at 0 C and the resulting mixture was stirred at room temperature for 3 h.
After consumption of the starting material (TLC, 5 % methanol in DCM), THF was removed under reduced pressure and the residue was diluted with water (20 mL), and washed with Et20 (2 x 15 mL) to remove un-reacted ethyl 2-bromoacetate. The aqueous layer was
õ OH
CI ¨1111P-Step 1 F _Step 2 CI CI
Br * OH Br goc B NH2 goc CI CI %FIN CI 101 C515'sir= Step 3 Step 4 Step OAOH
CI pi ¨40¨NH2 HCI CI is CI 1111111 Step 6 r\N Step 7 CI
6q Step 1: To a solution of 4-chloro-3-fluorophenol (3 g, 20.47 mmol, 1 equiv.) in DMF (20 mL) was added K2003 (8.47 g, 61.41 mmol, 3 equiv.) followed by the addition of ethyl 2-bromoacetate (6.83 g, 40.94 mmol, 2 equiv) dropwise at 0 C. The reaction mixture was allowed to stir at 80 C for 16 h. The resulting mixture was allowed to warm to 25 C (rt).
After consumption of the starting material (TLC, 10 % Et0Ac in Hexane), the reaction mixture was filtered through a Buchner funnel and the filtrate was concentrated under reduced pressure. The crude product was purified by flash column chromatography (Combiflashe) using a silica gel column (5 % ethyl acetate in hexane) to obtain the title compound ethyl 2-(4-chloro-3-fluorophenoxy)acetate (3.8 g, as a colorless liquid. LCMS
(ES) m/z= 232 [M+H]. 1H NMR (400 MHz, CDCI3) 6 ppm 1.30 ¨ 1.27 (m, 3 H), 4.29 ¨4.23 (m, 2 H), 4.60 (s, 2 H), 6.65¨ 6.63 (m, 1 H), 6.73 ¨ 6.70 (m, 1 H), 7.29 ¨
7.25 (m, 1H).
Step 2: To a solution of ethyl 2-(4-chloro-3-fluorophenoxy) acetate (3.8 g 16.334 mmol, 1 equiv.) in a mixture of THF (15 mL) and water (15 mL) was added Li0H.H20 (6.85 g, 41.95 mmol, 10 equiv.) at 0 C and the resulting mixture was stirred at room temperature for 3 h.
After consumption of the starting material (TLC, 5 % methanol in DCM), THF was removed under reduced pressure and the residue was diluted with water (20 mL), and washed with Et20 (2 x 15 mL) to remove un-reacted ethyl 2-bromoacetate. The aqueous layer was
- 212 -acidified with 1 N HCI up to pH -2 at 0 C. The product was extracted with Et0Ac (2 x 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain the title compound 2-(4-chloro-3-fluorophenoxy)acetic acid (0.720 g, 21% yield) as a white solid. LCMS (ES) m/z = 203.0 [M+H] 1H NMR (400 MHz, DMSO-d6) 6 ppm 4.71 (s, 2 H), 6.81 - 6.78 (m, 1 H), 7.07 -7.03 (m, 1 H), 7.47 - 7.43 (t, J = 9.2 Hz, 1 H), 13.06 (s, 1 H).
Step 3: To a solution of methyl 2,4-dibromobutanoate (4.01 g, 0.015 mmol, 1 equiv) in DMF (50 mL) was added 4-chlorophenol (2.0 g, 0.015 mmol, 1 equiv) at rt followed by K2003 (2.1 g, 0.015 mmol, 1 equiv) and the reaction was stirred at 60 C for 3 h. The reaction mixture was then allowed to come to rt. Water (5 mL) was added and the mixture was extracted with Et0Ac (3 X 100 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under vacuum. The crude material was purified by flash column chromatography (10 % Et0Ac in hexane) to afford methyl 4-bromo-2-(4-chlorophenoxy)butanoate as a colorless liquid (2.6 g). 1H NMR (400 MHz, CDCI3) 6 ppm 2.42 - 2.51 (m, 2 H), 3.58 - 3.62 (m, 2 H), 3.76 (s, 3 H), 4.82 - 4.85 (m, 1 H), 6.85 (d, J =
8.8 Hz, 2 H), 7.26 (d, J= 7.2 Hz, 2 H).
Step 4: Methyl 4-bromo-2-(4-chlorophenoxy)butanoate (0.4 g, 1.31 mmol, 1 equiv) and tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.26 g, 1.31 mmol, 1 equiv) were charged to a sealed tube and Et3N (0.73 mL) was added. The mixture was then heated at 100 C for 1 h. The reaction mixture was diluted with cold water (150 mL) and extracted with Et0Ac (2 X 200 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 50% Et0Ac in hexane to obtain the desired product tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (2.2 g, 47.41 %) (Reaction was performed in multiple batches: 0.26 g x 9). LCMS (ES) m/z = 337.1 [M+H] (loss of tert-butyl group). 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.36 (s, 9 H), 1.83 - 1.92 (m, 1 H), 2.16 - 2.22 (m, 6 H), 3.23 -3.25 (m, 1 H), 3.32 - 3.37 (m, 1 H), 4.96 (t, J= 8.0 Hz, 1 H), 7.02 (d, J= 9.2 Hz, 2 H), 7.3 (d, J= 8.8 Hz, 2 H), 7.55 (s, 1 H). Note: One proton was merged with solvent peak.
Step 5: To a solution of tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (2.6 g, 5.59 mmol) in DCM (30 mL) at 0 C was added 25 mL of 4 M HCI in 1,4-dioxane and the mixture was stirred at rt for 16 h. The reaction mixture was concentrated to give 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-
Step 3: To a solution of methyl 2,4-dibromobutanoate (4.01 g, 0.015 mmol, 1 equiv) in DMF (50 mL) was added 4-chlorophenol (2.0 g, 0.015 mmol, 1 equiv) at rt followed by K2003 (2.1 g, 0.015 mmol, 1 equiv) and the reaction was stirred at 60 C for 3 h. The reaction mixture was then allowed to come to rt. Water (5 mL) was added and the mixture was extracted with Et0Ac (3 X 100 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under vacuum. The crude material was purified by flash column chromatography (10 % Et0Ac in hexane) to afford methyl 4-bromo-2-(4-chlorophenoxy)butanoate as a colorless liquid (2.6 g). 1H NMR (400 MHz, CDCI3) 6 ppm 2.42 - 2.51 (m, 2 H), 3.58 - 3.62 (m, 2 H), 3.76 (s, 3 H), 4.82 - 4.85 (m, 1 H), 6.85 (d, J =
8.8 Hz, 2 H), 7.26 (d, J= 7.2 Hz, 2 H).
Step 4: Methyl 4-bromo-2-(4-chlorophenoxy)butanoate (0.4 g, 1.31 mmol, 1 equiv) and tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.26 g, 1.31 mmol, 1 equiv) were charged to a sealed tube and Et3N (0.73 mL) was added. The mixture was then heated at 100 C for 1 h. The reaction mixture was diluted with cold water (150 mL) and extracted with Et0Ac (2 X 200 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 50% Et0Ac in hexane to obtain the desired product tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (2.2 g, 47.41 %) (Reaction was performed in multiple batches: 0.26 g x 9). LCMS (ES) m/z = 337.1 [M+H] (loss of tert-butyl group). 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.36 (s, 9 H), 1.83 - 1.92 (m, 1 H), 2.16 - 2.22 (m, 6 H), 3.23 -3.25 (m, 1 H), 3.32 - 3.37 (m, 1 H), 4.96 (t, J= 8.0 Hz, 1 H), 7.02 (d, J= 9.2 Hz, 2 H), 7.3 (d, J= 8.8 Hz, 2 H), 7.55 (s, 1 H). Note: One proton was merged with solvent peak.
Step 5: To a solution of tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (2.6 g, 5.59 mmol) in DCM (30 mL) at 0 C was added 25 mL of 4 M HCI in 1,4-dioxane and the mixture was stirred at rt for 16 h. The reaction mixture was concentrated to give 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-
- 213 -chlorophenoxy)pyrrolidin-2-one, hydrochloride (crude yield 1.8 g, 82.9 %), which was taken to the next step without further purification. LCMS (ES) m/z = 293 [M+H] +. 1H
NMR (400 MHz, DMSO-d6) 6 ppm 1.87- 1.94 (m, 1 H), 2.28 - 2.33 (m, 6 H), 3.32 - 3.38 (m, 2 H), 4.99 (t, J= 7.6 Hz, 1 H), 7.02 (d, J= 8.8 Hz, 2 H), 7.31 (d, J= 8.4 Hz, 2 H), 8.76 (bs, 3 H).
Note: One proton was merged with solvent peak.
Step 6: To a solution of 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenoxy)pyrrolidin-2-one hydrochloride (0.34 g, 1.036 mmol, 1 equiv) in THF (4 mL) was added BH3.Me2S (0.3 mL, 0.61 mmol, 3 equiv) at 0 C. (Note: BH3.Me2S was added at 3 interval points of time: first 1.5 equivalents were added and stirred for 16 h and again 0.75 equivalents were added and stirred for 8 h. After that time reaction progress was monitored by LCMS, which showed the presence of starting material and again 0.75 equivalents were added and stirred for 8 h.). After completion, the reaction mixture was quenched with methanol at 0 C, stirred for 30 min, and then evaporated under reduced pressure to obtain the crude product, which was washed with dry n-pentane (50 mL) and dried to yield 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (Crude yield 1.4 g, 87 `)/0) (Reaction was performed in multiple batches: 0.34 g x 5), which was used for the next step without further purification. LCMS (ES) m/z= 279 [M+H]
.
Step 7: To a solution of 2-(4-chloro-3-fluorophenoxy)acetic acid (0.062 g, 0.303 mmol, 1.2 equiv) in DCM (20 mL) at 0 C was added triethylamine (0.1 mL, 0.718 mmol, 3 equiv) followed by T3P (50 wt% in Et0Ac) (0.2 mL, 0.380 mmol, 1.5 equiv) and the mixture was stirred at 0 C for 10 min. To this reaction mixture was added 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.08g, 0.253 mmol, 1 equiv) in DCM (10 mL) slowly at 0 C and the reaction was stirred at rt for 16 h. The reaction mixture was diluted with water (20 mL) and extracted with DCM (2 x 20 mL). The combined organic layer was washed with saturated aqueous NaHCO3 solution (10 mL) and then dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude material was purified by column chromatography twice by using an eluent of 3% Me0H in DCM to afford 2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.025 g, 18.79%) as a white solid.
LCMS (ES) m/z = 465.3 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.73- 1.77 (m, 1 H),1.95 (s,6 H), 2.21 - 2.30 (m, 1 H), 2.58 - 2.68 (m, 3 H), 2.84 - 2.88 (m, 1 H), 4.44 (s, 2 H), 4.84 (s, 1 H), 6.82 (d, J= 9.2 Hz, 1 H), 6.88 (d, J= 8.8 Hz, 2 H), 7.02 - 7.05 (m, 1 H), 7.28 (d, J= 8.8 Hz, 2 H), 7.46 (t, J= 8.8 Hz, 1 H), 8.62 (s, 1 H).
NMR (400 MHz, DMSO-d6) 6 ppm 1.87- 1.94 (m, 1 H), 2.28 - 2.33 (m, 6 H), 3.32 - 3.38 (m, 2 H), 4.99 (t, J= 7.6 Hz, 1 H), 7.02 (d, J= 8.8 Hz, 2 H), 7.31 (d, J= 8.4 Hz, 2 H), 8.76 (bs, 3 H).
Note: One proton was merged with solvent peak.
Step 6: To a solution of 1-(3-aminobicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenoxy)pyrrolidin-2-one hydrochloride (0.34 g, 1.036 mmol, 1 equiv) in THF (4 mL) was added BH3.Me2S (0.3 mL, 0.61 mmol, 3 equiv) at 0 C. (Note: BH3.Me2S was added at 3 interval points of time: first 1.5 equivalents were added and stirred for 16 h and again 0.75 equivalents were added and stirred for 8 h. After that time reaction progress was monitored by LCMS, which showed the presence of starting material and again 0.75 equivalents were added and stirred for 8 h.). After completion, the reaction mixture was quenched with methanol at 0 C, stirred for 30 min, and then evaporated under reduced pressure to obtain the crude product, which was washed with dry n-pentane (50 mL) and dried to yield 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (Crude yield 1.4 g, 87 `)/0) (Reaction was performed in multiple batches: 0.34 g x 5), which was used for the next step without further purification. LCMS (ES) m/z= 279 [M+H]
.
Step 7: To a solution of 2-(4-chloro-3-fluorophenoxy)acetic acid (0.062 g, 0.303 mmol, 1.2 equiv) in DCM (20 mL) at 0 C was added triethylamine (0.1 mL, 0.718 mmol, 3 equiv) followed by T3P (50 wt% in Et0Ac) (0.2 mL, 0.380 mmol, 1.5 equiv) and the mixture was stirred at 0 C for 10 min. To this reaction mixture was added 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.08g, 0.253 mmol, 1 equiv) in DCM (10 mL) slowly at 0 C and the reaction was stirred at rt for 16 h. The reaction mixture was diluted with water (20 mL) and extracted with DCM (2 x 20 mL). The combined organic layer was washed with saturated aqueous NaHCO3 solution (10 mL) and then dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude material was purified by column chromatography twice by using an eluent of 3% Me0H in DCM to afford 2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.025 g, 18.79%) as a white solid.
LCMS (ES) m/z = 465.3 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.73- 1.77 (m, 1 H),1.95 (s,6 H), 2.21 - 2.30 (m, 1 H), 2.58 - 2.68 (m, 3 H), 2.84 - 2.88 (m, 1 H), 4.44 (s, 2 H), 4.84 (s, 1 H), 6.82 (d, J= 9.2 Hz, 1 H), 6.88 (d, J= 8.8 Hz, 2 H), 7.02 - 7.05 (m, 1 H), 7.28 (d, J= 8.8 Hz, 2 H), 7.46 (t, J= 8.8 Hz, 1 H), 8.62 (s, 1 H).
- 214 -The Compound of Example 6r was prepared generally according to the procedure described above for Example 6q.
Table 16 LCMS 1H-NMR (400 MHz, DMSO-Cmpd # Structure Name m/z d6) [M+H]
CI
#
1.73 - 1.77 (m, 1 H), 1.95 = (s, 6 H), 2.21 - 2.30 (m, 1 d 2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-H), 2.58 - 2.68 (m, 3 H), N
2.84 - 2.88 (m, 1 H), 4.44 4)) cy 6q > yObiclo[1.1.1]pentan-1-yOacetamide 465.3 (s, 2 H), 4.84 (s, 1 H), 6.82 (d, J= 9.2 Hz, 1 H), 6.88 (d, J= 8.8 Hz, 2 H), 7.02 -7.05 oOYNH
(rrl, 1 H), 7.28 (d, J = 8.8 Hz, 2 H), 7.46 (t, J = 8.8 F * Hz, 1 H), 8.62(s, 1 H).
CI
4 0.54 - 0.56 (m, 2 H), 0.84 -0.86 (m, 2 H), 1.74 - 1.84 =
d N N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-(m, 2 H), 1.95 (s, 6 H), 2.20 -2.30 (m, 1 H), 2.53 - 2.70 6r yObicyclo[1.1.1]pentan-1-y1)-2-(4-(m, 3 H), 2.84 - 2.88 (m, 1 cyclopropylphenoxy)acetamide 453.4 H), 4.33 (s, 2 H), 4.85 (bs, 1 ol-1 H), 6.80 (d, J
= 8.4 Hz, 2 H), 6.88 (d, J = 8.8 Hz, 2 o) H), 6.97 (d, J = 8.4 Hz, 2 H), 7.28 (d, J = 8.8 Hz, 2 H), 8.54 (s, 1 H).
A
Table 16 LCMS 1H-NMR (400 MHz, DMSO-Cmpd # Structure Name m/z d6) [M+H]
CI
#
1.73 - 1.77 (m, 1 H), 1.95 = (s, 6 H), 2.21 - 2.30 (m, 1 d 2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-H), 2.58 - 2.68 (m, 3 H), N
2.84 - 2.88 (m, 1 H), 4.44 4)) cy 6q > yObiclo[1.1.1]pentan-1-yOacetamide 465.3 (s, 2 H), 4.84 (s, 1 H), 6.82 (d, J= 9.2 Hz, 1 H), 6.88 (d, J= 8.8 Hz, 2 H), 7.02 -7.05 oOYNH
(rrl, 1 H), 7.28 (d, J = 8.8 Hz, 2 H), 7.46 (t, J = 8.8 F * Hz, 1 H), 8.62(s, 1 H).
CI
4 0.54 - 0.56 (m, 2 H), 0.84 -0.86 (m, 2 H), 1.74 - 1.84 =
d N N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-(m, 2 H), 1.95 (s, 6 H), 2.20 -2.30 (m, 1 H), 2.53 - 2.70 6r yObicyclo[1.1.1]pentan-1-y1)-2-(4-(m, 3 H), 2.84 - 2.88 (m, 1 cyclopropylphenoxy)acetamide 453.4 H), 4.33 (s, 2 H), 4.85 (bs, 1 ol-1 H), 6.80 (d, J
= 8.4 Hz, 2 H), 6.88 (d, J = 8.8 Hz, 2 o) H), 6.97 (d, J = 8.4 Hz, 2 H), 7.28 (d, J = 8.8 Hz, 2 H), 8.54 (s, 1 H).
A
- 215 -Example 6s 2-(4-chlorophenoxv)-N-(3-(3-(pyridin-4-vloxV)PVrrolidin-1-yObicyclo[1.1.11pentan-1-Vnacetamide Di ci OH 0Ms 0 OH H2N ¨0¨ NH
Nia 0 ..
I lir pi step I dc) 0N
Step 2 c5a, Boc Step 3 0 -`riAl 1"---N=N**
BOC
F. CIFIlla NH2 'NCI
Step 4 Step 5 0 Step 6 I 0 "...ANS:1H
Step 7 CI 6S
Step 1: To a solution of pyridin-4-ol (2.0 g, 21.03 mmol, 1.0 equiv.) in DMF
(30 mL) was added Ag2003 (8.7 g, 31.54 mmol, 1.5 equiv.) at 0 C, stirred for 5 mins and then 3-bromodihydrofuran-2(3H)-one (2.3 mL, 25.23 mmol, 1.2 equiv.) was added and the reaction was stirred at 60 C for 2 h. After the consumption of the starting material (TLC, 5 % Me0H in DCM), the reaction mixture was filtered through a Celite bed and washed with Et0Ac (200 mL). The organic layer was washed with ice cold water (2 x 20 mL), dried over anhydrous Na2SO4, filtered and distilled under vacuum. The crude material was purified by flash column chromatography (5 ¨ 6 % Me0H in DCM) to afford 3-(pyridin-4-yloxy)dihydrofuran-2(3H)-one as a brown liquid (1.18 g, 31.4% yield). LCMS
(ES) m/z =
180.0 [M+Fl] , 1H NMR (400 MHz, CDCI3) 6 ppm 2.45 ¨ 2.55 (m, 1 H), 2.72 ¨
2.80 (m, 1 H), 4.33 ¨4.42 (m, 1 H), 4.52 ¨4.57 (m, 1 H), 5.05 (t, J= 7.8 Hz, 1 H), 6.95¨
6.97(m, 2 H), 8.47 ¨ 8.49 (m, 2 H).
Nia 0 ..
I lir pi step I dc) 0N
Step 2 c5a, Boc Step 3 0 -`riAl 1"---N=N**
BOC
F. CIFIlla NH2 'NCI
Step 4 Step 5 0 Step 6 I 0 "...ANS:1H
Step 7 CI 6S
Step 1: To a solution of pyridin-4-ol (2.0 g, 21.03 mmol, 1.0 equiv.) in DMF
(30 mL) was added Ag2003 (8.7 g, 31.54 mmol, 1.5 equiv.) at 0 C, stirred for 5 mins and then 3-bromodihydrofuran-2(3H)-one (2.3 mL, 25.23 mmol, 1.2 equiv.) was added and the reaction was stirred at 60 C for 2 h. After the consumption of the starting material (TLC, 5 % Me0H in DCM), the reaction mixture was filtered through a Celite bed and washed with Et0Ac (200 mL). The organic layer was washed with ice cold water (2 x 20 mL), dried over anhydrous Na2SO4, filtered and distilled under vacuum. The crude material was purified by flash column chromatography (5 ¨ 6 % Me0H in DCM) to afford 3-(pyridin-4-yloxy)dihydrofuran-2(3H)-one as a brown liquid (1.18 g, 31.4% yield). LCMS
(ES) m/z =
180.0 [M+Fl] , 1H NMR (400 MHz, CDCI3) 6 ppm 2.45 ¨ 2.55 (m, 1 H), 2.72 ¨
2.80 (m, 1 H), 4.33 ¨4.42 (m, 1 H), 4.52 ¨4.57 (m, 1 H), 5.05 (t, J= 7.8 Hz, 1 H), 6.95¨
6.97(m, 2 H), 8.47 ¨ 8.49 (m, 2 H).
- 216 -Step 2: To a solution of 3-(pyridin-4-yloxy)dihydrofuran-2(3H)-one (0.99 g, 5.54 mmol, 1.0 equiv.) in toluene (15.0 mL) was added tert-butyl (3-aminobicyclo[1.1.1]pentan-yl)carbamate (1.1 g, 5.54 mmol, 1.0 equiv) at room temperature and the mixture was then heated to 110 C using an oil bath for 16 h. After the consumption of the starting material (TLC, 5 % Me0H in DCM), the reaction mixture was concentrated under vacuum.
The crude material was purified by column chromatography using an eluent of 5 - 7 % Me0H in DCM to obtain the desired product tert-butyl (3-(4-hydroxy-2-(pyridin-4-yloxy)butanamido)bicyclo[1.1.1]pentan-1-yl)carbamate as a pale yellow liquid (1.2 g, 57.4 % yield). LCMS (ES) m/z = 378.1 [M+H] +.1H NMR (400 MHz, DMSO-d6) 6 ppm 1.34 (s, 9 H), 1.88 - 1.89 (m, 2 H), 2.06 (s, 6 H), 3.46 - 3.48 (m, 2 H), 4.60 (bs, 1 H), 4.71 ( bs, 1 H), 6.46 (s, 2 H), 7.44 (bs, 1 H), 8.36 (s, 2 H), 8.73 (s, 1 H).
Step 3: To a solution of tert-butyl (3-(4-hydroxy-2-(pyridin-4-yloxy)butanamido)bicyclo[1.1.1]pentan-1-yl)carbamate (1.2 g, 3.17 mmol, 1.0 equiv.) in DCM (20 mL) at 0 C was added triethylamine (1.33 mL, 9.51 mmol, 3.0 equiv.), stirred for 10 mins and then methanesulfonyl chloride (0.5 mL, 6.36 mmol, 2.0 equiv.) was added and the mixture was stirred at room temperature for 3 h. After the consumption of the starting material (TLC, 5 % Me0H in DCM), the reaction mixture was cooled to 0 C and quenched with ice. It was extracted with DCM (2 x 80 mL). Combined organic layer was dried over anhydrous Na2SO4, filtered and distilled under vacuum to afford 4-((3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentan-1-yl)amino)-4-oxo-3-(pyridin-4-yloxy)butyl methanesulfonate (1.6 g, crude), which was taken to the next step without further purification. LCMS (ES) m/z= 456.1 [M+H] .
Step 4: To a solution of 4-((3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentan-1-yl)amino)-4-oxo-3-(pyridin-4-yloxy)butyl methanesulfonate (1.6 g, 3.51 mmol, 1.0 equiv.) in THF (20 mL) was added 60% sodium hydride in mineral oil (0.17 g, 4.21 mmol, 1.2 equiv.) at 000 and the reaction was stirred at room temperature for 16 h. After the consumption of the starting material (TLC, 5 % Me0H in DCM), the reaction mixture was cooled to 0 C, quenched with ice and was extracted with ethyl acetate (2 x 100 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and distilled under reduced pressure to obtain the crude product. The crude material was purified by column chromatography using an eluent of 5 - 7 % Me0H in DCM to obtain tert-butyl (3-(2-oxo-3-(pyridin-4-yloxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (0.73 g, 45.3% yield). LCMS (ES) m/z = 360.1 [M+H] +.1H NMR (400 MHz, 0D013) 6 ppm
The crude material was purified by column chromatography using an eluent of 5 - 7 % Me0H in DCM to obtain the desired product tert-butyl (3-(4-hydroxy-2-(pyridin-4-yloxy)butanamido)bicyclo[1.1.1]pentan-1-yl)carbamate as a pale yellow liquid (1.2 g, 57.4 % yield). LCMS (ES) m/z = 378.1 [M+H] +.1H NMR (400 MHz, DMSO-d6) 6 ppm 1.34 (s, 9 H), 1.88 - 1.89 (m, 2 H), 2.06 (s, 6 H), 3.46 - 3.48 (m, 2 H), 4.60 (bs, 1 H), 4.71 ( bs, 1 H), 6.46 (s, 2 H), 7.44 (bs, 1 H), 8.36 (s, 2 H), 8.73 (s, 1 H).
Step 3: To a solution of tert-butyl (3-(4-hydroxy-2-(pyridin-4-yloxy)butanamido)bicyclo[1.1.1]pentan-1-yl)carbamate (1.2 g, 3.17 mmol, 1.0 equiv.) in DCM (20 mL) at 0 C was added triethylamine (1.33 mL, 9.51 mmol, 3.0 equiv.), stirred for 10 mins and then methanesulfonyl chloride (0.5 mL, 6.36 mmol, 2.0 equiv.) was added and the mixture was stirred at room temperature for 3 h. After the consumption of the starting material (TLC, 5 % Me0H in DCM), the reaction mixture was cooled to 0 C and quenched with ice. It was extracted with DCM (2 x 80 mL). Combined organic layer was dried over anhydrous Na2SO4, filtered and distilled under vacuum to afford 4-((3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentan-1-yl)amino)-4-oxo-3-(pyridin-4-yloxy)butyl methanesulfonate (1.6 g, crude), which was taken to the next step without further purification. LCMS (ES) m/z= 456.1 [M+H] .
Step 4: To a solution of 4-((3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentan-1-yl)amino)-4-oxo-3-(pyridin-4-yloxy)butyl methanesulfonate (1.6 g, 3.51 mmol, 1.0 equiv.) in THF (20 mL) was added 60% sodium hydride in mineral oil (0.17 g, 4.21 mmol, 1.2 equiv.) at 000 and the reaction was stirred at room temperature for 16 h. After the consumption of the starting material (TLC, 5 % Me0H in DCM), the reaction mixture was cooled to 0 C, quenched with ice and was extracted with ethyl acetate (2 x 100 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and distilled under reduced pressure to obtain the crude product. The crude material was purified by column chromatography using an eluent of 5 - 7 % Me0H in DCM to obtain tert-butyl (3-(2-oxo-3-(pyridin-4-yloxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (0.73 g, 45.3% yield). LCMS (ES) m/z = 360.1 [M+H] +.1H NMR (400 MHz, 0D013) 6 ppm
- 217 -1.44 (s, 9 H), 2.16- 2.22 (m, 1 H), 2.39 (s, 6 H), 2.54- 2.56 (m, 1 H), 3.33 -3.39 (m, 1 H), 3.45 - 3.48 (m, 1 H), 4.91 -4.95 (m, 2 H), 6.95 -6.96 (m, 2 H), 8.42 - 8.43 (m, 2 H).
Step 5: To a solution of tert-butyl (3-(2-oxo-3-(pyridin-4-yloxy)pyrrolidin-1 -yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.73 g, 2.03 mmol, 1.0 equiv.) in THF
(15 mL) was added borane dimethyl sulfide complex (0.39 mL, 4.06 mmol, 2.0 equiv.) at 0 C
and the reaction was stirred at room temperature for 16 h. After the consumption of the starting material (TLC, 5 % Me0H in DCM), the reaction mixture was cooled to 0 C, quenched with methanol, stirred for 1 h and distilled under reduced pressure to obtain the crude product. The crude material was purified by column chromatography using an eluent of 5 -7 % Me0H in DCM to obtain tert-butyl (3-(3-(pyridin-4-yloxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as a pale yellow sticky solid (0.1 g, 14.2 % yield).
LCMS (ES) m/z= 346.2 [M+H] .
Step 6: To a solution of tert-butyl (3-(3-(pyridin-4-yloxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.1 g, 0.29 mmol, 1.0 equiv.) in DCM (5 mL) was added 4M HCI
in 1,4-dioxane (2.0 mL) at 0 C and the reaction was stirred at room temperature for 24 h. After the consumption of the starting material (TLC, 10 % Me0H in DCM), the reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude material was triturated with n-pentane (2 x 5 mL) to obtain 3-(3-(pyridin-4-yloxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine dihydrochloride as an off-white solid (0.09 g, crude). LCMS
(ES) m/z= 246.3 [M+H] .
Step 7: To a solution of 2-(4-chlorophenoxy)acetic acid (0.079 g, 0.42 mmol, 1.5 equiv.) in DCM (8 mL) at 000 was added triethylamine (0.19 mL, 1.40 mmol, 5.0 equiv.), stirred for 10 mins, followed by addition of T3P (50 wt% in Et0Ac) (0.5 mL, 0.85 mmol, 3.0 equiv).
The mixture was stirred at 0 C for 10 min and then 3-(3-(pyridin-4-yloxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine dihydrochloride (0.09 g, 0.28 mmol, 1.0 equiv.) (which was neutralized with triethylamine in DCM (3 mL)) was slowly added at 0 C and the reaction was stirred at room temperature for 16 h. After the consumption of the starting material (TLC, 5 % Me0H in DCM), the reaction mixture was diluted with DCM (100 mL) and was washed with saturated NaH0O3 (2 x 5 mL) and water (2 x 5 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure.
The crude material was purified by column chromatography using an eluent of 5 -7 %
Me0H in DCM to obtain the desired product. It was further purified by Prep HPLC
[(Analytical condition: Column: lnertsil ODS 3V (250 mm x 4.6 mm x 5 mic);
Mobile phase
Step 5: To a solution of tert-butyl (3-(2-oxo-3-(pyridin-4-yloxy)pyrrolidin-1 -yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.73 g, 2.03 mmol, 1.0 equiv.) in THF
(15 mL) was added borane dimethyl sulfide complex (0.39 mL, 4.06 mmol, 2.0 equiv.) at 0 C
and the reaction was stirred at room temperature for 16 h. After the consumption of the starting material (TLC, 5 % Me0H in DCM), the reaction mixture was cooled to 0 C, quenched with methanol, stirred for 1 h and distilled under reduced pressure to obtain the crude product. The crude material was purified by column chromatography using an eluent of 5 -7 % Me0H in DCM to obtain tert-butyl (3-(3-(pyridin-4-yloxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as a pale yellow sticky solid (0.1 g, 14.2 % yield).
LCMS (ES) m/z= 346.2 [M+H] .
Step 6: To a solution of tert-butyl (3-(3-(pyridin-4-yloxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.1 g, 0.29 mmol, 1.0 equiv.) in DCM (5 mL) was added 4M HCI
in 1,4-dioxane (2.0 mL) at 0 C and the reaction was stirred at room temperature for 24 h. After the consumption of the starting material (TLC, 10 % Me0H in DCM), the reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude material was triturated with n-pentane (2 x 5 mL) to obtain 3-(3-(pyridin-4-yloxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine dihydrochloride as an off-white solid (0.09 g, crude). LCMS
(ES) m/z= 246.3 [M+H] .
Step 7: To a solution of 2-(4-chlorophenoxy)acetic acid (0.079 g, 0.42 mmol, 1.5 equiv.) in DCM (8 mL) at 000 was added triethylamine (0.19 mL, 1.40 mmol, 5.0 equiv.), stirred for 10 mins, followed by addition of T3P (50 wt% in Et0Ac) (0.5 mL, 0.85 mmol, 3.0 equiv).
The mixture was stirred at 0 C for 10 min and then 3-(3-(pyridin-4-yloxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine dihydrochloride (0.09 g, 0.28 mmol, 1.0 equiv.) (which was neutralized with triethylamine in DCM (3 mL)) was slowly added at 0 C and the reaction was stirred at room temperature for 16 h. After the consumption of the starting material (TLC, 5 % Me0H in DCM), the reaction mixture was diluted with DCM (100 mL) and was washed with saturated NaH0O3 (2 x 5 mL) and water (2 x 5 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure.
The crude material was purified by column chromatography using an eluent of 5 -7 %
Me0H in DCM to obtain the desired product. It was further purified by Prep HPLC
[(Analytical condition: Column: lnertsil ODS 3V (250 mm x 4.6 mm x 5 mic);
Mobile phase
- 218 -(A) : 0.1 % ammonia in water; Mobile phase (B): Acetonitrile; Flow rate: 1.0 mUmin)] to afford the desired product 2-(4-chlorophenoxy)-N-(3-(3-(pyridin-4-yloxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide as an off-white solid (0.033 g, 28.2%
yield). LCMS
(ES) m/z = 414.38 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.76 - 1.79 (m, 1 H), 1.96 (s, 6 H), 2.23 - 2.30 (m, 1 H), 2.48 (s, 1 H), 2.61 - 2.72 (m, 2 H), 2.86 - 2.90 (m, 1 H), 4.40 (s, 2 H), 4.96 (bs, 1 H), 6.88 (d, J= 4.8 Hz, 2 H), 6.94 (d, J= 8.0 Hz, 2 H), 7.31 (d, J=
8.4 Hz, 2 H), 8.34 (d, J= 5.6 Hz, 2 H), 8.61 (s, 1 H).
Examples 6t and 6u were prepared generally accordingly to the procedure described above for 6s.
Table 18 LCMS 1H-NMR (400 MHz, Cmpd # Structure Name m/z DMSO-d6) [M+H]
gN
1.76 - 1.79 (m, 1 H), 1.96 (s, 6 H), 2.23 - 2.30 (m, 1 H), 2.48 (s, 1 H), 2.61 -2.72 (m, 2 H), 2.86 - 2.90 2-(4-chlorophenoxy)-N-(3-(3-(m, 1 H), 4.40 (s, 2 H), (pyridin-4-yloxy)pyrrolidin-1-6s yObicyclo[1.1.1]pentan-1- 414.38 4.96 (bs, 1 H), 6.88 (d, J=
o:!\?:-1 4.8 Hz, 2 H), 6.94 (d, J=
yl)acetamide 8.0 Hz, 2 H), 7.31 (d, J =
=
8.4 Hz, 2 H), 8.34 (d, J =
5.6 Hz, 2 H), 8.61 (s, 1 H).
yield). LCMS
(ES) m/z = 414.38 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.76 - 1.79 (m, 1 H), 1.96 (s, 6 H), 2.23 - 2.30 (m, 1 H), 2.48 (s, 1 H), 2.61 - 2.72 (m, 2 H), 2.86 - 2.90 (m, 1 H), 4.40 (s, 2 H), 4.96 (bs, 1 H), 6.88 (d, J= 4.8 Hz, 2 H), 6.94 (d, J= 8.0 Hz, 2 H), 7.31 (d, J=
8.4 Hz, 2 H), 8.34 (d, J= 5.6 Hz, 2 H), 8.61 (s, 1 H).
Examples 6t and 6u were prepared generally accordingly to the procedure described above for 6s.
Table 18 LCMS 1H-NMR (400 MHz, Cmpd # Structure Name m/z DMSO-d6) [M+H]
gN
1.76 - 1.79 (m, 1 H), 1.96 (s, 6 H), 2.23 - 2.30 (m, 1 H), 2.48 (s, 1 H), 2.61 -2.72 (m, 2 H), 2.86 - 2.90 2-(4-chlorophenoxy)-N-(3-(3-(m, 1 H), 4.40 (s, 2 H), (pyridin-4-yloxy)pyrrolidin-1-6s yObicyclo[1.1.1]pentan-1- 414.38 4.96 (bs, 1 H), 6.88 (d, J=
o:!\?:-1 4.8 Hz, 2 H), 6.94 (d, J=
yl)acetamide 8.0 Hz, 2 H), 7.31 (d, J =
=
8.4 Hz, 2 H), 8.34 (d, J =
5.6 Hz, 2 H), 8.61 (s, 1 H).
- 219 -CI
1.77 - 1.88 (m, 1 H), 1.94 (s, 6 H), 2.18 - 2.26 (m, 1 2-(4-chlorophenoxy)-N-(3-(3-((5- H), 2.59 - 2.71 (m, 3 H), 2.84 - 2.87 (m, 1 H), 4.39 6t 448.0 chloropyridin-2-yl)oxy)pyrrolidin-1- (s, 2 H), 5.29 (s, 1 H), yObicyclo[1.1.1]pentan-1- 6.82 (d, J = 8.8 Hz, 1 H), o <>H yl)acetamide 6.94 (d, J = 8.8 Hz, 2 H), 7.31 (d, J = 8.8 Hz, 2 H), 7.76 (d, J = 7.2 Hz, 1 H), 011 8.17 (s, 1 H), 8.61 (s, 1 H) CI
1.76 - 1.80 (m, 1 H), 1.92 (s, 6 H), 2.17 - 2.26 (m, 1 2-((5-chloropyridin-2-yl)oxy)-N-(3- H), 2.58 - 2.70 (m, 3 H), 2.82 - 2.86 (m, 1 H), 4.63 (3-((5-chloropyridin-2-(s, 2 H), 5.29 (s, 1 H), 6u yl)oxy)pyrrolidin-1- 449.0 6.82 (d, J = 8.8 Hz, 1 H), o 4>H yObicyclo[1.1.1]pentan-1-6.92 (d, J = 8.4 Hz, 1 H), yl)acetamide 7.74 - 7.82 (m, 2 H), 8.15 -8.17 (m, 2 H), 8.55 (s, 1 H).
=
Examples 6v and 6w N-(3-(3-(4-chloro-3-fluorophenoxv)ovrrolidin-1-vnbicyclo11.1.11pentan-1-v1)-2-(4-chlorophenoxv)acetamide CI CI
*
jSOMer 2 isomer 1
1.77 - 1.88 (m, 1 H), 1.94 (s, 6 H), 2.18 - 2.26 (m, 1 2-(4-chlorophenoxy)-N-(3-(3-((5- H), 2.59 - 2.71 (m, 3 H), 2.84 - 2.87 (m, 1 H), 4.39 6t 448.0 chloropyridin-2-yl)oxy)pyrrolidin-1- (s, 2 H), 5.29 (s, 1 H), yObicyclo[1.1.1]pentan-1- 6.82 (d, J = 8.8 Hz, 1 H), o <>H yl)acetamide 6.94 (d, J = 8.8 Hz, 2 H), 7.31 (d, J = 8.8 Hz, 2 H), 7.76 (d, J = 7.2 Hz, 1 H), 011 8.17 (s, 1 H), 8.61 (s, 1 H) CI
1.76 - 1.80 (m, 1 H), 1.92 (s, 6 H), 2.17 - 2.26 (m, 1 2-((5-chloropyridin-2-yl)oxy)-N-(3- H), 2.58 - 2.70 (m, 3 H), 2.82 - 2.86 (m, 1 H), 4.63 (3-((5-chloropyridin-2-(s, 2 H), 5.29 (s, 1 H), 6u yl)oxy)pyrrolidin-1- 449.0 6.82 (d, J = 8.8 Hz, 1 H), o 4>H yObicyclo[1.1.1]pentan-1-6.92 (d, J = 8.4 Hz, 1 H), yl)acetamide 7.74 - 7.82 (m, 2 H), 8.15 -8.17 (m, 2 H), 8.55 (s, 1 H).
=
Examples 6v and 6w N-(3-(3-(4-chloro-3-fluorophenoxv)ovrrolidin-1-vnbicyclo11.1.11pentan-1-v1)-2-(4-chlorophenoxv)acetamide CI CI
*
jSOMer 2 isomer 1
- 220 -OH
Br F gr Bcic H2 µN
CI
CI CI
goc g5y Step )r Step 2 0 N' *
¨G¨NH2 HCI
Step 3 CI oN
Step CI
CI
JOH
Enantiomer separation by chiral prep HPLC
Step 5 ci \j(14,4010o CI CI
6V 6w isomer i isomer 2 Step 1: To a solution of 4-chloro-3-fluorophenol (1.0 g, 6.82 mmol, 1.0 equiv.) in DMF (20 mL) was added K2003 (0.94 g, 6.82 mmol, 1.0 equiv.) at 0 C, stirred for 10 mins and then methyl 2,4-dibromobutanoate (0.96 mL, 6.82 mmol, 1.0 equiv.) was added and the reaction was stirred at 60 C for 3 h. After the consumption of the starting material (TLC, 10 c)/0 ethyl acetate in hexane), the reaction mixture was diluted with ice cold water (50 mL) and was extracted with Et0Ac (2 X 100 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under vacuum. The crude material was purified by flash column chromatography (2 ¨ 5 c)/0 Et0Ac in hexane) to afford methyl 4-bromo-2-(4-chloro-3-fluorophenoxy)butanoate as a colorless liquid (1.18 g, crude). LCMS
(ES) m/z =
324.0 [M+H]+, Step 2: To a solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.6 g, 3.03 MMOI, 1.0 equiv.) in Et3N (1.7 mL, 12.12 mmol, 4.0 equiv.) was added methyl 4-bromo-2-(4-chloro-3-fluorophenoxy)butanoate (1.18 g, 3.63 mmol, 1.2 equiv) at room temperature in a sealed tube and the mixture was then heated at 100 C using an oil bath for 1 h. (Note:
The reaction was carried out by dividing 0.6 g into 3 batches). After the consumption of the starting material (TLC, 70 `)/0 ethyl acetate in hexane), the reaction mixture was diluted with ethyl acetate (100 mL) and was washed with water (2 X 20 mL). The combined Et0Ac
Br F gr Bcic H2 µN
CI
CI CI
goc g5y Step )r Step 2 0 N' *
¨G¨NH2 HCI
Step 3 CI oN
Step CI
CI
JOH
Enantiomer separation by chiral prep HPLC
Step 5 ci \j(14,4010o CI CI
6V 6w isomer i isomer 2 Step 1: To a solution of 4-chloro-3-fluorophenol (1.0 g, 6.82 mmol, 1.0 equiv.) in DMF (20 mL) was added K2003 (0.94 g, 6.82 mmol, 1.0 equiv.) at 0 C, stirred for 10 mins and then methyl 2,4-dibromobutanoate (0.96 mL, 6.82 mmol, 1.0 equiv.) was added and the reaction was stirred at 60 C for 3 h. After the consumption of the starting material (TLC, 10 c)/0 ethyl acetate in hexane), the reaction mixture was diluted with ice cold water (50 mL) and was extracted with Et0Ac (2 X 100 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under vacuum. The crude material was purified by flash column chromatography (2 ¨ 5 c)/0 Et0Ac in hexane) to afford methyl 4-bromo-2-(4-chloro-3-fluorophenoxy)butanoate as a colorless liquid (1.18 g, crude). LCMS
(ES) m/z =
324.0 [M+H]+, Step 2: To a solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (0.6 g, 3.03 MMOI, 1.0 equiv.) in Et3N (1.7 mL, 12.12 mmol, 4.0 equiv.) was added methyl 4-bromo-2-(4-chloro-3-fluorophenoxy)butanoate (1.18 g, 3.63 mmol, 1.2 equiv) at room temperature in a sealed tube and the mixture was then heated at 100 C using an oil bath for 1 h. (Note:
The reaction was carried out by dividing 0.6 g into 3 batches). After the consumption of the starting material (TLC, 70 `)/0 ethyl acetate in hexane), the reaction mixture was diluted with ethyl acetate (100 mL) and was washed with water (2 X 20 mL). The combined Et0Ac
- 221 -extracts were dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 60 -70 %
Et0Ac in hexane to obtain the desired product tert-butyl (3-(3-(4-chloro-3-fluorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (0.48 g, 40.0 %). LCMS (ES) m/z= 411.3 [M+H]+
Step 3: To a solution of tert-butyl (3-(3-(4-chloro-3-fluorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.48 g, 1.17 mmol, 1.0 equiv.) in DCM
(10 mL) at 0 C was added 5 mL of 4 M HCI in 1,4-dioxane and the mixture was stirred at room .. temperature for 16 h. After the consumption of the starting material (TLC, 70 % ethyl acetate in hexane), the reaction mixture was concentrated and the crude was triturated with n-pentane (2 X 10 mL) and dried under high vacuum to afford 1-(3-aminobicyclo[1.1.1]pentan-1-y1)-3-(4-chloro-3-fluorophenoxy)pyrrolidin-2-one hydrochloride (0.37 g, 91.3 % yield), which was taken to the next step without further purification. LCMS
(ES) m/z = 311.1 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.91 (bs, 1 H), 2.31 (s, 6 H), 2.50 - 2.60 (m, 3 H), 5.05 (t, J = 7.6 Hz, 1 H), 6.88 (d, J = 8.8 Hz, 1 H), 7.14 (d, J =
10.8 Hz, 1 H), 7.41 - 7.50 (m, 1 H), 8.81 - 8.98 (m, 3 H).
Step 4: To a solution of 1-(3-am inobicyclo[1.1.1]pentan-1-yI)-3-(4-ch loro-3-fluorophenoxy)pyrrolidin-2-one hydrochloride (0.37 g, 1.06 mmol, 1.0 equiv.) in THF (10 mL) was added BH3.Me2S (0.31 mL, 3.30 mmol, 3.1 equiv.) at 0 C and the reaction was stirred for 40 h. (Note: 1.5 equiv. of BH3.Me2S complex was added initially, stirred for 16 h, monitored the progress of the reaction by LCMS, added again 0.8 equiv. of BH3.Me2S, stirred for 8 h, monitored the progress of the reaction by LCMS and again 0.8 equiv. of BH3.Me2S was added and the reaction was stirred for 16 h.) After the consumption of the starting material (TLC, 5 % Me0H in DCM), the reaction mixture was cooled to 0 C, quenched with Me0H (5 mL), stirred for 30 min, and concentrated under reduced pressure to obtain the crude product. This crude material was triturated with n-pentane (2 x 5 mL) and dried under high vacuum to yield 3-(3-(4-chloro-3-fluorophenoxy)pyrrolidin-yl)bicyclo[1.1.1]pentan-1-amine as an off-white solid (0.4 g, crude yield), which was used for the next step without further purification. LCMS (ES) m/z= 297.1 [M+H]+
Step 5: To a solution of 2-(4-chlorophenoxy)acetic acid (0.30 g, 1.62 mmol, 1.2 equiv.) in DCM (10 mL) at 0 C was added triethylamine (0.75 mL, 5.40 mmol, 4.0 equiv.), stirred for 10 mins, followed by addition of T3P (50 wt.% in Et0Ac) (1.62 mL, 2.70 mmol, 2 equiv).
The mixture was stirred at 0 C for 10 min and then 3-(3-(4-chloro-3-
Et0Ac in hexane to obtain the desired product tert-butyl (3-(3-(4-chloro-3-fluorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (0.48 g, 40.0 %). LCMS (ES) m/z= 411.3 [M+H]+
Step 3: To a solution of tert-butyl (3-(3-(4-chloro-3-fluorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (0.48 g, 1.17 mmol, 1.0 equiv.) in DCM
(10 mL) at 0 C was added 5 mL of 4 M HCI in 1,4-dioxane and the mixture was stirred at room .. temperature for 16 h. After the consumption of the starting material (TLC, 70 % ethyl acetate in hexane), the reaction mixture was concentrated and the crude was triturated with n-pentane (2 X 10 mL) and dried under high vacuum to afford 1-(3-aminobicyclo[1.1.1]pentan-1-y1)-3-(4-chloro-3-fluorophenoxy)pyrrolidin-2-one hydrochloride (0.37 g, 91.3 % yield), which was taken to the next step without further purification. LCMS
(ES) m/z = 311.1 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.91 (bs, 1 H), 2.31 (s, 6 H), 2.50 - 2.60 (m, 3 H), 5.05 (t, J = 7.6 Hz, 1 H), 6.88 (d, J = 8.8 Hz, 1 H), 7.14 (d, J =
10.8 Hz, 1 H), 7.41 - 7.50 (m, 1 H), 8.81 - 8.98 (m, 3 H).
Step 4: To a solution of 1-(3-am inobicyclo[1.1.1]pentan-1-yI)-3-(4-ch loro-3-fluorophenoxy)pyrrolidin-2-one hydrochloride (0.37 g, 1.06 mmol, 1.0 equiv.) in THF (10 mL) was added BH3.Me2S (0.31 mL, 3.30 mmol, 3.1 equiv.) at 0 C and the reaction was stirred for 40 h. (Note: 1.5 equiv. of BH3.Me2S complex was added initially, stirred for 16 h, monitored the progress of the reaction by LCMS, added again 0.8 equiv. of BH3.Me2S, stirred for 8 h, monitored the progress of the reaction by LCMS and again 0.8 equiv. of BH3.Me2S was added and the reaction was stirred for 16 h.) After the consumption of the starting material (TLC, 5 % Me0H in DCM), the reaction mixture was cooled to 0 C, quenched with Me0H (5 mL), stirred for 30 min, and concentrated under reduced pressure to obtain the crude product. This crude material was triturated with n-pentane (2 x 5 mL) and dried under high vacuum to yield 3-(3-(4-chloro-3-fluorophenoxy)pyrrolidin-yl)bicyclo[1.1.1]pentan-1-amine as an off-white solid (0.4 g, crude yield), which was used for the next step without further purification. LCMS (ES) m/z= 297.1 [M+H]+
Step 5: To a solution of 2-(4-chlorophenoxy)acetic acid (0.30 g, 1.62 mmol, 1.2 equiv.) in DCM (10 mL) at 0 C was added triethylamine (0.75 mL, 5.40 mmol, 4.0 equiv.), stirred for 10 mins, followed by addition of T3P (50 wt.% in Et0Ac) (1.62 mL, 2.70 mmol, 2 equiv).
The mixture was stirred at 0 C for 10 min and then 3-(3-(4-chloro-3-
- 222 -fluorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine (0.4g, 1.35 mmol, 1.0 equiv.) in DCM (5 mL) was slowly added at 0 C and the reaction was stirred at room temperature for 16 h. After the consumption of the starting material (TLC, 70 % ethyl acetate in hexane), the reaction mixture was diluted with DCM (200 mL) and was washed with saturated NaHCO3 (2 x 20 mL) and water (2 x 20 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude material was purified by column chromatography using an eluent of 65 - 80 % Et0Ac in hexane to obtain the desired product N-(3-(3-(4-chloro-3-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)-2-(4-chlorophenoxy)acetamide as an off-white solid (0.16 g, 25.4 /0).
The racemate product from step 5 was submitted for chiral prep HPLC to separate the isomers by using the following analytical conditions: [Column: CHIRALPAK IC
(100 mm x 4.6 mm x 3 mic); Flow rate: 1.0 mL/min; Mobile phase: n-Hexane:IPA with 0.1 %
DEA
(65:35).] Fractions containing the two isomers were separately evaporated under reduced pressure, triturated with n-pentane (10 mL, HPLC grade) and dried under high vacuum.
Example 6v: Isomer 1 (Single Unknown stereochemistry):
Recovery: 0.021 g (gum). LCMS (ES) m/z= 465.3 [M+H] . 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.74- 1.77 (m, 1 H), 1.95 (s, 6 H), 2.22 -2.30 (m, 1 H), 2.59 - 2.69 (m, 3 H), 2.84 -2.88 (m, 1 H), 4.40 (s, 2 H), 4.88 (bs, 1 H), 6.76 (d, J = 9.2 Hz, 1 H), 6.94 -7.00 (m, 3 H), 7.31 (d, J= 7.6 Hz, 2 H), 7.42 (t, J= 8.8 Hz, 1 H), 8.61 (s, 1 H). Chiral HPLC
purity: 100.0 % at 225 nm; % ee: 100.0%
Example 6w: Isomer 2 (Single Unknown stereochemistry):
Recovery: 0.025 g (gum). LCMS (ES) m/z= 465.3 [M+H] . 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.76- 1.77 (m, 1 H), 1.95 (s, 6 H), 2.24 -2.25 (m, 1 H), 2.59 - 2.69 (m, 3 H), 2.85 -2.90 (m, 1 H), 4.40 (s, 2 H), 4.89 (bs, 1 H), 6.76 (d, J = 9.2 Hz, 1 H), 6.94 -7.00 (m, 3 H), 7.31 (d, J= 7.6 Hz, 2 H), 7.42 (t, J= 8.6 Hz, 1 H), 8.61 (s, 1 H). Chiral HPLC
purity: 100.0 % at 225 nm; % ee: 100.0 /0.
The racemate product from step 5 was submitted for chiral prep HPLC to separate the isomers by using the following analytical conditions: [Column: CHIRALPAK IC
(100 mm x 4.6 mm x 3 mic); Flow rate: 1.0 mL/min; Mobile phase: n-Hexane:IPA with 0.1 %
DEA
(65:35).] Fractions containing the two isomers were separately evaporated under reduced pressure, triturated with n-pentane (10 mL, HPLC grade) and dried under high vacuum.
Example 6v: Isomer 1 (Single Unknown stereochemistry):
Recovery: 0.021 g (gum). LCMS (ES) m/z= 465.3 [M+H] . 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.74- 1.77 (m, 1 H), 1.95 (s, 6 H), 2.22 -2.30 (m, 1 H), 2.59 - 2.69 (m, 3 H), 2.84 -2.88 (m, 1 H), 4.40 (s, 2 H), 4.88 (bs, 1 H), 6.76 (d, J = 9.2 Hz, 1 H), 6.94 -7.00 (m, 3 H), 7.31 (d, J= 7.6 Hz, 2 H), 7.42 (t, J= 8.8 Hz, 1 H), 8.61 (s, 1 H). Chiral HPLC
purity: 100.0 % at 225 nm; % ee: 100.0%
Example 6w: Isomer 2 (Single Unknown stereochemistry):
Recovery: 0.025 g (gum). LCMS (ES) m/z= 465.3 [M+H] . 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.76- 1.77 (m, 1 H), 1.95 (s, 6 H), 2.24 -2.25 (m, 1 H), 2.59 - 2.69 (m, 3 H), 2.85 -2.90 (m, 1 H), 4.40 (s, 2 H), 4.89 (bs, 1 H), 6.76 (d, J = 9.2 Hz, 1 H), 6.94 -7.00 (m, 3 H), 7.31 (d, J= 7.6 Hz, 2 H), 7.42 (t, J= 8.6 Hz, 1 H), 8.61 (s, 1 H). Chiral HPLC
purity: 100.0 % at 225 nm; % ee: 100.0 /0.
- 223 -Table 17 LCMS 1H-NMR (400 MHz, Cmpd # Structure Name miz DMSO-d6) [M+H]
CI F 1.74 - 1.77 (m, 1 H), 1.95 1, (s, 6 H), 2.22 - 2.30 (m, 1 N-(3-(3-(4-chloro-3- H), 2.59 - 2.69 (m, 3 H), dfluorophenoxy)pyrrolidi 2.84 - 2.88 (m, 1 H), 4.40 6v N n-1- (s, 2 H), 4.88 (bs, 1 H), (Isomer 1) yl)bicyclo[1.1.1]pentan- 465.3 6.76 (d, J= 9.2 Hz, 1 H), 1-yI)-2-(4- 6.94 - 7.00 (m, 3 H), 7.31 ) chlorophenoxy)acetami (d, J= 7.6 Hz, 2 H), 7.42 0113 de (t, J= 8.8 Hz, 1 H), 8.61 (s, 1 H).
CI F 1.76 - 1.77 (m, 1 H),1.95 I, (s, 6 H), 2.24 - 2.25 (m, 1 N-(3-(3-(4-chloro-3- H), 2.59 - 2.69 (m, 3 H), dfluorophenoxy)pyrrolidi 2.85 - 2.90 (m, 1 H), 4.40 6w N n-1- (s, 2 H), 4.89 (bs, 1 H), (Isomer 2) yl)bicyclo[1.1.1]pentan- 465.3 6.76(d, J= 9.2 Hz, 1 H), 1-yI)-2-(4- 6.94 - 7.00 (m, 3 H), 7.31 ) chlorophenoxy)acetami (d, J= 7.6 Hz, 2 H), 7.42 4 de (t, J= 8.6 Hz, 1 H), 8.61 (s, 1 H).
CI F 1.74 - 1.77 (m, 1 H), 1.95 1, (s, 6 H), 2.22 - 2.30 (m, 1 N-(3-(3-(4-chloro-3- H), 2.59 - 2.69 (m, 3 H), dfluorophenoxy)pyrrolidi 2.84 - 2.88 (m, 1 H), 4.40 6v N n-1- (s, 2 H), 4.88 (bs, 1 H), (Isomer 1) yl)bicyclo[1.1.1]pentan- 465.3 6.76 (d, J= 9.2 Hz, 1 H), 1-yI)-2-(4- 6.94 - 7.00 (m, 3 H), 7.31 ) chlorophenoxy)acetami (d, J= 7.6 Hz, 2 H), 7.42 0113 de (t, J= 8.8 Hz, 1 H), 8.61 (s, 1 H).
CI F 1.76 - 1.77 (m, 1 H),1.95 I, (s, 6 H), 2.24 - 2.25 (m, 1 N-(3-(3-(4-chloro-3- H), 2.59 - 2.69 (m, 3 H), dfluorophenoxy)pyrrolidi 2.85 - 2.90 (m, 1 H), 4.40 6w N n-1- (s, 2 H), 4.89 (bs, 1 H), (Isomer 2) yl)bicyclo[1.1.1]pentan- 465.3 6.76(d, J= 9.2 Hz, 1 H), 1-yI)-2-(4- 6.94 - 7.00 (m, 3 H), 7.31 ) chlorophenoxy)acetami (d, J= 7.6 Hz, 2 H), 7.42 4 de (t, J= 8.6 Hz, 1 H), 8.61 (s, 1 H).
- 224 -Example 6x N-(3-(3-(bimiclo[4.2.0locta-1,3,5-trien-3-vloxv)pyrrolidin-1-v1)bimicloll.1.11pentan-1-v1)-2-(4-chlorophenoxv)acetamide CI pa *
OH
ONA Br,"=...01N.,Br 0 Step 1 ir Step 2 0--oms HO**
OA .LT 0 (101 fig6 Step 3 CI ir Step 1: To a solution of N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (3.0 g, 11 mmol, 1.0 equiv) in dimethylacetamide (30 mL) was added N,N-Di-isopropylethylamine (9.6 mL, 55 mmol, 5.0 equiv.) and 1,4-dibromobutan-2-01 (2.61 mL, 22 mmol, 2.0 equiv) at room temperature. The reaction mixture was maintained at 80 C for 1 h. After that, the reaction mixture was cooled to room temperature, quenched with crushed ice (150 mL), and extracted with Et0Ac (3 X
150 mL).
The combined organic layer was washed with cold water (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (neutral alumina column) using 0.1 %
to 5 %
methanol in DCM as eluent to obtain 2-(4-chlorophenoxy)-N-(3-(3-hydroxypyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (1.5 g, 13.2% yield, 3.0 g scale reactions with 3 batches (9.0 g) were done) as a viscous oil. LCMS (ES) m/z = 337.1 [M+H]. 1H
NMR
(400MHz, DMSO-d6) 6 ppm 1.49 ¨ 1.52 (m, 1 H), 1.88¨ 1.96 (m, 7 H), 2.27 ¨ 2.31 (m, 1 H), 2.38 ¨ 2.48 (m, 1 H), 2.54 ¨ 2.59 (m, 1 H), 2.64 ¨ 2.68 (m, 1 H), 4.15 ¨
4.16 (m, 1 H),
OH
ONA Br,"=...01N.,Br 0 Step 1 ir Step 2 0--oms HO**
OA .LT 0 (101 fig6 Step 3 CI ir Step 1: To a solution of N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (3.0 g, 11 mmol, 1.0 equiv) in dimethylacetamide (30 mL) was added N,N-Di-isopropylethylamine (9.6 mL, 55 mmol, 5.0 equiv.) and 1,4-dibromobutan-2-01 (2.61 mL, 22 mmol, 2.0 equiv) at room temperature. The reaction mixture was maintained at 80 C for 1 h. After that, the reaction mixture was cooled to room temperature, quenched with crushed ice (150 mL), and extracted with Et0Ac (3 X
150 mL).
The combined organic layer was washed with cold water (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (neutral alumina column) using 0.1 %
to 5 %
methanol in DCM as eluent to obtain 2-(4-chlorophenoxy)-N-(3-(3-hydroxypyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (1.5 g, 13.2% yield, 3.0 g scale reactions with 3 batches (9.0 g) were done) as a viscous oil. LCMS (ES) m/z = 337.1 [M+H]. 1H
NMR
(400MHz, DMSO-d6) 6 ppm 1.49 ¨ 1.52 (m, 1 H), 1.88¨ 1.96 (m, 7 H), 2.27 ¨ 2.31 (m, 1 H), 2.38 ¨ 2.48 (m, 1 H), 2.54 ¨ 2.59 (m, 1 H), 2.64 ¨ 2.68 (m, 1 H), 4.15 ¨
4.16 (m, 1 H),
- 225 -4.39 (s, 2 H), 4.63 (d, J= 4.4 Hz, 1 H), 6.94 (d, J= 8.8 Hz, 2 H), 7.31 (d, J=
8.8 Hz, 2 H), 8.58 (s, 1 H).
Step 2: To a solution of 2-(4-ch lorophenoxy)-N-(3-(3-hydroxypyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.20 g, 0.59 mmol, 1.0 equiv) in DCM
(50 mL) was added TEA (0.24 mL, 1.7 mmol, 3.0 equiv.) at 0 C. After 10 minutes at the same temperature, mesyl chloride (0.055 mL, 0.71 mmol, 1.2 equiv) was added at 0 C
and reaction mixture was maintained for 2 h at room temperature. The reaction mixture was diluted with DCM (150 mL), and washed with 10% aq. NaHCO3 solution (2 X 50 mL) followed by water (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to afford 1-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-Apyrrolidin-3-y1 methanesulfonate (0.22 g, crude) as a yellow solid. It was used in the next step without further purification. LCMS
(ES) m/z = 415.0 [M+H]. 1H NMR (400MHz, DMSO-d6) 6 ppm 1.87 - 1.93 (m, 1 H), 1.96 (s, 6 H), 2.15- 2.23 (m, 1 H), 2.39 - 2.48 (m, 1 H), 2.70 - 2.78 (m, 3 H), 3.15 (s, 3 H), 4.40 (s,2 H), 5.11 -5.14 (m, 1 H), 6.95 (d, J= 9.2 Hz, 2 H), 7.32 (d, J= 9.2 Hz, 2 H), 8.62 (s, 1 H).
Step 3: To a solution of bicyclo[4.2.0]octa-1,3,5-trien-3-ol (0.07 g, 0.57 mmol, 1.2 equiv.) in acetonitrile (10 mL) was added 0s2003 (0.4 g, 1.2 mmol, 2.5 equiv) and 1-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-Apyrrolidin-3-y1 methanesulfonate (0.2 g, 0.48 mmol, 1.0 equiv) at room temperature. The reaction mixture was maintained at 85 C
for 2 h under microwave irradiation. Then the reaction mixture was cooled to room temperature, diluted with Et0Ac (150 mL), washed with cold water (2 X 50 mL), and the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain the crude product. The crude mass was purified by flash column chromatography using 0.1 % to 5 % methanol in DCM as eluent and further re-purified by prep HPLC [Analytical conditions: Column: lnertsil ODS 3V (250 mm x 4.6 mm x 5 mic). Mobile phase (A): 0.1 A, Ammonia in water, Mobile phase (B):
Acetonitrile, TPY0B:
0/10, 2/10, 8/80, 13/80, 14/80, 15/10, Flow rate: 1.0 mL/min (35 : 65), compound RT:
16.15 minutes] to afford N-(3-(3-(bicyclo[4.2.0]octa-1,3,5-trien-3-yloxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)-2-(4-chlorophenoxy)acetamide (0.06 g, 28.4%
yield) as a white solid. LCMS (ES) m/z = 439 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.73 -1.76 (m, 1 H), 1.94 (s, 6 H), 2.14 - 2.22 (m, 1 H), 2.55 - 2.68 (m, 3 H), 2.82 - 2.86 (m, 1 H), 3.02 (d, J= 5.2 Hz, 4 H), 4.39 (s, 2 H), 4.78 (s, 1 H), 6.64 (d, J= 7.2 Hz, 2 H), 6.93 (t, J
= 8.8 Hz, 3 H), 7.31 (d, J= 8.0 Hz, 2 H), 8.60 (s, 1 H).
8.8 Hz, 2 H), 8.58 (s, 1 H).
Step 2: To a solution of 2-(4-ch lorophenoxy)-N-(3-(3-hydroxypyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.20 g, 0.59 mmol, 1.0 equiv) in DCM
(50 mL) was added TEA (0.24 mL, 1.7 mmol, 3.0 equiv.) at 0 C. After 10 minutes at the same temperature, mesyl chloride (0.055 mL, 0.71 mmol, 1.2 equiv) was added at 0 C
and reaction mixture was maintained for 2 h at room temperature. The reaction mixture was diluted with DCM (150 mL), and washed with 10% aq. NaHCO3 solution (2 X 50 mL) followed by water (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to afford 1-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-Apyrrolidin-3-y1 methanesulfonate (0.22 g, crude) as a yellow solid. It was used in the next step without further purification. LCMS
(ES) m/z = 415.0 [M+H]. 1H NMR (400MHz, DMSO-d6) 6 ppm 1.87 - 1.93 (m, 1 H), 1.96 (s, 6 H), 2.15- 2.23 (m, 1 H), 2.39 - 2.48 (m, 1 H), 2.70 - 2.78 (m, 3 H), 3.15 (s, 3 H), 4.40 (s,2 H), 5.11 -5.14 (m, 1 H), 6.95 (d, J= 9.2 Hz, 2 H), 7.32 (d, J= 9.2 Hz, 2 H), 8.62 (s, 1 H).
Step 3: To a solution of bicyclo[4.2.0]octa-1,3,5-trien-3-ol (0.07 g, 0.57 mmol, 1.2 equiv.) in acetonitrile (10 mL) was added 0s2003 (0.4 g, 1.2 mmol, 2.5 equiv) and 1-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-Apyrrolidin-3-y1 methanesulfonate (0.2 g, 0.48 mmol, 1.0 equiv) at room temperature. The reaction mixture was maintained at 85 C
for 2 h under microwave irradiation. Then the reaction mixture was cooled to room temperature, diluted with Et0Ac (150 mL), washed with cold water (2 X 50 mL), and the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain the crude product. The crude mass was purified by flash column chromatography using 0.1 % to 5 % methanol in DCM as eluent and further re-purified by prep HPLC [Analytical conditions: Column: lnertsil ODS 3V (250 mm x 4.6 mm x 5 mic). Mobile phase (A): 0.1 A, Ammonia in water, Mobile phase (B):
Acetonitrile, TPY0B:
0/10, 2/10, 8/80, 13/80, 14/80, 15/10, Flow rate: 1.0 mL/min (35 : 65), compound RT:
16.15 minutes] to afford N-(3-(3-(bicyclo[4.2.0]octa-1,3,5-trien-3-yloxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-y1)-2-(4-chlorophenoxy)acetamide (0.06 g, 28.4%
yield) as a white solid. LCMS (ES) m/z = 439 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.73 -1.76 (m, 1 H), 1.94 (s, 6 H), 2.14 - 2.22 (m, 1 H), 2.55 - 2.68 (m, 3 H), 2.82 - 2.86 (m, 1 H), 3.02 (d, J= 5.2 Hz, 4 H), 4.39 (s, 2 H), 4.78 (s, 1 H), 6.64 (d, J= 7.2 Hz, 2 H), 6.93 (t, J
= 8.8 Hz, 3 H), 7.31 (d, J= 8.0 Hz, 2 H), 8.60 (s, 1 H).
- 226 -Table 18B
LCMS miz 1H-NMR (400 MHz, Cmpd # Structure Name DMSO-d6) [M+H]
1.73 ¨ 1.76 (m, 1 1111 H), 1.94 (s, 6 H), 41 N-(3-(3- 2.14 ¨ 2.22 (m, 1 = H), 2.55 ¨ 2.68 (m, r._( (bicyclo[4.2.0]o 3 H), 2.82 ¨ 2.86 cta-1,3,5-trien-439 (m, 1 H), 3.02 (d, J
6x = 5.2 Hz, 4 H), 4.39 yloxy)pyrrolidin 0 4?PH (s, 2 H), 4.78 (s, 1 H), 6.64 (d, J= 7.2 oT yl)bicyclo[1.1.1 Hz, 2 H), 6.93 (t, J=
1010 ]pentan-1-yI)-2-8.8 Hz, 3 H), 7.31 (4-I (d, J= 8.0 Hz, 2 H), chlorophenoxy) 8.60 (s, 1 H).
acetamide Example 7a and 7b (S)-2-(4-chlorophenoxv)-N-(3-(4-(4-chlorophenoxv)-2-oxopwrolidin-l-Vnbicyclo[1.1.11pentan-l-ynacetamide and (S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-l-yObicyclo[1.1.11pentan-l-ynacetamide CI
o o CI * o\,....k ....40õ..... b., ,qo H
7a and CI
o Cl 46 o\j(N........_?,,,,, o H
7b
LCMS miz 1H-NMR (400 MHz, Cmpd # Structure Name DMSO-d6) [M+H]
1.73 ¨ 1.76 (m, 1 1111 H), 1.94 (s, 6 H), 41 N-(3-(3- 2.14 ¨ 2.22 (m, 1 = H), 2.55 ¨ 2.68 (m, r._( (bicyclo[4.2.0]o 3 H), 2.82 ¨ 2.86 cta-1,3,5-trien-439 (m, 1 H), 3.02 (d, J
6x = 5.2 Hz, 4 H), 4.39 yloxy)pyrrolidin 0 4?PH (s, 2 H), 4.78 (s, 1 H), 6.64 (d, J= 7.2 oT yl)bicyclo[1.1.1 Hz, 2 H), 6.93 (t, J=
1010 ]pentan-1-yI)-2-8.8 Hz, 3 H), 7.31 (4-I (d, J= 8.0 Hz, 2 H), chlorophenoxy) 8.60 (s, 1 H).
acetamide Example 7a and 7b (S)-2-(4-chlorophenoxv)-N-(3-(4-(4-chlorophenoxv)-2-oxopwrolidin-l-Vnbicyclo[1.1.11pentan-l-ynacetamide and (S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-l-yObicyclo[1.1.11pentan-l-ynacetamide CI
o o CI * o\,....k ....40õ..... b., ,qo H
7a and CI
o Cl 46 o\j(N........_?,,,,, o H
7b
- 227 -Br Br 0 CI
OH
CIStep 1(101 CI Step 2 3W. B" Prrrry.y..
µ1111 0 -311.41 Step 3 JOH
CI CI SO CI
at CI
Step 1114' 1111'0, 5 CI * CJ(ry 'IlDs.
C1H1-1,1,1-H
A Isomer separation by Chiral prep HPLC
(1, IT Absolute stereochemistry CIth' - .0 c, assignment (S) isomer (Ft) 0 isomer (isomer 1) (IS mer 2) *
ci c\---(....Or't."4 CI
cl 4 (s) isomer 7a 7b (Peak 1) Step 1: To a solution of chlorophenol (10.0 g, 78.12 mmol, 1.0 equiv.) in DMF
(160 mL), K2003 (10.8 g, 78.12 mmol, 1.0 equiv.) was added followed by the addition of methyl-2,4-dibromobutanoate (11.0 mL, 78.12 mmol, 1.0 equiv.) at 000 and the reaction was stirred at 60 C for 2 h. After completion of the reaction (TLC, 10 % Et0Ac in hexane), the reaction mixture was allowed to come to room temperature and was diluted with ice cold water (300 mL) and the mixture was extracted with Et0Ac (3 X 150 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under reduced pressure.
The crude material was purified by flash column chromatography eluting the product at 5 %
Et0Ac in hexane to afford methyl 4-bromo-2-(4-chlorophenoxy)butanoate as a colourless liquid (12.9 g, 53.75% yield). 1H NMR (400 MHz, CDCI3) 6 ppm 2.42 - 2.48 (m, 2 H), 3.59 - 3.60 (m, 2 H), 3.76 (s, 3 H), 4.82 - 4.84 (m, 1 H), 6.85 (d, J = 6.8 Hz, 2 H), 7.24 (d, J =
9.2 Hz, 2 H).
Step 2: To a solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (6.2 g, 31.31 mmol, 1.0 equiv) in Et3N (17.46 mL, 125.25 mmol, 4.0 equiv.) was added methyl 4-bromo-2-(4-chlorophenoxy)butanoate (9.6 g, 31.31 mmol, 1.0 equiv.). The mixture was heated at 100 C for 2 h. After completion of the reaction (TLC, 50 % Et0Ac in hexane), the reaction mixture was diluted with water (100 mL) and extracted with DCM (2 X
300 mL).
OH
CIStep 1(101 CI Step 2 3W. B" Prrrry.y..
µ1111 0 -311.41 Step 3 JOH
CI CI SO CI
at CI
Step 1114' 1111'0, 5 CI * CJ(ry 'IlDs.
C1H1-1,1,1-H
A Isomer separation by Chiral prep HPLC
(1, IT Absolute stereochemistry CIth' - .0 c, assignment (S) isomer (Ft) 0 isomer (isomer 1) (IS mer 2) *
ci c\---(....Or't."4 CI
cl 4 (s) isomer 7a 7b (Peak 1) Step 1: To a solution of chlorophenol (10.0 g, 78.12 mmol, 1.0 equiv.) in DMF
(160 mL), K2003 (10.8 g, 78.12 mmol, 1.0 equiv.) was added followed by the addition of methyl-2,4-dibromobutanoate (11.0 mL, 78.12 mmol, 1.0 equiv.) at 000 and the reaction was stirred at 60 C for 2 h. After completion of the reaction (TLC, 10 % Et0Ac in hexane), the reaction mixture was allowed to come to room temperature and was diluted with ice cold water (300 mL) and the mixture was extracted with Et0Ac (3 X 150 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under reduced pressure.
The crude material was purified by flash column chromatography eluting the product at 5 %
Et0Ac in hexane to afford methyl 4-bromo-2-(4-chlorophenoxy)butanoate as a colourless liquid (12.9 g, 53.75% yield). 1H NMR (400 MHz, CDCI3) 6 ppm 2.42 - 2.48 (m, 2 H), 3.59 - 3.60 (m, 2 H), 3.76 (s, 3 H), 4.82 - 4.84 (m, 1 H), 6.85 (d, J = 6.8 Hz, 2 H), 7.24 (d, J =
9.2 Hz, 2 H).
Step 2: To a solution of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (6.2 g, 31.31 mmol, 1.0 equiv) in Et3N (17.46 mL, 125.25 mmol, 4.0 equiv.) was added methyl 4-bromo-2-(4-chlorophenoxy)butanoate (9.6 g, 31.31 mmol, 1.0 equiv.). The mixture was heated at 100 C for 2 h. After completion of the reaction (TLC, 50 % Et0Ac in hexane), the reaction mixture was diluted with water (100 mL) and extracted with DCM (2 X
300 mL).
- 228 -The combined extracts were dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The crude material was purified by column chromatography using an eluent of 45% Et0Ac in hexane to obtain the desired product tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (6.0 g, 48.78%
yield). 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.44 (s, 9 H), 2.11 -2.15 (m, 1 H), 2.39 (s, 6 H), 2.49 (bs, 1 H), 3.31 -3.33 (m, 1 H), 3.42 -3.44 (m, 1 H), 4.77 (t, J= 6.6 Hz, 1 H), 4.94 (s, 1 H), 6.96 (d, J= 7.6 Hz, 2 H), 7.21 (d, J= 7.6 Hz, 2 H).
Step 3: To a solution of tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (6.0 g, 15.26 mmol, 1.0 equiv.) in THF
(20 mL) was added BH3S(CH3)2 (2.9 mL, 30.53 mmol, 2.0 equiv.) at 0 C. (Note: 6.0 g was divided into 2 batches and the reaction was performed.) The reaction stirred at room temperature for 24 h. After completion of the reaction (TLC, 50 `)/0 Et0Ac in hexane), the reaction mixture was quenched with methanol at 0 C and stirred for 2 h. The reaction mixture was then evaporated under reduced pressure to obtain the crude product, which was diluted with water (200 mL) and extracted with DCM (3 X 100 mL). The combined organic layer was washed with brine solution (100 mL) and dried over anhydrous Na2SO4, filtered and concentrated to obtain the crude which was purified by silica gel column chromatography using 55 - 60 `)/0 Et0Ac in hexane as an eluent to yield tert-butyl (3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (3.0 g, 52.0 `)/0 yield). LCMS (ES) m/z = 379.1 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.43 (s, 9 H), 2.02 (s, 7 H), 2.26 - 2.32 (m, 1 H), 2.60 (s, 1 H), 2.76 -2.82 (m, 2 H), 2.90 (s, 1 H), 4.78 (s, 1 H), 4.91 (s, 1 H), 6.76 (d, J= 6.8 Hz, 2 H), 7.20 (d, J= 7.2 Hz, 2 H).
Step 4: To a solution of tert-butyl (3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (3.0 g, 7.91 mmol, 1.0 equiv.) in DCM
(20 mL) at 0 C was added 15 mL of 4 M HCI solution in 1,4-dioxane and the mixture was stirred at room temperature for 16 h. After completion of the reaction (TLC, 50 `)/0 Et0Ac in hexane), the reaction mixture was concentrated to afford the crude product. It was triturated with dry diethyl ether (2 x 30 mL) and the solid was dried under high vacuum to afford 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine hydrochloride (2.2 g, crude), which was taken to the next step without further purification. LCMS (ES) m/z =
279.0 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.08 (s, 1 H), 2.24 (s, 6 H), 3.40 -3.50 (m, 5 H), 5.10 (s, 1 H), 6.97 (d, J= 8.4 Hz, 2 H), 7.34 (d, J= 8.4 Hz, 2 H), 9.07 (s, 3 H).
Step 5: To a solution of 2-(4-chlorophenoxy)acetic acid (1.18 g, 6.35 mmol, 2.0 equiv.) in
yield). 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.44 (s, 9 H), 2.11 -2.15 (m, 1 H), 2.39 (s, 6 H), 2.49 (bs, 1 H), 3.31 -3.33 (m, 1 H), 3.42 -3.44 (m, 1 H), 4.77 (t, J= 6.6 Hz, 1 H), 4.94 (s, 1 H), 6.96 (d, J= 7.6 Hz, 2 H), 7.21 (d, J= 7.6 Hz, 2 H).
Step 3: To a solution of tert-butyl (3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (6.0 g, 15.26 mmol, 1.0 equiv.) in THF
(20 mL) was added BH3S(CH3)2 (2.9 mL, 30.53 mmol, 2.0 equiv.) at 0 C. (Note: 6.0 g was divided into 2 batches and the reaction was performed.) The reaction stirred at room temperature for 24 h. After completion of the reaction (TLC, 50 `)/0 Et0Ac in hexane), the reaction mixture was quenched with methanol at 0 C and stirred for 2 h. The reaction mixture was then evaporated under reduced pressure to obtain the crude product, which was diluted with water (200 mL) and extracted with DCM (3 X 100 mL). The combined organic layer was washed with brine solution (100 mL) and dried over anhydrous Na2SO4, filtered and concentrated to obtain the crude which was purified by silica gel column chromatography using 55 - 60 `)/0 Et0Ac in hexane as an eluent to yield tert-butyl (3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate as an off-white solid (3.0 g, 52.0 `)/0 yield). LCMS (ES) m/z = 379.1 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.43 (s, 9 H), 2.02 (s, 7 H), 2.26 - 2.32 (m, 1 H), 2.60 (s, 1 H), 2.76 -2.82 (m, 2 H), 2.90 (s, 1 H), 4.78 (s, 1 H), 4.91 (s, 1 H), 6.76 (d, J= 6.8 Hz, 2 H), 7.20 (d, J= 7.2 Hz, 2 H).
Step 4: To a solution of tert-butyl (3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)carbamate (3.0 g, 7.91 mmol, 1.0 equiv.) in DCM
(20 mL) at 0 C was added 15 mL of 4 M HCI solution in 1,4-dioxane and the mixture was stirred at room temperature for 16 h. After completion of the reaction (TLC, 50 `)/0 Et0Ac in hexane), the reaction mixture was concentrated to afford the crude product. It was triturated with dry diethyl ether (2 x 30 mL) and the solid was dried under high vacuum to afford 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine hydrochloride (2.2 g, crude), which was taken to the next step without further purification. LCMS (ES) m/z =
279.0 [M+H]. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.08 (s, 1 H), 2.24 (s, 6 H), 3.40 -3.50 (m, 5 H), 5.10 (s, 1 H), 6.97 (d, J= 8.4 Hz, 2 H), 7.34 (d, J= 8.4 Hz, 2 H), 9.07 (s, 3 H).
Step 5: To a solution of 2-(4-chlorophenoxy)acetic acid (1.18 g, 6.35 mmol, 2.0 equiv.) in
- 229 -DCM (20 mL) at 0 C was added triethylamine (2.21 mL, 15387 mmol, 5.0 equiv), followed by the addition of T3P (50 wt% in Et0Ac, 3.78 mL, 6.35 mmol, 2.0 equiv.). The reaction mixture was stirred at 0 C for 5 min and then 3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-amine hydrochloride (1.0 g, 3.17 mmol, 1.0 equiv.) (which was neutralized with triethylamine (1.0 equiv.) in DCM) was added at 0 C and the reaction was stirred at room temperature for 16 h. After the consumption of the starting material (TLC, 50 `)/0 Et0Ac in hexane), the reaction mixture was diluted with water (100 mL) and was extracted with DCM (2 x 100 mL). The combined organic layer was washed with saturated aqueous NaHCO3 solution (100 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure to obtain the crude.
The crude product was purified by silica gel column chromatography using 65 `)/0 Et0Ac in hexane as an eluent to afford the desired product 2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (1.1 g, 71.0 `)/0 yield) as an off-white solid. LCMS (ES) m/z = 447.4 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 PPm 1.74 - 1.77 (m, 1 H), 1.95 (s, 6 H), 2.18 - 2.30 (m, 1 H), 2.48 - 2.70 (m, 3 H), 2.84 - 2.86 (m, 1 H), 4.40 (s,2 H), 4.83 -4.84 (m, 1 H), 6.88 (d, J= 8.8 Hz, 2 H), 6.94 (d, J= 9.2 Hz, 2 H), 7.28 (d, J= 8.8 Hz, 2 H), 7.31(d, J= 9.2 Hz, 2 H), 8.60 (s, 1 H).
The racemic product from step 5 was taken forward for isomer separation by chiral prep HPLC. [Analytical conditions: Column: CHIRALPAK IC (100 mm x 4.6 mm x 3 mic);
Mobile phase: n-hexane:IPA with 0.1 c)/0 DEA(85:15);Flow rate: 1.0 mL/ min).]
Fractions containing the separated isomers were concentrated under reduced pressure. The solid obtained was triturated with HPLC grade n-hexane (200 mL) and dried under high vacuum.
Based on VCD analysis Isomer 1 was assigned as (S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide and Isomer 2 as (R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide.
(S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide.
Recovery: 0.34 g (off-white solid). LCMS (ES) m/z = 447.0 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.74 - 1.77 (m, 1 H), 1.95 (s, 6 H), 2.18 - 2.30 (m, 1 H), 2.48 - 2.70 (m, 3 H), 2.84 - 2.86 (m, 1 H), 4.40 (s, 2 H), 4.83 - 4.84 (m, 1 H), 6.88 (d, J =
8.8 Hz, 2 H), 6.94 (d, J= 9.2 Hz, 2 H), 7.28 (d, J= 8.8 Hz, 2 H), 7.31(d, J= 9.2 Hz, 2 H), 8.60 (s, 1 H).
The crude product was purified by silica gel column chromatography using 65 `)/0 Et0Ac in hexane as an eluent to afford the desired product 2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (1.1 g, 71.0 `)/0 yield) as an off-white solid. LCMS (ES) m/z = 447.4 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 PPm 1.74 - 1.77 (m, 1 H), 1.95 (s, 6 H), 2.18 - 2.30 (m, 1 H), 2.48 - 2.70 (m, 3 H), 2.84 - 2.86 (m, 1 H), 4.40 (s,2 H), 4.83 -4.84 (m, 1 H), 6.88 (d, J= 8.8 Hz, 2 H), 6.94 (d, J= 9.2 Hz, 2 H), 7.28 (d, J= 8.8 Hz, 2 H), 7.31(d, J= 9.2 Hz, 2 H), 8.60 (s, 1 H).
The racemic product from step 5 was taken forward for isomer separation by chiral prep HPLC. [Analytical conditions: Column: CHIRALPAK IC (100 mm x 4.6 mm x 3 mic);
Mobile phase: n-hexane:IPA with 0.1 c)/0 DEA(85:15);Flow rate: 1.0 mL/ min).]
Fractions containing the separated isomers were concentrated under reduced pressure. The solid obtained was triturated with HPLC grade n-hexane (200 mL) and dried under high vacuum.
Based on VCD analysis Isomer 1 was assigned as (S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide and Isomer 2 as (R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide.
(S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide.
Recovery: 0.34 g (off-white solid). LCMS (ES) m/z = 447.0 [M+H] +. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.74 - 1.77 (m, 1 H), 1.95 (s, 6 H), 2.18 - 2.30 (m, 1 H), 2.48 - 2.70 (m, 3 H), 2.84 - 2.86 (m, 1 H), 4.40 (s, 2 H), 4.83 - 4.84 (m, 1 H), 6.88 (d, J =
8.8 Hz, 2 H), 6.94 (d, J= 9.2 Hz, 2 H), 7.28 (d, J= 8.8 Hz, 2 H), 7.31(d, J= 9.2 Hz, 2 H), 8.60 (s, 1 H).
- 230 -Chiral HPLC purity: 100% at RI 12.719 min. % ee: 100%
(R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide.
.. Recovery: 0.37 g (off-white solid). LCMS (ES) m/z = 447.0 [M+H] +. 1H NMR
(400 MHz, DMSO-d6) 6 ppm 1.73 - 1.77 (m, 1 H), 1.95 (s, 6 H), 2.12 - 2.26 (m, 1 H), 2.65 - 2.70 (m, 3 H), 2.84 - 2.88 (m, 1 H), 4.40 (s, 2 H), 4.84 (bs, 1 H), 6.88 (d, J= 8.8 Hz, 2 H), 6.94 (d, J
= 8.8 Hz, 2 H), 7.28 (d, J= 8.8 Hz, 2 H), 7.31(d, J= 8.8 Hz, 2 H), 8.60 (s, 1 H). Chiral HPLC. purity: 100% at RI 15.67 min; % ee: 100%.
Step 6: To a solution of (S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.07 g, 0.15 mmol, 1.0 equiv.) in ethyl acetate (5.0 mL) was added ruthenium (IV) oxide monohydrate (0.012 g, 0.078 mmol, 0.5 equiv.) at 0 C, and then 10% aqueous sodium periodate solution (0.16 g, 0.78 mmol, 5.0 equiv.) was added and the reaction was stirred at room temperature for 2 h. After the consumption of the starting material (TLC, 50 % ethyl acetate in hexane), the reaction mixture was diluted with Et0Ac (100 mL) and was washed with water (2 x 10 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under reduced pressure.
The crude material was purified by preparative TLC using 40 % Et0Ac in hexane (eluted twice) as an eluent. Both the products were isolated separately to afford (S)-2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (compound 7a, (0.032 g, 44.4 % yield) and (S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (compound 7b, 0.035 g, 48.6 % yield) as off-white solid.
(S)-2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide 7a:_LCMS (ES) m/z = 461.0 [M+H] +. 1H
NMR (400 MHz, DMSO-d6) 6 ppm 2.29 (s, 6 H), 2.81 - 2.87 (m, 2 H), 3.33 (d, J = 11.2 Hz, 1 H), 3.75 -3.80 (m, 1 H), 4.41 (s,2 H), 4.99 (bs, 1 H), 6.94 (t, J= 7.8 Hz, 4 H), 7.31 (d, J= 8.4 Hz, 4 H), 8.70 (s, 1 H). Chiral HPLC purity: 99.77 % at 280 n m . % ee: 99.54 /0.
(S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide 7b: LCMS (ES) m/z = 461.0 [M+H] +. 1H
NMR (400 MHz, DMSO-d6) 6 ppm 1.85 - 1.90 (m, 2 H), 2.31 (s, 6 H), 3.34 - 3.36 (m, 2 H), 4.42 (s, 2 .. H), 4.95 - 4.96 (m, 1 H), 6.95 (d, J= 8.8 Hz, 2 H), 7.01 (d, J= 8.8 Hz, 2 H), 7.31 (t, J= 9.2 Hz, 4 H), 8.72 (s, 1 H). Chiral HPLC purity: 100.0% at 280 nm. % ee: 100.0%
(R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide.
.. Recovery: 0.37 g (off-white solid). LCMS (ES) m/z = 447.0 [M+H] +. 1H NMR
(400 MHz, DMSO-d6) 6 ppm 1.73 - 1.77 (m, 1 H), 1.95 (s, 6 H), 2.12 - 2.26 (m, 1 H), 2.65 - 2.70 (m, 3 H), 2.84 - 2.88 (m, 1 H), 4.40 (s, 2 H), 4.84 (bs, 1 H), 6.88 (d, J= 8.8 Hz, 2 H), 6.94 (d, J
= 8.8 Hz, 2 H), 7.28 (d, J= 8.8 Hz, 2 H), 7.31(d, J= 8.8 Hz, 2 H), 8.60 (s, 1 H). Chiral HPLC. purity: 100% at RI 15.67 min; % ee: 100%.
Step 6: To a solution of (S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.07 g, 0.15 mmol, 1.0 equiv.) in ethyl acetate (5.0 mL) was added ruthenium (IV) oxide monohydrate (0.012 g, 0.078 mmol, 0.5 equiv.) at 0 C, and then 10% aqueous sodium periodate solution (0.16 g, 0.78 mmol, 5.0 equiv.) was added and the reaction was stirred at room temperature for 2 h. After the consumption of the starting material (TLC, 50 % ethyl acetate in hexane), the reaction mixture was diluted with Et0Ac (100 mL) and was washed with water (2 x 10 mL). The combined Et0Ac extracts were dried over anhydrous Na2SO4, filtered and distilled under reduced pressure.
The crude material was purified by preparative TLC using 40 % Et0Ac in hexane (eluted twice) as an eluent. Both the products were isolated separately to afford (S)-2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (compound 7a, (0.032 g, 44.4 % yield) and (S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (compound 7b, 0.035 g, 48.6 % yield) as off-white solid.
(S)-2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide 7a:_LCMS (ES) m/z = 461.0 [M+H] +. 1H
NMR (400 MHz, DMSO-d6) 6 ppm 2.29 (s, 6 H), 2.81 - 2.87 (m, 2 H), 3.33 (d, J = 11.2 Hz, 1 H), 3.75 -3.80 (m, 1 H), 4.41 (s,2 H), 4.99 (bs, 1 H), 6.94 (t, J= 7.8 Hz, 4 H), 7.31 (d, J= 8.4 Hz, 4 H), 8.70 (s, 1 H). Chiral HPLC purity: 99.77 % at 280 n m . % ee: 99.54 /0.
(S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide 7b: LCMS (ES) m/z = 461.0 [M+H] +. 1H
NMR (400 MHz, DMSO-d6) 6 ppm 1.85 - 1.90 (m, 2 H), 2.31 (s, 6 H), 3.34 - 3.36 (m, 2 H), 4.42 (s, 2 .. H), 4.95 - 4.96 (m, 1 H), 6.95 (d, J= 8.8 Hz, 2 H), 7.01 (d, J= 8.8 Hz, 2 H), 7.31 (t, J= 9.2 Hz, 4 H), 8.72 (s, 1 H). Chiral HPLC purity: 100.0% at 280 nm. % ee: 100.0%
- 231 -The ruthenium (IV) oxide oxidation reaction was performed with (R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide as described above and the products 7c and 7d were isolated by preparative TLC
purification.
The Compounds of Examples 7c to 7d were prepared generally according to the procedure described above for Example 7a and 7b.
Table 19 1H-NMR (400 MHz, Cmpd LCMS m/z Structure Name DMSO-d6) # [M+H]
ci # 2.29 (s, 6 H), 2.81 - 2.87 (m, 2 H), 3.33 (d, J= 11.2 P
N-(3-(4-(4-. (S)-2-(4-chlorophenoxy)-Hz, 1 H), 3.75 - 3.80 (m, 0.4> 1 H), 4.41 (s, 2 H), 4.99 4k chlorophenoxy)-2-7a oxopyrrolidin-1- 461.0 (bs, 1 H), 6.94 (t, J = 7.8 Hz, 4 H), 7.31 (d, J = 8.4 yl)bicyclo[1.1.1]pentan-1-Hz, 4 H), 8.70 (s, 1 H).
0) yl)acetamide CI
1.85 - 1.90 (m, 2 H), 2.31 P (S)-2-(4-chlorophenoxy)-C>o N-(3-(3-(4-(s, 6 H), 3.34 - 3.36 (m, 2 7b lk chlorophenoxy)-2-oxopyrrolidin-1-H), 4.42 (s, 2 H), 4.95 -461.0 4.96 (m, 1 H), 6.95 (d, J =
oc.,, 8.8 Hz, 2 H), 7.01 (d, J=
yl)bicyclo[1.1.1]pentan-1-8.8 Hz, 2 H), 7.31 (t, J =
0) yl)acetamide 4 9.2 Hz, 4 H), 8.72 (s, 1 H).
purification.
The Compounds of Examples 7c to 7d were prepared generally according to the procedure described above for Example 7a and 7b.
Table 19 1H-NMR (400 MHz, Cmpd LCMS m/z Structure Name DMSO-d6) # [M+H]
ci # 2.29 (s, 6 H), 2.81 - 2.87 (m, 2 H), 3.33 (d, J= 11.2 P
N-(3-(4-(4-. (S)-2-(4-chlorophenoxy)-Hz, 1 H), 3.75 - 3.80 (m, 0.4> 1 H), 4.41 (s, 2 H), 4.99 4k chlorophenoxy)-2-7a oxopyrrolidin-1- 461.0 (bs, 1 H), 6.94 (t, J = 7.8 Hz, 4 H), 7.31 (d, J = 8.4 yl)bicyclo[1.1.1]pentan-1-Hz, 4 H), 8.70 (s, 1 H).
0) yl)acetamide CI
1.85 - 1.90 (m, 2 H), 2.31 P (S)-2-(4-chlorophenoxy)-C>o N-(3-(3-(4-(s, 6 H), 3.34 - 3.36 (m, 2 7b lk chlorophenoxy)-2-oxopyrrolidin-1-H), 4.42 (s, 2 H), 4.95 -461.0 4.96 (m, 1 H), 6.95 (d, J =
oc.,, 8.8 Hz, 2 H), 7.01 (d, J=
yl)bicyclo[1.1.1]pentan-1-8.8 Hz, 2 H), 7.31 (t, J =
0) yl)acetamide 4 9.2 Hz, 4 H), 8.72 (s, 1 H).
- 232 -CI
* 2.29 (s, 6 H), 2.81 - 2.87 (m, 2 H), 3.33 (d, J= 11.2 . (R)-2-(4-chlorophenoxy)-N-(3-(4-(4-Hz, 1 H), 3.75 - 3.79 (m, crin-5 1 H), 4.41 (s, 2 H), 4.99 7c chlorophenoxy)-2-461.4 (bs, 1 H), 6.94 (t, J = 8.0 oxopyrrolidin-1 -k Hz, 4 H), 7.31 (d, J = 8.8 yl)bicyclo[1.1.1]pentan-1-Hz, 4 H), 8.70 (s, 1 H).
0) yl)acetamide CI
1.85 - 1.90 (m, 2 H), 2.31 c... (R)-2-(4-chlorophenoxy)-(s, 6 H), 3.34 - 3.39 (m, 2 0 N-(3-(3-(4-H), 4.42 (s, 2 H), 4.97 (t, J
chlorophenoxy)-2-7d 461.4 = 7.4 Hz, 1 H), 6.95 (d, J
oxopyrrolidin-1 -4 4? 'H
c.
= 8.8 Hz, 2 H), 7.01 (d, J
,, yl)bicyclo[1.1.1]pentan-1-= 8.4 Hz, 2 H), 7.31 (t, J=
0) yl)acetamide 4 9.0 Hz, 4 H), 8.73 (s, 1 H).
Example 8a 2-(4-chlorophenoxv)-N-(3-(4-(4-chlorophenoxv)piperidin-1-vnbicycloll .1.11pentan-1-vl)acetamide o 0_0 io CI
o)(N
a g 1 I 11' H
8a
* 2.29 (s, 6 H), 2.81 - 2.87 (m, 2 H), 3.33 (d, J= 11.2 . (R)-2-(4-chlorophenoxy)-N-(3-(4-(4-Hz, 1 H), 3.75 - 3.79 (m, crin-5 1 H), 4.41 (s, 2 H), 4.99 7c chlorophenoxy)-2-461.4 (bs, 1 H), 6.94 (t, J = 8.0 oxopyrrolidin-1 -k Hz, 4 H), 7.31 (d, J = 8.8 yl)bicyclo[1.1.1]pentan-1-Hz, 4 H), 8.70 (s, 1 H).
0) yl)acetamide CI
1.85 - 1.90 (m, 2 H), 2.31 c... (R)-2-(4-chlorophenoxy)-(s, 6 H), 3.34 - 3.39 (m, 2 0 N-(3-(3-(4-H), 4.42 (s, 2 H), 4.97 (t, J
chlorophenoxy)-2-7d 461.4 = 7.4 Hz, 1 H), 6.95 (d, J
oxopyrrolidin-1 -4 4? 'H
c.
= 8.8 Hz, 2 H), 7.01 (d, J
,, yl)bicyclo[1.1.1]pentan-1-= 8.4 Hz, 2 H), 7.31 (t, J=
0) yl)acetamide 4 9.0 Hz, 4 H), 8.73 (s, 1 H).
Example 8a 2-(4-chlorophenoxv)-N-(3-(4-(4-chlorophenoxv)piperidin-1-vnbicycloll .1.11pentan-1-vl)acetamide o 0_0 io CI
o)(N
a g 1 I 11' H
8a
- 233 -46.6 OH
ci BoC CI 10 0/.1N
_v.. CI 10 0/.1NH2.HCI
Step 1 Step 2 )ko Ni.:yNH2 -3111. ci Step 3 Step 4 step 5 OH
r\ A N C;r 00,0H
CI 41111111killi c))ci j:cr Step 6 MSOOMS step 7 CI
Step 8 CI
00,0MS a 0 c, stel9 31-*I
CI
CI 8a Step 1: To a solution of 2-(4-chlorophenoxy)acetic acid (33.87 g, 181.57 mmol, 1.2 equiv) in DCM ( 300 mL) at 0 C was added triethylamine (63.35 mL, 453.93 mmol, 3equiv) and T3P (50 wt. % in ethyl acetate) (135.1 mL, 226.96 mmol, 1.5 equiv) and was stirred for minutes at 000. After that tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (30.0 g, 151.31 mmol, 1 equiv) was added to the reaction mixture and the reaction mixture was stirred at room temperature for 16 hours. After completion (monitored by TLC), the reaction mixture was diluted with water (200 mL) and extracted with DCM (2 x 300 mL).
The combined organic extract was washed with aqueous saturated sodium bicarbonate solution (200 mL), and the organic layer was filtered and concentrated under reduced pressure to obtain the crude product. Following the same procedure, another 30 g batch reaction of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate was performed to obtain the final combined yield of 108 g of tert-butyl (3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate (97.24 % yield) as an off-white solid. LCMS (ES) m/z = 311.1 [M+H] (t- butyl cleavage mass was observed). 1H
ci BoC CI 10 0/.1N
_v.. CI 10 0/.1NH2.HCI
Step 1 Step 2 )ko Ni.:yNH2 -3111. ci Step 3 Step 4 step 5 OH
r\ A N C;r 00,0H
CI 41111111killi c))ci j:cr Step 6 MSOOMS step 7 CI
Step 8 CI
00,0MS a 0 c, stel9 31-*I
CI
CI 8a Step 1: To a solution of 2-(4-chlorophenoxy)acetic acid (33.87 g, 181.57 mmol, 1.2 equiv) in DCM ( 300 mL) at 0 C was added triethylamine (63.35 mL, 453.93 mmol, 3equiv) and T3P (50 wt. % in ethyl acetate) (135.1 mL, 226.96 mmol, 1.5 equiv) and was stirred for minutes at 000. After that tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate (30.0 g, 151.31 mmol, 1 equiv) was added to the reaction mixture and the reaction mixture was stirred at room temperature for 16 hours. After completion (monitored by TLC), the reaction mixture was diluted with water (200 mL) and extracted with DCM (2 x 300 mL).
The combined organic extract was washed with aqueous saturated sodium bicarbonate solution (200 mL), and the organic layer was filtered and concentrated under reduced pressure to obtain the crude product. Following the same procedure, another 30 g batch reaction of tert-butyl (3-aminobicyclo[1.1.1]pentan-1-yl)carbamate was performed to obtain the final combined yield of 108 g of tert-butyl (3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate (97.24 % yield) as an off-white solid. LCMS (ES) m/z = 311.1 [M+H] (t- butyl cleavage mass was observed). 1H
- 234 -NMR (400MHz, DMSO-d6) 6 ppm 1.35 (s, 9 H), 2.11 (s, 6 H), 4.39 (s, 2 H), 6.94 (d, J= 8.8 Hz, 2 H), 7.31 (d, J= 8.8 Hz, 2 H), 7.46 (bs, 1 H), 8.60 (s, 1 H).
Step 2: To a solution of tert-butyl (3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate (27 g, 73.57 mmol, 1 equiv) in DCM (400 mL) was added a solution of 4 M
HCI in 1,4-dioxane (90 mL) at 0 C. The reaction mixture was allowed to warm and stir at room temperature for 12 h. After consumption of the starting material (TLC, 5 `)/0 Methanol in DCM), DCM was evaporated under reduced pressure. The obtained solid was triturated with diethyl ether (300 mL) and dried under high vacuum to obtain N-(3-am inobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetam ide hydrochloride.
Following the same procedure, another 3 batches were performed to afford a total of 84 g (94.52 `)/0 yield) of N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide hydrochloride as an off-white solid. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.22 (s, 6 H), 4.44 (s, 2 H), 6.95 (d, J= 8.8 Hz, 2 H), 7.32 (d, J= 9.2 Hz, 2 H), 8.87 (s, 1 H), 9.0 (bs, 3 H).
Step 3: N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide hydrochloride (10.0 g, 33.16 mmol, 1 equiv) was added to an aqueous sodium bicarbonate solution (5.57 g, 66.30 mmol, 2 equiv. in 100 mL of water) and stirred at room temperature for 1 h. The reaction mixture was extracted with DCM (2 x 250 mL). The combined organic extract was washed with water (100 mL) and brine solution (50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain the crude N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (18 g, crude, 10.0 g scale reactions in 2 batches (20.0 g) were performed). 8 g of the crude material was further purified by reverse phase purification: [Column: 018, Mobile phase (A): 0.1%
ammonia in water, Mobile phase (B): Acetonitrile] to yield N-(3-aminobicyclo[1.1.1]pentan-1-y1)-2-(4-chlorophenoxy)acetamide (6.6 g, 50.7% yield) as a white solid. LCMS
(ES) m/z =
250.2 [M+H]+ (loss of -NH2). 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.91 (s,6 H), 2.10 (s, 2 H), 4.38 (s, 2 H), 6.94 (d, J= 8.8 Hz, 2 H), 7.31 (d, J= 8.8 Hz, 2 H), 8.47 (s, 1 H).
Step 4: To a solution of diethyl-3-oxopentanedioate (5.0 g, 24 mmol, 1.0 equiv) in ethanol (50 mL) was added sodium borohydride (0.93 g, 24 mmol, 1.0 equiv.) at 0 C in portions over a period of 15 minutes and the reaction mixture was maintained for 10 minutes at room temperature. The reaction mixture was quenched with saturated aqueous solution of NH401 (30 mL) at 0 C, extracted with DCM (2 X 250 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford diethy1-3-hydroxypentanedioate (3.5 g, crude) as a viscous liquid. LCMS (ES) m/z = 205.0 [M+H].
Step 2: To a solution of tert-butyl (3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)carbamate (27 g, 73.57 mmol, 1 equiv) in DCM (400 mL) was added a solution of 4 M
HCI in 1,4-dioxane (90 mL) at 0 C. The reaction mixture was allowed to warm and stir at room temperature for 12 h. After consumption of the starting material (TLC, 5 `)/0 Methanol in DCM), DCM was evaporated under reduced pressure. The obtained solid was triturated with diethyl ether (300 mL) and dried under high vacuum to obtain N-(3-am inobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetam ide hydrochloride.
Following the same procedure, another 3 batches were performed to afford a total of 84 g (94.52 `)/0 yield) of N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide hydrochloride as an off-white solid. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.22 (s, 6 H), 4.44 (s, 2 H), 6.95 (d, J= 8.8 Hz, 2 H), 7.32 (d, J= 9.2 Hz, 2 H), 8.87 (s, 1 H), 9.0 (bs, 3 H).
Step 3: N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide hydrochloride (10.0 g, 33.16 mmol, 1 equiv) was added to an aqueous sodium bicarbonate solution (5.57 g, 66.30 mmol, 2 equiv. in 100 mL of water) and stirred at room temperature for 1 h. The reaction mixture was extracted with DCM (2 x 250 mL). The combined organic extract was washed with water (100 mL) and brine solution (50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain the crude N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (18 g, crude, 10.0 g scale reactions in 2 batches (20.0 g) were performed). 8 g of the crude material was further purified by reverse phase purification: [Column: 018, Mobile phase (A): 0.1%
ammonia in water, Mobile phase (B): Acetonitrile] to yield N-(3-aminobicyclo[1.1.1]pentan-1-y1)-2-(4-chlorophenoxy)acetamide (6.6 g, 50.7% yield) as a white solid. LCMS
(ES) m/z =
250.2 [M+H]+ (loss of -NH2). 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.91 (s,6 H), 2.10 (s, 2 H), 4.38 (s, 2 H), 6.94 (d, J= 8.8 Hz, 2 H), 7.31 (d, J= 8.8 Hz, 2 H), 8.47 (s, 1 H).
Step 4: To a solution of diethyl-3-oxopentanedioate (5.0 g, 24 mmol, 1.0 equiv) in ethanol (50 mL) was added sodium borohydride (0.93 g, 24 mmol, 1.0 equiv.) at 0 C in portions over a period of 15 minutes and the reaction mixture was maintained for 10 minutes at room temperature. The reaction mixture was quenched with saturated aqueous solution of NH401 (30 mL) at 0 C, extracted with DCM (2 X 250 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford diethy1-3-hydroxypentanedioate (3.5 g, crude) as a viscous liquid. LCMS (ES) m/z = 205.0 [M+H].
- 235 -1H NMR (400 MHz, DMSO-d6) 6 ppm 1.16 (t, J= 7.0 Hz, 6 H), 2.31 -2.38 (m, 2 H), 2.43 -2.48 (m, 2 H), 4.03 (q, J= 7.2 Hz, 4 H), 4.20 - 4.25 (m, 1 H), 5.01 (d, J= 6.4 Hz, 1 H).
Step 5: To a solution of diethyl 3-hydroxypentanedioate (3.0 g, 14 mmol, 1.0 equiv) in dry THF (100 mL) under N2 atmosphere was added 1 M Lithium aluminiumhydride solution in THF (58.7 mL, 58 mmol, 4.0 equiv.) at 0 C slowly dropwise over a period of 30 minutes.
The reaction mixture was stirred for 16 h at room temperature. The reaction was quenched with aqueous 1 N NaOH solution (20 mL) at 0 C, diluted with DCM (150 mL), and filtered through a Celite bed. The Celite bed was washed with a solution of 10 %
methanol in DCM (2 X 100 mL). The filtrate was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford pentane-1,3,5-triol (1.4 g, 86.5% yield) as a viscous liquid. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.40- 1.49 (m, 4 H), 3.35 (s, 1 H), 3.40 -3.48 (m, 4 H).
Step 6: To a solution of pentane-1,3,5-triol (1.4 g, 11 mmol, 1.0 equi) in pyridine (6 mL) was added mesyl chloride (1.89 mL, 24 mmol, 2.1 equiv) at 0 C over a period of 30 minutes. The reaction mixture was stirred for 2 h at room temperature. The reaction was quenched with aqueous 2 N HCI solution (50 mL) at 0 C and extracted with DCM
(2 X 100 mL). The organic layer was washed with aq. 2 N HCI solution (2 X 50 mL), water (50 mL), 10 % aq. NaHCO3 (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated to afford 3-hydroxypentane-1,5-diy1 dimethanesulfonate (1.2 g, crude) as a viscous liquid.
LCMS (ES) m/z= 277.0 [M+H].
Step 7: To a solution of N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (0.5 g, 1.8 mmol, 1.0 equiv) in dimethylacetamide (10 mL) was added N,N-Di-isopropylethylamine (1.57 mL, 9 mmol, 5.0 equi) and 3-hydroxypentane-1,5-diy1 dimethanesulfonate (1.0 g, 3.6 mmol, 2.0 equiv.) at room temperature. The reaction mixture was maintained at 80 C for 1.5 h under microwave irradiation. It was then cooled to room temperature and quenched with crushed ice (100 mL) and extracted with DCM (2 X 100 mL). The combined organic extract was washed with cold water (25 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
The crude product was purified by flash chromatography (neutral alumina column) using 0.1 % to 10 % methanol in DCM as an eluent to obtain 2-(4-chlorophenoxy)-N-(3-(4-hydroxypiperidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.3 g, 47.6% yield) as a gum. LCMS
(ES) m/z =
351.0 [M+H].
Step 5: To a solution of diethyl 3-hydroxypentanedioate (3.0 g, 14 mmol, 1.0 equiv) in dry THF (100 mL) under N2 atmosphere was added 1 M Lithium aluminiumhydride solution in THF (58.7 mL, 58 mmol, 4.0 equiv.) at 0 C slowly dropwise over a period of 30 minutes.
The reaction mixture was stirred for 16 h at room temperature. The reaction was quenched with aqueous 1 N NaOH solution (20 mL) at 0 C, diluted with DCM (150 mL), and filtered through a Celite bed. The Celite bed was washed with a solution of 10 %
methanol in DCM (2 X 100 mL). The filtrate was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford pentane-1,3,5-triol (1.4 g, 86.5% yield) as a viscous liquid. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.40- 1.49 (m, 4 H), 3.35 (s, 1 H), 3.40 -3.48 (m, 4 H).
Step 6: To a solution of pentane-1,3,5-triol (1.4 g, 11 mmol, 1.0 equi) in pyridine (6 mL) was added mesyl chloride (1.89 mL, 24 mmol, 2.1 equiv) at 0 C over a period of 30 minutes. The reaction mixture was stirred for 2 h at room temperature. The reaction was quenched with aqueous 2 N HCI solution (50 mL) at 0 C and extracted with DCM
(2 X 100 mL). The organic layer was washed with aq. 2 N HCI solution (2 X 50 mL), water (50 mL), 10 % aq. NaHCO3 (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated to afford 3-hydroxypentane-1,5-diy1 dimethanesulfonate (1.2 g, crude) as a viscous liquid.
LCMS (ES) m/z= 277.0 [M+H].
Step 7: To a solution of N-(3-aminobicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide (0.5 g, 1.8 mmol, 1.0 equiv) in dimethylacetamide (10 mL) was added N,N-Di-isopropylethylamine (1.57 mL, 9 mmol, 5.0 equi) and 3-hydroxypentane-1,5-diy1 dimethanesulfonate (1.0 g, 3.6 mmol, 2.0 equiv.) at room temperature. The reaction mixture was maintained at 80 C for 1.5 h under microwave irradiation. It was then cooled to room temperature and quenched with crushed ice (100 mL) and extracted with DCM (2 X 100 mL). The combined organic extract was washed with cold water (25 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
The crude product was purified by flash chromatography (neutral alumina column) using 0.1 % to 10 % methanol in DCM as an eluent to obtain 2-(4-chlorophenoxy)-N-(3-(4-hydroxypiperidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.3 g, 47.6% yield) as a gum. LCMS
(ES) m/z =
351.0 [M+H].
- 236 -Step 8: To a solution of 2-(4-chlorophenoxy)-N-(3-(4-hydroxypiperidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (0.20 g, 0.57 mmol, 1.0 equiv) in DCM
(30 mL) was added TEA (0.24 mL, 1.7 mmol, 3.0 equiv) at 0 C and stirred for 30 minutes at the same temperature. Then mesyl chloride (0.052 mL, 0.68 mmol, 1.2 equiv) was added at and the reaction mixture was stirred for 3 h at room temperature. The reaction mixture was diluted with DCM (100 mL) and washed with 10 % aq. NaH0O3 solution (2 X 25 mL) and water (2 X 25 mL). The separated organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 1-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-Apiperidin-4-y1 methanesulfonate (0.22 g, crude) as a gum. LCMS (ES) m/z = 429.1 [M+H]. It was taken to next step without further purification.
Step 9: To a solution of 4-chlorophenol (0.05 g, 0.39 mmol, 1.0 equiv) in DMF
(10 mL) was added K2003 (0.16 g, 1.1 mmol, 3.0 equiv) and 1-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-Apiperidin-4-y1 methanesulfonate (0.2 g, 0.46 mmol, 1.2 equiv) at room temperature. The reaction mixture was stirred at 80 C for 16 h, after which the reaction mixture was cooled to room temperature and quenched with crushed ice (50 mL). The aqueous was extracted with DCM (2 X 100 mL) and the combined organic layers were washed with cold water (25 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain the crude product. It was purified by flash chromatography using 0.1 % to 10 % methanol in DCM as an eluent and further re-purified by prep HPLC [Analytical conditions: Column:
XBRIDGE.
Mobile phase (A): 0.1 % Ammonia in water, Mobile phase (B): Acetonitrile, T/
/013: 0/10, 2/10, 8/80, 13/80, 14/80, 15/10, compound RT: 9.60 minutes] to obtain 2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)piperidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (8.0 mg, 4.4% yield) as a white solid. LCMS (ES) m/z = 461 [M+H].
(400 MHz, DMSO-d6) 6 ppm 1.55 - 1.60 (m, 2 H), 1.88 - 1.91 (m, 2 H), 1.94 (s, 6 H), 2.22 (t, J= 9.4 Hz, 2 H), 2.64 (bs, 2 H), 4.32 (bs, 1 H), 4.40 (s, 2 H), 6.94 (d, J= 8.8 Hz, 4 H), 7.27 (d, J= 8.8 Hz, 2 H), 7.31 (d, J= 8.8 Hz, 2 H), 8.60 (s, 1 H).
(30 mL) was added TEA (0.24 mL, 1.7 mmol, 3.0 equiv) at 0 C and stirred for 30 minutes at the same temperature. Then mesyl chloride (0.052 mL, 0.68 mmol, 1.2 equiv) was added at and the reaction mixture was stirred for 3 h at room temperature. The reaction mixture was diluted with DCM (100 mL) and washed with 10 % aq. NaH0O3 solution (2 X 25 mL) and water (2 X 25 mL). The separated organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 1-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-Apiperidin-4-y1 methanesulfonate (0.22 g, crude) as a gum. LCMS (ES) m/z = 429.1 [M+H]. It was taken to next step without further purification.
Step 9: To a solution of 4-chlorophenol (0.05 g, 0.39 mmol, 1.0 equiv) in DMF
(10 mL) was added K2003 (0.16 g, 1.1 mmol, 3.0 equiv) and 1-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-Apiperidin-4-y1 methanesulfonate (0.2 g, 0.46 mmol, 1.2 equiv) at room temperature. The reaction mixture was stirred at 80 C for 16 h, after which the reaction mixture was cooled to room temperature and quenched with crushed ice (50 mL). The aqueous was extracted with DCM (2 X 100 mL) and the combined organic layers were washed with cold water (25 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain the crude product. It was purified by flash chromatography using 0.1 % to 10 % methanol in DCM as an eluent and further re-purified by prep HPLC [Analytical conditions: Column:
XBRIDGE.
Mobile phase (A): 0.1 % Ammonia in water, Mobile phase (B): Acetonitrile, T/
/013: 0/10, 2/10, 8/80, 13/80, 14/80, 15/10, compound RT: 9.60 minutes] to obtain 2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)piperidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (8.0 mg, 4.4% yield) as a white solid. LCMS (ES) m/z = 461 [M+H].
(400 MHz, DMSO-d6) 6 ppm 1.55 - 1.60 (m, 2 H), 1.88 - 1.91 (m, 2 H), 1.94 (s, 6 H), 2.22 (t, J= 9.4 Hz, 2 H), 2.64 (bs, 2 H), 4.32 (bs, 1 H), 4.40 (s, 2 H), 6.94 (d, J= 8.8 Hz, 4 H), 7.27 (d, J= 8.8 Hz, 2 H), 7.31 (d, J= 8.8 Hz, 2 H), 8.60 (s, 1 H).
- 237 -Table 20 LCM
Name S 1H-NMR (400 MHz, DMSO-Cmpd# Structure miz d6) [M+H
]+
c, 1.55¨ 1.60 (m, 2 H), 1.88 aN
2-(4-chlorophenoxy)-N-(3-(4-(4-¨ 1.91 (m, 2 H), 1.94 (s, 6 H), 2.22 (t, J = 9.4 Hz, 2 8a 461 .4 chlorophenoxy)piperidin- H), 2.64 (bs, 2 H), 4.32 (bs, Fi 1-1 H), 4.40 (s, 2 H), 6.94 (d, ci yl)bicyclo[1.1.1]pentan- J= 8.8 Hz, 4 H), 7.27 (d, J
0) 01 1-yl)acetamide = 8.8 Hz, 2 H), 7.31 (d, J=
8.8 Hz, 2 H), 8.60 (s, 1 H).
Assay Example 1: ATF4 Cell Based Assay The ATF4 reporter assay measures the effect of Thapsigargin induced cellular stress on ATF4 expression. For this reporter assay, a stable cell line was created by transfecting SH-SY5Y cells with a plasmid containing the NanoLuce luciferase gene fused to the 5'-UTR of ATF4, under the control of the CMV promoter. The ATF4 5'-UTR
contains two open reading frames which mediate the cellular stress-dependent translation of the reporter gene. Clones stably expressing the reporter construct were isolated and selected based on the luminescence response to thapsigargin and inhibition of this signal by test compounds. Briefly, SH-SY5Y-ATF4-NanoLuc cells were challenged with Thapsigargin for 14-18 hours to determine the stress effect with or without test compounds.
Cells were propagated in growth media consisting of 90% DMEM F12 (InVitrogen #
11320-033), 10% Fetal Bovine Serum (Gibco # 10438-026), 5mM Glutamax (Gibco #
35050-061), 5mM Hepes, (Gibco # 15630-080), and 0.5mg/m1 Geneticin (Gibco #
Name S 1H-NMR (400 MHz, DMSO-Cmpd# Structure miz d6) [M+H
]+
c, 1.55¨ 1.60 (m, 2 H), 1.88 aN
2-(4-chlorophenoxy)-N-(3-(4-(4-¨ 1.91 (m, 2 H), 1.94 (s, 6 H), 2.22 (t, J = 9.4 Hz, 2 8a 461 .4 chlorophenoxy)piperidin- H), 2.64 (bs, 2 H), 4.32 (bs, Fi 1-1 H), 4.40 (s, 2 H), 6.94 (d, ci yl)bicyclo[1.1.1]pentan- J= 8.8 Hz, 4 H), 7.27 (d, J
0) 01 1-yl)acetamide = 8.8 Hz, 2 H), 7.31 (d, J=
8.8 Hz, 2 H), 8.60 (s, 1 H).
Assay Example 1: ATF4 Cell Based Assay The ATF4 reporter assay measures the effect of Thapsigargin induced cellular stress on ATF4 expression. For this reporter assay, a stable cell line was created by transfecting SH-SY5Y cells with a plasmid containing the NanoLuce luciferase gene fused to the 5'-UTR of ATF4, under the control of the CMV promoter. The ATF4 5'-UTR
contains two open reading frames which mediate the cellular stress-dependent translation of the reporter gene. Clones stably expressing the reporter construct were isolated and selected based on the luminescence response to thapsigargin and inhibition of this signal by test compounds. Briefly, SH-SY5Y-ATF4-NanoLuc cells were challenged with Thapsigargin for 14-18 hours to determine the stress effect with or without test compounds.
Cells were propagated in growth media consisting of 90% DMEM F12 (InVitrogen #
11320-033), 10% Fetal Bovine Serum (Gibco # 10438-026), 5mM Glutamax (Gibco #
35050-061), 5mM Hepes, (Gibco # 15630-080), and 0.5mg/m1 Geneticin (Gibco #
- 238 -027). Cells were prepared for the assay by removing all media from cells, washing the plated cells with phosphate buffered saline, and detached by adding a solution comprised of 10% Tryple express solution (InVitrogen12604-021) and 90% enzyme-free cell dissociation buffer HANKS base (Gibco 13150-016). The trypsin was deactivated by adding assay media comprised of 90% phenol-red free DMEM F12 (InVitrogen, 11039), 10% Fetal Bovine Serum (Gibco # 10438-026),(5mM Glutamax (Gibco #35050-061), 5mM
Hepes, (Gibco # 15630-080), and 0.5mg/m1 Geneticin (Gibco # 10131-027).
Suspended cells were spun down at 300g for 5 min, the supernatant was removed and the cell pellet was suspended in warm media (30-37 C) comprised as above but without 10% Fetal Bovine Serum to a concentration of 1e6 cells/ml.
Assay plates were prepared by adding 250 nL of compound stock solution in 100%
DMSO to each well, followed by dispensing 20 microliters/well cell suspension to deliver 15-20k cell/well. Cells were incubated for 1hour at 37 C. Then, 51..11_ of 1.5 M or 1 1..1M of Thapsigargin (final concentration: 200-300nM) was added to each well of cells.
Assay plates containing cells were incubated for 14-18 hours at 37 C.
The measurement of luciferase produced by the ATF4 constructs was measured as follows. Aliquots of the Nano-Glo reagent (Nano-Glo Luciferase Assay Substrate, Promega, N113, Nano-Glo Luciferase Assay Buffer, Promega, N112 (parts of Nano-Glo Luciferase Assay System , N1150) were brought to room temperature, the substrate and buffer were mixed according to manufacturer's instructions.
The cell plates were equilibrated to room temperature. 25 microliters/well of the mixed Nano-Glo reagent were dispensed into assay wells and pulse spun to settle contents and the plate was sealed with film. The plates were incubated at room temperature for 1 hour before detecting luminescence on an EnVision plate reader.
Formulation Example 1 - Capsule Composition An oral dosage form for administering the present invention is produced by filing a standard two piece hard gelatin capsule with the ingredients in the proportions shown in Formulation Table 21, below.
Hepes, (Gibco # 15630-080), and 0.5mg/m1 Geneticin (Gibco # 10131-027).
Suspended cells were spun down at 300g for 5 min, the supernatant was removed and the cell pellet was suspended in warm media (30-37 C) comprised as above but without 10% Fetal Bovine Serum to a concentration of 1e6 cells/ml.
Assay plates were prepared by adding 250 nL of compound stock solution in 100%
DMSO to each well, followed by dispensing 20 microliters/well cell suspension to deliver 15-20k cell/well. Cells were incubated for 1hour at 37 C. Then, 51..11_ of 1.5 M or 1 1..1M of Thapsigargin (final concentration: 200-300nM) was added to each well of cells.
Assay plates containing cells were incubated for 14-18 hours at 37 C.
The measurement of luciferase produced by the ATF4 constructs was measured as follows. Aliquots of the Nano-Glo reagent (Nano-Glo Luciferase Assay Substrate, Promega, N113, Nano-Glo Luciferase Assay Buffer, Promega, N112 (parts of Nano-Glo Luciferase Assay System , N1150) were brought to room temperature, the substrate and buffer were mixed according to manufacturer's instructions.
The cell plates were equilibrated to room temperature. 25 microliters/well of the mixed Nano-Glo reagent were dispensed into assay wells and pulse spun to settle contents and the plate was sealed with film. The plates were incubated at room temperature for 1 hour before detecting luminescence on an EnVision plate reader.
Formulation Example 1 - Capsule Composition An oral dosage form for administering the present invention is produced by filing a standard two piece hard gelatin capsule with the ingredients in the proportions shown in Formulation Table 21, below.
- 239 -Formulation Table 21 INGREDIENTS AMOUNTS
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenyI)-2- 7 mg oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (Compound of Example la) Lactose 53 mg Talc 16 mg Magnesium Stearate 4 mg Formulation Example 2 - Injectable Parenteral Composition An injectable form for administering the present invention is produced by stirring 1.7% by weight of N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenyl)cyclopropane-1-carboxamide (Compound of Example 2b) in 10% by volume propylene glycol in water.
Formulation Example 3 Tablet Composition The sucrose, calcium sulfate dihydrate and an ATF4 pathway inhibitor as shown in FormulationTable 22 below, are mixed and granulated in the proportions shown with a 10%
gelatin solution. The wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.
Formulation Table 22 INGREDIENTS AMOUNTS
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin- 12 mg 1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (Compound of Example 6a) calcium sulfate dihydrate 30 mg Sucrose 4 mg
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenyI)-2- 7 mg oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (Compound of Example la) Lactose 53 mg Talc 16 mg Magnesium Stearate 4 mg Formulation Example 2 - Injectable Parenteral Composition An injectable form for administering the present invention is produced by stirring 1.7% by weight of N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenyl)cyclopropane-1-carboxamide (Compound of Example 2b) in 10% by volume propylene glycol in water.
Formulation Example 3 Tablet Composition The sucrose, calcium sulfate dihydrate and an ATF4 pathway inhibitor as shown in FormulationTable 22 below, are mixed and granulated in the proportions shown with a 10%
gelatin solution. The wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.
Formulation Table 22 INGREDIENTS AMOUNTS
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin- 12 mg 1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide (Compound of Example 6a) calcium sulfate dihydrate 30 mg Sucrose 4 mg
- 240 -Starch 2 mg Talc 1 mg stearic acid 0.5 mg Biological Activity Compounds of the invention are tested for activity against ATF4 translation in the above assay.
The compounds of Examples I to IV were tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC50) < 125 nM.
The compounds of Examples I to XXIII were tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC50) <325 nM.
The compound of Example III was tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC50) of 8.89 nM.
The compound of Example VI was tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC50) of 4.1 nM.
The compound of Example IX was tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC50) of 300.05 nM.
The compound of Example XII was tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC50) of 25.2 nM.
The compound of Example XVI was tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4
The compounds of Examples I to IV were tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC50) < 125 nM.
The compounds of Examples I to XXIII were tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC50) <325 nM.
The compound of Example III was tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC50) of 8.89 nM.
The compound of Example VI was tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC50) of 4.1 nM.
The compound of Example IX was tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC50) of 300.05 nM.
The compound of Example XII was tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC50) of 25.2 nM.
The compound of Example XVI was tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4
- 241 -pathway inhibitory activity (1050) of 13 nM.
The compound of Example XXI was tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (1050) of 33 nM.
The compound of Example XXII was tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 1.3 nM.
The compound of Example XXIV and 6a was tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 7.3 nM.
The compounds of Examples la to 1v were tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) from 0.6 to 384 nM.
The compound of Example la was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 2.1 nM.
The compound of Example 1g was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 17 nM.
The compound of Example 1k was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 34 nM.
The compound of Example 11 was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 1.6 nM.
The compound of Example lm was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an
The compound of Example XXI was tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (1050) of 33 nM.
The compound of Example XXII was tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 1.3 nM.
The compound of Example XXIV and 6a was tested generally according to the above ATF4 cell based assay and in a set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 7.3 nM.
The compounds of Examples la to 1v were tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) from 0.6 to 384 nM.
The compound of Example la was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 2.1 nM.
The compound of Example 1g was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 17 nM.
The compound of Example 1k was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 34 nM.
The compound of Example 11 was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 1.6 nM.
The compound of Example lm was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an
- 242 -average ATF4 pathway inhibitory activity (I050) of 0.6 nM.
The compound of Example 10 was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (I050) of 10.3 nM.
The compound of Example 1r was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 1.8 nM.
The compound of Example it was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 51.7 nM.
The compound of Example 1v was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 23.2 nM.
The compounds of Examples 2a to 2c were tested generally according to the above .. ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) from 12.3 to 27.4 nM.
The compounds of Examples 3a and 3b were tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) from 3.6 to 13.6 nM.
The compounds of Examples 4a to 4e were tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) from 4.7 to 326 nM.
The compound of Example 4d was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 12.2 nM.
The compounds of Examples 5a to Sc were tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited
The compound of Example 10 was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (I050) of 10.3 nM.
The compound of Example 1r was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 1.8 nM.
The compound of Example it was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 51.7 nM.
The compound of Example 1v was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 23.2 nM.
The compounds of Examples 2a to 2c were tested generally according to the above .. ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) from 12.3 to 27.4 nM.
The compounds of Examples 3a and 3b were tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) from 3.6 to 13.6 nM.
The compounds of Examples 4a to 4e were tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) from 4.7 to 326 nM.
The compound of Example 4d was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 12.2 nM.
The compounds of Examples 5a to Sc were tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited
- 243 -an average ATF4 pathway inhibitory activity (I050) from 36 to 2097 nM.
The compounds of Examples 6a to 6x were tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) from 1.11 to 210 nM.
The compound of Example 6c was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 6.7 nM.
The compound of Example 6e was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 20 nM.
The compound of Example 6i was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 6.9 nM.
The compound of Example 6k was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 24.57 nM.
The compound of Example 60 was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 5.7 nM.
The compound of Example 6q was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 1.1 nM.
The compound of Example 6v was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 9.9 nM.
The compounds of Examples 7a to 7c were tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited
The compounds of Examples 6a to 6x were tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) from 1.11 to 210 nM.
The compound of Example 6c was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 6.7 nM.
The compound of Example 6e was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 20 nM.
The compound of Example 6i was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 6.9 nM.
The compound of Example 6k was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 24.57 nM.
The compound of Example 60 was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 5.7 nM.
The compound of Example 6q was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 1.1 nM.
The compound of Example 6v was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (IC) of 9.9 nM.
The compounds of Examples 7a to 7c were tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited
- 244 -an average ATF4 pathway inhibitory activity (1050) from 1.2 to 65.8 nM.
The compound of Example 8a was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (1050) of 5.1 nM.
References.
1. Wek RC, Jiang H-Y, Anthony TG. Coping with stress: elF2 kinases and translational control. Biochem. Soc. Trans. 2006 Feb;34(Pt I):7-11.
2. Hinnebusch AG,Lorsch JR. The mechanism of eukaryotic translation initiation: new insights and challenges. Cold Spring Harb Perspect Biol. 2012;4(10): a011544..
3. Krishnamoorthy T, Pavitt GD, Zhang F, Dever TE, Hinnebusch AG. Tight binding of the phosphorylated alpha subunit of initiation factor 2 (eIF2alpha) to the regulatory subunits of guanine nucleotide exchange factor elF2B is required for inhibition of translation initiation. Mol Cell Biol. 2001 Aug;21(15):5018-30.
4. Hinnebusch AG. Translational regulation of GCN4 and the general amino acid control of yeast. Annu. Rev. Microbiol. 2005;59:407-50.
5. Jackson RJ, Hellen CUT, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol. 2010 Feb 1;1 1(2):113-27.
6. Harding HP, Novoa 1, Zhang Y, Zeng H, Wek R, Schapira M, et al.
Regulated translation initiation controls stress-induced gene expression in mammalian cells.
Mol. Cell. 2000 Nov;6(5):1099-108.
7. Palam LR, Baird TD, Wek RC. Phosphorylation of elF2 facilitates ribosomal bypass of an inhibitory upstream ORF to enhance CHOP translation. Journal of Biological Chemistry. 2011 Apr I;286(13):10939-49.
The compound of Example 8a was tested generally according to the above ATF4 cell based assay and in at least one set of two or more experimental runs exhibited an average ATF4 pathway inhibitory activity (1050) of 5.1 nM.
References.
1. Wek RC, Jiang H-Y, Anthony TG. Coping with stress: elF2 kinases and translational control. Biochem. Soc. Trans. 2006 Feb;34(Pt I):7-11.
2. Hinnebusch AG,Lorsch JR. The mechanism of eukaryotic translation initiation: new insights and challenges. Cold Spring Harb Perspect Biol. 2012;4(10): a011544..
3. Krishnamoorthy T, Pavitt GD, Zhang F, Dever TE, Hinnebusch AG. Tight binding of the phosphorylated alpha subunit of initiation factor 2 (eIF2alpha) to the regulatory subunits of guanine nucleotide exchange factor elF2B is required for inhibition of translation initiation. Mol Cell Biol. 2001 Aug;21(15):5018-30.
4. Hinnebusch AG. Translational regulation of GCN4 and the general amino acid control of yeast. Annu. Rev. Microbiol. 2005;59:407-50.
5. Jackson RJ, Hellen CUT, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol. 2010 Feb 1;1 1(2):113-27.
6. Harding HP, Novoa 1, Zhang Y, Zeng H, Wek R, Schapira M, et al.
Regulated translation initiation controls stress-induced gene expression in mammalian cells.
Mol. Cell. 2000 Nov;6(5):1099-108.
7. Palam LR, Baird TD, Wek RC. Phosphorylation of elF2 facilitates ribosomal bypass of an inhibitory upstream ORF to enhance CHOP translation. Journal of Biological Chemistry. 2011 Apr I;286(13):10939-49.
- 245 -8. Vattem KM, Wek RC. Reinitiation involving upstream ORFs regulates ATF4 mRNA
translation in mammalian cells. Proc Natl Acad Sci USA. 2004 Aug 3;101(31):11269-74.
9. Ma Y, Brewer JW, Diehl JA, Hendershot LM. Two distinct stress signaling pathways converge upon the CHOP promoter during the mammalian unfolded protein response. J. Mol. Biol. 2002 May 17;318(5):1351-65.
10. Pavitt GD, Ron D. New insights into translational regulation in the endoplasmic reticulum unfolded protein response. Cold Spring Harb Perspect Biol. 2012 Jun;4(6): a012278.
11. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007 Jul;8(7):519-29.
12. Gardner BM, Walter P. Unfolded proteins are Irel-activating ligands that directly induce the unfolded protein response. Science. 2011 Sep 30;333(6051):1891-4.
13. Harding HP, Zhang Y, Bertolotti A, Zeng H, Ron D. Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol Cell. 2000 May;5(5):897-904.
14. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011 Nov 25;334(6059):1081-6.
15. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol. 2011 Mar I;13(3):184-90.
16. Shore GCG, Papa FRF, Oakes SAS. Signaling cell death from the endoplasmic reticulum stress response. Current Opinion in Cell Biology. 2011 Apr I;23(2):143-9.
17. Bi M, Naczki C, Koritzinsky M, Fels D, 174 WO 2014/144952 PC
Blais J, Hu N, Harking H, Novoa I, Varia M, Raleigh J, Scheuner D, Kaufman RJ, Bell J, Ron D, Wouters BG, Koumenis C. 2005. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J.
24:3470-3481.
translation in mammalian cells. Proc Natl Acad Sci USA. 2004 Aug 3;101(31):11269-74.
9. Ma Y, Brewer JW, Diehl JA, Hendershot LM. Two distinct stress signaling pathways converge upon the CHOP promoter during the mammalian unfolded protein response. J. Mol. Biol. 2002 May 17;318(5):1351-65.
10. Pavitt GD, Ron D. New insights into translational regulation in the endoplasmic reticulum unfolded protein response. Cold Spring Harb Perspect Biol. 2012 Jun;4(6): a012278.
11. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007 Jul;8(7):519-29.
12. Gardner BM, Walter P. Unfolded proteins are Irel-activating ligands that directly induce the unfolded protein response. Science. 2011 Sep 30;333(6051):1891-4.
13. Harding HP, Zhang Y, Bertolotti A, Zeng H, Ron D. Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol Cell. 2000 May;5(5):897-904.
14. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011 Nov 25;334(6059):1081-6.
15. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol. 2011 Mar I;13(3):184-90.
16. Shore GCG, Papa FRF, Oakes SAS. Signaling cell death from the endoplasmic reticulum stress response. Current Opinion in Cell Biology. 2011 Apr I;23(2):143-9.
17. Bi M, Naczki C, Koritzinsky M, Fels D, 174 WO 2014/144952 PC
Blais J, Hu N, Harking H, Novoa I, Varia M, Raleigh J, Scheuner D, Kaufman RJ, Bell J, Ron D, Wouters BG, Koumenis C. 2005. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J.
24:3470-3481.
- 246 -18. Bobrovnikova-Marjon E, Pytel D, Vaites LP, Singh N, Koretzky GA, Diehl JA. 2010.
PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. Oncogene 29: 3881-3895.
19. Avivar-Valderas A, Bobrovnikova-Marjon E, Diehl A, Nagi C, Debnath J, Aguirre-Guiso JA 2011. PERK integrates autophagy and oxidative stress responses to promote survival during extracellular matrix detachment. Mol Gel Biol 31:3616-3629.
20. Axten JM., Medina J. R., Feng Y., Shu A., Romeril S. P. et al. 2012.
Discovery of 7-methy-5(I-(13-10 (trifluoromethyl)phenyllacetyl)-2, 3-dihydro-IH-indo1-5y1)-7H-pyrrolo 12,3-01pyrimidin-4 amine (GSK2606414), a potent and selective first-in class inhibitor of protein kinase R (PKR)-like endplasmic reticulum kinase (PERK).
J.
Med. Chem. 55(16):7193-7207 21. Ye J. Kumanova M., Hart L. S., Sloane K., Zhang H. et al. 2010. The pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J. 29: 2082-2096.
22. Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Martin MG, Halliday M, Morgan J, Dinsdale D, Ortori CA, Barrett DA, Tsaytler P, Bertolotti A, Willis AE, Bushell M, Mallucci GR. 2012. Sustained translational repression by elF2n-P
mediates prion neurodegeneration. Nature 485:507-511.
23. Pavitt GD and Proud CG. 2009. Protein synthesis and its control in neuronal cells with a focus on vanishing white matter disease. Biochem Soc Trans 37:1298-20 1310.
24. Costa-Mattioli M. Gobert D., Harding H., Herdy B.Azzi M., Bruno M. et al, 2005.
Translational control of hippocampal synaptic plasticity and memory by the elF2n kinase GCN2. Nature 436:1166-1173.
25. Costa-Mattioli M., Gobert D., Stern E., Garnache K., Colina RI, Cuello C., Sossin W., Kaufman R., Pelletier J., Rosenblum et al. 2007. elF2n phosphorylation bidirectionally regulates the switch from short to long term synaptic plasticity and memory. Cell 129: 195-206.
PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. Oncogene 29: 3881-3895.
19. Avivar-Valderas A, Bobrovnikova-Marjon E, Diehl A, Nagi C, Debnath J, Aguirre-Guiso JA 2011. PERK integrates autophagy and oxidative stress responses to promote survival during extracellular matrix detachment. Mol Gel Biol 31:3616-3629.
20. Axten JM., Medina J. R., Feng Y., Shu A., Romeril S. P. et al. 2012.
Discovery of 7-methy-5(I-(13-10 (trifluoromethyl)phenyllacetyl)-2, 3-dihydro-IH-indo1-5y1)-7H-pyrrolo 12,3-01pyrimidin-4 amine (GSK2606414), a potent and selective first-in class inhibitor of protein kinase R (PKR)-like endplasmic reticulum kinase (PERK).
J.
Med. Chem. 55(16):7193-7207 21. Ye J. Kumanova M., Hart L. S., Sloane K., Zhang H. et al. 2010. The pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J. 29: 2082-2096.
22. Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Martin MG, Halliday M, Morgan J, Dinsdale D, Ortori CA, Barrett DA, Tsaytler P, Bertolotti A, Willis AE, Bushell M, Mallucci GR. 2012. Sustained translational repression by elF2n-P
mediates prion neurodegeneration. Nature 485:507-511.
23. Pavitt GD and Proud CG. 2009. Protein synthesis and its control in neuronal cells with a focus on vanishing white matter disease. Biochem Soc Trans 37:1298-20 1310.
24. Costa-Mattioli M. Gobert D., Harding H., Herdy B.Azzi M., Bruno M. et al, 2005.
Translational control of hippocampal synaptic plasticity and memory by the elF2n kinase GCN2. Nature 436:1166-1173.
25. Costa-Mattioli M., Gobert D., Stern E., Garnache K., Colina RI, Cuello C., Sossin W., Kaufman R., Pelletier J., Rosenblum et al. 2007. elF2n phosphorylation bidirectionally regulates the switch from short to long term synaptic plasticity and memory. Cell 129: 195-206.
- 247 -26. Zhu P. J, Huan W., Kalikulov D., Yoo J. W., Placzek A. N. , Stoica L, Zhou H. , Bell J. C., Frielander M. J., Krnjevic K., Noebels J. L., Costa-Mattioli M. 2011.
Suppression of PKR promotes network excitability and enhanced cognition by interferon-7-mediated disinhibition. Cell 147: 1384-1396.
27. Borck G., Shin B.S., Stiller B., et al 2012. elF2y mutation that disrupts elF2 complex integrity links intellectual disability to impaired translation 30 initiation.
Mol Cell 48:1-6.
28. Zeenko V. V., Wang C, Majumder M, Komar A. A., Snider M. D., Merrick W.
C., Kaufman R. J. and Hatzoglou M. (2008). An efficient in vitro translation system from mammalian cell lacking translational inhibition caused by elF2 phosphorylation.
RNA 14: 593-602.
29. Mikami S., Masutani M., Sonenber N., Yokoyama S. And lmataka H. 175 WO
2014/144952 PC T/U52014/029568 2006. An efficient mammalian cell-free translation system supplemented with translation factors. Protein Expr. Purif.
46:348-357.
While the preferred embodiments of the invention are illustrated by the above, it is to be understood that the invention is not limited to the precise instructions herein disclosed and that the right to all modifications coming within the scope of the following claims is reserved.
Suppression of PKR promotes network excitability and enhanced cognition by interferon-7-mediated disinhibition. Cell 147: 1384-1396.
27. Borck G., Shin B.S., Stiller B., et al 2012. elF2y mutation that disrupts elF2 complex integrity links intellectual disability to impaired translation 30 initiation.
Mol Cell 48:1-6.
28. Zeenko V. V., Wang C, Majumder M, Komar A. A., Snider M. D., Merrick W.
C., Kaufman R. J. and Hatzoglou M. (2008). An efficient in vitro translation system from mammalian cell lacking translational inhibition caused by elF2 phosphorylation.
RNA 14: 593-602.
29. Mikami S., Masutani M., Sonenber N., Yokoyama S. And lmataka H. 175 WO
2014/144952 PC T/U52014/029568 2006. An efficient mammalian cell-free translation system supplemented with translation factors. Protein Expr. Purif.
46:348-357.
While the preferred embodiments of the invention are illustrated by the above, it is to be understood that the invention is not limited to the precise instructions herein disclosed and that the right to all modifications coming within the scope of the following claims is reserved.
- 248 -
Claims (39)
1. A compound represented by the following Formula (IIIQ):
wherein:
L82' is selected from: a bond, -NH-, -O-, -S-, -S(O)-, -S(O)2-, cycloalkyl, -O-cycloalkyl, cycloalkyl-O-, -NH-cycloalkyl, cycloalkyl-NH-, azetidinyl, -O-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, substituted or unsubstituted C1-6alkylene and substituted or unsubstituted C1-6heteroalkylene, or L82' is taken together with R83' to form:
heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-, or, L82' is taken together with an R85' substituent adjacent to the point of attachment of L82' to C8' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to C8';
L83' is selected from: cycloalkyl, -O-cycloalkyl, cycloalkyl-O-, -NH-cycloalkyl, cycloalkyl-NH-, azetidinyl, -O-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, or L83' and R81' are taken together to form: heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-, or, L83' is taken together with an R88' substituent adjacent to the point of attachment of L83' to D8' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to D8';
R81' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and heterocycloalkyl, or R81' is taken together with L83' to form:
heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-;
R83' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and heterocycloalkyl, or R83' is taken together with L82' to form:
heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-;
R85' is selected from: fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(O)Ph, -CF3, -CN, -S(O)CH3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(O)CH3, -C.ident.CH, -CH2C.ident.CH, -SCH3, -SO3H, -SO2NH2, -NHC(O)NH2, -NHC(O)H, -NHOH, -OCF3, -OCHF2, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or, two adjacent R85' substituents can combine to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to C8', or, an R85 substituent adjacent to the point of attachment of L82' to C8' can combine with L82' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to C8';
R86' is selected from: fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(O)Ph, -CF3, -CN, -S(O)CH3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(O)CH3, -C.ident.CH, -CH2C.ident.CH, -SCH3, -SO3H, -SO2NH2, -NHC(O)NH2, -NHC(O)H, -NHOH, -OCF3, -OCHF2, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or, two adjacent R86' substituents can combine to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to D8', or, an R86' substituent adjacent to the point of attachment of L83' to D8' can combine with L83' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to D8';
R82' and R84' are independently NR88', O, CH2, or S;
R88' is selected from: hydrogen, C1-6alkyl and C1-6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
C8' and D8' are independently phenyl or pyridyl;
X6' is C1-3alkylene or C1-3alkylene substituted 1 to 3 times by fluoro;
Z82' and z84' are independently 0 or 1; and Z85' and z86' are independently an integer from 0 to 5;
or a pharmaceutically acceptable salt thereof.
wherein:
L82' is selected from: a bond, -NH-, -O-, -S-, -S(O)-, -S(O)2-, cycloalkyl, -O-cycloalkyl, cycloalkyl-O-, -NH-cycloalkyl, cycloalkyl-NH-, azetidinyl, -O-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, substituted or unsubstituted C1-6alkylene and substituted or unsubstituted C1-6heteroalkylene, or L82' is taken together with R83' to form:
heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-, or, L82' is taken together with an R85' substituent adjacent to the point of attachment of L82' to C8' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to C8';
L83' is selected from: cycloalkyl, -O-cycloalkyl, cycloalkyl-O-, -NH-cycloalkyl, cycloalkyl-NH-, azetidinyl, -O-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, or L83' and R81' are taken together to form: heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-, or, L83' is taken together with an R88' substituent adjacent to the point of attachment of L83' to D8' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to D8';
R81' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and heterocycloalkyl, or R81' is taken together with L83' to form:
heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-;
R83' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and heterocycloalkyl, or R83' is taken together with L82' to form:
heterocycloalkyl, heterocycloalkyl-O-, heterocycloalkyl-NH-, heterocycloalkyl-CH2-, oxoheterocycloalkyl, oxoheterocycloalkyl-O-, oxoheterocycloalkyl-N-, or oxoheterocycloalkyl-CH2-;
R85' is selected from: fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(O)Ph, -CF3, -CN, -S(O)CH3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(O)CH3, -C.ident.CH, -CH2C.ident.CH, -SCH3, -SO3H, -SO2NH2, -NHC(O)NH2, -NHC(O)H, -NHOH, -OCF3, -OCHF2, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or, two adjacent R85' substituents can combine to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to C8', or, an R85 substituent adjacent to the point of attachment of L82' to C8' can combine with L82' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to C8';
R86' is selected from: fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(O)Ph, -CF3, -CN, -S(O)CH3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(O)CH3, -C.ident.CH, -CH2C.ident.CH, -SCH3, -SO3H, -SO2NH2, -NHC(O)NH2, -NHC(O)H, -NHOH, -OCF3, -OCHF2, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or, two adjacent R86' substituents can combine to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to D8', or, an R86' substituent adjacent to the point of attachment of L83' to D8' can combine with L83' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to D8';
R82' and R84' are independently NR88', O, CH2, or S;
R88' is selected from: hydrogen, C1-6alkyl and C1-6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
C8' and D8' are independently phenyl or pyridyl;
X6' is C1-3alkylene or C1-3alkylene substituted 1 to 3 times by fluoro;
Z82' and z84' are independently 0 or 1; and Z85' and z86' are independently an integer from 0 to 5;
or a pharmaceutically acceptable salt thereof.
2. The compound of Claim 1 represented by Formula (IVQ):
wherein:
L92' is selected from: a bond, -NH-, -O-, -S-, -S(O)-, -S(O)2-, substituted or unsubstituted C1-6alkylene and substituted or unsubstituted C1-6heteroalkylene;
L93' is selected from: cycloalkyl, -O-cycloalkyl, and cycloalkyl-O-, azetidinyl, -O-azetidinyl, azetidinyl-O-, or L93' is taken together with R91' to form:
heterocycloalkyl, heterocycloalkyl-O-, oxoheterocycloalkyl, or oxoheterocycloalkyl-O-, or, L93' is taken together with an R96' substituent adjacent to the point of attachment of L93' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring;
R91' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and heterocycloalkyl, or R91' is taken together with L93' to form:
heterocycloalkyl, heterocycloalkyl-O-, oxoheterocycloalkyl, or oxoheterocycloalkyl-O-;
R93' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and heterocycloalkyl;
R95' is selected from: fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(O)Ph, -CF3, -CN, -S(O)CH3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(O)CH3,-C.ident.CH, -CH2C.ident.CH, -SCH3, -SO3H, -SO2NH2, -NHC(O)NH2, -NHC(O)H, -NHOH, -OCF3, -OCHF2, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R96' is selected from: fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(O)Ph, -CF3, -CN, -S(O)CH3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(O)CH3, -C.ident.CH, -CH2C.ident.CH, -SCH3, -SO3H, -SO2NH2, -NHC(O)NH2, -NHC(O)H, -NHOH, -OCF3, -OCHF2, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or, two adjacent R96' substituents can combine to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to D9', or, an R96' substituent adjacent to the point of attachment of L93' to D9' can combine with L93' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to D9';
R92' and R94' are independently NR98', O, or S;
R98' is selected from: hydrogen, C1-6alkyl and C1-6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
C9' and D9' are independently phenyl or pyridyl;
X7' is C1-3alkylene or C1-3alkylene substituted 1 to 3 times by fluoro;
Z92' and z94' are independently 0 or 1; and Z95' and z96' are independently an integer from 0 to 5;
or a pharmaceutically acceptable salt thereof.
wherein:
L92' is selected from: a bond, -NH-, -O-, -S-, -S(O)-, -S(O)2-, substituted or unsubstituted C1-6alkylene and substituted or unsubstituted C1-6heteroalkylene;
L93' is selected from: cycloalkyl, -O-cycloalkyl, and cycloalkyl-O-, azetidinyl, -O-azetidinyl, azetidinyl-O-, or L93' is taken together with R91' to form:
heterocycloalkyl, heterocycloalkyl-O-, oxoheterocycloalkyl, or oxoheterocycloalkyl-O-, or, L93' is taken together with an R96' substituent adjacent to the point of attachment of L93' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring;
R91' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and heterocycloalkyl, or R91' is taken together with L93' to form:
heterocycloalkyl, heterocycloalkyl-O-, oxoheterocycloalkyl, or oxoheterocycloalkyl-O-;
R93' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and heterocycloalkyl;
R95' is selected from: fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(O)Ph, -CF3, -CN, -S(O)CH3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(O)CH3,-C.ident.CH, -CH2C.ident.CH, -SCH3, -SO3H, -SO2NH2, -NHC(O)NH2, -NHC(O)H, -NHOH, -OCF3, -OCHF2, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R96' is selected from: fluoro, chloro, bromo, iodo, -OCH3, -OCH2Ph, -C(O)Ph, -CF3, -CN, -S(O)CH3, -OH, -NH2, -COOH, -CONH2, -NO2, -C(O)CH3, -C.ident.CH, -CH2C.ident.CH, -SCH3, -SO3H, -SO2NH2, -NHC(O)NH2, -NHC(O)H, -NHOH, -OCF3, -OCHF2, substituted or unsubstituted C1-6alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or, two adjacent R96' substituents can combine to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to D9', or, an R96' substituent adjacent to the point of attachment of L93' to D9' can combine with L93' to form a cycloalkyl ring, a heterocycloalkyl ring, or heteroaryl ring fused to D9';
R92' and R94' are independently NR98', O, or S;
R98' is selected from: hydrogen, C1-6alkyl and C1-6alkyl substituted 1 to 6 times by fluoro;
a and b are independently 0 or 1;
C9' and D9' are independently phenyl or pyridyl;
X7' is C1-3alkylene or C1-3alkylene substituted 1 to 3 times by fluoro;
Z92' and z94' are independently 0 or 1; and Z95' and z96' are independently an integer from 0 to 5;
or a pharmaceutically acceptable salt thereof.
3. The compound of Claim 1 represented by Formula (VQ):
wherein:
L102' is selected from: a bond, -CH2-, -NH-, CH2-O-, -O-CH2-, cyclopropyl, -O-cyclopropyl, cyclopropyl-O-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -O-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, -O-CH2-CH2-, and -CH2-CH2-O-, or L102' is taken together with R101' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, PYrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-, or, L102' is taken together with an R105' substituent adjacent to the point of attachment of L102' to form a heterocycloalkyl ring;
L103' is selected from: cyclopropyl, -O-cyclopropyl, cyclopropyl-O-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -O-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, or L103' is taken together with R103' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, PYrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-, or, L103' is taken together with an R106' substituent adjacent to the point of attachment of L103' to form a heterocycloalkyl ring;
R101' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and oxetanyl, or R101 is taken together with L102' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, Pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R103' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and oxetanyl, or R103' is taken together with L103' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R105 is selected from: methyl, cyclopropyl, -OCF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R105 substituent adjacent to the point of attachment of L102' to C10' can combine with L102' to form a heterocycloalkyl ring fused to C10';
R106' is selected from: methyl, cyclopropyl, -OCF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R106' substituent adjacent to the point of attachment of L103' to D10' can combine with L103' to form a heterocycloalkyl ring fused to D10';
R102' and R104' are O;
a and b are independently 0 or 1;
C10' and D10' are independently phenyl or pyridyl;
X8' is selected from -CH2- and -CH2-CH2-;
Z102' and z104' are independently 0 or 1; and Z105 and z106' are independently an integer from 0 to 5;
or a pharmaceutically acceptable salt thereof.
wherein:
L102' is selected from: a bond, -CH2-, -NH-, CH2-O-, -O-CH2-, cyclopropyl, -O-cyclopropyl, cyclopropyl-O-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -O-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, -O-CH2-CH2-, and -CH2-CH2-O-, or L102' is taken together with R101' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, PYrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-, or, L102' is taken together with an R105' substituent adjacent to the point of attachment of L102' to form a heterocycloalkyl ring;
L103' is selected from: cyclopropyl, -O-cyclopropyl, cyclopropyl-O-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -O-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, or L103' is taken together with R103' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, PYrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-, or, L103' is taken together with an R106' substituent adjacent to the point of attachment of L103' to form a heterocycloalkyl ring;
R101' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and oxetanyl, or R101 is taken together with L102' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, Pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R103' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and oxetanyl, or R103' is taken together with L103' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R105 is selected from: methyl, cyclopropyl, -OCF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R105 substituent adjacent to the point of attachment of L102' to C10' can combine with L102' to form a heterocycloalkyl ring fused to C10';
R106' is selected from: methyl, cyclopropyl, -OCF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R106' substituent adjacent to the point of attachment of L103' to D10' can combine with L103' to form a heterocycloalkyl ring fused to D10';
R102' and R104' are O;
a and b are independently 0 or 1;
C10' and D10' are independently phenyl or pyridyl;
X8' is selected from -CH2- and -CH2-CH2-;
Z102' and z104' are independently 0 or 1; and Z105 and z106' are independently an integer from 0 to 5;
or a pharmaceutically acceptable salt thereof.
4. The compound of Claim 1 represented by Formula (VIQ):
wherein:
L112' is selected from: a bond, -CH2-, -NH-, CH2-O-, -O-CH2-, -O-CH2-CH2-, and -CH2-CH2-O-;
L113' is selected from: cyclopropyl, -O-cyclopropyl, cyclopropyl-O-, azetidinyl, -O-azetidinyl, azetidinyl-O-, or L113' is taken together with R113' to form:
imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-, or, L113' is taken together with an R116' substituent adjacent to the point of attachment of L113' to form a heterocycloalkyl ring;
R113' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and oxetanyl or R113' is taken together with L113' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-;
R111' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and oxetanyl;
R115' is selected from: methyl, cyclopropyl, -OCF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3;
R116' is selected from: methyl, cyclopropyl, -OCF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R116' substituent adjacent to the point of attachment of L113' to D11' can combine with L113' to form a heterocycloalkyl ring fused to D11';
R112' and R114' are O;
a and b are independently 0 or 1;
C11' and D11' are independently phenyl or pyridyl;
X9' is selected from -CH2- and -CH2-CH2-;
Z112' and z114' are independently 0 or 1; and Z-115' and z116' are independently an integer from 0 to 5;
or a pharmaceutically acceptable salt thereof.
wherein:
L112' is selected from: a bond, -CH2-, -NH-, CH2-O-, -O-CH2-, -O-CH2-CH2-, and -CH2-CH2-O-;
L113' is selected from: cyclopropyl, -O-cyclopropyl, cyclopropyl-O-, azetidinyl, -O-azetidinyl, azetidinyl-O-, or L113' is taken together with R113' to form:
imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-, or, L113' is taken together with an R116' substituent adjacent to the point of attachment of L113' to form a heterocycloalkyl ring;
R113' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and oxetanyl or R113' is taken together with L113' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-;
R111' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and oxetanyl;
R115' is selected from: methyl, cyclopropyl, -OCF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3;
R116' is selected from: methyl, cyclopropyl, -OCF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R116' substituent adjacent to the point of attachment of L113' to D11' can combine with L113' to form a heterocycloalkyl ring fused to D11';
R112' and R114' are O;
a and b are independently 0 or 1;
C11' and D11' are independently phenyl or pyridyl;
X9' is selected from -CH2- and -CH2-CH2-;
Z112' and z114' are independently 0 or 1; and Z-115' and z116' are independently an integer from 0 to 5;
or a pharmaceutically acceptable salt thereof.
5. The compound of Claim 1 represented by Formula (VIIQ):
wherein:
W is selected from bicyclopentanyl and bicyclohexanyl;
L122' is selected from: a bond, -CH2-, -NH-, CH2-O-, -O-CH2-, cyclopropyl, -O-cyclopropyl, cyclopropyl-O-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -o-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, -O-CH2-CH2-, and -CH2-CH2-O-, or L122' is taken together with R121' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-, or, L122' is taken together with an R125' substituent adjacent to the point of attachment of L122' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring;
L123' is selected from: cyclopropyl, azetidinyl, -o-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, or L123' is taken together with R123' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-, or, L123' is taken together with an R126' substituent adjacent to the point of attachment of L123' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring;
R121' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and oxetanyl, or R121' is taken together with L122' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R123' is hydrogen or R123' is taken together with L123' to form:
imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R125' is selected from: methyl, cyclopropyl, -OCF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R125' substituent adjacent to the point of attachment of L122' to C12' can combine with L122' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring fused to C12';
R126' is selected from: methyl, cyclopropyl, -OCF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R126' substituent adjacent to the point of attachment of L123' to D12' can combine with L123' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring fused to D12';
R122' and R124' are O;
C12' and D12 are independently phenyl or pyridyl;
Z122' and z124' are independently 0 or 1; and Z125' and z126' are independently an integer from 0 to 3;
or a salt thereof including a pharmaceutically acceptable salt thereof.
wherein:
W is selected from bicyclopentanyl and bicyclohexanyl;
L122' is selected from: a bond, -CH2-, -NH-, CH2-O-, -O-CH2-, cyclopropyl, -O-cyclopropyl, cyclopropyl-O-, -NH-cyclopropyl, cyclopropyl-NH-, azetidinyl, -o-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, -O-CH2-CH2-, and -CH2-CH2-O-, or L122' is taken together with R121' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-, or, L122' is taken together with an R125' substituent adjacent to the point of attachment of L122' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring;
L123' is selected from: cyclopropyl, azetidinyl, -o-azetidinyl, azetidinyl-O-, -N-azetidinyl, azetidinyl-N-, or L123' is taken together with R123' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-, or, L123' is taken together with an R126' substituent adjacent to the point of attachment of L123' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring;
R121' is selected from: hydrogen, C1-6alkyl, substituted C1-6alkyl, and oxetanyl, or R121' is taken together with L122' to form: imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R123' is hydrogen or R123' is taken together with L123' to form:
imidazolidinyl, azetidinyl, azetidinyl-O-, azetidinyl-N-, azetidinyl-CH2-, piperidinyl, piperidinyl-O-, piperidinyl-N-, piperidinyl-CH2-, piperazinyl, piperazinyl-O-, piperazinyl-N-, piperazinyl-CH2-, oxopiperazinyl, oxopiperazinyl-O-, oxopiperazinyl-N-, oxopiperazinyl-CH2-, pyrrolidinyl, pyrrolidinyl-O-, pyrrolidinyl-N-, pyrrolidinyl-CH2-, oxopyrrolidinyl, oxopyrrolidinyl-O-, oxopyrrolidinyl-N-, or oxopyrrolidinyl-CH2-;
R125' is selected from: methyl, cyclopropyl, -OCF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R125' substituent adjacent to the point of attachment of L122' to C12' can combine with L122' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring fused to C12';
R126' is selected from: methyl, cyclopropyl, -OCF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R126' substituent adjacent to the point of attachment of L123' to D12' can combine with L123' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring fused to D12';
R122' and R124' are O;
C12' and D12 are independently phenyl or pyridyl;
Z122' and z124' are independently 0 or 1; and Z125' and z126' are independently an integer from 0 to 3;
or a salt thereof including a pharmaceutically acceptable salt thereof.
6. The compound of Claim 1 represented by Formula (VIIIQ):
wherein:
W1 is selected from bicyclopentanyl and bicyclohexanyl;
L132' is selected from: a bond, -CH2-, -NH-, CH2-O-, -O-CH2-, -O-CH2-CH2-, and -CH2-CH2-O-;
L133' is selected from: cyclopropyl, -O-cyclopropyl, cyclopropyl-O-, azetidinyl, -O-azetidinyl, azetidinyl-O-, or L133' is taken together with R133' to form:
imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-or, L133' is taken together with an R136' substituent adjacent to the point of attachment of L133' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring;
R133' is hydrogen or R133' is taken together with L133' to form:
imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-;
R135' is selected from: methyl, cyclopropyl, -OCF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3;
R136' is selected from: methyl, cyclopropyl, -OCF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R136' substituent adjacent to the point of attachment of L133' to D13' can combine with L133' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring fused to D13';
R132' and R134' are O;
C13' and D13' are each independently phenyl or pyridyl;
Z132' and z134' are each independently 0 or 1; and Z135 and z136' are each independently an integer from 0 to 3;
or a salt thereof including a pharmaceutically acceptable salt thereof.
wherein:
W1 is selected from bicyclopentanyl and bicyclohexanyl;
L132' is selected from: a bond, -CH2-, -NH-, CH2-O-, -O-CH2-, -O-CH2-CH2-, and -CH2-CH2-O-;
L133' is selected from: cyclopropyl, -O-cyclopropyl, cyclopropyl-O-, azetidinyl, -O-azetidinyl, azetidinyl-O-, or L133' is taken together with R133' to form:
imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-or, L133' is taken together with an R136' substituent adjacent to the point of attachment of L133' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring;
R133' is hydrogen or R133' is taken together with L133' to form:
imidazolidinyl, azetidinyl, azetidinyl-O-, piperidinyl, piperidinyl-O-, piperazinyl, piperazinyl-O-, oxopiperazinyl, oxopiperazinyl-O-, pyrrolidinyl, pyrrolidinyl-O-, oxopyrrolidinyl, or oxopyrrolidinyl-O-;
R135' is selected from: methyl, cyclopropyl, -OCF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3;
R136' is selected from: methyl, cyclopropyl, -OCF3, fluoro, chloro, -SCH3, -OCH3, -OCHF2, and -CF3, or, an R136' substituent adjacent to the point of attachment of L133' to D13' can combine with L133' to form a cyclohexyl ring, a cyclobutyl ring, or a tetrahydro-pyran ring fused to D13';
R132' and R134' are O;
C13' and D13' are each independently phenyl or pyridyl;
Z132' and z134' are each independently 0 or 1; and Z135 and z136' are each independently an integer from 0 to 3;
or a salt thereof including a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 selected from:
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-(4-fluorophenoxy)acetamide;
N-(3-(3-(4-chloro-2-methylphenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-(4-chlorophenoxy)acetamide;
N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-(4-cyclopropylphenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(5-chloropyridin-2-yl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(3-chlorophenoxy)-N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-(4-(trifluoromethoxy)phenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chloro-3-(trifluoromethyl)phenoxy)-N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(3-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-(4-chlorophenyl)cyclopropane-1-carboxamide;
N-(4-(2-(4-chlorophenoxy)acetamido)bicyclo[2.1.1]hexan-1-yI)-2-(4-chlorophenyl)cyclopropane-1-carboxamide;
2-(4-chlorophenoxy)-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)cyclopropane-1-carboxamide;
2-(4-chlorophenoxy)-N-(3-((1-(4-chlorophenyl)azetidin-3-yl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)azetidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
5-chloro-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yI)-2,3-dihydrobenzofuran-2-carboxamide;
2-(bicyclo[4.2.0]octa-1(6),2,4-trien-3-yloxy)-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(chroman-6-yloxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenyl)piperidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenyl)piperazin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(bicyclo[4.2.0]octa-1,3,5-trien-3-yloxy)-N-(4-(2-(4-chlorophenoxy)acetamido)bicyclo[2.2.1]heptan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
(S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
(R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-fluorophenoxy)acetamide isomer 1;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-fluorophenoxy)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(3-chloro-4-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide isomer 1;
N-(3-(3-(3-chloro-4-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide isomer 2;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-((5-chloropyridin-2-yl)oxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-(trifluoromethoxy)phenoxy)acetamide;
2-(4-chloro-3-(trifluoromethyl)phenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-cyclopropylphenoxy)acetamide;
N-(3-(3-(4-chloro-3-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide isomer 1;
N-(3-(3-(4-chloro-3-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-(pyridin-4-yloxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
1-(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenyl)imidazolidin-2-one;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-(4-methoxyphenoxy)acetamide;
2-(3-chloro-4-fluorophenoxy)-N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(4-chloro-3-(trifluoromethyl)phenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-(4-chlorophenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluoro-3-(trifluoromethyl)phenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(5-chloroisoindolin-2-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide;
N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-((5-chloropyridin-2-yl)oxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-oxo-3-(4-(trifluoromethyl)phenyl)imidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-(4-fluoro-3-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-fluoro-3-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-(difluoromethoxy)phenoxy)acetamide;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide isomer 1;
(R)-2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-((5-chloropyridin-2-yl)oxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-((5-chloropyridin-2-yl)oxy)-N-(3-(3-((5-chloropyridin-2-yl)oxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-methoxyphenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(4-chloro-2-fluorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-(4-chlorophenoxy)acetamide;
N-(3-(3-(bicyclo[4.2.0]octa-1,3,5-trien-3-yloxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1 -yl)-2-(4-chlorophenoxy)acetamide;
(S)-2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
(S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
(R)-2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
(R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-(methylthio)phenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide; and 2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)piperidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
or a pharmaceutically acceptable salt thereof.
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-(4-fluorophenoxy)acetamide;
N-(3-(3-(4-chloro-2-methylphenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-(4-chlorophenoxy)acetamide;
N-(3-(3-(4-chlorophenyI)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-(4-cyclopropylphenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(5-chloropyridin-2-yl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(3-chlorophenoxy)-N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-(4-(trifluoromethoxy)phenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chloro-3-(trifluoromethyl)phenoxy)-N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(3-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-(4-chlorophenyl)cyclopropane-1-carboxamide;
N-(4-(2-(4-chlorophenoxy)acetamido)bicyclo[2.1.1]hexan-1-yI)-2-(4-chlorophenyl)cyclopropane-1-carboxamide;
2-(4-chlorophenoxy)-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)cyclopropane-1-carboxamide;
2-(4-chlorophenoxy)-N-(3-((1-(4-chlorophenyl)azetidin-3-yl)amino)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)azetidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
5-chloro-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yI)-2,3-dihydrobenzofuran-2-carboxamide;
2-(bicyclo[4.2.0]octa-1(6),2,4-trien-3-yloxy)-N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-(chroman-6-yloxy)acetamido)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenyl)piperidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenyl)piperazin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(bicyclo[4.2.0]octa-1,3,5-trien-3-yloxy)-N-(4-(2-(4-chlorophenoxy)acetamido)bicyclo[2.2.1]heptan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
(S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
(R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-fluorophenoxy)acetamide isomer 1;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-fluorophenoxy)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(3-chloro-4-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide isomer 1;
N-(3-(3-(3-chloro-4-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide isomer 2;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-((5-chloropyridin-2-yl)oxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-(trifluoromethoxy)phenoxy)acetamide;
2-(4-chloro-3-(trifluoromethyl)phenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-cyclopropylphenoxy)acetamide;
N-(3-(3-(4-chloro-3-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide isomer 1;
N-(3-(3-(4-chloro-3-fluorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-(pyridin-4-yloxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
1-(3-((2-(4-chlorophenoxy)ethyl)amino)bicyclo[1.1.1]pentan-1-yI)-3-(4-chlorophenyl)imidazolidin-2-one;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-(4-methoxyphenoxy)acetamide;
2-(3-chloro-4-fluorophenoxy)-N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(4-chloro-3-(trifluoromethyl)phenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-(4-chlorophenoxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-fluoro-3-(trifluoromethyl)phenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(5-chloroisoindolin-2-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-chlorophenoxy)acetamide;
N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-((5-chloropyridin-2-yl)oxy)acetamide;
2-(4-chlorophenoxy)-N-(3-(2-oxo-3-(4-(trifluoromethyl)phenyl)imidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(4-chlorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-(4-fluoro-3-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-fluoro-3-(trifluoromethyl)phenoxy)acetamide;
N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yI)-2-(4-(difluoromethoxy)phenoxy)acetamide;
2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide isomer 1;
(R)-2-(4-chloro-3-fluorophenoxy)-N-(3-(3-(4-chlorophenoxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide isomer 2;
2-(4-chlorophenoxy)-N-(3-(3-((5-chloropyridin-2-yl)oxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-((5-chloropyridin-2-yl)oxy)-N-(3-(3-((5-chloropyridin-2-yl)oxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-methoxyphenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
N-(3-(3-(4-chloro-2-fluorophenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)-2-(4-chlorophenoxy)acetamide;
N-(3-(3-(bicyclo[4.2.0]octa-1,3,5-trien-3-yloxy)pyrrolidin-1-yl)bicyclo[1.1.1]pentan-1 -yl)-2-(4-chlorophenoxy)acetamide;
(S)-2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
(S)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
(R)-2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
(R)-2-(4-chlorophenoxy)-N-(3-(3-(4-chlorophenoxy)-2-oxopyrrolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
2-(4-chlorophenoxy)-N-(3-(3-(4-(methylthio)phenyl)-2-oxoimidazolidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide; and 2-(4-chlorophenoxy)-N-(3-(4-(4-chlorophenoxy)piperidin-1-yl)bicyclo[1.1.1]pentan-1-yl)acetamide;
or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising the compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
9. A method of treating a disease selected from: cancer, pre-cancerous syndromes, Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, neurological disorders, pain, in organ transplantation and arrhythmias, in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of the compound as described in any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof.
10. The method of claim 9 wherein the mammal is a human.
11. A method of treating a disease selected from: cancer, pre-cancerous syndromes, Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, neurological disorders, pain, in organ transplantation and arrhythmias in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of a compound of claim 7 or a pharmaceutically acceptable salt thereof.
12. The method of claim 11 wherein the mammal is a human.
13. The method according to claim 9 wherein said cancer is selected from:
brain (gliomas), glioblastomas, astrocytomas, glioblastoma multiforme, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast, colon, head and neck, kidney, lung, liver, melanoma, ovarian, pancreatic, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, insulinoma, prostate, sarcoma and thyroid.
brain (gliomas), glioblastomas, astrocytomas, glioblastoma multiforme, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast, colon, head and neck, kidney, lung, liver, melanoma, ovarian, pancreatic, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, insulinoma, prostate, sarcoma and thyroid.
14. The method according to claim 11 wherein said cancer is selected from:
brain (gliomas), glioblastomas, astrocytomas, glioblastoma multiforme, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast, colon, head and neck, kidney, lung, liver, melanoma, ovarian, pancreatic, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, insulinoma, prostate, sarcoma and thyroid.
brain (gliomas), glioblastomas, astrocytomas, glioblastoma multiforme, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast, colon, head and neck, kidney, lung, liver, melanoma, ovarian, pancreatic, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, insulinoma, prostate, sarcoma and thyroid.
15. Use of a compound as described in any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer.
16. A method of inhibiting the ATF4 pathway in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of the compound as described in any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof.
17. The method of claim 16 wherein the mammal is a human.
18. A method of treating cancer in a mammal in need thereof, which comprises:
administering to such mammal a therapeutically effective amount of a) the compound as described in any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof; and b) at least one anti-neoplastic agent.
administering to such mammal a therapeutically effective amount of a) the compound as described in any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof; and b) at least one anti-neoplastic agent.
19. The method claim 18, wherein the at least one anti-neoplastic agent is selected from the group consisting of: anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, cell cycle signaling inhibitors, proteasome inhibitors, and inhibitors of cancer metabolism.
20. A pharmaceutical combination comprising:
a) the compound as described in any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof; and b) at least one anti-neoplastic agent.
a) the compound as described in any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof; and b) at least one anti-neoplastic agent.
21. The pharmaceutical combination as claimed in claim 20 for use in the treatment of cancer.
22. The method according to claim 9 wherein said cancer is selected from:
breast cancer, inflammatory breast cancer, ductal carcinoma, lobular carcinoma, colon cancer, pancreatic cancer, insulinomas, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, skin cancer, melanoma, metastatic melanoma, lung cancer, small cell lung cancer, non-small cell lung cancer, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, brain (gliomas), glioblastomas, astrocytomas, glioblastoma multiforme, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma, medulloblastoma, head and neck, kidney, liver, melanoma, ovarian, pancreatic, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, insulinoma, prostate, sarcoma, osteosarcoma, giant cell tumor of bone, thyroid, lymphoblastic T cell leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, hairy-cell leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic neutrophilic leukemia, acute lymphoblastic T cell leukemia, plasmacytoma, lmmunoblastic large cell leukemia, mantle cell leukemia, multiple myeloma, megakaryoblastic leukemia, multiple myeloma, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, malignant lymphoma, hodgkins lymphoma, non-hodgkins lymphoma, lymphoblastic T cell lymphoma, Burkitt's lymphoma, follicular lymphoma, neuroblastoma, bladder cancer, urothelial cancer, vulval cancer, cervical cancer, endometrial cancer, renal cancer, mesothelioma, esophageal cancer, salivary gland cancer, hepatocellular cancer, gastric cancer, nasopharangeal cancer, buccal cancer, cancer of the mouth, GIST (gastrointestinal stromal tumor), neuroendocrine cancers and testicular cancer.
breast cancer, inflammatory breast cancer, ductal carcinoma, lobular carcinoma, colon cancer, pancreatic cancer, insulinomas, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, skin cancer, melanoma, metastatic melanoma, lung cancer, small cell lung cancer, non-small cell lung cancer, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, brain (gliomas), glioblastomas, astrocytomas, glioblastoma multiforme, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma, medulloblastoma, head and neck, kidney, liver, melanoma, ovarian, pancreatic, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, insulinoma, prostate, sarcoma, osteosarcoma, giant cell tumor of bone, thyroid, lymphoblastic T cell leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, hairy-cell leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic neutrophilic leukemia, acute lymphoblastic T cell leukemia, plasmacytoma, lmmunoblastic large cell leukemia, mantle cell leukemia, multiple myeloma, megakaryoblastic leukemia, multiple myeloma, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, malignant lymphoma, hodgkins lymphoma, non-hodgkins lymphoma, lymphoblastic T cell lymphoma, Burkitt's lymphoma, follicular lymphoma, neuroblastoma, bladder cancer, urothelial cancer, vulval cancer, cervical cancer, endometrial cancer, renal cancer, mesothelioma, esophageal cancer, salivary gland cancer, hepatocellular cancer, gastric cancer, nasopharangeal cancer, buccal cancer, cancer of the mouth, GIST (gastrointestinal stromal tumor), neuroendocrine cancers and testicular cancer.
23. The method of claim 22 wherein the mammal is a human.
24. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable excipient and an effective amount of a compound as described in any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, which process comprises bringing the compound or a pharmaceutically acceptable salt thereof into association with a pharmaceutically acceptable excipient.
25. The method according to claim 9 or claim 10 wherein said pre-cancerous syndrome is selected from: cervical intraepithelial neoplasia, monoclonal gammapathy of unknown significance (MGUS), myelodysplastic syndrome, aplastic anemia, cervical lesions, skin nevi (pre-melanoma), prostatic intraepithleial (intraductal) neoplasia (PIN), Ductal Carcinoma in situ (DCIS), colon polyps and severe hepatitis or cirrhosis.
26. The method of claim 18, wherein the at least one anti-neoplastic agent is pazopanib.
27. A method of treating ocular diseases in a human in need thereof, which comprises administering to such human a therapeutically effective amount of a compound as described in any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof.
28. The method according to claim 27 wherein the ocular disease is selected from:
rubeosis irides; neovascular glaucoma; pterygium; vascularized glaucoma filtering blebs;
conjunctival papilloma; choroidal neovascularization associated with age-related macular degeneration (AMD), myopia, prior uveitis, trauma, or idiopathic; macular edema; retinal neovascularization due to diabetes; age-related macular degeneration (AMD);
macular degeneration (AMD); ocular ischemic syndrome from carotid artery disease;
ophthalmic or retinal artery occlusion; sickle cell retinopathy; retinopathy of prematurity;
Eale's Disease;
and VonHippel-Lindau syndrome.
rubeosis irides; neovascular glaucoma; pterygium; vascularized glaucoma filtering blebs;
conjunctival papilloma; choroidal neovascularization associated with age-related macular degeneration (AMD), myopia, prior uveitis, trauma, or idiopathic; macular edema; retinal neovascularization due to diabetes; age-related macular degeneration (AMD);
macular degeneration (AMD); ocular ischemic syndrome from carotid artery disease;
ophthalmic or retinal artery occlusion; sickle cell retinopathy; retinopathy of prematurity;
Eale's Disease;
and VonHippel-Lindau syndrome.
29. The method according to claim 27 wherein the ocular disease is selected from:
age-related macular degeneration (AMD) and macular degeneration.
age-related macular degeneration (AMD) and macular degeneration.
30. A method of treating neurodegeneration in a human in need thereof, which comprises administering to such human a therapeutically effective amount of the compound as described in any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof.
31. A method of preventing organ damage during the transportation of organs for transplantation, which comprises adding the compound as described in any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, to a solution housing the organ during transportation.
32. The compound or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 7, for use in therapy.
33. Use of the compound or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 7, in the manufacture of a medicament for use in treating a disease state selected from: cancer, pre-cancerous syndromes, Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, neurological disorders, pain, in organ transplantation and arrhythmias.
34. The compound or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 7, for use in treating a disease state selected from: cancer, pre-cancerous syndromes, Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, in organ transplantation and arrhythmias.
35. The compound or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 7, for use in the treatment of an integrated stress response associated disease.
36. The compound or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 7, for use in the treatment of a disease associated with phosphorylation of elF2.alpha..
37. Use of the compound or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 7, in the manufacture of a medicament for use in treating or lessening the severity of an integrated stress response associated disease.
38. Use of the compound or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 7, in the manufacture of a medicament for use in treating a disease associated with phosphorylation of elF2.alpha..
39. A pharmaceutical composition comprising from 0.5 to 1,000 mg of the compound or pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 7, and from 0.5 to 1,000 mg of a pharmaceutically acceptable excipient.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IBPCT/IB2017/053373 | 2017-06-07 | ||
IB2017053373 | 2017-06-07 | ||
US201762595245P | 2017-12-06 | 2017-12-06 | |
US62/595,245 | 2017-12-06 | ||
IN201811002087 | 2018-01-18 | ||
IN201811002087 | 2018-01-18 | ||
PCT/IN2018/050375 WO2018225093A1 (en) | 2017-06-07 | 2018-06-07 | Chemical compounds as atf4 pathway inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3066328A1 true CA3066328A1 (en) | 2018-12-13 |
Family
ID=62716102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3066328A Abandoned CA3066328A1 (en) | 2017-06-07 | 2018-06-07 | Chemical compounds as atf4 pathway inhibitors |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3634952A1 (en) |
JP (1) | JP2020522553A (en) |
CN (1) | CN110730777A (en) |
BR (1) | BR112019025883A2 (en) |
CA (1) | CA3066328A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020001352A (en) * | 2017-08-09 | 2020-03-20 | Denali Therapeutics Inc | Compounds, compositions and methods. |
UY37958A (en) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | INTEGRATED STRESS ROAD MODULATORS |
MX2020004557A (en) | 2017-11-02 | 2020-10-05 | Calico Life Sciences Llc | Modulators of the integrated stress pathway. |
CR20230226A (en) * | 2020-10-30 | 2024-02-13 | Calico Life Sciences Llc | MODULATORS OF THE INTEGRATED STRESS PATHWAY |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI538905B (en) * | 2010-12-22 | 2016-06-21 | H 朗德貝克公司 | Bicyclo [3.2.1] octyl amide derivatives and uses of same |
JP6806562B2 (en) * | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Regulator of the eIF2α pathway |
TW201808914A (en) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | Modulators of the integrated stress pathway |
TW201808888A (en) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | Modulators of the integrated stress pathway |
TW202304851A (en) * | 2016-05-05 | 2023-02-01 | 美商嘉來克生命科學有限責任公司 | Modulators of the integrated stress pathway |
MX2020001352A (en) * | 2017-08-09 | 2020-03-20 | Denali Therapeutics Inc | Compounds, compositions and methods. |
EP3704091A1 (en) * | 2017-11-02 | 2020-09-09 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
UY37958A (en) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | INTEGRATED STRESS ROAD MODULATORS |
-
2018
- 2018-06-07 BR BR112019025883-3A patent/BR112019025883A2/en not_active Application Discontinuation
- 2018-06-07 CA CA3066328A patent/CA3066328A1/en not_active Abandoned
- 2018-06-07 CN CN201880038106.7A patent/CN110730777A/en active Pending
- 2018-06-07 JP JP2019567684A patent/JP2020522553A/en active Pending
- 2018-06-07 EP EP18733953.6A patent/EP3634952A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP3634952A1 (en) | 2020-04-15 |
BR112019025883A2 (en) | 2020-06-30 |
CN110730777A (en) | 2020-01-24 |
JP2020522553A (en) | 2020-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3468960B1 (en) | Chemical compounds as atf4 pathway inhibitors | |
WO2018225093A1 (en) | Chemical compounds as atf4 pathway inhibitors | |
US10851053B2 (en) | Chemical compounds | |
WO2020012339A1 (en) | Chemical compounds | |
WO2019008506A1 (en) | N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases | |
RU2632907C2 (en) | Dyetered diaminopyrimidine compounds and pharmaceutical compositions containing such connections | |
WO2020031107A1 (en) | Chemical compounds | |
WO2019008507A1 (en) | 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases | |
WO2019193540A1 (en) | Heteroaryl derivatives of formula (i) as atf4 inhibitors | |
CA3066328A1 (en) | Chemical compounds as atf4 pathway inhibitors | |
CA2935071A1 (en) | Piperidine-dione derivatives | |
CA3111649A1 (en) | Tricyclic compounds acting on crbn proteins | |
CA3199496A1 (en) | Heterocycle derivatives for treating trpm3 mediated disorders | |
US20210093619A1 (en) | Chemical Compounds as ATF-4 Pathway Inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20231207 |